8752018
D008094_D003072 CID Lithium_0\NN| (r_npadvmod) associated_2\VBN|lithium|- (r_amod) deficits_6\NNS|associated|cognitive|reduced|.
D008094_D003072 CID lithium_15\NN| (r_pobj) of_14\IN|lithium (r_prep) effects_13\NNS|the|common|adverse|of|,|as (r_pobj) of_8\IN|effects (r_prep) management_7\NN|the|of (r_pobj) about_5\IN|management (r_prep) written_4\VBN|although|much|has|been|about (r_advcl) remain_40\VBP|written|,|effects|understudied|. (l_nsubj) effects_27\NNS|subtle|lithium|side|as (l_prep) as_29\IN|such|deficits (l_pobj) deficits_31\NNS|cognitive|,|loss
D008094_D003072 CID lithium_15\NN| (r_pobj) of_14\IN|lithium (r_prep) effects_13\NNS|the|common|adverse|of|,|as (r_pobj) of_8\IN|effects (r_prep) management_7\NN|the|of (r_pobj) about_5\IN|management (r_prep) written_4\VBN|although|much|has|been|about (r_advcl) remain_40\VBP|written|,|effects|understudied|. (l_nsubj) effects_27\NNS|subtle|lithium|side|as (l_prep) as_29\IN|such|deficits (l_pobj) deficits_31\NNS|cognitive|,|loss (l_conj) loss_33\NN|of|,|and|impairments (l_prep) of_34\IN|creativity (l_pobj) creativity_35\NN|
D008094_D003072 CID lithium_15\NN| (r_pobj) of_14\IN|lithium (r_prep) effects_13\NNS|the|common|adverse|of|,|as (r_pobj) of_8\IN|effects (r_prep) management_7\NN|the|of (r_pobj) about_5\IN|management (r_prep) written_4\VBN|although|much|has|been|about (r_advcl) remain_40\VBP|written|,|effects|understudied|. (l_nsubj) effects_27\NNS|subtle|lithium|side|as (l_prep) as_29\IN|such|deficits (l_pobj) deficits_31\NNS|cognitive|,|loss (l_conj) loss_33\NN|of|,|and|impairments (l_conj) impairments_39\NNS|functional
D008094_D003072 CID lithium_25\NN| (r_compound) effects_27\NNS|subtle|lithium|side|as (l_prep) as_29\IN|such|deficits (l_pobj) deficits_31\NNS|cognitive|,|loss
D008094_D003072 CID lithium_25\NN| (r_compound) effects_27\NNS|subtle|lithium|side|as (l_prep) as_29\IN|such|deficits (l_pobj) deficits_31\NNS|cognitive|,|loss (l_conj) loss_33\NN|of|,|and|impairments (l_prep) of_34\IN|creativity (l_pobj) creativity_35\NN|
D008094_D003072 CID lithium_25\NN| (r_compound) effects_27\NNS|subtle|lithium|side|as (l_prep) as_29\IN|such|deficits (l_pobj) deficits_31\NNS|cognitive|,|loss (l_conj) loss_33\NN|of|,|and|impairments (l_conj) impairments_39\NNS|functional
D008094_D003072 CID lithium_10\NN| (r_pobj) from_9\IN|lithium (r_prep) switching_6\VBG|patients|from|divalproex (l_advcl) divalproex_12\NN|to|sodium|alleviate (l_xcomp) alleviate_15\VB|to|impairments (l_dobj) impairments_20\NNS|such|cognitive
D008094_D003072 CID lithium_8\NN| (r_pobj) of_7\IN|lithium (r_prep) substitution_6\NN|of|,|fully|,|with (r_nsubj) was_18\VBD|where|substitution|helpful (l_acomp) helpful_20\JJ|extremely|in (l_prep) in_21\IN|reducing (l_pcomp) reducing_22\VBG|cognitive (l_dobj) cognitive_24\JJ|the|,|motivational|attributed (l_conj) motivational_26\JJ|,|or|deficits (l_conj) deficits_30\NNS|creative
D008094_D003072 CID lithium_33\NN|in (r_pobj) to_32\IN|lithium (r_prep) attributed_31\VBN|to (r_acl) cognitive_24\JJ|the|,|motivational|attributed (l_conj) motivational_26\JJ|,|or|deficits (l_conj) deficits_30\NNS|creative
D008094_D003072 CID lithium_12\NN|in (l_prep) in_13\IN|patients (l_pobj) patients_15\NNS|bipolar|experiencing (l_acl) experiencing_16\VBG|deficits (l_dobj) deficits_18\NNS|cognitive|,|loss
D008094_D003072 CID lithium_12\NN|in (l_prep) in_13\IN|patients (l_pobj) patients_15\NNS|bipolar|experiencing (l_acl) experiencing_16\VBG|deficits (l_dobj) deficits_18\NNS|cognitive|,|loss (l_conj) loss_20\NN|of (l_prep) of_21\IN|creativity (l_pobj) creativity_22\NN|,|and|impairments
D008094_D003072 CID lithium_12\NN|in (l_prep) in_13\IN|patients (l_pobj) patients_15\NNS|bipolar|experiencing (l_acl) experiencing_16\VBG|deficits (l_dobj) deficits_18\NNS|cognitive|,|loss (l_conj) loss_20\NN|of (l_prep) of_21\IN|creativity (l_pobj) creativity_22\NN|,|and|impairments (l_conj) impairments_26\NNS|functional
D014635_D003072 NONE sodium_13\NN|:|series (r_dobj) divalproex_12\NN|to|sodium (r_advcl) reduced_7\VBN|by|divalproex (r_acl) deficits_6\NNS|associated|cognitive|reduced|.
D014635_D003072 NONE sodium_13\NN| (r_dobj) divalproex_12\NN|to|sodium|alleviate (l_xcomp) alleviate_15\VB|to|impairments (l_dobj) impairments_20\NNS|such|cognitive
D014635_D003072 NONE sodium_17\NN|divalproex (r_pobj) with_15\IN|sodium (r_prep) substitution_6\NN|of|,|fully|,|with (r_nsubj) was_18\VBD|where|substitution|helpful (l_acomp) helpful_20\JJ|extremely|in (l_prep) in_21\IN|reducing (l_pcomp) reducing_22\VBG|cognitive (l_dobj) cognitive_24\JJ|the|,|motivational|attributed (l_conj) motivational_26\JJ|,|or|deficits (l_conj) deficits_30\NNS|creative
D014635_D003072 NONE sodium_6\NN|divalproex (r_nsubj) was_7\VBD|in|,|sodium|alternative|. (l_attr) alternative_10\NN|a|superior|to (l_prep) to_11\IN|lithium (l_pobj) lithium_12\NN|in (l_prep) in_13\IN|patients (l_pobj) patients_15\NNS|bipolar|experiencing (l_acl) experiencing_16\VBG|deficits (l_dobj) deficits_18\NNS|cognitive|,|loss
D014635_D003072 NONE sodium_6\NN|divalproex (r_nsubj) was_7\VBD|in|,|sodium|alternative|. (l_attr) alternative_10\NN|a|superior|to (l_prep) to_11\IN|lithium (l_pobj) lithium_12\NN|in (l_prep) in_13\IN|patients (l_pobj) patients_15\NNS|bipolar|experiencing (l_acl) experiencing_16\VBG|deficits (l_dobj) deficits_18\NNS|cognitive|,|loss (l_conj) loss_20\NN|of (l_prep) of_21\IN|creativity (l_pobj) creativity_22\NN|,|and|impairments
D014635_D003072 NONE sodium_6\NN|divalproex (r_nsubj) was_7\VBD|in|,|sodium|alternative|. (l_attr) alternative_10\NN|a|superior|to (l_prep) to_11\IN|lithium (l_pobj) lithium_12\NN|in (l_prep) in_13\IN|patients (l_pobj) patients_15\NNS|bipolar|experiencing (l_acl) experiencing_16\VBG|deficits (l_dobj) deficits_18\NNS|cognitive|,|loss (l_conj) loss_20\NN|of (l_prep) of_21\IN|creativity (l_pobj) creativity_22\NN|,|and|impairments (l_conj) impairments_26\NNS|functional
D008094_D001714 NONE Lithium_0\NN| (r_nsubj) remains_1\VBZ|lithium|treatment|. (l_attr) treatment_6\NN|a|line|for (l_prep) for_7\IN|treatment (l_pobj) treatment_12\NN|the|acute|of (l_prep) of_13\IN|disorder (l_pobj) disorder_15\NN|bipolar
D008094_D001714 NONE lithium_10\NN| (r_pobj) from_9\IN|lithium (r_prep) switching_6\VBG|patients|from|divalproex (l_dobj) patients_8\NNS|bipolar (l_amod) bipolar_7\JJ|
D008094_D001714 NONE lithium_8\NN| (r_pobj) of_7\IN|lithium (r_prep) substitution_6\NN|of|,|fully|,|with (r_nsubj) was_18\VBD|where|substitution|helpful (l_acomp) helpful_20\JJ|extremely|in (l_prep) in_21\IN|reducing (l_pcomp) reducing_22\VBG|cognitive (l_dobj) cognitive_24\JJ|the|,|motivational|attributed (l_acl) attributed_31\VBN|to (l_prep) to_32\IN|lithium (l_pobj) lithium_33\NN|in (l_prep) in_34\IN|patients (l_pobj) patients_37\NNS|our|bipolar (l_amod) bipolar_36\JJ|
D008094_D001714 NONE lithium_33\NN|in (l_prep) in_34\IN|patients (l_pobj) patients_37\NNS|our|bipolar (l_amod) bipolar_36\JJ|
D008094_D001714 NONE lithium_12\NN|in (l_prep) in_13\IN|patients (l_pobj) patients_15\NNS|bipolar|experiencing (l_amod) bipolar_14\JJ|
D008094_D011141 NONE lithium_15\NN| (r_pobj) of_14\IN|lithium (r_prep) effects_13\NNS|the|common|adverse|of|,|as (l_prep) as_18\IN|such|polyuria (l_pobj) polyuria_19\NN|and|tremor
D008094_D011141 NONE lithium_25\NN| (r_compound) effects_27\NNS|subtle|lithium|side|as (r_nsubj) remain_40\VBP|written|,|effects|understudied|. (l_advcl) written_4\VBN|although|much|has|been|about (l_prep) about_5\IN|management (l_pobj) management_7\NN|the|of (l_prep) of_8\IN|effects (l_pobj) effects_13\NNS|the|common|adverse|of|,|as (l_prep) as_18\IN|such|polyuria (l_pobj) polyuria_19\NN|and|tremor
D008094_D014202 NONE lithium_15\NN| (r_pobj) of_14\IN|lithium (r_prep) effects_13\NNS|the|common|adverse|of|,|as (l_prep) as_18\IN|such|polyuria (l_pobj) polyuria_19\NN|and|tremor (l_conj) tremor_21\NN|
D008094_D014202 NONE lithium_25\NN| (r_compound) effects_27\NNS|subtle|lithium|side|as (r_nsubj) remain_40\VBP|written|,|effects|understudied|. (l_advcl) written_4\VBN|although|much|has|been|about (l_prep) about_5\IN|management (l_pobj) management_7\NN|the|of (l_prep) of_8\IN|effects (l_pobj) effects_13\NNS|the|common|adverse|of|,|as (l_prep) as_18\IN|such|polyuria (l_pobj) polyuria_19\NN|and|tremor (l_conj) tremor_21\NN|
D014635_D001714 NONE sodium_13\NN| (r_dobj) divalproex_12\NN|to|sodium|alleviate (r_advcl) switching_6\VBG|patients|from|divalproex (l_dobj) patients_8\NNS|bipolar (l_amod) bipolar_7\JJ|
D014635_D001714 NONE sodium_17\NN|divalproex (r_pobj) with_15\IN|sodium (r_prep) substitution_6\NN|of|,|fully|,|with (r_nsubj) was_18\VBD|where|substitution|helpful (l_acomp) helpful_20\JJ|extremely|in (l_prep) in_21\IN|reducing (l_pcomp) reducing_22\VBG|cognitive (l_dobj) cognitive_24\JJ|the|,|motivational|attributed (l_acl) attributed_31\VBN|to (l_prep) to_32\IN|lithium (l_pobj) lithium_33\NN|in (l_prep) in_34\IN|patients (l_pobj) patients_37\NNS|our|bipolar (l_amod) bipolar_36\JJ|
D014635_D001714 NONE sodium_6\NN|divalproex (r_nsubj) was_7\VBD|in|,|sodium|alternative|. (l_attr) alternative_10\NN|a|superior|to (l_prep) to_11\IN|lithium (l_pobj) lithium_12\NN|in (l_prep) in_13\IN|patients (l_pobj) patients_15\NNS|bipolar|experiencing (l_amod) bipolar_14\JJ|
18464113
D019259_D006509 NONE Lamivudine_0\NNP|for|. (l_prep) for_1\IN|prevention (l_pobj) prevention_3\NN|the|of (l_prep) of_4\IN|reactivation (l_pobj) reactivation_8\NN|virus|in (l_compound) virus_7\NN|b (l_compound) B_6\NNP|hepatitis
D019259_D006509 NONE lamivudine_20\NN|the|agent (r_dobj) received_16\VBD|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS|cancer|have (l_relcl) have_7\VBP|who|malignancies (l_dobj) malignancies_11\NNS|solid|with (l_prep) with_12\IN|infection (l_pobj) infection_15\NN|chronic|hbv
D019259_D006509 NONE lamivudine_34\NN| (r_dobj) receive_33\VB|who|did|not|lamivudine (r_relcl) group_29\NN|historical|control|receive (r_pobj) with_26\IN|group (r_prep) compared_25\VBN|with (r_prep) received_16\VBD|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS|cancer|have (l_relcl) have_7\VBP|who|malignancies (l_dobj) malignancies_11\NNS|solid|with (l_prep) with_12\IN|infection (l_pobj) infection_15\NN|chronic|hbv
D019259_D009369 NONE Lamivudine_0\NNP|for|. (l_prep) for_1\IN|prevention (l_pobj) prevention_3\NN|the|of (l_prep) of_4\IN|reactivation (l_pobj) reactivation_8\NN|virus|in (l_prep) in_9\IN|patients (l_pobj) patients_20\NNS|antigen|(|hbsag|)|seropositive|cancer|undergoing (l_compound) cancer_19\NN|
D019259_D009369 NONE lamivudine_20\NN|the|agent (r_dobj) received_16\VBD|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS|cancer|have (l_compound) cancer_4\NN|
D019259_D009369 NONE lamivudine_34\NN| (r_dobj) receive_33\VB|who|did|not|lamivudine (r_relcl) group_29\NN|historical|control|receive (r_pobj) with_26\IN|group (r_prep) compared_25\VBN|with (r_prep) received_16\VBD|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS|cancer|have (l_compound) cancer_4\NN|
D019259_D009369 NONE lamivudine_5\NN|prophylactic (r_nsubj) decreases_7\VBZ|that|lamivudine|significantly|incidence|during (l_dobj) incidence_9\NN|the|of (l_prep) of_10\IN|reactivation (l_pobj) reactivation_12\NN|hbv|and|morbidity (l_conj) morbidity_15\NN|overall|in (l_prep) in_16\IN|patients (l_pobj) patients_18\NNS|cancer (l_compound) cancer_17\NN|
D006514_D006509 CID antigen_14\NN|b|surface (r_nmod) patients_20\NNS|antigen|(|hbsag|)|seropositive|cancer|undergoing (r_pobj) in_9\IN|patients (r_prep) reactivation_8\NN|virus|in (l_compound) virus_7\NN|b (l_compound) B_6\NNP|hepatitis
D006514_D006509 CID HBSAG_16\NNP| (r_nmod) patients_20\NNS|antigen|(|hbsag|)|seropositive|cancer|undergoing (r_pobj) in_9\IN|patients (r_prep) reactivation_8\NN|virus|in (l_compound) virus_7\NN|b (l_compound) B_6\NNP|hepatitis
D006514_D009369 NONE antigen_14\NN|b|surface (r_nmod) patients_20\NNS|antigen|(|hbsag|)|seropositive|cancer|undergoing (l_compound) cancer_19\NN|
D006514_D009369 NONE HBSAG_16\NNP| (r_nmod) patients_20\NNS|antigen|(|hbsag|)|seropositive|cancer|undergoing (l_compound) cancer_19\NN|
D019259_D019337 NONE lamivudine_20\NN|the|agent (r_dobj) received_16\VBD|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS|cancer|have (l_relcl) have_7\VBP|who|malignancies (l_dobj) malignancies_11\NNS|solid|with
D019259_D019337 NONE lamivudine_34\NN| (r_dobj) receive_33\VB|who|did|not|lamivudine (r_relcl) group_29\NN|historical|control|receive (r_pobj) with_26\IN|group (r_prep) compared_25\VBN|with (r_prep) received_16\VBD|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS|cancer|have (l_relcl) have_7\VBP|who|malignancies (l_dobj) malignancies_11\NNS|solid|with
D019259_D056486 NONE lamivudine_3\NN| (r_compound) group_4\NN|the|prophylactic|lamivudine (r_pobj) In_0\IN|group (r_prep) observed_8\VBN|in|hepatitis|were|patient|. (l_nsubjpass) hepatitis_6\NN|severe
7504976
D002231_D056486 CID carbimazole_16\NN|and|benzylthiouracil (r_pobj) between_15\IN|carbimazole (r_prep) reactivity_14\NN|cross|-|between (r_pobj) with_11\IN|reactivity (r_prep) one_10\CD|with (r_pobj) including_9\VBG|one (r_prep) cases_8\NNS|four|including (r_appos) induced_2\VBN|hepatitis|by|:|cases|. (l_nsubj) hepatitis_1\NN|toxic
D002231_D056486 CID carbimazole_8\NN|(|omercazole|) (r_pobj) by_7\IN|carbimazole (r_agent) induced_6\VBN|hepatitis|by (l_nsubj) hepatitis_5\NN|a|cholestatic
D002231_D056486 CID omercazole_11\NN|n (r_appos) carbimazole_8\NN|(|omercazole|) (r_pobj) by_7\IN|carbimazole (r_agent) induced_6\VBN|hepatitis|by (l_nsubj) hepatitis_5\NN|a|cholestatic
D002231_D056486 CID carbimazole_12\NN|a|mixed|)|following (l_amod) following_11\VBG|hepatitis (l_compound) hepatitis_10\NN|
D002231_D056486 CID carbimazole_21\NN| (r_dobj) replaced_20\VBN|experienced|had|carbimazole|. (l_nsubj) experienced_7\VBD|one|further|hepatitis|) (l_dobj) hepatitis_10\NN|a|cytolytic|appeared
C019269_D056486 NONE benzylthiouracil_18\NN| (r_conj) carbimazole_16\NN|and|benzylthiouracil (r_pobj) between_15\IN|carbimazole (r_prep) reactivity_14\NN|cross|-|between (r_pobj) with_11\IN|reactivity (r_prep) one_10\CD|with (r_pobj) including_9\VBG|one (r_prep) cases_8\NNS|four|including (r_appos) induced_2\VBN|hepatitis|by|:|cases|. (l_nsubj) hepatitis_1\NN|toxic
C019269_D056486 NONE Benzylthiouracil_14\NNP|ne (r_pobj) after_13\IN|benzylthiouracil (r_prep) appeared_12\VBD|which|after (r_relcl) hepatitis_10\NN|a|cytolytic|appeared
C019269_D056486 NONE ne_17\NNP|(|basd (r_appos) Benzylthiouracil_14\NNP|ne (r_pobj) after_13\IN|benzylthiouracil (r_prep) appeared_12\VBD|which|after (r_relcl) hepatitis_10\NN|a|cytolytic|appeared
D002231_D002779 CID carbimazole_8\NN|(|omercazole|) (r_pobj) by_7\IN|carbimazole (r_agent) induced_6\VBN|hepatitis|by (l_nsubj) hepatitis_5\NN|a|cholestatic
D002231_D002779 CID omercazole_11\NN|n (r_appos) carbimazole_8\NN|(|omercazole|) (r_pobj) by_7\IN|carbimazole (r_agent) induced_6\VBN|hepatitis|by (l_nsubj) hepatitis_5\NN|a|cholestatic
D002231_D002779 CID carbimazole_12\NN|a|mixed|)|following (l_amod) mixed_4\JJ|(|cholestatic (l_conj) cholestatic_6\JJ|and|cytolytic
15515654
D003676_D006311 NONE DFO_6\NNP| (r_pobj) than_5\IN|dfo (r_prep) other_4\JJ|than (r_amod) factor_2\NN|no|ototoxic|,|other|, (l_compound) ototoxic_1\JJ|
D003676_D006319 CID DFO_6\NNP| (r_compound) reduction_7\NN|dfo|or|withdrawal (r_pobj) to_5\IN|reduction (r_prep) submitted_4\VBN|subjects|were|to|. (l_nsubjpass) Subjects_0\NNS|with (l_prep) with_1\IN|snhl (l_pobj) SNHL_2\NNP|
D003676_D034381 NONE DFO_5\NNP|'s (r_poss) role_8\NN|dfo|contributing|in (l_prep) in_9\IN|development (l_pobj) development_11\NN|the|of (l_prep) of_12\IN|impairment (l_pobj) impairment_14\NN|hearing
3409645
D008727_D007172 CID methotrexate_23\NNP| (r_pobj) of_22\IN|methotrexate (r_prep) taking_21\NN|the|of (r_conj) was_1\VBD|impotence|common|and|found|and|taking|. (l_nsubj) Impotence_0\NN|
16740173
2024540
D004656_D006333 NONE enalapril_11\NN|and|prazosin (r_pobj) of_10\IN|enalapril (r_prep) safety_9\NN|of|in (l_prep) in_14\IN|phase (l_pobj) phase_18\NN|the|initial|treatment|of (l_prep) of_19\IN|patients (l_pobj) patients_20\NNS|with (l_prep) with_21\IN|failure (l_pobj) failure_24\NN|heart
D011224_D006333 NONE prazosin_13\NN| (r_conj) enalapril_11\NN|and|prazosin (r_pobj) of_10\IN|enalapril (r_prep) safety_9\NN|of|in (l_prep) in_14\IN|phase (l_pobj) phase_18\NN|the|initial|treatment|of (l_prep) of_19\IN|patients (l_pobj) patients_20\NNS|with (l_prep) with_21\IN|failure (l_pobj) failure_24\NN|heart
D000806_D006333 NONE inhibitors_10\NNS|(|ace|) (r_appos) enzyme_6\NN|inhibitors (r_dobj) converting_5\VBG|enzyme|into (l_prep) into_11\IN|treatment (l_pobj) treatment_14\NN|the|adjunctive|of (l_prep) of_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|failure (l_pobj) failure_20\NN|congestive|heart|,|cases
D000806_D007022 CID inhibitors_10\NNS|(|ace|) (r_appos) enzyme_6\NN|inhibitors (r_dobj) converting_5\VBG|enzyme|into (l_prep) into_11\IN|treatment (l_pobj) treatment_14\NN|the|adjunctive|of (l_prep) of_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|failure (l_pobj) failure_20\NN|congestive|heart|,|cases (l_conj) cases_22\NNS|of (l_prep) of_23\IN|hypotension (l_pobj) hypotension_25\NN|severe
D000806_D007022 CID inhibitor_7\NN|the|ace|enalapril (r_pobj) of_4\IN|inhibitor (r_prep) safety_3\NN|the|of (r_dobj) assess_1\VB|to|safety (r_advcl) designed_19\VBN|assess|trial|was|that|compared|. (l_prep) compared_21\VBD|incidence (l_pobj) incidence_23\NN|the|and|severity|of (l_prep) of_26\IN|hypotension (l_pobj) hypotension_28\NN|symptomatic|on
D004656_D007022 NONE enalapril_8\NN| (r_appos) inhibitor_7\NN|the|ace|enalapril (r_pobj) of_4\IN|inhibitor (r_prep) safety_3\NN|the|of (r_dobj) assess_1\VB|to|safety (r_advcl) designed_19\VBN|assess|trial|was|that|compared|. (l_prep) compared_21\VBD|incidence (l_pobj) incidence_23\NN|the|and|severity|of (l_prep) of_26\IN|hypotension (l_pobj) hypotension_28\NN|symptomatic|on
D004656_D007022 NONE enalapril_3\RB| (r_dobj) received_2\VBD|who|enalapril (r_relcl) Patients_0\NNS|received (r_nsubj) experienced_4\VBD|patients|hypotension|. (l_dobj) hypotension_11\NN|clinically|(|%|)|than
D011224_D007022 CID prazosin_14\NN| (r_npadvmod) controlled_16\VBN|prazosin|- (r_amod) trial_17\NN|a|multicenter|,|randomized|,|controlled (r_nsubjpass) designed_19\VBN|assess|trial|was|that|compared|. (l_prep) compared_21\VBD|incidence (l_pobj) incidence_23\NN|the|and|severity|of (l_prep) of_26\IN|hypotension (l_pobj) hypotension_28\NN|symptomatic|on
D011224_D007022 CID prazosin_21\NN|(|%|) (r_dobj) received_20\VBD|who|prazosin (r_relcl) patients_18\NNS|the|received (r_pobj) than_16\IN|patients (r_prep) hypotension_11\NN|clinically|(|%|)|than
10791295
D001058_D010554 CID apomorphine_2\NN| (r_pobj) of_1\IN|apomorphine (r_prep) Development_0\NN|of (r_nsubj) induced_4\VBN|development|-|behavior|:|comparison|. (l_dobj) behavior_6\NN|aggressive
D001058_D010554 CID apomorphine_3\NN| (r_pobj) of_2\IN|apomorphine (r_prep) development_1\NN|the|of (r_nsubj) induced_5\VBN|development|-|s.c.|daily|)|behavior|studied|. (l_dobj) behavior_14\NN|aggressive|of|obtained
D001058_D010554 CID apomorphine_5\NN| (r_compound) treatment_6\NN|repeated|apomorphine (r_nsubj) induced_7\VBD|in|,|treatment|development|evidenced|. (l_dobj) development_10\NN|a|gradual|of (l_prep) of_11\IN|behavior (l_pobj) behavior_13\NN|aggressive
D001058_D010554 CID apomorphine_5\NN| (r_compound) treatment_6\NN|repeated|apomorphine (r_nsubj) induced_7\VBD|in|,|treatment|development|evidenced|. (l_advcl) evidenced_15\VBN|as|by|and|shortened (l_agent) by_16\IN|intensity (l_pobj) intensity_19\NN|the|increased|of (l_prep) of_20\IN|aggressiveness (l_pobj) aggressiveness_21\NN|
D001058_D010554 CID apomorphine_14\NN| (r_preconj) the_13\DT|apomorphine (r_det) behavior_18\NN|the|induced|aggressive
14698717
D010672_D011605 NONE phenytoin_6\NN| (r_pobj) with_5\IN|phenytoin (r_prep) treatment_4\NN|with|in (r_pobj) due_2\IN|to|treatment (r_amod) psychosis_1\NN|acute|due|.
D010672_D011605 NONE phenytoin_10\JJ| (r_compound) treatment_11\NN|phenytoin|for (r_dobj) following_9\VBG|treatment (r_acl) psychosis_8\NN|following
D010672_D011605 NONE phenytoin_10\JJ| (r_compound) treatment_11\NN|phenytoin|in (r_pobj) following_9\VBG|treatment (r_prep) occur_8\VBP|that|following (r_relcl) symptoms_6\NNS|the|psychotic|occur
D010672_D014277 NONE phenytoin_10\JJ| (r_compound) treatment_11\NN|phenytoin|for (l_prep) for_12\IN|neuralgia (l_pobj) neuralgia_14\NN|trigeminal
D010672_D004827 NONE phenytoin_10\JJ| (r_compound) treatment_11\NN|phenytoin|in (l_prep) in_12\IN|patients (l_pobj) patients_15\NNS|some|epileptic (l_amod) epileptic_14\JJ|
D010672_D012640 NONE phenytoin_10\JJ| (r_compound) treatment_11\NN|phenytoin|in (r_pobj) following_9\VBG|treatment (r_prep) occur_8\VBP|that|following (r_relcl) symptoms_6\NNS|the|psychotic|occur (r_nsubj) be_17\VB|that|symptoms|may|result (l_attr) result_20\NN|the|direct|of|,|unrelated (l_amod) unrelated_24\JJ|to (l_prep) to_25\IN|seizures (l_pobj) seizures_26\NNS|
150790
D011736_D002653 NONE pyridoxine_1\JJ| (r_advmod) dependent_3\JJ|pyridoxine|- (r_amod) disorder_5\NN|a|dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_8\NN| (r_pobj) by_7\IN|isoniazid (r_agent) unmasked_6\VBD|by (r_acl) disorder_5\NN|a|dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_22\NN| (r_pobj) of_21\IN|isoniazid (r_prep) administration_20\NN|the|therapeutic|of (r_pobj) after_17\IN|administration (r_prep) sleeping_15\VBG|difficulties|after (r_conj) irritability_12\NN|,|and|sleeping (r_conj) hyperkinesis_10\NN|,|irritability (r_pobj) with_9\IN|hyperkinesis (r_prep) had_5\VBD|girl|deterioration|,|with|. (l_dobj) deterioration_7\NN|behavioral
D007538_D006948 CID isoniazid_22\NN| (r_pobj) of_21\IN|isoniazid (r_prep) administration_20\NN|the|therapeutic|of (r_pobj) after_17\IN|administration (r_prep) sleeping_15\VBG|difficulties|after (r_conj) irritability_12\NN|,|and|sleeping (r_conj) hyperkinesis_10\NN|,|irritability
D007538_D001523 NONE isoniazid_22\NN| (r_pobj) of_21\IN|isoniazid (r_prep) administration_20\NN|the|therapeutic|of (r_pobj) after_17\IN|administration (r_prep) sleeping_15\VBG|difficulties|after (r_conj) irritability_12\NN|,|and|sleeping
D007538_D012893 NONE isoniazid_22\NN| (r_pobj) of_21\IN|isoniazid (r_prep) administration_20\NN|the|therapeutic|of (r_pobj) after_17\IN|administration (r_prep) sleeping_15\VBG|difficulties|after (l_dobj) difficulties_16\NNS|
D011736_D006948 NONE pyridoxine_3\NN| (r_pobj) of_2\IN|pyridoxine (r_prep) withdrawal_1\NN|periodic|of (r_nsubjpass) associated_5\VBN|withdrawal|was|with|. (l_prep) with_6\IN|return (l_pobj) return_7\NN|of (l_prep) of_8\IN|hyperkinesis (l_pobj) hyperkinesis_10\NN|the
20698227
D012254_D000743 NONE ribavirin_8\RB| (r_pobj) for_7\IN|ribavirin (r_prep) treatment_6\NN|for (r_pobj) of_5\IN|treatment (r_prep) target_4\NN|a|of|associated (l_acl) associated_9\VBN|anemia (l_dobj) anemia_11\NN|hemolytic
D012254_D006461 NONE ribavirin_1\RB|recently (r_nsubjpass) found_4\VBN|ribavirin|has|been|inhibit|found (l_conj) found_21\VBN|number|have|been|cause|. (l_advcl) cause_23\VB|to|hemolysis (l_dobj) hemolysis_25\NN|acute
C473478_D006461 CID sunitinib_16\JJ|and|sorafenib (r_pobj) as_15\IN|such|sunitinib (r_prep) inhibitors_13\NNS|angiogenesis|as (r_pobj) of_11\IN|inhibitors (r_prep) number_10\NN|a|of (r_nsubjpass) found_21\VBN|number|have|been|cause|. (l_advcl) cause_23\VB|to|hemolysis (l_dobj) hemolysis_25\NN|acute
C471405_D006461 CID sorafenib_18\NNS| (r_conj) sunitinib_16\JJ|and|sorafenib (r_pobj) as_15\IN|such|sunitinib (r_prep) inhibitors_13\NNS|angiogenesis|as (r_pobj) of_11\IN|inhibitors (r_prep) number_10\NN|a|of (r_nsubjpass) found_21\VBN|number|have|been|cause|. (l_advcl) cause_23\VB|to|hemolysis (l_dobj) hemolysis_25\NN|acute
C100416_D019698 NONE 2a_14\CD|pegylated|interferon|alpha|and|ribavirin (r_pobj) by_10\IN|2a (r_agent) treated_9\VBN|infected|were|by|. (l_csubjpass) infected_3\VBN|patients|chronically|with (l_prep) with_4\IN|virus (l_pobj) virus_7\NN|c
D012254_D019698 NONE ribavirin_16\RB| (r_conj) 2a_14\CD|pegylated|interferon|alpha|and|ribavirin (r_pobj) by_10\IN|2a (r_agent) treated_9\VBN|infected|were|by|. (l_csubjpass) infected_3\VBN|patients|chronically|with (l_prep) with_4\IN|virus (l_pobj) virus_7\NN|c
D012254_D019698 NONE ribavirin_16\RB| (r_conj) markers_14\NNS|soluble|and|ribavirin (r_dobj) angiogenesis_12\NN|markers (r_pobj) between_11\IN|angiogenesis (r_prep) link_10\NN|a|between (r_dobj) investigating_8\VBG|link (r_acl) study_4\NN|the|first|in|investigating (r_attr) is_1\VBZ|this|study|induced (l_advcl) induced_17\VBD|anemia|and|find (l_dobj) anemia_18\NN|in (l_prep) in_19\IN|patients (l_pobj) patients_20\NNS|with (l_prep) with_21\IN|c (l_pobj) C_23\NNP|hepatitis
D012254_D000740 NONE ribavirin_16\RB| (r_conj) markers_14\NNS|soluble|and|ribavirin (r_dobj) angiogenesis_12\NN|markers (r_pobj) between_11\IN|angiogenesis (r_prep) link_10\NN|a|between (r_dobj) investigating_8\VBG|link (r_acl) study_4\NN|the|first|in|investigating (r_attr) is_1\VBZ|this|study|induced (l_advcl) induced_17\VBD|anemia|and|find (l_dobj) anemia_18\NN|in
3107448
D005905_D056486 CID Glyburide_0\NN| (r_npadvmod) induced_2\VBN|glyburide|- (r_amod) hepatitis_3\NN|induced|.
D005905_D056486 CID glyburide_1\NN| (r_pobj) For_0\IN|glyburide (r_prep) exist_15\VBP|for|,|sulfonylurea|,|reports|. (l_nsubj) reports_12\NNS|two|brief|of (l_prep) of_13\IN|hepatotoxicity (l_pobj) hepatotoxicity_14\NN|
D005905_D056486 CID glyburide_18\NN| (r_amod) therapy_19\NN|glyburide (r_pobj) of_17\IN|therapy (r_prep) initiation_16\NN|of (r_pobj) after_15\IN|soon|initiation (r_prep) developed_7\VBD|patients|syndrome|after|. (l_dobj) syndrome_13\NN|an|acute|like
D005905_D056486 CID Glyburide_0\NNP| (r_nsubj) produce_2\VB|glyburide|can|illness|. (l_dobj) illness_8\NN|an|acute|like|in
D013453_D056486 NONE sulfonylureas_14\NNS| (r_pobj) with_13\IN|sulfonylureas (r_prep) reported_10\VBN|hepatotoxicity|,|common|,|has|been|infrequently|with|. (l_nsubjpass) hepatotoxicity_3\NN|induced
D013453_D056486 NONE sulfonylurea_7\NN|a|generation (r_nsubj) exist_15\VBP|for|,|sulfonylurea|,|reports|. (l_nsubj) reports_12\NNS|two|brief|of (l_prep) of_13\IN|hepatotoxicity (l_pobj) hepatotoxicity_14\NN|
D005905_D003924 NONE glyburide_18\NN| (r_amod) therapy_19\NN|glyburide (r_pobj) of_17\IN|therapy (r_prep) initiation_16\NN|of (r_pobj) after_15\IN|soon|initiation (r_prep) developed_7\VBD|patients|syndrome|after|. (l_nsubj) patients_1\NNS|two|with (l_prep) with_2\IN|mellitus (l_pobj) mellitus_6\NN|diabetes
20520283
C522667_D012559 NONE asenapine_4\NN| (r_pobj) of_3\IN|asenapine (r_prep) Efficacy_0\NN|and|safety|of|in|. (l_prep) in_5\IN|trial (l_pobj) trial_12\NN|placebo-|controlled|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|exacerbation (l_pobj) exacerbation_17\NN|acute|of (l_prep) of_18\IN|schizophrenia (l_pobj) schizophrenia_19\NN|
C522667_D012559 NONE Asenapine_0\NNP| (r_nsubjpass) approved_2\VBN|asenapine|is|by|in|. (l_prep) in_9\IN|adults (l_pobj) adults_10\NNS|for (l_prep) for_11\IN|treatment|or|of (l_pobj) treatment_13\NN|acute|of (l_prep) of_14\IN|schizophrenia (l_pobj) schizophrenia_15\NN|
C522667_D012559 NONE asenapine_22\NN| (r_pobj) with_21\IN|asenapine (r_prep) treatment_20\NN|dose|with (r_pobj) to_16\IN|treatment (r_prep) assigned_15\VBN|in|,|patients|were|randomly|to|at|,|asenapine|)|. (l_nsubjpass) patients_9\NNS|458|with (l_prep) with_10\IN|schizophrenia (l_pobj) schizophrenia_12\NN|acute
C522667_D012559 NONE asenapine_32\NN|at|verify (r_dep) assigned_15\VBN|in|,|patients|were|randomly|to|at|,|asenapine|)|. (l_nsubjpass) patients_9\NNS|458|with (l_prep) with_10\IN|schizophrenia (l_pobj) schizophrenia_12\NN|acute
D006220_D012559 NONE haloperidol_9\NN| (r_npadvmod) controlled_11\VBN|haloperidol|- (r_amod) trial_12\NN|placebo-|controlled|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|exacerbation (l_pobj) exacerbation_17\NN|acute|of (l_prep) of_18\IN|schizophrenia (l_pobj) schizophrenia_19\NN|
D006220_D012559 NONE haloperidol_41\NN|at (r_conj) placebo_38\NN|,|or|haloperidol (r_conj) BID_36\NN|mg|,|placebo (r_pobj) at_33\IN|bid (r_prep) asenapine_32\NN|at|verify (r_dep) assigned_15\VBN|in|,|patients|were|randomly|to|at|,|asenapine|)|. (l_nsubjpass) patients_9\NNS|458|with (l_prep) with_10\IN|schizophrenia (l_pobj) schizophrenia_12\NN|acute
C522667_D001714 NONE Asenapine_0\NNP| (r_nsubjpass) approved_2\VBN|asenapine|is|by|in|. (l_prep) in_9\IN|adults (l_pobj) adults_10\NNS|for (l_prep) for_11\IN|treatment|or|of (l_conj) of_17\IN|episodes (l_pobj) episodes_21\NNS|manic|associated (l_amod) manic_18\JJ|or|mixed
C522667_D001714 NONE Asenapine_0\NNP| (r_nsubjpass) approved_2\VBN|asenapine|is|by|in|. (l_prep) in_9\IN|adults (l_pobj) adults_10\NNS|for (l_prep) for_11\IN|treatment|or|of (l_conj) of_17\IN|episodes (l_pobj) episodes_21\NNS|manic|associated (l_acl) associated_22\VBN|with (l_prep) with_23\IN|disorder (l_pobj) disorder_26\NN|bipolar|i|with
C522667_D011618 NONE Asenapine_0\NNP| (r_nsubjpass) approved_2\VBN|asenapine|is|by|in|. (l_prep) in_9\IN|adults (l_pobj) adults_10\NNS|for (l_prep) for_11\IN|treatment|or|of (l_conj) of_17\IN|episodes (l_pobj) episodes_21\NNS|manic|associated (l_acl) associated_22\VBN|with (l_prep) with_23\IN|disorder (l_pobj) disorder_26\NN|bipolar|i|with (l_prep) with_27\IN|or|without (l_conj) without_29\IN|features (l_pobj) features_31\NNS|psychotic (l_amod) psychotic_30\JJ|
C522667_D001480 CID asenapine_21\NN|the (r_pobj) of_19\IN|asenapine (r_prep) %_18\NN|10|of|at (r_conj) %_14\NN|34|,|and|% (r_appos) %_8\NN|15|and|%|,|%|respectively (r_pobj) in_6\IN|% (r_prep) occurred_5\VBD|as|aes|in (r_advcl) reported_2\VBD|symptoms|occurred|. (l_nsubj) symptoms_1\NNS|extrapyramidal
C522667_D001480 CID asenapine_9\NN|and|haloperidol (r_pobj) with_8\IN|asenapine (r_prep) similar_7\JJ|with (r_acomp) was_6\VBD|that|efficacy|similar (r_ccomp) indicated_3\VBD|analyses|was (r_ccomp) seen_16\VBN|indicated|;|contrasts|were|in|. (l_prep) in_17\IN|aes (l_pobj) AEs_18\NNS|,|symptoms (l_appos) symptoms_22\NNS|extrapyramidal
D006220_D001480 CID haloperidol_29\NN|,|and|groups (r_conj) BID_27\NN|mg|,|haloperidol (r_pobj) at_22\IN|bid (r_prep) %_18\NN|10|of|at (r_conj) %_14\NN|34|,|and|% (r_appos) %_8\NN|15|and|%|,|%|respectively (r_pobj) in_6\IN|% (r_prep) occurred_5\VBD|as|aes|in (r_advcl) reported_2\VBD|symptoms|occurred|. (l_nsubj) symptoms_1\NNS|extrapyramidal
D006220_D001480 CID haloperidol_11\NN| (r_conj) asenapine_9\NN|and|haloperidol (r_pobj) with_8\IN|asenapine (r_prep) similar_7\JJ|with (r_acomp) was_6\VBD|that|efficacy|similar (r_ccomp) indicated_3\VBD|analyses|was (r_ccomp) seen_16\VBN|indicated|;|contrasts|were|in|. (l_prep) in_17\IN|aes (l_pobj) AEs_18\NNS|,|symptoms (l_appos) symptoms_22\NNS|extrapyramidal
17466854
D008775_D002386 NONE methylprednisolone_13\NN| (r_pobj) of_12\IN|methylprednisolone (r_prep) administration_11\NN|the|of (r_pobj) after_9\IN|administration (r_prep) incidence_3\NN|the|of|after (r_dobj) assess_1\VB|to|incidence|and|gentamicin|. (l_conj) gentamicin_15\NN|into|at (l_prep) at_24\IN|end (l_pobj) end_26\NN|the|of (l_prep) of_27\IN|surgery (l_pobj) surgery_30\NN|routine|cataract (l_compound) cataract_29\NN|
D005839_D002386 NONE gentamicin_15\NN|into|at (l_prep) at_24\IN|end (l_pobj) end_26\NN|the|of (l_prep) of_27\IN|surgery (l_pobj) surgery_30\NN|routine|cataract (l_compound) cataract_29\NN|
D008775_D020250 CID methylprednisolone_3\NN| (r_pobj) of_2\IN|methylprednisolone (r_prep) administration_1\NN|the|of|and|gentamicin (r_nsubjpass) related_15\VBN|administration|was|to|. (l_prep) to_16\IN|incidence (l_pobj) incidence_19\NN|a|high|of (l_prep) of_20\IN|effects (l_pobj) effects_22\NNS|side|including (l_prep) including_23\VBG|nausea (l_pobj) nausea_24\NN|,|vomiting (l_conj) vomiting_26\NN|,|and|headache
D008775_D006261 CID methylprednisolone_3\NN| (r_pobj) of_2\IN|methylprednisolone (r_prep) administration_1\NN|the|of|and|gentamicin (r_nsubjpass) related_15\VBN|administration|was|to|. (l_prep) to_16\IN|incidence (l_pobj) incidence_19\NN|a|high|of (l_prep) of_20\IN|effects (l_pobj) effects_22\NNS|side|including (l_prep) including_23\VBG|nausea (l_pobj) nausea_24\NN|,|vomiting (l_conj) vomiting_26\NN|,|and|headache (l_conj) headache_29\NN|
D005839_D020250 CID gentamicin_5\NN|in (r_conj) administration_1\NN|the|of|and|gentamicin (r_nsubjpass) related_15\VBN|administration|was|to|. (l_prep) to_16\IN|incidence (l_pobj) incidence_19\NN|a|high|of (l_prep) of_20\IN|effects (l_pobj) effects_22\NNS|side|including (l_prep) including_23\VBG|nausea (l_pobj) nausea_24\NN|,|vomiting (l_conj) vomiting_26\NN|,|and|headache
D005839_D006261 CID gentamicin_5\NN|in (r_conj) administration_1\NN|the|of|and|gentamicin (r_nsubjpass) related_15\VBN|administration|was|to|. (l_prep) to_16\IN|incidence (l_pobj) incidence_19\NN|a|high|of (l_prep) of_20\IN|effects (l_pobj) effects_22\NNS|side|including (l_prep) including_23\VBG|nausea (l_pobj) nausea_24\NN|,|vomiting (l_conj) vomiting_26\NN|,|and|headache (l_conj) headache_29\NN|
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin_10\NNP|pirarubicin (r_dobj) bolus_9\NN|4'-0-tetrahydropyranyladriamycin (r_appos) Phase_1\NN|a|study|bolus|) (r_nsubjpass) done_15\VBN|phase|was|in|. (l_prep) in_16\IN|patients (l_pobj) patients_18\NNS|55|in (l_prep) in_19\IN|status (l_pobj) status_22\NN|good|performance|with (l_prep) with_23\IN|tumors (l_pobj) tumors_25\NNS|refractory
C027260_D009369 NONE Pirarubicin_12\NNP|( (r_appos) 4'-0-tetrahydropyranyladriamycin_10\NNP|pirarubicin (r_dobj) bolus_9\NN|4'-0-tetrahydropyranyladriamycin (r_appos) Phase_1\NN|a|study|bolus|) (r_nsubjpass) done_15\VBN|phase|was|in|. (l_prep) in_16\IN|patients (l_pobj) patients_18\NNS|55|in (l_prep) in_19\IN|status (l_pobj) status_22\NN|good|performance|with (l_prep) with_23\IN|tumors (l_pobj) tumors_25\NNS|refractory
19299179
D015662_D002779 NONE trimoxazole_11\NN|- (r_amod) treatment_12\NN|dose|trimoxazole|for|--|report (r_pobj) after_5\IN|treatment (r_prep) cholestasis_4\NN|severe|after|.
D015662_D011020 NONE trimoxazole_11\NN|- (r_amod) treatment_12\NN|dose|trimoxazole|for|--|report (l_prep) for_13\IN|pneumonia (l_pobj) pneumonia_15\NN|pneumocystis|in
D015662_D011020 NONE trimoxazole_25\NN|- (r_punct) ._26\.|trimoxazole (r_punct) treated_18\VBN|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN|pneumocystis|(|pcp|)|,|infection|,
D015662_D011020 NONE trimoxazole_25\NN|- (r_punct) ._26\.|trimoxazole (r_punct) treated_18\VBN|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN|pneumocystis|(|pcp|)|,|infection|, (l_appos) PCP_3\NNP|
D015662_D011020 NONE trimoxazole_35\NN|- (r_amod) treatment_36\NN|trimoxazole|for (l_prep) for_37\IN|pcp (l_pobj) PCP_38\NNP|
D015662_D015658 NONE trimoxazole_11\NN|- (r_amod) treatment_12\NN|dose|trimoxazole|for|--|report (l_prep) for_13\IN|pneumonia (l_pobj) pneumonia_15\NN|pneumocystis|in (l_prep) in_16\IN|patients (l_pobj) patients_20\NNS|infected (l_amod) infected_19\VBN|hiv|-
D015662_D015658 NONE trimoxazole_25\NN|- (r_punct) ._26\.|trimoxazole (r_punct) treated_18\VBN|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN|pneumocystis|(|pcp|)|,|infection|, (l_appos) infection_9\NN|a|common|opportunistic|in (l_prep) in_10\IN|individuals (l_pobj) individuals_14\NNS|infected (l_amod) infected_13\VBN|hiv|-
D015662_D015658 NONE trimoxazole_35\NN|- (r_amod) treatment_36\NN|trimoxazole|for (r_dobj) report_3\VBP|here|,|we|cases|treatment|. (l_dobj) cases_5\NNS|two|of|and|in (l_prep) of_6\IN|patients (l_pobj) patients_12\NNS|immunocompromised|infected|developed (l_amod) infected_11\VBN|hiv|-
D015662_D009894 NONE trimoxazole_25\NN|- (r_punct) ._26\.|trimoxazole (r_punct) treated_18\VBN|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN|pneumocystis|(|pcp|)|,|infection|, (l_appos) infection_9\NN|a|common|opportunistic|in
D015662_D002780 CID trimoxazole_35\NN|- (r_amod) treatment_36\NN|trimoxazole|for (r_dobj) report_3\VBP|here|,|we|cases|treatment|. (l_dobj) cases_5\NNS|two|of|and|in (l_prep) of_6\IN|patients (l_pobj) patients_12\NNS|immunocompromised|infected|developed (l_relcl) developed_14\VBD|who|cholestasis|, (l_dobj) cholestasis_17\NN|severe|intrahepatic
D015662_D008100 NONE trimoxazole_35\NN|- (r_amod) treatment_36\NN|trimoxazole|for (r_dobj) report_3\VBP|here|,|we|cases|treatment|. (l_dobj) cases_5\NNS|two|of|and|in (l_conj) in_20\IN|lesions|, (l_pobj) lesions_23\NNS|one|patient|mimicking (l_acl) mimicking_24\VBG|formation (l_dobj) formation_27\NN|liver|abscess|on (l_compound) abscess_26\NN|
424937
D008750_D056486 CID methyldopa_6\NN| (r_pobj) by_5\IN|methyldopa (r_agent) induced_4\VBN|patterns|by|. (l_nsubj) Patterns_0\NNS|of (l_prep) of_1\IN|injury (l_pobj) injury_3\NN|hepatic
D008750_D056486 CID methyldopa_22\NN| (r_npadvmod) induced_24\VBN|methyldopa|- (r_amod) hepatitis_25\NN|induced
D008750_D056486 CID methyldopa_14\NN|and|dysfunction (r_pobj) between_13\IN|methyldopa (r_prep) relationship_12\NN|the|causal|between (r_nsubjpass) proved_19\VBN|in|in|,|relationship|was|with|. (l_prep) with_20\IN|recurrence (l_pobj) recurrence_22\NN|the|of|within|to (l_prep) of_23\IN|hepatitis (l_pobj) hepatitis_24\NN|
D008750_D008107 NONE methyldopa_7\NN| (r_pobj) to_6\IN|methyldopa (r_prep) related_5\VBN|to (r_acl) disease_4\NN|liver|related
D008750_D008107 NONE methyldopa_14\NN|and|dysfunction (l_conj) dysfunction_17\NN|hepatic
D008750_D017093 NONE methyldopa_17\NN| (r_dobj) taking_16\VBG|who|had|been|methyldopa|for (r_relcl) another_11\DT|,|taking|, (r_nsubj) showed_22\VBD|another|resolution|over (r_conj) presented_5\VBN|having|in|,|and|showed (l_prep) in_6\IN|failure (l_pobj) failure_8\NN|hepatic
D008750_D017114 NONE methyldopa_22\NN| (r_npadvmod) induced_24\VBN|methyldopa|- (r_amod) hepatitis_25\NN|induced (r_pobj) of_21\IN|hepatitis (r_prep) episode_20\NN|a|prior|of (r_pobj) after_17\IN|episode (r_prep) recommenced_14\VBN|when|drug|was|accidentally|year|after (r_advcl) developed_6\VBD|patient|hepatitis|recommenced|. (l_dobj) hepatitis_8\NN|fulminant
12041669
D000961_D000741 NONE globulin_1\NN|antithymocyte|in|. (l_prep) in_2\IN|treatment (l_pobj) treatment_4\NN|the|of (l_prep) of_5\IN|anemia (l_pobj) anemia_12\NN|induced|aplastic
D000961_D000741 NONE globulin_5\NN| (r_compound) therapy_6\NN|globulin (r_dobj) received_3\VBD|who|antithymocyte|therapy|for|due (l_prep) for_7\IN|anemia (l_pobj) anemia_9\NN|aplastic
D000961_D000741 NONE globulin_3\NN| (r_dobj) Use_0\NN|of|globulin (r_nsubj) be_5\VB|use|may|treatment|. (l_attr) treatment_8\NN|the|optimal|of (l_prep) of_9\IN|anemia (l_pobj) anemia_16\NN|induced|aplastic
D010396_D000741 CID penicillamine_8\NN|d|- (r_npadvmod) induced_10\VBN|penicillamine|- (r_amod) anemia_12\NN|induced|aplastic
D010396_D000741 CID penicillamine_14\NN|d|- (r_compound) therapy_15\NN|penicillamine (r_nsubjpass) described_17\VBN|patient|therapy|is|. (l_nsubjpass) patient_1\NN|a|received (l_relcl) received_3\VBD|who|antithymocyte|therapy|for|due (l_prep) for_7\IN|anemia (l_pobj) anemia_9\NN|aplastic
D010396_D000741 CID penicillamine_12\NN|d|- (r_npadvmod) induced_14\VBN|penicillamine|- (r_amod) anemia_16\NN|induced|aplastic
6133211
D012460_D015212 NONE sulphasalazine_15\NN|throughout (r_pobj) with_14\IN|sulphasalazine (r_prep) treatment_13\NN|with (r_dobj) received_12\VBD|who|treatment (r_relcl) disease_10\NN|inflammatory|bowel|received
D012460_D000013 NONE sulphasalazine_15\NN|throughout (r_pobj) with_14\IN|sulphasalazine (r_prep) treatment_13\NN|with (r_dobj) received_12\VBD|who|treatment (r_relcl) disease_10\NN|inflammatory|bowel|received (r_pobj) with_7\IN|disease (r_prep) mothers_6\NNS|two|with (r_pobj) of_4\IN|mothers (r_prep) born_3\VBN|of (r_acl) infants_1\NNS|three|,|born|, (r_nsubjpass) found_20\VBN|infants|were|have|. (l_xcomp) have_22\VB|to|anomalies (l_dobj) anomalies_25\NNS|major|congenital
2802551
D012964_D007674 NONE Sodium_0\NN| (r_compound) status_1\NN|sodium (r_nsubj) influences_2\VBZ|status|nephrotoxicity|. (l_dobj) nephrotoxicity_6\NN|chronic|b|in
D000666_D007674 CID B_5\NN|amphotericin (r_compound) nephrotoxicity_6\NN|chronic|b|in
D000666_D007674 CID B_5\NNP|amphotericin|mg/kg (r_pobj) of_3\IN|b (r_prep) potential_2\NN|the|nephrotoxic|of (l_amod) nephrotoxic_1\JJ|
8073369
C007112_D001176 CID coniine_2\NN| (r_nsubj) failed_4\VBN|however|,|coniine|has|produce|and|is|. (l_xcomp) produce_6\VB|to|arthrogryposis (l_dobj) arthrogryposis_7\NN|in
C007112_D001176 CID coniine_15\RB| (r_npadvmod) induced_17\VBN|coniine|- (r_amod) arthrogryposis_18\NN|induced
C007112_D009140 NONE coniine_5\NN|both|and|sulfate (r_pobj) by_3\IN|coniine (r_agent) caused_2\VBN|by (r_acl) deformations_1\NNS|the|caused
C007112_D009140 NONE coniine_5\NN|both|and|sulfate (r_pobj) by_3\IN|coniine (r_agent) caused_2\VBN|by (r_acl) deformations_1\NNS|the|caused (r_nsubj) were_9\VBD|deformations|flexion|. (l_attr) flexion_11\NN|excessive|or|extension|of (l_prep) of_14\IN|toes (l_pobj) toes_18\NNS|one
D009538_D009140 NONE nicotine_7\NN| (r_compound) sulfate_8\NN|nicotine (r_conj) coniine_5\NN|both|and|sulfate (r_pobj) by_3\IN|coniine (r_agent) caused_2\VBN|by (r_acl) deformations_1\NNS|the|caused
D009538_D009140 NONE nicotine_7\NN| (r_compound) sulfate_8\NN|nicotine (r_conj) coniine_5\NN|both|and|sulfate (r_pobj) by_3\IN|coniine (r_agent) caused_2\VBN|by (r_acl) deformations_1\NNS|the|caused (r_nsubj) were_9\VBD|deformations|flexion|. (l_attr) flexion_11\NN|excessive|or|extension|of (l_prep) of_14\IN|toes (l_pobj) toes_18\NNS|one
D009538_D002543 CID nicotine_30\NN| (r_nmod) chicks_34\NNS|all|nicotine|treated (r_pobj) in_28\IN|chicks (r_prep) occurred_27\VBD|seen|;|however|,|hemorrhage|in|. (l_nsubj) hemorrhage_26\NN|extensive|cranial
15009014
D002211_D006940 CID Capsaicin_0\NNS|mm (r_nsubj) applied_7\VBN|capsaicin|to|induced|. (l_conj) induced_13\VBN|increases|provoked (l_dobj) increases_14\NNS|in|and (l_prep) in_15\IN|flow (l_pobj) flow_20\NN|dural|blood
D001285_D006940 NONE atropine_16\NN|of|mm (r_pobj) by_10\IN|atropine (r_agent) abolished_9\VBN|increases|were|also|by|. (l_nsubjpass) increases_2\NNS|the|evoked|in (l_prep) in_3\IN|flow (l_pobj) flow_6\NN|dural|blood
15338796
D000420_D014202 CID salbutamol_4\NN| (r_pobj) of_3\IN|salbutamol (r_prep) effects_2\NNS|tremor|side|of|,|quantified|. (l_compound) Tremor_0\NNP|
D000420_D014202 CID salbutamol_6\NN| (r_pobj) of_5\IN|salbutamol (r_prep) effects_4\NNS|tremor|side|of (l_compound) tremor_2\JJ|
D000420_D014202 CID salbutamol_19\NN| (r_pobj) of_18\IN|salbutamol (r_prep) doses_17\NNS|cumulative|of (r_pobj) of_15\IN|doses (r_prep) administration_14\NN|of (r_pobj) after_13\IN|administration (r_prep) disease_12\NN|obstructive|lung|after (r_pobj) with_9\IN|disease (r_prep) patients_8\NNS|44|with (r_pobj) in_6\IN|patients (r_prep) assessed_4\VBD|determine|we|tremor|in|. (l_dobj) tremor_5\NN|
D000420_D014202 CID Salbutamol_0\NNP| (r_nsubj) increased_2\VBD|salbutamol|significantly|severity|in|. (l_dobj) severity_4\NN|tremor (l_compound) tremor_3\NN|
D000420_D008173 NONE salbutamol_19\NN| (r_pobj) of_18\IN|salbutamol (r_prep) doses_17\NNS|cumulative|of (r_pobj) of_15\IN|doses (r_prep) administration_14\NN|of (r_pobj) after_13\IN|administration (r_prep) disease_12\NN|obstructive|lung|after
11642480
D015283_D004409 CID citalopram_7\NN| (r_pobj) on_6\IN|citalopram (r_prep) adolescent_5\NN|a|depressed|on (r_pobj) in_2\IN|adolescent (r_prep) twitching_1\VBG|palpebral|in|.
D015283_D004409 CID citalopram_8\NN| (r_pobj) with_7\IN|citalopram (r_prep) treatment_6\NN|with|by (l_prep) by_9\IN|boy (l_pobj) boy_14\NN|a|old|with (l_prep) with_15\IN|depression (l_pobj) depression_17\NN|major|exhibited (l_relcl) exhibited_19\VBD|who|twitching|during (l_dobj) twitching_21\NN|palpebral
D015283_D003866 NONE citalopram_7\NN| (r_pobj) on_6\IN|citalopram (r_prep) adolescent_5\NN|a|depressed|on (l_amod) depressed_4\JJ|
D015283_D003865 NONE citalopram_8\NN| (r_pobj) with_7\IN|citalopram (r_prep) treatment_6\NN|with|by (l_prep) by_9\IN|boy (l_pobj) boy_14\NN|a|old|with (l_prep) with_15\IN|depression (l_pobj) depression_17\NN|major|exhibited
18261172
D020123_D011507 CID sirolimus_6\NN| (r_npadvmod) based_8\VBN|sirolimus|- (r_amod) immunosuppression_9\NN|based|in (r_pobj) to_5\IN|immunosuppression (r_prep) switch_4\NN|to (r_pobj) after_3\IN|switch (r_prep) Development_0\NN|of|after|. (l_prep) of_1\IN|proteinuria (l_pobj) proteinuria_2\NN|
D020123_D011507 CID sirolmus_7\NN|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ|immunosuppressive|(|is|sirolmus|effects (r_ccomp) reported_23\VBN|lacks|;|however|,|proteinuria|has|been|following|. (l_nsubjpass) proteinuria_17\NN|associated
D020123_D011507 CID Srl_9\NNP| (r_appos) sirolmus_7\NN|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ|immunosuppressive|(|is|sirolmus|effects (r_ccomp) reported_23\VBN|lacks|;|however|,|proteinuria|has|been|following|. (l_nsubjpass) proteinuria_17\NN|associated
D020123_D011507 CID Srl_20\NNP| (r_pobj) with_19\IN|srl (r_prep) associated_18\VBN|with (r_acl) proteinuria_17\NN|associated
D020123_D011507 CID Srl_10\NNP| (r_pobj) with_9\IN|srl (r_prep) associated_8\VBN|with (r_acl) incidence_5\NN|the|of|associated (l_prep) of_6\IN|proteinuria (l_pobj) proteinuria_7\NN|
D020123_D011507 CID Srl_12\NNP|,|have (r_pobj) to_11\IN|srl (r_prep) switch_10\NN|to (r_pobj) after_9\IN|switch (r_prep) develop_4\VB|thus|,|proteinuria|may|in|after|. (l_nsubj) proteinuria_2\NN|
D020123_D011507 CID Srl_0\NNP| (r_nsubjpass) used_3\VBN|srl|should|be|with|and|increased|. (l_prep) with_4\IN|therapy (l_pobj) therapy_8\NN|acei|/|arb|and|patients|monitored (l_acl) monitored_11\VBD|for (l_prep) for_12\IN|proteinuria (l_pobj) proteinuria_13\NN|
D020123_D007674 NONE sirolmus_7\NN|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ|immunosuppressive|(|is|sirolmus|effects (l_dobj) effects_13\NNS|nephrotoxic (l_amod) nephrotoxic_12\JJ|
D020123_D007674 NONE Srl_9\NNP| (r_appos) sirolmus_7\NN|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ|immunosuppressive|(|is|sirolmus|effects (l_dobj) effects_13\NNS|nephrotoxic (l_amod) nephrotoxic_12\JJ|
D020123_D007674 NONE Srl_20\NNP| (r_pobj) with_19\IN|srl (r_prep) associated_18\VBN|with (r_acl) proteinuria_17\NN|associated (r_nsubjpass) reported_23\VBN|lacks|;|however|,|proteinuria|has|been|following|. (l_ccomp) lacks_11\VBZ|immunosuppressive|(|is|sirolmus|effects (l_dobj) effects_13\NNS|nephrotoxic (l_amod) nephrotoxic_12\JJ|
D020123_D007674 NONE Srl_0\NNP| (r_nsubjpass) used_3\VBN|srl|should|be|with|and|increased|. (l_conj) increased_15\VBD|dysfunction (l_dobj) dysfunction_17\NN|renal
D000806_D011507 NONE inhibitor_1\NN|ace|and|therapy (r_nsubj) reduced_11\VBN|inhibitor|development|. (l_dobj) development_13\NN|proteinuria (l_compound) proteinuria_12\NN|
D000806_D011507 NONE ACEi_5\NNP| (r_nmod) therapy_8\NN|acei|/|arb|and|patients|monitored (l_acl) monitored_11\VBD|for (l_prep) for_12\IN|proteinuria (l_pobj) proteinuria_13\NN|
D057911_D011507 NONE blocker_6\NN|releasing (r_nmod) therapy_10\NN|blocker|(|arb|) (r_conj) inhibitor_1\NN|ace|and|therapy (r_nsubj) reduced_11\VBN|inhibitor|development|. (l_dobj) development_13\NN|proteinuria (l_compound) proteinuria_12\NN|
D057911_D011507 NONE ARB_8\NNP| (r_nmod) therapy_10\NN|blocker|(|arb|) (r_conj) inhibitor_1\NN|ace|and|therapy (r_nsubj) reduced_11\VBN|inhibitor|development|. (l_dobj) development_13\NN|proteinuria (l_compound) proteinuria_12\NN|
D057911_D011507 NONE ARB_7\NNP| (r_compound) therapy_8\NN|acei|/|arb|and|patients|monitored (l_acl) monitored_11\VBD|for (l_prep) for_12\IN|proteinuria (l_pobj) proteinuria_13\NN|
D000806_D007674 NONE ACEi_5\NNP| (r_nmod) therapy_8\NN|acei|/|arb|and|patients|monitored (r_pobj) with_4\IN|therapy (r_prep) used_3\VBN|srl|should|be|with|and|increased|. (l_conj) increased_15\VBD|dysfunction (l_dobj) dysfunction_17\NN|renal
D057911_D007674 NONE ARB_7\NNP| (r_compound) therapy_8\NN|acei|/|arb|and|patients|monitored (r_pobj) with_4\IN|therapy (r_prep) used_3\VBN|srl|should|be|with|and|increased|. (l_conj) increased_15\VBD|dysfunction (l_dobj) dysfunction_17\NN|renal
7628595
D014805_D064420 NONE B12_6\NN|vitamin|and|supplementation (l_conj) supplementation_10\NN|folinic|acid|in (l_prep) in_11\IN|preventing (l_pcomp) preventing_12\VBG|toxicity (l_dobj) toxicity_14\NN|hematologic|of
D002955_D064420 NONE acid_9\NN| (r_compound) supplementation_10\NN|folinic|acid|in (l_prep) in_11\IN|preventing (l_pcomp) preventing_12\VBG|toxicity (l_dobj) toxicity_14\NN|hematologic|of
D015215_D064420 NONE zidovudine_16\NN| (r_pobj) of_15\IN|zidovudine (r_prep) toxicity_14\NN|hematologic|of
D014805_D001855 NONE B12_13\NN|vitamin|and|supplementation (l_conj) supplementation_17\NN|folinic|acid|in (l_prep) in_18\IN|preventing (l_pcomp) preventing_19\VBG|suppression (l_dobj) suppression_25\NN|zidovudine|(|zdv)-induced|marrow
D014805_D001855 NONE B12_6\NN|vitamin|or|levels (l_conj) levels_9\NNS|folate|and|development (l_conj) development_11\NN|of (l_prep) of_12\IN|myelosuppression (l_pobj) myelosuppression_13\NN|
D014805_D001855 NONE B12_1\NN|vitamin|and|supplementation (r_nsubj) seem_11\VB|b12|does|not|useful|,|excluded|. (l_oprd) useful_12\JJ|in (l_prep) in_13\IN|preventing (l_pcomp) preventing_14\VBG|or|reducing (l_conj) reducing_16\VBG|myelotoxicity|in (l_dobj) myelotoxicity_20\NN|induced
D002955_D001855 NONE acid_16\NN| (r_compound) supplementation_17\NN|folinic|acid|in (l_prep) in_18\IN|preventing (l_pcomp) preventing_19\VBG|suppression (l_dobj) suppression_25\NN|zidovudine|(|zdv)-induced|marrow
D002955_D001855 NONE acid_4\NN| (r_compound) supplementation_5\NN|folinic|acid|of (r_conj) B12_1\NN|vitamin|and|supplementation (r_nsubj) seem_11\VB|b12|does|not|useful|,|excluded|. (l_oprd) useful_12\JJ|in (l_prep) in_13\IN|preventing (l_pcomp) preventing_14\VBG|or|reducing (l_conj) reducing_16\VBG|myelotoxicity|in (l_dobj) myelotoxicity_20\NN|induced
D015215_D001855 CID zidovudine_20\NNP| (r_nmod) suppression_25\NN|zidovudine|(|zdv)-induced|marrow
D015215_D001855 CID ZDV)-induced_22\VBN| (r_amod) suppression_25\NN|zidovudine|(|zdv)-induced|marrow
D015215_D001855 CID ZDV_7\NNP| (r_compound) therapy_8\NN|zdv (r_pobj) of_6\IN|therapy (r_prep) supplementation_5\NN|folinic|acid|of (r_conj) B12_1\NN|vitamin|and|supplementation (r_nsubj) seem_11\VB|b12|does|not|useful|,|excluded|. (l_oprd) useful_12\JJ|in (l_prep) in_13\IN|preventing (l_pcomp) preventing_14\VBG|or|reducing (l_conj) reducing_16\VBG|myelotoxicity|in (l_dobj) myelotoxicity_20\NN|induced
D015215_D001855 CID ZDV_17\NNP| (r_npadvmod) induced_19\VBN|zdv|- (r_amod) myelotoxicity_20\NN|induced
D015215_D015658 NONE ZDV_21\NNP|either|(|daily|) (r_dobj) receive_19\VB|to|zdv|alone (r_xcomp) randomized_17\VBN|virus|were|receive (l_nsubjpass) virus_5\NN|five|human|immunodeficiency|patients (l_appos) patients_8\NNS|(|hiv)-infected|with (l_amod) HIV)-infected_7\VBN|
D005492_D001855 NONE folate_8\JJ| (r_compound) levels_9\NNS|folate|and|development (l_conj) development_11\NN|of (l_prep) of_12\IN|myelosuppression (l_pobj) myelosuppression_13\NN|
20882060
D009496_D002375 NONE neurotensin_3\NN|pallidal|on (l_prep) on_4\IN|catalepsy (l_pobj) catalepsy_9\NN|induced|parkinsonian|:|studies
D009496_D002375 NONE neurotensin_3\NN|into (r_pobj) of_2\IN|neurotensin (r_prep) infusions_1\NNS|bilateral|of (r_nsubj) reversed_8\VBD|infusions|catalepsy|in|. (l_dobj) catalepsy_13\NN|induced|parkinsonian
D006220_D002375 CID haloperidol_5\NN| (r_npadvmod) induced_7\VBN|haloperidol|- (r_amod) catalepsy_9\NN|induced|parkinsonian|:|studies
D006220_D002375 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|haloperidol|- (r_amod) catalepsy_13\NN|induced|parkinsonian
D009496_D010302 NONE neurotensin_10\NN|pallidal|on (l_prep) on_11\IN|symptoms (l_pobj) symptoms_16\NNS|induced|parkinsonian
D006220_D010302 NONE haloperidol_12\NN| (r_npadvmod) induced_14\VBN|haloperidol|- (r_amod) symptoms_16\NNS|induced|parkinsonian
16755009
D003975_D000647 CID Diazepam-_0\NN|,|amnesia|. (l_appos) amnesia_7\NN|scopolamine-|served
D003975_D000647 CID diazepam_16\NN|mg/kg (r_conj) scopolamine_8\NN|(|mg/kg|)|and|diazepam (r_pobj) by_7\IN|scopolamine (r_agent) induced_6\VBN|by (r_acl) amnesia_5\NN|the|induced
D012601_D000647 CID scopolamine-_2\NN|and|induced (r_nmod) amnesia_7\NN|scopolamine-|served
D012601_D000647 CID scopolamine_8\NN|(|mg/kg|)|and|diazepam (r_pobj) by_7\IN|scopolamine (r_agent) induced_6\VBN|by (r_acl) amnesia_5\NN|the|induced
D010936_D000647 NONE DCE_2\NNP| (r_nsubj) reversed_3\VBD|furthermore|,|dce|amnesia|. (l_dobj) amnesia_5\NN|the|induced
D010936_D003072 NONE DCE_2\NNP| (r_nsubj) prove_4\VB|therefore|,|dce|may|be|. (l_xcomp) be_6\VB|to|remedy (l_attr) remedy_9\NN|a|useful|for|improving (l_prep) for_10\IN|management (l_pobj) management_12\NN|the|of (l_prep) of_13\IN|dysfunctions (l_pobj) dysfunctions_15\NNS|cognitive|on
D002784_D003072 NONE cholesterol_30\NN| (r_nsubj) lowering_31\VBG|cholesterol|activity (r_conj) property_28\NN|,|lowering (r_dobj) improving_27\VBG|memory|property (r_acl) remedy_9\NN|a|useful|for|improving (l_prep) for_10\IN|management (l_pobj) management_12\NN|the|of (l_prep) of_13\IN|dysfunctions (l_pobj) dysfunctions_15\NNS|cognitive|on
6773726
D005996_D007022 CID nitroglycerin_5\NN|in (r_pobj) by_4\IN|nitroglycerin (r_prep) hypotension_3\NN|postural|by
D005996_D003929 NONE nitroglycerin_5\NN|in (l_prep) in_6\IN|neuropathy (l_pobj) neuropathy_9\NN|diabetic|autonomic
D005996_D003920 NONE nitroglycerin_3\NN|on (r_pobj) of_2\IN|nitroglycerin (r_prep) effect_1\NN|the|of (r_nsubjpass) compared_12\VBN|effect|was|in|. (l_prep) in_13\IN|subjects (l_pobj) subjects_16\NNS|5|normal|,|subjects (l_appos) subjects_20\NNS|12|diabetic|without|,|and|subjects (l_amod) diabetic_19\JJ|
D005996_D003920 NONE nitroglycerin_3\NN|on (r_pobj) of_2\IN|nitroglycerin (r_prep) effect_1\NN|the|of (r_nsubjpass) compared_12\VBN|effect|was|in|. (l_prep) in_13\IN|subjects (l_pobj) subjects_16\NNS|5|normal|,|subjects (l_appos) subjects_20\NNS|12|diabetic|without|,|and|subjects (l_conj) subjects_28\NNS|5|diabetic|with (l_amod) diabetic_27\JJ|
D005996_D003920 NONE nitroglycerin_19\NN| (r_pobj) after_18\IN|nitroglycerin (r_prep) decrease_13\NN|the|in|after (r_conj) increase_7\NN|the|in|and|decrease (r_pobj) of_5\IN|increase (r_prep) course_4\NN|magnitude|of (r_nsubj) were_20\VBD|course|similar|,|occurred|. (l_acomp) similar_21\JJ|in (l_prep) in_22\IN|subjects (l_pobj) subjects_27\NNS|the|normal|without (l_amod) normal_24\JJ|and|diabetic (l_conj) diabetic_26\JJ|
D005996_D003920 NONE nitroglycerin_19\NN| (r_pobj) after_18\IN|nitroglycerin (r_prep) decrease_13\NN|the|in|after (r_conj) increase_7\NN|the|in|and|decrease (r_pobj) of_5\IN|increase (r_prep) course_4\NN|magnitude|of (r_nsubj) were_20\VBD|course|similar|,|occurred|. (l_advcl) occurred_47\VBD|whereas|increase|in (l_prep) in_48\IN|subjects (l_pobj) subjects_51\NNS|the|diabetic|with (l_amod) diabetic_50\JJ|
D005996_D009422 NONE nitroglycerin_3\NN|on (r_pobj) of_2\IN|nitroglycerin (r_prep) effect_1\NN|the|of (r_nsubjpass) compared_12\VBN|effect|was|in|. (l_prep) in_13\IN|subjects (l_pobj) subjects_16\NNS|5|normal|,|subjects (l_appos) subjects_20\NNS|12|diabetic|without|,|and|subjects (l_prep) without_21\IN|neuropathy (l_pobj) neuropathy_23\NN|autonomic
D005996_D009422 NONE nitroglycerin_3\NN|on (r_pobj) of_2\IN|nitroglycerin (r_prep) effect_1\NN|the|of (r_nsubjpass) compared_12\VBN|effect|was|in|. (l_prep) in_13\IN|subjects (l_pobj) subjects_16\NNS|5|normal|,|subjects (l_appos) subjects_20\NNS|12|diabetic|without|,|and|subjects (l_conj) subjects_28\NNS|5|diabetic|with (l_prep) with_29\IN|neuropathy (l_pobj) neuropathy_31\NN|autonomic
D005996_D009422 NONE nitroglycerin_19\NN| (r_pobj) after_18\IN|nitroglycerin (r_prep) decrease_13\NN|the|in|after (r_conj) increase_7\NN|the|in|and|decrease (r_pobj) of_5\IN|increase (r_prep) course_4\NN|magnitude|of (r_nsubj) were_20\VBD|course|similar|,|occurred|. (l_acomp) similar_21\JJ|in (l_prep) in_22\IN|subjects (l_pobj) subjects_27\NNS|the|normal|without (l_prep) without_28\IN|neuropathy (l_pobj) neuropathy_30\NN|autonomic
D005996_D009422 NONE nitroglycerin_19\NN| (r_pobj) after_18\IN|nitroglycerin (r_prep) decrease_13\NN|the|in|after (r_conj) increase_7\NN|the|in|and|decrease (r_pobj) of_5\IN|increase (r_prep) course_4\NN|magnitude|of (r_nsubj) were_20\VBD|course|similar|,|occurred|. (l_advcl) occurred_47\VBD|whereas|increase|in (l_prep) in_48\IN|subjects (l_pobj) subjects_51\NNS|the|diabetic|with (l_prep) with_52\IN|neuropathy (l_pobj) neuropathy_54\NN|autonomic
12574103
D003907_D006973 CID dexamethasone_1\NN| (r_compound) programs_2\NNS|prenatal|dexamethasone (r_compound) hypertension_3\NN|programs|and|injury|in|.
D003907_D006973 CID dexamethasone_11\NN|prenatal (r_nsubj) programmed_12\VBD|if|dexamethasone|increase (l_dobj) increase_15\NN|a|progressive|in (l_prep) in_16\IN|pressure (l_pobj) pressure_18\NN|blood|and|injury
D003907_D006973 CID dexamethasone_5\NN|prenatal (r_dobj) received_3\VBD|that|dexamethasone|on (r_relcl) rats_1\NNS|male|received (r_nsubj) elevated_23\VBN|rats|had|pressures|at (l_dobj) pressures_25\NNS|blood
D003907_D006973 CID dexamethasone_5\NN|prenatal|in (r_nsubj) results_8\VBZ|that|dexamethasone|in (l_prep) in_9\IN|reduction (l_pobj) reduction_11\NN|a|in (l_prep) in_12\IN|number (l_pobj) number_14\NN|glomerular|,|glomerulosclerosis|administered (l_conj) glomerulosclerosis_16\NN|,|and|hypertension (l_conj) hypertension_19\NN|
D003907_D007674 CID dexamethasone_1\NN| (r_compound) programs_2\NNS|prenatal|dexamethasone (r_compound) hypertension_3\NN|programs|and|injury|in|. (l_conj) injury_6\NN|renal
D003907_D007674 CID dexamethasone_11\NN|prenatal (r_nsubj) programmed_12\VBD|if|dexamethasone|increase (l_dobj) increase_15\NN|a|progressive|in (l_prep) in_16\IN|pressure (l_pobj) pressure_18\NN|blood|and|injury (l_conj) injury_21\NN|renal|in
D003907_D007674 CID dexamethasone_4\NN| (r_dobj) administered_3\VBN|offspring|dexamethasone|on (r_csubj) had_11\VBD|administered|reduction|compared|. (l_dobj) reduction_15\NN|a|%|in (l_prep) in_16\IN|number (l_pobj) number_18\NN|glomerular
D003907_D007674 CID dexamethasone_5\NN|prenatal (r_dobj) received_3\VBD|that|dexamethasone|on (r_relcl) rats_1\NNS|male|received (r_nsubj) elevated_23\VBN|rats|had|pressures|at (r_ccomp) have_37\VB|elevated|;|group|did|not|reduction|. (l_dobj) reduction_39\NN|a|in (l_prep) in_40\IN|number (l_pobj) number_42\NN|glomerular
D003907_D007674 CID dexamethasone_5\NN|prenatal|in (r_nsubj) results_8\VBZ|that|dexamethasone|in (l_prep) in_9\IN|reduction (l_pobj) reduction_11\NN|a|in (l_prep) in_12\IN|number (l_pobj) number_14\NN|glomerular|,|glomerulosclerosis|administered
D003907_D005921 NONE dexamethasone_3\NN| (r_dobj) given_2\VBN|rats|dexamethasone|on|had|. (l_advcl) had_11\VBD|glomeruli (l_dobj) glomeruli_13\NNS|more|with|than (l_prep) with_14\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_15\NN|
D003907_D005921 NONE dexamethasone_5\NN|prenatal|in (r_nsubj) results_8\VBZ|that|dexamethasone|in (l_prep) in_9\IN|reduction (l_pobj) reduction_11\NN|a|in (l_prep) in_12\IN|number (l_pobj) number_14\NN|glomerular|,|glomerulosclerosis|administered (l_conj) glomerulosclerosis_16\NN|,|and|hypertension
17639754
D014859_D006470 CID warfarin_18\NN|and|levofloxacin (r_pobj) between_17\IN|warfarin (r_prep) interaction_16\NN|the|between (r_pobj) of_14\IN|interaction (r_prep) result_13\NN|the|of (r_attr) be_11\VB|to|result (r_xcomp) appear_9\VBP|that|be (r_relcl) complications_7\NNS|serious|bleeding|appear (l_compound) bleeding_6\NN|
D064704_D006470 CID levofloxacin_20\JJ| (r_conj) warfarin_18\NN|and|levofloxacin (r_pobj) between_17\IN|warfarin (r_prep) interaction_16\NN|the|between (r_pobj) of_14\IN|interaction (r_prep) result_13\NN|the|of (r_attr) be_11\VB|to|result (r_xcomp) appear_9\VBP|that|be (r_relcl) complications_7\NNS|serious|bleeding|appear (l_compound) bleeding_6\NN|
2549018
D005473_D017109 CID Fluoxetine_0\NNP| (r_npadvmod) induced_2\VBN|fluoxetine|- (r_amod) akathisia_3\NN|induced|:|implications|.
D005473_D017109 CID fluoxetine_3\NN| (r_dobj) receiving_2\VBG|fluoxetine|for (r_acl) patients_1\NNS|five|receiving (r_nsubj) developed_14\VBD|patients|akathisia|. (l_dobj) akathisia_15\NN|
D005473_D017109 CID fluoxetine_2\NN| (r_npadvmod) induced_4\VBN|fluoxetine|- (r_amod) symptoms_5\NNS|the|typical|induced|of (r_nsubj) were_23\VBD|symptoms|indistinguishable|. (l_acomp) indistinguishable_24\JJ|from (l_prep) from_25\IN|those (l_pobj) those_26\DT|of (l_prep) of_27\IN|akathisia (l_pobj) akathisia_31\NN|induced
D005473_D017109 CID fluoxetine_17\NN| (r_advmod) induced_19\VBN|fluoxetine|- (r_amod) akathisia_20\NN|induced (r_pobj) of_16\IN|akathisia (r_prep) symptoms_15\NNS|the|of (r_nsubj) were_21\VBD|that|symptoms|identical|,|milder (r_ccomp) reported_12\VBD|patients|were|. (l_nsubj) patients_1\NNS|three|experienced (l_relcl) experienced_4\VBN|who|had|akathisia (l_dobj) akathisia_8\NN|induced|in
D005473_D017109 CID fluoxetine_17\NN| (r_advmod) induced_19\VBN|fluoxetine|- (r_amod) akathisia_20\NN|induced
D005473_D017109 CID fluoxetine_9\NN| (r_pobj) of_8\IN|fluoxetine (r_prep) effect_7\NN|a|common|side|of (r_attr) be_3\VB|to|effect (r_xcomp) appeared_1\VBD|akathisia|be|and|responded|. (l_nsubj) Akathisia_0\NNP|
D005473_D017109 CID fluoxetine_4\NN| (r_advmod) induced_6\VBN|fluoxetine|- (r_amod) akathisia_7\NN|induced
D005473_D017109 CID fluoxetine_4\NN| (r_advmod) induced_6\VBN|fluoxetine|- (r_amod) akathisia_7\NN|induced (r_nsubjpass) caused_10\VBN|that|akathisia|may|be|by|be (l_conj) be_36\VB|that|pathophysiology|"|may|identical (l_nsubj) pathophysiology_21\NN|the|of (l_prep) of_22\IN|akathisia (l_pobj) akathisia_26\NN|induced|and|jitteriness
D005473_D017109 CID fluoxetine_23\NN| (r_advmod) induced_25\VBN|fluoxetine|- (r_amod) akathisia_26\NN|induced|and|jitteriness (r_pobj) of_22\IN|akathisia (r_prep) pathophysiology_21\NN|the|of (r_nsubj) be_36\VB|that|pathophysiology|"|may|identical (r_conj) caused_10\VBN|that|akathisia|may|be|by|be (l_nsubjpass) akathisia_7\NN|induced
D005473_D017109 CID fluoxetine_23\NN| (r_advmod) induced_25\VBN|fluoxetine|- (r_amod) akathisia_26\NN|induced|and|jitteriness
D005473_D009771 NONE fluoxetine_3\NN| (r_dobj) receiving_2\VBG|fluoxetine|for (l_prep) for_4\IN|treatment (l_pobj) treatment_6\NN|the|of (l_prep) of_7\IN|disorder (l_pobj) disorder_10\NN|obsessive|compulsive|or|depression
D005473_D003865 NONE fluoxetine_3\NN| (r_dobj) receiving_2\VBG|fluoxetine|for (l_prep) for_4\IN|treatment (l_pobj) treatment_6\NN|the|of (l_prep) of_7\IN|disorder (l_pobj) disorder_10\NN|obsessive|compulsive|or|depression (l_conj) depression_13\NN|major
D005473_D001008 NONE fluoxetine_2\NN| (r_npadvmod) induced_4\VBN|fluoxetine|- (r_amod) symptoms_5\NNS|the|typical|induced|of (l_prep) of_6\IN|restlessness (l_pobj) restlessness_7\NN|,|pacing (l_conj) pacing_10\NN|constant|,|movements (l_conj) movements_13\NNS|purposeless|of|,|and|anxiety (l_conj) anxiety_22\NN|marked
D011433_D017109 NONE propranolol_22\NN| (r_acl) antagonist_21\NN|the|adrenergic|propranolol|,|reduction (r_pobj) with_16\IN|antagonist (r_prep) treatment_15\NN|with (r_pobj) to_14\IN|treatment (r_prep) responded_12\VBD|generally|well|to (r_conj) appeared_1\VBD|akathisia|be|and|responded|. (l_nsubj) Akathisia_0\NNP|
D000928_D017109 NONE antidepressant_29\NN| (r_npadvmod) induced_31\VBN|antidepressant|- (r_amod) jitteriness_33\NN|tricyclic|induced|" (r_conj) akathisia_26\NN|induced|and|jitteriness (r_pobj) of_22\IN|akathisia (r_prep) pathophysiology_21\NN|the|of (r_nsubj) be_36\VB|that|pathophysiology|"|may|identical (r_conj) caused_10\VBN|that|akathisia|may|be|by|be (l_nsubjpass) akathisia_7\NN|induced
D000928_D017109 NONE antidepressant_29\NN| (r_npadvmod) induced_31\VBN|antidepressant|- (r_amod) jitteriness_33\NN|tricyclic|induced|" (r_conj) akathisia_26\NN|induced|and|jitteriness
6692345
D001241_D001749 NONE aspirin_5\NN|with (r_pobj) of_4\IN|aspirin (r_prep) administration_3\NN|the|-|of|to (r_nsubj) resulted_13\VBD|administration|in|. (l_prep) in_14\IN|incidence (l_pobj) incidence_17\NN|a|reduced|of|but|induction (l_prep) of_18\IN|carcinomas (l_pobj) carcinomas_23\NNS|induced|bladder
D001241_D013274 NONE aspirin_5\NN|with (r_pobj) of_4\IN|aspirin (r_prep) administration_3\NN|the|-|of|to (r_nsubj) resulted_13\VBD|administration|in|. (l_prep) in_14\IN|incidence (l_pobj) incidence_17\NN|a|reduced|of|but|induction (l_conj) induction_27\NN|a|concomitant|of (l_prep) of_28\IN|tumors (l_pobj) tumors_30\NNS|forestomach
D005200_D001749 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|fanft (r_pobj) with_6\IN|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN|with (r_pobj) of_4\IN|aspirin (r_prep) administration_3\NN|the|-|of|to (r_nsubj) resulted_13\VBD|administration|in|. (l_prep) in_14\IN|incidence (l_pobj) incidence_17\NN|a|reduced|of|but|induction (l_prep) of_18\IN|carcinomas (l_pobj) carcinomas_23\NNS|induced|bladder
D005200_D001749 CID FANFT_9\NNP|(|) (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|fanft (r_pobj) with_6\IN|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN|with (r_pobj) of_4\IN|aspirin (r_prep) administration_3\NN|the|-|of|to (r_nsubj) resulted_13\VBD|administration|in|. (l_prep) in_14\IN|incidence (l_pobj) incidence_17\NN|a|reduced|of|but|induction (l_prep) of_18\IN|carcinomas (l_pobj) carcinomas_23\NNS|induced|bladder
D005200_D001749 CID FANFT_19\NNP| (r_npadvmod) induced_21\VBN|fanft|- (r_amod) carcinomas_23\NNS|induced|bladder
D005200_D013274 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|fanft (r_pobj) with_6\IN|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN|with (r_pobj) of_4\IN|aspirin (r_prep) administration_3\NN|the|-|of|to (r_nsubj) resulted_13\VBD|administration|in|. (l_prep) in_14\IN|incidence (l_pobj) incidence_17\NN|a|reduced|of|but|induction (l_conj) induction_27\NN|a|concomitant|of (l_prep) of_28\IN|tumors (l_pobj) tumors_30\NNS|forestomach
D005200_D013274 CID FANFT_9\NNP|(|) (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|fanft (r_pobj) with_6\IN|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN|with (r_pobj) of_4\IN|aspirin (r_prep) administration_3\NN|the|-|of|to (r_nsubj) resulted_13\VBD|administration|in|. (l_prep) in_14\IN|incidence (l_pobj) incidence_17\NN|a|reduced|of|but|induction (l_conj) induction_27\NN|a|concomitant|of (l_prep) of_28\IN|tumors (l_pobj) tumors_30\NNS|forestomach
D005200_D013274 CID FANFT_19\NNP| (r_npadvmod) induced_21\VBN|fanft|- (r_amod) carcinomas_23\NNS|induced|bladder (r_pobj) of_18\IN|carcinomas (r_prep) incidence_17\NN|a|reduced|of|but|induction (l_conj) induction_27\NN|a|concomitant|of (l_prep) of_28\IN|tumors (l_pobj) tumors_30\NNS|forestomach
D005200_D063646 NONE FANFT_16\NNP| (r_compound) carcinogenesis_17\NN|fanft|in
D005200_D063646 NONE FANFT_30\NNP| (r_pobj) on_29\IN|fanft (r_prep) effect_28\NN|aspirin|on|in (r_nsubj) is_34\VBZ|that|effect|not|due (r_conj) involved_14\VBN|that|mechanisms|are|in|,|and|is (l_prep) in_15\IN|carcinogenesis (l_pobj) carcinogenesis_17\NN|fanft|in
D001241_D063646 NONE aspirin_26\NN|'s (r_poss) effect_28\NN|aspirin|on|in (r_nsubj) is_34\VBZ|that|effect|not|due (r_conj) involved_14\VBN|that|mechanisms|are|in|,|and|is (l_prep) in_15\IN|carcinogenesis (l_pobj) carcinogenesis_17\NN|fanft|in
11431197
D011899_D009395 CID Ranitidine_0\NNP| (r_npadvmod) induced_2\VBN|ranitidine|- (r_amod) nephritis_5\NN|induced|acute|interstitial|in|.
D011899_D009395 CID ranitidine_5\NN| (r_npadvmod) induced_7\VBN|ranitidine|- (r_amod) nephritis_10\NN|induced|acute|interstitial
18410508
D008694_D020258 NONE Methamphetamine_0\NN| (r_npadvmod) induced_2\VBN|methamphetamine|- (r_amod) activation_6\NN|induced|neurotoxicity (l_nmod) neurotoxicity_3\NN|and|microglial
D008694_D020258 NONE METH_6\NNP|and|mptp (r_pobj) by_5\IN|meth (r_agent) caused_4\VBN|by (r_acl) damage_3\NN|the|cns|caused (r_nsubj) is_9\VBZ|because|damage|selective|for (l_prep) for_12\IN|system (l_pobj) system_16\NN|the|da|neuronal|in (l_prep) in_17\IN|models (l_pobj) models_19\NNS|mouse|of (l_prep) of_20\IN|neurotoxicity (l_pobj) neurotoxicity_21\NN|
D008694_D020258 NONE METH_6\NNP|and|mptp (r_pobj) by_5\IN|meth (r_agent) caused_4\VBN|by (r_acl) damage_3\NN|the|cns|caused (r_nsubj) is_9\VBZ|because|damage|selective|for (r_advcl) hypothesized_24\VBD|is|,|we|plays|. (l_ccomp) plays_28\VBZ|that|cx3cr1|role (l_dobj) role_30\NN|a|in (l_prep) in_31\IN|neurotoxicity (l_pobj) neurotoxicity_35\NN|induced|and|activation
D008694_D020258 NONE METH_32\NNP| (r_npadvmod) induced_34\VBN|meth|- (r_amod) neurotoxicity_35\NN|induced|and|activation (r_pobj) in_31\IN|neurotoxicity (r_prep) role_30\NN|a|in (r_dobj) plays_28\VBZ|that|cx3cr1|role (r_ccomp) hypothesized_24\VBD|is|,|we|plays|. (l_advcl) is_9\VBZ|because|damage|selective|for (l_prep) for_12\IN|system (l_pobj) system_16\NN|the|da|neuronal|in (l_prep) in_17\IN|models (l_pobj) models_19\NNS|mouse|of (l_prep) of_20\IN|neurotoxicity (l_pobj) neurotoxicity_21\NN|
D008694_D020258 NONE METH_32\NNP| (r_npadvmod) induced_34\VBN|meth|- (r_amod) neurotoxicity_35\NN|induced|and|activation
D008694_D020258 NONE METH_25\NNP| (r_pobj) with_24\IN|meth (r_prep) treated_23\VBN|mice|were|with|and|examined|. (l_conj) examined_27\VBN|for (l_prep) for_28\IN|neurotoxicity (l_pobj) neurotoxicity_30\NN|striatal
D008694_D020258 NONE METH_11\NNP| (r_compound) neurotoxicity_12\NN|meth|or|activation
D015632_D009422 CID MPTP_17\NNP| (r_npadvmod) induced_19\VBN|mptp|- (r_amod) neurodegeneration_20\NN|induced|of
D015632_D009422 CID MPTP_8\NNP| (r_conj) METH_6\NNP|and|mptp (r_pobj) by_5\IN|meth (r_agent) caused_4\VBN|by (r_acl) damage_3\NN|the|cns|caused
D004298_D009422 NONE DA_22\NNP| (r_compound) neurons_23\NNS|da (r_pobj) of_21\IN|neurons (r_prep) neurodegeneration_20\NN|induced|of
D004298_D009422 NONE DA_14\NNP| (r_compound) system_16\NN|the|da|neuronal|in (r_pobj) for_12\IN|system (r_prep) is_9\VBZ|because|damage|selective|for (l_nsubj) damage_3\NN|the|cns|caused
D008694_D009422 CID METH_6\NNP|and|mptp (r_pobj) by_5\IN|meth (r_agent) caused_4\VBN|by (r_acl) damage_3\NN|the|cns|caused
D008694_D009422 CID METH_32\NNP| (r_npadvmod) induced_34\VBN|meth|- (r_amod) neurotoxicity_35\NN|induced|and|activation (r_pobj) in_31\IN|neurotoxicity (r_prep) role_30\NN|a|in (r_dobj) plays_28\VBZ|that|cx3cr1|role (r_ccomp) hypothesized_24\VBD|is|,|we|plays|. (l_advcl) is_9\VBZ|because|damage|selective|for (l_nsubj) damage_3\NN|the|cns|caused
D015632_D020258 NONE MPTP_8\NNP| (r_conj) METH_6\NNP|and|mptp (r_pobj) by_5\IN|meth (r_agent) caused_4\VBN|by (r_acl) damage_3\NN|the|cns|caused (r_nsubj) is_9\VBZ|because|damage|selective|for (l_prep) for_12\IN|system (l_pobj) system_16\NN|the|da|neuronal|in (l_prep) in_17\IN|models (l_pobj) models_19\NNS|mouse|of (l_prep) of_20\IN|neurotoxicity (l_pobj) neurotoxicity_21\NN|
D015632_D020258 NONE MPTP_8\NNP| (r_conj) METH_6\NNP|and|mptp (r_pobj) by_5\IN|meth (r_agent) caused_4\VBN|by (r_acl) damage_3\NN|the|cns|caused (r_nsubj) is_9\VBZ|because|damage|selective|for (r_advcl) hypothesized_24\VBD|is|,|we|plays|. (l_ccomp) plays_28\VBZ|that|cx3cr1|role (l_dobj) role_30\NN|a|in (l_prep) in_31\IN|neurotoxicity (l_pobj) neurotoxicity_35\NN|induced|and|activation
D004298_D020258 NONE DA_14\NNP| (r_compound) system_16\NN|the|da|neuronal|in (l_prep) in_17\IN|models (l_pobj) models_19\NNS|mouse|of (l_prep) of_20\IN|neurotoxicity (l_pobj) neurotoxicity_21\NN|
D004298_D020258 NONE DA_14\NNP| (r_compound) system_16\NN|the|da|neuronal|in (r_pobj) for_12\IN|system (r_prep) is_9\VBZ|because|damage|selective|for (r_advcl) hypothesized_24\VBD|is|,|we|plays|. (l_ccomp) plays_28\VBZ|that|cx3cr1|role (l_dobj) role_30\NN|a|in (l_prep) in_31\IN|neurotoxicity (l_pobj) neurotoxicity_35\NN|induced|and|activation
11379838
D000928_D001714 CID Antidepressant_0\NNP| (r_npadvmod) induced_2\VBN|antidepressant|- (r_amod) mania_3\NN|induced|in|:|identification|.
D000928_D001714 CID Antidepressant_0\NNP| (r_npadvmod) induced_2\VBN|antidepressant|- (r_amod) mania_3\NN|induced|in|:|identification|. (l_prep) in_4\IN|patients (l_pobj) patients_6\NNS|bipolar (l_amod) bipolar_5\JJ|
D000928_D001714 CID antidepressants_10\NNS| (r_pobj) with_9\IN|antidepressants (r_prep) associated_8\VBN|with (r_acl) mania_7\NN|associated
D000928_D001714 CID antidepressants_10\NNS| (r_pobj) with_9\IN|antidepressants (r_prep) associated_8\VBN|with (r_acl) mania_7\NN|associated (r_pobj) to_6\IN|mania (r_prep) switching_5\VBG|to (r_pcomp) of_4\IN|switching (r_prep) risks_3\NNS|possible|of (r_pobj) about_1\IN|risks (r_prep) Concerns_0\NNS|about (r_nsubj) continue_11\VBP|concerns|interfere|. (l_xcomp) interfere_13\VB|to|with (l_prep) with_14\IN|establishment (l_pobj) establishment_16\NN|the|of (l_prep) of_17\IN|paradigm (l_pobj) paradigm_21\NN|an|optimal|treatment|for (l_prep) for_22\IN|depression (l_pobj) depression_24\NN|bipolar
D000928_D001714 CID antidepressant_43\NN| (r_amod) therapy_44\NN|antidepressant (r_pobj) of_42\IN|therapy (r_prep) type_41\NN|of (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic
D000928_D001714 CID antidepressant_43\NN| (r_amod) therapy_44\NN|antidepressant (r_pobj) of_42\IN|therapy (r_prep) type_41\NN|of (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic (l_conj) hypomanic_6\JJ|
D000928_D001714 CID antidepressant_43\NN| (r_amod) therapy_44\NN|antidepressant (r_pobj) of_42\IN|therapy (r_prep) type_41\NN|of (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs.
D000928_D001714 CID antidepressant_43\NN| (r_amod) therapy_44\NN|antidepressant (r_pobj) of_42\IN|therapy (r_prep) type_41\NN|of (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs. (l_prep) vs._30\IN|ii (l_pobj) II_32\NNP|bipolar
D000928_D001714 CID antidepressant_43\NN| (r_amod) therapy_44\NN|antidepressant (r_pobj) of_42\IN|therapy (r_prep) type_41\NN|of (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ|
D000928_D001714 CID antidepressant_50\NN| (r_amod) drugs_51\NNS|antidepressant (r_pobj) vs._49\IN|drugs (r_prep) therapy_48\NN|electroconvulsive|vs.|and (r_dobj) used_45\VBN|therapy|, (r_acl) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic
D000928_D001714 CID antidepressant_50\NN| (r_amod) drugs_51\NNS|antidepressant (r_pobj) vs._49\IN|drugs (r_prep) therapy_48\NN|electroconvulsive|vs.|and (r_dobj) used_45\VBN|therapy|, (r_acl) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic (l_conj) hypomanic_6\JJ|
D000928_D001714 CID antidepressant_50\NN| (r_amod) drugs_51\NNS|antidepressant (r_pobj) vs._49\IN|drugs (r_prep) therapy_48\NN|electroconvulsive|vs.|and (r_dobj) used_45\VBN|therapy|, (r_acl) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs.
D000928_D001714 CID antidepressant_50\NN| (r_amod) drugs_51\NNS|antidepressant (r_pobj) vs._49\IN|drugs (r_prep) therapy_48\NN|electroconvulsive|vs.|and (r_dobj) used_45\VBN|therapy|, (r_acl) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs. (l_prep) vs._30\IN|ii (l_pobj) II_32\NNP|bipolar
D000928_D001714 CID antidepressant_50\NN| (r_amod) drugs_51\NNS|antidepressant (r_pobj) vs._49\IN|drugs (r_prep) therapy_48\NN|electroconvulsive|vs.|and (r_dobj) used_45\VBN|therapy|, (r_acl) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ|
D017367_D001714 CID inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic
D017367_D001714 CID inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic (l_conj) hypomanic_6\JJ|
D017367_D001714 CID inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs.
D017367_D001714 CID inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs. (l_prep) vs._30\IN|ii (l_pobj) II_32\NNP|bipolar
D017367_D001714 CID inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ|
D017367_D001714 CID SSRIs_62\NNPS|[|]|) (r_appos) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic
D017367_D001714 CID SSRIs_62\NNPS|[|]|) (r_appos) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic (l_conj) hypomanic_6\JJ|
D017367_D001714 CID SSRIs_62\NNPS|[|]|) (r_appos) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs.
D017367_D001714 CID SSRIs_62\NNPS|[|]|) (r_appos) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs. (l_prep) vs._30\IN|ii (l_pobj) II_32\NNP|bipolar
D017367_D001714 CID SSRIs_62\NNPS|[|]|) (r_appos) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ|
D017367_D001714 CID SSRIs_29\NNS|[|8/33|] (r_pobj) with_28\IN|ssris (r_prep) treated_27\VBN|with (r_acl) patients_26\NNS|treated (r_pobj) of_25\IN|patients (r_prep) subgroup_24\NN|the|of (r_pobj) of_22\IN|subgroup (r_prep) %_21\NN|24|of (r_pobj) in_19\IN|%|) (r_prep) experienced_42\JJ|(|(|and|in|;|%|episodes|, (r_parataxis) patients_11\NNS|all|experienced (r_pobj) of_9\IN|patients (r_prep) %_8\NN|27|of|and|% (r_pobj) in_6\IN|% (r_prep) occurred_5\VBD|switches|in|episodes|. (l_nsubj) Switches_0\NNS|to (l_prep) to_1\IN|hypomania (l_pobj) hypomania_2\NN|or|mania
D017367_D001714 CID SSRIs_29\NNS|[|8/33|] (r_pobj) with_28\IN|ssris (r_prep) treated_27\VBN|with (r_acl) patients_26\NNS|treated (r_pobj) of_25\IN|patients (r_prep) subgroup_24\NN|the|of (r_pobj) of_22\IN|subgroup (r_prep) %_21\NN|24|of (r_pobj) in_19\IN|%|) (r_prep) experienced_42\JJ|(|(|and|in|;|%|episodes|, (r_parataxis) patients_11\NNS|all|experienced (r_pobj) of_9\IN|patients (r_prep) %_8\NN|27|of|and|% (r_pobj) in_6\IN|% (r_prep) occurred_5\VBD|switches|in|episodes|. (l_nsubj) Switches_0\NNS|to (l_prep) to_1\IN|hypomania (l_pobj) hypomania_2\NN|or|mania (l_conj) mania_4\NN|
D017367_D001714 CID SSRIs_29\NNS|[|8/33|] (r_pobj) with_28\IN|ssris (r_prep) treated_27\VBN|with (r_acl) patients_26\NNS|treated (r_pobj) of_25\IN|patients (r_prep) subgroup_24\NN|the|of (r_pobj) of_22\IN|subgroup (r_prep) %_21\NN|24|of (r_pobj) in_19\IN|%|) (r_prep) experienced_42\JJ|(|(|and|in|;|%|episodes|, (l_dobj) episodes_44\NNS|manic (l_amod) manic_43\JJ|
D017367_D001714 CID SSRIs_29\NNS|[|8/33|] (r_pobj) with_28\IN|ssris (r_prep) treated_27\VBN|with (r_acl) patients_26\NNS|treated (r_pobj) of_25\IN|patients (r_prep) subgroup_24\NN|the|of (r_pobj) of_22\IN|subgroup (r_prep) %_21\NN|24|of (r_pobj) in_19\IN|%|) (r_prep) experienced_42\JJ|(|(|and|in|;|%|episodes|, (r_parataxis) patients_11\NNS|all|experienced (r_pobj) of_9\IN|patients (r_prep) %_8\NN|27|of|and|% (r_pobj) in_6\IN|% (r_prep) occurred_5\VBD|switches|in|episodes|. (l_npadvmod) episodes_56\NNS|experienced|hypomanic (l_amod) hypomanic_55\JJ|
D008094_D001714 NONE lithium_73\NN|vs. (r_appos) stabilizers_71\NNS|mood|(|lithium|) (r_pobj) of_69\IN|stabilizers (r_prep) type_68\NN|of (r_conj) use_66\NN|and|type|,|and|temperament (r_conj) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic
D008094_D001714 NONE lithium_73\NN|vs. (r_appos) stabilizers_71\NNS|mood|(|lithium|) (r_pobj) of_69\IN|stabilizers (r_prep) type_68\NN|of (r_conj) use_66\NN|and|type|,|and|temperament (r_conj) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (r_pobj) with_10\IN|those (r_prep) compared_9\VBN|patients|were|with|. (l_nsubjpass) Patients_0\NNS|experienced (l_relcl) experienced_2\VBD|who|switch (l_dobj) switch_7\NN|a|manic (l_amod) manic_4\JJ|or|hypomanic (l_conj) hypomanic_6\JJ|
D008094_D001714 NONE lithium_73\NN|vs. (r_appos) stabilizers_71\NNS|mood|(|lithium|) (r_pobj) of_69\IN|stabilizers (r_prep) type_68\NN|of (r_conj) use_66\NN|and|type|,|and|temperament (r_conj) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs.
D008094_D001714 NONE lithium_73\NN|vs. (r_appos) stabilizers_71\NNS|mood|(|lithium|) (r_pobj) of_69\IN|stabilizers (r_prep) type_68\NN|of (r_conj) use_66\NN|and|type|,|and|temperament (r_conj) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN|episodes (r_prep) number_35\NN|of (r_appos) those_11\DT|did|,|number (l_relcl) did_13\VBD|who|not|on (l_prep) on_15\IN|variables (l_pobj) variables_17\NNS|several|including (l_prep) including_18\VBG|age (l_pobj) age_19\NN|,|sex (l_conj) sex_21\NN|,|diagnosis (l_conj) diagnosis_23\NN|iv (l_appos) IV_27\NNP|(|dsm|-|bipolar|i|) (l_appos) I_29\PRP|vs. (l_prep) vs._30\IN|ii (l_pobj) II_32\NNP|bipolar
D008094_D001714 NONE lithium_73\NN|vs. (r_appos) stabilizers_71\NNS|mood|(|lithium|) (r_pobj) of_69\IN|stabilizers (r_prep) type_68\NN|of (r_conj) use_66\NN|and|type|,|and|temperament (r_conj) inhibitors_60\NNS|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ|
6534871
D007545_D009203 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|isoproterenol|- (r_amod) infarction_12\NN|induced|myocardial
19957053
D010656_D002534 CID Phenylephrine_0\NNP|but|ephedrine (r_nsubj) reduces_4\VBZ|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN|frontal|lobe|following
D010656_D007022 NONE Phenylephrine_0\NNP|but|ephedrine (r_nsubj) reduces_4\VBZ|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN|frontal|lobe|following (l_prep) following_8\VBG|hypotension (l_dobj) hypotension_12\NN|induced
D010656_D007022 NONE phenylephrine_5\NN|and|ephedrine (r_pobj) of_4\IN|phenylephrine (r_prep) effect_3\NN|the|of|on (r_dobj) describe_1\VBP|we|effect|following|. (l_prep) following_16\VBG|hypotension (l_dobj) hypotension_20\NN|induced
D010656_D007022 NONE phenylephrine_3\NN| (r_pobj) of_2\IN|phenylephrine (r_prep) utilization_1\NN|the|of|correct (l_acl) correct_5\VB|to|hypotension (l_dobj) hypotension_6\NN|induced
D004809_D002534 NONE ephedrine_3\JJ|not (r_conj) Phenylephrine_0\NNP|but|ephedrine (r_nsubj) reduces_4\VBZ|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN|frontal|lobe|following
D004809_D007022 NONE ephedrine_3\JJ|not (r_conj) Phenylephrine_0\NNP|but|ephedrine (r_nsubj) reduces_4\VBZ|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN|frontal|lobe|following (l_prep) following_8\VBG|hypotension (l_dobj) hypotension_12\NN|induced
D004809_D007022 NONE ephedrine_7\JJ| (r_conj) phenylephrine_5\NN|and|ephedrine (r_pobj) of_4\IN|phenylephrine (r_prep) effect_3\NN|the|of|on (r_dobj) describe_1\VBP|we|effect|following|. (l_prep) following_16\VBG|hypotension (l_dobj) hypotension_20\NN|induced
D004809_D007022 NONE ephedrine_18\JJ| (r_nsubj) maintains_19\VBZ|while|ephedrine|oxygenation (r_advcl) has_10\VBZ|utilization|impact|)|maintains|. (l_nsubj) utilization_1\NN|the|of|correct (l_acl) correct_5\VB|to|hypotension (l_dobj) hypotension_6\NN|induced
18631865
D020123_D051436 NONE rapamycin_16\NNS| (r_nmod) inhibitors_20\NNS|rapamycin|mtor|,|sirolimus|, (r_pobj) of_15\IN|inhibitors (r_prep) target_14\NN|mammalian|of (r_pobj) to_12\IN|target (r_prep) conversion_8\NN|from|to|in (l_prep) in_25\IN|recipients (l_pobj) recipients_28\NNS|renal|transplant|with (l_prep) with_29\IN|nephropathy (l_pobj) nephropathy_32\NN|chronic|allograft
D020123_D051436 NONE sirolimus_23\NN|especially (r_appos) inhibitors_20\NNS|rapamycin|mtor|,|sirolimus|, (r_pobj) of_15\IN|inhibitors (r_prep) target_14\NN|mammalian|of (r_pobj) to_12\IN|target (r_prep) conversion_8\NN|from|to|in (l_prep) in_25\IN|recipients (l_pobj) recipients_28\NNS|renal|transplant|with (l_prep) with_29\IN|nephropathy (l_pobj) nephropathy_32\NN|chronic|allograft
D020123_D011507 CID sirolimus_5\NN|or|consequence (r_pobj) to_4\IN|sirolimus (r_prep) due_3\JJ|to (r_acomp) was_2\VBD|whether|proteinuria|due (l_nsubj) proteinuria_1\NN|
D020123_D011507 CID sirolimus_5\NN|or|consequence (r_pobj) to_4\IN|sirolimus (r_prep) due_3\JJ|to (r_acomp) was_2\VBD|whether|proteinuria|due (r_csubj) remained_14\VBD|was|unsolved|observed|. (l_advcl) observed_22\VBN|until|proteinuria|has|been|during|in (l_nsubjpass) proteinuria_19\NN|range
D020123_D011507 CID sirolimus_24\NN| (r_compound) therapy_25\NN|sirolimus (r_pobj) during_23\IN|therapy (r_prep) observed_22\VBN|until|proteinuria|has|been|during|in (r_advcl) remained_14\VBD|was|unsolved|observed|. (l_csubj) was_2\VBD|whether|proteinuria|due (l_nsubj) proteinuria_1\NN|
D020123_D011507 CID sirolimus_24\NN| (r_compound) therapy_25\NN|sirolimus (r_pobj) during_23\IN|therapy (r_prep) observed_22\VBN|until|proteinuria|has|been|during|in (l_nsubjpass) proteinuria_19\NN|range
D020123_D011507 CID sirolimus_34\NN| (r_nmod) novo_36\NNP|sirolimus|de (r_dobj) received_33\VBD|who|novo (r_relcl) patients_31\NNS|received (r_pobj) in_30\IN|patients (r_conj) in_26\IN|transplantation|and|in (r_prep) observed_22\VBN|until|proteinuria|has|been|during|in (r_advcl) remained_14\VBD|was|unsolved|observed|. (l_csubj) was_2\VBD|whether|proteinuria|due (l_nsubj) proteinuria_1\NN|
D020123_D011507 CID sirolimus_34\NN| (r_nmod) novo_36\NNP|sirolimus|de (r_dobj) received_33\VBD|who|novo (r_relcl) patients_31\NNS|received (r_pobj) in_30\IN|patients (r_conj) in_26\IN|transplantation|and|in (r_prep) observed_22\VBN|until|proteinuria|has|been|during|in (l_nsubjpass) proteinuria_19\NN|range
7088431
D004054_D018262 CID DES_6\NNP| (r_npadvmod) exposed_8\VBN|des|- (r_amod) offspring_9\NN|exposed|under (r_pobj) in_5\IN|offspring (r_prep) Development_0\NN|of|in|. (l_prep) of_1\IN|adenocarcinoma (l_pobj) adenocarcinoma_4\NN|clear|cell
D004054_D018262 CID diethylstilbestrol_21\NN| (r_pobj) to_20\IN|diethylstilbestrol (r_prep) exposed_17\VBN|in|to (r_acl) women_16\NNS|young|exposed (r_pobj) in_14\IN|women (r_prep) up_13\NN|follow|-|in (r_pobj) at_10\IN|up (r_prep) detected_9\VBD|cases|at (l_nsubj) cases_1\NNS|two|of (l_prep) of_2\IN|adenocarcinoma (l_pobj) adenocarcinoma_5\NN|clear|cell|of (l_prep) of_6\IN|vagina (l_pobj) vagina_8\NN|the
D004054_D014625 CID diethylstilbestrol_21\NN| (r_pobj) to_20\IN|diethylstilbestrol (r_prep) exposed_17\VBN|in|to (r_acl) women_16\NNS|young|exposed (r_pobj) in_14\IN|women (r_prep) up_13\NN|follow|-|in (r_pobj) at_10\IN|up (r_prep) detected_9\VBD|cases|at (l_nsubj) cases_1\NNS|two|of (l_prep) of_2\IN|adenocarcinoma (l_pobj) adenocarcinoma_5\NN|clear|cell|of (l_prep) of_6\IN|vagina (l_pobj) vagina_8\NN|the
16160878
D014579_D006973 NONE II_8\NNP|u|- (r_pobj) of_5\IN|ii (r_prep) injection_4\NN|of (r_nsubj) causes_9\NNS|intracerebroventricular|injection|hypertension|and|stimulates|. (l_dobj) hypertension_10\NN|and|bradycardia
D014579_D001919 NONE II_8\NNP|u|- (r_pobj) of_5\IN|ii (r_prep) injection_4\NN|of (r_nsubj) causes_9\NNS|intracerebroventricular|injection|hypertension|and|stimulates|. (l_dobj) hypertension_10\NN|and|bradycardia (l_conj) bradycardia_12\NN|
D014579_D010409 NONE II_11\NNP|u|- (r_pobj) of_8\IN|ii (r_prep) administration_7\NN|the|central|of (r_nsubj) had_12\VBD|was|,|administration|effect|erection|,|and|level|. (l_dobj) erection_25\NN|induced|penile|and|behavior
D001058_D010409 CID apomorphine_21\NN| (r_npadvmod) induced_23\VBN|apomorphine|- (r_amod) erection_25\NN|induced|penile|and|behavior
D003345_D010409 NONE corticosterone_35\NN|plasma (r_compound) level_36\NN|induced|corticosterone (r_conj) had_12\VBD|was|,|administration|effect|erection|,|and|level|. (l_dobj) erection_25\NN|induced|penile|and|behavior
D014579_D001523 NONE II_6\NNP|u|- (r_nsubjpass) involved_9\VBN|that|ii|may|be|in (l_prep) in_10\IN|aspects (l_pobj) aspects_12\NNS|some|of (l_prep) of_13\IN|disorders (l_pobj) disorders_15\NNS|psychiatric
16298782
D019331_D006311 NONE ester_6\NN|arginine|methyl|:|protector|. (l_appos) protector_10\NN|a|potential|against (l_prep) against_11\IN|ototoxicity (l_pobj) ototoxicity_13\NN|gentamicin
D005839_D006311 NONE gentamicin_12\NN| (r_compound) ototoxicity_13\NN|gentamicin
D009569_D006316 NONE oxide_2\NN|the|nitric|(|ester (r_nsubj) act_20\VB|oxide|may|as|,|but|needed (l_prep) as_21\IN|otoprotectant (l_pobj) otoprotectant_23\NN|an|against (l_prep) against_24\IN|loss (l_pobj) loss_29\NN|frequency|hearing|caused
D009569_D006316 NONE NO_4\NNP| (r_intj) ester_13\NN|no|inhibitor|arginine|methyl|(|name|) (r_appos) oxide_2\NN|the|nitric|(|ester (r_nsubj) act_20\VB|oxide|may|as|,|but|needed (l_prep) as_21\IN|otoprotectant (l_pobj) otoprotectant_23\NN|an|against (l_prep) against_24\IN|loss (l_pobj) loss_29\NN|frequency|hearing|caused
D019331_D006316 NONE ester_13\NN|no|inhibitor|arginine|methyl|(|name|) (r_appos) oxide_2\NN|the|nitric|(|ester (r_nsubj) act_20\VB|oxide|may|as|,|but|needed (l_prep) as_21\IN|otoprotectant (l_pobj) otoprotectant_23\NN|an|against (l_prep) against_24\IN|loss (l_pobj) loss_29\NN|frequency|hearing|caused
D019331_D006316 NONE NAME_17\NN|l|- (r_appos) ester_13\NN|no|inhibitor|arginine|methyl|(|name|) (r_appos) oxide_2\NN|the|nitric|(|ester (r_nsubj) act_20\VB|oxide|may|as|,|but|needed (l_prep) as_21\IN|otoprotectant (l_pobj) otoprotectant_23\NN|an|against (l_prep) against_24\IN|loss (l_pobj) loss_29\NN|frequency|hearing|caused
D005839_D006316 NONE gentamicin_32\NN| (r_pobj) by_31\IN|gentamicin (r_agent) caused_30\VBN|by (r_acl) loss_29\NN|frequency|hearing|caused
D009569_D006311 NONE NO_17\DT| (r_pobj) of_16\IN|no (r_prep) production_15\NN|the|of (r_dobj) involves_13\VBZ|as|mechanism|production (r_conj) is_2\VBZ|ototoxicity|problem|and|,|involves (l_nsubj) ototoxicity_1\NN|their
D009569_D006311 NONE NO_17\DT| (r_pobj) of_16\IN|no (r_prep) production_15\NN|the|of (r_dobj) involves_13\VBZ|as|mechanism|production (l_nsubj) mechanism_12\NN|their|ototoxic (l_compound) ototoxic_11\JJ|
D009569_D006311 NONE NO_26\DT| (r_det) inhibitors_27\NNS|no (r_pobj) of_25\IN|inhibitors (r_prep) use_24\NN|the|of|for (r_dobj) assess_22\VB|to|use (r_xcomp) need_20\VBP|is|,|we|assess|. (l_ccomp) is_2\VBZ|ototoxicity|problem|and|,|involves (l_nsubj) ototoxicity_1\NN|their
D009569_D006311 NONE NO_26\DT| (r_det) inhibitors_27\NNS|no (r_pobj) of_25\IN|inhibitors (r_prep) use_24\NN|the|of|for (r_dobj) assess_22\VB|to|use (r_xcomp) need_20\VBP|is|,|we|assess|. (l_ccomp) is_2\VBZ|ototoxicity|problem|and|,|involves (l_conj) involves_13\VBZ|as|mechanism|production (l_nsubj) mechanism_12\NN|their|ototoxic (l_compound) ototoxic_11\JJ|
D009569_D006319 NONE NO_17\DT| (r_pobj) of_16\IN|no (r_prep) production_15\NN|the|of (r_dobj) involves_13\VBZ|as|mechanism|production (r_conj) is_2\VBZ|ototoxicity|problem|and|,|involves (r_ccomp) need_20\VBP|is|,|we|assess|. (l_xcomp) assess_22\VB|to|use (l_dobj) use_24\NN|the|of|for (l_prep) for_28\IN|prevention (l_pobj) prevention_30\NN|the|of (l_prep) of_31\IN|loss (l_pobj) loss_37\NN|induced|hearing
D009569_D006319 NONE NO_26\DT| (r_det) inhibitors_27\NNS|no (r_pobj) of_25\IN|inhibitors (r_prep) use_24\NN|the|of|for (l_prep) for_28\IN|prevention (l_pobj) prevention_30\NN|the|of (l_prep) of_31\IN|loss (l_pobj) loss_37\NN|induced|hearing
D000617_D006311 NONE aminoglycoside_32\NN| (r_npadvmod) induced_34\VBN|aminoglycoside|- (r_amod) loss_37\NN|induced|hearing (r_pobj) of_31\IN|loss (r_prep) prevention_30\NN|the|of (r_pobj) for_28\IN|prevention (r_prep) use_24\NN|the|of|for (r_dobj) assess_22\VB|to|use (r_xcomp) need_20\VBP|is|,|we|assess|. (l_ccomp) is_2\VBZ|ototoxicity|problem|and|,|involves (l_nsubj) ototoxicity_1\NN|their
D000617_D006311 NONE aminoglycoside_32\NN| (r_npadvmod) induced_34\VBN|aminoglycoside|- (r_amod) loss_37\NN|induced|hearing (r_pobj) of_31\IN|loss (r_prep) prevention_30\NN|the|of (r_pobj) for_28\IN|prevention (r_prep) use_24\NN|the|of|for (r_dobj) assess_22\VB|to|use (r_xcomp) need_20\VBP|is|,|we|assess|. (l_ccomp) is_2\VBZ|ototoxicity|problem|and|,|involves (l_conj) involves_13\VBZ|as|mechanism|production (l_nsubj) mechanism_12\NN|their|ototoxic (l_compound) ototoxic_11\JJ|
D000617_D006319 NONE aminoglycoside_32\NN| (r_npadvmod) induced_34\VBN|aminoglycoside|- (r_amod) loss_37\NN|induced|hearing
D019331_D034381 NONE NAME_2\NN|l|- (r_nsubj) reduced_3\VBN|name|loss|in|,|but|gave|. (l_dobj) loss_8\NN|induced|hearing
D005839_D034381 CID gentamicin_4\NN| (r_npadvmod) induced_6\VBN|gentamicin|- (r_amod) loss_8\NN|induced|hearing
16680561
D003891_D009325 CID desipramine_8\NN| (r_pobj) with_7\IN|desipramine (r_prep) treatment_6\NN|with (r_dobj) following_5\VBG|treatment (r_acl) events_4\NNS|adverse|following|alone (r_dobj) reported_2\VBD|subjects|events (r_ccomp) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|)
D003891_D009325 CID desipramine_13\NN| (r_dobj) receiving_12\VBG|when|desipramine|with|% (r_pcomp) than_10\IN|receiving (r_prep) alone_9\RB|than (r_amod) events_4\NNS|adverse|following|alone (r_dobj) reported_2\VBD|subjects|events (r_ccomp) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|)
D003891_D009325 CID desipramine_41\NN|either|or|cinacalcet (r_pobj) with_39\IN|desipramine (r_prep) treated_38\VBN|with (r_acl) patients_37\NNS|treated (r_pobj) for_36\IN|patients (r_prep) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|)
D003891_D006261 CID desipramine_8\NN| (r_pobj) with_7\IN|desipramine (r_prep) treatment_6\NN|with (r_dobj) following_5\VBG|treatment (r_acl) events_4\NNS|adverse|following|alone (r_dobj) reported_2\VBD|subjects|events (r_ccomp) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|) (l_conj) headache_31\NN|
D003891_D006261 CID desipramine_13\NN| (r_dobj) receiving_12\VBG|when|desipramine|with|% (r_pcomp) than_10\IN|receiving (r_prep) alone_9\RB|than (r_amod) events_4\NNS|adverse|following|alone (r_dobj) reported_2\VBD|subjects|events (r_ccomp) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|) (l_conj) headache_31\NN|
D003891_D006261 CID desipramine_41\NN|either|or|cinacalcet (r_pobj) with_39\IN|desipramine (r_prep) treated_38\VBN|with (r_acl) patients_37\NNS|treated (r_pobj) for_36\IN|patients (r_prep) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|) (l_conj) headache_31\NN|
C476217_D009325 CID cinacalcet_15\NN| (r_pobj) with_14\IN|cinacalcet (r_prep) receiving_12\VBG|when|desipramine|with|% (r_pcomp) than_10\IN|receiving (r_prep) alone_9\RB|than (r_amod) events_4\NNS|adverse|following|alone (r_dobj) reported_2\VBD|subjects|events (r_ccomp) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|)
C476217_D009325 CID cinacalcet_43\NN| (r_conj) desipramine_41\NN|either|or|cinacalcet (r_pobj) with_39\IN|desipramine (r_prep) treated_38\VBN|with (r_acl) patients_37\NNS|treated (r_pobj) for_36\IN|patients (r_prep) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|)
C476217_D006261 CID cinacalcet_15\NN| (r_pobj) with_14\IN|cinacalcet (r_prep) receiving_12\VBG|when|desipramine|with|% (r_pcomp) than_10\IN|receiving (r_prep) alone_9\RB|than (r_amod) events_4\NNS|adverse|following|alone (r_dobj) reported_2\VBD|subjects|events (r_ccomp) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|) (l_conj) headache_31\NN|
C476217_D006261 CID cinacalcet_43\NN| (r_conj) desipramine_41\NN|either|or|cinacalcet (r_pobj) with_39\IN|desipramine (r_prep) treated_38\VBN|with (r_acl) patients_37\NNS|treated (r_pobj) for_36\IN|patients (r_prep) reported_35\VBN|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN|(|and|headache|) (l_conj) headache_31\NN|
435349
D013390_D005207 CID Suxamethonium_0\JJ| (r_compound) rate_2\NN|suxamethonium|infusion|and|observed|. (l_conj) observed_4\JJ|fasciculations (l_dobj) fasciculations_5\NNS|
D013390_D013746 NONE Sch_20\NNP| (r_nsubjpass) exceeded_24\VBN|when|sch|mg|was (r_advcl) was_7\VBD|either|when|there|response|exceeded (l_attr) response_10\NN|no|muscular|to (l_prep) to_11\IN|stimulation (l_pobj) stimulation_13\NN|tetanic|of|or (l_compound) tetanic_12\JJ|
16181582
D014635_D001927 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|- (r_amod) encephalopathy_3\NN|induced|.
D014635_D001927 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|- (r_amod) encephalopathy_3\NN|induced
D014635_D001927 CID valproate_3\NN| (r_npadvmod) induced_5\VBN|valproate|- (r_amod) encephalopathy_6\NN|induced
D014635_D004827 NONE Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|- (r_amod) encephalopathy_3\NN|induced (r_nsubj) is_4\VBZ|encephalopathy|syndrome|. (l_attr) syndrome_7\NN|a|rare|manifest (l_relcl) manifest_10\VB|that|may|in (l_prep) in_11\RP|individuals (l_pobj) individuals_15\NNS|normal|epileptic (l_amod) epileptic_14\JJ|
1728522
D019980_D006099 CID acid_9\NN|amoxicillin (r_pobj) of_5\IN|acid (r_prep) combination_4\NN|of (r_pobj) due_2\JJ|to|combination (r_prep) hepatitis_1\NN|granulomatous|due|.
D019980_D006099 CID acid_11\NN| (r_npadvmod) induced_13\VBN|acid|- (r_amod) hepatitis_14\NN|clavulanic|induced (r_pobj) with_7\IN|hepatitis (r_prep) patient_6\NN|a|with (r_pobj) of_4\IN|patient (r_prep) case_3\NN|the|of|with (l_prep) with_15\IN|granulomas (l_pobj) granulomas_18\NNS|histologic|multiple
D019980_D056486 CID acid_9\NN|amoxicillin (r_pobj) of_5\IN|acid (r_prep) combination_4\NN|of (r_pobj) due_2\JJ|to|combination (r_prep) hepatitis_1\NN|granulomatous|due|.
D019980_D056486 CID acid_11\NN| (r_npadvmod) induced_13\VBN|acid|- (r_amod) hepatitis_14\NN|clavulanic|induced
16574712
D018817_D003072 CID MDMA_0\NN| (r_compound) users_2\NNS|mdma|polydrug (r_nsubj) show_3\VBP|users|impairments|. (l_dobj) impairments_9\NNS|specific|central|executive|coupled (l_acl) coupled_10\VBN|with (l_prep) with_11\IN|processes (l_pobj) processes_17\NNS|impaired|social|judgement
D018817_D008569 NONE MDMA_12\NNP|(|3,4-methylenedioxymethamphetamine|ecstasy (r_pobj) of_11\IN|mdma (r_prep) users_10\NNS|of (r_pobj) in_9\IN|users (r_prep) reported_8\VBN|in|deficits|have|been|in|. (l_nsubjpass) deficits_5\NNS|working|memory
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14\CD| (r_intj) MDMA_12\NNP|(|3,4-methylenedioxymethamphetamine|ecstasy (r_pobj) of_11\IN|mdma (r_prep) users_10\NNS|of (r_pobj) in_9\IN|users (r_prep) reported_8\VBN|in|deficits|have|been|in|. (l_nsubjpass) deficits_5\NNS|working|memory
D018817_D008569 NONE ecstasy_16\NN|,|) (r_appos) MDMA_12\NNP|(|3,4-methylenedioxymethamphetamine|ecstasy (r_pobj) of_11\IN|mdma (r_prep) users_10\NNS|of (r_pobj) in_9\IN|users (r_prep) reported_8\VBN|in|deficits|have|been|in|. (l_nsubjpass) deficits_5\NNS|working|memory
20196116
D000995_D017114 CID Antituberculosis_0\NNP| (r_nsubj) induced_3\VBN|antituberculosis|therapy|-|failure|profile|. (l_dobj) failure_6\NN|acute|liver|:
D000995_D017114 CID Antituberculosis_0\NN| (r_compound) therapy_1\NN|antituberculosis|(|failure (l_appos) failure_6\NN|att)-associated|acute|liver|(|alf|)
D000995_D017114 CID Antituberculosis_0\NN| (r_compound) therapy_1\NN|antituberculosis|(|failure (l_appos) failure_6\NN|att)-associated|acute|liver|(|alf|) (l_appos) ALF_10\NNP|att|-
D000995_D017114 CID Antituberculosis_0\NN| (r_compound) therapy_1\NN|antituberculosis|(|failure (r_nsubj) is_12\VBZ|therapy|alf|. (l_attr) ALF_18\NNP|the|commonest|induced|in
D001663_D001927 NONE bilirubin_11\NN|serum|(|dl|)|,|time (l_appos) time_21\NN|prothrombin|prolongation|,|and|encephalopathy (l_conj) encephalopathy_37\NN|grade|iv|at
18208574
D006493_D013927 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|heparin|- (r_amod) thrombocytopenia_15\NN|induced (r_pobj) with_11\IN|thrombocytopenia (r_prep) patients_10\NNS|with (r_pobj) in_9\IN|patients (r_prep) thrombosis_8\NN|in
D006493_D013927 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|heparin|- (r_amod) thrombocytopenia_15\NN|a|step|induced|assay (l_appos) assay_20\NN|(|hit|)|antigen|with (l_prep) with_21\IN|thrombosis (l_pobj) thrombosis_22\NN|
D006493_D013927 CID heparin_33\JJ| (r_compound) concentration_34\NN|a|high|heparin (r_pobj) of_30\IN|concentration (r_prep) characteristics_29\NNS|inhibition|of (r_dobj) utilizes_26\VBZ|correlate|;|assay|characteristics|. (l_advcl) correlate_1\VB|to|density (l_dobj) density_3\NN|optical|and|inhibition|of (l_prep) of_7\IN|thrombocytopenia (l_pobj) thrombocytopenia_15\NN|a|step|induced|assay (l_appos) assay_20\NN|(|hit|)|antigen|with (l_prep) with_21\IN|thrombosis (l_pobj) thrombosis_22\NN|
D006493_D013921 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|heparin|- (r_amod) thrombocytopenia_15\NN|induced
D006493_D013921 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|heparin|- (r_amod) thrombocytopenia_15\NN|a|step|induced|assay
D006493_D013921 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|heparin|- (r_amod) thrombocytopenia_15\NN|a|step|induced|assay (l_appos) assay_20\NN|(|hit|)|antigen|with (l_nmod) HIT_17\NN|
D006493_D013921 CID heparin_33\JJ| (r_compound) concentration_34\NN|a|high|heparin (r_pobj) of_30\IN|concentration (r_prep) characteristics_29\NNS|inhibition|of (r_dobj) utilizes_26\VBZ|correlate|;|assay|characteristics|. (l_advcl) correlate_1\VB|to|density (l_dobj) density_3\NN|optical|and|inhibition|of (l_prep) of_7\IN|thrombocytopenia (l_pobj) thrombocytopenia_15\NN|a|step|induced|assay
D006493_D013921 CID heparin_33\JJ| (r_compound) concentration_34\NN|a|high|heparin (r_pobj) of_30\IN|concentration (r_prep) characteristics_29\NNS|inhibition|of (r_dobj) utilizes_26\VBZ|correlate|;|assay|characteristics|. (l_advcl) correlate_1\VB|to|density (l_dobj) density_3\NN|optical|and|inhibition|of (l_prep) of_7\IN|thrombocytopenia (l_pobj) thrombocytopenia_15\NN|a|step|induced|assay (l_appos) assay_20\NN|(|hit|)|antigen|with (l_nmod) HIT_17\NN|
D006493_D013921 CID heparin_21\NN|,|had|] (r_pobj) to_20\IN|heparin (r_prep) exposure_19\NN|to (r_pobj) after_18\IN|exposure (r_prep) Patients_0\NNS|with|after (l_prep) with_1\IN|decrease (l_pobj) decrease_6\NN|%|in|or|thrombocytopenia|) (l_conj) thrombocytopenia_11\NNP|10(9)/l
D006493_D013921 CID heparin_48\NN| (r_pobj) of_47\IN|heparin (r_prep) concentration_46\NN|high|of (r_pobj) with_44\IN|concentration (r_prep) inhibition_43\NN|50|with (r_dobj) had_24\VBD|who|assay|inhibition (r_relcl) heparin_21\NN|,|had|] (r_pobj) to_20\IN|heparin (r_prep) exposure_19\NN|to (r_pobj) after_18\IN|exposure (r_prep) Patients_0\NNS|with|after (l_prep) with_1\IN|decrease (l_pobj) decrease_6\NN|%|in|or|thrombocytopenia|) (l_conj) thrombocytopenia_11\NNP|10(9)/l
16787750
D014635_D001927 CID acid_1\NN|valproic (r_nsubj) induced_2\VBD|acid|encephalopathy--19|cases|from|to|. (l_advmod) encephalopathy--19_3\NNP|
D014635_D001927 CID VPA_18\NNP| (r_compound) therapy_20\NN|vpa|- (r_pobj) to_17\IN|therapy (r_prep) associated_16\VBN|to|in (r_acl) effect_15\NN|2003|-a|side|associated (r_pobj) to_10\IN|effect (r_prep) induced_2\VBD|acid|encephalopathy--19|cases|from|to|. (l_advmod) encephalopathy--19_3\NNP|
D014635_D001927 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|vpa|- (r_amod) hepatotoxicity_20\NN|,|induced|and|encephalopathy (l_conj) encephalopathy_25\NN|induced
D014635_D001927 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|vpa|- (r_compound) encephalopathy_25\NN|induced
D014635_D001927 CID VPA_4\NNP| (r_npadvmod) induced_6\VBN|vpa|- (r_amod) encephalopathy_7\NN|induced
D014635_D001927 CID VPA_9\NNP| (r_pobj) of_8\IN|vpa (r_prep) effect_7\NN|causative|of|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|encephalopathy (l_pobj) encephalopathy_13\JJ|
D014635_D001927 CID VPA_5\NNP| (r_npadvmod) associated_7\VBN|vpa|- (r_amod) encephalopathy_8\NN|associated|in
D014635_D010195 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|vpa|- (r_amod) hepatotoxicity_20\NN|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN|patients (l_pobj) patients_7\NNS|some|,|including (l_prep) including_9\VBG|pancreatitis (l_pobj) pancreatitis_11\NN|haemorrhagic|,|suppression
D014635_D010195 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|vpa|- (r_compound) encephalopathy_25\NN|induced (r_conj) hepatotoxicity_20\NN|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN|patients (l_pobj) patients_7\NNS|some|,|including (l_prep) including_9\VBG|pancreatitis (l_pobj) pancreatitis_11\NN|haemorrhagic|,|suppression
D014635_D001855 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|vpa|- (r_amod) hepatotoxicity_20\NN|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN|patients (l_pobj) patients_7\NNS|some|,|including (l_prep) including_9\VBG|pancreatitis (l_pobj) pancreatitis_11\NN|haemorrhagic|,|suppression (l_conj) suppression_15\NN|bone|marrow
D014635_D001855 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|vpa|- (r_compound) encephalopathy_25\NN|induced (r_conj) hepatotoxicity_20\NN|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN|patients (l_pobj) patients_7\NNS|some|,|including (l_prep) including_9\VBG|pancreatitis (l_pobj) pancreatitis_11\NN|haemorrhagic|,|suppression (l_conj) suppression_15\NN|bone|marrow
D014635_D056486 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|vpa|- (r_amod) hepatotoxicity_20\NN|,|induced|and|encephalopathy
D014635_D056486 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|vpa|- (r_compound) encephalopathy_25\NN|induced (r_conj) hepatotoxicity_20\NN|,|induced|and|encephalopathy
D014635_D003244 CID VPA_4\NNP| (r_npadvmod) induced_6\VBN|vpa|- (r_amod) encephalopathy_7\NN|induced (r_pobj) of_3\IN|encephalopathy (r_prep) signs_2\NNS|the|typical|of (r_nsubj) are_8\VBP|signs|consciousness|,|marked|. (l_attr) consciousness_10\NN|impaired
D014635_D012640 NONE VPA_4\NNP| (r_npadvmod) induced_6\VBN|vpa|- (r_amod) encephalopathy_7\NN|induced (r_pobj) of_3\IN|encephalopathy (r_prep) signs_2\NNS|the|typical|of (r_nsubj) are_8\VBP|signs|consciousness|,|marked|. (l_advcl) marked_13\VBD|sometimes|slowing (l_ccomp) slowing_16\VBG|background|,|frequency (l_dobj) frequency_20\NN|increased|seizure|,|with (l_compound) seizure_19\NN|
D014635_D022124 NONE VPA_4\NNP| (r_npadvmod) induced_6\VBN|vpa|- (r_amod) encephalopathy_7\NN|induced (r_pobj) of_3\IN|encephalopathy (r_prep) signs_2\NNS|the|typical|of (r_nsubj) are_8\VBP|signs|consciousness|,|marked|. (l_advcl) marked_13\VBD|sometimes|slowing (l_ccomp) slowing_16\VBG|background|,|frequency (l_dobj) frequency_20\NN|increased|seizure|,|with (l_prep) with_22\IN|or|without (l_conj) without_24\IN|hyperammonemia (l_pobj) hyperammonemia_25\NN|
9862868
D004997_D002780 CID estradiol_9\NNP| (r_nmod) treatment_13\NN|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN|treatment|by (r_dobj) used_1\VBD|we|models|cholestasis|determine|. (l_dobj) models_3\NNS|rat|of (l_prep) of_4\IN|cholestasis (l_pobj) cholestasis_6\NN|intrahepatic|by
D004997_D002780 CID EE_11\NNP| (r_nmod) treatment_13\NN|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN|treatment|by (r_dobj) used_1\VBD|we|models|cholestasis|determine|. (l_dobj) models_3\NNS|rat|of (l_prep) of_4\IN|cholestasis (l_pobj) cholestasis_6\NN|intrahepatic|by
D004997_D001651 NONE estradiol_9\NNP| (r_nmod) treatment_13\NN|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN|treatment|by
D004997_D001651 NONE EE_11\NNP| (r_nmod) treatment_13\NN|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN|treatment|by
18308784
C035054_D007859 NONE Rg1_1\NNP|ginsenoside (r_nsubj) restores_2\VBZ|rg1|impairment|. (l_dobj) impairment_4\NN|the|of|induced (l_prep) of_5\IN|learning (l_pobj) learning_6\VBG|
C035054_D007859 NONE Rg1_0\NNP|,|ameliorate|. (l_advcl) ameliorate_11\VB|as|,|could|impairment (l_dobj) impairment_14\NN|spatial|learning
C035054_D007859 NONE Rg1_11\NN| (r_pobj) of_10\IN|rg1 (r_prep) effect_9\NN|the|of|on (l_prep) on_12\IN|impairment (l_pobj) impairment_14\NN|learning|by
D009020_D007859 CID morphine_10\NN| (r_compound) administration_11\NN|chronic|morphine|in (r_pobj) by_8\IN|administration (r_agent) induced_7\VBN|by (r_acl) impairment_4\NN|the|of|induced (l_prep) of_5\IN|learning (l_pobj) learning_6\VBG|
D009020_D007859 CID morphine_17\NN| (r_compound) administration_18\NN|chronic|morphine|and|mechanism (r_pobj) by_15\IN|administration (r_prep) impairment_14\NN|learning|by
D036145_D007859 NONE ginsenoside_4\NN|a|extracted (r_pobj) as_2\IN|ginsenoside (r_prep) ameliorate_11\VB|as|,|could|impairment (l_dobj) impairment_14\NN|spatial|learning
16867021
D006632_D002375 NONE histamine_10\NN| (r_nmod) ligands_12\NNS|histamine|h(3)-receptor|on (l_prep) on_13\IN|catalepsy (l_pobj) catalepsy_17\NN|induced|,
D001058_D002375 NONE apomorphine_19\NN| (r_npadvmod) induced_21\VBN|apomorphine|- (r_amod) behavior_23\NN|induced|climbing|and|activities (r_dobj) study_6\VB|to|effect|behavior (l_dobj) effect_8\NN|the|of (l_prep) of_9\IN|ligands (l_pobj) ligands_12\NNS|histamine|h(3)-receptor|on (l_prep) on_13\IN|catalepsy (l_pobj) catalepsy_17\NN|induced|,
D001058_D002375 NONE apomorphine_12\NN|(|mg/kg|)|and|amphetamine (r_nsubjpass) used_26\VBN|while|apomorphine|were|for (r_advcl) induced_2\VBN|catalepsy|was|by|,|used|. (l_nsubjpass) Catalepsy_0\NNP|
D001058_D002375 NONE apomorphine_21\NN| (r_dobj) reducing_20\VBG|apomorphine (r_conj) reducing_14\VBG|hyperactivity|and|reducing (r_conj) potentiating_8\VBG|catalepsy|,|reducing (l_dobj) catalepsy_12\NN|induced
D000661_D002375 NONE amphetamine_25\NN| (r_npadvmod) induced_27\VBN|amphetamine|- (r_amod) activities_29\NNS|induced|locomotor|in (r_conj) behavior_23\NN|induced|climbing|and|activities (r_dobj) study_6\VB|to|effect|behavior (l_dobj) effect_8\NN|the|of (l_prep) of_9\IN|ligands (l_pobj) ligands_12\NNS|histamine|h(3)-receptor|on (l_prep) on_13\IN|catalepsy (l_pobj) catalepsy_17\NN|induced|,
D000661_D002375 NONE amphetamine_19\NN|(|mg/kg|) (r_conj) apomorphine_12\NN|(|mg/kg|)|and|amphetamine (r_nsubjpass) used_26\VBN|while|apomorphine|were|for (r_advcl) induced_2\VBN|catalepsy|was|by|,|used|. (l_nsubjpass) Catalepsy_0\NNP|
D000661_D002375 NONE amphetamine_15\NN| (r_npadvmod) induced_17\VBN|amphetamine|- (r_amod) hyperactivity_18\NN|induced (r_dobj) reducing_14\VBG|hyperactivity|and|reducing (r_conj) potentiating_8\VBG|catalepsy|,|reducing (l_dobj) catalepsy_12\NN|induced
D006220_D002375 CID haloperidol_4\NN|(|mg/kg|) (r_pobj) by_3\IN|haloperidol (r_agent) induced_2\VBN|catalepsy|was|by|,|used|. (l_nsubjpass) Catalepsy_0\NNP|
D006220_D002375 CID haloperidol_4\NN| (r_pobj) to_3\IN|haloperidol (r_prep) prior_2\RB|to (r_advmod) resulted_5\VBD|1|h|prior|in|. (l_prep) in_6\IN|increase (l_pobj) increase_11\NN|a|dependent|in|(|p|) (l_prep) in_12\IN|catalepsy (l_pobj) catalepsy_14\NN|the|times
D006220_D002375 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|haloperidol|- (r_amod) catalepsy_12\NN|induced
C069357_D002375 NONE methylhistamine_3\NN|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN|
C069357_D002375 NONE RAMH_5\NNP|(|) (r_appos) methylhistamine_3\NN|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN|
C052075_D002375 CID thioperamide_13\JJ|(|thp|) (r_conj) microg_9\NN|(|5|i.c.v.|)|and|thioperamide|(|mg/kg|) (r_parataxis) methylhistamine_3\NN|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN|
C052075_D002375 CID THP_15\NNP| (r_appos) thioperamide_13\JJ|(|thp|) (r_conj) microg_9\NN|(|5|i.c.v.|)|and|thioperamide|(|mg/kg|) (r_parataxis) methylhistamine_3\NN|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN|
C052075_D002375 CID THP_0\NNP| (r_nsubj) exhibited_1\VBD|thp|profile|climbing|. (l_dobj) profile_6\NN|an|like|by (l_prep) by_7\IN|potentiating (l_pcomp) potentiating_8\VBG|catalepsy|,|reducing (l_dobj) catalepsy_12\NN|induced
D000661_D006948 CID amphetamine_1\NN| (r_npadvmod) induced_3\VBN|amphetamine|- (r_amod) hyperactivity_4\NN|induced
D000661_D006948 CID amphetamine_15\NN| (r_npadvmod) induced_17\VBN|amphetamine|- (r_amod) hyperactivity_18\NN|induced
C052075_D006948 NONE THP_6\NNP| (r_nmod) time_16\NN|thp|mg/kg|i.p.|)|reduced|locomotor (r_npadvmod) traveled_19\VBD|on|,|time|,|distance|and|speed|. (l_prep) On_0\IN|hyperactivity (l_pobj) hyperactivity_4\NN|induced
C052075_D006948 NONE THP_0\NNP| (r_nsubj) exhibited_1\VBD|thp|profile|climbing|. (l_dobj) profile_6\NN|an|like|by (l_prep) by_7\IN|potentiating (l_pcomp) potentiating_8\VBG|catalepsy|,|reducing (l_conj) reducing_14\VBG|hyperactivity|and|reducing (l_dobj) hyperactivity_18\NN|induced
D006220_D006948 NONE haloperidol_9\NN| (r_npadvmod) induced_11\VBN|haloperidol|- (r_amod) catalepsy_12\NN|induced (r_dobj) potentiating_8\VBG|catalepsy|,|reducing (l_conj) reducing_14\VBG|hyperactivity|and|reducing (l_dobj) hyperactivity_18\NN|induced
D001058_D006948 NONE apomorphine_21\NN| (r_dobj) reducing_20\VBG|apomorphine (r_conj) reducing_14\VBG|hyperactivity|and|reducing (l_dobj) hyperactivity_18\NN|induced
9698967
D008619_D006973 CID mepivacaine_43\NN| (r_amod) mg_45\NN|mepivacaine|850 (r_pobj) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_prep) in_2\IN|pressure (l_pobj) pressure_4\NN|blood
D008619_D001281 CID mepivacaine_43\NN| (r_amod) mg_45\NN|mepivacaine|850 (r_pobj) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_acl) accompanied_6\VBN|by (l_agent) by_7\IN|fibrillation (l_pobj) fibrillation_9\NN|atrial|,|agitation
D008619_D011595 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|mepivacaine|850 (r_pobj) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_acl) accompanied_6\VBN|by (l_agent) by_7\IN|fibrillation (l_pobj) fibrillation_9\NN|atrial|,|agitation (l_conj) agitation_11\NN|,|shouts
D008619_D019954 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|mepivacaine|850 (r_pobj) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_acl) accompanied_6\VBN|by (l_agent) by_7\IN|fibrillation (l_pobj) fibrillation_9\NN|atrial|,|agitation (l_conj) agitation_11\NN|,|shouts (l_conj) shouts_14\NNS|incomprehensible|and|loss|of
D008619_D014474 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|mepivacaine|850 (r_pobj) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_acl) accompanied_6\VBN|by (l_agent) by_7\IN|fibrillation (l_pobj) fibrillation_9\NN|atrial|,|agitation (l_conj) agitation_11\NN|,|shouts (l_conj) shouts_14\NNS|incomprehensible|and|loss|of (l_prep) of_17\IN|consciousness (l_pobj) consciousness_18\NN|
D008619_D004387 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|mepivacaine|850 (r_pobj) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (l_prep) for_51\IN|correction (l_pobj) correction_52\NN|of (l_prep) of_53\IN|contracture (l_pobj) contracture_56\NN|dupuytren
D004837_D006973 CID adrenaline_47\NN|mg (r_dobj) containing_46\VBG|adrenaline (r_pcomp) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_prep) in_2\IN|pressure (l_pobj) pressure_4\NN|blood
D004837_D001281 CID adrenaline_47\NN|mg (r_dobj) containing_46\VBG|adrenaline (r_pcomp) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_acl) accompanied_6\VBN|by (l_agent) by_7\IN|fibrillation (l_pobj) fibrillation_9\NN|atrial|,|agitation
D004837_D011595 NONE adrenaline_47\NN|mg (r_dobj) containing_46\VBG|adrenaline (r_pcomp) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_acl) accompanied_6\VBN|by (l_agent) by_7\IN|fibrillation (l_pobj) fibrillation_9\NN|atrial|,|agitation (l_conj) agitation_11\NN|,|shouts
D004837_D019954 NONE adrenaline_47\NN|mg (r_dobj) containing_46\VBG|adrenaline (r_pcomp) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_acl) accompanied_6\VBN|by (l_agent) by_7\IN|fibrillation (l_pobj) fibrillation_9\NN|atrial|,|agitation (l_conj) agitation_11\NN|,|shouts (l_conj) shouts_14\NNS|incomprehensible|and|loss|of
D004837_D014474 NONE adrenaline_47\NN|mg (r_dobj) containing_46\VBG|adrenaline (r_pcomp) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN|an|in|,|accompanied|, (l_acl) accompanied_6\VBN|by (l_agent) by_7\IN|fibrillation (l_pobj) fibrillation_9\NN|atrial|,|agitation (l_conj) agitation_11\NN|,|shouts (l_conj) shouts_14\NNS|incomprehensible|and|loss|of (l_prep) of_17\IN|consciousness (l_pobj) consciousness_18\NN|
D004837_D004387 NONE adrenaline_47\NN|mg (r_dobj) containing_46\VBG|adrenaline (r_pcomp) with_42\IN|mg|containing (r_prep) block_41\NN|axillary|with (r_pobj) of_39\IN|block (r_prep) performance_38\NN|of (r_pobj) after_37\IN|performance (r_prep) min_36\NN|12|after (r_appos) group_28\NN|asa|classification|ii|,|male|min|,|for (l_prep) for_51\IN|correction (l_pobj) correction_52\NN|of (l_prep) of_53\IN|contracture (l_pobj) contracture_56\NN|dupuytren
8919272
D014635_D001927 CID valproate_11\NN|features|to|. (l_nsubj) features_1\NNS|morphological|of|after (l_prep) of_2\IN|encephalopathy (l_pobj) encephalopathy_3\NN|
D014635_D001927 CID valproate_10\NN|application|polfa|at|to|disorders|. (l_dobj) disorders_43\NNS|revealed|neurological|indicating (l_acl) indicating_44\VBG|damage (l_dobj) damage_46\NN|cerebellum|encephalopathy (l_appos) encephalopathy_50\JJ|(|"|valproate|"|)
D014635_D001927 CID valproate_49\NNP| (r_amod) encephalopathy_50\JJ|(|"|valproate|"|)
D014635_D001927 CID valproate_15\NNP| (r_amod) encephalopathy_16\NNP|valproate
D014635_D009422 NONE valproate_10\NN|application|polfa|at|to|disorders|. (l_dobj) disorders_43\NNS|revealed|neurological|indicating
D014635_D009422 NONE valproate_49\NNP| (r_amod) encephalopathy_50\JJ|(|"|valproate|"|) (r_appos) damage_46\NN|cerebellum|encephalopathy (r_dobj) indicating_44\VBG|damage (r_acl) disorders_43\NNS|revealed|neurological|indicating
D014635_D002526 NONE valproate_10\NN|application|polfa|at|to|disorders|. (l_dobj) disorders_43\NNS|revealed|neurological|indicating (l_acl) indicating_44\VBG|damage (l_dobj) damage_46\NN|cerebellum|encephalopathy
D014635_D002526 NONE valproate_49\NNP| (r_amod) encephalopathy_50\JJ|(|"|valproate|"|) (r_appos) damage_46\NN|cerebellum|encephalopathy
D014635_D056486 NONE valproate_15\NNP| (r_amod) encephalopathy_16\NNP|valproate (r_pobj) of_14\IN|encephalopathy (r_prep) development_13\NN|the|of (r_pobj) upon_11\IN|development (r_prep) hyperammonemia_9\NN|influence|mainly|,|upon (l_nsubj) influence_2\NN|the|possible|of|, (l_prep) of_3\IN|damage (l_pobj) damage_6\NN|the|hepatic
D014635_D022124 NONE valproate_15\NNP| (r_amod) encephalopathy_16\NNP|valproate (r_pobj) of_14\IN|encephalopathy (r_prep) development_13\NN|the|of (r_pobj) upon_11\IN|development (r_prep) hyperammonemia_9\NN|influence|mainly|,|upon
17615423
D019821_D012206 CID simvastatin_11\NN|,|amiodarone (r_pobj) of_10\IN|simvastatin (r_prep) use_9\NN|concomitant|of (r_pobj) to_7\IN|use (r_prep) secondary_6\JJ|to (r_amod) failure_5\NN|acute|renal|secondary (r_conj) rhabdomyolysis_1\NN|severe|and|failure|.
D019821_D012206 CID simvastatin_9\NN|,|amiodarone (l_conj) amiodarone_11\NN|,|and|atazanavir (l_conj) atazanavir_14\NNS|resulting (l_acl) resulting_15\VBG|in (l_prep) in_16\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN|and|failure
D019821_D012206 CID simvastatin_14\NN| (r_amod) metabolism_15\NN|simvastatin (r_dobj) inhibit_13\VBP|that|metabolism (r_relcl) drugs_11\NNS|concomitant|inhibit (r_pobj) of_9\IN|drugs (r_prep) presence_8\NN|the|of (r_pobj) in_6\IN|presence (r_prep) increased_5\VBN|risk|is|in|. (l_nsubjpass) risk_1\NN|the|of (l_prep) of_2\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_3\NN|
D019821_D058186 CID simvastatin_11\NN|,|amiodarone (r_pobj) of_10\IN|simvastatin (r_prep) use_9\NN|concomitant|of (r_pobj) to_7\IN|use (r_prep) secondary_6\JJ|to (r_amod) failure_5\NN|acute|renal|secondary
D019821_D058186 CID simvastatin_9\NN|,|amiodarone (l_conj) amiodarone_11\NN|,|and|atazanavir (l_conj) atazanavir_14\NNS|resulting (l_acl) resulting_15\VBG|in (l_prep) in_16\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN|and|failure (l_conj) failure_21\NN|acute|renal
D000638_D012206 CID amiodarone_13\NN|,|and|atazanavir (r_conj) simvastatin_11\NN|,|amiodarone (r_pobj) of_10\IN|simvastatin (r_prep) use_9\NN|concomitant|of (r_pobj) to_7\IN|use (r_prep) secondary_6\JJ|to (r_amod) failure_5\NN|acute|renal|secondary (r_conj) rhabdomyolysis_1\NN|severe|and|failure|.
D000638_D012206 CID amiodarone_11\NN|,|and|atazanavir (l_conj) atazanavir_14\NNS|resulting (l_acl) resulting_15\VBG|in (l_prep) in_16\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN|and|failure
D000638_D058186 CID amiodarone_13\NN|,|and|atazanavir (r_conj) simvastatin_11\NN|,|amiodarone (r_pobj) of_10\IN|simvastatin (r_prep) use_9\NN|concomitant|of (r_pobj) to_7\IN|use (r_prep) secondary_6\JJ|to (r_amod) failure_5\NN|acute|renal|secondary
D000638_D058186 CID amiodarone_11\NN|,|and|atazanavir (l_conj) atazanavir_14\NNS|resulting (l_acl) resulting_15\VBG|in (l_prep) in_16\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN|and|failure (l_conj) failure_21\NN|acute|renal
C413408_D012206 CID atazanavir_16\NNS| (r_conj) amiodarone_13\NN|,|and|atazanavir (r_conj) simvastatin_11\NN|,|amiodarone (r_pobj) of_10\IN|simvastatin (r_prep) use_9\NN|concomitant|of (r_pobj) to_7\IN|use (r_prep) secondary_6\JJ|to (r_amod) failure_5\NN|acute|renal|secondary (r_conj) rhabdomyolysis_1\NN|severe|and|failure|.
C413408_D012206 CID atazanavir_14\NNS|resulting (l_acl) resulting_15\VBG|in (l_prep) in_16\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN|and|failure
C413408_D058186 CID atazanavir_16\NNS| (r_conj) amiodarone_13\NN|,|and|atazanavir (r_conj) simvastatin_11\NN|,|amiodarone (r_pobj) of_10\IN|simvastatin (r_prep) use_9\NN|concomitant|of (r_pobj) to_7\IN|use (r_prep) secondary_6\JJ|to (r_amod) failure_5\NN|acute|renal|secondary
C413408_D058186 CID atazanavir_14\NNS|resulting (l_acl) resulting_15\VBG|in (l_prep) in_16\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN|and|failure (l_conj) failure_21\NN|acute|renal
D019821_D015658 NONE Simvastatin_0\NNP|,|amiodarone (r_nmod) medications_11\NNS|simvastatin|patient|human|virus (l_compound) virus_10\NN|immunodeficiency
D000638_D015658 NONE amiodarone_2\NN|,|and (r_conj) Simvastatin_0\NNP|,|amiodarone (r_nmod) medications_11\NNS|simvastatin|patient|human|virus (l_compound) virus_10\NN|immunodeficiency
9855119
D016559_D005922 NONE FK506_28\NN| (r_compound) nephropathy_29\NN|type|chronic|fk506|(|n|)|,|and|nephropathy (r_conj) findings_17\NNS|,|normal|n|,|nephropathy (r_conj) nephropathy_9\NN|,|recurrent|iga|n|findings|.
D016559_D005922 NONE FK506_40\NN|type (r_compound) nephropathy_41\NN|fk506|(|n|) (r_conj) nephropathy_29\NN|type|chronic|fk506|(|n|)|,|and|nephropathy (r_conj) findings_17\NNS|,|normal|n|,|nephropathy (r_conj) nephropathy_9\NN|,|recurrent|iga|n|findings|.
D016559_D007674 NONE FK506_28\NN| (r_compound) nephropathy_29\NN|type|chronic|fk506|(|n|)|,|and|nephropathy
D016559_D007674 NONE FK506_28\NN| (r_compound) nephropathy_29\NN|type|chronic|fk506|(|n|)|,|and|nephropathy (l_conj) nephropathy_41\NN|fk506|(|n|)
D016559_D007674 NONE FK506_40\NN|type (r_compound) nephropathy_41\NN|fk506|(|n|) (r_conj) nephropathy_29\NN|type|chronic|fk506|(|n|)|,|and|nephropathy
D016559_D007674 NONE FK506_40\NN|type (r_compound) nephropathy_41\NN|fk506|(|n|)
D016559_D007674 NONE FK506_18\NN| (r_compound) nephropathy_19\NN|type|chronic|fk506
D016559_D007674 NONE FK506_1\NNP|chronic (r_compound) nephropathy_2\NN|fk506
D016559_D007674 NONE FK506_12\NN| (r_compound) nephropathy_13\NN|fk506
D016559_D007674 NONE FK506_12\NN| (r_compound) nephropathy_13\NN|fk506 (r_compound) group_14\NN|the|type|chronic|nephropathy|,|included|, (r_pobj) in_6\IN|group (r_prep) patients_5\NNS|in (r_pobj) of_4\IN|patients (r_prep) levels_3\NNS|the|serum|creatinine|of (r_nsubj) were_22\VBD|levels|higher|. (l_acomp) higher_24\JJR|statistically|than (l_prep) than_25\IN|those (l_pobj) those_26\DT|in (l_prep) in_27\IN|group (l_pobj) group_34\NN|the|type|fk506-nephropathy|(|p|) (l_compound) FK506-nephropathy_33\NNP|chronic
D016559_D007674 NONE FK506-nephropathy_33\NNP|chronic (r_compound) group_34\NN|the|type|fk506-nephropathy|(|p|) (r_pobj) in_27\IN|group (r_prep) those_26\DT|in (r_pobj) than_25\IN|those (r_prep) higher_24\JJR|statistically|than (r_acomp) were_22\VBD|levels|higher|. (l_nsubj) levels_3\NNS|the|serum|creatinine|of (l_prep) of_4\IN|patients (l_pobj) patients_5\NNS|in (l_prep) in_6\IN|group (l_pobj) group_14\NN|the|type|chronic|nephropathy|,|included|, (l_compound) nephropathy_13\NN|fk506
D016559_D007674 NONE FK506-nephropathy_33\NNP|chronic
D016559_D007674 NONE FK506_5\NNP| (r_compound) nephropathy_6\NN|chronic|fk506
D016559_D007674 NONE FK506_5\NNP| (r_compound) nephropathy_6\NN|chronic|fk506 (r_nsubj) consists_7\VBZ|that|nephropathy|primarily|of|, (r_ccomp) demonstrates_2\VBZ|study|consists|and|suggests|. (l_conj) suggests_21\VBZ|is (l_ccomp) is_29\VBZ|that|nephropathy|condition (l_nsubj) nephropathy_28\NN|type|chronic|fk506
D016559_D007674 NONE FK506_27\NN| (r_compound) nephropathy_28\NN|type|chronic|fk506 (r_nsubj) is_29\VBZ|that|nephropathy|condition (r_ccomp) suggests_21\VBZ|is (r_conj) demonstrates_2\VBZ|study|consists|and|suggests|. (l_ccomp) consists_7\VBZ|that|nephropathy|primarily|of|, (l_nsubj) nephropathy_6\NN|chronic|fk506
D016559_D007674 NONE FK506_27\NN| (r_compound) nephropathy_28\NN|type|chronic|fk506
D016559_D005923 CID FK506_1\NNP|chronic (r_compound) nephropathy_2\NN|fk506 (r_nsubj) consisted_3\VBD|nephropathy|of|, (r_ccomp) angiodegeneration_17\NN|consisted|arteriolopathy|(|of|;|biopsies|. (l_appos) biopsies_24\NNS|20|)|,|glomerulosclerosis (l_conj) glomerulosclerosis_29\NN|focal|segmental|(|biopsies|)|and|form
D016559_D005355 NONE FK506_1\NNP|chronic (r_compound) nephropathy_2\NN|fk506 (r_nsubj) consisted_3\VBD|nephropathy|of|, (r_ccomp) angiodegeneration_17\NN|consisted|arteriolopathy|(|of|;|biopsies|. (l_appos) biopsies_24\NNS|20|)|,|glomerulosclerosis (l_conj) glomerulosclerosis_29\NN|focal|segmental|(|biopsies|)|and|form (l_conj) form_37\NN|the|striped|of (l_prep) of_38\IN|fibrosis (l_pobj) fibrosis_40\NN|interstitial|(|biopsies|)
D003404_D007674 NONE creatinine_2\NN| (r_compound) levels_3\NNS|the|serum|creatinine|of (l_prep) of_4\IN|patients (l_pobj) patients_5\NNS|in (l_prep) in_6\IN|group (l_pobj) group_14\NN|the|type|chronic|nephropathy|,|included|, (l_compound) nephropathy_13\NN|fk506
D003404_D007674 NONE creatinine_2\NN| (r_compound) levels_3\NNS|the|serum|creatinine|of (r_nsubj) were_22\VBD|levels|higher|. (l_acomp) higher_24\JJR|statistically|than (l_prep) than_25\IN|those (l_pobj) those_26\DT|in (l_prep) in_27\IN|group (l_pobj) group_34\NN|the|type|fk506-nephropathy|(|p|) (l_compound) FK506-nephropathy_33\NNP|chronic
8955532
D001920_D006973 NONE bradykinin_4\NN|receptors|in (l_prep) in_7\IN|disruption (l_pobj) disruption_8\NN|of|during (l_prep) during_15\IN|hypertension (l_pobj) hypertension_17\NN|acute
D001920_D006973 NONE bradykinin_15\NN| (r_pobj) of_14\IN|bradykinin (r_prep) release_13\NN|synthesis|/|of (r_pobj) of_10\IN|release (r_prep) role_9\NN|the|of (r_dobj) determine_7\VB|to|role|activate (l_xcomp) activate_17\VB|to|receptors|in (l_prep) in_20\IN|disruption (l_pobj) disruption_21\NN|of|during (l_prep) during_28\IN|hypertension (l_pobj) hypertension_30\NN|acute
D001920_D006973 NONE bradykinin_23\NN| (r_pobj) of_22\IN|bradykinin (r_prep) release_21\NN|the|synthesis|/|of (r_pobj) to_17\IN|release (r_prep) related_16\VBN|is|not|to|activate (l_auxpass) is_14\VBZ|that|disruption (l_nsubj) disruption_4\NN|of|during (l_prep) during_11\IN|hypertension (l_pobj) hypertension_13\NN|acute
D003911_D006973 NONE dextran_15\NN|labeled (r_pobj) of_11\IN|dextran (r_prep) clearance_10\NN|of|before (l_prep) before_16\IN|and|during (l_conj) during_18\IN|hypertension (l_pobj) hypertension_23\NN|induced|acute|in
D010656_D006973 CID phenylephrine_19\NN| (r_npadvmod) induced_21\VBN|phenylephrine|- (r_amod) hypertension_23\NN|induced|acute|in
C065679_D006973 NONE Hoe-140_30\NNP| (r_conj) vehicle_28\NN|and|hoe-140|microm (r_pobj) with_27\IN|vehicle (r_prep) treated_26\VBN|with (r_acl) rats_25\NNS|treated (r_pobj) in_24\IN|rats (r_prep) hypertension_23\NN|induced|acute|in
8638206
D001279_D010243 CID atracurium_6\NN| (r_pobj) of_5\IN|atracurium (r_prep) use_4\NN|prolonged|of|in (r_pobj) after_2\IN|use (r_prep) paralysis_1\NN|persistent|after|.
D001279_D010243 CID besylate_1\NN|atracurium|,|nmba|, (r_nsubjpass) associated_22\VBN|besylate|has|also|been|with|,|but|used (l_prep) with_23\IN|paralysis (l_pobj) paralysis_25\NN|persistent
D001279_D010243 CID atracurium_5\NN| (r_npadvmod) related_7\VBN|atracurium|- (r_amod) paralysis_8\NN|related|persisting
D014673_D010243 CID bromide_21\NN|vecuronium (r_pobj) as_19\IN|such|bromide (r_prep) NMBAs_17\NNS|based|as (r_dobj) involved_13\VBN|reports|have|often|nmbas|,|used|. (l_nsubj) Reports_0\NNS|of|after (l_prep) of_1\IN|paralysis (l_pobj) paralysis_3\NN|persistent
-1_D010243 NONE benzylisoquinolinium_7\NN| (r_amod) NMBA_8\NNP|a|acting|benzylisoquinolinium|eliminated (r_appos) besylate_1\NN|atracurium|,|nmba|, (r_nsubjpass) associated_22\VBN|besylate|has|also|been|with|,|but|used (l_prep) with_23\IN|paralysis (l_pobj) paralysis_25\NN|persistent
8953972
D004837_D013345 CID epinephrine_8\NN| (r_pobj) of_7\IN|epinephrine (r_prep) use_6\NN|prehospital|of (r_pobj) with_4\IN|use (r_prep) associated_3\VBN|with (r_acl) bleeding_2\NN|fatal|intracranial|associated|.
D004837_D012128 NONE epinephrine_26\NN|subcutaneous (r_dobj) administer_24\VB|to|epinephrine (r_xcomp) led_16\VBD|onset|paramedics|administer|. (l_nsubj) onset_2\NN|the|sudden|of (l_prep) of_3\IN|distress (l_pobj) distress_5\NN|respiratory|,|rash
D004837_D005076 NONE epinephrine_26\NN|subcutaneous (r_dobj) administer_24\VB|to|epinephrine (r_xcomp) led_16\VBD|onset|paramedics|administer|. (l_nsubj) onset_2\NN|the|sudden|of (l_prep) of_3\IN|distress (l_pobj) distress_5\NN|respiratory|,|rash (l_conj) rash_7\JJ|,|and|history
D004837_D006323 CID Epinephrine_0\NN| (r_nsubj) has_1\VBZ|epinephrine|role (l_dobj) role_4\NN|a|proven|in (l_prep) in_5\IN|arrest (l_pobj) arrest_7\NN|cardiac|in
D004837_D004342 NONE Epinephrine_0\NN| (r_nsubj) has_1\VBZ|epinephrine|role (r_ccomp) use_14\NN|has|;|however|,|by (l_prep) by_15\IN|paramedics (l_pobj) paramedics_16\NNS|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|reaction (l_pobj) reaction_22\NN|suspected|allergic|and|hypertension
D004837_D006973 NONE Epinephrine_0\NN| (r_nsubj) has_1\VBZ|epinephrine|role (r_ccomp) use_14\NN|has|;|however|,|by (l_prep) by_15\IN|paramedics (l_pobj) paramedics_16\NNS|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|reaction (l_pobj) reaction_22\NN|suspected|allergic|and|hypertension (l_conj) hypertension_25\NN|severe
2334618
D009020_D001049 NONE morphine_17\NN| (r_pobj) of_16\IN|morphine (r_prep) infusion_15\NN|a|continuous|i.v.|of (r_dobj) receiving_11\VBG|infusion (r_acl) patients_10\NNS|five|receiving|mean|and|patients (r_pobj) between_8\IN|patients (r_prep) compared_7\VBN|incidence|was|between|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|apnoea (l_pobj) apnoea_5\NN|postoperative|respiratory
D002045_D001049 NONE bupivacaine_34\NN|% (r_pobj) of_31\IN|bupivacaine (r_prep) infusion_30\NN|a|continuous|extradural|of (r_dobj) receiving_26\VBG|infusion (r_acl) patients_25\NNS|five|receiving|mean|in (r_conj) patients_10\NNS|five|receiving|mean|and|patients (r_pobj) between_8\IN|patients (r_prep) compared_7\VBN|incidence|was|between|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|apnoea (l_pobj) apnoea_5\NN|postoperative|respiratory
D009020_D020181 CID morphine_25\NN| (r_compound) infusion_26\NN|a|morphine (r_dobj) had_23\VBD|who|infusion (r_relcl) patients_21\NNS|had (r_pobj) in_20\IN|patients (r_prep) occurred_17\VBD|obstructive|frequently|in|. (l_nsubj) obstructive_1\JJ|both|(|p (l_appos) P_3\NN|0.05|)|and|apnoea (l_conj) apnoea_10\NN|central|(|p|)
D009020_D020182 CID morphine_25\NN| (r_compound) infusion_26\NN|a|morphine (r_dobj) had_23\VBD|who|infusion (r_relcl) patients_21\NNS|had (r_pobj) in_20\IN|patients (r_prep) occurred_17\VBD|obstructive|frequently|in|. (l_nsubj) obstructive_1\JJ|both|(|p (l_appos) P_3\NN|0.05|)|and|apnoea (l_conj) apnoea_10\NN|central|(|p|)
D009020_D013610 NONE morphine_26\NN| (r_compound) infusion_27\NN|morphine (r_compound) group_28\NN|the|infusion (r_pobj) in_24\IN|group (r_prep) beats_17\NNS|ventricular|ectopic|(|p|)|in (r_conj) tachyarrhythmias_7\NNS|(|p|)|and|beats
D009020_D018879 CID morphine_26\NN| (r_compound) infusion_27\NN|morphine (r_compound) group_28\NN|the|infusion (r_pobj) in_24\IN|group (r_prep) beats_17\NNS|ventricular|ectopic|(|p|)|in
3997294
D000638_D010996 CID amiodarone_9\NN| (r_compound) therapy_10\NN|amiodarone (r_pobj) during_8\IN|therapy (r_prep) effusion_5\NN|pleural|and|neuropathy|during
D000638_D010490 CID amiodarone_9\NN| (r_compound) therapy_10\NN|amiodarone (r_pobj) during_8\IN|therapy (r_prep) effusion_5\NN|pleural|and|neuropathy|during
D000638_D009422 NONE amiodarone_9\NN| (r_compound) therapy_10\NN|amiodarone (r_pobj) during_8\IN|therapy (r_prep) effusion_5\NN|pleural|and|neuropathy|during (l_conj) neuropathy_7\NN|
D000638_D002318 NONE amiodarone_11\NN|(|dose|,|for (r_pobj) with_10\IN|amiodarone (r_prep) treated_9\VBN|patient|was|with|. (l_nsubjpass) patient_1\NN|a|with|and|pacemaker (l_prep) with_2\IN|disease (l_pobj) disease_4\NN|sinuatrial
D000638_D013617 NONE amiodarone_11\NN|(|dose|,|for (l_prep) for_28\IN|control (l_pobj) control_29\NN|of (l_prep) of_30\IN|tachyarrhythmias (l_pobj) tachyarrhythmias_32\NNS|supraventricular
D000638_D011014 CID amiodarone_14\NN| (r_compound) pneumonitis_15\NN|amiodarone
D000638_D011014 CID amiodarone_20\NN| (r_pobj) of_19\IN|amiodarone (r_prep) withdrawal_18\NN|immediate|of|,|and|prompt (r_dobj) indicates_7\VBZ|review|need|,|withdrawal|. (l_dobj) need_9\NN|the|for (l_prep) for_10\IN|diagnosis (l_pobj) diagnosis_12\NN|early|of (l_prep) of_13\IN|pneumonitis (l_pobj) pneumonitis_15\NN|amiodarone
D013256_D011014 NONE steroid_26\NN| (r_compound) therapy_27\NN|continued|steroid (r_conj) prompt_23\JJ|but|therapy|ensure (r_conj) withdrawal_18\NN|immediate|of|,|and|prompt (r_dobj) indicates_7\VBZ|review|need|,|withdrawal|. (l_dobj) need_9\NN|the|for (l_prep) for_10\IN|diagnosis (l_pobj) diagnosis_12\NN|early|of (l_prep) of_13\IN|pneumonitis (l_pobj) pneumonitis_15\NN|amiodarone
9869257
C087567_D000647 NONE PG-9_8\NNP|mg/kg|, (r_nsubj) administered_18\VBN|in|,|pg-9|before|,|prevented|. (l_conj) prevented_26\VBN|amnesia (l_dobj) amnesia_27\NN|induced
C087567_D000647 NONE PG-9_6\NNP|20 (r_nmod) microg_11\NN|pg-9|per|,|i.c.v.|) (r_nsubj) was_17\VBD|in|,|microg|also|able|,|demonstrating|. (l_acomp) able_19\JJ|prevent (l_xcomp) prevent_21\VB|to|amnesia (l_dobj) amnesia_25\NN|induced
D012601_D000647 CID scopolamine_36\NN|both|the|non|selective|antimuscarinic|drug|and|antagonist (r_pobj) by_29\IN|scopolamine (r_agent) induced_28\VBN|by (r_acl) amnesia_27\NN|induced
C098725_D000647 CID S-(-)-ET-126_41\NNP| (r_appos) antagonist_40\NN|the|m1-selective|s-(-)-et-126 (r_conj) scopolamine_36\NN|both|the|non|selective|antimuscarinic|drug|and|antagonist (r_pobj) by_29\IN|scopolamine (r_agent) induced_28\VBN|by (r_acl) amnesia_27\NN|induced
10526274
C056507_D002289 NONE Gemcitabine_0\NNP|plus|vinorelbine (l_conj) vinorelbine_2\NN|in (l_prep) in_3\IN|patients (l_pobj) patients_8\NNS|nonsmall|carcinoma (l_compound) carcinoma_7\NN|lung
C056507_D002289 NONE GEM_12\NNP|and|vnb (r_pobj) of_11\IN|gem (r_prep) combination_10\NN|the|of|in (l_prep) in_15\IN|patients (l_pobj) patients_17\NNS|elderly|with (l_prep) with_18\IN|nsclc (l_pobj) NSCLC_20\NNP|advanced|or|those
C030852_D002289 NONE vinorelbine_2\NN|in (l_prep) in_3\IN|patients (l_pobj) patients_8\NNS|nonsmall|carcinoma (l_compound) carcinoma_7\NN|lung
C030852_D002289 NONE VNB_14\NNP| (r_conj) GEM_12\NNP|and|vnb (r_pobj) of_11\IN|gem (r_prep) combination_10\NN|the|of|in (l_prep) in_15\IN|patients (l_pobj) patients_17\NNS|elderly|with (l_prep) with_18\IN|nsclc (l_pobj) NSCLC_20\NNP|advanced|or|those
D002945_D002289 NONE cisplatin_20\NN| (r_dobj) receive_19\VB|who|can|not|cisplatin (r_relcl) years_11\NNS|70|or|older|or|patients|receive (r_npadvmod) age_9\NN|gemcitabine|years|. (l_nsubj) Gemcitabine_0\NNP|plus|vinorelbine (l_conj) vinorelbine_2\NN|in (l_prep) in_3\IN|patients (l_pobj) patients_8\NNS|nonsmall|carcinoma (l_compound) carcinoma_7\NN|lung
D002945_D002289 NONE cisplatin_28\NN| (r_dobj) receiving_27\VBG|cisplatin (r_pcomp) to_26\IN|receiving (r_prep) contraindication_25\NN|some|to (r_pobj) with_23\IN|contraindication (r_prep) those_22\DT|with (r_conj) NSCLC_20\NNP|advanced|or|those
D002945_D002289 NONE cisplatin_33\NN| (r_dobj) receiving_32\VBG|cisplatin (r_pcomp) to_31\IN|receiving (r_prep) contraindication_30\NN|some|to (r_dobj) had_28\VBD|who|contraindication (r_conj) were_21\VBD|11|age|but|had (r_conj) /=_16\NFP|years|and|were (r_punct) included_8\VBN|patients|were|,|were|/=|. (l_nsubjpass) patients_3\NNS|nine|with (l_prep) with_4\IN|nsclc (l_pobj) NSCLC_6\NNP|advanced
C056507_D064420 NONE GEM_1\NNP| (r_nsubj) obtain_4\VB|(|gem|)|may|rate|,|with|. (l_prep) with_17\IN|toxicity (l_pobj) toxicity_19\NN|acceptable|and|improvement|in
C056507_D064420 NONE GEM_12\NNP|and|vnb (r_pobj) of_11\IN|gem (r_prep) combination_10\NN|the|of|in (r_pobj) of_8\IN|combination (r_prep) efficacy_5\NN|the|and|toxicity|of (l_conj) toxicity_7\NN|
C030852_D064420 NONE VNB_14\NNP| (r_conj) GEM_12\NNP|and|vnb (r_pobj) of_11\IN|gem (r_prep) combination_10\NN|the|of|in (r_pobj) of_8\IN|combination (r_prep) efficacy_5\NN|the|and|toxicity|of (l_conj) toxicity_7\NN|
D002945_D064420 NONE cisplatin_28\NN| (r_dobj) receiving_27\VBG|cisplatin (r_pcomp) to_26\IN|receiving (r_prep) contraindication_25\NN|some|to (r_pobj) with_23\IN|contraindication (r_prep) those_22\DT|with (r_conj) NSCLC_20\NNP|advanced|or|those (r_pobj) with_18\IN|nsclc (r_prep) patients_17\NNS|elderly|with (r_pobj) in_15\IN|patients (r_prep) combination_10\NN|the|of|in (r_pobj) of_8\IN|combination (r_prep) efficacy_5\NN|the|and|toxicity|of (l_conj) toxicity_7\NN|
20098969
D008694_D001145 NONE Methamphetamine_0\NN| (r_nsubj) is_1\VBZ|methamphetamine|stimulant|. (l_attr) stimulant_7\NN|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ|that|wakefulness|and|produce (l_conj) produce_16\VB|can|effects (l_dobj) effects_18\NNS|other|as (l_prep) as_20\IN|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS|cardiac|,|hypertension
D008694_D006973 NONE Methamphetamine_0\NN| (r_nsubj) is_1\VBZ|methamphetamine|stimulant|. (l_attr) stimulant_7\NN|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ|that|wakefulness|and|produce (l_conj) produce_16\VB|can|effects (l_dobj) effects_18\NNS|other|as (l_prep) as_20\IN|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS|cardiac|,|hypertension (l_conj) hypertension_24\NN|,|hallucinations
D008694_D006212 NONE Methamphetamine_0\NN| (r_nsubj) is_1\VBZ|methamphetamine|stimulant|. (l_attr) stimulant_7\NN|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ|that|wakefulness|and|produce (l_conj) produce_16\VB|can|effects (l_dobj) effects_18\NNS|other|as (l_prep) as_20\IN|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS|cardiac|,|hypertension (l_conj) hypertension_24\NN|,|hallucinations (l_conj) hallucinations_26\NNS|,|and|behavior
D008694_D001523 NONE Methamphetamine_0\NN| (r_nsubj) is_1\VBZ|methamphetamine|stimulant|. (l_attr) stimulant_7\NN|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ|that|wakefulness|and|produce (l_conj) produce_16\VB|can|effects (l_dobj) effects_18\NNS|other|as (l_prep) as_20\IN|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS|cardiac|,|hypertension (l_conj) hypertension_24\NN|,|hallucinations (l_conj) hallucinations_26\NNS|,|and|behavior (l_conj) behavior_30\NN|violent
D008694_D014987 NONE methamphetamine_3\NN| (r_dobj) abusing_2\VBG|methamphetamine (r_acl) patients_1\NNS|dental|abusing (r_nsubj) present_5\VB|patients|can|with|. (l_prep) with_6\IN|hygiene (l_pobj) hygiene_9\NN|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN|,|caries
D008694_D003731 CID methamphetamine_3\NN| (r_dobj) abusing_2\VBG|methamphetamine (r_acl) patients_1\NNS|dental|abusing (r_nsubj) present_5\VB|patients|can|with|. (l_prep) with_6\IN|hygiene (l_pobj) hygiene_9\NN|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN|,|caries (l_conj) caries_14\NNS|rampant|(|mouth|,|and|wear
D008694_D003731 CID methamphetamine_5\NN| (r_pobj) of_4\IN|methamphetamine (r_prep) use_3\NN|her|of|for (r_dobj) reported_1\VBD|she|use|and|experienced|. (l_conj) experienced_12\VBN|had|not|episodes|started (l_dobj) episodes_16\NNS|any|major|carious
D008694_-1 NONE methamphetamine_3\NN| (r_dobj) abusing_2\VBG|methamphetamine (r_acl) patients_1\NNS|dental|abusing (r_nsubj) present_5\VB|patients|can|with|. (l_prep) with_6\IN|hygiene (l_pobj) hygiene_9\NN|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN|,|caries (l_conj) caries_14\NNS|rampant|(|mouth|,|and|wear (l_appos) mouth_18\NN|"|meth|"|)
D008694_-1 NONE methamphetamines_23\NNS| (r_dobj) abusing_22\VBG|who|may|be|methamphetamines (r_relcl) patients_18\NNS|abusing (r_dobj) manage_17\VBP|patients (r_conj) recognize_15\VBP|practitioners|and|manage (r_ccomp) help_12\VB|to|recognize (r_advcl) presented_10\VBN|case|was|help|. (l_nsubjpass) case_2\NN|this|clinical|showing (l_acl) showing_3\VBG|manifestations (l_dobj) manifestations_5\NNS|oral|of (l_prep) of_6\IN|mouth (l_pobj) mouth_8\NN|meth
D008694_D057085 NONE methamphetamine_3\NN| (r_dobj) abusing_2\VBG|methamphetamine (r_acl) patients_1\NNS|dental|abusing (r_nsubj) present_5\VB|patients|can|with|. (l_prep) with_6\IN|hygiene (l_pobj) hygiene_9\NN|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN|,|caries (l_conj) caries_14\NNS|rampant|(|mouth|,|and|wear (l_conj) wear_25\NN|excessive|tooth
3425586
D003622_D000743 CID Dapsone_0\NN| (r_npadvmod) associated_2\VBN|dapsone|- (r_amod) anemia_6\NN|associated|heinz|body|hemolytic|in|.
D003622_D000743 CID dapsone_23\NN|day|) (r_pobj) of_22\IN|dapsone (r_prep) dose_21\NN|a|of|associated (r_dobj) taking_19\VBG|while|dose (r_advcl) developed_12\VBD|woman|anemia|taking|. (l_dobj) anemia_17\NN|a|heinz|body|hemolytic
D003622_D000743 CID dapsone_21\NN| (r_nsubj) cause_24\VB|since|dapsone|does|not|anemia|at (l_dobj) anemia_26\NN|hemolytic
D003622_D007918 NONE dapsone_23\NN|day|) (r_pobj) of_22\IN|dapsone (r_prep) dose_21\NN|a|of|associated (r_dobj) taking_19\VBG|while|dose (r_advcl) developed_12\VBD|woman|anemia|taking|. (l_nsubj) woman_2\NN|a|cambodian|with|leprosy (l_conj) leprosy_11\NN|
D003622_D006461 NONE dapsone_23\NN|day|) (r_pobj) of_22\IN|dapsone (r_prep) dose_21\NN|a|of|associated (l_acl) associated_32\VBN|not|usually|with (l_prep) with_33\IN|hemolysis (l_pobj) hemolysis_35\NN|clinical
354896
D008012_D006323 CID Lidocaine_0\NN| (r_npadvmod) induced_2\VBN|lidocaine|- (r_amod) asystole_4\NN|induced|cardiac|.
D008012_D003866 NONE lidocaine_8\NN| (r_pobj) of_7\IN|lidocaine (r_prep) bolus_6\NN|a|single|50-mg|of|in (r_pobj) of_2\IN|bolus (r_prep) administration_1\NN|intravenous|of (r_nsubj) resulted_15\VBD|administration|in|. (l_prep) in_16\IN|depression (l_pobj) depression_18\NN|profound|of
D008012_D001919 NONE lidocaine_29\NN| (r_pobj) to_28\IN|lidocaine (r_prep) idiosyncrasy_27\NN|a|true|to (r_dobj) represented_24\VBD|,|thus|,|this|probably|idiosyncrasy|. (r_conj) had_2\VBD|patient|conditions|;|and|represented (l_dobj) conditions_6\NNS|no|apparent|associated|predisposed (l_relcl) predisposed_10\VBN|which|might|have|him|to (l_prep) to_12\IN|development (l_pobj) development_14\NN|the|of (l_prep) of_15\IN|bradyarrhythmias (l_pobj) bradyarrhythmias_16\NNS|
2670794
D000809_D011665 NONE angiotensin_5\NN|converting (l_acl) converting_6\VBG|enzyme|on (l_prep) on_11\IN|insufficiency (l_pobj) insufficiency_15\NN|pulmonary
D000809_D011665 NONE angiotensin_11\NN|converting (r_pobj) of_10\IN|angiotensin (r_prep) inhibitor_9\NN|an|of (r_appos) Injection_0\NN|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD|injection|insufficiency|. (l_dobj) insufficiency_23\NN|pulmonary|in
D000809_D051437 NONE angiotensin_5\NN|converting (l_acl) converting_6\VBG|enzyme|on (l_prep) on_11\IN|insufficiency (l_pobj) insufficiency_15\NN|pulmonary
D000809_D051437 NONE angiotensin_11\NN|converting (r_pobj) of_10\IN|angiotensin (r_prep) inhibitor_9\NN|an|of (r_appos) Injection_0\NN|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD|injection|insufficiency|. (l_dobj) insufficiency_23\NN|pulmonary|in
D000809_D004211 NONE angiotensin_5\NN|converting (r_pobj) of_4\IN|angiotensin (r_prep) inhibitor_3\NN|an|of (r_pobj) of_1\IN|inhibitor (r_prep) Effects_0\NNS|of|due|. (l_amod) due_16\IN|to|coagulation (l_pobj) coagulation_19\NN|intravascular|in
D002216_D011665 NONE Captopril_9\NNP| (r_appos) enzyme_7\NN|(|captopril|) (r_dobj) converting_6\VBG|enzyme|on (l_prep) on_11\IN|insufficiency (l_pobj) insufficiency_15\NN|pulmonary
D002216_D011665 NONE Captopril_2\NNP| (r_pobj) of_1\IN|captopril (r_prep) Injection_0\NN|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD|injection|insufficiency|. (l_dobj) insufficiency_23\NN|pulmonary|in
D002216_D051437 NONE Captopril_9\NNP| (r_appos) enzyme_7\NN|(|captopril|) (r_dobj) converting_6\VBG|enzyme|on (l_prep) on_11\IN|insufficiency (l_pobj) insufficiency_15\NN|pulmonary
D002216_D051437 NONE Captopril_2\NNP| (r_pobj) of_1\IN|captopril (r_prep) Injection_0\NN|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD|injection|insufficiency|. (l_dobj) insufficiency_23\NN|pulmonary|in
D002216_D004211 NONE Captopril_9\NNP| (r_appos) enzyme_7\NN|(|captopril|) (r_dobj) converting_6\VBG|enzyme|on (r_acl) angiotensin_5\NN|converting (r_pobj) of_4\IN|angiotensin (r_prep) inhibitor_3\NN|an|of (r_pobj) of_1\IN|inhibitor (r_prep) Effects_0\NNS|of|due|. (l_amod) due_16\IN|to|coagulation (l_pobj) coagulation_19\NN|intravascular|in
D014148_D004211 CID acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (l_prep) of_1\IN|coagulation (l_pobj) coagulation_3\NN|intravascular|and|inhibition
D014148_D004211 CID AMCA_16\NNP|(|) (r_appos) acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (l_prep) of_1\IN|coagulation (l_pobj) coagulation_3\NN|intravascular|and|inhibition
D014148_D011665 NONE acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (r_nsubj) gives_21\VBZ|induction|rise|resembling|. (l_dobj) rise_22\NN|to (l_prep) to_23\IN|insufficiency (l_pobj) insufficiency_27\NN|pulmonary
D014148_D011665 NONE AMCA_16\NNP|(|) (r_appos) acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (r_nsubj) gives_21\VBZ|induction|rise|resembling|. (l_dobj) rise_22\NN|to (l_prep) to_23\IN|insufficiency (l_pobj) insufficiency_27\NN|pulmonary
D014148_D051437 NONE acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (r_nsubj) gives_21\VBZ|induction|rise|resembling|. (l_dobj) rise_22\NN|to (l_prep) to_23\IN|insufficiency (l_pobj) insufficiency_27\NN|pulmonary
D014148_D051437 NONE AMCA_16\NNP|(|) (r_appos) acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (r_nsubj) gives_21\VBZ|induction|rise|resembling|. (l_dobj) rise_22\NN|to (l_prep) to_23\IN|insufficiency (l_pobj) insufficiency_27\NN|pulmonary
D014148_D014947 NONE acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (r_nsubj) gives_21\VBZ|induction|rise|resembling|. (l_advcl) resembling_28\VBG|occurring (l_ccomp) occurring_30\VBG|that|after (l_prep) after_31\IN|trauma (l_pobj) trauma_32\NN|or|sepsis|in
D014148_D014947 NONE AMCA_16\NNP|(|) (r_appos) acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (r_nsubj) gives_21\VBZ|induction|rise|resembling|. (l_advcl) resembling_28\VBG|occurring (l_ccomp) occurring_30\VBG|that|after (l_prep) after_31\IN|trauma (l_pobj) trauma_32\NN|or|sepsis|in
D014148_D018805 NONE acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (r_nsubj) gives_21\VBZ|induction|rise|resembling|. (l_advcl) resembling_28\VBG|occurring (l_ccomp) occurring_30\VBG|that|after (l_prep) after_31\IN|trauma (l_pobj) trauma_32\NN|or|sepsis|in (l_conj) sepsis_34\NN|
D014148_D018805 NONE AMCA_16\NNP|(|) (r_appos) acid_14\NN|tranexamic|amca (r_conj) thrombin_11\NN|and|acid (r_pobj) of_10\IN|thrombin (r_prep) injection_9\NN|of|in (r_pobj) by_8\IN|injection (r_prep) Induction_0\NN|of|by (r_nsubj) gives_21\VBZ|induction|rise|resembling|. (l_advcl) resembling_28\VBG|occurring (l_ccomp) occurring_30\VBG|that|after (l_prep) after_31\IN|trauma (l_pobj) trauma_32\NN|or|sepsis|in (l_conj) sepsis_34\NN|
D014508_D007674 NONE urea_9\NN|serum (r_pobj) in_7\IN|urea|and|in (r_prep) increase_6\NN|an|in (r_pobj) by_4\IN|increase (r_agent) reflected_3\VBN|as|by (r_advcl) damage_1\NN|renal|reflected
D002216_D007674 NONE Captopril_17\NNP| (r_pobj) by_16\IN|captopril (r_agent) prevented_15\VBN|damage|was|by|. (l_nsubjpass) damage_1\NN|renal|reflected
D002216_D007674 NONE Captopril_0\NNP| (r_nsubj) reduce_8\VB|captopril|may|,|by|,|increase|,|diminishing|. (l_advcl) diminishing_26\VBG|thereby|aggregation|,|with (l_prep) with_36\IN|result (l_pobj) result_38\NN|the|deposited (l_acl) deposited_44\VBN|that|fibrin|will|be|and|produced (l_conj) produced_52\VBN|damage|will|be (l_nsubjpass) damage_49\NN|less|kidney
9931093
D016559_D006973 CID 506-induced_3\JJ|mechanisms (r_nummod) hypertension_4\NN|506-induced|in|.
D016559_D006973 CID 506_5\CD| (r_nummod) FK_4\NNP|506 (r_pobj) of_3\IN|fk (r_prep) utility_2\NN|the|clinical|of (r_nsubjpass) complicated_7\VBN|utility|is|by|. (l_agent) by_8\IN|hypertension (l_pobj) hypertension_10\NN|substantial|and|nephrotoxicity
D016559_D006973 CID 506-induced_6\JJ| (r_compound) hypertension_7\NN|fk|506-induced
D016559_D006973 CID 506_16\CD| (r_nummod) FK_15\NNP|506 (r_pobj) of_14\IN|fk (r_prep) effects_13\NNS|the|chronic|of|on (r_dobj) studied_10\VBD|clarify|,|we|effects|expression (l_advcl) clarify_1\VB|to|mechanisms (l_dobj) mechanisms_3\NNS|the|of (l_prep) of_4\IN|hypertension (l_pobj) hypertension_7\NN|fk|506-induced
D016559_D006973 CID 506-induced_17\JJ| (r_nummod) FK_16\NNP|506-induced (r_poss) hypertension_18\NN|fk|in
D016559_D006973 CID 506-induced_4\JJ| (r_nummod) hypertension_5\NN|fk|506-induced|in
D016559_D007674 NONE 506_5\CD| (r_nummod) FK_4\NNP|506 (r_pobj) of_3\IN|fk (r_prep) utility_2\NN|the|clinical|of (r_nsubjpass) complicated_7\VBN|utility|is|by|. (l_agent) by_8\IN|hypertension (l_pobj) hypertension_10\NN|substantial|and|nephrotoxicity (l_conj) nephrotoxicity_12\NN|
D009569_D006973 NONE oxide_44\NN| (r_compound) synthase_45\NN|,|the|endothelial|nitric|oxide|(|activity|. (r_conj) expression_27\NN|,|the|of|et-1|and|converting|synthase (r_dobj) studied_10\VBD|clarify|,|we|effects|expression (l_advcl) clarify_1\VB|to|mechanisms (l_dobj) mechanisms_3\NNS|the|of (l_prep) of_4\IN|hypertension (l_pobj) hypertension_7\NN|fk|506-induced
C079574_D006973 NONE 139317_14\CD| (r_nummod) FR_13\NNP|139317|on (l_prep) on_15\IN|hypertension (l_pobj) hypertension_18\NN|fk|in
1919871
D001241_D007681 CID aspirin_20\NN|and|paracetamol|in (r_pobj) with_19\IN|aspirin (r_prep) treatment_18\NN|continuous|term|with (r_pobj) during_13\IN|treatment (r_prep) developed_12\VBN|during (r_acl) ability_11\NN|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN|renal|papillary|(|rpn|)|and|ability|.
D001241_D007681 CID aspirin_20\NN|and|paracetamol|in (r_pobj) with_19\IN|aspirin (r_prep) treatment_18\NN|continuous|term|with (r_pobj) during_13\IN|treatment (r_prep) developed_12\VBN|during (r_acl) ability_11\NN|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN|renal|papillary|(|rpn|)|and|ability|. (l_appos) RPN_4\NNP|
D000082_D007681 CID paracetamol_22\JJ| (r_conj) aspirin_20\NN|and|paracetamol|in (r_pobj) with_19\IN|aspirin (r_prep) treatment_18\NN|continuous|term|with (r_pobj) during_13\IN|treatment (r_prep) developed_12\VBN|during (r_acl) ability_11\NN|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN|renal|papillary|(|rpn|)|and|ability|.
D000082_D007681 CID paracetamol_22\JJ| (r_conj) aspirin_20\NN|and|paracetamol|in (r_pobj) with_19\IN|aspirin (r_prep) treatment_18\NN|continuous|term|with (r_pobj) during_13\IN|treatment (r_prep) developed_12\VBN|during (r_acl) ability_11\NN|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN|renal|papillary|(|rpn|)|and|ability|. (l_appos) RPN_4\NNP|
18996674
D004837_D011317 NONE epinephrine_1\NN|intracavernous|:|treatment|. (l_appos) treatment_6\NN|a|invasive|for (l_prep) for_7\IN|priapism (l_pobj) priapism_8\NN|in
D003042_D011317 CID cocaine_9\NN| (r_compound) user_10\NN|an|admitted|frequent|cocaine (r_appos) man_4\NN|a|old|,|user|, (r_nsubj) presented_12\VBN|man|to|on|. (l_prep) on_20\IN|occasions (l_pobj) occasions_23\NNS|two|separate|with (l_prep) with_24\IN|history (l_pobj) history_26\NN|a|of|after (l_prep) of_27\IN|priapism (l_pobj) priapism_28\NN|
D003042_D011317 CID cocaine_30\NN| (r_compound) use_31\NN|cocaine (r_pobj) after_29\IN|use (r_prep) history_26\NN|a|of|after (l_prep) of_27\IN|priapism (l_pobj) priapism_28\NN|
8386779
D017693_D004414 NONE bicarbonate_1\NN|sodium (r_nsubj) alleviates_2\VBZ|bicarbonate|pain|induced|. (l_dobj) pain_4\NN|penile
D017693_D004414 NONE bicarbonate_43\NN|sodium|to (r_pobj) of_41\IN|bicarbonate (r_prep) addition_40\NN|the|of (r_pobj) without_38\IN|addition (r_conj) with_36\IN|or|without (r_prep) injections_35\NNS|intracorporeal|with (r_pobj) following_33\VBG|injections (r_prep) comparing_27\VBG|incidence|following (r_acl) study_26\NN|a|randomized|comparing (r_dobj) performed_23\VBD|in|,|we|study|medications. (l_prep) In_0\IN|attempt (l_pobj) attempt_2\NN|an|determine (l_acl) determine_4\VB|to|be (l_ccomp) be_13\VB|whether|pain|could|due (l_nsubj) pain_7\NN|penile|associated
D017693_D004414 NONE bicarbonate_43\NN|sodium|to (r_pobj) of_41\IN|bicarbonate (r_prep) addition_40\NN|the|of (r_pobj) without_38\IN|addition (r_conj) with_36\IN|or|without (r_prep) injections_35\NNS|intracorporeal|with (r_pobj) following_33\VBG|injections (r_prep) comparing_27\VBG|incidence|following (l_dobj) incidence_29\NN|the|of (l_prep) of_30\IN|pain (l_pobj) pain_32\NN|penile
D017693_D004414 NONE bicarbonate_6\NN|sodium (r_pobj) without_4\IN|bicarbonate (r_prep) patients_3\NNS|the|19|without|added (r_pobj) Of_0\IN|patients (r_prep) complained_16\VBD|of|of|due|,|complained|. (l_prep) of_17\IN|pain (l_pobj) pain_19\NN|penile
D017693_D004414 NONE bicarbonate_6\NN|sodium (r_pobj) without_4\IN|bicarbonate (r_prep) patients_3\NNS|the|19|without|added (r_pobj) Of_0\IN|patients (r_prep) complained_16\VBD|of|of|due|,|complained|. (l_advcl) complained_40\VBD|while|1|of (l_prep) of_41\IN|pain (l_pobj) pain_43\NN|penile
D017693_D004414 NONE bicarbonate_39\NN|sodium (r_dobj) received_37\VBD|who|bicarbonate (r_relcl) men_31\NNS|the|19|(|%|)|received (r_pobj) of_28\IN|men (r_prep) 1_27\CD|only|of (r_nsubj) complained_40\VBD|while|1|of (r_advcl) complained_16\VBD|of|of|due|,|complained|. (l_prep) of_17\IN|pain (l_pobj) pain_19\NN|penile
D017693_D004414 NONE bicarbonate_39\NN|sodium (r_dobj) received_37\VBD|who|bicarbonate (r_relcl) men_31\NNS|the|19|(|%|)|received (r_pobj) of_28\IN|men (r_prep) 1_27\CD|only|of (r_nsubj) complained_40\VBD|while|1|of (l_prep) of_41\IN|pain (l_pobj) pain_43\NN|penile
D017693_D007172 NONE bicarbonate_1\NN|sodium (r_nsubj) alleviates_2\VBZ|bicarbonate|pain|induced|. (l_advcl) induced_5\VBN|by (l_agent) by_6\IN|injections (l_pobj) injections_8\NNS|intracavernous|for (l_prep) for_9\IN|dysfunction (l_pobj) dysfunction_11\NN|erectile
D010208_D007172 NONE papaverine_25\NN|6|mg.|,|micrograms (r_appos) drugs_21\NNS|3|:|papaverine (r_pobj) of_19\IN|drugs (r_prep) combination_18\NN|a|of (r_pobj) of_16\IN|combination (r_prep) ml._15\NN|0.2|of (r_dobj) received_13\VBD|total|ml.|. (l_nsubj) total_1\NN|a|of (l_prep) of_2\IN|patients (l_pobj) patients_5\NNS|38|consecutive|presented (l_relcl) presented_7\VBD|who|to|with (l_prep) with_11\IN|impotence (l_pobj) impotence_12\NN|
3187073
D005472_D002637 CID 5-FU_6\CD| (r_compound) treatment_7\NN|5-fu (r_pobj) on_5\IN|treatment (r_prep) patients_4\NNS|on (r_nsubj) be_9\VB|that|patients|should|under|and|discontinued (l_conj) discontinued_19\VBN|that|treatment|should|be|observed (l_advcl) observed_26\VBN|if|pain|is (l_nsubjpass) pain_22\NN|chest|or|tachyarrhythmia
D005472_D013610 NONE 5-FU_6\CD| (r_compound) treatment_7\NN|5-fu (r_pobj) on_5\IN|treatment (r_prep) patients_4\NNS|on (r_nsubj) be_9\VB|that|patients|should|under|and|discontinued (l_conj) discontinued_19\VBN|that|treatment|should|be|observed (l_advcl) observed_26\VBN|if|pain|is (l_nsubjpass) pain_22\NN|chest|or|tachyarrhythmia (l_conj) tachyarrhythmia_24\NN|
16274958
D017255_D055154 CID acitretin_3\NN| (r_conj) dysphonia_1\NN|recurrent|and|acitretin|.
D017255_D055154 CID acitretin_15\NN| (r_pobj) by_14\IN|acitretin (r_agent) treated_13\VBN|while|she|was|by (r_advcl) report_1\VBP|we|case|treated|. (l_dobj) case_3\NN|the|of (l_prep) of_4\IN|woman (l_pobj) woman_6\NN|a|complaining (l_acl) complaining_7\VBG|of (l_prep) of_8\IN|dysphonia (l_pobj) dysphonia_9\NN|
D017255_D055154 CID acitretin_10\NN| (r_advmod) induced_12\VBN|acitretin|- (r_amod) dysphonia_13\NN|induced
1732369
D004280_D009369 NONE Dobutamine_0\NNP| (r_nsubj) stress_1\VBP|dobutamine|echocardiography|:|indicator|. (l_appos) indicator_6\NN|a|sensitive|of (l_prep) of_7\IN|function (l_pobj) function_10\NN|diminished|myocardial|in (l_prep) in_11\IN|survivors (l_pobj) survivors_19\NNS|asymptomatic|treated|term|of (l_prep) of_20\IN|cancer (l_pobj) cancer_22\NN|childhood
D004280_D009369 NONE dobutamine_21\NN| (r_compound) infusion_22\NN|dobutamine (r_dobj) using_20\VBG|infusion|differentiate (l_xcomp) differentiate_24\VB|to|survivors (l_dobj) survivors_29\NNS|asymptomatic|term|of|treated (l_prep) of_30\IN|cancer (l_pobj) cancer_32\NN|childhood
D004317_D009369 NONE doxorubicin_13\NN| (r_npadvmod) treated_15\VBN|doxorubicin|- (r_amod) survivors_19\NNS|asymptomatic|treated|term|of (l_prep) of_20\IN|cancer (l_pobj) cancer_22\NN|childhood
D004317_D009369 NONE doxorubicin_13\NN| (r_pobj) due_11\IN|to|doxorubicin (r_amod) damage_10\NN|cardiac|due (r_pobj) for_8\IN|damage (r_prep) test_7\NN|a|sensitive|echocardiographic|screening|for (r_dobj) develop_1\VB|to|test (r_advcl) performed_19\VBN|develop|,|study|was|using|. (l_xcomp) using_20\VBG|infusion|differentiate (l_xcomp) differentiate_24\VB|to|survivors (l_dobj) survivors_29\NNS|asymptomatic|term|of|treated (l_prep) of_30\IN|cancer (l_pobj) cancer_32\NN|childhood
D004317_D009369 NONE doxorubicin_35\NN| (r_pobj) with_34\IN|doxorubicin (r_prep) treated_33\VBN|with|from (r_acl) survivors_29\NNS|asymptomatic|term|of|treated (l_prep) of_30\IN|cancer (l_pobj) cancer_32\NN|childhood
D004317_D009202 CID Doxorubicin_0\NNP| (r_nsubj) is_1\VBZ|doxorubicin|agent|. (l_attr) agent_6\NN|an|effective|anticancer|chemotherapeutic|known (l_acl) known_7\VBN|cause (l_xcomp) cause_9\VB|to|cardiomyopathy (l_dobj) cardiomyopathy_13\NN|acute
D004317_D006331 NONE doxorubicin_13\NN| (r_pobj) due_11\IN|to|doxorubicin (r_amod) damage_10\NN|cardiac|due
D004317_D006331 NONE doxorubicin_35\NN| (r_pobj) with_34\IN|doxorubicin (r_prep) treated_33\VBN|with|from (r_acl) survivors_29\NNS|asymptomatic|term|of|treated (r_dobj) differentiate_24\VB|to|survivors (r_xcomp) using_20\VBG|infusion|differentiate (r_xcomp) performed_19\VBN|develop|,|study|was|using|. (l_advcl) develop_1\VB|to|test (l_dobj) test_7\NN|a|sensitive|echocardiographic|screening|for (l_prep) for_8\IN|damage (l_pobj) damage_10\NN|cardiac|due
D004280_D006331 NONE dobutamine_21\NN| (r_compound) infusion_22\NN|dobutamine (r_dobj) using_20\VBG|infusion|differentiate (r_xcomp) performed_19\VBN|develop|,|study|was|using|. (l_advcl) develop_1\VB|to|test (l_dobj) test_7\NN|a|sensitive|echocardiographic|screening|for (l_prep) for_8\IN|damage (l_pobj) damage_10\NN|cardiac|due
11166519
D003042_D012640 CID cocaine_1\NN| (r_npadvmod) induced_3\VBN|cocaine|- (r_amod) seizures_4\NNS|acute|induced|:|sensitivity|.
D003042_D012640 CID cocaine_22\NN| (r_pobj) of_21\IN|cocaine (r_prep) injection_20\NN|a|single|of (r_pobj) by_17\IN|injection (r_agent) induced_16\VBN|by (r_acl) seizures_15\NNS|behavioral|induced
D003042_D012640 CID cocaine_14\NN| (r_npadvmod) induced_16\VBN|cocaine|- (r_amod) seizures_17\NNS|induced
9625142
D002443_D056486 CID ceftriaxone_11\NN| (r_pobj) by_10\IN|ceftriaxone (r_prep) induced_9\VBN|hepatitis|by|. (l_nsubj) hepatitis_1\NNP|acute|,|anemia
D002443_D056486 CID ceftriaxone_12\NN|oral (r_dobj) ingesting_10\VBG|ceftriaxone (r_pcomp) after_9\IN|shortly|ingesting (r_prep) developed_5\VBD|man|hepatitis|after|. (l_dobj) hepatitis_7\NN|acute
D002443_D000744 CID ceftriaxone_11\NN| (r_pobj) by_10\IN|ceftriaxone (r_prep) induced_9\VBN|hepatitis|by|. (l_nsubj) hepatitis_1\NNP|acute|,|anemia (l_appos) anemia_5\NN|autoimmune|hemolytic|,|and|erythroblastocytopenia
D002443_-1 NONE ceftriaxone_11\NN| (r_pobj) by_10\IN|ceftriaxone (r_prep) induced_9\VBN|hepatitis|by|. (l_nsubj) hepatitis_1\NNP|acute|,|anemia (l_appos) anemia_5\NN|autoimmune|hemolytic|,|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_8\NN|
D047090_D000744 NONE lactam_11\NN|beta (r_compound) antibiotic_12\NN|the|lactam (r_dobj) withholding_8\VBG|antibiotic (r_pcomp) after_7\IN|withholding (r_prep) returned_4\VBD|although|transaminases|gradually|to|after (r_advcl) was_15\VBD|returned|,|there|increase|. (l_attr) increase_18\NN|a|gradual|in|and|decrease (l_conj) decrease_24\NN|a|in (l_prep) in_25\IN|concentration (l_pobj) concentration_27\NN|hemoglobin|caused (l_acl) caused_28\VBN|by (l_agent) by_29\IN|anemia (l_pobj) anemia_33\NN|an|autoimmune|hemolytic|and|erythroblastocytopenia
D047090_-1 NONE lactam_11\NN|beta (r_compound) antibiotic_12\NN|the|lactam (r_dobj) withholding_8\VBG|antibiotic (r_pcomp) after_7\IN|withholding (r_prep) returned_4\VBD|although|transaminases|gradually|to|after (r_advcl) was_15\VBD|returned|,|there|increase|. (l_attr) increase_18\NN|a|gradual|in|and|decrease (l_conj) decrease_24\NN|a|in (l_prep) in_25\IN|concentration (l_pobj) concentration_27\NN|hemoglobin|caused (l_acl) caused_28\VBN|by (l_agent) by_29\IN|anemia (l_pobj) anemia_33\NN|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN|
D001663_D000744 NONE bilirubin_21\NN|serum (r_pobj) in_19\IN|bilirubin (r_prep) increase_18\NN|a|gradual|in|and|decrease (l_conj) decrease_24\NN|a|in (l_prep) in_25\IN|concentration (l_pobj) concentration_27\NN|hemoglobin|caused (l_acl) caused_28\VBN|by (l_agent) by_29\IN|anemia (l_pobj) anemia_33\NN|an|autoimmune|hemolytic|and|erythroblastocytopenia
D001663_-1 NONE bilirubin_21\NN|serum (r_pobj) in_19\IN|bilirubin (r_prep) increase_18\NN|a|gradual|in|and|decrease (l_conj) decrease_24\NN|a|in (l_prep) in_25\IN|concentration (l_pobj) concentration_27\NN|hemoglobin|caused (l_acl) caused_28\VBN|by (l_agent) by_29\IN|anemia (l_pobj) anemia_33\NN|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN|
9284778
-1_D008107 NONE hydrochlorofluorocarbons_6\NNS|used (r_pobj) by_5\IN|hydrochlorofluorocarbons (r_agent) caused_4\VBN|by (r_acl) Epidemic_0\NN|of|caused|. (l_prep) of_1\IN|disease (l_pobj) disease_3\NN|liver
D010126_D008107 NONE ozone_9\NN| (r_npadvmod) sparing_11\VBG|ozone|- (r_amod) substitutes_12\NNS|sparing|of (r_pobj) as_8\IN|substitutes (r_prep) used_7\VBN|as (r_acl) hydrochlorofluorocarbons_6\NNS|used (r_pobj) by_5\IN|hydrochlorofluorocarbons (r_agent) caused_4\VBN|by (r_acl) Epidemic_0\NN|of|caused|. (l_prep) of_1\IN|disease (l_pobj) disease_3\NN|liver
D017402_D008107 NONE chlorofluorocarbons_14\NNS| (r_pobj) of_13\IN|chlorofluorocarbons (r_prep) substitutes_12\NNS|sparing|of (r_pobj) as_8\IN|substitutes (r_prep) used_7\VBN|as (r_acl) hydrochlorofluorocarbons_6\NNS|used (r_pobj) by_5\IN|hydrochlorofluorocarbons (r_agent) caused_4\VBN|by (r_acl) Epidemic_0\NN|of|caused|. (l_prep) of_1\IN|disease (l_pobj) disease_3\NN|liver
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21\CD|(|hcfc (r_pobj) of_20\IN|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN|a|of (r_pobj) to_17\IN|mixture (r_prep) exposure_16\NN|accidental|to (r_dobj) repeated_14\VBN|who|had|had|exposure (r_relcl) workers_10\NNS|nine|industrial|repeated (r_pobj) in_7\IN|workers (r_prep) epidemic_3\NN|an|of|in (l_prep) of_4\IN|disease (l_pobj) disease_6\NN|liver
C067411_D008107 CID 123_24\CD| (r_nummod) HCFC_23\NNP|123|)|and|1-chloro-1,2,2,2-tetrafluoroethane|(|hcfc|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD|(|hcfc (r_pobj) of_20\IN|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN|a|of (r_pobj) to_17\IN|mixture (r_prep) exposure_16\NN|accidental|to (r_dobj) repeated_14\VBN|who|had|had|exposure (r_relcl) workers_10\NNS|nine|industrial|repeated (r_pobj) in_7\IN|workers (r_prep) epidemic_3\NN|an|of|in (l_prep) of_4\IN|disease (l_pobj) disease_6\NN|liver
C067411_D008107 CID 124_8\CD| (r_conj) HCFCs_5\NNS|123|and|124 (r_nsubj) result_10\VB|whether|hcfcs|can|in (l_prep) in_11\IN|disease (l_pobj) disease_14\NN|serious|liver
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27\NN| (r_conj) HCFC_23\NNP|123|)|and|1-chloro-1,2,2,2-tetrafluoroethane|(|hcfc|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD|(|hcfc (r_pobj) of_20\IN|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN|a|of (r_pobj) to_17\IN|mixture (r_prep) exposure_16\NN|accidental|to (r_dobj) repeated_14\VBN|who|had|had|exposure (r_relcl) workers_10\NNS|nine|industrial|repeated (r_pobj) in_7\IN|workers (r_prep) epidemic_3\NN|an|of|in (l_prep) of_4\IN|disease (l_pobj) disease_6\NN|liver
C072959_D008107 CID 124_30\CD| (r_nummod) HCFC_29\NNP|124 (r_appos) HCFC_23\NNP|123|)|and|1-chloro-1,2,2,2-tetrafluoroethane|(|hcfc|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD|(|hcfc (r_pobj) of_20\IN|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN|a|of (r_pobj) to_17\IN|mixture (r_prep) exposure_16\NN|accidental|to (r_dobj) repeated_14\VBN|who|had|had|exposure (r_relcl) workers_10\NNS|nine|industrial|repeated (r_pobj) in_7\IN|workers (r_prep) epidemic_3\NN|an|of|in (l_prep) of_4\IN|disease (l_pobj) disease_6\NN|liver
C072959_D008107 CID 124_8\CD| (r_conj) HCFCs_5\NNS|123|and|124 (r_nsubj) result_10\VB|whether|hcfcs|can|in (l_prep) in_11\IN|disease (l_pobj) disease_14\NN|serious|liver
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD|halothane (r_pobj) as_8\IN|1-bromo-1-chloro-2,2,2-trifluoroethane (r_prep) way_7\NN|the|same|as (r_pobj) in_4\IN|way (r_prep) metabolised_3\VBN|compounds|are|in|form|. (l_advcl) form_14\VB|to|intermediates (l_dobj) intermediates_18\NNS|reactive|halide|,|implicated (l_relcl) implicated_23\VBN|which|have|been|in (l_prep) in_24\IN|hepatotoxicity (l_pobj) hepatotoxicity_26\NN|the|of
D006221_D056486 NONE halothane_11\NN|(|) (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD|halothane (r_pobj) as_8\IN|1-bromo-1-chloro-2,2,2-trifluoroethane (r_prep) way_7\NN|the|same|as (r_pobj) in_4\IN|way (r_prep) metabolised_3\VBN|compounds|are|in|form|. (l_advcl) form_14\VB|to|intermediates (l_dobj) intermediates_18\NNS|reactive|halide|,|implicated (l_relcl) implicated_23\VBN|which|have|been|in (l_prep) in_24\IN|hepatotoxicity (l_pobj) hepatotoxicity_26\NN|the|of
D006221_D056486 NONE halothane_28\NN| (r_pobj) of_27\IN|halothane (r_prep) hepatotoxicity_26\NN|the|of
D014269_D056486 NONE trifluoroacetyl_16\NNS| (r_compound) halide_17\NN|trifluoroacetyl (r_compound) intermediates_18\NNS|reactive|halide|,|implicated (l_relcl) implicated_23\VBN|which|have|been|in (l_prep) in_24\IN|hepatotoxicity (l_pobj) hepatotoxicity_26\NN|the|of
D014269_D056486 NONE trifluoroacetyl_17\NN| (r_npadvmod) altered_19\VBN|trifluoroacetyl|- (r_amod) proteins_21\NNS|altered|liver (r_nsubjpass) involved_23\VBN|that|proteins|are (r_ccomp) suggest_15\VBP|known|,|results|involved|. (l_advcl) known_11\VBN|although|mechanism|is|not (l_nsubjpass) mechanism_3\NN|the|exact|of (l_prep) of_4\IN|hepatotoxicity (l_pobj) hepatotoxicity_5\NN|of
C067411_D056486 NONE 124_9\CD| (r_conj) HCFCs_6\NNS|123|and|124 (r_pobj) to_5\IN|hcfcs (r_prep) exposure_1\NN|repeated|of|to (r_nsubj) result_11\VB|exposure|can|in|. (l_prep) in_12\IN|injury (l_pobj) injury_15\NN|serious|liver|in
C072959_D056486 NONE 124_9\CD| (r_conj) HCFCs_6\NNS|123|and|124 (r_pobj) to_5\IN|hcfcs (r_prep) exposure_1\NN|repeated|of|to (r_nsubj) result_11\VB|exposure|can|in|. (l_prep) in_12\IN|injury (l_pobj) injury_15\NN|serious|liver|in
7292072
D003891_D017180 CID desipramine_4\JJ| (r_amod) toxicity_5\NN|desipramine (r_pobj) in_3\IN|toxicity (r_prep) tachycardia_2\NN|variant|ventricular|in|.
D003891_D017180 CID desipramine_10\NN| (r_amod) toxicity_11\NN|desipramine (r_pobj) by_9\IN|toxicity (r_agent) induced_8\VBN|by (r_acl) tachycardia_7\NN|variant|ventricular|induced
D003891_D064420 NONE desipramine_4\JJ| (r_amod) toxicity_5\NN|desipramine
D003891_D064420 NONE desipramine_10\NN| (r_amod) toxicity_11\NN|desipramine
12905102
D003024_D003693 CID clozapine_2\NN| (r_amod) treatment_3\NN|clozapine (r_pobj) during_1\IN|treatment (r_prep) Delirium_0\NN|during|:|factors|.
D003024_D003693 CID clozapine_7\NN| (r_compound) treatment_8\NN|clozapine (r_pobj) during_6\IN|treatment (r_prep) factors_3\NNS|incidence|for|during (l_prep) for_4\IN|delirium (l_pobj) delirium_5\NN|
D003024_D003693 CID clozapine_13\NN|(|1995|) (r_pobj) with_12\IN|clozapine (r_prep) treated_11\VBN|with (r_acl) inpatients_10\NNS|all|adult|psychiatric|treated (r_dobj) identify_6\VB|to|inpatients (r_xcomp) used_1\VBD|we|records|identify|,|reviewed|. (l_conj) reviewed_20\VBD|records|score|,|and|tested (l_advcl) score_25\VB|to|incidence (l_dobj) incidence_26\NN|and|severity|of (l_prep) of_29\IN|delirium (l_pobj) delirium_30\NN|
D003024_D003693 CID clozapine_7\NN| (r_npadvmod) treated_9\VBN|clozapine|- (r_amod) inpatients_10\NNS|treated (r_pobj) of_6\IN|inpatients (r_prep) %_5\NN|10|of (r_pobj) in_3\IN|% (r_prep) found_2\VBN|delirium|was|in|,|in|. (l_nsubjpass) Delirium_0\NNP|
D003024_D001523 NONE clozapine_13\NN|(|1995|) (r_pobj) with_12\IN|clozapine (r_prep) treated_11\VBN|with (r_acl) inpatients_10\NNS|all|adult|psychiatric|treated (l_amod) psychiatric_9\JJ|
10091617
D012642_D007024 CID Selegiline_0\NNP| (r_advmod) induced_2\VBN|selegiline|-|hypotension|:|study|. (l_dobj) hypotension_4\NN|postural|in
D012642_D007024 CID selegiline_7\NN| (r_pobj) with_6\IN|selegiline (r_prep) therapy_5\NN|with|and|dopa (r_nsubjpass) associated_13\VBN|that|therapy|was|with (l_prep) with_14\IN|hypotension (l_pobj) hypotension_18\NN|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_25\NN| (r_pobj) of_24\IN|selegiline (r_prep) withdrawal_23\NN|of (r_pobj) by_22\IN|withdrawal (r_agent) abolished_21\VBN|which|was|by (r_relcl) hypotension_18\NN|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_29\NN| (r_dobj) stopping_28\VBG|selegiline|in (l_prep) in_30\IN|expectation (l_pobj) expectation_32\NN|the|shed (l_acl) shed_36\VB|that|this|might|light|on (l_prep) on_38\IN|mechanisms (l_pobj) mechanisms_40\NNS|the|causes (l_relcl) causes_45\VBZ|by|drug|hypotension (l_dobj) hypotension_47\NN|orthostatic
D012642_D007024 CID selegiline_18\NN| (r_pobj) on_17\IN|selegiline (r_prep) marked_10\VBN|which|was|in|on (r_relcl) hypotension_7\NN|systolic|orthostatic|marked|,|lost
D012642_D007024 CID selegiline_9\NN| (r_pobj) of_8\IN|selegiline (r_prep) withdrawal_7\NN|of (r_pobj) after_6\IN|days|withdrawal (r_prep) ameliorated_3\VBN|hypotension|was|after|and|abolished|. (l_nsubjpass) hypotension_1\NN|orthostatic
D012642_D007024 CID selegiline_1\NN| (r_dobj) Stopping_0\VBG|selegiline (r_csubj) reduced_4\VBD|stopping|also|significantly|pressures|. (l_dobj) pressures_11\NNS|the|supine|systolic|blood|consistent
D012642_D007024 CID selegiline_7\NN|that|in (r_nsubjpass) associated_15\VBN|selegiline|is|with (l_prep) with_16\IN|hypotension (l_pobj) hypotension_19\NN|selective|orthostatic
D012642_D010300 NONE Selegiline_0\NNP| (r_advmod) induced_2\VBN|selegiline|-|hypotension|:|study|. (l_dobj) hypotension_4\NN|postural|in (l_prep) in_5\IN|disease (l_pobj) disease_8\NN|parkinson
D012642_D010300 NONE selegiline_30\NN|mg|per (r_dobj) receive_27\VB|to|selegiline (r_xcomp) randomized_25\VBN|receive (r_acl) mortality_15\NN|an|increased|in|randomized (r_dobj) found_12\VBD|trial|mortality|and|compared (l_nsubj) trial_11\NN|group|(|ukpdrg|) (l_nmod) Group_7\NNP|parkinson|disease|research (l_compound) Disease_5\NNP|
D012642_D010300 NONE selegiline_30\NN|mg|per (r_dobj) receive_27\VB|to|selegiline (r_xcomp) randomized_25\VBN|receive (r_acl) mortality_15\NN|an|increased|in|randomized (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|disease (l_pobj) disease_21\NN|parkinson|(|pd|)
D012642_D010300 NONE selegiline_30\NN|mg|per (r_dobj) receive_27\VB|to|selegiline (r_xcomp) randomized_25\VBN|receive (r_acl) mortality_15\NN|an|increased|in|randomized (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|disease (l_pobj) disease_21\NN|parkinson|(|pd|) (l_appos) PD_23\NNP|
D012642_D010300 NONE selegiline_17\RB| (r_dobj) receiving_16\VBG|selegiline (r_acl) patients_15\NNS|pd|receiving (l_compound) PD_14\NNP|
D012642_D010300 NONE selegiline_18\NN| (r_pobj) on_17\IN|selegiline (r_prep) marked_10\VBN|which|was|in|on (l_prep) in_11\IN|patients (l_pobj) patients_16\NNS|20|pd (l_compound) PD_15\NNP|
D007980_D010300 NONE dopa_36\NN|l|- (r_nsubj) compared_37\VBN|dopa|with|. (r_conj) found_12\VBD|trial|mortality|and|compared (l_nsubj) trial_11\NN|group|(|ukpdrg|) (l_nmod) Group_7\NNP|parkinson|disease|research (l_compound) Disease_5\NNP|
D007980_D010300 NONE dopa_36\NN|l|- (r_nsubj) compared_37\VBN|dopa|with|. (r_conj) found_12\VBD|trial|mortality|and|compared (l_dobj) mortality_15\NN|an|increased|in|randomized (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|disease (l_pobj) disease_21\NN|parkinson|(|pd|)
D007980_D010300 NONE dopa_36\NN|l|- (r_nsubj) compared_37\VBN|dopa|with|. (r_conj) found_12\VBD|trial|mortality|and|compared (l_dobj) mortality_15\NN|an|increased|in|randomized (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|disease (l_pobj) disease_21\NN|parkinson|(|pd|) (l_appos) PD_23\NNP|
D007980_D010300 NONE dopa_43\NN|l|- (r_dobj) taking_40\VBG|dopa|alone (r_acl) those_39\DT|taking (r_pobj) with_38\IN|those (r_prep) compared_37\VBN|dopa|with|. (r_conj) found_12\VBD|trial|mortality|and|compared (l_nsubj) trial_11\NN|group|(|ukpdrg|) (l_nmod) Group_7\NNP|parkinson|disease|research (l_compound) Disease_5\NNP|
D007980_D010300 NONE dopa_43\NN|l|- (r_dobj) taking_40\VBG|dopa|alone (r_acl) those_39\DT|taking (r_pobj) with_38\IN|those (r_prep) compared_37\VBN|dopa|with|. (r_conj) found_12\VBD|trial|mortality|and|compared (l_dobj) mortality_15\NN|an|increased|in|randomized (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|disease (l_pobj) disease_21\NN|parkinson|(|pd|)
D007980_D010300 NONE dopa_43\NN|l|- (r_dobj) taking_40\VBG|dopa|alone (r_acl) those_39\DT|taking (r_pobj) with_38\IN|those (r_prep) compared_37\VBN|dopa|with|. (r_conj) found_12\VBD|trial|mortality|and|compared (l_dobj) mortality_15\NN|an|increased|in|randomized (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|disease (l_pobj) disease_21\NN|parkinson|(|pd|) (l_appos) PD_23\NNP|
D007980_D007024 NONE dopa_11\NNP|l|- (r_conj) therapy_5\NN|with|and|dopa (r_nsubjpass) associated_13\VBN|that|therapy|was|with (l_prep) with_14\IN|hypotension (l_pobj) hypotension_18\NN|selective|systolic|orthostatic|abolished
D007980_D007024 NONE dopa_13\NNP|l|- (r_pobj) with_10\IN|dopa (r_prep) combination_9\NN|with (r_pobj) in_8\IN|combination (r_prep) selegiline_7\NN|that|in (r_nsubjpass) associated_15\VBN|selegiline|is|with (l_prep) with_16\IN|hypotension (l_pobj) hypotension_19\NN|selective|orthostatic
3560095
D005480_D001171 NONE Flurbiprofen_0\NNP|in|. (l_prep) in_1\IN|treatment (l_pobj) treatment_3\NN|the|of (l_prep) of_4\IN|arthritis (l_pobj) arthritis_7\NN|juvenile|rheumatoid
D005480_D001171 NONE flurbiprofen_13\JJ| (r_pobj) with_12\IN|flurbiprofen (r_prep) treated_11\VBN|who|were|with|at|day (r_relcl) arthritis_7\NN|juvenile|rheumatoid|,|treated
D005480_D001168 NONE flurbiprofen_13\JJ| (r_pobj) with_12\IN|flurbiprofen (r_prep) treated_11\VBN|who|were|with|at|day (r_relcl) arthritis_7\NN|juvenile|rheumatoid|,|treated (r_pobj) with_4\IN|arthritis (r_prep) patients_3\NNS|four|with|, (r_nsubj) had_26\VBD|patients|decreases|. (l_dobj) decreases_29\NNS|significant|from|in|after (l_prep) in_32\IN|indices (l_pobj) indices_35\NNS|6|arthritis (l_compound) arthritis_34\NN|
20722491
D005472_D009369 NONE 5-FU_1\CD|(|) (r_nsubj) been_5\VBN|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN|the|of|for (l_prep) of_8\IN|treatment (l_pobj) treatment_9\NN|for (l_prep) for_10\IN|tumors (l_pobj) tumors_13\NNS|several|solid|,|including|,
D005472_D015179 NONE 5-FU_1\CD|(|) (r_nsubj) been_5\VBN|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN|the|of|for (l_prep) of_8\IN|treatment (l_pobj) treatment_9\NN|for (l_prep) for_10\IN|tumors (l_pobj) tumors_13\NNS|several|solid|,|including|, (l_prep) including_15\VBG|colorectal (l_pobj) colorectal_16\NN|,|breast (l_conj) breast_18\NN|and|cancers (l_conj) cancers_23\NNS|head
D005472_D001943 NONE 5-FU_1\CD|(|) (r_nsubj) been_5\VBN|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN|the|of|for (l_prep) of_8\IN|treatment (l_pobj) treatment_9\NN|for (l_prep) for_10\IN|tumors (l_pobj) tumors_13\NNS|several|solid|,|including|, (l_prep) including_15\VBG|colorectal (l_pobj) colorectal_16\NN|,|breast (l_conj) breast_18\NN|and|cancers (l_conj) cancers_23\NNS|head
D005472_D006258 NONE 5-FU_1\CD|(|) (r_nsubj) been_5\VBN|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN|the|of|for (l_prep) of_8\IN|treatment (l_pobj) treatment_9\NN|for (l_prep) for_10\IN|tumors (l_pobj) tumors_13\NNS|several|solid|,|including|, (l_prep) including_15\VBG|colorectal (l_pobj) colorectal_16\NN|,|breast (l_conj) breast_18\NN|and|cancers (l_conj) cancers_23\NNS|head
C110904_D007674 NONE capecitabine_10\NN| (r_pobj) of_9\IN|capecitabine (r_prep) safety_8\NN|the|of|in (l_prep) in_11\IN|populations (l_pobj) populations_13\NNS|special|as (l_prep) as_15\IN|such|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|disease (l_pobj) disease_24\NN|age|renal
C110904_D007674 NONE Capecitabine_0\NNP| (r_nsubj) has_1\VBZ|capecitabine|profile|and|given|. (l_conj) given_11\VBN|can|be|safely|to (l_prep) to_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|dysfunctions (l_pobj) dysfunctions_22\NNS|age
C110904_D003967 CID capecitabine_7\NN| (r_pobj) of_6\IN|capecitabine (r_prep) effects_5\NNS|the|reported|toxic|of (r_nsubj) are_8\VBP|effects|diarrhea|. (l_attr) diarrhea_9\NN|,|nausea
C110904_D009325 CID capecitabine_7\NN| (r_pobj) of_6\IN|capecitabine (r_prep) effects_5\NNS|the|reported|toxic|of (r_nsubj) are_8\VBP|effects|diarrhea|. (l_attr) diarrhea_9\NN|,|nausea (l_appos) nausea_11\NN|,|vomiting
C110904_D014839 CID capecitabine_7\NN| (r_pobj) of_6\IN|capecitabine (r_prep) effects_5\NNS|the|reported|toxic|of (r_nsubj) are_8\VBP|effects|diarrhea|. (l_attr) diarrhea_9\NN|,|nausea (l_appos) nausea_11\NN|,|vomiting (l_conj) vomiting_13\NN|,|stomatitis
C110904_D013280 CID capecitabine_7\NN| (r_pobj) of_6\IN|capecitabine (r_prep) effects_5\NNS|the|reported|toxic|of (r_nsubj) are_8\VBP|effects|diarrhea|. (l_attr) diarrhea_9\NN|,|nausea (l_appos) nausea_11\NN|,|vomiting (l_conj) vomiting_13\NN|,|stomatitis (l_conj) stomatitis_15\JJ|and|syndrome
C110904_D060831 CID capecitabine_7\NN| (r_pobj) of_6\IN|capecitabine (r_prep) effects_5\NNS|the|reported|toxic|of (r_nsubj) are_8\VBP|effects|diarrhea|. (l_attr) diarrhea_9\NN|,|nausea (l_appos) nausea_11\NN|,|vomiting (l_conj) vomiting_13\NN|,|stomatitis (l_conj) stomatitis_15\JJ|and|syndrome (l_conj) syndrome_20\NN|foot
C110904_D008107 NONE Capecitabine_0\NNP| (r_nsubj) has_1\VBZ|capecitabine|profile|and|given|. (l_conj) given_11\VBN|can|be|safely|to (l_prep) to_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|dysfunctions (l_pobj) dysfunctions_22\NNS|age
12921865
D013256_D012640 NONE steroids_4\NNS|neuroactive|against (l_prep) against_5\IN|seizures (l_pobj) seizures_9\NNS|cocaine|kindled|-
D013256_D012640 NONE steroid_13\NN|two|endogenous|one|synthetic|neuroactive|modulate (l_relcl) modulate_16\VBP|that|positively|acid (l_dobj) acid_21\NN|the|aminobutyric|(|gaba(a|)|)|receptor (l_appos) receptor_26\NN|against (l_prep) against_27\IN|increase (l_pobj) increase_29\NN|the|in (l_prep) in_30\IN|sensitivity (l_pobj) sensitivity_31\NN|to (l_prep) to_32\IN|effects (l_pobj) effects_35\NNS|the|convulsant|of (l_prep) of_36\IN|cocaine (l_pobj) cocaine_37\NN|engendered (l_acl) engendered_38\VBN|by (l_agent) by_39\IN|administration (l_pobj) administration_42\NN|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN|seizure (l_compound) seizure_44\NN|
D003042_D012640 CID cocaine_6\NN| (r_compound) seizures_9\NNS|cocaine|kindled|-
D003042_D012640 CID cocaine_37\NN|engendered (l_acl) engendered_38\VBN|by (l_agent) by_39\IN|administration (l_pobj) administration_42\NN|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN|seizure (l_compound) seizure_44\NN|
D003042_D012640 CID cocaine_41\NN| (r_compound) administration_42\NN|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN|seizure (l_compound) seizure_44\NN|
D003042_D012640 CID cocaine_53\NN| (r_npadvmod) kindled_55\VBN|cocaine|- (r_amod) seizures_56\NNS|kindled|in
D003042_D012640 CID cocaine_10\NN|mg/kg (r_pobj) of_7\IN|cocaine (r_prep) administration_6\NN|daily|of (r_pobj) by_4\IN|administration (r_agent) induced_3\VBN|kindled|were|by|for|. (l_csubjpass) Kindled_0\VBN|seizures (l_dobj) seizures_1\NNS|
D013256_D009422 NONE steroids_1\NNS|neuroactive (r_nsubj) demonstrate_2\VBP|steroids|actions|. (l_dobj) actions_4\NNS|pharmacological|have (l_relcl) have_6\VBP|that|relevance (l_dobj) relevance_7\NN|for (l_prep) for_8\IN|host (l_pobj) host_10\NN|a|of (l_prep) of_11\IN|disorders (l_pobj) disorders_15\NNS|neurological
D013256_D001523 NONE steroids_1\NNS|neuroactive (r_nsubj) demonstrate_2\VBP|steroids|actions|. (l_dobj) actions_4\NNS|pharmacological|have (l_relcl) have_6\VBP|that|relevance (l_dobj) relevance_7\NN|for (l_prep) for_8\IN|host (l_pobj) host_10\NN|a|of (l_prep) of_11\IN|disorders (l_pobj) disorders_15\NNS|neurological
D005680_D012640 NONE acid_21\NN|the|aminobutyric|(|gaba(a|)|)|receptor (l_appos) receptor_26\NN|against (l_prep) against_27\IN|increase (l_pobj) increase_29\NN|the|in (l_prep) in_30\IN|sensitivity (l_pobj) sensitivity_31\NN|to (l_prep) to_32\IN|effects (l_pobj) effects_35\NNS|the|convulsant|of (l_prep) of_36\IN|cocaine (l_pobj) cocaine_37\NN|engendered (l_acl) engendered_38\VBN|by (l_agent) by_39\IN|administration (l_pobj) administration_42\NN|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN|seizure (l_compound) seizure_44\NN|
D005680_D012640 NONE GABA(A_23\NNP| (r_appos) acid_21\NN|the|aminobutyric|(|gaba(a|)|)|receptor (l_appos) receptor_26\NN|against (l_prep) against_27\IN|increase (l_pobj) increase_29\NN|the|in (l_prep) in_30\IN|sensitivity (l_pobj) sensitivity_31\NN|to (l_prep) to_32\IN|effects (l_pobj) effects_35\NNS|the|convulsant|of (l_prep) of_36\IN|cocaine (l_pobj) cocaine_37\NN|engendered (l_acl) engendered_38\VBN|by (l_agent) by_39\IN|administration (l_pobj) administration_42\NN|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN|seizure (l_compound) seizure_44\NN|
D005680_D012640 NONE GABA(A_4\NN| (r_nmod) modulators_6\NNS|these|positive|gaba(a|) (r_pobj) of_1\IN|modulators (r_prep) All_0\DT|of (r_nsubj) suppressed_7\VBD|all|expression|,|inhibited|. (l_dobj) expression_9\NN|the|of (l_prep) of_10\IN|seizures (l_pobj) seizures_12\NNS|kindled
D011280_D012640 NONE Allopregnanolone_0\NN|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN|allopregnanolone|were|for|. (l_prep) for_35\IN|ability (l_pobj) ability_37\NN|their|suppress (l_acl) suppress_39\VB|to|expression (l_dobj) expression_41\NN|the|(|effect (l_appos) effect_44\NN|anticonvulsant|)|and|development (l_conj) development_47\NN|(|effect|)|of (l_prep) of_52\IN|seizures (l_pobj) seizures_56\NNS|kindled|in
D011280_D012640 NONE pregnan-20-one_6\NNP|hydroxy-5alpha|- (r_advmod) 3alpha_2\CD|pregnan-20-one (r_appos) Allopregnanolone_0\NN|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN|allopregnanolone|were|for|. (l_prep) for_35\IN|ability (l_pobj) ability_37\NN|their|suppress (l_acl) suppress_39\VB|to|expression (l_dobj) expression_41\NN|the|(|effect (l_appos) effect_44\NN|anticonvulsant|)|and|development (l_conj) development_47\NN|(|effect|)|of (l_prep) of_52\IN|seizures (l_pobj) seizures_56\NNS|kindled|in
D011280_D012640 NONE pregnanolone_9\NN|pregnan-20-one|and|ganaxolone (r_appos) Allopregnanolone_0\NN|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN|allopregnanolone|were|for|. (l_prep) for_35\IN|ability (l_pobj) ability_37\NN|their|suppress (l_acl) suppress_39\VB|to|expression (l_dobj) expression_41\NN|the|(|effect (l_appos) effect_44\NN|anticonvulsant|)|and|development (l_conj) development_47\NN|(|effect|)|of (l_prep) of_52\IN|seizures (l_pobj) seizures_56\NNS|kindled|in
D011280_D012640 NONE pregnan-20-one_15\NNP|(|3alpha|-|hydroxy-5beta|-|) (r_parataxis) pregnanolone_9\NN|pregnan-20-one|and|ganaxolone (r_appos) Allopregnanolone_0\NN|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN|allopregnanolone|were|for|. (l_prep) for_35\IN|ability (l_pobj) ability_37\NN|their|suppress (l_acl) suppress_39\VB|to|expression (l_dobj) expression_41\NN|the|(|effect (l_appos) effect_44\NN|anticonvulsant|)|and|development (l_conj) development_47\NN|(|effect|)|of (l_prep) of_52\IN|seizures (l_pobj) seizures_56\NNS|kindled|in
D011280_D012640 NONE allopregnanolone_24\NN|3alpha (r_pobj) of_23\IN|allopregnanolone (r_prep) derivative_22\NN|a|synthetic|of (r_appos) ganaxolone_18\NN|(|derivative|) (r_conj) pregnanolone_9\NN|pregnan-20-one|and|ganaxolone (r_appos) Allopregnanolone_0\NN|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN|allopregnanolone|were|for|. (l_prep) for_35\IN|ability (l_pobj) ability_37\NN|their|suppress (l_acl) suppress_39\VB|to|expression (l_dobj) expression_41\NN|the|(|effect (l_appos) effect_44\NN|anticonvulsant|)|and|development (l_conj) development_47\NN|(|effect|)|of (l_prep) of_52\IN|seizures (l_pobj) seizures_56\NNS|kindled|in
D011280_D012640 NONE allopregnanolone_16\NN|only|and|ganaxolone (r_nsubj) inhibited_19\VBD|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD|all|expression|,|inhibited|. (l_dobj) expression_9\NN|the|of (l_prep) of_10\IN|seizures (l_pobj) seizures_12\NNS|kindled
C105051_D012640 NONE ganaxolone_18\NN|(|derivative|) (r_conj) pregnanolone_9\NN|pregnan-20-one|and|ganaxolone (r_appos) Allopregnanolone_0\NN|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN|allopregnanolone|were|for|. (l_prep) for_35\IN|ability (l_pobj) ability_37\NN|their|suppress (l_acl) suppress_39\VB|to|expression (l_dobj) expression_41\NN|the|(|effect (l_appos) effect_44\NN|anticonvulsant|)|and|development (l_conj) development_47\NN|(|effect|)|of (l_prep) of_52\IN|seizures (l_pobj) seizures_56\NNS|kindled|in
C105051_D012640 NONE pregnan-20-one_31\NNP|methyl-5alpha|- (r_appos) 3alpha_25\CD|pregnan-20-one (r_appos) allopregnanolone_24\NN|3alpha (r_pobj) of_23\IN|allopregnanolone (r_prep) derivative_22\NN|a|synthetic|of (r_appos) ganaxolone_18\NN|(|derivative|) (r_conj) pregnanolone_9\NN|pregnan-20-one|and|ganaxolone (r_appos) Allopregnanolone_0\NN|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN|allopregnanolone|were|for|. (l_prep) for_35\IN|ability (l_pobj) ability_37\NN|their|suppress (l_acl) suppress_39\VB|to|expression (l_dobj) expression_41\NN|the|(|effect (l_appos) effect_44\NN|anticonvulsant|)|and|development (l_conj) development_47\NN|(|effect|)|of (l_prep) of_52\IN|seizures (l_pobj) seizures_56\NNS|kindled|in
C105051_D012640 NONE ganaxolone_18\NN| (r_conj) allopregnanolone_16\NN|only|and|ganaxolone (r_nsubj) inhibited_19\VBD|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD|all|expression|,|inhibited|. (l_dobj) expression_9\NN|the|of (l_prep) of_10\IN|seizures (l_pobj) seizures_12\NNS|kindled
16167916
D020849_D054556 CID raloxifene_11\NN| (r_compound) treatment_12\NN|raloxifene (r_pobj) to_10\IN|treatment (r_pcomp) due_9\IN|to (r_amod) thromboembolism_8\NN|venous|due
220563
C023470_D010523 CID maleate_1\NN|perhexiline|and|neuropathy|. (l_conj) neuropathy_4\NN|peripheral
C023470_D010523 CID maleate_12\NN|perhexiline|,|drug|( (r_pobj) with_10\IN|maleate|and|in (r_prep) complication_7\NN|a|of|with|for (r_pobj) as_5\IN|complication (r_prep) noted_4\VBN|neuropathy|has|been|as|. (l_nsubjpass) neuropathy_1\NN|peripheral
C023470_D000787 NONE maleate_12\NN|perhexiline|,|drug|( (r_pobj) with_10\IN|maleate|and|in (r_prep) complication_7\NN|a|of|with|for (l_prep) for_30\IN|treatment (l_pobj) treatment_33\NN|the|prophylactic|of (l_prep) of_34\IN|pectoris (l_pobj) pectoris_36\NN|angina
12084448
D007069_D001927 CID Ifosfamide_0\NNP| (r_compound) encephalopathy_1\NN|ifosfamide|presenting|.
D007069_D020820 NONE Ifosfamide_0\NNP| (r_compound) encephalopathy_1\NN|ifosfamide|presenting|. (l_acl) presenting_2\VBG|with (l_prep) with_3\IN|asterixis (l_pobj) asterixis_4\NNS|
D007069_D020820 NONE ifosfamide_3\NN| (r_pobj) of_2\IN|ifosfamide (r_prep) administration_1\NN|the|of (r_nsubjpass) discontinued_5\VBN|administration|was|and|resolved (l_conj) resolved_12\VBD|within|asterixis|completely|. (l_nsubj) asterixis_11\NNS|the
D007069_D020820 NONE ifosfamide_12\JJ| (r_pobj) of_11\IN|ifosfamide (r_prep) infusion_10\NN|of (r_pobj) during_9\IN|infusion (r_prep) presence_6\NN|the|of|during|,|findings|following (l_prep) of_7\IN|asterixis (l_pobj) asterixis_8\NNS|
D007069_D020820 NONE IFX_41\NNP| (r_pobj) of_40\IN|ifx (r_prep) use_39\NN|the|of (r_pobj) with_37\IN|use (r_prep) associated_36\VBN|that|myoclonus|is|with (r_ccomp) suggest_31\VBP|in|,|presence|associated|. (l_nsubj) presence_6\NN|the|of|during|,|findings|following (l_prep) of_7\IN|asterixis (l_pobj) asterixis_8\NNS|
D007069_D009207 CID ifosfamide_27\NN| (r_pobj) of_26\IN|ifosfamide (r_prep) infusion_25\NN|the|of|for (r_pobj) after_23\IN|infusion (r_prep) disabling_14\VBG|myoclonus|after (l_dobj) myoclonus_16\NN|negative|of
D007069_D009207 CID ifosfamide_12\JJ| (r_pobj) of_11\IN|ifosfamide (r_prep) infusion_10\NN|of (r_pobj) during_9\IN|infusion (r_prep) presence_6\NN|the|of|during|,|findings|following (r_nsubj) suggest_31\VBP|in|,|presence|associated|. (l_ccomp) associated_36\VBN|that|myoclonus|is|with (l_nsubjpass) myoclonus_34\NN|negative
D007069_D009207 CID IFX_41\NNP| (r_pobj) of_40\IN|ifx (r_prep) use_39\NN|the|of (r_pobj) with_37\IN|use (r_prep) associated_36\VBN|that|myoclonus|is|with (l_nsubjpass) myoclonus_34\NN|negative
D007069_D010954 NONE ifosfamide_27\NN| (r_pobj) of_26\IN|ifosfamide (r_prep) infusion_25\NN|the|of|for (l_prep) for_28\IN|plasmacytoma (l_pobj) plasmacytoma_29\NN|
12063090
D004177_D003248 NONE Metamizol_0\NNP| (r_nsubj) potentiates_1\VBZ|metamizol|antinociception|. (l_dobj) antinociception_3\NN|morphine|but|constipation (l_conj) constipation_6\NN|not|after
D004177_D003248 NONE metamizol_20\NN|mg/kg|s.c. (r_pobj) with_16\IN|metamizol (r_prep) effects_7\NNS|the|antinociceptive|of|with|in (l_amod) antinociceptive_4\NN|and|constipating (l_conj) constipating_6\JJ|
D004177_D003248 NONE metamizol_20\NN|that (r_nsubj) potentiate_23\VB|metamizol|did|not|constipation (l_dobj) constipation_27\NN|induced
D009020_D003248 CID morphine_2\NN| (r_compound) antinociception_3\NN|morphine|but|constipation (l_conj) constipation_6\NN|not|after
D009020_D003248 CID morphine_15\NN|mg/kg|s.c. (r_pobj) of_11\IN|morphine (r_prep) combination_10\NN|the|of (r_pobj) of_8\IN|combination (r_prep) effects_7\NNS|the|antinociceptive|of|with|in (l_amod) antinociceptive_4\NN|and|constipating (l_conj) constipating_6\JJ|
D009020_D003248 CID morphine_4\NN| (r_nsubj) inhibited_5\VBD|in|,|morphine|transit|after|,|respectively|,|suggesting|. (l_advcl) suggesting_23\VBG|develop (l_ccomp) develop_28\VB|that|tolerance|did|not|to (l_prep) to_29\IN|effects (l_pobj) effects_32\NNS|the|constipating (l_amod) constipating_31\JJ|
D009020_D003248 CID morphine_10\NN| (r_pobj) by_9\IN|morphine (r_agent) produced_8\VBN|by|regardless (r_acl) that_7\DT|produced (r_pobj) to_6\IN|that (r_prep) similar_5\JJ|to (r_amod) transit_4\NN|intestinal|similar (r_dobj) inhibited_2\VBD|combination|transit|,|suggesting|. (l_advcl) suggesting_18\VBG|potentiate (l_ccomp) potentiate_23\VB|metamizol|did|not|constipation (l_dobj) constipation_27\NN|induced
D009020_D003248 CID morphine_24\NN| (r_npadvmod) induced_26\VBN|morphine|- (r_amod) constipation_27\NN|induced
D002606_D010146 NONE charcoal_25\NN| (r_compound) meal_26\NN|charcoal (r_compound) test_27\NN|the|meal (r_nsubjpass) used_29\VBN|test|was|evaluate|. (r_conj) assessed_8\VBN|on|,|effects|were|using|,|model|used (l_conj) model_21\NN|induced|impairment|,|and (l_amod) induced_18\VBN|pain|- (l_npadvmod) pain_16\NN|
D009020_D059350 NONE morphine_7\NN|and|metamizol|in (r_pobj) between_6\IN|morphine (r_prep) interaction_5\NN|a|significant|between (r_dobj) show_2\VBP|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG|be (l_ccomp) be_20\VB|that|combination|could|useful (l_acomp) useful_21\JJ|for (l_prep) for_22\IN|treatment (l_pobj) treatment_24\NN|the|of (l_prep) of_25\IN|pain (l_pobj) pain_27\NN|chronic
D004177_D059350 NONE metamizol_9\NN| (r_conj) morphine_7\NN|and|metamizol|in (r_pobj) between_6\IN|morphine (r_prep) interaction_5\NN|a|significant|between (r_dobj) show_2\VBP|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG|be (l_ccomp) be_20\VB|that|combination|could|useful (l_acomp) useful_21\JJ|for (l_prep) for_22\IN|treatment (l_pobj) treatment_24\NN|the|of (l_prep) of_25\IN|pain (l_pobj) pain_27\NN|chronic
15957009
C507242_D008569 NONE Ro4368554_5\NN| (r_nsubj) restores_6\VBZ|antagonist|ro4368554|performance|in|. (l_prep) in_9\IN|models (l_pobj) models_13\NNS|cholinergic|of|in (l_prep) of_14\IN|deficiency (l_pobj) deficiency_16\NN|memory
C507242_D008569 NONE Ro4368554_2\NNP|(|3|mg/kg|,|intraperitoneally|and|metrifonate|p.o. (r_nsubj) reversed_24\VBD|both|,|ro4368554|deficits|)|. (l_dobj) deficits_26\NNS|memory|induced
C507242_D008569 NONE Ro4368554_4\NN| (r_nsubj) improve_7\VB|although|ro4368554|did|not|deficit (r_advcl) reversed_16\VBD|in|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_18\JJ|a|and|deficit (l_conj) deficit_23\NN|a|serotonergic|memory
C507242_D008569 NONE Ro4368554_39\NN| (r_pobj) by_38\IN|ro4368554 (r_prep) facilitation_34\NN|the|of|by (r_pobj) in_32\IN|facilitation (r_prep) involved_31\VBN|that|mechanisms|may|be|in|and|antagonists (r_ccomp) suggesting_25\VBG|involved (r_advcl) reversed_16\VBD|in|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_18\JJ|a|and|deficit (l_conj) deficit_23\NN|a|serotonergic|memory
D014236_D008569 NONE metrifonate_15\NN|(|mg/kg|, (r_conj) Ro4368554_2\NNP|(|3|mg/kg|,|intraperitoneally|and|metrifonate|p.o. (r_nsubj) reversed_24\VBD|both|,|ro4368554|deficits|)|. (l_dobj) deficits_26\NNS|memory|induced
D012601_D008569 CID scopolamine_29\NN|and|depletion|(|mg/kg|,|i.p.|,|and|mg/kg (r_pobj) by_28\IN|scopolamine (r_agent) induced_27\VBN|by (r_acl) deficits_26\NNS|memory|induced
D014364_D008569 NONE TRP_31\NNP| (r_compound) depletion_32\NN|trp (r_conj) scopolamine_29\NN|and|depletion|(|mg/kg|,|i.p.|,|and|mg/kg (r_pobj) by_28\IN|scopolamine (r_agent) induced_27\VBN|by (r_acl) deficits_26\NNS|memory|induced
D012701_D008569 NONE 5-HT(6_45\CD| (r_compound) antagonists_48\NNS|,|possibly|,|other|5-ht(6|receptor (r_conj) involved_31\VBN|that|mechanisms|may|be|in|and|antagonists (r_ccomp) suggesting_25\VBG|involved (r_advcl) reversed_16\VBD|in|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_18\JJ|a|and|deficit (l_conj) deficit_23\NN|a|serotonergic|memory
9401499
D013988_D000741 CID Ticlopidine_0\NNP| (r_npadvmod) induced_2\VBN|ticlopidine|- (r_amod) anemia_4\NN|induced|aplastic|:|report|.
D013988_D000741 CID ticlopidine_8\NN| (r_npadvmod) induced_10\VBN|ticlopidine|- (r_amod) anemia_12\NN|induced|aplastic
D013988_D000741 CID ticlopidine_2\NN| (r_npadvmod) induced_4\VBN|ticlopidine|- (r_amod) anemia_6\NN|induced|aplastic|with
D013988_D000380 CID ticlopidine_9\NN| (r_pobj) of_8\IN|ticlopidine (r_prep) initiation_7\NN|of (r_pobj) after_6\IN|weeks|initiation (r_prep) occurred_1\VBD|agranulocytosis|after|, (l_nsubj) Agranulocytosis_0\NN|
1833784
D004298_D006948 NONE dopamine_8\NN|d2 (r_conj) D1_5\NN|and|dopamine (r_nmod) receptors_9\NNS|d1 (r_pobj) of_4\IN|receptors (r_prep) involvement_3\NN|an|of|in (l_prep) in_10\IN|mediating (l_pcomp) mediating_11\VBG|hyperactivity (l_dobj) hyperactivity_15\NN|induced|in
D009538_D006948 CID nicotine_12\NN| (r_npadvmod) induced_14\VBN|nicotine|- (r_amod) hyperactivity_15\NN|induced|in
D009538_D006948 CID Nicotine_0\NNP|mg/kg (r_nsubj) caused_5\VBD|nicotine|increase|,|but|had|. (l_dobj) increase_8\NN|a|significant|in|habituated (l_prep) in_9\IN|activity (l_pobj) activity_11\NN|locomotor|in
D009538_D006948 CID Nicotine_0\NN| (r_npadvmod) induced_2\VBN|nicotine|- (r_amod) hyperactivity_3\NN|induced
D009538_D006948 CID nicotine_7\NN| (r_npadvmod) induced_9\VBN|nicotine|- (r_amod) hyperactivity_10\NN|enhanced|induced
D009538_D006948 CID nicotine_5\NN| (r_compound) injection_6\NN|acute|nicotine (r_nsubj) induces_7\VBZ|that|injection|hyperactivity (l_dobj) hyperactivity_10\NN|a|pronounced|in
C534628_D006948 NONE 23390_12\CD| (r_nummod) SCH_11\NNP|23390 (r_appos) antagonist_10\NN|the|selective|d1|sch (r_pobj) by_6\IN|antagonist (r_agent) blocked_5\VBN|hyperactivity|was|by (l_nsubjpass) hyperactivity_3\NN|induced
D020891_D006948 NONE raclopride_18\NN|blocked|,|antagonist|and|fluphenazine|. (l_ccomp) blocked_5\VBN|hyperactivity|was|by (l_nsubjpass) hyperactivity_3\NN|induced
D005476_D006948 NONE fluphenazine_23\NN|the|d1/d2|antagonist (r_conj) raclopride_18\NN|blocked|,|antagonist|and|fluphenazine|. (l_ccomp) blocked_5\VBN|hyperactivity|was|by (l_nsubjpass) hyperactivity_3\NN|induced
-1_D006948 NONE PHNO_5\NNP| (r_npadvmod) enhanced_6\VBN|phno (r_amod) hyperactivity_10\NN|enhanced|induced
D015647_D006948 NONE 38393_17\CD| (r_nummod) SKF_16\NNP|38393 (r_appos) agonist_15\NN|the|d1|skf (r_nsubj) had_18\VBD|whereas|agonist|effect (r_advcl) Pretreatment_0\NN|with|,|had|. (l_prep) with_1\IN|agonist (l_pobj) agonist_4\NN|the|d2|hyperactivity (l_appos) hyperactivity_10\NN|enhanced|induced
3750012
D010396_D009157 CID penicillamine_4\NN|and|therapy (r_pobj) by_3\IN|penicillamine (r_agent) caused_2\VBN|by (r_acl) gravis_1\NN|myasthenia|caused|.
D010396_D009157 CID penicillamine_16\NN|and|therapy (r_pobj) after_15\IN|penicillamine (r_prep) had_7\VBD|who|gravis|after (l_dobj) gravis_14\NN|reversible|myasthenia
D010396_D001172 NONE penicillamine_4\NN|and|therapy (l_conj) therapy_7\NN|chloroquine|for (l_prep) for_8\IN|arthritis (l_pobj) arthritis_10\NN|rheumatoid
D010396_D001172 NONE penicillamine_16\NN|and|therapy (l_conj) therapy_19\NN|chloroquine|for (l_prep) for_20\IN|arthritis (l_pobj) arthritis_22\NN|rheumatoid
D002738_D009157 CID chloroquine_6\NN| (r_amod) therapy_7\NN|chloroquine|for (r_conj) penicillamine_4\NN|and|therapy (r_pobj) by_3\IN|penicillamine (r_agent) caused_2\VBN|by (r_acl) gravis_1\NN|myasthenia|caused|.
D002738_D009157 CID chloroquine_18\NN| (r_compound) therapy_19\NN|chloroquine|for (r_conj) penicillamine_16\NN|and|therapy (r_pobj) after_15\IN|penicillamine (r_prep) had_7\VBD|who|gravis|after (l_dobj) gravis_14\NN|reversible|myasthenia
D002738_D001172 NONE chloroquine_6\NN| (r_amod) therapy_7\NN|chloroquine|for (l_prep) for_8\IN|arthritis (l_pobj) arthritis_10\NN|rheumatoid
D002738_D001172 NONE chloroquine_18\NN| (r_compound) therapy_19\NN|chloroquine|for (l_prep) for_20\IN|arthritis (l_pobj) arthritis_22\NN|rheumatoid
18703024
D006220_D002375 CID haloperidol_3\NN| (r_npadvmod) induced_5\VBN|haloperidol|- (r_amod) catalepsy_6\NN|induced|or|locomotion
D016291_D002375 NONE MK-801-induced_8\JJ| (r_compound) locomotion_9\NN|mk-801-induced (r_conj) catalepsy_6\NN|induced|or|locomotion
11426838
-1_D012640 NONE BD1018_10\NN|,|bd1063 (r_pobj) with_9\IN|bd1018 (r_punct) attenuated_17\VBD|treatment|with|significantly (r_amod) convulsions_21\NNS|attenuated|induced|and|lethality
-1_D012640 NONE LR132_15\NNS| (r_conj) BD1063_12\NNP|,|or|lr132 (r_conj) BD1018_10\NN|,|bd1063 (r_pobj) with_9\IN|bd1018 (r_punct) attenuated_17\VBD|treatment|with|significantly (r_amod) convulsions_21\NNS|attenuated|induced|and|lethality
C093337_D012640 NONE BD1063_12\NNP|,|or|lr132 (r_conj) BD1018_10\NN|,|bd1063 (r_pobj) with_9\IN|bd1018 (r_punct) attenuated_17\VBD|treatment|with|significantly (r_amod) convulsions_21\NNS|attenuated|induced|and|lethality
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|cocaine|- (r_amod) convulsions_21\NNS|attenuated|induced|and|lethality
D003042_D012640 CID cocaine_9\NN|anti|- (r_compound) effects_10\NNS|the|cocaine|of (r_nsubjpass) shown_29\VBN|that|effects|was|also|attenuate (l_xcomp) attenuate_32\VB|to|significantly|effects (l_dobj) effects_38\NNS|the|convulsive|stimulatory|of (l_amod) convulsive_34\JJ|and|locomotor
D003042_D012640 CID cocaine_40\NN| (r_pobj) of_39\IN|cocaine (r_prep) effects_38\NNS|the|convulsive|stimulatory|of (l_amod) convulsive_34\JJ|and|locomotor
C050232_D064420 NONE tolylguanidine_22\NN|di|o|-|( (r_nmod) DTG_24\NNP|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS|the|putative|,|dtg (r_pobj) by_6\IN|antagonists (r_agent) provided_5\VBN|by (r_acl) protection_4\NN|the|provided (r_pobj) to_2\IN|protection (r_prep) contrast_1\NN|to (r_pobj) In_0\IN|contrast (r_prep) worsened_37\VBD|in|each|toxicity|. (l_dobj) toxicity_40\NN|the|behavioral|of
C050232_D064420 NONE DTG_24\NNP|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS|the|putative|,|dtg (r_pobj) by_6\IN|antagonists (r_agent) provided_5\VBN|by (r_acl) protection_4\NN|the|provided (r_pobj) to_2\IN|protection (r_prep) contrast_1\NN|to (r_pobj) In_0\IN|contrast (r_prep) worsened_37\VBD|in|each|toxicity|. (l_dobj) toxicity_40\NN|the|behavioral|of
-1_D064420 NONE BD1031_32\NN|the|novel|agonist|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_conj) DTG_24\NNP|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS|the|putative|,|dtg (r_pobj) by_6\IN|antagonists (r_agent) provided_5\VBN|by (r_acl) protection_4\NN|the|provided (r_pobj) to_2\IN|protection (r_prep) contrast_1\NN|to (r_pobj) In_0\IN|contrast (r_prep) worsened_37\VBD|in|each|toxicity|. (l_dobj) toxicity_40\NN|the|behavioral|of
-1_D064420 NONE 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_34\NN|(|) (r_appos) BD1031_32\NN|the|novel|agonist|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_conj) DTG_24\NNP|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS|the|putative|,|dtg (r_pobj) by_6\IN|antagonists (r_agent) provided_5\VBN|by (r_acl) protection_4\NN|the|provided (r_pobj) to_2\IN|protection (r_prep) contrast_1\NN|to (r_pobj) In_0\IN|contrast (r_prep) worsened_37\VBD|in|each|toxicity|. (l_dobj) toxicity_40\NN|the|behavioral|of
D003042_D064420 NONE cocaine_42\NN| (r_pobj) of_41\IN|cocaine (r_prep) toxicity_40\NN|the|behavioral|of
D009838_D012640 NONE oligodeoxynucleotide_23\NN|an|antisense|against (r_appos) receptors_19\NNS|sigma|,|oligodeoxynucleotide (r_pobj) of_17\IN|receptors (r_prep) antagonism_16\NN|of (r_dobj) involved_15\VBD|antagonism (r_acl) ligands_14\NNS|the|novel|involved (r_pobj) of_11\IN|ligands (r_prep) effects_10\NNS|the|cocaine|of (r_nsubjpass) shown_29\VBN|that|effects|was|also|attenuate (l_xcomp) attenuate_32\VB|to|significantly|effects (l_dobj) effects_38\NNS|the|convulsive|stimulatory|of (l_amod) convulsive_34\JJ|and|locomotor
2924746
D002220_D064420 NONE carbamazepine_1\NN|chronic (r_compound) treatment_2\NN|carbamazepine|in|:|efficacy|. (l_appos) efficacy_7\NN|,|toxicity (l_conj) toxicity_9\NN|,|and|effect
D005492_D064420 NONE folate_17\JJ| (r_compound) concentrations_18\NNS|tissue|folate (r_conj) plasma_14\NN|and|concentrations (r_pobj) on_13\IN|plasma (r_prep) effect_12\NN|on (r_conj) toxicity_9\NN|,|and|effect
D019946_D012640 NONE glycol_13\NN|propylene (r_appos) vehicle_10\NN|a|common|,|glycol (r_nsubjpass) found_22\VBN|in|,|vehicle|,|by|,|was|exhibit|. (l_xcomp) exhibit_24\VB|to|properties (l_dobj) properties_26\NNS|protective|against (l_prep) against_27\IN|seizures (l_pobj) seizures_29\NNS|induced|and|gain
D019946_D015430 NONE glycol_13\NN|propylene (r_appos) vehicle_10\NN|a|common|,|glycol (r_nsubjpass) found_22\VBN|in|,|vehicle|,|by|,|was|exhibit|. (l_xcomp) exhibit_24\VB|to|properties (l_dobj) properties_26\NNS|protective|against (l_prep) against_27\IN|seizures (l_pobj) seizures_29\NNS|induced|and|gain (l_conj) gain_33\NN|inhibited|weight
D005481_D012640 CID ether_4\NN|hexafluorodiethyl|hfde (r_pobj) by_2\IN|ether (r_prep) induced_1\VBN|seizures|by|found|. (l_nsubj) Seizures_0\NNS|
D005481_D012640 CID ether_4\NN|hexafluorodiethyl|hfde (r_pobj) by_2\IN|ether (r_prep) induced_1\VBN|seizures|by|found|. (l_conj) found_10\VBN|were|also|be (l_xcomp) be_12\VB|to|measure|than (l_prep) than_21\IN|seizures (l_pobj) seizures_22\NNS|induced
D005481_D012640 CID HFDE_6\NNP|(|) (r_appos) ether_4\NN|hexafluorodiethyl|hfde (r_pobj) by_2\IN|ether (r_prep) induced_1\VBN|seizures|by|found|. (l_nsubj) Seizures_0\NNS|
D005481_D012640 CID HFDE_6\NNP|(|) (r_appos) ether_4\NN|hexafluorodiethyl|hfde (r_pobj) by_2\IN|ether (r_prep) induced_1\VBN|seizures|by|found|. (l_conj) found_10\VBN|were|also|be (l_xcomp) be_12\VB|to|measure|than (l_prep) than_21\IN|seizures (l_pobj) seizures_22\NNS|induced
D005481_D012640 CID HFDE_21\NNP| (r_npadvmod) induced_23\VBN|hfde|- (r_amod) seizures_24\NNS|induced
D002220_D012640 NONE CBZ_20\NN| (r_pobj) by_19\IN|cbz (r_prep) protection_18\NN|by (r_pobj) of_17\IN|protection (r_prep) measure_16\NN|a|sensitive|of (r_attr) be_12\VB|to|measure|than (r_xcomp) found_10\VBN|were|also|be (r_conj) induced_1\VBN|seizures|by|found|. (l_nsubj) Seizures_0\NNS|
D002220_D012640 NONE CBZ_20\NN| (r_pobj) by_19\IN|cbz (r_prep) protection_18\NN|by (r_pobj) of_17\IN|protection (r_prep) measure_16\NN|a|sensitive|of (r_attr) be_12\VB|to|measure|than (l_prep) than_21\IN|seizures (l_pobj) seizures_22\NNS|induced
D002220_D012640 NONE CBZ_3\NNP| (r_pobj) of_2\IN|cbz (r_prep) administration_1\NN|oral|of|as|h (r_nsubj) was_17\VBD|administration|protective|and|was|. (l_acomp) protective_19\JJ|continuously|against (l_prep) against_20\IN|seizures (l_pobj) seizures_24\NNS|induced
D002220_D015430 NONE CBZ_3\NNP| (r_pobj) of_2\IN|cbz (r_prep) administration_1\NN|oral|of|as|h (r_nsubj) was_17\VBD|administration|protective|and|was|. (l_conj) was_26\VBD|toxic|measured (l_advcl) measured_30\VBN|as|by|over (l_agent) by_31\IN|gain (l_pobj) gain_33\NN|weight
D005481_D015430 NONE HFDE_21\NNP| (r_npadvmod) induced_23\VBN|hfde|- (r_amod) seizures_24\NNS|induced (r_pobj) against_20\IN|seizures (r_prep) protective_19\JJ|continuously|against (r_acomp) was_17\VBD|administration|protective|and|was|. (l_conj) was_26\VBD|toxic|measured (l_advcl) measured_30\VBN|as|by|over (l_agent) by_31\IN|gain (l_pobj) gain_33\NN|weight
15188772
D004837_D018487 NONE epinephrine_12\NN| (r_amod) overdose_13\NN|accidental|iatrogenic|epinephrine (r_pobj) due_8\IN|to|overdose (r_prep) dysfunction_7\NN|severe|left|ventricular|systolic|due|.
D004837_D018487 NONE epinephrine_15\NN| (r_pobj) of_14\IN|epinephrine (r_prep) mg_13\NN|8|of (r_nsubj) developed_16\VBN|woman|mg|markers|. (l_dobj) markers_44\NNS|stunning|elevated|biochemical|of (l_amod) stunning_18\JJ|myocardial|characterized (l_relcl) characterized_21\VBN|that|was|by|left|,|and (l_conj) left_32\VBD|dysfunction (l_dobj) dysfunction_37\NN|ventricular|systolic
D004837_D062787 NONE epinephrine_12\NN| (r_amod) overdose_13\NN|accidental|iatrogenic|epinephrine
D002395_D009202 NONE Catecholamine_0\NN| (r_npadvmod) induced_2\VBN|catecholamine|- (r_amod) cardiomyopathy_3\NN|induced|due
D002395_D009202 NONE catecholamines_10\NNS|endogenous (r_pobj) of_8\IN|catecholamines (r_prep) excess_7\NN|chronic|of (r_pobj) due_4\IN|to|excess (r_prep) cardiomyopathy_3\NN|induced|due
D004837_D017682 CID epinephrine_15\NN| (r_pobj) of_14\IN|epinephrine (r_prep) mg_13\NN|8|of (r_nsubj) developed_16\VBN|woman|mg|markers|. (l_dobj) markers_44\NNS|stunning|elevated|biochemical|of (l_amod) stunning_18\JJ|myocardial|characterized
D004837_D009202 NONE epinephrine_15\NN| (r_pobj) of_14\IN|epinephrine (r_prep) mg_13\NN|8|of (r_nsubj) developed_16\VBN|woman|mg|markers|. (l_dobj) markers_44\NNS|stunning|elevated|biochemical|of (l_prep) of_45\IN|necrosis (l_pobj) necrosis_47\NN|myocardial
19631624
D018817_D007859 CID ecstasy_5\NN| (r_compound) users_6\NNS|ecstasy (r_pobj) in_4\IN|users (r_prep) deficits_3\NNS|learning|in|and|correlates
D018817_D007859 CID ecstasy_6\NN| (r_compound) users_7\NNS|ecstasy (r_nsubj) display_8\VBP|that|users|impairments (l_dobj) impairments_9\NNS|in (l_prep) in_10\IN|performance (l_pobj) performance_14\NN|learning (l_nmod) learning_11\NN|and|memory (l_conj) memory_13\NN|
D018817_D008569 CID ecstasy_5\NN| (r_compound) users_6\NNS|ecstasy (r_pobj) in_4\IN|users (r_prep) deficits_3\NNS|learning|in|and|correlates
D018817_D008569 CID ecstasy_6\NN| (r_compound) users_7\NNS|ecstasy (r_nsubj) display_8\VBP|that|users|impairments (l_dobj) impairments_9\NNS|in (l_prep) in_10\IN|performance (l_pobj) performance_14\NN|learning (l_nmod) learning_11\NN|and|memory (l_conj) memory_13\NN|
D002188_D007859 NONE cannabis_12\NN| (r_compound) users_13\NNS|cannabis (r_pobj) in_11\IN|users (r_prep) hypoactivity_10\NN|frontocortical|in (r_conj) hyperactivity_7\NN|parahippocampal|and|hypoactivity (r_appos) Deficits_0\NNS|in|:|hyperactivity|. (l_prep) in_1\IN|learning (l_pobj) learning_2\NN|and|memory (l_conj) memory_4\NN|
D002188_D008569 NONE cannabis_12\NN| (r_compound) users_13\NNS|cannabis (r_pobj) in_11\IN|users (r_prep) hypoactivity_10\NN|frontocortical|in (r_conj) hyperactivity_7\NN|parahippocampal|and|hypoactivity (r_appos) Deficits_0\NNS|in|:|hyperactivity|. (l_prep) in_1\IN|learning (l_pobj) learning_2\NN|and|memory (l_conj) memory_4\NN|
D002188_D006948 NONE cannabis_12\NN| (r_compound) users_13\NNS|cannabis (r_pobj) in_11\IN|users (r_prep) hypoactivity_10\NN|frontocortical|in (r_conj) hyperactivity_7\NN|parahippocampal|and|hypoactivity
D018817_D006948 NONE ecstasy_13\NN| (r_npadvmod) specific_15\JJ|ecstasy|- (r_amod) hyperactivity_16\NN|specific|in
D018817_D020258 NONE ecstasy_1\NN| (r_npadvmod) specific_3\JJ|ecstasy|- (r_amod) effects_4\NNS|these|specific (r_nsubjpass) related_7\VBN|effects|may|be|to|. (l_prep) to_8\IN|vulnerability (l_pobj) vulnerability_10\NN|the|of|to (l_prep) to_16\IN|effects (l_pobj) effects_19\NNS|the|neurotoxic|of (l_amod) neurotoxic_18\JJ|
D018817_D020258 NONE ecstasy_21\NN| (r_pobj) of_20\IN|ecstasy (r_prep) effects_19\NNS|the|neurotoxic|of (l_amod) neurotoxic_18\JJ|
11147747
D018490_D014549 CID antidepressants_1\NNS|serotonergic|and|incontinence|. (l_conj) incontinence_4\NN|urinary
D018490_D014549 CID antidepressants_8\NNS|serotonergic (r_pobj) to_6\IN|antidepressants (r_prep) secondary_5\JJ|to (r_amod) incontinence_4\NN|secondary
C047426_D014549 CID venlafaxine_10\NN| (r_dobj) taking_9\VBG|while|venlafaxine (r_advcl) experienced_6\VBD|who|incontinence|taking (l_dobj) incontinence_7\NN|
C047426_D014549 CID venlafaxine_35\NNP| (r_pobj) on_34\IN|venlafaxine (r_prep) developed_30\VBD|who|effect|on (r_relcl) third_28\NN|a|developed (r_conj) paroxetine_20\NN|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN|paroxetine (r_prep) developed_11\VBD|who|secondary|to (l_dobj) secondary_13\JJ|incontinence (l_compound) incontinence_12\NN|
D012701_D014549 NONE serotonin_17\NN| (r_compound) paroxetine_20\NN|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN|paroxetine (r_prep) developed_11\VBD|who|secondary|to (l_dobj) secondary_13\JJ|incontinence (l_compound) incontinence_12\NN|
D017374_D014549 CID paroxetine_20\NN|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN|paroxetine (r_prep) developed_11\VBD|who|secondary|to (l_dobj) secondary_13\JJ|incontinence (l_compound) incontinence_12\NN|
D020280_D014549 CID sertraline_22\NN| (r_conj) paroxetine_20\NN|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN|paroxetine (r_prep) developed_11\VBD|who|secondary|to (l_dobj) secondary_13\JJ|incontinence (l_compound) incontinence_12\NN|
D016651_D014549 CID carbonate_12\NN|lithium|and|blockers (r_dobj) taking_10\VBG|patients|were|also|carbonate (r_relcl) cases_5\NNS|the|3|taking (r_pobj) of_2\IN|cases (r_prep) 2_1\CD|of (r_pobj) In_0\IN|2 (r_prep) contributed_23\VBN|in|,|both|could|have|to|. (l_prep) to_24\IN|incontinence (l_pobj) incontinence_26\NN|the
19300402
D001920_D006930 NONE Bradykinin_0\NN| (r_compound) antagonists_2\NNS|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN|in
D001920_D006930 NONE bradykinin_9\NN| (r_compound) receptors_10\NNS|bradykinin (r_pobj) of_8\IN|receptors (r_prep) inhibition_7\NN|of|and|synthase|but (r_nsubj) reduces_21\VBZ|that|inhibition|activity|hyperalgesia (l_dobj) hyperalgesia_23\NN|diabetic
D001920_D006930 NONE bradykinin_19\NN| (r_conj) activation_15\NN|neuronal|no|synthase|as|bradykinin (r_conj) synthase_10\NN|inducible|no|and|activation (r_pobj) of_7\IN|synthase (r_prep) products_6\NNS|both|of (r_nsubjpass) involved_21\VBN|that|products|are|in (l_prep) in_22\IN|hyperalgesia (l_pobj) hyperalgesia_23\NN|produced
D001920_D006930 NONE bradykinin_14\NN| (r_pobj) of_13\IN|bradykinin (r_prep) activity_12\NN|pronociceptive|of (r_pobj) in_10\IN|activity (r_prep) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_prep) In_0\IN|hyperalgesia (l_pobj) hyperalgesia_4\NN|induced
D001920_D006930 NONE bradykinin_14\NN| (r_pobj) of_13\IN|bradykinin (r_prep) activity_12\NN|pronociceptive|of (r_pobj) in_10\IN|activity (r_prep) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN|
D001920_D006930 NONE bradykinin_22\NN| (r_nsubj) seemed_23\VBD|bradykinin|activate|. (r_conj) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_prep) In_0\IN|hyperalgesia (l_pobj) hyperalgesia_4\NN|induced
D001920_D006930 NONE bradykinin_22\NN| (r_nsubj) seemed_23\VBD|bradykinin|activate|. (r_conj) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN|
D001920_D003929 NONE Bradykinin_0\NN| (r_compound) antagonists_2\NNS|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN|in (l_prep) in_14\IN|chemotherapy (l_pobj) chemotherapy_15\NN|and|model (l_conj) model_20\NN|diabetic|rat (l_compound) rat_19\NN|neuropathy (l_compound) neuropathy_18\NN|
D009569_D006930 NONE oxide_5\NN| (r_compound) synthase_6\NN|nitric|oxide (r_compound) inhibitors_7\NNS|synthase (r_conj) antagonists_2\NNS|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN|in
D009569_D006930 NONE NO_13\DT| (r_det) synthase_14\NN|inducible|no (r_conj) inhibition_7\NN|of|and|synthase|but (r_nsubj) reduces_21\VBZ|that|inhibition|activity|hyperalgesia (l_dobj) hyperalgesia_23\NN|diabetic
D009569_D006930 NONE NO_18\DT| (r_det) activity_20\NN|not|neuronal|no|synthase (r_nsubj) reduces_21\VBZ|that|inhibition|activity|hyperalgesia (l_dobj) hyperalgesia_23\NN|diabetic
D009569_D006930 NONE NO_9\DT| (r_compound) synthase_10\NN|inducible|no|and|activation (r_pobj) of_7\IN|synthase (r_prep) products_6\NNS|both|of (r_nsubjpass) involved_21\VBN|that|products|are|in (l_prep) in_22\IN|hyperalgesia (l_pobj) hyperalgesia_23\NN|produced
D009569_D006930 NONE NO_13\DT| (r_det) activation_15\NN|neuronal|no|synthase|as|bradykinin (r_conj) synthase_10\NN|inducible|no|and|activation (r_pobj) of_7\IN|synthase (r_prep) products_6\NNS|both|of (r_nsubjpass) involved_21\VBN|that|products|are|in (l_prep) in_22\IN|hyperalgesia (l_pobj) hyperalgesia_23\NN|produced
D009569_D006930 NONE NO_7\DT| (r_compound) synthase_8\NN|inducible|no (r_nsubj) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_prep) In_0\IN|hyperalgesia (l_pobj) hyperalgesia_4\NN|induced
D009569_D006930 NONE NO_7\DT| (r_compound) synthase_8\NN|inducible|no (r_nsubj) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN|
D009569_D006930 NONE NO_27\DT| (r_det) pathway_29\NN|neuronal|no|synthase (r_dobj) activate_25\VB|to|pathway (r_xcomp) seemed_23\VBD|bradykinin|activate|. (r_conj) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_prep) In_0\IN|hyperalgesia (l_pobj) hyperalgesia_4\NN|induced
D009569_D006930 NONE NO_27\DT| (r_det) pathway_29\NN|neuronal|no|synthase (r_dobj) activate_25\VB|to|pathway (r_xcomp) seemed_23\VBD|bradykinin|activate|. (r_conj) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN|
D009569_D003929 NONE oxide_5\NN| (r_compound) synthase_6\NN|nitric|oxide (r_compound) inhibitors_7\NNS|synthase (r_conj) antagonists_2\NNS|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN|in (l_prep) in_14\IN|chemotherapy (l_pobj) chemotherapy_15\NN|and|model (l_conj) model_20\NN|diabetic|rat (l_compound) rat_19\NN|neuropathy (l_compound) neuropathy_18\NN|
D014750_D006930 CID vincristine_9\NN| (r_pobj) in_8\IN|vincristine (r_prep) antagonists_2\NNS|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN|in
D014750_D006930 CID vincristine_26\NN| (r_pobj) by_25\IN|vincristine (r_agent) produced_24\VBN|by (r_acl) hyperalgesia_23\NN|produced
D014750_D006930 CID vincristine_18\NN| (r_pobj) in_17\IN|vincristine (r_prep) induced_20\VBN|whereas|in|-|hyperalgesia (r_advcl) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_prep) In_0\IN|hyperalgesia (l_pobj) hyperalgesia_4\NN|induced
D014750_D006930 CID vincristine_18\NN| (r_pobj) in_17\IN|vincristine (r_prep) induced_20\VBN|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN|
D014750_D003929 NONE vincristine_9\NN| (r_pobj) in_8\IN|vincristine (r_prep) antagonists_2\NNS|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN|in (l_prep) in_14\IN|chemotherapy (l_pobj) chemotherapy_15\NN|and|model (l_conj) model_20\NN|diabetic|rat (l_compound) rat_19\NN|neuropathy (l_compound) neuropathy_18\NN|
D013311_D006930 CID streptozotocin_11\NNS| (r_conj) antagonists_2\NNS|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN|in
D013311_D006930 CID streptozotocin_1\JJ| (r_npadvmod) induced_3\VBN|streptozotocin|- (r_amod) hyperalgesia_4\NN|induced
D013311_D006930 CID streptozotocin_1\JJ| (r_npadvmod) induced_3\VBN|streptozotocin|- (r_amod) hyperalgesia_4\NN|induced (r_pobj) In_0\IN|hyperalgesia (r_prep) participates_9\VBZ|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN|
D013311_D003929 CID streptozotocin_11\NNS| (r_conj) antagonists_2\NNS|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN|in (l_prep) in_14\IN|chemotherapy (l_pobj) chemotherapy_15\NN|and|model (l_conj) model_20\NN|diabetic|rat (l_compound) rat_19\NN|neuropathy (l_compound) neuropathy_18\NN|
D001920_D009437 NONE bradykinin_8\NN|antagonists (r_pobj) of_7\IN|bradykinin (r_prep) doses_6\NNS|small|of (r_pobj) of_4\IN|doses (r_prep) administration_3\NN|concomitant|of (r_nsubj) be_16\VB|therefore|,|administration|can|effective|,|in|. (l_acomp) effective_17\JJ|in (l_prep) in_18\IN|alleviation (l_pobj) alleviation_19\NN|of (l_prep) of_20\IN|pain (l_pobj) pain_22\NN|neuropathic
D009569_D009437 NONE NO_12\DT| (r_det) inhibitors_14\NNS|no|synthase (r_conj) antagonists_10\NNS|receptor|and|inhibitors (r_dobj) bradykinin_8\NN|antagonists (r_pobj) of_7\IN|bradykinin (r_prep) doses_6\NNS|small|of (r_pobj) of_4\IN|doses (r_prep) administration_3\NN|concomitant|of (r_nsubj) be_16\VB|therefore|,|administration|can|effective|,|in|. (l_acomp) effective_17\JJ|in (l_prep) in_18\IN|alleviation (l_pobj) alleviation_19\NN|of (l_prep) of_20\IN|pain (l_pobj) pain_22\NN|neuropathic
21029050
D013390_D001049 CID succinylcholine_9\NN|for (r_pobj) after_8\IN|succinylcholine (r_prep) mutations_2\NNS|gene|in|after|. (l_prep) in_3\IN|patients (l_pobj) patients_4\NNS|with (l_prep) with_5\IN|apnea (l_pobj) apnea_7\NN|prolonged
D013390_D001049 CID succinylcholine_11\NN| (r_pobj) of_10\IN|succinylcholine (r_prep) action_9\NN|of (r_pobj) of_8\IN|action (r_prep) duration_7\NN|a|prolonged|of (r_pobj) with_4\IN|duration (r_prep) patients_3\NNS|13|with (r_pobj) of_1\IN|patients (r_prep) eleven_0\CD|of (r_nsubj) had_12\VBD|eleven|mutations|,|indicating|. (l_advcl) indicating_17\VBG|is (l_ccomp) is_20\VBZ|that|this|reason (l_attr) reason_23\NN|the|possible|for (l_prep) for_24\IN|period (l_pobj) period_27\NN|a|prolonged|of (l_prep) of_28\IN|apnea (l_pobj) apnea_29\NN|
10737864
D003000_D001919 CID clonidine_14\NN|that (r_pobj) given_12\VBN|clonidine (r_prep) induces_15\VBZ|given|withdrawal (l_dobj) withdrawal_17\NN|sympathetic|and|bradycardia (l_conj) bradycardia_19\NNP|
D003000_D001919 CID clonidine_24\NN|'s (r_poss) effects_27\NNS|clonidine|developmental|on (r_nsubj) mirror_35\VB|that|effects|would|other (r_ccomp) hypothesized_22\VBD|exhibits|,|we|mirror|. (l_ccomp) exhibits_5\VBZ|given|pattern|,|and|induces (l_conj) induces_15\VBZ|given|withdrawal (l_dobj) withdrawal_17\NN|sympathetic|and|bradycardia (l_conj) bradycardia_19\NNP|
D003000_D001919 CID clonidine_19\NN| (r_npadvmod) induced_21\VBN|clonidine|- (r_amod) bradycardia_22\NN|induced
18544179
D005283_D009325 NONE fentanyl_1\NN| (r_dobj) Omitting_0\VBG|fentanyl (r_csubj) reduces_2\VBZ|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN|and|vomiting
D005283_D009325 NONE fentanyl_2\NN| (r_pobj) of_1\IN|fentanyl (r_prep) Omission_0\NN|of (r_nsubj) reduce_5\VB|omission|did|not|incidence|,|but|reduce|. (l_conj) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ|to (l_prep) to_24\TO|nausea (l_pobj) nausea_26\NN|severe
D005283_D009325 NONE fentanyl_37\NN|and (r_nmod) dexamethasone_41\NN|fentanyl|fentanyl|- (r_pobj) with_36\IN|dexamethasone (r_prep) %_35\NN|17|with (r_conj) %_32\NN|20|and|% (r_pobj) from_30\IN|% (r_prep) discharge_29\NN|from|,|respectively (r_pobj) to_28\IN|discharge (r_prep) prior_27\RB|to (r_advmod) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ|to (l_prep) to_24\TO|nausea (l_pobj) nausea_26\NN|severe
D005283_D009325 NONE fentanyl_39\NN| (r_compound) dexamethasone_41\NN|fentanyl|fentanyl|- (r_pobj) with_36\IN|dexamethasone (r_prep) %_35\NN|17|with (r_conj) %_32\NN|20|and|% (r_pobj) from_30\IN|% (r_prep) discharge_29\NN|from|,|respectively (r_pobj) to_28\IN|discharge (r_prep) prior_27\RB|to (r_advmod) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ|to (l_prep) to_24\TO|nausea (l_pobj) nausea_26\NN|severe
D005283_D009325 NONE fentanyl_3\NN|two (r_compound) groups_4\NNS|the|fentanyl (r_dobj) Combining_0\VBG|groups (r_csubj) revealed_5\VBD|combining|benefits|,|reducing|(|p|decreased|. (l_advcl) reducing_15\VBG|nausea|prior (l_dobj) nausea_17\NN|postoperative|and|vomiting (l_conj) vomiting_19\NN|and|nausea (l_conj) nausea_21\NN|
D005283_D009325 NONE fentanyl_3\NN|two (r_compound) groups_4\NNS|the|fentanyl (r_dobj) Combining_0\VBG|groups (r_csubj) revealed_5\VBD|combining|benefits|,|reducing|(|p|decreased|. (l_advcl) decreased_57\VBN|while|nausea|was|from|(|p|) (l_nsubjpass) nausea_50\NN|in|h
D005283_D014839 NONE fentanyl_1\NN| (r_dobj) Omitting_0\VBG|fentanyl (r_csubj) reduces_2\VBZ|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN|and|vomiting (l_conj) vomiting_5\NN|
D005283_D014839 NONE fentanyl_2\NN| (r_pobj) of_1\IN|fentanyl (r_prep) Omission_0\NN|of (r_nsubj) reduce_5\VB|omission|did|not|incidence|,|but|reduce|. (l_conj) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN|the|of (l_prep) of_20\IN|vomiting (l_pobj) vomiting_21\NN|
D005283_D014839 NONE fentanyl_37\NN|and (r_nmod) dexamethasone_41\NN|fentanyl|fentanyl|- (r_pobj) with_36\IN|dexamethasone (r_prep) %_35\NN|17|with (r_conj) %_32\NN|20|and|% (r_pobj) from_30\IN|% (r_prep) discharge_29\NN|from|,|respectively (r_pobj) to_28\IN|discharge (r_prep) prior_27\RB|to (r_advmod) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN|the|of (l_prep) of_20\IN|vomiting (l_pobj) vomiting_21\NN|
D005283_D014839 NONE fentanyl_39\NN| (r_compound) dexamethasone_41\NN|fentanyl|fentanyl|- (r_pobj) with_36\IN|dexamethasone (r_prep) %_35\NN|17|with (r_conj) %_32\NN|20|and|% (r_pobj) from_30\IN|% (r_prep) discharge_29\NN|from|,|respectively (r_pobj) to_28\IN|discharge (r_prep) prior_27\RB|to (r_advmod) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN|the|of (l_prep) of_20\IN|vomiting (l_pobj) vomiting_21\NN|
D005283_D010146 NONE fentanyl_1\NN| (r_dobj) Omitting_0\VBG|fentanyl (r_csubj) reduces_2\VBZ|omitting|nausea|,|without|,|after|. (l_prep) without_7\IN|increasing (l_pcomp) increasing_8\VBG|pain (l_dobj) pain_9\NN|
D005283_D010146 NONE fentanyl_11\NN| (r_pobj) of_10\IN|fentanyl (r_prep) omission_9\NN|the|of (r_pobj) by_7\IN|omission (r_prep) unaffected_6\JJ|by (r_acomp) were_5\VBD|severity|unaffected|. (l_nsubj) severity_1\NN|pain|and|requirements (l_compound) Pain_0\NN|
C009250_D009325 NONE sevoflurane_12\NN|for (r_pobj) after_11\IN|sevoflurane (r_prep) reduces_2\VBZ|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN|and|vomiting
C009250_D014839 NONE sevoflurane_12\NN|for (r_pobj) after_11\IN|sevoflurane (r_prep) reduces_2\VBZ|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN|and|vomiting (l_conj) vomiting_5\NN|
C009250_D010146 NONE sevoflurane_12\NN|for (r_pobj) after_11\IN|sevoflurane (r_prep) reduces_2\VBZ|omitting|nausea|,|without|,|after|. (l_prep) without_7\IN|increasing (l_pcomp) increasing_8\VBG|pain (l_dobj) pain_9\NN|
C009250_D010146 NONE sevoflurane_23\NN| (r_compound) anaesthesia_24\NN|sevoflurane|in (r_pobj) after_22\IN|anaesthesia (r_prep) h_21\NN|the|first|24|after (r_pobj) in_17\IN|h (r_prep) examined_5\VBD|study|incidence|in|. (l_dobj) incidence_7\NN|the|and|severity|of (l_prep) of_10\IN|nausea (l_pobj) nausea_12\NN|postoperative|and|vomiting (l_conj) vomiting_14\NN|and|pain (l_conj) pain_16\NN|
C009250_D020250 NONE sevoflurane_9\NN|, (r_pobj) with_8\IN|sevoflurane (r_prep) advantages_1\NNS|of|with (r_pobj) Despite_0\IN|advantages (r_prep) occurs_15\VBZ|despite|nausea|frequently|. (l_nsubj) nausea_12\NN|postoperative|and|vomiting (l_conj) vomiting_14\NN|
C009250_D020250 NONE sevoflurane_23\NN| (r_compound) anaesthesia_24\NN|sevoflurane|in (r_pobj) after_22\IN|anaesthesia (r_prep) h_21\NN|the|first|24|after (r_pobj) in_17\IN|h (r_prep) examined_5\VBD|study|incidence|in|. (l_dobj) incidence_7\NN|the|and|severity|of (l_prep) of_10\IN|nausea (l_pobj) nausea_12\NN|postoperative|and|vomiting (l_conj) vomiting_14\NN|and|pain
C009250_D020250 NONE sevoflurane_31\NN|to|in (r_relcl) supplement_29\NN|an|unnecessary|sevoflurane (r_attr) be_23\VB|to|supplement (r_xcomp) appears_21\VBZ|exacerbated|,|it|be|. (l_advcl) exacerbated_2\VBD|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN|postoperative|and|vomiting (l_conj) vomiting_6\VBG|without
D005283_D020250 CID fentanyl_2\NN| (r_pobj) of_1\IN|fentanyl (r_prep) Omission_0\NN|of (r_nsubj) reduce_5\VB|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN|the|overall|of (l_prep) of_9\IN|nausea (l_pobj) nausea_11\NN|postoperative|and|vomiting (l_conj) vomiting_13\NN|
D005283_D020250 CID fentanyl_37\NN|and (r_nmod) dexamethasone_41\NN|fentanyl|fentanyl|- (r_pobj) with_36\IN|dexamethasone (r_prep) %_35\NN|17|with (r_conj) %_32\NN|20|and|% (r_pobj) from_30\IN|% (r_prep) discharge_29\NN|from|,|respectively (r_pobj) to_28\IN|discharge (r_prep) prior_27\RB|to (r_advmod) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (r_conj) reduce_5\VB|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN|the|overall|of (l_prep) of_9\IN|nausea (l_pobj) nausea_11\NN|postoperative|and|vomiting (l_conj) vomiting_13\NN|
D005283_D020250 CID fentanyl_39\NN| (r_compound) dexamethasone_41\NN|fentanyl|fentanyl|- (r_pobj) with_36\IN|dexamethasone (r_prep) %_35\NN|17|with (r_conj) %_32\NN|20|and|% (r_pobj) from_30\IN|% (r_prep) discharge_29\NN|from|,|respectively (r_pobj) to_28\IN|discharge (r_prep) prior_27\RB|to (r_advmod) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (r_conj) reduce_5\VB|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN|the|overall|of (l_prep) of_9\IN|nausea (l_pobj) nausea_11\NN|postoperative|and|vomiting (l_conj) vomiting_13\NN|
D005283_D020250 CID fentanyl_3\NN|two (r_compound) groups_4\NNS|the|fentanyl (r_dobj) Combining_0\VBG|groups (r_csubj) revealed_5\VBD|combining|benefits|,|reducing|(|p|decreased|. (l_advcl) reducing_15\VBG|nausea|prior (l_dobj) nausea_17\NN|postoperative|and|vomiting (l_conj) vomiting_19\NN|and|nausea
D005283_D020250 CID fentanyl_1\NN| (r_nsubj) exacerbated_2\VBD|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN|postoperative|and|vomiting (l_conj) vomiting_6\VBG|without
D003907_D020250 NONE dexamethasone_41\NN|fentanyl|fentanyl|- (r_pobj) with_36\IN|dexamethasone (r_prep) %_35\NN|17|with (r_conj) %_32\NN|20|and|% (r_pobj) from_30\IN|% (r_prep) discharge_29\NN|from|,|respectively (r_pobj) to_28\IN|discharge (r_prep) prior_27\RB|to (r_advmod) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (r_conj) reduce_5\VB|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN|the|overall|of (l_prep) of_9\IN|nausea (l_pobj) nausea_11\NN|postoperative|and|vomiting (l_conj) vomiting_13\NN|
D003907_D020250 NONE Dexamethasone_0\NNP| (r_nsubj) had_1\VBD|dexamethasone|effect|. (l_dobj) effect_4\NN|no|significant|on (l_prep) on_5\IN|incidence (l_pobj) incidence_7\NN|the|or|severity|of (l_prep) of_10\IN|nausea (l_pobj) nausea_12\NN|postoperative|and|vomiting (l_conj) vomiting_14\NN|
D003907_D014839 NONE dexamethasone_41\NN|fentanyl|fentanyl|- (r_pobj) with_36\IN|dexamethasone (r_prep) %_35\NN|17|with (r_conj) %_32\NN|20|and|% (r_pobj) from_30\IN|% (r_prep) discharge_29\NN|from|,|respectively (r_pobj) to_28\IN|discharge (r_prep) prior_27\RB|to (r_advmod) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN|the|of (l_prep) of_20\IN|vomiting (l_pobj) vomiting_21\NN|
D003907_D009325 NONE dexamethasone_41\NN|fentanyl|fentanyl|- (r_pobj) with_36\IN|dexamethasone (r_prep) %_35\NN|17|with (r_conj) %_32\NN|20|and|% (r_pobj) from_30\IN|% (r_prep) discharge_29\NN|from|,|respectively (r_pobj) to_28\IN|discharge (r_prep) prior_27\RB|to (r_advmod) reduce_17\VB|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ|to (l_prep) to_24\TO|nausea (l_pobj) nausea_26\NN|severe
D005283_D012131 CID Fentanyl_0\NNP| (r_nsubj) reduce_2\VB|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD|effect|and|depression (l_conj) depression_16\NN|increased|respiratory|,|hypotension
D005283_D007022 CID Fentanyl_0\NNP| (r_nsubj) reduce_2\VB|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD|effect|and|depression (l_conj) depression_16\NN|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN|and|bradycardia
D005283_D001919 CID Fentanyl_0\NNP| (r_nsubj) reduce_2\VB|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD|effect|and|depression (l_conj) depression_16\NN|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN|and|bradycardia (l_conj) bradycardia_20\NN|
C009250_D012131 NONE sevoflurane_9\NN| (r_npadvmod) sparing_11\VBG|sevoflurane|- (r_amod) effect_12\NN|no|sparing (r_dobj) had_7\VBD|effect|and|depression (l_conj) depression_16\NN|increased|respiratory|,|hypotension
C009250_D007022 NONE sevoflurane_9\NN| (r_npadvmod) sparing_11\VBG|sevoflurane|- (r_amod) effect_12\NN|no|sparing (r_dobj) had_7\VBD|effect|and|depression (l_conj) depression_16\NN|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN|and|bradycardia
C009250_D001919 NONE sevoflurane_9\NN| (r_npadvmod) sparing_11\VBG|sevoflurane|- (r_amod) effect_12\NN|no|sparing (r_dobj) had_7\VBD|effect|and|depression (l_conj) depression_16\NN|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN|and|bradycardia (l_conj) bradycardia_20\NN|
D005283_D010149 NONE fentanyl_1\NN| (r_nsubj) exacerbated_2\VBD|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN|postoperative|and|vomiting (l_conj) vomiting_6\VBG|without (l_prep) without_7\IN|improvement (l_pobj) improvement_9\NN|an|in (l_prep) in_10\IN|pain (l_pobj) pain_12\NN|postoperative
C009250_D010149 NONE sevoflurane_31\NN|to|in (r_relcl) supplement_29\NN|an|unnecessary|sevoflurane (r_attr) be_23\VB|to|supplement (r_xcomp) appears_21\VBZ|exacerbated|,|it|be|. (l_advcl) exacerbated_2\VBD|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN|postoperative|and|vomiting (l_conj) vomiting_6\VBG|without (l_prep) without_7\IN|improvement (l_pobj) improvement_9\NN|an|in (l_prep) in_10\IN|pain (l_pobj) pain_12\NN|postoperative
11672959
D012460_D003872 CID sulphasalazine_27\NN|oral|for (r_pobj) of_25\IN|sulphasalazine (r_prep) course_24\NN|a|of (r_pobj) of_22\IN|course (r_prep) day_21\NN|the|17th|of (r_pobj) on_18\IN|day (r_prep) beginning_17\VBG|on (r_advcl) developed_5\VBD|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN|a|of (l_prep) of_8\IN|dermatitis (l_pobj) dermatitis_9\NN|,|fever
D012460_D005334 CID sulphasalazine_27\NN|oral|for (r_pobj) of_25\IN|sulphasalazine (r_prep) course_24\NN|a|of (r_pobj) of_22\IN|course (r_prep) day_21\NN|the|17th|of (r_pobj) on_18\IN|day (r_prep) beginning_17\VBG|on (r_advcl) developed_5\VBD|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN|a|of (l_prep) of_8\IN|dermatitis (l_pobj) dermatitis_9\NN|,|fever (l_conj) fever_11\NN|,|lymphadenopathy
D012460_D008206 CID sulphasalazine_27\NN|oral|for (r_pobj) of_25\IN|sulphasalazine (r_prep) course_24\NN|a|of (r_pobj) of_22\IN|course (r_prep) day_21\NN|the|17th|of (r_pobj) on_18\IN|day (r_prep) beginning_17\VBG|on (r_advcl) developed_5\VBD|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN|a|of (l_prep) of_8\IN|dermatitis (l_pobj) dermatitis_9\NN|,|fever (l_conj) fever_11\NN|,|lymphadenopathy (l_conj) lymphadenopathy_13\NN|and|hepatitis
D012460_D056486 CID sulphasalazine_27\NN|oral|for (r_pobj) of_25\IN|sulphasalazine (r_prep) course_24\NN|a|of (r_pobj) of_22\IN|course (r_prep) day_21\NN|the|17th|of (r_pobj) on_18\IN|day (r_prep) beginning_17\VBG|on (r_advcl) developed_5\VBD|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN|a|of (l_prep) of_8\IN|dermatitis (l_pobj) dermatitis_9\NN|,|fever (l_conj) fever_11\NN|,|lymphadenopathy (l_conj) lymphadenopathy_13\NN|and|hepatitis (l_conj) hepatitis_15\NN|
D012460_D001172 NONE sulphasalazine_27\NN|oral|for (l_prep) for_28\IN|arthritis (l_pobj) arthritis_33\NN|negative|rheumatoid
15649445
D012110_D004409 CID reserpine_1\NN|acute|and|subchronic (r_nsubj) change_6\VBP|reserpine|haloperidol|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP|dyskinesia (l_dobj) dyskinesia_14\NN|orofacial|in
D012110_D004409 CID Reserpine-_0\NNP|and|dyskinesia (l_conj) dyskinesia_6\NN|induced|orofacial
D012110_D004409 CID Reserpine-_0\NNP|and|dyskinesia (r_nsubj) are_7\VBP|reserpine-|models|. (l_attr) models_10\NNS|putative|animal|of|related (l_prep) of_11\IN|dyskinesia (l_pobj) dyskinesia_13\JJ|tardive|td
D012110_D004409 CID Reserpine-_0\NNP|and|dyskinesia (r_nsubj) are_7\VBP|reserpine-|models|. (l_attr) models_10\NNS|putative|animal|of|related (l_prep) of_11\IN|dyskinesia (l_pobj) dyskinesia_13\JJ|tardive|td (l_appos) TD_15\NN|(|)
D012110_D004409 CID reserpine_12\NN|acute|and|administration|to (r_pobj) by_10\IN|reserpine (r_prep) induced_7\VBD|in|,|authors|dyskinesia|by|. (l_dobj) dyskinesia_9\NN|orofacial
D006220_D004409 CID haloperidol_4\NN| (r_compound) change_6\VBP|reserpine|haloperidol|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP|dyskinesia (l_dobj) dyskinesia_14\NN|orofacial|in
D006220_D004409 CID haloperidol_2\NN| (r_npadvmod) induced_4\VBN|haloperidol|- (r_amod) dyskinesia_6\NN|induced|orofacial
D006220_D004409 CID haloperidol_2\NN| (r_npadvmod) induced_4\VBN|haloperidol|- (r_amod) dyskinesia_6\NN|induced|orofacial (r_conj) Reserpine-_0\NNP|and|dyskinesia (r_nsubj) are_7\VBP|reserpine-|models|. (l_attr) models_10\NNS|putative|animal|of|related (l_prep) of_11\IN|dyskinesia (l_pobj) dyskinesia_13\JJ|tardive|td
D006220_D004409 CID haloperidol_2\NN| (r_npadvmod) induced_4\VBN|haloperidol|- (r_amod) dyskinesia_6\NN|induced|orofacial (r_conj) Reserpine-_0\NNP|and|dyskinesia (r_nsubj) are_7\VBP|reserpine-|models|. (l_attr) models_10\NNS|putative|animal|of|related (l_prep) of_11\IN|dyskinesia (l_pobj) dyskinesia_13\JJ|tardive|td (l_appos) TD_15\NN|(|)
D006220_D004409 CID haloperidol_15\NN| (r_compound) administration_16\NN|subchronic|haloperidol (r_conj) reserpine_12\NN|acute|and|administration|to (r_pobj) by_10\IN|reserpine (r_prep) induced_7\VBD|in|,|authors|dyskinesia|by|. (l_dobj) dyskinesia_9\NN|orofacial
D018698_D004409 NONE glutamate_9\NN|brain (r_compound) uptake_10\NN|synaptosomal|glutamate (r_dobj) change_6\VBP|reserpine|haloperidol|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP|dyskinesia (l_dobj) dyskinesia_14\NN|orofacial|in
D018698_D004409 NONE glutamate_5\NN| (r_compound) uptake_6\NN|glutamate (r_pobj) in_4\IN|uptake (r_prep) decrease_3\NN|a|in (r_nsubj) correlates_7\VBZ|importantly|,|decrease|negatively|with|. (l_prep) with_9\IN|increase (l_pobj) increase_11\NN|an|in (l_prep) in_12\IN|incidence (l_pobj) incidence_14\NN|the|of (l_prep) of_15\IN|diskinesia (l_pobj) diskinesia_17\NN|orofacial
12707296
D001120_D006973 NONE arginine_2\NN|l|- (r_compound) transport_3\NN|arginine|in|with|. (l_prep) with_6\IN|hypertension (l_pobj) hypertension_10\NN|induced
D001120_D006973 NONE arginine_4\NN| (r_compound) nitric_6\NN|l|-|arginine|- (r_compound) system_8\NN|a|deficient|nitric|oxide (r_nsubjpass) implicated_10\VBN|system|is|in|. (l_prep) in_11\IN|hypertension (l_pobj) hypertension_15\NN|induced
D001120_D006973 NONE arginine_19\NN|l|- (r_compound) system_21\NN|the|arginine|transport (r_pobj) in_15\IN|system (r_prep) abnormalities_14\NNS|in (r_pobj) with_13\IN|abnormalities (r_prep) associated_12\VBN|that|increases|are|not|with (l_nsubjpass) increases_6\NNS|induced|in (l_prep) in_7\IN|pressure (l_pobj) pressure_9\NN|blood
D006854_D006973 NONE cortisol_7\NN| (r_npadvmod) induced_9\VBN|cortisol|- (r_amod) hypertension_10\NN|induced
D006854_D006973 NONE cortisol_12\NN| (r_npadvmod) induced_14\VBN|cortisol|- (r_amod) hypertension_15\NN|induced
D006854_D006973 NONE cortisol_3\NN| (r_npadvmod) induced_5\VBN|cortisol|- (r_amod) increases_6\NNS|induced|in (l_prep) in_7\IN|pressure (l_pobj) pressure_9\NN|blood
D009569_D006973 NONE oxide_7\NN| (r_compound) system_8\NN|a|deficient|nitric|oxide (r_nsubjpass) implicated_10\VBN|system|is|in|. (l_prep) in_11\IN|hypertension (l_pobj) hypertension_15\NN|induced
6466532
D006024_D001919 NONE glycopyrrolate_3\NN|i.v.|and|atropine|in (l_prep) in_6\IN|prevention (l_pobj) prevention_8\NN|the|of (l_prep) of_9\IN|bradycardia (l_pobj) bradycardia_10\NN|and|arrhythmias|following
D006024_D001919 NONE glycopyrrolate_5\NN|kg-1 (r_pobj) of_4\IN|glycopyrrolate (r_prep) administration_3\NN|of (r_pobj) of_2\IN|administration (r_prep) effectiveness_1\NN|the|of|before|,|prevent (l_acl) prevent_27\VB|to|arrhythmia|following (l_dobj) arrhythmia_28\NN|and|bradycardia (l_conj) bradycardia_30\NNP|
D006024_D001145 NONE glycopyrrolate_3\NN|i.v.|and|atropine|in (l_prep) in_6\IN|prevention (l_pobj) prevention_8\NN|the|of (l_prep) of_9\IN|bradycardia (l_pobj) bradycardia_10\NN|and|arrhythmias|following (l_conj) arrhythmias_12\NNS|
D006024_D001145 NONE glycopyrrolate_5\NN|kg-1 (r_pobj) of_4\IN|glycopyrrolate (r_prep) administration_3\NN|of (r_pobj) of_2\IN|administration (r_prep) effectiveness_1\NN|the|of|before|,|prevent (l_acl) prevent_27\VB|to|arrhythmia|following (l_dobj) arrhythmia_28\NN|and|bradycardia
D001285_D001919 NONE atropine_5\NN| (r_conj) glycopyrrolate_3\NN|i.v.|and|atropine|in (l_prep) in_6\IN|prevention (l_pobj) prevention_8\NN|the|of (l_prep) of_9\IN|bradycardia (l_pobj) bradycardia_10\NN|and|arrhythmias|following
D001285_D001919 NONE atropine_12\NN|micrograms (r_conj) kg-1_10\NNS|micrograms|and|atropine (r_dobj) glycopyrrolate_5\NN|kg-1 (r_pobj) of_4\IN|glycopyrrolate (r_prep) administration_3\NN|of (r_pobj) of_2\IN|administration (r_prep) effectiveness_1\NN|the|of|before|,|prevent (l_acl) prevent_27\VB|to|arrhythmia|following (l_dobj) arrhythmia_28\NN|and|bradycardia (l_conj) bradycardia_30\NNP|
D001285_D001145 NONE atropine_5\NN| (r_conj) glycopyrrolate_3\NN|i.v.|and|atropine|in (l_prep) in_6\IN|prevention (l_pobj) prevention_8\NN|the|of (l_prep) of_9\IN|bradycardia (l_pobj) bradycardia_10\NN|and|arrhythmias|following (l_conj) arrhythmias_12\NNS|
D001285_D001145 NONE atropine_12\NN|micrograms (r_conj) kg-1_10\NNS|micrograms|and|atropine (r_dobj) glycopyrrolate_5\NN|kg-1 (r_pobj) of_4\IN|glycopyrrolate (r_prep) administration_3\NN|of (r_pobj) of_2\IN|administration (r_prep) effectiveness_1\NN|the|of|before|,|prevent (l_acl) prevent_27\VB|to|arrhythmia|following (l_dobj) arrhythmia_28\NN|and|bradycardia
D013390_D001919 CID suxamethonium_17\NN|in (r_pobj) of_16\IN|suxamethonium (r_prep) doses_15\NNS|repeated|of (r_pobj) following_13\VBG|doses (r_prep) bradycardia_10\NN|and|arrhythmias|following
D013390_D001919 CID suxamethonium_35\NN|in (r_pobj) of_34\IN|suxamethonium (r_prep) doses_33\NNS|repeated|of (r_pobj) following_31\VBG|doses (r_prep) prevent_27\VB|to|arrhythmia|following (l_dobj) arrhythmia_28\NN|and|bradycardia (l_conj) bradycardia_30\NNP|
D013390_D001145 NONE suxamethonium_17\NN|in (r_pobj) of_16\IN|suxamethonium (r_prep) doses_15\NNS|repeated|of (r_pobj) following_13\VBG|doses (r_prep) bradycardia_10\NN|and|arrhythmias|following (l_conj) arrhythmias_12\NNS|
D013390_D001145 NONE suxamethonium_35\NN|in (r_pobj) of_34\IN|suxamethonium (r_prep) doses_33\NNS|repeated|of (r_pobj) following_31\VBG|doses (r_prep) prevent_27\VB|to|arrhythmia|following (l_dobj) arrhythmia_28\NN|and|bradycardia
9672936
D008614_D012640 CID Pethidine_0\NNP| (r_npadvmod) associated_2\VBN|pethidine|- (r_amod) seizure_3\NN|associated|in|.
D008614_D012640 CID pethidine_9\NN| (r_dobj) receiving_8\VBG|pethidine|for (r_acl) adolescent_7\JJ|a|healthy|receiving (r_pobj) in_4\IN|adolescent (r_prep) seizure_3\NN|associated|in|.
D008614_D010149 NONE Pethidine_0\NNP| (r_npadvmod) associated_2\VBN|pethidine|- (r_amod) seizure_3\NN|associated|in|. (l_prep) in_4\IN|adolescent (l_pobj) adolescent_7\JJ|a|healthy|receiving (l_acl) receiving_8\VBG|pethidine|for (l_prep) for_10\IN|control (l_pobj) control_13\NN|postoperative|pain (l_compound) pain_12\NN|
D008614_D010149 NONE pethidine_9\NN| (r_dobj) receiving_8\VBG|pethidine|for (l_prep) for_10\IN|control (l_pobj) control_13\NN|postoperative|pain (l_compound) pain_12\NN|
D008614_D010149 NONE pethidine_11\NN| (r_pobj) of_10\IN|pethidine (r_prep) doses_9\NNS|a|healthy|old|received|standard|intermittent|of|via (r_nsubj) pump_21\NN|doses|for|. (l_prep) for_22\IN|management (l_pobj) management_23\NN|of (l_prep) of_24\IN|control (l_pobj) control_27\NN|postoperative|pain (l_compound) pain_26\NN|
10579464
C121249_D006948 NONE NRA0160_0\NNP|and|clozapine (r_nsubj) antagonized_3\VBN|nra0160|hyperactivity|. (l_dobj) hyperactivity_5\NN|locomotor|induced
D003024_D006948 NONE clozapine_2\NN| (r_conj) NRA0160_0\NNP|and|clozapine (r_nsubj) antagonized_3\VBN|nra0160|hyperactivity|. (l_dobj) hyperactivity_5\NN|locomotor|induced
D008694_D006948 CID methamphetamine_8\NN|(|map|) (r_pobj) by_7\IN|methamphetamine (r_agent) induced_6\VBN|by|in (r_acl) hyperactivity_5\NN|locomotor|induced
D008694_D006948 CID MAP_10\NNP| (r_appos) methamphetamine_8\NN|(|map|) (r_pobj) by_7\IN|methamphetamine (r_agent) induced_6\VBN|by|in (r_acl) hyperactivity_5\NN|locomotor|induced
C121249_D002375 CID NRA0160_0\NNP|and|clozapine (r_nsubj) induced_4\VBN|nra0160|significantly|catalepsy|in|,|exceed|. (l_dobj) catalepsy_5\NN|
D003024_D002375 CID clozapine_2\NN| (r_conj) NRA0160_0\NNP|and|clozapine (r_nsubj) induced_4\VBN|nra0160|significantly|catalepsy|in|,|exceed|. (l_dobj) catalepsy_5\NN|
14568327
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|levodopa|- (r_amod) dyskinesias_5\NNS|induced|in
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesias_3\NNS|induced|(|lids|)
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesias_3\NNS|induced|(|lids|) (l_appos) LIDs_5\NNPS|
D007980_D004409 CID levodopa_34\NN| (r_compound) therapy_35\NN|levodopa (r_pobj) of_33\IN|therapy (r_prep) duration_32\NN|of (r_conj) response_29\NN|to|and|duration (r_conj) severity_26\NN|rate|,|symptom|,|and|response (r_nsubjpass) involved_38\VBN|to|severity|may|be|in (l_prep) in_39\IN|development (l_pobj) development_41\NN|the|of (l_prep) of_42\IN|lids (l_pobj) LIDs_43\NNS|
D007980_D004409 CID levodopa_22\NN| (r_compound) therapy_23\NN|levodopa (r_pobj) of_21\IN|therapy (r_prep) initiation_20\NN|of (r_pobj) to_19\IN|initiation (r_prep) prior_18\RB|to (r_advmod) developed_24\VBD|monkeys|prior|dyskinesia|days|. (l_dobj) dyskinesia_25\RB|
D007980_D004409 CID levodopa_33\JJ| (r_compound) administration_34\NN|daily|levodopa (r_pobj) of_31\IN|administration (r_prep) days_30\NNS|11|of (r_npadvmod) developed_24\VBD|monkeys|prior|dyskinesia|days|. (l_dobj) dyskinesia_25\RB|
D007980_D004409 CID levodopa_22\NN| (r_compound) therapy_23\NN|levodopa (r_pobj) of_21\IN|therapy (r_prep) initiation_20\NN|of (r_pobj) to_19\IN|initiation (r_prep) prior_18\RB|to (r_advmod) progression_13\NN|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD|progression|resistant|developed|. (l_acomp) resistant_26\JJ|more|to (l_prep) to_27\IN|developing (l_pcomp) developing_28\VBG|lids (l_dobj) LIDs_29\NNS|
D007980_D004409 CID levodopa_22\NN| (r_compound) therapy_23\NN|levodopa (r_pobj) of_21\IN|therapy (r_prep) initiation_20\NN|of (r_pobj) to_19\IN|initiation (r_prep) prior_18\RB|to (r_advmod) progression_13\NN|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD|progression|resistant|developed|. (l_parataxis) developed_34\VBD|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_33\NN|
D007980_D004409 CID levodopa_42\JJ| (r_compound) administration_43\NN|chronic|levodopa (r_pobj) of_40\IN|administration (r_prep) days_39\NNS|146|of (r_pobj) than_37\IN|days (r_prep) sooner_36\RBR|no|than (r_advmod) developed_34\VBD|(|e.g.|,|dyskinesia|sooner|) (r_parataxis) were_24\VBD|progression|resistant|developed|. (l_acomp) resistant_26\JJ|more|to (l_prep) to_27\IN|developing (l_pcomp) developing_28\VBG|lids (l_dobj) LIDs_29\NNS|
D007980_D004409 CID levodopa_42\JJ| (r_compound) administration_43\NN|chronic|levodopa (r_pobj) of_40\IN|administration (r_prep) days_39\NNS|146|of (r_pobj) than_37\IN|days (r_prep) sooner_36\RBR|no|than (r_advmod) developed_34\VBD|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_33\NN|
D007980_D004409 CID levodopa_24\VB| (r_pobj) to_23\IN|levodopa (r_prep) prior_22\RB|to (r_advmod) develop_9\VB|to|lids|with|prior (l_dobj) LIDs_10\NNS|in
D007980_D004409 CID levodopa_24\VB| (r_pobj) to_23\IN|levodopa (r_prep) prior_22\RB|to (r_advmod) develop_9\VB|to|lids|with|prior (r_acl) propensity_7\NN|the|develop (r_pobj) in_5\IN|propensity (r_prep) differences_4\NNS|distinct|in (r_dobj) suggest_2\VBP|data|differences|and|demonstrate|. (l_conj) demonstrate_26\VB|value (l_dobj) value_28\NN|the|of|for (l_prep) for_32\IN|studying (l_pcomp) studying_34\VBG|further|pathophysiology (l_dobj) pathophysiology_36\NN|the|of (l_prep) of_37\IN|lids (l_pobj) LIDs_38\NNS|
D007980_D010300 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|levodopa|- (r_amod) dyskinesias_5\NNS|induced|in (l_prep) in_6\IN|monkeys (l_pobj) monkeys_8\NNS|parkinsonian (l_amod) parkinsonian_7\JJ|
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesias_3\NNS|induced|(|lids|) (r_nsubj) present_7\VBP|dyskinesias|problem|. (l_dobj) problem_10\NN|a|major|for (l_prep) for_11\IN|management (l_pobj) management_16\NN|the|term|of (l_prep) of_17\IN|patients (l_pobj) patients_24\NNS|disease|(|pd|) (l_nmod) disease_20\NN|parkinson
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesias_3\NNS|induced|(|lids|) (r_nsubj) present_7\VBP|dyskinesias|problem|. (l_dobj) problem_10\NN|a|major|for (l_prep) for_11\IN|management (l_pobj) management_16\NN|the|term|of (l_prep) of_17\IN|patients (l_pobj) patients_24\NNS|disease|(|pd|) (l_nmod) PD_22\NNP|
D015632_D010302 CID MPTP_7\NNP| (r_npadvmod) induced_9\VBN|mptp|- (r_amod) parkinsonism_10\NN|induced
D015632_D004409 NONE MPTP_7\NNP| (r_npadvmod) induced_9\VBN|mptp|- (r_amod) parkinsonism_10\NN|induced (r_pobj) of_6\IN|parkinsonism (r_prep) types_5\NNS|different|of (r_pobj) with_3\IN|types (r_prep) Using_0\VBG|monkeys|with (r_advcl) evaluated_15\VBD|using|,|study|degree|. (l_dobj) degree_17\NN|the|involved (l_relcl) involved_38\VBN|to|severity|may|be|in (l_prep) in_39\IN|development (l_pobj) development_41\NN|the|of (l_prep) of_42\IN|lids (l_pobj) LIDs_43\NNS|
D015632_D004409 NONE MPTP_8\NNP|) (r_compound) exposure_9\NN|acute|mptp|,|onset (r_pobj) with_1\IN|exposure (r_prep) Monkeys_0\NNS|with (r_nsubj) developed_24\VBD|monkeys|prior|dyskinesia|days|. (l_dobj) dyskinesia_25\RB|
D015632_D004409 NONE MPTP_8\NNP| (r_compound) exposure_9\NN|term|mptp (r_pobj) with_4\IN|exposure (r_prep) monkeys_3\NNS|with (r_nsubj) progression_13\NN|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD|progression|resistant|developed|. (l_acomp) resistant_26\JJ|more|to (l_prep) to_27\IN|developing (l_pcomp) developing_28\VBG|lids (l_dobj) LIDs_29\NNS|
D015632_D004409 NONE MPTP_8\NNP| (r_compound) exposure_9\NN|term|mptp (r_pobj) with_4\IN|exposure (r_prep) monkeys_3\NNS|with (r_nsubj) progression_13\NN|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD|progression|resistant|developed|. (l_parataxis) developed_34\VBD|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_33\NN|
D007980_D010302 NONE levodopa_34\NN| (r_compound) therapy_35\NN|levodopa (r_pobj) of_33\IN|therapy (r_prep) duration_32\NN|of (r_conj) response_29\NN|to|and|duration (r_conj) severity_26\NN|rate|,|symptom|,|and|response (r_nsubjpass) involved_38\VBN|to|severity|may|be|in (r_relcl) degree_17\NN|the|involved (r_dobj) evaluated_15\VBD|using|,|study|degree|. (l_advcl) Using_0\VBG|monkeys|with (l_prep) with_3\IN|types (l_pobj) types_5\NNS|different|of (l_prep) of_6\IN|parkinsonism (l_pobj) parkinsonism_10\NN|induced
869641
D007980_D001919 NONE dopa_9\NN|l|- (r_pobj) by_6\IN|dopa (r_prep) Mediation_0\NN|of|by|via|. (l_prep) of_1\IN|bradycardia (l_pobj) bradycardia_5\NNP|enhanced|reflex|vagal
D007980_D001919 NONE dopa_15\NNP|l|-|,|dihydroxyphenylserine (r_pobj) by_12\IN|dopa (r_agent) enhanced_11\VBN|in|,|bradycardia|was|significantly|by|had|. (l_nsubjpass) bradycardia_4\NN|reflex|caused
D007980_D001919 NONE dopa_28\NNP|l|- (r_pobj) of_25\IN|dopa (r_prep) effect_24\NN|bradycardia|of (l_amod) bradycardia_19\NN|or|enhancing
D007980_D001919 NONE dopa_4\NNP|l|- (r_nsubj) restored_5\VBD|however|,|dopa|bradycardia|. (l_dobj) bradycardia_7\NN|the|caused
D007980_D001919 NONE dopa_6\NNP|l|- (r_nsubj) enhances_7\VBZ|that|dopa|bradycardia|through (l_dobj) bradycardia_9\NN|reflex
D004298_D001919 NONE dopamine_12\NN| (r_compound) formation_13\NN|central|dopamine|in (r_pobj) via_10\IN|formation (r_prep) Mediation_0\NN|of|by|via|. (l_prep) of_1\IN|bradycardia (l_pobj) bradycardia_5\NNP|enhanced|reflex|vagal
D004298_D001919 NONE dopamine_3\NN| (r_compound) oxidase_7\NN|dopamine|-|beta|- (r_compound) inhibitor_8\NN|a|oxidase (r_nsubj) have_12\VB|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN|any|on (l_prep) on_15\IN|hypotension (l_pobj) hypotension_17\NN|the|,|effect (l_appos) effect_24\NN|bradycardia|of (l_amod) bradycardia_19\NN|or|enhancing
D009638_D001919 CID norepinephrine_8\NN|injected (r_pobj) by_6\IN|norepinephrine (r_agent) caused_5\VBN|by (r_acl) bradycardia_4\NN|reflex|caused
D009638_D001919 CID norepinephrine_35\NN| (r_pobj) to_34\IN|norepinephrine (r_prep) responses_33\NNS|reflex|to (r_conj) rate_30\NN|heart|or|responses (r_conj) pressure_27\NN|blood|,|rate (r_pobj) on_25\IN|pressure (r_prep) effect_24\NN|no|on (r_dobj) had_22\VBD|effect (r_conj) enhanced_11\VBN|in|,|bradycardia|was|significantly|by|had|. (l_nsubjpass) bradycardia_4\NN|reflex|caused
D009638_D001919 CID norepinephrine_10\NN| (r_pobj) by_9\IN|norepinephrine (r_agent) caused_8\VBN|by|in (r_acl) bradycardia_7\NN|the|caused
D009638_D001919 CID norepinephrine_18\NN| (r_pobj) to_17\IN|norepinephrine (r_prep) bradycardia_16\NN|the|reflex|to
D015103_D001919 NONE dihydroxyphenylserine_21\NN|threo|- (r_conj) dopa_15\NNP|l|-|,|dihydroxyphenylserine (r_pobj) by_12\IN|dopa (r_agent) enhanced_11\VBN|in|,|bradycardia|was|significantly|by|had|. (l_nsubjpass) bradycardia_4\NN|reflex|caused
D005406_D007022 NONE FLA-63_0\NN| (r_mark) have_12\VB|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN|any|on (l_prep) on_15\IN|hypotension (l_pobj) hypotension_17\NN|the|,|effect
D005406_D001919 NONE FLA-63_0\NN| (r_mark) have_12\VB|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN|any|on (l_prep) on_15\IN|hypotension (l_pobj) hypotension_17\NN|the|,|effect (l_appos) effect_24\NN|bradycardia|of (l_amod) bradycardia_19\NN|or|enhancing
D004298_D007022 NONE dopamine_3\NN| (r_compound) oxidase_7\NN|dopamine|-|beta|- (r_compound) inhibitor_8\NN|a|oxidase (r_nsubj) have_12\VB|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN|any|on (l_prep) on_15\IN|hypotension (l_pobj) hypotension_17\NN|the|,|effect
D007980_D007022 NONE dopa_28\NNP|l|- (r_pobj) of_25\IN|dopa (r_prep) effect_24\NN|bradycardia|of (r_appos) hypotension_17\NN|the|,|effect
D006916_D001919 NONE 5-HTP_0\NNP|i.v.|) (r_nsubj) decreased_6\VBD|5-htp|pressure|and|decreased|. (l_conj) decreased_13\VBD|bradycardia (l_dobj) bradycardia_16\NN|the|reflex|to
3412544
D000082_D014523 NONE paracetamol_1\JJ| (r_nsubj) cause_2\VB|does|paracetamol|cancer|? (l_dobj) cancer_4\NN|urothelial|or|necrosis
D000082_D007681 NONE paracetamol_1\JJ| (r_nsubj) cause_2\VB|does|paracetamol|cancer|? (l_dobj) cancer_4\NN|urothelial|or|necrosis (l_conj) necrosis_8\NN|renal|papillary
D000082_D007681 NONE paracetamol_24\NNP| (r_conj) phenacetin_22\JJ|either|or|paracetamol (r_pobj) of_20\IN|phenacetin (r_prep) consumption_19\NN|of (r_pobj) with_18\IN|consumption (r_prep) associated_17\VBN|with (r_acl) pelvis_12\NN|the|renal|,|ureter|associated (r_pobj) of_9\IN|pelvis (r_prep) necrosis_6\NN|renal|papillary|or|cancer|of
D000082_D007681 NONE paracetamol_12\JJ| (r_compound) consumption_13\NN|paracetamol (r_pobj) from_11\IN|consumption (r_prep) risk_10\NN|an|increased|from|for|or|any (l_prep) for_14\IN|necrosis (l_pobj) necrosis_17\NN|renal|papillary
D010615_D007681 CID phenacetin_22\JJ|either|or|paracetamol (r_pobj) of_20\IN|phenacetin (r_prep) consumption_19\NN|of (r_pobj) with_18\IN|consumption (r_prep) associated_17\VBN|with (r_acl) pelvis_12\NN|the|renal|,|ureter|associated (r_pobj) of_9\IN|pelvis (r_prep) necrosis_6\NN|renal|papillary|or|cancer|of
D010615_D007681 CID phenacetin_13\NN| (r_pobj) of_12\IN|phenacetin (r_prep) consumption_11\NN|of|,|increased (r_pobj) by_10\IN|consumption (r_agent) increased_7\VBN|risk|was|20-fold|by|. (l_nsubjpass) risk_1\NN|the|of (l_prep) of_2\IN|necrosis (l_pobj) necrosis_5\NN|renal|papillary
D010615_D007680 CID phenacetin_13\NN| (r_pobj) of_12\IN|phenacetin (r_prep) consumption_11\NN|of|,|increased (l_relcl) increased_17\VBD|which|also|risk|but|for (l_dobj) risk_19\NN|the|for (l_prep) for_20\IN|cancer (l_pobj) cancer_21\NN|of (l_prep) of_22\IN|pelvis (l_pobj) pelvis_25\NN|the|renal|and|bladder (l_conj) bladder_27\NN|
D010615_D007680 NONE phenacetin_22\JJ|either|or|paracetamol (r_pobj) of_20\IN|phenacetin (r_prep) consumption_19\NN|of (r_pobj) with_18\IN|consumption (r_prep) associated_17\VBN|with (r_acl) pelvis_12\NN|the|renal|,|ureter|associated (l_conj) ureter_14\NN|or|bladder (l_conj) bladder_16\NN|
D010615_D014516 NONE phenacetin_22\JJ|either|or|paracetamol (r_pobj) of_20\IN|phenacetin (r_prep) consumption_19\NN|of (r_pobj) with_18\IN|consumption (r_prep) associated_17\VBN|with (r_acl) pelvis_12\NN|the|renal|,|ureter|associated (l_conj) ureter_14\NN|or|bladder (l_conj) bladder_16\NN|
D010615_D014516 NONE phenacetin_13\NN| (r_pobj) of_12\IN|phenacetin (r_prep) consumption_11\NN|of|,|increased (l_relcl) increased_17\VBD|which|also|risk|but|for (l_conj) for_30\IN|not|cancer (l_pobj) cancer_32\NN|ureteric
D010615_D001749 CID phenacetin_13\NN| (r_pobj) of_12\IN|phenacetin (r_prep) consumption_11\NN|of|,|increased (l_relcl) increased_17\VBD|which|also|risk|but|for (l_dobj) risk_19\NN|the|for (l_prep) for_20\IN|cancer (l_pobj) cancer_21\NN|of (l_prep) of_22\IN|pelvis (l_pobj) pelvis_25\NN|the|renal|and|bladder (l_conj) bladder_27\NN|
D010615_D001749 NONE phenacetin_22\JJ|either|or|paracetamol (r_pobj) of_20\IN|phenacetin (r_prep) consumption_19\NN|of (r_pobj) with_18\IN|consumption (r_prep) associated_17\VBN|with (r_acl) pelvis_12\NN|the|renal|,|ureter|associated (l_conj) ureter_14\NN|or|bladder (l_conj) bladder_16\NN|
D000082_D007680 NONE paracetamol_24\NNP| (r_conj) phenacetin_22\JJ|either|or|paracetamol (r_pobj) of_20\IN|phenacetin (r_prep) consumption_19\NN|of (r_pobj) with_18\IN|consumption (r_prep) associated_17\VBN|with (r_acl) pelvis_12\NN|the|renal|,|ureter|associated (l_conj) ureter_14\NN|or|bladder (l_conj) bladder_16\NN|
D000082_D014516 NONE paracetamol_24\NNP| (r_conj) phenacetin_22\JJ|either|or|paracetamol (r_pobj) of_20\IN|phenacetin (r_prep) consumption_19\NN|of (r_pobj) with_18\IN|consumption (r_prep) associated_17\VBN|with (r_acl) pelvis_12\NN|the|renal|,|ureter|associated (l_conj) ureter_14\NN|or|bladder (l_conj) bladder_16\NN|
D000082_D014516 NONE paracetamol_12\JJ| (r_compound) consumption_13\NN|paracetamol (r_pobj) from_11\IN|consumption (r_prep) risk_10\NN|an|increased|from|for|or|any (r_dobj) substantiate_7\VB|to|risk (r_xcomp) unable_5\JJ|substantiate (r_acomp) were_4\VBD|by|,|we|unable|was|. (l_advcl) was_25\VBD|although|there|suggestion (l_attr) suggestion_27\NN|a|of (l_prep) of_28\IN|association (l_pobj) association_30\NN|an|with (l_prep) with_31\IN|cancer (l_pobj) cancer_32\NN|of (l_prep) of_33\IN|ureter (l_pobj) ureter_35\NN|the
D000082_D001749 NONE paracetamol_24\NNP| (r_conj) phenacetin_22\JJ|either|or|paracetamol (r_pobj) of_20\IN|phenacetin (r_prep) consumption_19\NN|of (r_pobj) with_18\IN|consumption (r_prep) associated_17\VBN|with (r_acl) pelvis_12\NN|the|renal|,|ureter|associated (l_conj) ureter_14\NN|or|bladder (l_conj) bladder_16\NN|
D000082_D009369 NONE paracetamol_12\JJ| (r_compound) consumption_13\NN|paracetamol (r_pobj) from_11\IN|consumption (r_prep) risk_10\NN|an|increased|from|for|or|any (l_conj) any_19\DT|of (l_prep) of_20\IN|cancers (l_pobj) cancers_22\NNS|these
11961407
D014443_D009401 NONE tyrosine_2\NN| (r_compound) phosphatase_3\NN|glepp1|receptor|tyrosine|ptpro|in|. (l_prep) in_7\IN|nephrosis (l_pobj) nephrosis_10\NN|rat|pan
D011692_D009401 CID PAN_9\NNP| (r_compound) nephrosis_10\NN|rat|pan
D011692_D009401 CID aminonucleoside_1\JJ| (r_amod) nephrosis_2\NN|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_11\NN|pan (r_advmod) induced_4\VBN|nephrosis|was|by|aminonucleoside|. (l_nsubjpass) nephrosis_2\NN|puromycin|aminonucleoside
D011692_D009401 CID PAN_13\NNP|(|,|mg/100|bw|) (r_appos) aminonucleoside_11\NN|pan (r_advmod) induced_4\VBN|nephrosis|was|by|aminonucleoside|. (l_nsubjpass) nephrosis_2\NN|puromycin|aminonucleoside
D011692_D011507 CID PAN_21\NNP| (r_compound) injection_22\NN|pan (r_pobj) after_20\IN|injection (r_prep) days_19\NNS|5|80|after (r_npadvmod) analyzed_2\VBN|tissues|were|at|days|include|. (l_advcl) include_26\VB|so|as|to|phase (l_dobj) phase_30\NN|both|the|acute|of|associated|(|days (l_prep) of_31\IN|proteinuria (l_pobj) proteinuria_32\NN|
D011692_D011507 CID PAN_21\NNP| (r_compound) injection_22\NN|pan (r_pobj) after_20\IN|injection (r_prep) days_19\NNS|5|80|after (r_npadvmod) analyzed_2\VBN|tissues|were|at|days|include|. (l_advcl) include_26\VB|so|as|to|phase (l_dobj) phase_30\NN|both|the|acute|of|associated|(|days (l_appos) days_39\NNS|5|)|and|phase (l_conj) phase_47\NN|the|chronic|of|associated (l_prep) of_48\IN|proteinuria (l_pobj) proteinuria_49\NN|
D011692_D005921 NONE PAN_21\NNP| (r_compound) injection_22\NN|pan (r_pobj) after_20\IN|injection (r_prep) days_19\NNS|5|80|after (r_npadvmod) analyzed_2\VBN|tissues|were|at|days|include|. (l_advcl) include_26\VB|so|as|to|phase (l_dobj) phase_30\NN|both|the|acute|of|associated|(|days (l_appos) days_39\NNS|5|)|and|phase (l_conj) phase_47\NN|the|chronic|of|associated (l_acl) associated_50\VBN|with (l_prep) with_51\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_52\NN|(|days|)
3800626
D010423_D009408 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|pentazocine|- (r_amod) myopathy_12\NNS|induced|fibrous (r_pobj) due_6\IN|to|myopathy (r_prep) neuropathy_1\NN|compression|of|due|. (l_prep) of_2\IN|nerve (l_pobj) nerve_5\NN|the|radial
D010423_D009408 CID pentazocine_10\NN| (r_npadvmod) induced_12\VBN|pentazocine|- (r_compound) myopathy_13\NN|induced (r_pobj) by_9\IN|myopathy (r_agent) affected_8\VBN|by (r_acl) muscle_7\NN|fibrotic|affected (r_pobj) due_4\IN|to|muscle (r_amod) neuropathy_3\NN|compression|due
D010423_D020425 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|pentazocine|- (r_amod) myopathy_12\NNS|induced|fibrous (r_pobj) due_6\IN|to|myopathy (r_prep) neuropathy_1\NN|compression|of|due|. (l_prep) of_2\IN|nerve (l_pobj) nerve_5\NN|the|radial
D010423_D005355 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|pentazocine|- (r_amod) myopathy_12\NNS|induced|fibrous
D010423_D005355 CID pentazocine_13\NN| (r_compound) injection_14\NN|repeated|pentazocine (r_pobj) of_11\IN|injection (r_prep) effect_10\NN|a|common|,|known|side|of (r_attr) is_2\VBZ|myopathy|effect|. (l_nsubj) myopathy_1\NN|fibrous
D010423_D005355 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|pentazocine|- (r_amod) myopathy_12\NNS|documented|induced|fibrous|of
D010423_D005355 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|pentazocine|- (r_amod) myopathy_12\NNS|documented|induced|fibrous|of (r_pobj) with_6\IN|myopathy (r_prep) woman_5\NN|a|old|with|bilaterally|and|history (r_pobj) In_0\IN|woman (r_prep) showed_32\VBD|in|,|examination|lesion|,|in|. (l_prep) in_51\IN|addition (l_pobj) addition_52\NN|to (l_prep) to_53\IN|myopathy (l_pobj) myopathy_56\NN|the|fibrous
D010423_D009135 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|pentazocine|- (r_amod) myopathy_12\NNS|induced|fibrous
D010423_D009135 CID pentazocine_13\NN| (r_compound) injection_14\NN|repeated|pentazocine (r_pobj) of_11\IN|injection (r_prep) effect_10\NN|a|common|,|known|side|of (r_attr) is_2\VBZ|myopathy|effect|. (l_nsubj) myopathy_1\NN|fibrous
D010423_D009135 CID pentazocine_10\NN| (r_npadvmod) induced_12\VBN|pentazocine|- (r_compound) myopathy_13\NN|induced
D010423_D009135 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|pentazocine|- (r_amod) myopathy_12\NNS|documented|induced|fibrous|of
D010423_D009135 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|pentazocine|- (r_amod) myopathy_12\NNS|documented|induced|fibrous|of (r_pobj) with_6\IN|myopathy (r_prep) woman_5\NN|a|old|with|bilaterally|and|history (r_pobj) In_0\IN|woman (r_prep) showed_32\VBD|in|,|examination|lesion|,|in|. (l_prep) in_51\IN|addition (l_pobj) addition_52\NN|to (l_prep) to_53\IN|myopathy (l_pobj) myopathy_56\NN|the|fibrous
19387625
D002211_D010146 NONE capsaicin_7\NN| (r_npadvmod) induced_9\VBN|capsaicin|- (r_amod) hyperalgesia_11\NN|induced|secondary (r_pobj) in_6\IN|hyperalgesia (r_prep) intensity_5\NN|perceived|pain|in (l_compound) pain_4\NN|
D002211_D010146 NONE capsaicin_16\NN| (r_npadvmod) induced_18\VBN|capsaicin|- (r_amod) hyperalgesia_20\NN|induced|secondary (r_pobj) in_15\IN|hyperalgesia (r_prep) attention_14\NN|in (r_pobj) by_13\IN|attention (r_agent) affected_12\VBN|that|how|ratings|are|by (l_nsubjpass) ratings_10\NNS|intensity (l_compound) intensity_9\NN|pain (l_compound) pain_8\NN|
D002211_D010146 NONE capsaicin_7\NN| (r_compound) treatment_8\NN|capsaicin|and|modulation (r_pobj) between_6\IN|treatment (r_prep) interaction_5\NN|no|between (r_dobj) showing_3\VBG|interaction (r_csubj) suggest_12\VBP|findings|,|showing|affect|. (l_ccomp) affect_22\VB|that|hyperalgesia|might|pain|through (l_dobj) pain_24\NN|mechanical
D002211_D010146 NONE capsaicin_14\NN| (r_npadvmod) induced_16\VBN|capsaicin|- (r_amod) hyperalgesia_18\NN|induced|secondary|and|attention (r_nsubj) affect_22\VB|that|hyperalgesia|might|pain|through (l_dobj) pain_24\NN|mechanical
D002211_D006930 CID capsaicin_7\NN| (r_npadvmod) induced_9\VBN|capsaicin|- (r_amod) hyperalgesia_11\NN|induced|secondary
D002211_D006930 CID capsaicin_16\NN| (r_npadvmod) induced_18\VBN|capsaicin|- (r_amod) hyperalgesia_20\NN|induced|secondary
D002211_D006930 CID capsaicin_20\NN| (r_npadvmod) untreated_22\VBN|capsaicin|- (r_amod) condition_25\NN|untreated|,|control (r_pobj) of_19\IN|condition (r_prep) that_18\DT|of (r_pobj) to_17\IN|that (r_prep) similar_16\JJ|very|to (r_acomp) is_14\VBZ|that|magnitude|similar (l_nsubj) magnitude_7\NN|the|of (l_prep) of_8\IN|modulation (l_pobj) modulation_10\NN|attentional|in (l_prep) in_11\IN|hyperalgesia (l_pobj) hyperalgesia_13\NN|secondary
D002211_D006930 CID capsaicin_7\NN| (r_compound) treatment_8\NN|capsaicin|and|modulation (r_pobj) between_6\IN|treatment (r_prep) interaction_5\NN|no|between (r_dobj) showing_3\VBG|interaction (r_csubj) suggest_12\VBP|findings|,|showing|affect|. (l_ccomp) affect_22\VB|that|hyperalgesia|might|pain|through (l_nsubj) hyperalgesia_18\NN|induced|secondary|and|attention
D002211_D006930 CID capsaicin_14\NN| (r_npadvmod) induced_16\VBN|capsaicin|- (r_amod) hyperalgesia_18\NN|induced|secondary|and|attention
26094
D008750_D003866 CID dopa_13\NN|methyl (r_pobj) in_11\IN|dopa (r_prep) occurring_10\VBG|in (r_acl) depressions_9\NNS|occurring
D008750_D001523 NONE dopa_13\NN|methyl (r_pobj) in_11\IN|dopa (r_prep) occurring_10\VBG|in (r_acl) depressions_9\NNS|occurring (r_pobj) of_8\IN|depressions (r_prep) number_7\NN|a|significant|of|treated (l_acl) treated_14\VBD|patients (l_dobj) patients_15\NNS|with (l_prep) with_16\IN|histories (l_pobj) histories_18\NNS|psychiatric (l_amod) psychiatric_17\JJ|
10365197
D003042_D019964 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) disorder_4\NN|induced|mood|:|rates|.
D003042_D019964 CID cocaine_14\NN| (r_npadvmod) dependent_16\JJ|cocaine|- (r_amod) sample_17\NN|an|outpatient|dependent (r_pobj) in_11\IN|sample (r_prep) rates_7\NNS|prevalence|and|symptoms|in (r_appos) disorder_4\NN|induced|mood|:|rates|.
D003042_D019964 CID cocaine_1\NN| (r_npadvmod) dependent_3\JJ|cocaine|- (r_amod) outpatients_4\NNS|243|dependent|with|,|disorders (l_prep) with_5\IN|disorder (l_pobj) disorder_10\NN|induced|mood|(|cimd|)
D003042_D019964 CID cocaine_1\NN| (r_npadvmod) dependent_3\JJ|cocaine|- (r_amod) outpatients_4\NNS|243|dependent|with|,|disorders (l_conj) disorders_17\NNS|other|mood|,|or|disorder
D003042_D019964 CID cocaine_1\NN| (r_npadvmod) dependent_3\JJ|cocaine|- (r_amod) outpatients_4\NNS|243|dependent|with|,|disorders (l_conj) disorders_17\NNS|other|mood|,|or|disorder (l_conj) disorder_22\NN|no|mood
D003042_D019964 CID cocaine_6\NN| (r_npadvmod) induced_8\VBN|cocaine|- (r_amod) disorder_10\NN|induced|mood|(|cimd|)
D003042_D019964 CID cocaine_6\NN| (r_npadvmod) induced_8\VBN|cocaine|- (r_amod) disorder_10\NN|induced|mood|(|cimd|) (r_pobj) with_5\IN|disorder (r_prep) outpatients_4\NNS|243|dependent|with|,|disorders (l_conj) disorders_17\NNS|other|mood|,|or|disorder
D003042_D019964 CID cocaine_6\NN| (r_npadvmod) induced_8\VBN|cocaine|- (r_amod) disorder_10\NN|induced|mood|(|cimd|) (r_pobj) with_5\IN|disorder (r_prep) outpatients_4\NNS|243|dependent|with|,|disorders (l_conj) disorders_17\NNS|other|mood|,|or|disorder (l_conj) disorder_22\NN|no|mood
D003042_D001523 NONE Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) disorder_4\NN|induced|mood|:|rates|. (l_appos) rates_7\NNS|prevalence|and|symptoms|in (l_conj) symptoms_10\NNS|psychiatric (l_amod) psychiatric_9\JJ|
D003042_D001523 NONE cocaine_14\NN| (r_npadvmod) dependent_16\JJ|cocaine|- (r_amod) sample_17\NN|an|outpatient|dependent (r_pobj) in_11\IN|sample (r_prep) rates_7\NNS|prevalence|and|symptoms|in (l_conj) symptoms_10\NNS|psychiatric (l_amod) psychiatric_9\JJ|
D003042_D001523 NONE cocaine_1\NN| (r_npadvmod) dependent_3\JJ|cocaine|- (r_amod) outpatients_4\NNS|243|dependent|with|,|disorders (r_nsubjpass) compared_24\VBN|outpatients|were|on|. (l_prep) on_25\IN|measures (l_pobj) measures_26\NNS|of (l_prep) of_27\IN|symptoms (l_pobj) symptoms_29\NNS|psychiatric (l_amod) psychiatric_28\JJ|
D003042_D001523 NONE cocaine_6\NN| (r_npadvmod) induced_8\VBN|cocaine|- (r_amod) disorder_10\NN|induced|mood|(|cimd|) (r_pobj) with_5\IN|disorder (r_prep) outpatients_4\NNS|243|dependent|with|,|disorders (r_nsubjpass) compared_24\VBN|outpatients|were|on|. (l_prep) on_25\IN|measures (l_pobj) measures_26\NNS|of (l_prep) of_27\IN|symptoms (l_pobj) symptoms_29\NNS|psychiatric (l_amod) psychiatric_28\JJ|
D003042_D019970 NONE cocaine_1\NN| (r_npadvmod) dependent_3\JJ|cocaine|- (r_amod) outpatients_4\NNS|243|dependent|with|,|disorders (l_prep) with_5\IN|disorder (l_pobj) disorder_10\NN|induced|mood|(|cimd|) (l_appos) CIMD_12\NNP|
D003042_D019970 NONE cocaine_6\NN| (r_npadvmod) induced_8\VBN|cocaine|- (r_amod) disorder_10\NN|induced|mood|(|cimd|) (l_appos) CIMD_12\NNP|
7881871
D011692_D007674 CID aminonucleoside_7\NN| (r_advmod) induced_9\VBN|aminonucleoside|- (r_amod) nephropathy_10\NN|puromycin|induced
D011692_D007674 CID aminonucleoside_12\NN| (r_nmod) nephropathy_15\NN|puromycin|aminonucleoside|(|pan)-induced
D011692_D007674 CID PAN)-induced_14\JJ| (r_amod) nephropathy_15\NN|puromycin|aminonucleoside|(|pan)-induced
D011692_D007674 CID PAN_14\NNP| (r_compound) nephropathy_15\NN|pan
D010100_D007674 NONE oxygen_1\NN| (r_compound) species_2\NNS|reactive|oxygen (r_nsubjpass) implicated_5\VBN|species|have|been|in|,|with|. (l_prep) in_6\IN|pathogenesis (l_pobj) pathogenesis_8\NN|the|of (l_prep) of_9\IN|nephropathy (l_pobj) nephropathy_15\NN|puromycin|aminonucleoside|(|pan)-induced
D010100_D011507 NONE oxygen_1\NN| (r_compound) species_2\NNS|reactive|oxygen (r_nsubjpass) implicated_5\VBN|species|have|been|in|,|with|. (l_prep) with_17\IN|reducing (l_pcomp) reducing_20\VBG|antioxidants|significantly|proteinuria (l_dobj) proteinuria_22\NN|the
D011692_D011507 CID aminonucleoside_12\NN| (r_nmod) nephropathy_15\NN|puromycin|aminonucleoside|(|pan)-induced (r_pobj) of_9\IN|nephropathy (r_prep) pathogenesis_8\NN|the|of (r_pobj) in_6\IN|pathogenesis (r_prep) implicated_5\VBN|species|have|been|in|,|with|. (l_prep) with_17\IN|reducing (l_pcomp) reducing_20\VBG|antioxidants|significantly|proteinuria (l_dobj) proteinuria_22\NN|the
D011692_D011507 CID PAN)-induced_14\JJ| (r_amod) nephropathy_15\NN|puromycin|aminonucleoside|(|pan)-induced (r_pobj) of_9\IN|nephropathy (r_prep) pathogenesis_8\NN|the|of (r_pobj) in_6\IN|pathogenesis (r_prep) implicated_5\VBN|species|have|been|in|,|with|. (l_prep) with_17\IN|reducing (l_pcomp) reducing_20\VBG|antioxidants|significantly|proteinuria (l_dobj) proteinuria_22\NN|the
D011692_D011507 CID PAN_14\NNP| (r_compound) nephropathy_15\NN|pan (r_pobj) in_13\IN|nephropathy (r_prep) injury_12\NN|the|proteinuric|in
1009330
C004658_D003556 NONE choloroaniline_10\NN|p|- (r_appos) product_7\NN|the|degradation|choloroaniline (r_nsubj) is_11\VBZ|that|product|not|factor (l_attr) factor_15\NN|a|significant|in (l_prep) in_16\IN|cystitis (l_pobj) cystitis_22\NN|associated|erosive
C010882_D003556 CID digluconate_19\NN|chlorhexidine|- (r_npadvmod) associated_20\VBN|digluconate (r_amod) cystitis_22\NN|associated|erosive
D007612_D003556 CID kanamycin_4\NN| (r_compound) colistin_6\NN|kanamycin|-|and|iodine (r_nmod) irrigations_11\NNS|colistin (r_pobj) of_3\IN|irrigations (r_prep) percentage_2\NN|a|high|of (r_nsubjpass) associated_13\VBN|percentage|were|with|and|suggested|. (l_prep) with_14\IN|cystitis (l_pobj) cystitis_16\NN|erosive
D003091_D003556 CID colistin_6\NN|kanamycin|-|and|iodine (r_nmod) irrigations_11\NNS|colistin (r_pobj) of_3\IN|irrigations (r_prep) percentage_2\NN|a|high|of (r_nsubjpass) associated_13\VBN|percentage|were|with|and|suggested|. (l_prep) with_14\IN|cystitis (l_pobj) cystitis_16\NN|erosive
D011206_D003556 CID iodine_10\NN|povidone|- (r_conj) colistin_6\NN|kanamycin|-|and|iodine (r_nmod) irrigations_11\NNS|colistin (r_pobj) of_3\IN|irrigations (r_prep) percentage_2\NN|a|high|of (r_nsubjpass) associated_13\VBN|percentage|were|with|and|suggested|. (l_prep) with_14\IN|cystitis (l_pobj) cystitis_16\NN|erosive
C005253_D003556 NONE Picloxydine_0\NNP| (r_compound) irrigations_1\NNS|picloxydine (r_nsubj) appeared_2\VBD|irrigations|have|but|have (l_xcomp) have_4\VB|to|incidence (l_dobj) incidence_7\NN|a|lower|of (l_prep) of_8\IN|cystitis (l_pobj) cystitis_10\NN|erosive
19729346
D010098_D010146 NONE oxycodone_18\NN|release (r_pobj) of_14\IN|oxycodone (r_prep) dose_13\NN|a|single|10-mg|of|in (r_pobj) of_9\IN|dose (r_prep) effects_8\NNS|the|objective|neurocognitive|of (r_dobj) measured_2\VBD|study|effects|)|,|and|years|adults|. (l_dobj) adults_39\NNS|suffering (l_relcl) suffering_43\VBG|who|were|not|from (l_prep) from_44\IN|pain (l_pobj) pain_49\NN|chronic|daily
D010098_D059350 NONE oxycodone_30\NN|release (r_pobj) of_26\IN|oxycodone (r_prep) dose_25\NN|a|10-mg|of (r_pobj) to_22\IN|dose (r_prep) response_21\NN|to (r_pobj) in_20\IN|response (r_prep) changes_19\NNS|in (r_dobj) suffering_11\VBG|who|are|not|from|changes (l_prep) from_12\IN|pain (l_pobj) pain_14\NN|chronic|,|neurocognitive
12202650
D002211_D063806 NONE Capsaicin_0\NN| (r_npadvmod) induced_2\VBN|capsaicin|- (r_amod) pain_4\NN|induced|muscle
D002211_D010146 CID Capsaicin_0\NNS|g (r_nsubjpass) injected_7\VBN|capsaicin|was|into|induce|. (l_advcl) induce_13\VB|to|pain|in (l_dobj) pain_14\NN|
18439803
C108761_D012640 NONE N-(2-propylpentanoyl)urea_3\NNP| (r_pobj) of_2\IN|n-(2-propylpentanoyl)urea (r_prep) effects_1\NNS|acute|of|on|in|. (l_prep) in_9\IN|seizure (l_pobj) seizure_13\NN|induced|in
C108761_D012640 NONE VPU_0\NNS| (r_nsubj) was_1\VBD|vpu|potent|,|exhibiting|. (l_advcl) exhibiting_7\VBG|dose|was (l_dobj) dose_11\NN|the|median|effective|ed(50|)|of (l_prep) of_16\IN|mg/kg (l_pobj) mg/kg_18\NNS|49|in (l_prep) in_19\IN|protecting (l_pcomp) protecting_20\VBG|rats|against (l_prep) against_22\IN|seizure (l_pobj) seizure_26\NN|induced
C108761_D012640 NONE VPU_5\NNPS|and|vpa (r_nsubj) protect_9\VB|that|vpu|could|animals (l_dobj) animals_11\NNS|the|against (l_prep) against_12\IN|seizure (l_pobj) seizure_16\NN|induced
C108761_D012640 NONE VPU_8\NNP| (r_nsubj) reduce_11\VB|that|vpu|could|drastically|increases (r_relcl) finding_6\NN|the|reduce (r_appos) VPA_3\NNP|,|finding (r_pobj) like_2\IN|vpa (r_prep) account_21\VB|therefore|,|like|should|,|for|. (l_prep) for_27\IN|partly|,|activity (l_pobj) activity_30\NN|its|anticonvulsant|observed (l_acl) observed_31\VBN|in (l_prep) in_32\IN|seizure (l_pobj) seizure_36\NN|induced|in
D000596_D012640 NONE acid_7\NN|amino (r_compound) neurotransmitters_8\NNS|hippocampal|acid (r_pobj) on_4\IN|neurotransmitters (r_prep) effects_1\NNS|acute|of|on|in|. (l_prep) in_9\IN|seizure (l_pobj) seizure_13\NN|induced|in
D000596_D012640 NONE acid_26\NN|amino (r_compound) neurotransmitters_27\NNS|inhibitory|acid (r_pobj) of_23\IN|neurotransmitters (r_prep) reduction_22\NN|the|of (r_nsubj) was_28\VBD|that|reduction|minor|and|offset (r_ccomp) suggested_19\VBN|based|it|is|was|. (l_prep) Based_0\VBN|on (l_prep) on_1\IN|finding (l_pobj) finding_3\NN|the|protect (l_acl) protect_9\VB|that|vpu|could|animals (l_dobj) animals_11\NNS|the|against (l_prep) against_12\IN|seizure (l_pobj) seizure_16\NN|induced
D010862_D012640 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|pilocarpine|- (r_amod) seizure_13\NN|induced|in
D010862_D012640 CID pilocarpine_23\NN| (r_npadvmod) induced_25\VBN|pilocarpine|- (r_amod) seizure_26\NN|induced
D010862_D012640 CID pilocarpine_13\NN| (r_npadvmod) induced_15\VBN|pilocarpine|- (r_amod) seizure_16\NN|induced
D010862_D012640 CID pilocarpine_12\NN| (r_npadvmod) induced_14\VBN|pilocarpine|- (r_amod) increases_15\NNS|induced|in (r_dobj) reduce_11\VB|that|vpu|could|drastically|increases (r_relcl) finding_6\NN|the|reduce (r_appos) VPA_3\NNP|,|finding (r_pobj) like_2\IN|vpa (r_prep) account_21\VB|therefore|,|like|should|,|for|. (l_prep) for_27\IN|partly|,|activity (l_pobj) activity_30\NN|its|anticonvulsant|observed (l_acl) observed_31\VBN|in (l_prep) in_32\IN|seizure (l_pobj) seizure_36\NN|induced|in
D010862_D012640 CID pilocarpine_33\NN| (r_npadvmod) induced_35\VBN|pilocarpine|- (r_amod) seizure_36\NN|induced|in
D014635_D012640 NONE VPA_5\NNP| (r_pobj) than_4\IN|vpa (r_prep) potent_3\JJ|more|than (r_acomp) was_1\VBD|vpu|potent|,|exhibiting|. (l_advcl) exhibiting_7\VBG|dose|was (l_dobj) dose_11\NN|the|median|effective|ed(50|)|of (l_prep) of_16\IN|mg/kg (l_pobj) mg/kg_18\NNS|49|in (l_prep) in_19\IN|protecting (l_pcomp) protecting_20\VBG|rats|against (l_prep) against_22\IN|seizure (l_pobj) seizure_26\NN|induced
D014635_D012640 NONE VPA_32\NNP| (r_pobj) for_31\IN|vpa (r_prep) value_30\NN|the|corresponding|for (r_nsubj) was_33\VBD|whereas|value|mg/kg (r_advcl) exhibiting_7\VBG|dose|was (l_dobj) dose_11\NN|the|median|effective|ed(50|)|of (l_prep) of_16\IN|mg/kg (l_pobj) mg/kg_18\NNS|49|in (l_prep) in_19\IN|protecting (l_pcomp) protecting_20\VBG|rats|against (l_prep) against_22\IN|seizure (l_pobj) seizure_26\NN|induced
D014635_D012640 NONE VPA_7\NNP| (r_conj) VPU_5\NNPS|and|vpa (r_nsubj) protect_9\VB|that|vpu|could|animals (l_dobj) animals_11\NNS|the|against (l_prep) against_12\IN|seizure (l_pobj) seizure_16\NN|induced
D014635_D012640 NONE VPA_3\NNP|,|finding (r_pobj) like_2\IN|vpa (r_prep) account_21\VB|therefore|,|like|should|,|for|. (l_prep) for_27\IN|partly|,|activity (l_pobj) activity_30\NN|its|anticonvulsant|observed (l_acl) observed_31\VBN|in (l_prep) in_32\IN|seizure (l_pobj) seizure_36\NN|induced|in
D018698_D012640 NONE glutamate_38\NN|and|aspartate (r_pobj) of_37\IN|glutamate (r_prep) reduction_36\NN|a|pronounced|of (r_pobj) by_33\IN|reduction (r_agent) offset_32\VBN|by (r_conj) was_28\VBD|that|reduction|minor|and|offset (r_ccomp) suggested_19\VBN|based|it|is|was|. (l_prep) Based_0\VBN|on (l_prep) on_1\IN|finding (l_pobj) finding_3\NN|the|protect (l_acl) protect_9\VB|that|vpu|could|animals (l_dobj) animals_11\NNS|the|against (l_prep) against_12\IN|seizure (l_pobj) seizure_16\NN|induced
D018698_D012640 NONE glutamate_17\NN|and|aspartate (r_pobj) in_16\IN|glutamate (r_prep) increases_15\NNS|induced|in (r_dobj) reduce_11\VB|that|vpu|could|drastically|increases (r_relcl) finding_6\NN|the|reduce (r_appos) VPA_3\NNP|,|finding (r_pobj) like_2\IN|vpa (r_prep) account_21\VB|therefore|,|like|should|,|for|. (l_prep) for_27\IN|partly|,|activity (l_pobj) activity_30\NN|its|anticonvulsant|observed (l_acl) observed_31\VBN|in (l_prep) in_32\IN|seizure (l_pobj) seizure_36\NN|induced|in
D001224_D012640 NONE aspartate_40\NN| (r_conj) glutamate_38\NN|and|aspartate (r_pobj) of_37\IN|glutamate (r_prep) reduction_36\NN|a|pronounced|of (r_pobj) by_33\IN|reduction (r_agent) offset_32\VBN|by (r_conj) was_28\VBD|that|reduction|minor|and|offset (r_ccomp) suggested_19\VBN|based|it|is|was|. (l_prep) Based_0\VBN|on (l_prep) on_1\IN|finding (l_pobj) finding_3\NN|the|protect (l_acl) protect_9\VB|that|vpu|could|animals (l_dobj) animals_11\NNS|the|against (l_prep) against_12\IN|seizure (l_pobj) seizure_16\NN|induced
D001224_D012640 NONE aspartate_19\NN| (r_conj) glutamate_17\NN|and|aspartate (r_pobj) in_16\IN|glutamate (r_prep) increases_15\NNS|induced|in (r_dobj) reduce_11\VB|that|vpu|could|drastically|increases (r_relcl) finding_6\NN|the|reduce (r_appos) VPA_3\NNP|,|finding (r_pobj) like_2\IN|vpa (r_prep) account_21\VB|therefore|,|like|should|,|for|. (l_prep) for_27\IN|partly|,|activity (l_pobj) activity_30\NN|its|anticonvulsant|observed (l_acl) observed_31\VBN|in (l_prep) in_32\IN|seizure (l_pobj) seizure_36\NN|induced|in
8590259
C016986_D015814 CID apraclonidine_8\NN| (r_npadvmod) treated_10\VBN|apraclonidine|- (r_amod) eyes_11\NNS|treated (r_pobj) for_7\IN|eyes (r_prep) significant_6\JJ|statistically|for|throughout|and|significant (r_acomp) were_4\VBD|effects|significant|. (l_nsubj) effects_3\NNS|the|ocular|hypotensive (l_amod) hypotensive_2\JJ|
C016986_D015814 CID apraclonidine_31\NN|% (r_pobj) of_28\IN|apraclonidine (r_prep) administration_27\NN|topical|of (r_pobj) after_25\IN|administration (r_prep) hours_24\NNS|three|after (r_pobj) from_22\IN|hours (r_prep) significant_18\JJ|also|statistically|for|from (r_conj) significant_6\JJ|statistically|for|throughout|and|significant (r_acomp) were_4\VBD|effects|significant|. (l_nsubj) effects_3\NNS|the|ocular|hypotensive (l_amod) hypotensive_2\JJ|
12596116
D015282_D000860 NONE Octreotide_0\NNP| (r_npadvmod) induced_2\VBN|octreotide|-|hypoxemia|. (l_dobj) hypoxemia_3\NN|and|hypertension|in
D015282_D006976 CID Octreotide_0\NNP| (r_npadvmod) induced_2\VBN|octreotide|-|hypoxemia|. (l_dobj) hypoxemia_3\NN|and|hypertension|in (l_conj) hypertension_6\NN|pulmonary
D015282_D006976 CID octreotide_10\NN| (r_advmod) developed_2\VBD|hypertension|after|octreotide|,|enhance|. (l_nsubj) hypertension_1\NN|pulmonary
D015282_D005402 NONE octreotide_10\NN| (r_advmod) developed_2\VBD|hypertension|after|octreotide|,|enhance|. (l_advcl) enhance_13\VB|to|resolution (l_dobj) resolution_14\NN|of (l_prep) of_15\IN|fistula (l_pobj) fistula_17\NN|the
2304736
D011224_D014550 CID Prazosin_0\NN| (r_npadvmod) induced_2\VBN|prazosin|- (r_amod) incontinence_4\NN|induced|stress|.
D011224_D014550 CID prazosin_8\NN|,|drug|, (r_pobj) due_6\IN|to|prazosin (r_amod) case_1\NN|a|of|due (l_prep) of_2\IN|incontinence (l_pobj) incontinence_5\NN|genuine|stress
D011224_D014550 CID prazosin_8\NN| (r_dobj) taking_7\VBG|while|prazosin (r_advcl) present_2\VBP|who|with|taking (l_prep) with_3\IN|incontinence (l_pobj) incontinence_5\NN|stress
D011224_D014549 NONE prazosin_8\NN| (r_dobj) taking_7\VBG|while|prazosin (r_advcl) present_2\VBP|who|with|taking (r_relcl) Patients_0\NNS|present (r_nsubj) change_10\VB|patients|should|medication|before|,|resolve|. (l_advcl) resolve_22\VB|because|incontinence|may|spontaneously|with (l_nsubj) incontinence_20\NN|their
18821488
C080436_D064420 NONE 8-aminoquinoline_8\JJ| (r_compound) 8-[(4-amino_9\CD|8-aminoquinoline (r_compound) l_11\NN|8-[(4-amino|- (r_compound) methylbutyl)amino]-_13\NN|l|- (r_punct) WR242511_18\NNP|the|methylbutyl)amino]-|hexyloxy)-6-methoxy-4-methylquinoline|( (r_pobj) of_6\IN|wr242511 (r_prep) administration_5\NN|of (r_pobj) following_4\VBG|administration (r_prep) Toxicity_0\NN|in|following|)|.
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline_16\NNP|5-(l|- (r_nmod) WR242511_18\NNP|the|methylbutyl)amino]-|hexyloxy)-6-methoxy-4-methylquinoline|( (r_pobj) of_6\IN|wr242511 (r_prep) administration_5\NN|of (r_pobj) following_4\VBG|administration (r_prep) Toxicity_0\NN|in|following|)|.
C068820_D064420 NONE WR242511_18\NNP|the|methylbutyl)amino]-|hexyloxy)-6-methoxy-4-methylquinoline|( (r_pobj) of_6\IN|wr242511 (r_prep) administration_5\NN|of (r_pobj) following_4\VBG|administration (r_prep) Toxicity_0\NN|in|following|)|.
C068820_D064420 NONE WR242511_4\NNP| (r_nsubjpass) pursued_8\VBN|that|wr242511|should|not|be|as|dissociated (l_advcl) dissociated_27\VBN|unless|characteristics|can|be|successfully|from (l_prep) from_28\IN|those (l_pobj) those_29\DT|producing (l_acl) producing_30\VBG|toxicity (l_dobj) toxicity_32\NN|undesirable
C068820_D008708 NONE WR242511_4\NNP|,|produced|, (l_relcl) produced_7\VBD|which|methemoglobinemia|in (l_dobj) methemoglobinemia_9\NN|significant|in
C068820_D006456 CID WR242511_11\NNP|(|3.5|) (r_pobj) of_10\IN|wr242511 (r_prep) postinjection_9\NN|minutes|of (r_dobj) noted_5\VBN|furthermore|,|hemoglobinuria|was|postinjection|,|and|occurred (l_nsubjpass) hemoglobinuria_3\NN|transient
C068820_D011041 NONE WR242511_4\NNP| (r_nsubjpass) pursued_8\VBN|that|wr242511|should|not|be|as|dissociated (l_prep) as_9\IN|pretreatment (l_pobj) pretreatment_11\NN|a|for (l_prep) for_12\IN|poisoning (l_pobj) poisoning_14\NN|cn
8319760
D019808_D009401 NONE 753_1\CD| (r_nummod) Dup_0\NN|753 (r_nsubj) prevents_2\VBZ|dup|development|. (l_dobj) development_4\NN|the|of (l_prep) of_5\IN|puromycin|nephrosis (l_pobj) nephrosis_10\NN|induced
D011692_D009401 NONE aminonucleoside_7\NN| (r_advmod) induced_9\VBN|aminonucleoside|- (r_amod) nephrosis_10\NN|induced
D011692_D009401 NONE aminonucleoside_17\NN| (r_advmod) induced_19\VBN|aminonucleoside|- (r_amod) nephrosis_20\NN|induced
D001806_D009404 NONE urea_17\NN|nitrogen (r_pobj) in_14\IN|urea (r_prep) increase_13\NN|in (r_conj) hypercholesterolemia_11\NN|and|increase (r_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia (r_conj) proteinuria_7\NN|,|hypoalbuminemia (r_pobj) as_6\IN|such|proteinuria (r_prep) syndromes_4\NNS|nephrotic|as
D001806_D011507 NONE urea_17\NN|nitrogen (r_pobj) in_14\IN|urea (r_prep) increase_13\NN|in (r_conj) hypercholesterolemia_11\NN|and|increase (r_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia (r_conj) proteinuria_7\NN|,|hypoalbuminemia
D001806_D034141 NONE urea_17\NN|nitrogen (r_pobj) in_14\IN|urea (r_prep) increase_13\NN|in (r_conj) hypercholesterolemia_11\NN|and|increase (r_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia
D001806_D006937 NONE urea_17\NN|nitrogen (r_pobj) in_14\IN|urea (r_prep) increase_13\NN|in (r_conj) hypercholesterolemia_11\NN|and|increase
D011692_D009404 CID aminonucleoside_26\NN| (r_advmod) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as
D011692_D011507 CID aminonucleoside_26\NN| (r_advmod) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia
D011692_D034141 CID aminonucleoside_26\NN| (r_advmod) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia
D011692_D006937 CID aminonucleoside_26\NN| (r_advmod) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN|and|increase
D019808_D009404 NONE 753_35\CD| (r_nummod) Dup_34\NN|753 (r_nmod) losartan_37\NN|dup|( (r_pobj) of_33\IN|losartan (r_prep) administration_32\NN|oral|of (r_pobj) by_30\IN|administration (r_agent) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as
D019808_D009404 NONE losartan_37\NN|dup|( (r_pobj) of_33\IN|losartan (r_prep) administration_32\NN|oral|of (r_pobj) by_30\IN|administration (r_agent) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as
D019808_D011507 NONE 753_35\CD| (r_nummod) Dup_34\NN|753 (r_nmod) losartan_37\NN|dup|( (r_pobj) of_33\IN|losartan (r_prep) administration_32\NN|oral|of (r_pobj) by_30\IN|administration (r_agent) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia
D019808_D011507 NONE losartan_37\NN|dup|( (r_pobj) of_33\IN|losartan (r_prep) administration_32\NN|oral|of (r_pobj) by_30\IN|administration (r_agent) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia
D019808_D034141 NONE 753_35\CD| (r_nummod) Dup_34\NN|753 (r_nmod) losartan_37\NN|dup|( (r_pobj) of_33\IN|losartan (r_prep) administration_32\NN|oral|of (r_pobj) by_30\IN|administration (r_agent) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia
D019808_D034141 NONE losartan_37\NN|dup|( (r_pobj) of_33\IN|losartan (r_prep) administration_32\NN|oral|of (r_pobj) by_30\IN|administration (r_agent) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia
D019808_D006937 NONE 753_35\CD| (r_nummod) Dup_34\NN|753 (r_nmod) losartan_37\NN|dup|( (r_pobj) of_33\IN|losartan (r_prep) administration_32\NN|oral|of (r_pobj) by_30\IN|administration (r_agent) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN|and|increase
D019808_D006937 NONE losartan_37\NN|dup|( (r_pobj) of_33\IN|losartan (r_prep) administration_32\NN|oral|of (r_pobj) by_30\IN|administration (r_agent) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN|and|increase
D000804_D009404 NONE II_43\NNP| (r_compound) antagonist_45\NN|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as
D000804_D011507 NONE II_43\NNP| (r_compound) antagonist_45\NN|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia
D000804_D034141 NONE II_43\NNP| (r_compound) antagonist_45\NN|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia
D000804_D006937 NONE II_43\NNP| (r_compound) antagonist_45\NN|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|syndromes (l_pobj) syndromes_4\NNS|nephrotic|as (l_prep) as_6\IN|such|proteinuria (l_pobj) proteinuria_7\NN|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN|and|increase
D000809_D009401 NONE angiotensin_10\NN|renin|- (r_compound) system_11\NN|the|angiotensin|in (l_prep) in_12\IN|development (l_pobj) development_14\NN|the|of (l_prep) of_15\IN|puromycin|nephrosis (l_pobj) nephrosis_20\NN|induced
12820454
D016729_D000740 CID acetate_6\NN|cab|[|leuprolide|(|a|)|mg|,|intramuscularly|,|days (r_dobj) received_2\VBD|patients|acetate|and|evaluated|. (l_conj) evaluated_32\VBN|were|for|by (l_prep) for_33\IN|anemia (l_pobj) anemia_34\NN|
D016729_D000740 CID A_10\NNP|lhrh|- (r_appos) acetate_6\NN|cab|[|leuprolide|(|a|)|mg|,|intramuscularly|,|days (r_dobj) received_2\VBD|patients|acetate|and|evaluated|. (l_conj) evaluated_32\VBN|were|for|by (l_prep) for_33\IN|anemia (l_pobj) anemia_34\NN|
D005485_D000740 CID flutamide_23\NN| (r_nmod) tid_25\NN|mg|flutamide|,|,|per (r_conj) days_19\NNS|every|28|plus|tid (r_appos) acetate_6\NN|cab|[|leuprolide|(|a|)|mg|,|intramuscularly|,|days (r_dobj) received_2\VBD|patients|acetate|and|evaluated|. (l_conj) evaluated_32\VBN|were|for|by (l_prep) for_33\IN|anemia (l_pobj) anemia_34\NN|
19767176
C020972_D013226 NONE dithiocarbamate_1\NN|pyrrolidine (r_nsubj) protects_2\VBZ|dithiocarbamate|cortex|. (l_dobj) cortex_5\NN|the|piriform|in (l_prep) in_6\IN|model (l_pobj) model_11\NN|the|pilocarpine|status|epilepticus (l_amod) epilepticus_10\NN|
C020972_D013226 NONE PDTC_3\NNP| (r_pobj) of_2\IN|pdtc (r_prep) effect_1\NN|the|of|on (l_prep) on_4\IN|loss (l_pobj) loss_10\NN|status|associated|cell|in (l_amod) associated_8\VBN|epilepticus|- (l_npadvmod) epilepticus_6\NN|
C020972_D013226 NONE PDTC_4\NNP|mg/kg (r_pobj) with_1\IN|pdtc (r_prep) Treatment_0\NN|with|before (r_nsubj) increased_11\VBD|treatment|epilepticus|significantly|rate|to|. (l_advmod) epilepticus_9\NN|
C020972_D013226 NONE PDTC_4\NNP| (r_nmod) dose_8\NN|mg/kg|pdtc|(|low|- (r_pobj) of_1\IN|dose (r_prep) Administration_0\NN|of|) (r_nsubj) exert_12\VB|administration|did|not|effects|. (l_dobj) effects_14\NNS|major|on (l_prep) on_15\IN|development (l_pobj) development_17\NN|the|of (l_prep) of_18\IN|epilepticus (l_pobj) epilepticus_21\NN|status|or|rate
C020972_D013226 NONE PDTC_16\NNP| (r_npadvmod) treated_18\VBN|pdtc|- (r_amod) rats_19\NNS|treated (r_conj) vehicle-_14\NN|and|rats (r_pobj) in_13\IN|vehicle- (r_prep) identified_12\VBN|decrease|was|in|following|. (l_prep) following_20\VBG|epilepticus (l_pobj) epilepticus_22\NN|status
D010862_D013226 CID pilocarpine_8\NN| (r_amod) model_11\NN|the|pilocarpine|status|epilepticus (l_amod) epilepticus_10\NN|
D010862_D013226 CID pilocarpine_23\NN| (r_compound) model_24\NN|the|rat|fractionated|pilocarpine (r_pobj) in_19\IN|model (r_prep) evaluated_18\VBN|effect|was|in|. (l_nsubjpass) effect_1\NN|the|of|on (l_prep) on_4\IN|loss (l_pobj) loss_10\NN|status|associated|cell|in (l_amod) associated_8\VBN|epilepticus|- (l_npadvmod) epilepticus_6\NN|
D010100_D009410 NONE oxygen_5\NN| (r_compound) species_6\NNS|reactive|oxygen (r_pobj) of_3\IN|species (r_prep) production_2\NN|of|as|activation (r_nsubjpass) implicated_17\VBN|both|,|production|have|been|in|. (l_prep) in_18\IN|damage (l_pobj) damage_21\NN|severe|neuronal|in
D010100_D009410 NONE oxygen_9\NN| (r_compound) species_10\NNS|reactive|oxygen|and|activation|of (r_pobj) of_7\IN|species (r_prep) generation_6\NN|the|of (r_nsubj) plays_17\VBZ|that|generation|role|compared (l_dobj) role_21\NN|a|central|in (l_prep) in_22\IN|damage (l_pobj) damage_27\NN|associated|neuronal|in
C020972_D009410 NONE PDTC_10\NNP|antioxidant (r_conj) inhibitor_7\NN|the|kappab|and|pdtc (r_nsubj) protected_11\VBD|in|,|inhibitor|cortex|,|affect|. (l_advcl) affect_20\VB|whereas|it|did|not|loss (l_dobj) loss_23\NN|hilar|neuronal
D010100_D012640 NONE oxygen_9\NN| (r_compound) species_10\NNS|reactive|oxygen|and|activation|of (r_pobj) of_7\IN|species (r_prep) generation_6\NN|the|of (r_nsubj) plays_17\VBZ|that|generation|role|compared (l_dobj) role_21\NN|a|central|in (l_prep) in_22\IN|damage (l_pobj) damage_27\NN|associated|neuronal|in (l_amod) associated_25\VBN|seizure|- (l_npadvmod) seizure_23\NN|
2312209
D007548_D009203 CID dinitrate_7\NN|isosorbide (r_pobj) of_5\IN|dinitrate (r_prep) administration_4\NN|sublingual|of (r_dobj) following_2\VBG|administration (r_prep) infarction_1\NN|myocardial|following|.
D007548_D009203 CID dinitrate_22\NN|isosorbide (r_pobj) of_20\IN|dinitrate (r_prep) administration_19\NN|the|of (r_pobj) following_17\VBG|administration (r_prep) suffered_8\VBD|necrosis|infarction|following|sublingually|. (l_dobj) infarction_12\NN|a|recurrent|myocardial|of
D007548_D009336 NONE dinitrate_22\NN|isosorbide (r_pobj) of_20\IN|dinitrate (r_prep) administration_19\NN|the|of (r_pobj) following_17\VBG|administration (r_prep) suffered_8\VBD|necrosis|infarction|following|sublingually|. (l_nsubj) necrosis_7\NN|a|old|with|healed|septal
2476560
D001556_D012532 NONE lindane_12\NN|(|hexachloride|)|treatment (r_dobj) consider_11\VBP|initiated|;|most|lindane|. (l_ccomp) initiated_5\VBN|treatment|is|usually|by (l_nsubjpass) Treatment_0\NN|for (l_prep) for_1\IN|scabies (l_pobj) scabies_2\NNS|
D001556_D012532 NONE hexachloride_16\NN|gamma|benzene (r_appos) lindane_12\NN|(|hexachloride|)|treatment (r_dobj) consider_11\VBP|initiated|;|most|lindane|. (l_ccomp) initiated_5\VBN|treatment|is|usually|by (l_nsubjpass) Treatment_0\NN|for (l_prep) for_1\IN|scabies (l_pobj) scabies_2\NNS|
D001556_D002493 CID lindane_4\NN|that (r_dobj) accumulating_2\VBG|evidence|is|lindane (r_csubj) be_6\VB|accumulating|can|toxic|and|associated|. (l_acomp) toxic_7\JJ|to (l_prep) to_8\IN|system (l_pobj) system_12\NN|the|central|nervous
D001556_D000741 CID lindane_4\NN|that (r_dobj) accumulating_2\VBG|evidence|is|lindane (r_csubj) be_6\VB|accumulating|can|toxic|and|associated|. (l_conj) associated_16\VBN|may|be|with (l_prep) with_17\IN|anaemia (l_pobj) anaemia_19\NN|aplastic
10835440
D009553_D020521 NONE nimodipine_3\NN|intravenous|on (r_pobj) of_1\IN|nimodipine (r_prep) Effect_0\NN|of|after|. (l_prep) after_9\IN|stroke (l_pobj) stroke_11\NN|acute
D009553_D020521 NONE Nimodipine_2\NNP| (r_compound) Trial_6\NN|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (l_compound) Stroke_5\NNP|
D009553_D020521 NONE Nimodipine_2\NNP| (r_compound) Trial_6\NN|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (r_nsubj) found_10\VBD|trial|correlation|. (l_dobj) correlation_12\NN|a|between (l_prep) between_13\IN|reduction (l_pobj) reduction_17\NN|induced|in|and|outcome (l_conj) outcome_27\NN|an|unfavorable|in (l_prep) in_28\IN|stroke (l_pobj) stroke_30\NN|acute
D009553_D020521 NONE nimodipine_14\NN| (r_npadvmod) induced_16\VBN|nimodipine|- (r_amod) reduction_17\NN|induced|in|and|outcome (r_pobj) between_13\IN|reduction (r_prep) correlation_12\NN|a|between (r_dobj) found_10\VBD|trial|correlation|. (l_nsubj) Trial_6\NN|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (l_compound) Stroke_5\NNP|
D009553_D020521 NONE nimodipine_14\NN| (r_npadvmod) induced_16\VBN|nimodipine|- (r_amod) reduction_17\NN|induced|in|and|outcome (l_conj) outcome_27\NN|an|unfavorable|in (l_prep) in_28\IN|stroke (l_pobj) stroke_30\NN|acute
D009553_D020521 NONE nimodipine_15\NN|dose (r_pobj) of_11\IN|nimodipine (r_prep) administration_10\NN|the|intravenous|of (r_pobj) after_7\IN|administration (r_prep) worsening_6\VBG|neurological|after|after (l_prep) after_16\IN|stroke (l_pobj) stroke_18\NN|acute
D009553_D007022 CID Nimodipine_2\NNP| (r_compound) Trial_6\NN|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (r_nsubj) found_10\VBD|trial|correlation|. (l_dobj) correlation_12\NN|a|between (l_prep) between_13\IN|reduction (l_pobj) reduction_17\NN|induced|in|and|outcome (l_prep) in_18\IN|pressure (l_pobj) pressure_20\NN|blood|(|bp|)
D009553_D007022 CID nimodipine_14\NN| (r_npadvmod) induced_16\VBN|nimodipine|- (r_amod) reduction_17\NN|induced|in|and|outcome (l_prep) in_18\IN|pressure (l_pobj) pressure_20\NN|blood|(|bp|)
D009553_D007022 CID Nimodipine_0\NNP| (r_compound) treatment_1\NN|nimodipine (r_nsubj) resulted_2\VBD|treatment|in|. (l_prep) in_3\IN|reduction (l_pobj) reduction_7\NN|a|significant|in (l_prep) in_8\IN|bp (l_pobj) BP_10\NNP|systolic|sbp|and|bp
D009553_D002544 NONE nimodipine_34\NN|(|dose|)|n=101|or|nimodipine (r_parataxis) h_28\NN|1|mg|/|nimodipine (r_appos) receive_19\VB|to|placebo|,|h (r_advcl) allocated_17\VBN|methods|were|consecutively|receive|. (l_nsubjpass) METHODS_0\NNS|:|patients (l_appos) Patients_2\NNS|with|(|within|) (l_prep) with_3\IN|diagnosis (l_pobj) diagnosis_6\NN|a|clinical|of (l_prep) of_7\IN|stroke (l_pobj) stroke_9\NN|ischemic
D009553_D002544 NONE nimodipine_49\NN|h|(|dose|)|n=94 (r_conj) nimodipine_34\NN|(|dose|)|n=101|or|nimodipine (r_parataxis) h_28\NN|1|mg|/|nimodipine (r_appos) receive_19\VB|to|placebo|,|h (r_advcl) allocated_17\VBN|methods|were|consecutively|receive|. (l_nsubjpass) METHODS_0\NNS|:|patients (l_appos) Patients_2\NNS|with|(|within|) (l_prep) with_3\IN|diagnosis (l_pobj) diagnosis_6\NN|a|clinical|of (l_prep) of_7\IN|stroke (l_pobj) stroke_9\NN|ischemic
10406016
C007789_D002543 NONE fucoidan_2\JJ| (r_compound) treatment_3\NN|fucoidan|on (l_prep) on_4\IN|hemorrhage (l_pobj) hemorrhage_9\NN|induced|intracerebral|in
C007789_D002543 NONE fucoidan_5\RB|the|sulfated|polysaccharide|,|reported|, (r_dobj) tested_1\VBD|we|fucoidan|in|. (l_prep) in_17\IN|model (l_pobj) model_20\NN|a|rat|of|induced (l_prep) of_21\IN|hemorrhage (l_pobj) hemorrhage_23\NN|intracerebral
C007789_D001925 NONE fucoidan_5\RB|the|sulfated|polysaccharide|,|reported|, (l_relcl) reported_10\VBN|which|has|been|reduce (l_xcomp) reduce_12\VB|to|damage (l_dobj) damage_15\NN|inflammatory|brain
C007789_D020141 CID Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|fucoidan|- (r_amod) rats_3\NNS|treated (r_nsubj) exhibited_4\VBD|rats|evidence|,|had|. (l_dobj) evidence_5\NN|of (l_prep) of_6\IN|clotting (l_pobj) clotting_9\NN|impaired|blood|and|hemodilution
C007789_D020141 CID Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|fucoidan|- (r_amod) rats_3\NNS|treated (r_nsubj) exhibited_4\VBD|rats|evidence|,|had|. (l_dobj) evidence_5\NN|of (l_prep) of_6\IN|clotting (l_pobj) clotting_9\NN|impaired|blood|and|hemodilution (l_conj) hemodilution_11\NN|
C007789_D006406 NONE Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|fucoidan|- (r_amod) rats_3\NNS|treated (r_nsubj) exhibited_4\VBD|rats|evidence|,|had|. (l_conj) had_13\VBD|hematomas|,|and|tended (l_dobj) hematomas_15\NNS|larger
C007789_D006406 NONE Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|fucoidan|- (r_amod) rats_3\NNS|treated (r_nsubj) exhibited_4\VBD|rats|evidence|,|had|. (l_conj) had_13\VBD|hematomas|,|and|tended (l_conj) tended_18\VBD|have (l_xcomp) have_20\VB|to|inflammation|after (l_dobj) inflammation_22\NN|less|in (l_prep) in_23\IN|vicinity (l_pobj) vicinity_25\NN|the|of (l_prep) of_26\IN|hematoma (l_pobj) hematoma_28\NN|the
C007789_D007249 NONE Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|fucoidan|- (r_amod) rats_3\NNS|treated (r_nsubj) exhibited_4\VBD|rats|evidence|,|had|. (l_conj) had_13\VBD|hematomas|,|and|tended (l_conj) tended_18\VBD|have (l_xcomp) have_20\VB|to|inflammation|after (l_dobj) inflammation_22\NN|less|in
19356053
D020123_D011507 CID sirolimus_7\NN| (r_pobj) of_6\IN|sirolimus (r_prep) administration_5\NN|the|of (r_pobj) following_3\VBG|administration|to (r_prep) proteinuria_2\NN|significant|following|.
D020123_D011507 CID sirolimus_16\NN| (r_pobj) of_15\IN|sirolimus (r_prep) use_14\NN|the|of (r_pobj) with_12\IN|use (r_prep) linked_11\VBN|with (r_acl) proteinuria_10\NN|significant|linked
D020123_D011507 CID sirolimus_11\NN| (r_compound) use_12\NN|sirolimus (r_pobj) with_10\IN|use (r_prep) associated_9\VBN|with (r_acl) proteinuria_8\NN|substantial|associated
D020123_D011507 CID sirolimus_12\NN| (r_compound) therapy_13\NN|sirolimus|and|proteinuria (l_conj) proteinuria_15\NN|
D020123_D011507 CID sirolimus_12\NN| (r_compound) therapy_13\NN|sirolimus|and|proteinuria (r_pobj) of_11\IN|therapy (r_prep) commencement_10\NN|the|of (r_pobj) between_8\IN|commencement (r_prep) association_7\NN|the|close|temporal|between (r_nsubj) implicated_16\VBN|in|,|association|sirolimus|as|. (l_prep) as_18\IN|etiology (l_pobj) etiology_22\NN|the|likely|of (l_prep) of_23\IN|proteinuria (l_pobj) proteinuria_25\NN|the
D020123_D011507 CID sirolimus_17\NN| (r_dobj) implicated_16\VBN|in|,|association|sirolimus|as|. (l_nsubj) association_7\NN|the|close|temporal|between (l_prep) between_8\IN|commencement (l_pobj) commencement_10\NN|the|of (l_prep) of_11\IN|therapy (l_pobj) therapy_13\NN|sirolimus|and|proteinuria (l_conj) proteinuria_15\NN|
D020123_D011507 CID sirolimus_17\NN| (r_dobj) implicated_16\VBN|in|,|association|sirolimus|as|. (l_prep) as_18\IN|etiology (l_pobj) etiology_22\NN|the|likely|of (l_prep) of_23\IN|proteinuria (l_pobj) proteinuria_25\NN|the
D020123_D011507 CID sirolimus_16\NN| (r_pobj) of_15\IN|sirolimus (r_prep) initiation_14\NN|the|of|and|development (l_conj) development_19\NN|the|of (l_prep) of_20\IN|proteinuria (l_pobj) proteinuria_24\NN|range
D020123_D011507 CID sirolimus_5\NN| (r_compound) therapy_6\NN|sirolimus (r_pobj) with_4\IN|therapy (r_prep) correlated_1\VBD|proteinuria|strongly|with|compared|. (l_nsubj) Proteinuria_0\NNP|
D020123_D011507 CID sirolimus_6\NN| (r_pobj) of_5\IN|sirolimus (r_prep) discontinuation_4\NN|of (r_nsubj) resulted_7\VBD|in|,|discontinuation|in|,|but|resolution|. (l_conj) resolution_14\NN|not|,|of (l_prep) of_16\IN|proteinuria (l_pobj) proteinuria_17\NN|
D020123_D011507 CID Sirolimus_0\NNP| (r_nsubj) induces_1\VBZ|sirolimus|or|aggravates|. (l_conj) aggravates_3\VBZ|proteinuria|in (l_dobj) proteinuria_7\NN|existing
D020123_D011507 CID sirolimus_10\NN| (r_nsubjpass) withdrawn_12\VBN|when|sirolimus|is (r_advcl) resolve_7\VB|does|not|,|withdrawn (r_conj) improve_2\VB|proteinuria|may|,|but|resolve|. (l_nsubj) Proteinuria_0\NNP|
D020123_D007674 NONE Sirolimus_0\NNP| (r_nsubj) is_1\VBZ|sirolimus|agent|,|and|have|. (l_conj) have_13\VB|may|nephrotoxicity (l_dobj) nephrotoxicity_15\NN|less|than
D003404_D011507 NONE creatinine_22\NN| (r_compound) ratios_23\NNS|creatinine|,|estimate (r_conj) measurement_16\NN|turbidometric|or|protein|ratios (r_pobj) by_14\IN|measurement (r_agent) assessed_9\VBN|in|,|magnitude|was|on|by|. (l_nsubjpass) magnitude_5\NN|the|of (l_prep) of_6\IN|proteinuria (l_pobj) proteinuria_7\NN|
D003404_D011507 NONE creatinine_22\NN| (r_compound) ratios_23\NNS|creatinine|,|estimate (l_appos) estimate_26\NN|an|of|day (l_prep) of_27\IN|grams (l_pobj) grams_28\NNS|of (l_prep) of_29\IN|proteinuria (l_pobj) proteinuria_30\NN|
D020123_D009404 NONE sirolimus_16\NN| (r_pobj) of_15\IN|sirolimus (r_prep) initiation_14\NN|the|of|and|development (l_conj) development_19\NN|the|of (l_prep) of_20\IN|proteinuria (l_pobj) proteinuria_24\NN|range (l_compound) range_23\NN|nephrotic|- (l_amod) nephrotic_21\JJ|
17042910
C065179_D006973 NONE atorvastatin_5\NN| (r_pobj) of_4\IN|atorvastatin (r_prep) effects_3\NNS|oxidant|of|in|. (l_prep) in_6\IN|hypertension (l_pobj) hypertension_10\NN|induced|in
C065179_D006973 NONE Atorvastatin_0\NNP|ato|) (r_nsubj) possesses_4\VBZ|atorvastatin|properties|. (l_dobj) properties_6\NNS|pleiotropic|reported (l_relcl) reported_10\VBN|that|have|been|improve (l_xcomp) improve_12\VB|to|function|through (l_prep) through_15\IN|availability (l_pobj) availability_17\NN|increased|of (l_prep) of_18\IN|production (l_pobj) production_23\NN|no|reduced|o2-|in (l_prep) in_24\IN|forms (l_pobj) forms_26\NNS|various|of (l_prep) of_27\IN|hypertension (l_pobj) hypertension_28\NN|
C065179_D006973 NONE Ato_2\NNP|( (r_appos) Atorvastatin_0\NNP|ato|) (r_nsubj) possesses_4\VBZ|atorvastatin|properties|. (l_dobj) properties_6\NNS|pleiotropic|reported (l_relcl) reported_10\VBN|that|have|been|improve (l_xcomp) improve_12\VB|to|function|through (l_prep) through_15\IN|availability (l_pobj) availability_17\NN|increased|of (l_prep) of_18\IN|production (l_pobj) production_23\NN|no|reduced|o2-|in (l_prep) in_24\IN|forms (l_pobj) forms_26\NNS|various|of (l_prep) of_27\IN|hypertension (l_pobj) hypertension_28\NN|
D003907_D006973 CID dexamethasone_7\NN| (r_npadvmod) induced_9\VBN|dexamethasone|- (r_amod) hypertension_10\NN|induced|in
D003907_D006973 CID Dexamethasone_0\NNP|characterized|production (l_parataxis) characterized_5\VBN|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN|dex)-induced
D003907_D006973 CID Dex)-induced_2\JJ| (r_amod) hypertension_3\NN|dex)-induced
D009569_D006973 NONE oxide_12\NN|nitric (r_nmod) deficiency_16\NN|oxide|(|no|) (r_pobj) with_10\IN|deficiency (r_prep) associated_9\VBN|with (r_acl) dysfunction_8\NN|endothelial|associated (r_pobj) by_6\IN|dysfunction (r_agent) characterized_5\VBN|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN|dex)-induced
D009569_D006973 NONE NO_14\NNP| (r_intj) deficiency_16\NN|oxide|(|no|) (r_pobj) with_10\IN|deficiency (r_prep) associated_9\VBN|with (r_acl) dysfunction_8\NN|endothelial|associated (r_pobj) by_6\IN|dysfunction (r_agent) characterized_5\VBN|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN|dex)-induced
D009569_D006973 NONE NO_19\DT|and (r_amod) production_23\NN|no|reduced|o2-|in (l_prep) in_24\IN|forms (l_pobj) forms_26\NNS|various|of (l_prep) of_27\IN|hypertension (l_pobj) hypertension_28\NN|
D013481_D006973 NONE superoxide_19\NN| (r_advmod) increased_18\VBN|superoxide (r_conj) characterized_5\VBN|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN|dex)-induced
D013481_D006973 NONE O2-_21\NNPS| (r_nmod) production_23\NN|(|o2-|)|. (r_appos) Dexamethasone_0\NNP|characterized|production (l_parataxis) characterized_5\VBN|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN|dex)-induced
D013481_D006973 NONE O2-_22\JJ| (r_compound) production_23\NN|no|reduced|o2-|in (l_prep) in_24\IN|forms (l_pobj) forms_26\NNS|various|of (l_prep) of_27\IN|hypertension (l_pobj) hypertension_28\NN|
17600377
C524754_D003072 NONE coumarate_7\NN|maltolyl|p|- (r_appos) compound_2\NN|a|novel|,|coumarate|, (r_nsubj) attenuates_9\VBZ|compound|deficits|and|shows|. (l_dobj) deficits_11\NNS|cognitive
C524754_D003072 NONE coumarate_11\NN|p|- (r_nsubj) improve_13\VB|whether|coumarate|could|decline (l_dobj) decline_15\NN|cognitive|in
C524754_D003072 NONE coumarate_3\NN|maltolyl|p|- (r_nsubjpass) found_5\VBN|coumarate|was|attenuate|beta|. (l_xcomp) attenuate_7\VB|to|deficits (l_dobj) deficits_9\NNS|cognitive|in|using|observed
C524754_D003072 NONE coumarate_17\NN|p|- (r_nsubj) is_18\VBZ|that|maltolyl|coumarate|candidate (l_attr) candidate_22\NN|a|effective|against|characterized (l_relcl) characterized_29\VBN|that|is|by (l_agent) by_30\IN|death (l_pobj) death_34\NN|spread|neuronal|and|decline (l_conj) decline_37\NN|progressive|of (l_prep) of_38\IN|function (l_pobj) function_40\NN|cognitive
C524754_D003704 NONE coumarate_7\NN|maltolyl|p|- (r_appos) compound_2\NN|a|novel|,|coumarate|, (r_nsubj) attenuates_9\VBZ|compound|deficits|and|shows|. (l_conj) shows_13\VBZ|effects (l_dobj) effects_15\NNS|neuroprotective|in (l_prep) in_16\IN|vitro (l_amod) vitro_17\FW|and|in (l_conj) in_19\IN|models (l_pobj) models_22\NNS|dementia (l_compound) dementia_21\NN|vivo
D012601_D003072 CID scopolamine_17\NN| (r_npadvmod) injected_19\VBN|scopolamine|- (r_amod) rats_20\NNS|injected (r_pobj) in_16\IN|rats|and|in (r_prep) decline_15\NN|cognitive|in
C544092_D003072 NONE beta_24\NN|amyloid (r_pobj) in_22\IN|beta (r_conj) in_16\IN|rats|and|in (r_prep) decline_15\NN|cognitive|in
C544092_D003072 NONE 42)-infused_34\VBN|peptide(1|- (r_amod) rats_35\NNS|42)-infused (r_dobj) beta_31\NN|amyloid|rats (r_advcl) found_5\VBN|coumarate|was|attenuate|beta|. (l_xcomp) attenuate_7\VB|to|deficits (l_dobj) deficits_9\NNS|cognitive|in|using|observed
C524754_D000544 NONE coumarate_17\NN|p|- (r_nsubj) is_18\VBZ|that|maltolyl|coumarate|candidate (l_attr) candidate_22\NN|a|effective|against|characterized (l_prep) against_23\IN|disease (l_pobj) disease_26\NN|alzheimer
C524754_D009410 NONE coumarate_17\NN|p|- (r_nsubj) is_18\VBZ|that|maltolyl|coumarate|candidate (l_attr) candidate_22\NN|a|effective|against|characterized (l_relcl) characterized_29\VBN|that|is|by (l_agent) by_30\IN|death (l_pobj) death_34\NN|spread|neuronal|and|decline
6747681
D002330_D005910 NONE BCNU_3\NNP| (r_compound) chemotherapy_4\NN|arterial|bcnu|for|. (l_prep) for_5\IN|treatment (l_pobj) treatment_6\NN|of (l_prep) of_7\IN|gliomas (l_pobj) gliomas_9\NNS|malignant|of
D002330_D005910 NONE BCNU_7\NNP| (r_nmod) 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN|bcnu|(|) (r_pobj) of_6\IN|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_prep) clearance_5\NN|the|rapid|systemic|of (r_pobj) Because_0\IN|of|clearance (r_prep) provide_17\VB|because|,|administration|should|advantage|. (l_dobj) advantage_20\NN|a|substantial|over (l_prep) over_21\IN|administration (l_pobj) administration_23\NN|intravenous|for (l_prep) for_24\IN|treatment (l_pobj) treatment_26\NN|the|of (l_prep) of_27\IN|gliomas (l_pobj) gliomas_29\NNS|malignant
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN|bcnu|(|) (r_pobj) of_6\IN|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_prep) clearance_5\NN|the|rapid|systemic|of (r_pobj) Because_0\IN|of|clearance (r_prep) provide_17\VB|because|,|administration|should|advantage|. (l_dobj) advantage_20\NN|a|substantial|over (l_prep) over_21\IN|administration (l_pobj) administration_23\NN|intravenous|for (l_prep) for_24\IN|treatment (l_pobj) treatment_26\NN|the|of (l_prep) of_27\IN|gliomas (l_pobj) gliomas_29\NNS|malignant
D002330_D001254 NONE BCNU_29\NNP| (r_compound) therapy_30\NN|arterial|bcnu (r_pobj) of_25\IN|therapy (r_prep) courses_24\NNS|eight|of (r_dobj) received_20\VBD|patients|courses|. (l_nsubj) patients_3\NNS|four|with|to (l_prep) to_8\IN|astrocytomas (l_pobj) astrocytomas_10\NN|iv|,|failed|,
D000431_D014786 NONE ethanol_11\NN| (r_compound) diluent_12\NN|the|ethanol (r_pobj) of_9\IN|diluent (r_prep) concentration_8\NN|the|of (r_nsubjpass) lowered_14\VBN|after|concentration|was (r_advcl) decreased_5\VBD|frequency|lowered|. (l_nsubj) frequency_1\NN|the|of (l_prep) of_2\IN|loss (l_pobj) loss_4\NN|visual
4027862
D003891_D003693 CID Desipramine_0\NN| (r_npadvmod) induced_2\VBN|desipramine|- (r_amod) delirium_3\NN|induced|at|.
D003891_D003693 CID Desipramine_7\NNP| (r_nsubj) developed_8\VBD|patient|desipramine|delirium|was|. (l_dobj) delirium_10\NN|a
18768591
D004317_D009404 CID doxorubicin_8\NN| (r_npadvmod) induced_10\VBN|doxorubicin|- (r_amod) syndrome_12\NN|induced|nephrotic
D004317_D009404 CID Doxorubicin_0\NNP| (r_compound) treatment_1\NN|doxorubicin (r_nsubj) resulted_2\VBD|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD|of (l_prep) of_22\IN|mice (l_pobj) mice_25\NNS|sgk1(-/-|)|leading (l_acl) leading_26\VBG|to (l_prep) to_27\IN|syndrome (l_pobj) syndrome_30\NN|severe|nephrotic|with
D004317_D007674 NONE Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|doxorubicin|- (r_amod) nephropathy_3\NN|induced
D004317_D016055 NONE Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|doxorubicin|- (r_amod) nephropathy_3\NN|induced (r_nsubj) leads_4\VBZ|nephropathy|to|. (l_prep) to_5\IN|channel (l_pobj) channel_8\NN|epithelial|sodium|retention (l_appos) retention_12\NN|(|enac)-dependent|volume|and|fibrosis
D004317_D005355 NONE Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|doxorubicin|- (r_amod) nephropathy_3\NN|induced (r_nsubj) leads_4\VBZ|nephropathy|to|. (l_prep) to_5\IN|channel (l_pobj) channel_8\NN|epithelial|sodium|retention (l_appos) retention_12\NN|(|enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_15\NN|renal
D012964_D007674 NONE sodium_7\NN| (r_compound) channel_8\NN|epithelial|sodium|retention (r_pobj) to_5\IN|channel (r_prep) leads_4\VBZ|nephropathy|to|. (l_nsubj) nephropathy_3\NN|induced
D012964_D016055 NONE sodium_7\NN| (r_compound) channel_8\NN|epithelial|sodium|retention (l_appos) retention_12\NN|(|enac)-dependent|volume|and|fibrosis
D012964_D005355 NONE sodium_7\NN| (r_compound) channel_8\NN|epithelial|sodium|retention (l_appos) retention_12\NN|(|enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_15\NN|renal
D000450_D005355 NONE aldosterone_1\NN| (r_npadvmod) sensitive_3\JJ|aldosterone|- (r_amod) SGK1_10\NNP|the|sensitive|kinase (r_nsubjpass) shown_13\VBN|sgk1|has|been|participate|. (l_xcomp) participate_15\VB|to|in|and|mediate (l_conj) mediate_23\VB|to|fibrosis (l_dobj) fibrosis_25\NN|renal|following
D004317_D011507 CID Doxorubicin_0\NNP| (r_compound) treatment_1\NN|doxorubicin (r_nsubj) resulted_2\VBD|treatment|in|)|and|15/44|. (l_prep) in_3\IN|proteinuria (l_pobj) proteinuria_5\NN|heavy|(|crea|)|in
D004317_D001201 CID Doxorubicin_0\NNP| (r_compound) treatment_1\NN|doxorubicin (r_nsubj) resulted_2\VBD|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD|of (l_prep) of_22\IN|mice (l_pobj) mice_25\NNS|sgk1(-/-|)|leading (l_acl) leading_26\VBG|to (l_prep) to_27\IN|syndrome (l_pobj) syndrome_30\NN|severe|nephrotic|with (l_prep) with_31\IN|ascites (l_pobj) ascites_32\NNS|,|lipidemia
D004317_D006949 CID Doxorubicin_0\NNP| (r_compound) treatment_1\NN|doxorubicin (r_nsubj) resulted_2\VBD|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD|of (l_prep) of_22\IN|mice (l_pobj) mice_25\NNS|sgk1(-/-|)|leading (l_acl) leading_26\VBG|to (l_prep) to_27\IN|syndrome (l_pobj) syndrome_30\NN|severe|nephrotic|with (l_prep) with_31\IN|ascites (l_pobj) ascites_32\NNS|,|lipidemia (l_conj) lipidemia_34\NN|,|and|hypoalbuminemia
D004317_D034141 CID Doxorubicin_0\NNP| (r_compound) treatment_1\NN|doxorubicin (r_nsubj) resulted_2\VBD|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD|of (l_prep) of_22\IN|mice (l_pobj) mice_25\NNS|sgk1(-/-|)|leading (l_acl) leading_26\VBG|to (l_prep) to_27\IN|syndrome (l_pobj) syndrome_30\NN|severe|nephrotic|with (l_prep) with_31\IN|ascites (l_pobj) ascites_32\NNS|,|lipidemia (l_conj) lipidemia_34\NN|,|and|hypoalbuminemia (l_conj) hypoalbuminemia_37\VB|in
D000450_D009404 NONE aldosterone_1\NN| (r_compound) levels_2\NNS|plasma|aldosterone (r_nsubj) increased_3\VBD|levels|in|and|followed|. (l_prep) in_4\IN|mice (l_pobj) mice_6\NNS|nephrotic|of (l_amod) nephrotic_5\JJ|
D014508_D009404 NONE urea_8\NN| (r_compound) concentrations_9\NNS|serum|urea (r_nsubj) increased_10\VBD|during|,|concentrations|faster|in|than|) (l_prep) During_0\IN|course (l_pobj) course_2\NN|the|of (l_prep) of_3\IN|syndrome (l_pobj) syndrome_5\NN|nephrotic
12584269
D020123_D007674 CID SRL_5\NN| (r_nsubj) seems_6\VBZ|srl|act|,|is|. (r_conj) are_1\VBP|these|nephrotoxic|,|but|seems (l_acomp) nephrotoxic_2\JJ|
D020123_D007674 CID SRL_5\NN| (r_nsubj) seems_6\VBZ|srl|act|,|is|. (l_xcomp) act_8\VB|to|differently|displaying (l_advcl) displaying_10\VBG|effects (l_dobj) effects_14\NNS|only|minor|nephrotoxic (l_amod) nephrotoxic_13\JJ|
D020123_D007674 CID SRL_7\NN| (r_nsubjpass) combined_9\VBN|where|srl|was|with (l_prep) with_10\IN|indications (l_pobj) indications_14\NNS|a|calcineurin|inhibitor|of (l_prep) of_15\IN|effect (l_pobj) effect_19\NN|a|synergistic|nephrotoxic (l_amod) nephrotoxic_18\JJ|
D020123_D007674 CID SRL_11\NNP| (r_conj) CsA_9\NNP|plus|srl (r_pobj) of_8\IN|csa (r_prep) effect_7\NN|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ|
D020123_D007674 CID SRL_16\NNP| (r_conj) FK506_14\NNP|plus|srl (r_nsubjpass) tolerated_19\VBN|whereas|fk506|was|better (r_advcl) demonstrated_3\VBD|study|effect|,|tolerated|. (l_dobj) effect_7\NN|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ|
D016559_D005355 NONE FK506_1\NNP|the|plus (r_nmod) combination_4\NN|fk506|srl (r_nsubj) showed_5\VBD|combination|degree|compared|. (l_dobj) degree_10\NN|only|a|higher|of (l_prep) of_11\IN|fibrosis (l_pobj) fibrosis_12\NN|
D020123_D005355 NONE SRL_3\NNP| (r_compound) combination_4\NN|fk506|srl (r_nsubj) showed_5\VBD|combination|degree|compared|. (l_dobj) degree_10\NN|only|a|higher|of (l_prep) of_11\IN|fibrosis (l_pobj) fibrosis_12\NN|
D016572_D007674 CID CsA_9\NNP|plus|srl (r_pobj) of_8\IN|csa (r_prep) effect_7\NN|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ|
D016559_D007674 CID FK506_14\NNP|plus|srl (r_nsubjpass) tolerated_19\VBN|whereas|fk506|was|better (r_advcl) demonstrated_3\VBD|study|effect|,|tolerated|. (l_dobj) effect_7\NN|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ|
8669433
D000082_D007676 NONE acetaminophen_3\NN| (r_pobj) of_2\IN|acetaminophen (r_prep) use_1\NN|habitual|of|as|:|comparison|. (l_prep) as_4\IN|factor (l_pobj) factor_7\NN|a|risk|for (l_prep) for_8\IN|failure (l_pobj) failure_11\NN|chronic|renal
D000082_D007676 NONE acetaminophen_27\NN| (r_pobj) of_26\IN|acetaminophen (r_prep) use_25\NN|habitual|of (r_nsubjpass) associated_30\VBN|that|use|is|also|with|,|with (l_prep) with_31\IN|failure (l_pobj) failure_34\NN|chronic|renal|and|esrd
D000082_D007676 NONE acetaminophen_27\NN| (r_pobj) of_26\IN|acetaminophen (r_prep) use_25\NN|habitual|of (r_nsubjpass) associated_30\VBN|that|use|is|also|with|,|with (l_prep) with_31\IN|failure (l_pobj) failure_34\NN|chronic|renal|and|esrd (l_conj) ESRD_36\NNP|
D000082_D007676 NONE acetaminophen_7\RB| (r_conj) phenacetin_5\NN|both|and|acetaminophen (r_nsubj) contribute_9\VB|that|phenacetin|may|to|,|with (l_prep) to_10\IN|burden (l_pobj) burden_12\NN|the|of (l_prep) of_13\IN|esrd (l_pobj) ESRD_14\NNP|
D000082_D007676 NONE acetaminophen_6\NN| (r_pobj) of_5\IN|acetaminophen (r_prep) use_4\NN|habitual|of|alone (r_nsubj) increases_8\VBZ|that|use|risk (l_dobj) risk_10\NN|the|of (l_prep) of_11\IN|esrd (l_pobj) ESRD_12\NNP|
D010615_D007676 CID phenacetin_16\NN| (r_pobj) with_15\IN|phenacetin (r_prep) comparison_14\NN|a|with (r_appos) use_1\NN|habitual|of|as|:|comparison|. (l_prep) as_4\IN|factor (l_pobj) factor_7\NN|a|risk|for (l_prep) for_8\IN|failure (l_pobj) failure_11\NN|chronic|renal
D010615_D007676 CID phenacetin_14\NN| (r_pobj) of_13\IN|phenacetin (r_prep) use_12\NN|habitual|of (r_nsubjpass) associated_16\VBN|that|use|is|with|,|with (l_prep) with_17\IN|development (l_pobj) development_19\NN|the|of (l_prep) of_20\IN|failure (l_pobj) failure_23\NN|chronic|renal|and|disease
D010615_D007676 CID phenacetin_14\NN| (r_pobj) of_13\IN|phenacetin (r_prep) use_12\NN|habitual|of (r_nsubjpass) associated_16\VBN|that|use|is|with|,|with (l_prep) with_17\IN|development (l_pobj) development_19\NN|the|of (l_prep) of_20\IN|failure (l_pobj) failure_23\NN|chronic|renal|and|disease (l_conj) disease_29\NN|stage|renal|(|esrd|)
D010615_D007676 CID phenacetin_14\NN| (r_pobj) of_13\IN|phenacetin (r_prep) use_12\NN|habitual|of (r_nsubjpass) associated_16\VBN|that|use|is|with|,|with (l_prep) with_17\IN|development (l_pobj) development_19\NN|the|of (l_prep) of_20\IN|failure (l_pobj) failure_23\NN|chronic|renal|and|disease (l_conj) disease_29\NN|stage|renal|(|esrd|) (l_appos) ESRD_31\NNP|
D010615_D007676 CID phenacetin_5\NN|both|and|acetaminophen (r_nsubj) contribute_9\VB|that|phenacetin|may|to|,|with (l_prep) to_10\IN|burden (l_pobj) burden_12\NN|the|of (l_prep) of_13\IN|esrd (l_pobj) ESRD_14\NNP|
234669
D000628_D014693 CID aminophylline_2\NN|on (r_pobj) of_1\IN|aminophylline (r_prep) Effects_0\NNS|of|for|. (l_prep) for_6\IN|initiating (l_pcomp) initiating_7\VBG|fibrillation|during (l_dobj) fibrillation_9\NN|ventricular
D000628_D014693 CID aminophylline_3\NN|on (l_prep) on_4\IN|threshold (l_pobj) threshold_8\NN|the|fibrillation|during (l_compound) fibrillation_7\NN|ventricular
D000628_D014693 CID aminophylline_4\NN| (r_pobj) of_3\IN|aminophylline (r_prep) infusion_2\NN|the|of (r_pobj) During_0\IN|infusion (r_prep) reduced_11\VBN|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN|the|ventricular|fibrillation (l_compound) fibrillation_8\NN|
D000628_D014693 CID aminophylline_30\NN| (r_pobj) of_29\IN|aminophylline (r_prep) infusion_28\NN|of (r_nsubj) resulted_31\VBD|produced|pc02|,|infusion|in|. (l_prep) in_32\IN|decrease (l_pobj) decrease_36\NN|an|greater|in (l_prep) in_37\IN|threshold (l_pobj) threshold_40\NN|fibrillation|to (l_compound) fibrillation_39\NN|ventricular
D000628_D012131 NONE aminophylline_2\NN|on (r_pobj) of_1\IN|aminophylline (r_prep) Effects_0\NNS|of|for|. (l_prep) for_6\IN|initiating (l_pcomp) initiating_7\VBG|fibrillation|during (l_prep) during_10\IN|failure (l_pobj) failure_12\NN|respiratory
D000628_D012131 NONE aminophylline_3\NN|on (r_pobj) of_2\IN|aminophylline (r_prep) effects_1\NNS|the|of|and|during (l_conj) during_16\IN|failure (l_pobj) failure_18\NN|respiratory
D000628_D012131 NONE aminophylline_30\NN| (r_pobj) of_29\IN|aminophylline (r_prep) infusion_28\NN|of (r_nsubj) resulted_31\VBD|produced|pc02|,|infusion|in|. (l_advcl) produced_4\VBN|when|failure|was|by (l_nsubjpass) failure_2\NN|respiratory
D000628_D012131 NONE aminophylline_24\NN|particularly (r_appos) agents_21\NNS|pharmacologic|,|aminophylline|, (r_nsubj) play_27\VB|that|contribute|,|agents|may|role (l_advcl) contribute_8\VB|although|factors|may|to (l_prep) to_9\IN|incidence (l_pobj) incidence_12\NN|the|increased|of (l_prep) of_13\IN|arrhythmias (l_pobj) arrhythmias_15\NNS|ventricular|in (l_prep) in_16\IN|failure (l_pobj) failure_18\NN|respiratory
D010100_D014693 NONE oxygen_26\NN|(|po2 (r_pobj) of_25\IN|oxygen (r_prep) pressures_24\NNS|ph|of (r_nsubjpass) kept_37\VBN|when|pressures|were|within (r_advcl) reduced_11\VBN|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN|the|ventricular|fibrillation (l_compound) fibrillation_8\NN|
C093415_D014693 NONE PO2_28\NNP|)|and|dioxide (r_appos) oxygen_26\NN|(|po2 (r_pobj) of_25\IN|oxygen (r_prep) pressures_24\NNS|ph|of (r_nsubjpass) kept_37\VBN|when|pressures|were|within (r_advcl) reduced_11\VBN|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN|the|ventricular|fibrillation (l_compound) fibrillation_8\NN|
D002245_D014693 NONE dioxide_32\NN|carbon|co2 (r_conj) PO2_28\NNP|)|and|dioxide (r_appos) oxygen_26\NN|(|po2 (r_pobj) of_25\IN|oxygen (r_prep) pressures_24\NNS|ph|of (r_nsubjpass) kept_37\VBN|when|pressures|were|within (r_advcl) reduced_11\VBN|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN|the|ventricular|fibrillation (l_compound) fibrillation_8\NN|
D002245_D014693 NONE CO2_34\NNP|(|) (r_appos) dioxide_32\NN|carbon|co2 (r_conj) PO2_28\NNP|)|and|dioxide (r_appos) oxygen_26\NN|(|po2 (r_pobj) of_25\IN|oxygen (r_prep) pressures_24\NNS|ph|of (r_nsubjpass) kept_37\VBN|when|pressures|were|within (r_advcl) reduced_11\VBN|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN|the|ventricular|fibrillation (l_compound) fibrillation_8\NN|
D000628_D007040 NONE aminophylline_30\NN| (r_pobj) of_29\IN|aminophylline (r_prep) infusion_28\NN|of (r_nsubj) resulted_31\VBD|produced|pc02|,|infusion|in|. (l_advcl) produced_4\VBN|when|failure|was|by (l_agent) by_5\IN|hypoventilation (l_pobj) hypoventilation_6\NN|(|ph|;
D000628_D001145 NONE aminophylline_24\NN|particularly (r_appos) agents_21\NNS|pharmacologic|,|aminophylline|, (r_nsubj) play_27\VB|that|contribute|,|agents|may|role (l_advcl) contribute_8\VB|although|factors|may|to (l_prep) to_9\IN|incidence (l_pobj) incidence_12\NN|the|increased|of (l_prep) of_13\IN|arrhythmias (l_pobj) arrhythmias_15\NNS|ventricular|in
11263551
D016572_D010146 CID cyclosporine-_3\NN|or (r_nmod) levels_7\NNS|cyclosporine-|trough (r_pobj) of_2\IN|levels (r_prep) reduction_1\NN|the|of|and|administration (r_nsubj) led_15\VBD|reduction|to|. (l_prep) to_16\IN|relief (l_pobj) relief_17\NN|of (l_prep) of_18\IN|pain (l_pobj) pain_19\NN|
D016572_D010146 CID cyclosporine_18\NN|or|tacrolimus (r_pobj) of_17\IN|cyclosporine (r_prep) effect_16\NN|a|rare|side|of (r_attr) is_10\VBZ|syndrome|effect|and|diagnosed|. (l_nsubj) Syndrome_6\NNP|the|inhibitor|pain|(|cips|) (l_compound) Pain_5\NNP|induced
D016559_D010146 CID tacrolimus_5\VB| (r_compound) trough_6\NN|tacrolimus (r_compound) levels_7\NNS|cyclosporine-|trough (r_pobj) of_2\IN|levels (r_prep) reduction_1\NN|the|of|and|administration (r_nsubj) led_15\VBD|reduction|to|. (l_prep) to_16\IN|relief (l_pobj) relief_17\NN|of (l_prep) of_18\IN|pain (l_pobj) pain_19\NN|
D016559_D010146 CID tacrolimus_20\NN| (r_conj) cyclosporine_18\NN|or|tacrolimus (r_pobj) of_17\IN|cyclosporine (r_prep) effect_16\NN|a|rare|side|of (r_attr) is_10\VBZ|syndrome|effect|and|diagnosed|. (l_nsubj) Syndrome_6\NNP|the|inhibitor|pain|(|cips|) (l_compound) Pain_5\NNP|induced
D002118_D010146 NONE calcium_12\NN| (r_compound) channel_13\NN|calcium (r_compound) blockers_14\NNS|channel (r_pobj) of_11\IN|blockers (r_prep) administration_10\NN|the|of (r_conj) reduction_1\NN|the|of|and|administration (r_nsubj) led_15\VBD|reduction|to|. (l_prep) to_16\IN|relief (l_pobj) relief_17\NN|of (l_prep) of_18\IN|pain (l_pobj) pain_19\NN|
D016572_-1 NONE cyclosporine_18\NN|or|tacrolimus (r_pobj) of_17\IN|cyclosporine (r_prep) effect_16\NN|a|rare|side|of (r_attr) is_10\VBZ|syndrome|effect|and|diagnosed|. (l_nsubj) Syndrome_6\NNP|the|inhibitor|pain|(|cips|) (l_appos) CIPS_8\NNP|
D016559_-1 NONE tacrolimus_20\NN| (r_conj) cyclosporine_18\NN|or|tacrolimus (r_pobj) of_17\IN|cyclosporine (r_prep) effect_16\NN|a|rare|side|of (r_attr) is_10\VBZ|syndrome|effect|and|diagnosed|. (l_nsubj) Syndrome_6\NNP|the|inhibitor|pain|(|cips|) (l_appos) CIPS_8\NNP|
6503301
D003606_D006504 CID dacarbazine_6\NN| (r_compound) therapy_7\NN|dacarbazine|(|dtic|)|for (r_pobj) after_5\IN|therapy (r_prep) disease_4\NN|occlusive|liver|after|.
D003606_D006504 CID DTIC_9\NNP| (r_appos) therapy_7\NN|dacarbazine|(|dtic|)|for (r_pobj) after_5\IN|therapy (r_prep) disease_4\NN|occlusive|liver|after|.
D003606_D006504 CID dacarbazine_14\NN| (r_nmod) therapy_18\NN|dacarbazine|(|dtic|)|for (r_nsubjpass) reported_22\VBN|case|after|therapy|is|. (l_nsubjpass) case_1\NN|a|of (l_prep) of_2\IN|disease (l_pobj) disease_6\NN|occlusive|of|with (l_prep) of_7\IN|liver (l_pobj) liver_9\NN|the
D003606_D006504 CID DTIC_16\NNP| (r_nmod) therapy_18\NN|dacarbazine|(|dtic|)|for (r_nsubjpass) reported_22\VBN|case|after|therapy|is|. (l_nsubjpass) case_1\NN|a|of (l_prep) of_2\IN|disease (l_pobj) disease_6\NN|occlusive|of|with (l_prep) of_7\IN|liver (l_pobj) liver_9\NN|the
D003606_D008545 NONE dacarbazine_6\NN| (r_compound) therapy_7\NN|dacarbazine|(|dtic|)|for (l_prep) for_11\IN|melanoma (l_pobj) melanoma_12\NN|
D003606_D008545 NONE DTIC_9\NNP| (r_appos) therapy_7\NN|dacarbazine|(|dtic|)|for (l_prep) for_11\IN|melanoma (l_pobj) melanoma_12\NN|
D003606_D008545 NONE dacarbazine_14\NN| (r_nmod) therapy_18\NN|dacarbazine|(|dtic|)|for (l_prep) for_19\IN|melanoma (l_pobj) melanoma_20\NN|
D003606_D008545 NONE DTIC_16\NNP| (r_nmod) therapy_18\NN|dacarbazine|(|dtic|)|for (l_prep) for_19\IN|melanoma (l_pobj) melanoma_20\NN|
15458908
D020849_D010024 NONE Raloxifene_4\NNP| (r_compound) Evaluation_5\NNP|raloxifene|,|trial|, (r_pobj) of_3\IN|evaluation (r_prep) Outcomes_2\NNPS|the|multiple|of (r_nsubj) enrolled_17\VBD|outcomes|women|with|. (l_prep) with_21\IN|osteoporosis (l_pobj) osteoporosis_22\NN|
D020849_D054556 CID raloxifene_11\NN| (r_nsubjpass) associated_13\VBN|:|during|,|raloxifene|was|with|. (l_prep) with_14\IN|risk (l_pobj) risk_17\NN|an|increased|for (l_prep) for_18\IN|thromboembolism (l_pobj) thromboembolism_20\NN|venous|(|risk|;|interval
D020849_D054556 CID Raloxifene_0\NNP| (r_nsubjpass) associated_2\VBN|raloxifene|was|with|,|but|was (l_prep) with_3\IN|risk (l_pobj) risk_6\NN|an|increased|for (l_prep) for_7\IN|thromboembolism (l_pobj) thromboembolism_9\NN|venous
D020849_D002386 NONE Raloxifene_0\NNP| (r_nsubj) increase_3\VB|raloxifene|did|not|risk|,|disease|. (l_dobj) risk_4\NN|for (l_prep) for_5\IN|cataracts (l_pobj) cataracts_6\NNS|(|ci|)
D020849_D002386 NONE Raloxifene_0\NNP| (r_nsubjpass) associated_2\VBN|raloxifene|was|with|,|but|was (l_conj) was_13\VBD|there|risk|. (l_attr) risk_16\NN|no|increased|for (l_prep) for_17\IN|cataracts (l_pobj) cataracts_18\NNS|,|disease
D020849_D005705 NONE Raloxifene_0\NNP| (r_nsubj) increase_3\VB|raloxifene|did|not|risk|,|disease|. (l_dep) disease_20\NN|gallbladder|(|rr|;|ci
D020849_D005705 NONE Raloxifene_0\NNP| (r_nsubjpass) associated_2\VBN|raloxifene|was|with|,|but|was (l_conj) was_13\VBD|there|risk|. (l_attr) risk_16\NN|no|increased|for (l_prep) for_17\IN|cataracts (l_pobj) cataracts_18\NNS|,|disease (l_conj) disease_21\NN|gallbladder|,|hyperplasia
D020849_D004714 NONE Raloxifene_0\NNP| (r_nsubj) increase_3\VB|raloxifene|did|not|risk|,|disease|. (l_dep) disease_20\NN|gallbladder|(|rr|;|ci (l_appos) CI_27\NNP|%|1.3|)|,|hyperplasia (l_appos) hyperplasia_34\NN|endometrial|(|%
D020849_D004714 NONE Raloxifene_0\NNP| (r_nsubjpass) associated_2\VBN|raloxifene|was|with|,|but|was (l_conj) was_13\VBD|there|risk|. (l_attr) risk_16\NN|no|increased|for (l_prep) for_17\IN|cataracts (l_pobj) cataracts_18\NNS|,|disease (l_conj) disease_21\NN|gallbladder|,|hyperplasia (l_conj) hyperplasia_24\NN|endometrial|,|or|cancer
D020849_D016889 NONE Raloxifene_0\NNP| (r_nsubj) increase_3\VB|raloxifene|did|not|risk|,|disease|. (l_dep) disease_20\NN|gallbladder|(|rr|;|ci (l_appos) CI_27\NNP|%|1.3|)|,|hyperplasia (l_appos) hyperplasia_34\NN|endometrial|(|% (l_appos) %_40\NN|rr|;|95|0.4|,|or|cancer|;|% (l_conj) cancer_49\NN|endometrial|(|rr
D020849_D016889 NONE Raloxifene_0\NNP| (r_nsubjpass) associated_2\VBN|raloxifene|was|with|,|but|was (l_conj) was_13\VBD|there|risk|. (l_attr) risk_16\NN|no|increased|for (l_prep) for_17\IN|cataracts (l_pobj) cataracts_18\NNS|,|disease (l_conj) disease_21\NN|gallbladder|,|hyperplasia (l_conj) hyperplasia_24\NN|endometrial|,|or|cancer (l_conj) cancer_28\NN|endometrial
227508
D003000_D006973 NONE clonidine_17\NN|intravenous (r_pobj) by_15\IN|clonidine (r_agent) produced_14\VBN|by (r_acl) pressure_10\NN|blood|and|rate|produced (r_pobj) in_8\IN|pressure (r_prep) decrease_7\NN|the|in (r_dobj) rats_5\NNS|in|,|hypertensive|decrease|,|inhibited|. (l_amod) hypertensive_4\JJ|spontaneously
D003000_D006973 NONE clonidine_7\NN|10(-8|to (r_preconj) In_0\IN|membranes|clonidine (l_pobj) membranes_2\NNS|brain|from (l_prep) from_3\IN|rats (l_pobj) rats_6\NNS|hypertensive (l_amod) hypertensive_5\JJ|spontaneously
D003000_D006973 NONE clonidine_42\NN| (r_npadvmod) suppressible_44\NN|clonidine|- (r_amod) binding_45\NN|suppressible|of (r_dobj) influence_41\VB|naloxone|did|not|binding|)|. (r_conj) influence_18\VB|in|,|did|not|binding|,|and|influence (l_prep) In_0\IN|membranes|clonidine (l_pobj) membranes_2\NNS|brain|from (l_prep) from_3\IN|rats (l_pobj) rats_6\NNS|hypertensive (l_amod) hypertensive_5\JJ|spontaneously
-1_D006973 NONE nalozone_31\NN| (r_pobj) by_30\IN|nalozone (r_agent) reversed_29\VBN|by (r_conj) inhibited_27\VBN|micrograms|,|was|or|reversed|,|mg/kg (r_conj) rats_5\NNS|in|,|hypertensive|decrease|,|inhibited|. (l_amod) hypertensive_4\JJ|spontaneously
-1_D006973 NONE 3H]-naloxone_23\CD|[|(|nm|) (r_pobj) of_21\IN|3h]-naloxone (r_prep) binding_20\NN|stereoselective|of (r_dobj) influence_18\VB|in|,|did|not|binding|,|and|influence (l_prep) In_0\IN|membranes|clonidine (l_pobj) membranes_2\NNS|brain|from (l_prep) from_3\IN|rats (l_pobj) rats_6\NNS|hypertensive (l_amod) hypertensive_5\JJ|spontaneously
-1_D006973 NONE 3H]-dihydroergocryptine_48\CD|[ (r_nummod) nM_51\NNP|3h]-dihydroergocryptine|(|1 (r_pobj) of_46\IN|nm (r_prep) binding_45\NN|suppressible|of (r_dobj) influence_41\VB|naloxone|did|not|binding|)|. (r_conj) influence_18\VB|in|,|did|not|binding|,|and|influence (l_prep) In_0\IN|membranes|clonidine (l_pobj) membranes_2\NNS|brain|from (l_prep) from_3\IN|rats (l_pobj) rats_6\NNS|hypertensive (l_amod) hypertensive_5\JJ|spontaneously
D008750_D007022 CID methyldopa_8\NN|mg/kg|alpha|- (r_pobj) of_3\IN|methyldopa (r_prep) effect_2\NN|the|hypotensive|of (l_amod) hypotensive_1\JJ|
D009270_D007022 NONE naloxone_14\NN| (r_pobj) by_13\IN|naloxone (r_agent) reversed_12\VBN|effect|was|also|partially|by|. (l_nsubjpass) effect_2\NN|the|hypotensive|of (l_amod) hypotensive_1\JJ|
D009270_D006973 NONE naloxone_30\NN|10(-8|to|, (r_nsubj) influence_41\VB|naloxone|did|not|binding|)|. (r_conj) influence_18\VB|in|,|did|not|binding|,|and|influence (l_prep) In_0\IN|membranes|clonidine (l_pobj) membranes_2\NNS|brain|from (l_prep) from_3\IN|rats (l_pobj) rats_6\NNS|hypertensive (l_amod) hypertensive_5\JJ|spontaneously
6286738
D002762_D064420 NONE D3_1\NN|vitamin (r_compound) toxicity_2\NN|d3|in|.
D002762_D064420 NONE D3_3\NNP|vitamin (r_compound) toxicity_4\NN|d3
D002762_D064420 NONE D3_3\NNP|vitamin (r_compound) toxicity_4\NN|d3 (r_pobj) of_1\IN|toxicity (r_prep) Signs_0\NNS|of (r_nsubjpass) observed_7\VBN|signs|were|not|in (r_ccomp) developed_18\VBN|observed|;|however|,|cows|commonly|signs|died|. (l_dobj) signs_20\NNS|severe|of (l_prep) of_21\IN|toxicity (l_pobj) toxicity_24\NN|d3|and|cows
D002762_D064420 NONE D3_23\NNP|vitamin (r_compound) toxicity_24\NN|d3|and|cows (r_pobj) of_21\IN|toxicity (r_prep) signs_20\NNS|severe|of (r_dobj) developed_18\VBN|observed|;|however|,|cows|commonly|signs|died|. (l_ccomp) observed_7\VBN|signs|were|not|in (l_nsubjpass) Signs_0\NNS|of (l_prep) of_1\IN|toxicity (l_pobj) toxicity_4\NN|d3
D002762_D064420 NONE D3_23\NNP|vitamin (r_compound) toxicity_24\NN|d3|and|cows
D002762_D064420 NONE D3_7\NN|vitamin (r_pobj) of_5\IN|d3 (r_prep) toxicity_4\NN|the|extreme|of|in|and|margin
D002762_D064420 NONE D3_22\NNP|vitamin|prevent (r_pobj) of_20\IN|d3 (r_prep) doses_19\NNS|of (r_pobj) between_18\IN|doses (r_prep) safety_17\NN|between (r_pobj) of_16\IN|safety (r_prep) margin_15\NN|the|low|of (r_conj) toxicity_4\NN|the|extreme|of|in|and|margin
D002762_D064420 NONE D3_38\NNP|vitamin (r_nsubjpass) used_42\VBN|that|d3|can|not|be|prevent|injected (r_ccomp) concluded_35\VBD|because|,|we|used|. (l_prep) Because_0\IN|of|toxicity (l_pobj) toxicity_4\NN|the|extreme|of|in|and|margin
D002762_D006934 CID D3_5\NNP|vitamin (r_pobj) of_3\IN|d3 (r_prep) doses_2\NNS|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN|doses|were|with|. (l_prep) with_19\IN|hypercalcemia (l_pobj) hypercalcemia_21\NN|prolonged|,|hyperphosphatemia
D002762_D006934 CID D3_15\NNP|17.5|x|iu|vitamin (r_appos) doses_2\NNS|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN|doses|were|with|. (l_prep) with_19\IN|hypercalcemia (l_pobj) hypercalcemia_21\NN|prolonged|,|hyperphosphatemia
D002762_D006934 CID D3_30\NNP|vitamin|and|metabolites (r_pobj) of_28\IN|d3 (r_prep) increases_27\NNS|large|of (r_conj) hyperphosphatemia_23\NN|,|and|increases (r_conj) hypercalcemia_21\NN|prolonged|,|hyperphosphatemia
D002762_D054559 CID D3_5\NNP|vitamin (r_pobj) of_3\IN|d3 (r_prep) doses_2\NNS|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN|doses|were|with|. (l_prep) with_19\IN|hypercalcemia (l_pobj) hypercalcemia_21\NN|prolonged|,|hyperphosphatemia (l_conj) hyperphosphatemia_23\NN|,|and|increases
D002762_D054559 CID D3_15\NNP|17.5|x|iu|vitamin (r_appos) doses_2\NNS|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN|doses|were|with|. (l_prep) with_19\IN|hypercalcemia (l_pobj) hypercalcemia_21\NN|prolonged|,|hyperphosphatemia (l_conj) hyperphosphatemia_23\NN|,|and|increases
D002762_D054559 CID D3_30\NNP|vitamin|and|metabolites (r_pobj) of_28\IN|d3 (r_prep) increases_27\NNS|large|of (r_conj) hyperphosphatemia_23\NN|,|and|increases
D002762_D010319 NONE D3_7\NNP|vitamin (r_pobj) with_5\IN|d3 (r_prep) treated_4\VBN|with (r_acl) cows_3\NNS|the|treated (r_pobj) of_1\IN|cows (r_prep) None_0\NN|of (r_nsubj) showed_8\VBD|none|signs|during (l_dobj) signs_9\NNS|of (l_prep) of_10\IN|fever (l_pobj) fever_12\NN|milk
D002762_D010319 NONE D3_7\NNP|vitamin (r_pobj) with_5\IN|d3 (r_prep) treated_4\VBN|with (r_acl) cows_3\NNS|the|treated (r_pobj) of_1\IN|cows (r_prep) None_0\NN|of (r_nsubj) showed_8\VBD|none|signs|during (r_ccomp) developed_26\VBD|showed|;|however|,|%|signs|during|. (l_dobj) signs_28\NNS|clinical|of (l_prep) of_29\IN|fever (l_pobj) fever_31\NN|milk
D002762_D010319 NONE D3_7\NN|vitamin (r_pobj) of_5\IN|d3 (r_prep) toxicity_4\NN|the|extreme|of|in|and|margin (l_conj) margin_15\NN|the|low|of (l_prep) of_16\IN|safety (l_pobj) safety_17\NN|between (l_prep) between_18\IN|doses (l_pobj) doses_19\NNS|of (l_prep) of_20\IN|d3 (l_pobj) D3_22\NNP|vitamin|prevent (l_relcl) prevent_24\VBP|that|fever (l_dobj) fever_26\NN|milk|and|doses|induce
D002762_D010319 NONE D3_7\NN|vitamin (r_pobj) of_5\IN|d3 (r_prep) toxicity_4\NN|the|extreme|of|in|and|margin (l_conj) margin_15\NN|the|low|of (l_prep) of_16\IN|safety (l_pobj) safety_17\NN|between (l_prep) between_18\IN|doses (l_pobj) doses_19\NNS|of (l_prep) of_20\IN|d3 (l_pobj) D3_22\NNP|vitamin|prevent (l_relcl) prevent_24\VBP|that|fever (l_dobj) fever_26\NN|milk|and|doses|induce (l_relcl) induce_30\VBP|that|fever (l_dobj) fever_32\NN|milk
D002762_D010319 NONE D3_7\NN|vitamin (r_pobj) of_5\IN|d3 (r_prep) toxicity_4\NN|the|extreme|of|in|and|margin (r_pobj) Because_0\IN|of|toxicity (r_prep) concluded_35\VBD|because|,|we|used|. (l_ccomp) used_42\VBN|that|d3|can|not|be|prevent|injected (l_xcomp) prevent_45\VB|practically|to|fever (l_dobj) fever_47\NN|milk
D002762_D010319 NONE D3_22\NNP|vitamin|prevent (l_relcl) prevent_24\VBP|that|fever (l_dobj) fever_26\NN|milk|and|doses|induce
D002762_D010319 NONE D3_22\NNP|vitamin|prevent (l_relcl) prevent_24\VBP|that|fever (l_dobj) fever_26\NN|milk|and|doses|induce (l_relcl) induce_30\VBP|that|fever (l_dobj) fever_32\NN|milk
D002762_D010319 NONE D3_22\NNP|vitamin|prevent (r_pobj) of_20\IN|d3 (r_prep) doses_19\NNS|of (r_pobj) between_18\IN|doses (r_prep) safety_17\NN|between (r_pobj) of_16\IN|safety (r_prep) margin_15\NN|the|low|of (r_conj) toxicity_4\NN|the|extreme|of|in|and|margin (r_pobj) Because_0\IN|of|toxicity (r_prep) concluded_35\VBD|because|,|we|used|. (l_ccomp) used_42\VBN|that|d3|can|not|be|prevent|injected (l_xcomp) prevent_45\VB|practically|to|fever (l_dobj) fever_47\NN|milk
D002762_D010319 NONE D3_38\NNP|vitamin (r_nsubjpass) used_42\VBN|that|d3|can|not|be|prevent|injected (r_ccomp) concluded_35\VBD|because|,|we|used|. (l_prep) Because_0\IN|of|toxicity (l_pobj) toxicity_4\NN|the|extreme|of|in|and|margin (l_conj) margin_15\NN|the|low|of (l_prep) of_16\IN|safety (l_pobj) safety_17\NN|between (l_prep) between_18\IN|doses (l_pobj) doses_19\NNS|of (l_prep) of_20\IN|d3 (l_pobj) D3_22\NNP|vitamin|prevent (l_relcl) prevent_24\VBP|that|fever (l_dobj) fever_26\NN|milk|and|doses|induce
D002762_D010319 NONE D3_38\NNP|vitamin (r_nsubjpass) used_42\VBN|that|d3|can|not|be|prevent|injected (r_ccomp) concluded_35\VBD|because|,|we|used|. (l_prep) Because_0\IN|of|toxicity (l_pobj) toxicity_4\NN|the|extreme|of|in|and|margin (l_conj) margin_15\NN|the|low|of (l_prep) of_16\IN|safety (l_pobj) safety_17\NN|between (l_prep) between_18\IN|doses (l_pobj) doses_19\NNS|of (l_prep) of_20\IN|d3 (l_pobj) D3_22\NNP|vitamin|prevent (l_relcl) prevent_24\VBP|that|fever (l_dobj) fever_26\NN|milk|and|doses|induce (l_relcl) induce_30\VBP|that|fever (l_dobj) fever_32\NN|milk
D002762_D010319 NONE D3_38\NNP|vitamin (r_nsubjpass) used_42\VBN|that|d3|can|not|be|prevent|injected (l_xcomp) prevent_45\VB|practically|to|fever (l_dobj) fever_47\NN|milk
11135224
D017239_D002289 NONE Paclitaxel_0\NNP|,|cisplatin|. (l_conj) cisplatin_2\NN|,|and|chemotherapy (l_conj) chemotherapy_7\NN|combination|within (l_prep) within_8\IN|approach (l_pobj) approach_12\NN|a|multidisciplinary|therapeutic|in (l_prep) in_13\IN|carcinoma (l_pobj) carcinoma_18\NN|metastatic|nonsmall|lung
D017239_D002289 NONE paclitaxel_18\NN|a|,|cisplatin|combination (r_pobj) of_16\IN|paclitaxel (r_prep) toxicity_15\NN|of (r_conj) rate_12\NN|response|,|and|toxicity (r_conj) feasibility_9\NN|the|,|rate (r_dobj) determine_7\VB|to|feasibility|treat (l_xcomp) treat_26\VB|to|nsclc (l_dobj) NSCLC_28\NN|metastatic
D017239_D002289 NONE paclitaxel_30\NN| (r_pobj) of_29\IN|paclitaxel (r_prep) combination_28\NN|a|of|(|m(2|) (r_pobj) with_26\IN|combination (r_prep) treated_25\VBN|patients|were|with|given|)|on|,|cisplatin|)|given|)|on|,|and|gemcitabine|given|. (l_nsubjpass) patients_7\NNS|five|consecutive|naive|with (l_prep) with_8\IN|nsclc (l_pobj) NSCLC_11\NNP|iv|and|status
D017239_D002289 NONE paclitaxel_3\NN|,|cisplatin (r_pobj) of_2\IN|paclitaxel (r_prep) combination_1\NN|the|of|,|and|gemcitabine (r_nsubjpass) tolerated_11\VBN|combination|is|well|and|shows|. (l_conj) shows_13\VBZ|activity|in (l_prep) in_16\IN|nsclc (l_pobj) NSCLC_18\NNP|metastatic
D002945_D002289 NONE cisplatin_2\NN|,|and|chemotherapy (l_conj) chemotherapy_7\NN|combination|within (l_prep) within_8\IN|approach (l_pobj) approach_12\NN|a|multidisciplinary|therapeutic|in (l_prep) in_13\IN|carcinoma (l_pobj) carcinoma_18\NN|metastatic|nonsmall|lung
D002945_D002289 NONE Cisplatin_0\NN| (r_npadvmod) based_2\VBN|cisplatin|- (r_amod) combinations_4\NNS|based|chemotherapy (r_nsubj) improve_5\VBP|combinations|quality|. (l_dobj) quality_6\NN|of|in (l_prep) in_11\IN|carcinoma (l_pobj) carcinoma_16\NN|advanced|nonsmall|lung|(|nsclc|)
D002945_D002289 NONE Cisplatin_0\NN| (r_npadvmod) based_2\VBN|cisplatin|- (r_amod) combinations_4\NNS|based|chemotherapy (r_nsubj) improve_5\VBP|combinations|quality|. (l_dobj) quality_6\NN|of|in (l_prep) in_11\IN|carcinoma (l_pobj) carcinoma_16\NN|advanced|nonsmall|lung|(|nsclc|) (l_appos) NSCLC_18\NNP|
D002945_D002289 NONE cisplatin_20\NN|,|and (r_conj) paclitaxel_18\NN|a|,|cisplatin|combination (r_pobj) of_16\IN|paclitaxel (r_prep) toxicity_15\NN|of (r_conj) rate_12\NN|response|,|and|toxicity (r_conj) feasibility_9\NN|the|,|rate (r_dobj) determine_7\VB|to|feasibility|treat (l_xcomp) treat_26\VB|to|nsclc (l_dobj) NSCLC_28\NN|metastatic
D002945_D002289 NONE cisplatin_47\NN| (r_conj) treated_25\VBN|patients|were|with|given|)|on|,|cisplatin|)|given|)|on|,|and|gemcitabine|given|. (l_nsubjpass) patients_7\NNS|five|consecutive|naive|with (l_prep) with_8\IN|nsclc (l_pobj) NSCLC_11\NNP|iv|and|status
D002945_D002289 NONE cisplatin_5\NN| (r_conj) paclitaxel_3\NN|,|cisplatin (r_pobj) of_2\IN|paclitaxel (r_prep) combination_1\NN|the|of|,|and|gemcitabine (r_nsubjpass) tolerated_11\VBN|combination|is|well|and|shows|. (l_conj) shows_13\VBZ|activity|in (l_prep) in_16\IN|nsclc (l_pobj) NSCLC_18\NNP|metastatic
C056507_D002289 NONE gemcitabine_5\NN| (r_compound) combination_6\NN|gemcitabine (r_compound) chemotherapy_7\NN|combination|within (l_prep) within_8\IN|approach (l_pobj) approach_12\NN|a|multidisciplinary|therapeutic|in (l_prep) in_13\IN|carcinoma (l_pobj) carcinoma_18\NN|metastatic|nonsmall|lung
C056507_D002289 NONE gemcitabine_23\NN| (r_compound) combination_24\NN|gemcitabine (r_conj) paclitaxel_18\NN|a|,|cisplatin|combination (r_pobj) of_16\IN|paclitaxel (r_prep) toxicity_15\NN|of (r_conj) rate_12\NN|response|,|and|toxicity (r_conj) feasibility_9\NN|the|,|rate (r_dobj) determine_7\VB|to|feasibility|treat (l_xcomp) treat_26\VB|to|nsclc (l_dobj) NSCLC_28\NN|metastatic
C056507_D002289 NONE gemcitabine_65\NN|) (r_conj) treated_25\VBN|patients|were|with|given|)|on|,|cisplatin|)|given|)|on|,|and|gemcitabine|given|. (l_nsubjpass) patients_7\NNS|five|consecutive|naive|with (l_prep) with_8\IN|nsclc (l_pobj) NSCLC_11\NNP|iv|and|status
C056507_D002289 NONE gemcitabine_8\NN| (r_conj) combination_1\NN|the|of|,|and|gemcitabine (r_nsubjpass) tolerated_11\VBN|combination|is|well|and|shows|. (l_conj) shows_13\VBZ|activity|in (l_prep) in_16\IN|nsclc (l_pobj) NSCLC_18\NNP|metastatic
D017239_D064420 NONE paclitaxel_18\NN|a|,|cisplatin|combination (r_pobj) of_16\IN|paclitaxel (r_prep) toxicity_15\NN|of
D002945_D064420 NONE cisplatin_20\NN|,|and (r_conj) paclitaxel_18\NN|a|,|cisplatin|combination (r_pobj) of_16\IN|paclitaxel (r_prep) toxicity_15\NN|of
C056507_D064420 NONE gemcitabine_23\NN| (r_compound) combination_24\NN|gemcitabine (r_conj) paclitaxel_18\NN|a|,|cisplatin|combination (r_pobj) of_16\IN|paclitaxel (r_prep) toxicity_15\NN|of
17343925
D012906_D034381 CID smoking_3\NN|during|on (r_pobj) of_2\IN|smoking (r_prep) influence_1\NN|the|of (r_nsubjpass) estimated_13\VBN|influence|has|not|been|,|associated|. (l_advcl) associated_20\VBN|although|smoking|has|been|positively|with (l_prep) with_21\IN|hearing (l_pcomp) hearing_22\VBG|loss (l_dobj) loss_23\NN|in
D012906_D034381 CID smoking_16\NN| (r_nsubjpass) associated_20\VBN|although|smoking|has|been|positively|with (l_prep) with_21\IN|hearing (l_pcomp) hearing_22\VBG|loss (l_dobj) loss_23\NN|in
6518066
D008094_D004437 CID lithium_1\NN|maternal|and|anomaly|. (l_conj) anomaly_6\NN|ebstein|:|evaluation
D008094_D006331 NONE lithium_9\NN| (r_pobj) to_8\IN|lithium (r_prep) exposed_7\VBN|screening|to|during (r_csubj) provide_13\VB|exposed|can|assessment|. (l_dobj) assessment_18\NN|accurate|,|noninvasive|of (l_prep) of_19\IN|presence (l_pobj) presence_21\NN|the|or|absence|of (l_prep) of_24\IN|malformations (l_pobj) malformations_29\NNS|induced|cardiac
D008094_D006331 NONE lithium_25\NN| (r_npadvmod) induced_27\VBN|lithium|- (r_amod) malformations_29\NNS|induced|cardiac
18442015
D014700_D006471 NONE verapamil_3\NN| (r_pobj) of_2\IN|verapamil (r_prep) effect_1\NN|protective|of|on|. (l_prep) on_4\IN|ulcers (l_pobj) ulcers_7\NNS|gastric|hemorrhagic|in (l_amod) hemorrhagic_6\JJ|
D014700_D006471 NONE verapamil_15\NN|daily|intragastric (r_pobj) by_12\IN|verapamil (r_agent) ameliorated_11\VBN|dependently|by (r_acomp) were_7\VBD|ulcer|ameliorated|. (l_nsubj) ulcer_2\NN|this|hemorrhagic|and|parameters (l_amod) hemorrhagic_1\JJ|
D014700_D006471 NONE verapamil_28\NN| (r_pobj) by_27\IN|verapamil (r_agent) ameliorated_26\VBN|that|could|be|by|in (r_relcl) generation_16\NN|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ|
D014700_D014456 NONE verapamil_3\NN| (r_pobj) of_2\IN|verapamil (r_prep) effect_1\NN|protective|of|on|. (l_prep) on_4\IN|ulcers (l_pobj) ulcers_7\NNS|gastric|hemorrhagic|in
D014700_D014456 NONE verapamil_6\NN| (r_pobj) of_5\IN|verapamil (r_prep) effect_4\NN|the|protective|of|on (l_prep) on_7\IN|model (l_pobj) model_10\NN|this|ulcer (l_compound) ulcer_9\NN|
D014700_D014456 NONE verapamil_15\NN|daily|intragastric (r_pobj) by_12\IN|verapamil (r_agent) ameliorated_11\VBN|dependently|by (r_acomp) were_7\VBD|ulcer|ameliorated|. (l_nsubj) ulcer_2\NN|this|hemorrhagic|and|parameters
D014700_D014456 NONE verapamil_28\NN| (r_pobj) by_27\IN|verapamil (r_agent) ameliorated_26\VBN|that|could|be|by|in (r_relcl) generation_16\NN|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN|gastric|hemorrhagic
D014700_D050197 NONE verapamil_3\NN| (r_pobj) of_2\IN|verapamil (r_prep) effect_1\NN|protective|of|on|. (l_prep) on_4\IN|ulcers (l_pobj) ulcers_7\NNS|gastric|hemorrhagic|in (l_prep) in_8\IN|rats (l_pobj) rats_11\NNS|severe|atherosclerotic (l_amod) atherosclerotic_10\JJ|
D014700_D050197 NONE verapamil_28\NN| (r_pobj) by_27\IN|verapamil (r_agent) ameliorated_26\VBN|that|could|be|by|in (r_relcl) generation_16\NN|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB|atherosclerosis|could|ulcer|via (l_nsubj) Atherosclerosis_0\NN|
D006632_D006471 NONE histamine_19\NN|cell (r_compound) release_20\NN|mast|histamine|,|peroxide (l_conj) peroxide_23\NN|lipid|permeability (l_appos) permeability_31\NN|generation|microvascular|in (l_prep) in_32\IN|modulating (l_pcomp) modulating_33\VBG|hemorrhage (l_dobj) hemorrhage_35\NN|gastric|and|ulcer|in
D006632_D006471 NONE histamine_6\NN| (r_pobj) of_5\IN|histamine (r_prep) correlation_4\NN|a|positive|of|to (l_prep) to_7\IN|hemorrhage|and|to (l_pobj) hemorrhage_9\NN|gastric
D006632_D006471 NONE histamine_18\NN| (r_compound) release_19\NN|histamine|and|permeability (r_conj) generation_16\NN|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ|
D006632_D014456 NONE histamine_19\NN|cell (r_compound) release_20\NN|mast|histamine|,|peroxide (l_conj) peroxide_23\NN|lipid|permeability (l_appos) permeability_31\NN|generation|microvascular|in (l_prep) in_32\IN|modulating (l_pcomp) modulating_33\VBG|hemorrhage (l_dobj) hemorrhage_35\NN|gastric|and|ulcer|in (l_conj) ulcer_37\NN|
D006632_D014456 NONE histamine_10\NN| (r_compound) concentration_11\NN|histamine|,|permeability (l_conj) permeability_14\NN|microvascular|,|content (l_conj) content_18\NN|luminal|hemoglobin|and|areas (l_conj) areas_21\NNS|ulcer (l_compound) ulcer_20\NN|
D006632_D014456 NONE histamine_16\NN| (r_compound) release_17\NN|histamine|,|generation (r_conj) diffusion_14\NN|gastric|acid|back|-|,|release (r_pobj) including_9\VBG|diffusion (r_prep) factors_7\NNS|increased|ulcerogenic|,|including (r_pobj) with_4\IN|factors (r_prep) accompanied_3\VBN|ulcers|with (l_nsubj) ulcers_2\NNS|severe|gastric
D006632_D014456 NONE histamine_6\NN| (r_pobj) of_5\IN|histamine (r_prep) correlation_4\NN|a|positive|of|to (l_prep) to_7\IN|hemorrhage|and|to (l_conj) to_11\IN|ulcer (l_pobj) ulcer_12\NN|
D006632_D014456 NONE histamine_18\NN| (r_compound) release_19\NN|histamine|and|permeability (r_conj) generation_16\NN|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN|gastric|hemorrhagic
D006632_D050197 NONE histamine_19\NN|cell (r_compound) release_20\NN|mast|histamine|,|peroxide (l_conj) peroxide_23\NN|lipid|permeability (l_appos) permeability_31\NN|generation|microvascular|in (l_prep) in_32\IN|modulating (l_pcomp) modulating_33\VBG|hemorrhage (l_dobj) hemorrhage_35\NN|gastric|and|ulcer|in (l_prep) in_38\IN|rats (l_pobj) rats_39\NNS|with (l_prep) with_40\IN|atherosclerosis (l_pobj) atherosclerosis_41\NN|
D006632_D050197 NONE histamine_6\NN| (r_pobj) of_5\IN|histamine (r_prep) correlation_4\NN|a|positive|of|to (r_nsubjpass) found_14\VBN|moreover|,|correlation|was|in|. (l_prep) in_15\IN|rats (l_pobj) rats_18\NNS|those|atherosclerotic (l_amod) atherosclerotic_17\JJ|
D006632_D050197 NONE histamine_18\NN| (r_compound) release_19\NN|histamine|and|permeability (r_conj) generation_16\NN|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB|atherosclerosis|could|ulcer|via (l_nsubj) Atherosclerosis_0\NN|
D004872_D006471 CID D2_47\NN|vitamin|and|cholesterol (r_pobj) of_45\IN|d2 (r_prep) coadministration_44\NN|of (r_pobj) by_43\IN|coadministration (r_prep) induced_42\VBN|,|release|by (l_nsubj) release_20\NN|mast|histamine|,|peroxide (l_conj) peroxide_23\NN|lipid|permeability (l_appos) permeability_31\NN|generation|microvascular|in (l_prep) in_32\IN|modulating (l_pcomp) modulating_33\VBG|hemorrhage (l_dobj) hemorrhage_35\NN|gastric|and|ulcer|in
D004872_D014456 CID D2_47\NN|vitamin|and|cholesterol (r_pobj) of_45\IN|d2 (r_prep) coadministration_44\NN|of (r_pobj) by_43\IN|coadministration (r_prep) induced_42\VBN|,|release|by (l_nsubj) release_20\NN|mast|histamine|,|peroxide (l_conj) peroxide_23\NN|lipid|permeability (l_appos) permeability_31\NN|generation|microvascular|in (l_prep) in_32\IN|modulating (l_pcomp) modulating_33\VBG|hemorrhage (l_dobj) hemorrhage_35\NN|gastric|and|ulcer|in (l_conj) ulcer_37\NN|
D004872_D050197 CID D2_47\NN|vitamin|and|cholesterol (r_pobj) of_45\IN|d2 (r_prep) coadministration_44\NN|of (r_pobj) by_43\IN|coadministration (r_prep) induced_42\VBN|,|release|by (l_nsubj) release_20\NN|mast|histamine|,|peroxide (l_conj) peroxide_23\NN|lipid|permeability (l_appos) permeability_31\NN|generation|microvascular|in (l_prep) in_32\IN|modulating (l_pcomp) modulating_33\VBG|hemorrhage (l_dobj) hemorrhage_35\NN|gastric|and|ulcer|in (l_prep) in_38\IN|rats (l_pobj) rats_39\NNS|with (l_prep) with_40\IN|atherosclerosis (l_pobj) atherosclerosis_41\NN|
D004872_D050197 CID D2_21\NN|vitamin|and|cholesterol (r_dobj) containing_19\VBG|kg|d2|induce (l_advcl) induce_25\VB|to|atherosclerosis (l_dobj) atherosclerosis_26\NN|
D002784_D006471 CID cholesterol_49\NN| (r_conj) D2_47\NN|vitamin|and|cholesterol (r_pobj) of_45\IN|d2 (r_prep) coadministration_44\NN|of (r_pobj) by_43\IN|coadministration (r_prep) induced_42\VBN|,|release|by (l_nsubj) release_20\NN|mast|histamine|,|peroxide (l_conj) peroxide_23\NN|lipid|permeability (l_appos) permeability_31\NN|generation|microvascular|in (l_prep) in_32\IN|modulating (l_pcomp) modulating_33\VBG|hemorrhage (l_dobj) hemorrhage_35\NN|gastric|and|ulcer|in
D002784_D014456 CID cholesterol_49\NN| (r_conj) D2_47\NN|vitamin|and|cholesterol (r_pobj) of_45\IN|d2 (r_prep) coadministration_44\NN|of (r_pobj) by_43\IN|coadministration (r_prep) induced_42\VBN|,|release|by (l_nsubj) release_20\NN|mast|histamine|,|peroxide (l_conj) peroxide_23\NN|lipid|permeability (l_appos) permeability_31\NN|generation|microvascular|in (l_prep) in_32\IN|modulating (l_pcomp) modulating_33\VBG|hemorrhage (l_dobj) hemorrhage_35\NN|gastric|and|ulcer|in (l_conj) ulcer_37\NN|
D002784_D050197 CID cholesterol_49\NN| (r_conj) D2_47\NN|vitamin|and|cholesterol (r_pobj) of_45\IN|d2 (r_prep) coadministration_44\NN|of (r_pobj) by_43\IN|coadministration (r_prep) induced_42\VBN|,|release|by (l_nsubj) release_20\NN|mast|histamine|,|peroxide (l_conj) peroxide_23\NN|lipid|permeability (l_appos) permeability_31\NN|generation|microvascular|in (l_prep) in_32\IN|modulating (l_pcomp) modulating_33\VBG|hemorrhage (l_dobj) hemorrhage_35\NN|gastric|and|ulcer|in (l_prep) in_38\IN|rats (l_pobj) rats_39\NNS|with (l_prep) with_40\IN|atherosclerosis (l_pobj) atherosclerosis_41\NN|
D002784_D050197 CID cholesterol_23\NN| (r_conj) D2_21\NN|vitamin|and|cholesterol (r_dobj) containing_19\VBG|kg|d2|induce (l_advcl) induce_25\VB|to|atherosclerosis (l_dobj) atherosclerosis_26\NN|
D002784_D050197 CID cholesterol_10\NN|total|and|concentration (r_conj) calcium_7\NN|serum|,|cholesterol (r_pobj) as_5\IN|such|calcium (r_prep) parameters_2\NNS|elevated|atherosclerotic|,|as (l_amod) atherosclerotic_1\JJ|
D002784_D050197 CID cholesterol_10\NN|total|and|concentration (r_conj) calcium_7\NN|serum|,|cholesterol (r_pobj) as_5\IN|such|calcium (r_prep) parameters_2\NNS|elevated|atherosclerotic|,|as (r_nsubjpass) obtained_18\VBN|parameters|were|in|. (l_prep) in_19\IN|rats (l_pobj) rats_21\NNS|atherosclerotic (l_amod) atherosclerotic_20\JJ|
D010634_D014456 NONE luminal_16\JJ| (r_amod) content_18\NN|luminal|hemoglobin|and|areas (l_conj) areas_21\NNS|ulcer (l_compound) ulcer_20\NN|
D010634_D014456 NONE luminal_22\JJ| (r_amod) content_24\NN|luminal|hemoglobin (r_conj) generation_20\NN|lpo|and|content (r_conj) release_17\NN|histamine|,|generation (r_conj) diffusion_14\NN|gastric|acid|back|-|,|release (r_pobj) including_9\VBG|diffusion (r_prep) factors_7\NNS|increased|ulcerogenic|,|including (r_pobj) with_4\IN|factors (r_prep) accompanied_3\VBN|ulcers|with (l_nsubj) ulcers_2\NNS|severe|gastric
D002118_D050197 NONE calcium_7\NN|serum|,|cholesterol (r_pobj) as_5\IN|such|calcium (r_prep) parameters_2\NNS|elevated|atherosclerotic|,|as (l_amod) atherosclerotic_1\JJ|
D002118_D050197 NONE calcium_7\NN|serum|,|cholesterol (r_pobj) as_5\IN|such|calcium (r_prep) parameters_2\NNS|elevated|atherosclerotic|,|as (r_nsubjpass) obtained_18\VBN|parameters|were|in|. (l_prep) in_19\IN|rats (l_pobj) rats_21\NNS|atherosclerotic (l_amod) atherosclerotic_20\JJ|
17931375
D006493_D003288 CID heparin_10\JJ| (r_compound) injection_11\NN|subcutaneous|heparin|on (l_prep) on_12\IN|bruising (l_pobj) bruising_13\VBG|and|pain
D006493_D003288 CID heparin_24\NN| (r_pobj) of_23\IN|heparin (r_prep) injection_22\NN|the|subcutaneous|of (r_pobj) of_19\IN|injection (r_prep) administration_18\NN|the|of (r_pobj) following_16\VBG|administration (r_prep) effect_8\NN|the|of|following (l_prep) of_9\IN|duration (l_pobj) duration_11\NN|injection|on (l_prep) on_12\IN|bruising (l_pobj) bruising_13\VBG|and|pain
D006493_D003288 CID heparin_13\NN| (r_pobj) of_12\IN|heparin (r_prep) injection_11\NN|the|subcutaneous|of (r_pobj) following_8\VBG|injection (r_prep) prevent_4\VB|to|bruising|following (l_dobj) bruising_5\NN|and|pain
D006493_D003288 CID heparin_13\NN| (r_pobj) of_12\IN|heparin (r_prep) injection_11\NN|the|subcutaneous|of (r_pobj) following_8\VBG|injection (r_prep) prevent_4\VB|to|bruising|following (r_acl) methods_2\NNS|different|prevent (r_nsubjpass) studied_17\VBN|although|methods|have|been|widely|and|described (r_advcl) documented_35\JJ|studied|,|effect|is|little|. (l_nsubjpass) effect_22\NN|the|of (l_prep) of_23\IN|duration (l_pobj) duration_25\NN|injection|on (l_prep) on_26\IN|occurrence (l_pobj) occurrence_28\NN|the|of (l_prep) of_29\IN|bruising (l_pobj) bruising_30\VBG|and|pain
D006493_D003288 CID heparin_6\NN|the (r_pobj) on_4\IN|heparin|areas (r_prep) bruising_3\NN|the|on
D006493_D003288 CID heparin_18\NN| (r_pobj) of_17\IN|heparin (r_prep) administration_16\NN|the|subcutaneous|of (r_pobj) following_13\VBG|administration (r_prep) had_6\VBD|that|duration|effect|following (l_dobj) effect_8\NN|an|on (l_prep) on_9\IN|bruising (l_pobj) bruising_10\VBG|and|pain
D006493_D010146 CID heparin_10\JJ| (r_compound) injection_11\NN|subcutaneous|heparin|on (l_prep) on_12\IN|bruising (l_pobj) bruising_13\VBG|and|pain (l_conj) pain_15\NN|
D006493_D010146 CID heparin_24\NN| (r_pobj) of_23\IN|heparin (r_prep) injection_22\NN|the|subcutaneous|of (r_pobj) of_19\IN|injection (r_prep) administration_18\NN|the|of (r_pobj) following_16\VBG|administration (r_prep) effect_8\NN|the|of|following (l_prep) of_9\IN|duration (l_pobj) duration_11\NN|injection|on (l_prep) on_12\IN|bruising (l_pobj) bruising_13\VBG|and|pain (l_conj) pain_15\NN|
D006493_D010146 CID heparin_13\NN| (r_pobj) of_12\IN|heparin (r_prep) injection_11\NN|the|subcutaneous|of (r_pobj) following_8\VBG|injection (r_prep) prevent_4\VB|to|bruising|following (l_dobj) bruising_5\NN|and|pain (l_conj) pain_7\NN|
D006493_D010146 CID heparin_13\NN| (r_pobj) of_12\IN|heparin (r_prep) injection_11\NN|the|subcutaneous|of (r_pobj) following_8\VBG|injection (r_prep) prevent_4\VB|to|bruising|following (r_acl) methods_2\NNS|different|prevent (r_nsubjpass) studied_17\VBN|although|methods|have|been|widely|and|described (r_advcl) documented_35\JJ|studied|,|effect|is|little|. (l_nsubjpass) effect_22\NN|the|of (l_prep) of_23\IN|duration (l_pobj) duration_25\NN|injection|on (l_prep) on_26\IN|occurrence (l_pobj) occurrence_28\NN|the|of (l_prep) of_29\IN|bruising (l_pobj) bruising_30\VBG|and|pain (l_conj) pain_32\NN|
D006493_D010146 CID heparin_18\NN| (r_pobj) of_17\IN|heparin (r_prep) administration_16\NN|the|subcutaneous|of (r_pobj) following_13\VBG|administration (r_prep) had_6\VBD|that|duration|effect|following (l_dobj) effect_8\NN|an|on (l_prep) on_9\IN|bruising (l_pobj) bruising_10\VBG|and|pain (l_conj) pain_12\NN|
12907309
C121465_D020258 NONE MPEP_3\NNP| (r_pobj) of_2\IN|mpep (r_prep) action_1\NN|neuroprotective|of|,|antagonist|,|in (l_prep) in_10\IN|neurotoxicity (l_pobj) neurotoxicity_15\NN|induced|dopaminergic
C121465_D005334 NONE MPEP_3\NNP| (r_pobj) of_2\IN|mpep (r_prep) action_1\NN|neuroprotective|of|,|antagonist|,|in (r_nsubjpass) associated_17\VBN|action|is|with|. (l_prep) with_18\IN|decrease (l_pobj) decrease_20\NN|a|in (l_prep) in_21\IN|outflow (l_pobj) outflow_23\NN|dopamine|and|inhibition|in (l_conj) inhibition_25\NN|of (l_prep) of_26\IN|hyperthermia (l_pobj) hyperthermia_27\NN|
C121465_D005334 NONE MPEP_3\NNP| (r_pobj) by_2\IN|mpep (r_agent) rendered_1\VBN|by (r_acl) Neuroprotection_0\NNP|rendered (r_nsubjpass) associated_6\VBN|neuroprotection|may|be|with|,|and|with|. (l_conj) with_29\IN|decrease (l_pobj) decrease_31\NN|a|in (l_prep) in_32\IN|hyperthermia (l_pobj) hyperthermia_33\NN|
D008694_D020258 NONE methamphetamine_11\NN| (r_npadvmod) induced_13\VBN|methamphetamine|- (r_amod) neurotoxicity_15\NN|induced|dopaminergic
D008694_D005334 CID methamphetamine_11\NN| (r_npadvmod) induced_13\VBN|methamphetamine|- (r_amod) neurotoxicity_15\NN|induced|dopaminergic (r_pobj) in_10\IN|neurotoxicity (r_prep) action_1\NN|neuroprotective|of|,|antagonist|,|in (r_nsubjpass) associated_17\VBN|action|is|with|. (l_prep) with_18\IN|decrease (l_pobj) decrease_20\NN|a|in (l_prep) in_21\IN|outflow (l_pobj) outflow_23\NN|dopamine|and|inhibition|in (l_conj) inhibition_25\NN|of (l_prep) of_26\IN|hyperthermia (l_pobj) hyperthermia_27\NN|
D008694_D005334 CID methamphetamine_12\NN| (r_npadvmod) induced_14\VBN|methamphetamine|- (r_amod) efflux_16\NN|the|induced|dopamine|in (r_pobj) of_10\IN|efflux (r_prep) reduction_9\NN|the|of|due (r_pobj) with_7\IN|reduction (r_prep) associated_6\VBN|neuroprotection|may|be|with|,|and|with|. (l_conj) with_29\IN|decrease (l_pobj) decrease_31\NN|a|in (l_prep) in_32\IN|hyperthermia (l_pobj) hyperthermia_33\NN|
D004298_D020258 NONE dopamine_22\NN| (r_compound) outflow_23\NN|dopamine|and|inhibition|in (r_pobj) in_21\IN|outflow (r_prep) decrease_20\NN|a|in (r_pobj) with_18\IN|decrease (r_prep) associated_17\VBN|action|is|with|. (l_nsubjpass) action_1\NN|neuroprotective|of|,|antagonist|,|in (l_prep) in_10\IN|neurotoxicity (l_pobj) neurotoxicity_15\NN|induced|dopaminergic
D004298_D005334 NONE dopamine_22\NN| (r_compound) outflow_23\NN|dopamine|and|inhibition|in (l_conj) inhibition_25\NN|of (l_prep) of_26\IN|hyperthermia (l_pobj) hyperthermia_27\NN|
D004298_D005334 NONE dopamine_15\NN| (r_compound) efflux_16\NN|the|induced|dopamine|in (r_pobj) of_10\IN|efflux (r_prep) reduction_9\NN|the|of|due (r_pobj) with_7\IN|reduction (r_prep) associated_6\VBN|neuroprotection|may|be|with|,|and|with|. (l_conj) with_29\IN|decrease (l_pobj) decrease_31\NN|a|in (l_prep) in_32\IN|hyperthermia (l_pobj) hyperthermia_33\NN|
C121465_D064420 NONE MPEP_12\NNP| (r_pobj) by_11\IN|mpep (r_prep) blockade_8\NN|the|of|by (r_nsubj) protect_14\VB|that|blockade|may|neurones (l_dobj) neurones_16\NNS|dopaminergic|against (l_prep) against_17\IN|toxicity (l_pobj) toxicity_21\NN|induced
D008694_D064420 NONE methamphetamine_18\NN| (r_npadvmod) induced_20\VBN|methamphetamine|- (r_amod) toxicity_21\NN|induced
8423889
D005473_D009069 CID fluoxetine_5\NN| (r_amod) medication_6\NN|fluoxetine (r_pobj) after_4\IN|medication (r_prep) Increase_0\NNP|of|after|. (l_prep) of_1\IN|disability (l_pobj) disability_3\NN|parkinson
D005473_D009069 CID fluoxetine_21\NN|the|antidepressant (r_pobj) to_18\IN|fluoxetine (r_prep) exposure_17\NN|to (r_pobj) after_16\IN|exposure (r_prep) amount_4\NN|the|increased|of|in|after (l_prep) of_5\IN|disability (l_pobj) disability_7\NN|motor
D000928_D009069 NONE antidepressant_20\JJ| (r_amod) fluoxetine_21\NN|the|antidepressant (r_pobj) to_18\IN|fluoxetine (r_prep) exposure_17\NN|to (r_pobj) after_16\IN|exposure (r_prep) amount_4\NN|the|increased|of|in|after (l_prep) of_5\IN|disability (l_pobj) disability_7\NN|motor
D000928_D010300 NONE antidepressant_20\JJ| (r_amod) fluoxetine_21\NN|the|antidepressant (r_pobj) to_18\IN|fluoxetine (r_prep) exposure_17\NN|to (r_pobj) after_16\IN|exposure (r_prep) amount_4\NN|the|increased|of|in|after (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|four|with (l_prep) with_11\IN|disease (l_pobj) disease_15\NN|parkinson
D005473_D010300 NONE fluoxetine_21\NN|the|antidepressant (r_pobj) to_18\IN|fluoxetine (r_prep) exposure_17\NN|to (r_pobj) after_16\IN|exposure (r_prep) amount_4\NN|the|increased|of|in|after (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|four|with (l_prep) with_11\IN|disease (l_pobj) disease_15\NN|parkinson
D005473_D010300 NONE fluoxetine_11\NN| (r_pobj) of_10\IN|fluoxetine (r_prep) capacity_9\NN|a|relevant|antagonistic|of|in (l_prep) in_12\IN|patients (l_pobj) patients_16\NNS|parkinson|disease (l_compound) disease_15\NN|
D004298_D010300 NONE dopamine_6\NN| (r_npadvmod) antagonistic_8\JJ|dopamine|- (r_amod) capacity_9\NN|a|relevant|antagonistic|of|in (l_prep) in_12\IN|patients (l_pobj) patients_16\NNS|parkinson|disease (l_compound) disease_15\NN|
3076126
D008148_D009135 NONE lovastatin_23\NN| (r_pobj) with_22\IN|lovastatin (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN|in|,|and|reported (r_acl) Myopathy_0\NNP|,|associated
D008148_D009212 CID lovastatin_23\NN| (r_pobj) with_22\IN|lovastatin (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN|in|,|and|reported (l_prep) in_3\IN|cases (l_pobj) cases_5\NNS|some|with (l_prep) with_6\IN|myoglobinuria (l_pobj) myoglobinuria_7\NNS|
D008148_D051437 CID lovastatin_23\NN| (r_pobj) with_22\IN|lovastatin (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN|cases (l_pobj) cases_12\NNS|2|with (l_prep) with_13\IN|failure (l_pobj) failure_16\NN|transient|renal
D016572_D009135 CID cyclosporin_31\NN|,|gemfibrozil (r_pobj) with_30\IN|cyclosporin (r_prep) treated_29\VBN|concomitantly|with (r_acl) patients_27\NNS|treated (r_pobj) in_26\IN|especially|patients (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN|in|,|and|reported (r_acl) Myopathy_0\NNP|,|associated
D016572_D009212 NONE cyclosporin_31\NN|,|gemfibrozil (r_pobj) with_30\IN|cyclosporin (r_prep) treated_29\VBN|concomitantly|with (r_acl) patients_27\NNS|treated (r_pobj) in_26\IN|especially|patients (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN|in|,|and|reported (l_prep) in_3\IN|cases (l_pobj) cases_5\NNS|some|with (l_prep) with_6\IN|myoglobinuria (l_pobj) myoglobinuria_7\NNS|
D016572_D051437 NONE cyclosporin_31\NN|,|gemfibrozil (r_pobj) with_30\IN|cyclosporin (r_prep) treated_29\VBN|concomitantly|with (r_acl) patients_27\NNS|treated (r_pobj) in_26\IN|especially|patients (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN|cases (l_pobj) cases_12\NNS|2|with (l_prep) with_13\IN|failure (l_pobj) failure_16\NN|transient|renal
D015248_D009135 CID gemfibrozil_33\NN|or|niacin (r_conj) cyclosporin_31\NN|,|gemfibrozil (r_pobj) with_30\IN|cyclosporin (r_prep) treated_29\VBN|concomitantly|with (r_acl) patients_27\NNS|treated (r_pobj) in_26\IN|especially|patients (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN|in|,|and|reported (r_acl) Myopathy_0\NNP|,|associated
D015248_D009212 NONE gemfibrozil_33\NN|or|niacin (r_conj) cyclosporin_31\NN|,|gemfibrozil (r_pobj) with_30\IN|cyclosporin (r_prep) treated_29\VBN|concomitantly|with (r_acl) patients_27\NNS|treated (r_pobj) in_26\IN|especially|patients (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN|in|,|and|reported (l_prep) in_3\IN|cases (l_pobj) cases_5\NNS|some|with (l_prep) with_6\IN|myoglobinuria (l_pobj) myoglobinuria_7\NNS|
D015248_D051437 NONE gemfibrozil_33\NN|or|niacin (r_conj) cyclosporin_31\NN|,|gemfibrozil (r_pobj) with_30\IN|cyclosporin (r_prep) treated_29\VBN|concomitantly|with (r_acl) patients_27\NNS|treated (r_pobj) in_26\IN|especially|patients (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN|cases (l_pobj) cases_12\NNS|2|with (l_prep) with_13\IN|failure (l_pobj) failure_16\NN|transient|renal
D009525_D009135 CID niacin_35\NN| (r_conj) gemfibrozil_33\NN|or|niacin (r_conj) cyclosporin_31\NN|,|gemfibrozil (r_pobj) with_30\IN|cyclosporin (r_prep) treated_29\VBN|concomitantly|with (r_acl) patients_27\NNS|treated (r_pobj) in_26\IN|especially|patients (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN|in|,|and|reported (r_acl) Myopathy_0\NNP|,|associated
D009525_D009212 NONE niacin_35\NN| (r_conj) gemfibrozil_33\NN|or|niacin (r_conj) cyclosporin_31\NN|,|gemfibrozil (r_pobj) with_30\IN|cyclosporin (r_prep) treated_29\VBN|concomitantly|with (r_acl) patients_27\NNS|treated (r_pobj) in_26\IN|especially|patients (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN|in|,|and|reported (l_prep) in_3\IN|cases (l_pobj) cases_5\NNS|some|with (l_prep) with_6\IN|myoglobinuria (l_pobj) myoglobinuria_7\NNS|
D009525_D051437 NONE niacin_35\NN| (r_conj) gemfibrozil_33\NN|or|niacin (r_conj) cyclosporin_31\NN|,|gemfibrozil (r_pobj) with_30\IN|cyclosporin (r_prep) treated_29\VBN|concomitantly|with (r_acl) patients_27\NNS|treated (r_pobj) in_26\IN|especially|patients (r_prep) reported_21\VBN|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN|cases (l_pobj) cases_12\NNS|2|with (l_prep) with_13\IN|failure (l_pobj) failure_16\NN|transient|renal
2054792
D004317_D005334 NONE adriamycin_2\NNS| (r_pobj) of_1\IN|adriamycin (r_prep) Effect_0\NN|of|combined|. (l_acl) combined_3\VBN|with|on (l_prep) with_4\IN|hyperthermia (l_pobj) hyperthermia_7\NN|body
D004317_D005334 NONE Adriamycin_3\NNP| (r_npadvmod) mediated_5\VBN|adriamycin|- (r_amod) activity_7\NN|mediated|antitumor|and|toxicities (l_conj) toxicities_11\NNS|normal|tissue|by (l_prep) by_12\IN|hyperthermia (l_pobj) hyperthermia_15\NN|whole|body
D004317_D005334 NONE Adriamycin_13\NNP| (r_npadvmod) mediated_15\VBN|adriamycin|- (r_amod) activity_17\NN|both|mediated|antitumor|and|effects (r_dobj) enhanced_11\VBD|hyperthermia|activity|. (l_nsubj) hyperthermia_2\NN|whole|body|(|min|)
D004317_D005334 NONE Adriamycin_7\NNP| (r_npadvmod) mediated_9\VBN|adriamycin|- (r_amod) effect_11\NN|mediated|antitumor (r_dobj) enhances_6\VBZ|while|hyperthermia|effect (l_nsubj) hyperthermia_5\NN|body
D004317_D009369 NONE adriamycin_2\NNS| (r_pobj) of_1\IN|adriamycin (r_prep) Effect_0\NN|of|combined|. (l_acl) combined_3\VBN|with|on (l_prep) on_8\IN|tumor (l_pobj) tumor_9\NN|and|tissues
D004317_D064420 NONE Adriamycin_3\NNP| (r_npadvmod) mediated_5\VBN|adriamycin|- (r_amod) activity_7\NN|mediated|antitumor|and|toxicities (l_conj) toxicities_11\NNS|normal|tissue|by
D004317_D064420 NONE Adriamycin_7\NNP| (r_npadvmod) mediated_9\VBN|adriamycin|- (r_amod) effect_11\NN|mediated|antitumor (r_dobj) enhances_6\VBZ|while|hyperthermia|effect (r_advcl) increased_18\VBN|thus|,|enhances|,|toxicity|is|also|,|and|eroded (l_nsubjpass) toxicity_15\NN|normal|tissue
322550
D009599_D007022 CID nitroprusside_8\RB| (r_advmod) induced_10\VBN|nitroprusside|- (r_amod) hypotension_11\NN|induced
D009599_D007022 CID nitroprusside_1\JJ| (r_amod) infusion_2\NN|nitroprusside (r_nsubj) produced_3\VBD|before|infusion|decrease|and|increased|. (l_dobj) decrease_6\NN|a|further|in (l_prep) in_7\IN|pressure (l_pobj) pressure_10\NN|arterial|blood
D009599_D007022 CID Nitroprusside_0\NNP| (r_nsubj) caused_1\VBD|nitroprusside|decreases|,|but|change|. (l_dobj) decreases_3\NNS|significant|in (l_prep) in_4\IN|pressure (l_pobj) pressure_7\NN|arterial|blood|and|resistance
D009599_D007022 NONE nitroprusside_1\JJ| (r_amod) levels_4\NNS|nitroprusside|infusion|low|of (r_pobj) During_0\IN|levels (r_prep) alter_10\VB|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP|,|decreasing|,|decreases (l_dobj) decreases_33\NNS|marked|in (l_prep) in_34\IN|pressure (l_pobj) pressure_37\NN|arterial|blood|and|output (l_conj) output_40\NN|cardiac
D009599_D002303 NONE nitroprusside_1\JJ| (r_amod) infusion_2\NN|nitroprusside (r_nsubj) produced_3\VBD|before|infusion|decrease|and|increased|. (l_conj) increased_13\VBN|significantly|rate|and|decreased (l_conj) decreased_17\VBD|output (l_dobj) output_19\NN|cardiac|and|qt
D009599_D002303 NONE nitroprusside_1\JJ| (r_amod) levels_4\NNS|nitroprusside|infusion|low|of (r_pobj) During_0\IN|levels (r_prep) alter_10\VB|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP|,|decreasing|,|decreases (l_dobj) decreases_33\NNS|marked|in (l_prep) in_34\IN|pressure (l_pobj) pressure_37\NN|arterial|blood|and|output (l_conj) output_40\NN|cardiac
D014867_D007022 NONE H2O_22\NNP|cm (r_punct) levels_16\NNS|high|of|h2o|) (r_conj) alter_10\VB|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP|,|decreasing|,|decreases (l_dobj) decreases_33\NNS|marked|in (l_prep) in_34\IN|pressure (l_pobj) pressure_37\NN|arterial|blood|and|output (l_conj) output_40\NN|cardiac
D014867_D002303 NONE H2O_22\NNP|cm (r_punct) levels_16\NNS|high|of|h2o|) (r_conj) alter_10\VB|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP|,|decreasing|,|decreases (l_dobj) decreases_33\NNS|marked|in (l_prep) in_34\IN|pressure (l_pobj) pressure_37\NN|arterial|blood|and|output (l_conj) output_40\NN|cardiac
12639165
D013988_D002779 CID Ticlopidine_0\NNP| (r_npadvmod) induced_2\VBN|ticlopidine|- (r_amod) hepatitis_4\NN|induced|cholestatic|.
D013988_D002779 CID ticlopidine_5\NN| (r_npadvmod) induced_7\VBN|ticlopidine|- (r_amod) hepatitis_9\NN|induced|cholestatic
D013988_D002779 CID ticlopidine_8\NN| (r_advmod) receiving_7\VBG|ticlopidine|following (r_pcomp) after_6\IN|receiving (r_prep) developed_2\VBD|patients|hepatitis|after|,|with|. (l_dobj) hepatitis_5\NN|prolonged|cholestatic
D013988_D002779 CID ticlopidine_10\NN| (r_advmod) complication_5\NN|a|rare|of|ticlopidine (r_attr) is_2\VBZ|hepatitis|complication (l_nsubj) hepatitis_1\NN|cholestatic
D013988_D002779 CID ticlopidine_7\NN| (r_pobj) with_6\IN|ticlopidine (r_prep) treatment_5\NN|with (r_pobj) following_4\VBG|treatment (r_prep) developed_2\VBD|patients|jaundice|following|and|showed|. (l_conj) showed_9\VBD|characteristics (l_dobj) characteristics_14\NNS|the|clinical|of|,|resolved (l_prep) of_15\IN|hepatitis (l_pobj) hepatitis_17\NN|cholestatic
D013988_D002779 CID ticlopidine_4\NN| (r_npadvmod) induced_6\VBN|ticlopidine|- (r_amod) cholestasis_7\NN|this|induced
D013988_D002779 CID ticlopidine_8\NN| (r_pobj) of_7\IN|ticlopidine (r_prep) effect_6\NN|a|rare|adverse|of|be (r_attr) is_2\VBZ|hepatitis|effect|. (l_nsubj) hepatitis_1\NN|cholestatic
D013988_D056486 CID Ticlopidine_0\NNP| (r_npadvmod) induced_2\VBN|ticlopidine|- (r_amod) hepatitis_4\NN|induced|cholestatic|.
D013988_D056486 CID ticlopidine_5\NN| (r_npadvmod) induced_7\VBN|ticlopidine|- (r_amod) hepatitis_9\NN|induced|cholestatic
D013988_D056486 CID ticlopidine_8\NN| (r_advmod) receiving_7\VBG|ticlopidine|following (r_pcomp) after_6\IN|receiving (r_prep) developed_2\VBD|patients|hepatitis|after|,|with|. (l_dobj) hepatitis_5\NN|prolonged|cholestatic
D013988_D056486 CID ticlopidine_10\NN| (r_advmod) complication_5\NN|a|rare|of|ticlopidine (r_attr) is_2\VBZ|hepatitis|complication (l_nsubj) hepatitis_1\NN|cholestatic
D013988_D056486 CID ticlopidine_7\NN| (r_pobj) with_6\IN|ticlopidine (r_prep) treatment_5\NN|with (r_pobj) following_4\VBG|treatment (r_prep) developed_2\VBD|patients|jaundice|following|and|showed|. (l_conj) showed_9\VBD|characteristics (l_dobj) characteristics_14\NNS|the|clinical|of|,|resolved (l_prep) of_15\IN|hepatitis (l_pobj) hepatitis_17\NN|cholestatic
D013988_D056486 CID ticlopidine_8\NN| (r_pobj) of_7\IN|ticlopidine (r_prep) effect_6\NN|a|rare|adverse|of|be (r_attr) is_2\VBZ|hepatitis|effect|. (l_nsubj) hepatitis_1\NN|cholestatic
D013988_D007565 CID ticlopidine_7\NN| (r_pobj) with_6\IN|ticlopidine (r_prep) treatment_5\NN|with (r_pobj) following_4\VBG|treatment (r_prep) developed_2\VBD|patients|jaundice|following|and|showed|. (l_dobj) jaundice_3\NN|
809711
D010656_D009203 NONE phenylephrine_2\NN|of (l_prep) of_3\IN|effects (l_pobj) effects_6\NNS|the|beneficial|of|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|infarction (l_pobj) infarction_15\NN|acute|myocardial
D010656_D009203 NONE phenylephrine_6\NN|to (r_pobj) of_5\IN|phenylephrine (r_prep) addition_4\NN|of (r_nsubj) is_9\VBZ|that|addition|not|beneficial (l_acomp) beneficial_11\JJ|in (l_prep) in_12\IN|treatment (l_pobj) treatment_14\NN|the|of (l_prep) of_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|infarction (l_pobj) infarction_20\NN|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN|intravenous (r_pobj) of_7\IN|nitroglycerin (r_prep) effects_6\NNS|the|beneficial|of|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|infarction (l_pobj) infarction_15\NN|acute|myocardial
D005996_D009203 NONE Nitroglycerin_0\NNP| (r_nsubjpass) shown_3\VBN|nitroglycerin|has|been|reduce (l_xcomp) reduce_5\VB|to|elevation|during (l_prep) during_10\IN|infarction (l_pobj) infarction_13\NN|acute|myocardial
D005996_D009203 NONE nitroglycerin_25\NN| (r_npadvmod) induced_27\VBN|nitroglycerin|- (r_amod) hypotension_28\NN|induced (r_dobj) reverse_24\VBP|that|hypotension (r_relcl) agents_22\NNS|reverse (r_pobj) by_21\IN|agents (r_agent) potentiated_17\VBN|shown|,|effect|in|by|. (l_ccomp) shown_3\VBN|nitroglycerin|has|been|reduce (l_xcomp) reduce_5\VB|to|elevation|during (l_prep) during_10\IN|infarction (l_pobj) infarction_13\NN|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN|intravenous|,|sufficient (r_dobj) received_7\VBD|patients|nitroglycerin|+/- (l_nsubj) patients_1\NNS|ten|with (l_prep) with_2\IN|infarctions (l_pobj) infarctions_6\NNS|acute|transmural|myocardial
D005996_D009203 NONE nitroglycerin_8\NN| (r_pobj) to_7\IN|nitroglycerin (r_prep) phenylephrine_6\NN|to (r_pobj) of_5\IN|phenylephrine (r_prep) addition_4\NN|of (r_nsubj) is_9\VBZ|that|addition|not|beneficial (l_acomp) beneficial_11\JJ|in (l_prep) in_12\IN|treatment (l_pobj) treatment_14\NN|the|of (l_prep) of_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|infarction (l_pobj) infarction_20\NN|acute|myocardial
D005996_D007022 CID Nitroglycerin_0\NNP| (r_nsubjpass) shown_3\VBN|nitroglycerin|has|been|reduce (r_ccomp) potentiated_17\VBN|shown|,|effect|in|by|. (l_agent) by_21\IN|agents (l_pobj) agents_22\NNS|reverse (l_relcl) reverse_24\VBP|that|hypotension (l_dobj) hypotension_28\NN|induced
D005996_D007022 CID nitroglycerin_25\NN| (r_npadvmod) induced_27\VBN|nitroglycerin|- (r_amod) hypotension_28\NN|induced
16858720
D014859_D002543 CID warfarin_4\NN|- (r_pobj) by_3\IN|warfarin (r_agent) induced_2\VBN|by|influence (r_acl) haemorrhage_1\NN|cerebral|induced|.
D014859_D002543 CID warfarin_9\RB| (r_npadvmod) induced_11\VBN|warfarin|- (r_amod) haemorrhages_13\NNS|induced|cerebral
D014859_D002543 CID warfarin_16\JJ|and|interactions (r_pobj) due_14\IN|to|warfarin (r_prep) evaluate_1\VB|to|frequency|due|. (l_dobj) frequency_3\NN|the|,|severity|of (l_prep) of_8\IN|haemorrhages (l_pobj) haemorrhages_13\NNS|induced|cerebral
D014859_D002543 CID warfarin_18\JJ| (r_compound) drug_20\NN|warfarin|- (r_compound) interactions_21\NNS|drug|in (r_conj) warfarin_16\JJ|and|interactions (r_pobj) due_14\IN|to|warfarin (r_prep) evaluate_1\VB|to|frequency|due|. (l_dobj) frequency_3\NN|the|,|severity|of (l_prep) of_8\IN|haemorrhages (l_pobj) haemorrhages_13\NNS|induced|cerebral
D014859_D002543 CID warfarin_8\JJ|and|drug (r_nmod) interactions_13\NNS|warfarin (r_nsubj) caused_16\VBN|whether|interactions|could|have|haemorrhage (l_dobj) haemorrhage_19\NN|the|cerebral
D014859_D002543 CID warfarin_10\JJ| (r_compound) drug_12\NN|warfarin|- (r_conj) warfarin_8\JJ|and|drug (r_nmod) interactions_13\NNS|warfarin (r_nsubj) caused_16\VBN|whether|interactions|could|have|haemorrhage (l_dobj) haemorrhage_19\NN|the|cerebral
D014859_D002543 CID warfarin_17\JJ| (r_compound) treatment_18\NN|warfarin (r_pobj) to_16\IN|treatment (r_prep) related_15\VBN|to (r_amod) as_14\IN|related (r_prep) assessed_13\VBN|among|were|as|. (l_prep) Among_0\IN|patients (l_pobj) patients_2\NNS|593|with (l_prep) with_3\IN|haemorrhage (l_pobj) haemorrhage_5\NN|cerebral|,|%|)
D014859_D002543 CID Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|warfarin|- (r_amod) haemorrhages_4\NNS|induced|cerebral
D014859_D002543 CID warfarin_4\RB| (r_npadvmod) related_6\VBN|warfarin|- (r_amod) haemorrhages_8\NNS|related|cerebral
D014859_D002543 CID warfarin_26\NN| (r_pobj) with_25\IN|warfarin (r_prep) interact_24\VB|to|with (r_xcomp) known_22\VBN|interact (r_acl) drugs_21\NNS|known (r_dobj) prescribing_20\VBG|when|drugs (r_advcl) taken_18\VBN|if|caution|had|been|prescribing (r_advcl) prevented_12\VBN|proportion|might|have|been|taken|. (l_nsubjpass) proportion_2\NN|a|significant|of (l_prep) of_3\IN|haemorrhages (l_pobj) haemorrhages_8\NNS|related|cerebral
D014859_D006470 NONE warfarin_1\JJ| (r_compound) drug_3\NN|warfarin|- (r_compound) interaction_4\NN|a|drug (r_nsubj) contributed_7\VBN|interaction|could|have|to|in|considered|. (l_prep) to_8\IN|haemorrhage (l_pobj) haemorrhage_10\NN|the
D014859_D006470 NONE warfarin_1\JJ| (r_compound) drug_3\NN|warfarin|- (r_compound) interaction_4\NN|a|drug (r_nsubj) contributed_7\VBN|interaction|could|have|to|in|considered|. (l_conj) considered_34\VBN|complication|was|being (l_nsubjpass) complication_32\NN|the|bleeding (l_amod) bleeding_31\VBG|
D014859_D006470 NONE warfarin_19\JJ| (r_compound) patients_20\NNS|the|warfarin (r_pobj) of_17\IN|patients (r_prep) %_15\NN|24|(|41|)|of (r_pobj) in_11\IN|%|and|in (r_prep) contributed_7\VBN|interaction|could|have|to|in|considered|. (l_prep) to_8\IN|haemorrhage (l_pobj) haemorrhage_10\NN|the
D014859_D006470 NONE warfarin_19\JJ| (r_compound) patients_20\NNS|the|warfarin (r_pobj) of_17\IN|patients (r_prep) %_15\NN|24|(|41|)|of (r_pobj) in_11\IN|%|and|in (r_prep) contributed_7\VBN|interaction|could|have|to|in|considered|. (l_conj) considered_34\VBN|complication|was|being (l_nsubjpass) complication_32\NN|the|bleeding (l_amod) bleeding_31\VBG|
20633755
D013390_D001049 CID Suxamethonium_0\NNS| (r_nsubj) induced_1\VBD|suxamethonium|apnea|. (l_dobj) apnea_3\NN|prolonged|in
D013390_D001049 CID Suxamethonium_0\JJ| (r_nsubj) causes_1\VBZ|suxamethonium|apnea|. (l_dobj) apnea_3\NN|prolonged|in
D009943_D001049 CID poisons_17\NNS|organophosphorus|(|op|) (r_pobj) by_12\IN|poisons (r_agent) deactivated_11\VBN|in|enzyme|gets|by (r_relcl) patients_5\NNS|deactivated (r_pobj) in_4\IN|patients (r_prep) apnea_3\NN|prolonged|in
D009943_D001049 CID compound_14\NN|op (r_pobj) by_12\IN|compound (r_prep) attempt_11\NN|suicidal|by (r_pobj) about_9\IN|attempt (r_prep) information_8\NN|the|about (r_nsubjpass) concealed_16\VBN|because|information|was|from (r_advcl) ensued_5\VBD|apnea|concealed|. (l_nsubj) apnea_1\NN|prolonged|in
7858459
D005472_D003221 CID 5-fluorouracil_10\CD| (r_punct) of_9\IN|5-fluorouracil (r_prep) infusion_8\NN|a|dose|of|and|acid (r_pobj) by_3\IN|infusion (r_agent) induced_2\VBN|confusion|by|. (l_nsubj) confusion_1\NN|acute
D005472_D003221 CID 5-fluorouracil_35\CD| (r_punct) of_34\IN|5-fluorouracil (r_prep) dose_29\NN|the|first|day|of|and (r_nmod) infusion_39\NN|dose|folinic|acid (r_pobj) during_26\IN|infusion (r_prep) lasting_21\VBG|for|during (r_advcl) lapsed_15\VBD|then|into|,|lasting (r_conj) developed_1\VBD|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS|acute|neurologic|of (l_prep) of_5\IN|confusion (l_pobj) confusion_7\NN|mental|,|disorientation
D005472_D003221 CID 5-fluorouracil_35\CD| (r_punct) of_34\IN|5-fluorouracil (r_prep) dose_29\NN|the|first|day|of|and (r_nmod) infusion_39\NN|dose|folinic|acid (r_pobj) during_26\IN|infusion (r_prep) lasting_21\VBG|for|during (r_advcl) lapsed_15\VBD|then|into|,|lasting (r_conj) developed_1\VBD|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS|acute|neurologic|of (l_prep) of_5\IN|confusion (l_pobj) confusion_7\NN|mental|,|disorientation (l_conj) disorientation_9\NN|and|irritability
D002955_D003221 CID acid_13\NN|folinic (r_conj) infusion_8\NN|a|dose|of|and|acid (r_pobj) by_3\IN|infusion (r_agent) induced_2\VBN|confusion|by|. (l_nsubj) confusion_1\NN|acute
D002955_D003221 CID acid_38\NN| (r_compound) infusion_39\NN|dose|folinic|acid (r_pobj) during_26\IN|infusion (r_prep) lasting_21\VBG|for|during (r_advcl) lapsed_15\VBD|then|into|,|lasting (r_conj) developed_1\VBD|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS|acute|neurologic|of (l_prep) of_5\IN|confusion (l_pobj) confusion_7\NN|mental|,|disorientation
D002955_D003221 CID acid_38\NN| (r_compound) infusion_39\NN|dose|folinic|acid (r_pobj) during_26\IN|infusion (r_prep) lasting_21\VBG|for|during (r_advcl) lapsed_15\VBD|then|into|,|lasting (r_conj) developed_1\VBD|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS|acute|neurologic|of (l_prep) of_5\IN|confusion (l_pobj) confusion_7\NN|mental|,|disorientation (l_conj) disorientation_9\NN|and|irritability
D002945_D013274 NONE cisplatinum_11\NN|,|etoposide|hours (l_appos) hours_24\NNS|m2/24|)|and|acid (l_conj) acid_28\NN|folinic|for (l_prep) for_29\IN|adenocarcinoma (l_pobj) adenocarcinoma_33\NN|an|inoperable|gastric
D005047_D013274 NONE etoposide_13\NN| (r_conj) cisplatinum_11\NN|,|etoposide|hours (l_appos) hours_24\NNS|m2/24|)|and|acid (l_conj) acid_28\NN|folinic|for (l_prep) for_29\IN|adenocarcinoma (l_pobj) adenocarcinoma_33\NN|an|inoperable|gastric
D005472_D013274 NONE 5-fluorouracil_18\CD| (r_punct) m2/24_23\NN|,|dose|5-fluorouracil|(|mg|/ (r_compound) hours_24\NNS|m2/24|)|and|acid (l_conj) acid_28\NN|folinic|for (l_prep) for_29\IN|adenocarcinoma (l_pobj) adenocarcinoma_33\NN|an|inoperable|gastric
D002955_D013274 NONE acid_28\NN|folinic|for (l_prep) for_29\IN|adenocarcinoma (l_pobj) adenocarcinoma_33\NN|an|inoperable|gastric
D005472_D001523 NONE 5-fluorouracil_35\CD| (r_punct) of_34\IN|5-fluorouracil (r_prep) dose_29\NN|the|first|day|of|and (r_nmod) infusion_39\NN|dose|folinic|acid (r_pobj) during_26\IN|infusion (r_prep) lasting_21\VBG|for|during (r_advcl) lapsed_15\VBD|then|into|,|lasting (r_conj) developed_1\VBD|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS|acute|neurologic|of (l_prep) of_5\IN|confusion (l_pobj) confusion_7\NN|mental|,|disorientation (l_conj) disorientation_9\NN|and|irritability (l_conj) irritability_11\NN|
D005472_D003128 CID 5-fluorouracil_35\CD| (r_punct) of_34\IN|5-fluorouracil (r_prep) dose_29\NN|the|first|day|of|and (r_nmod) infusion_39\NN|dose|folinic|acid (r_pobj) during_26\IN|infusion (r_prep) lasting_21\VBG|for|during (r_advcl) lapsed_15\VBD|then|into|,|lasting (l_prep) into_16\IN|coma (l_pobj) coma_19\NN|a|deep
D002955_D001523 NONE acid_38\NN| (r_compound) infusion_39\NN|dose|folinic|acid (r_pobj) during_26\IN|infusion (r_prep) lasting_21\VBG|for|during (r_advcl) lapsed_15\VBD|then|into|,|lasting (r_conj) developed_1\VBD|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS|acute|neurologic|of (l_prep) of_5\IN|confusion (l_pobj) confusion_7\NN|mental|,|disorientation (l_conj) disorientation_9\NN|and|irritability (l_conj) irritability_11\NN|
D002955_D003128 CID acid_38\NN| (r_compound) infusion_39\NN|dose|folinic|acid (r_pobj) during_26\IN|infusion (r_prep) lasting_21\VBG|for|during (r_advcl) lapsed_15\VBD|then|into|,|lasting (l_prep) into_16\IN|coma (l_pobj) coma_19\NN|a|deep
D002955_D020258 NONE acid_2\NN|folinic (r_nsubj) was_3\VBD|because|acid|unlikely (r_advcl) suspected_21\VBN|was|,|neurotoxicity|5-fluorouracil|was|highly|. (l_nsubjpass) neurotoxicity_12\NN|due
D005472_D020258 NONE 5-fluorouracil_18\CD| (r_punct) suspected_21\VBN|was|,|neurotoxicity|5-fluorouracil|was|highly|. (l_nsubjpass) neurotoxicity_12\NN|due
D005472_D020258 NONE 5-fluorouracil_3\CD| (r_punct) neurotoxicity_4\NN|5-fluorouracil
D005463_D020258 NONE fluoroacetate_14\NN|and|fluorocitrate (r_pobj) by_13\IN|fluoroacetate (r_prep) blockade_12\NN|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN|blockade (r_prep) due_7\JJ|to (r_acomp) be_6\VB|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN|the|of (l_prep) of_2\IN|neurotoxicity (l_pobj) neurotoxicity_4\NN|5-fluorouracil
C007744_D020258 NONE fluorocitrate_16\NN| (r_conj) fluoroacetate_14\NN|and|fluorocitrate (r_pobj) by_13\IN|fluoroacetate (r_prep) blockade_12\NN|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN|blockade (r_prep) due_7\JJ|to (r_acomp) be_6\VB|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN|the|of (l_prep) of_2\IN|neurotoxicity (l_pobj) neurotoxicity_4\NN|5-fluorouracil
D013831_D020258 NONE thiamine_18\NN| (r_compound) deficiency_19\NN|thiamine|,|or|deficiency (r_conj) blockade_12\NN|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN|blockade (r_prep) due_7\JJ|to (r_acomp) be_6\VB|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN|the|of (l_prep) of_2\IN|neurotoxicity (l_pobj) neurotoxicity_4\NN|5-fluorouracil
C007419_D020258 NONE dihydrouracil_22\VBN| (r_compound) dehydrogenase_23\NN|dihydrouracil (r_compound) deficiency_24\NN|dehydrogenase (r_conj) deficiency_19\NN|thiamine|,|or|deficiency (r_conj) blockade_12\NN|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN|blockade (r_prep) due_7\JJ|to (r_acomp) be_6\VB|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN|the|of (l_prep) of_2\IN|neurotoxicity (l_pobj) neurotoxicity_4\NN|5-fluorouracil
D005472_D009369 NONE 5-fluorouracil_3\CD| (r_punct) folinic_5\JJ|5-fluorouracil|/ (r_amod) therapy_8\NN|dose|folinic|infusion (r_nsubj) become_11\VBN|therapy|has|recently|regimen|. (l_attr) regimen_14\NN|a|popular|for (l_prep) for_15\IN|cancers (l_pobj) cancers_17\NNS|various
D002955_D009369 NONE acid_6\NN| (r_compound) infusion_7\NN|acid (r_compound) therapy_8\NN|dose|folinic|infusion (r_nsubj) become_11\VBN|therapy|has|recently|regimen|. (l_attr) regimen_14\NN|a|popular|for (l_prep) for_15\IN|cancers (l_pobj) cancers_17\NNS|various
9249847
D014700_D013611 CID verapamil_7\NN|and (r_nmod) ablation_10\NN|verapamil|catheter|in|and|cardiomyopathy (r_pobj) after_6\IN|ablation (r_prep) induced_1\VBD|iatrogenically|tachycardia|after|. (l_dobj) tachycardia_5\NN|intractable|atrioventricular|reentrant
D014700_D013611 CID verapamil_10\NN|or (r_nmod) block_14\NN|verapamil|unidirectional|antegrade|of (r_pobj) after_9\IN|block (r_prep) beats_8\NNS|junctional|escape|after|after (r_pobj) by_5\IN|beats (r_agent) caused_4\VBN|by (r_acl) QRS_0\UH|without|,|caused|, (r_nsubj) established_22\VBD|qrs|attack|. (l_dobj) attack_25\NN|frequent|avrt (l_compound) AVRT_24\NN|
D014700_D014927 NONE verapamil_7\NN|and (r_nmod) ablation_10\NN|verapamil|catheter|in|and|cardiomyopathy (l_prep) in_11\IN|patient (l_pobj) patient_13\NN|a|with (l_prep) with_14\IN|syndrome (l_pobj) syndrome_20\NN|white
D014700_D002311 NONE verapamil_7\NN|and (r_nmod) ablation_10\NN|verapamil|catheter|in|and|cardiomyopathy (l_conj) cardiomyopathy_24\NN|idiopathic|dilated
20080983
C048833_D012893 NONE modafinil_15\NN|dosed|on|sleepiness (l_conj) sleepiness_20\NN|daytime|in
C048833_D012893 NONE Modafinil_0\NNP| (r_nsubjpass) associated_2\VBN|modafinil|was|with|,|measured|. (l_advcl) measured_10\VBN|as|by|,|and|decrease (l_conj) decrease_22\NN|a|significant|in (l_prep) in_23\IN|sleepiness (l_pobj) sleepiness_26\NN|subjective|daytime
C048833_D012893 NONE modafinil_3\NN|dosed (r_nsubj) promotes_4\VBZ|modafinil|sleep|,|normalizes|. (l_conj) normalizes_8\VBZ|architecture|,|and|decreases (l_conj) decreases_13\VBZ|sleepiness (l_dobj) sleepiness_15\NN|daytime|in
D003042_D012893 CID cocaine_23\NN| (r_compound) users_24\NNS|chronic|cocaine (r_pobj) in_21\IN|users (r_prep) sleepiness_20\NN|daytime|in
D003042_D012893 CID cocaine_18\NN| (r_compound) users_19\NNS|abstinent|cocaine (r_pobj) in_16\IN|users (r_prep) sleepiness_15\NN|daytime|in
11198499
C023754_D007022 CID tizanidine_5\NN| (r_pobj) of_4\IN|tizanidine (r_prep) initiation_3\NN|the|of|in (r_dobj) following_1\VBG|initiation (r_acl) Hypotension_0\NN|following|.
C023754_D007022 CID tizanidine_29\NN|,|agonist|, (r_pobj) of_28\IN|tizanidine (r_prep) addition_27\NN|the|of|for (r_pobj) following_25\VBG|addition (r_prep) developed_23\VBD|who|hypotension|following (l_dobj) hypotension_24\NN|
C023754_D006973 NONE tizanidine_5\NN| (r_pobj) of_4\IN|tizanidine (r_prep) initiation_3\NN|the|of|in (l_prep) in_6\IN|patient (l_pobj) patient_8\NN|a|treated (l_acl) treated_9\VBN|with (l_prep) with_10\IN|angiotensin (l_pobj) angiotensin_12\NN|an|converting (l_acl) converting_13\VBG|inhibitor|for (l_prep) for_16\IN|hypertension (l_pobj) hypertension_18\NN|chronic
C023754_D006973 NONE tizanidine_29\NN|,|agonist|, (r_pobj) of_28\IN|tizanidine (r_prep) addition_27\NN|the|of|for (r_pobj) following_25\VBG|addition (r_prep) developed_23\VBD|who|hypotension|following (r_relcl) hypertension_21\NN|developed
C023754_D006973 NONE tizanidine_4\NN|and|agents (r_pobj) of_3\IN|tizanidine (r_prep) interaction_2\NN|the|possible|of (r_nsubjpass) kept_11\VBN|interaction|should|be|in|prescribing|. (l_advcl) prescribing_15\VBG|when|therapy|treat (l_xcomp) treat_18\VB|to|hypertension (l_dobj) hypertension_20\NN|either|or|spasticity|in
D000809_D007022 NONE angiotensin_12\NN|an|converting (r_pobj) with_10\IN|angiotensin (r_prep) treated_9\VBN|with (r_acl) patient_8\NN|a|treated (r_pobj) in_6\IN|patient (r_prep) initiation_3\NN|the|of|in (r_dobj) following_1\VBG|initiation (r_acl) Hypotension_0\NN|following|.
D000809_D007022 NONE angiotensin_4\NN|converting (r_pobj) with_3\IN|angiotensin (r_prep) treated_2\VBN|adults|chronically|with (r_csubj) have_9\VB|treated|may|ability|. (l_dobj) ability_12\NN|a|limited|respond (l_acl) respond_14\VB|to|to|blocked (l_prep) to_15\IN|hypotension (l_pobj) hypotension_16\NN|
D000809_D007022 NONE angiotensin_14\NN|an|converting (r_appos) lisinopril_11\NN|,|angiotensin (r_pobj) with_10\IN|lisinopril (r_prep) treated_9\VBN|chronically|with (r_acl) boy_7\NN|a|old|treated|, (r_dobj) present_2\VBP|authors|boy|control|. (l_advcl) control_20\VB|to|hypertension (l_dobj) hypertension_21\NN|developed (l_relcl) developed_23\VBD|who|hypotension|following (l_dobj) hypotension_24\NN|
D000809_D006973 NONE angiotensin_12\NN|an|converting (l_acl) converting_13\VBG|inhibitor|for (l_prep) for_16\IN|hypertension (l_pobj) hypertension_18\NN|chronic
D000809_D006973 NONE angiotensin_14\NN|an|converting (r_appos) lisinopril_11\NN|,|angiotensin (r_pobj) with_10\IN|lisinopril (r_prep) treated_9\VBN|chronically|with (r_acl) boy_7\NN|a|old|treated|, (r_dobj) present_2\VBP|authors|boy|control|. (l_advcl) control_20\VB|to|hypertension (l_dobj) hypertension_21\NN|developed
D017706_D006973 NONE lisinopril_11\NN|,|angiotensin (r_pobj) with_10\IN|lisinopril (r_prep) treated_9\VBN|chronically|with (r_acl) boy_7\NN|a|old|treated|, (r_dobj) present_2\VBP|authors|boy|control|. (l_advcl) control_20\VB|to|hypertension (l_dobj) hypertension_21\NN|developed
D017706_D007022 CID lisinopril_11\NN|,|angiotensin (r_pobj) with_10\IN|lisinopril (r_prep) treated_9\VBN|chronically|with (r_acl) boy_7\NN|a|old|treated|, (r_dobj) present_2\VBP|authors|boy|control|. (l_advcl) control_20\VB|to|hypertension (l_dobj) hypertension_21\NN|developed (l_relcl) developed_23\VBD|who|hypotension|following (l_dobj) hypotension_24\NN|
D017706_D009128 NONE lisinopril_11\NN|,|angiotensin (r_pobj) with_10\IN|lisinopril (r_prep) treated_9\VBN|chronically|with (r_acl) boy_7\NN|a|old|treated|, (r_dobj) present_2\VBP|authors|boy|control|. (l_advcl) control_20\VB|to|hypertension (l_dobj) hypertension_21\NN|developed (l_relcl) developed_23\VBD|who|hypotension|following (l_prep) following_25\VBG|addition (l_pobj) addition_27\NN|the|of|for (l_prep) for_35\IN|treatment (l_pobj) treatment_37\NN|the|of (l_prep) of_38\IN|spasticity (l_pobj) spasticity_39\NN|
D000809_D009128 NONE angiotensin_14\NN|an|converting (r_appos) lisinopril_11\NN|,|angiotensin (r_pobj) with_10\IN|lisinopril (r_prep) treated_9\VBN|chronically|with (r_acl) boy_7\NN|a|old|treated|, (r_dobj) present_2\VBP|authors|boy|control|. (l_advcl) control_20\VB|to|hypertension (l_dobj) hypertension_21\NN|developed (l_relcl) developed_23\VBD|who|hypotension|following (l_prep) following_25\VBG|addition (l_pobj) addition_27\NN|the|of|for (l_prep) for_35\IN|treatment (l_pobj) treatment_37\NN|the|of (l_prep) of_38\IN|spasticity (l_pobj) spasticity_39\NN|
C023754_D009128 NONE tizanidine_29\NN|,|agonist|, (r_pobj) of_28\IN|tizanidine (r_prep) addition_27\NN|the|of|for (l_prep) for_35\IN|treatment (l_pobj) treatment_37\NN|the|of (l_prep) of_38\IN|spasticity (l_pobj) spasticity_39\NN|
C023754_D009128 NONE tizanidine_4\NN|and|agents (r_pobj) of_3\IN|tizanidine (r_prep) interaction_2\NN|the|possible|of (r_nsubjpass) kept_11\VBN|interaction|should|be|in|prescribing|. (l_advcl) prescribing_15\VBG|when|therapy|treat (l_xcomp) treat_18\VB|to|hypertension (l_dobj) hypertension_20\NN|either|or|spasticity|in (l_conj) spasticity_22\NN|
20588063
D011692_D009401 CID aminonucleoside_17\JJ| (r_amod) nephrosis_18\NN|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_2\JJ| (r_amod) nephrosis_3\NN|aminonucleoside
3015567
D009599_D007022 CID Nitroprusside_0\NNP| (r_npadvmod) induced_2\VBN|nitroprusside|- (r_amod) hypotension_3\NN|induced
D009599_D007022 CID nitroprusside_7\RB| (r_advmod) induced_9\VBN|nitroprusside|- (r_amod) hypotension_10\NN|induced
D003345_D007022 NONE corticosterone_18\NN|plasma (r_compound) level_19\NN|a|corticosterone|between (r_pobj) at_15\IN|level (r_prep) occurs_14\VBZ|at (r_conj) observed_12\VBN|suppression|is|and|occurs|. (l_nsubjpass) Suppression_0\NN|of|secretion (l_appos) secretion_3\NN|in (l_prep) in_4\IN|response (l_pobj) response_5\NN|to (l_prep) to_6\IN|hypotension (l_pobj) hypotension_10\NN|induced
7449470
D004317_D066126 NONE doxorubicin_3\NN| (r_compound) cardiotoxicity_4\NN|late|,|late|doxorubicin|.
D004317_D066126 NONE adriamycin_11\NNS| (r_pobj) of_10\IN|adriamycin (r_prep) use_9\NN|the|of|as (r_dobj) limits_7\VBZ|which|use (r_relcl) complication_5\NN|a|major|limits (r_attr) is_2\VBZ|toxicity|complication|. (l_nsubj) toxicity_1\NN|cardiac
8739323
D008466_D007674 NONE nitrogranulogen_8\NN|ng|,|methotrexate (r_pobj) as_7\IN|such|nitrogranulogen (r_prep) drugs_5\NNS|anticancer|as (r_pobj) of_3\IN|drugs (r_prep) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D008466_D007674 NONE NG_10\NNP|(|) (r_appos) nitrogranulogen_8\NN|ng|,|methotrexate (r_pobj) as_7\IN|such|nitrogranulogen (r_prep) drugs_5\NNS|anticancer|as (r_pobj) of_3\IN|drugs (r_prep) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D008727_D007674 NONE methotrexate_13\NNP|mtx|, (r_conj) nitrogranulogen_8\NN|ng|,|methotrexate (r_pobj) as_7\IN|such|nitrogranulogen (r_prep) drugs_5\NNS|anticancer|as (r_pobj) of_3\IN|drugs (r_prep) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D008727_D007674 NONE MTX_15\NNP|(|) (r_appos) methotrexate_13\NNP|mtx|, (r_conj) nitrogranulogen_8\NN|ng|,|methotrexate (r_pobj) as_7\IN|such|nitrogranulogen (r_prep) drugs_5\NNS|anticancer|as (r_pobj) of_3\IN|drugs (r_prep) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D008727_D007674 NONE MTX_33\NNP|[|+|5-fu (r_appos) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D008727_D007674 NONE MTX_6\NNP| (r_pobj) of_5\IN|mtx (r_prep) nephrotoxicity_4\NN|that|of|+
D005472_D007674 NONE 5-fluorouracil_18\CD| (r_punct) 5-FU_20\CD|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D005472_D007674 NONE 5-FU_20\CD|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D005472_D007674 NONE 5-FU_35\CD|+|cy (r_conj) MTX_33\NNP|[|+|5-fu (r_appos) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D005472_D007674 NONE 5-FU_8\CD|+|cy|administered (r_nsubj) is_13\VBZ|5-fu|lower (r_ccomp) indicate_2\VBP|studies|nephrotoxicity|is|. (l_dobj) nephrotoxicity_4\NN|that|of|+
D003520_D007674 NONE cyclophosphamide_23\NN|cy (r_conj) 5-FU_20\CD|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D003520_D007674 NONE CY_25\NNP|(|) (r_appos) cyclophosphamide_23\NN|cy (r_conj) 5-FU_20\CD|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D003520_D007674 NONE CY_37\NNP|cmf|] (r_conj) 5-FU_35\CD|+|cy (r_conj) MTX_33\NNP|[|+|5-fu (r_appos) action_2\NN|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ|
D003520_D007674 NONE CY_10\NNP| (r_conj) 5-FU_8\CD|+|cy|administered (r_nsubj) is_13\VBZ|5-fu|lower (r_ccomp) indicate_2\VBP|studies|nephrotoxicity|is|. (l_dobj) nephrotoxicity_4\NN|that|of|+
D003520_D006470 CID CY_0\NNP| (r_nsubj) caused_1\VBD|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN|hemorrhagic
D003520_D003556 CID CY_0\NNP| (r_nsubj) caused_1\VBD|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN|hemorrhagic
D005472_D006470 NONE 5-FU_20\CD|and|mtx (r_pobj) with_19\IN|5-fu (r_prep) combined_18\VBN|when|with (r_advcl) cause_14\VB|it|did|not|complication|combined|. (r_conj) caused_1\VBD|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN|hemorrhagic
D005472_D003556 NONE 5-FU_20\CD|and|mtx (r_pobj) with_19\IN|5-fu (r_prep) combined_18\VBN|when|with (r_advcl) cause_14\VB|it|did|not|complication|combined|. (r_conj) caused_1\VBD|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN|hemorrhagic
D008727_D006470 NONE MTX_22\NNP| (r_conj) 5-FU_20\CD|and|mtx (r_pobj) with_19\IN|5-fu (r_prep) combined_18\VBN|when|with (r_advcl) cause_14\VB|it|did|not|complication|combined|. (r_conj) caused_1\VBD|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN|hemorrhagic
D008727_D003556 NONE MTX_22\NNP| (r_conj) 5-FU_20\CD|and|mtx (r_pobj) with_19\IN|5-fu (r_prep) combined_18\VBN|when|with (r_advcl) cause_14\VB|it|did|not|complication|combined|. (r_conj) caused_1\VBD|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN|hemorrhagic
7930386
D002997_D012893 CID Clomipramine_0\NNP| (r_npadvmod) induced_2\VBN|clomipramine|- (r_amod) disturbance_4\NN|induced|sleep
D002997_D012893 CID clomipramine_15\NN| (r_compound) administration_16\NN|clomipramine (r_pobj) by_14\IN|administration (r_agent) induced_13\VBN|by (r_conj) examine_6\VB|to|role|,|induced|,|on (l_dobj) role_8\NN|the|of (l_prep) of_9\IN|disturbance (l_pobj) disturbance_11\NN|sleep
3564823
D008012_D013035 NONE lidocaine_7\NN| (r_pobj) by_6\IN|lidocaine (r_prep) relieved_5\VBN|spasm|by|. (l_nsubj) spasm_4\NN|induced|arterial
D013874_D002545 NONE pentothal_12\NNS|sodium (r_nsubjpass) infused_15\VBN|following|,|pentothal|was|intravenously|minimize|. (l_advcl) minimize_17\VB|to|ischaemia (l_dobj) ischaemia_19\NN|cerebral
D008012_D020301 NONE lidocaine_11\NN| (r_nsubjpass) given_13\VBN|precluded|,|lidocaine|was|,|with|,|counteract|. (l_advcl) counteract_24\VB|to|vasospasm (l_dobj) vasospasm_26\NN|the
7053303
D002927_D003704 CID cimetidine_10\NN|(|with|hr|)|in (r_pobj) due_8\IN|possibly|to|cimetidine (r_amod) case_4\NN|one|of|due (l_prep) of_5\IN|dementia (l_pobj) dementia_6\NN|
D002927_D003704 CID cimetidine_40\JJ| (r_compound) levels_41\NNS|cimetidine (r_dobj) had_39\VBD|who|levels|above (r_relcl) disease_37\NN|liver|had (r_pobj) without_33\IN|disease (r_prep) patients_32\NNS|13|without (r_pobj) of_30\IN|patients (r_prep) group_29\NN|a|of (r_pobj) in_27\IN|group (r_prep) cimetidine_10\NN|(|with|hr|)|in (r_pobj) due_8\IN|possibly|to|cimetidine (r_amod) case_4\NN|one|of|due (l_prep) of_5\IN|dementia (l_pobj) dementia_6\NN|
D002927_D003704 CID cimetidine_3\NN| (r_compound) levels_4\NNS|high|cimetidine|alone (r_nsubj) induce_9\VB|thus|,|levels|do|not|always|dementia|. (l_dobj) dementia_10\NN|
D002927_D008107 NONE cimetidine_10\NN|(|with|hr|)|in (l_prep) in_27\IN|group (l_pobj) group_29\NN|a|of (l_prep) of_30\IN|patients (l_pobj) patients_32\NNS|13|without (l_prep) without_33\IN|disease (l_pobj) disease_37\NN|liver|had
D002927_D008107 NONE cimetidine_40\JJ| (r_compound) levels_41\NNS|cimetidine (r_dobj) had_39\VBD|who|levels|above (r_relcl) disease_37\NN|liver|had
D002927_D007674 NONE cimetidine_10\NN|(|with|hr|)|in (l_prep) in_27\IN|group (l_pobj) group_29\NN|a|of (l_prep) of_30\IN|patients (l_pobj) patients_32\NNS|13|without (l_prep) without_33\IN|disease (l_pobj) disease_37\NN|liver|had
D002927_D007674 NONE cimetidine_40\JJ| (r_compound) levels_41\NNS|cimetidine (r_dobj) had_39\VBD|who|levels|above (r_relcl) disease_37\NN|liver|had
19657887
D000431_D005483 CID alcohol_9\NN| (r_pobj) of_8\IN|alcohol (r_prep) ingestion_7\NN|the|of (r_pobj) after_5\IN|ingestion (r_prep) hour_4\NN|1|after (r_pobj) In_0\IN|hour (r_prep) developed_12\VBD|in|,|he|malaise|. (l_dobj) malaise_13\NN|with (l_prep) with_14\IN|flushing (l_pobj) flushing_15\NN|of (l_prep) of_16\IN|face (l_pobj) face_18\NN|the|,|tachycardia
D000431_D013610 CID alcohol_9\NN| (r_pobj) of_8\IN|alcohol (r_prep) ingestion_7\NN|the|of (r_pobj) after_5\IN|ingestion (r_prep) hour_4\NN|1|after (r_pobj) In_0\IN|hour (r_prep) developed_12\VBD|in|,|he|malaise|. (l_dobj) malaise_13\NN|with (l_prep) with_14\IN|flushing (l_pobj) flushing_15\NN|of (l_prep) of_16\IN|face (l_pobj) face_18\NN|the|,|tachycardia (l_conj) tachycardia_20\NN|,|and|dyspnea
D000431_D004417 CID alcohol_9\NN| (r_pobj) of_8\IN|alcohol (r_prep) ingestion_7\NN|the|of (r_pobj) after_5\IN|ingestion (r_prep) hour_4\NN|1|after (r_pobj) In_0\IN|hour (r_prep) developed_12\VBD|in|,|he|malaise|. (l_dobj) malaise_13\NN|with (l_prep) with_14\IN|flushing (l_pobj) flushing_15\NN|of (l_prep) of_16\IN|face (l_pobj) face_18\NN|the|,|tachycardia (l_conj) tachycardia_20\NN|,|and|dyspnea (l_conj) dyspnea_23\NN|
D004221_D005483 NONE disulfiram_7\NN| (r_npadvmod) like_9\JJ|disulfiram|- (r_amod) syndrome_10\NN|like|with (l_prep) with_11\IN|flushing (l_pcomp) flushing_12\NN|,|tachycardia|after
D004221_D013610 NONE disulfiram_7\NN| (r_npadvmod) like_9\JJ|disulfiram|- (r_amod) syndrome_10\NN|like|with (l_prep) with_11\IN|flushing (l_pcomp) flushing_12\NN|,|tachycardia|after (l_conj) tachycardia_14\NN|,|and|hypotension
D004221_D007022 NONE disulfiram_7\NN| (r_npadvmod) like_9\JJ|disulfiram|- (r_amod) syndrome_10\NN|like|with (l_prep) with_11\IN|flushing (l_pcomp) flushing_12\NN|,|tachycardia|after (l_conj) tachycardia_14\NN|,|and|hypotension (l_conj) hypotension_18\NN|arterial
11250767
D011441_D014657 NONE Propylthiouracil_0\NNP| (r_npadvmod) induced_2\VBN|propylthiouracil|- (r_amod) vasculitis_11\NN|induced|staining|antineutrophil|cytoplasmic|positive|in|.
D011441_D014657 NONE propylthiouracil_5\NN| (r_npadvmod) induced_7\VBN|propylthiouracil|- (r_amod) vasculitis_8\NN|induced|manifesting
D011441_D014657 NONE uracil_20\NN| (r_compound) therapy_21\NN|propylthio-|uracil (r_pobj) with_18\IN|therapy (r_prep) associated_17\VBN|with (r_acl) vasculitis_16\NN|mpo|positive|associated
D011441_D014657 NONE uracil_14\NN| (r_compound) therapy_15\NN|uracil (r_appos) propylthio-_13\VB|therapy (r_pobj) to_12\IN|propylthio- (r_prep) attributable_11\JJ|to (r_amod) manifestation_5\NN|the|initial|of|attributable (l_prep) of_6\IN|vasculitis (l_pobj) vasculitis_10\NN|induced
D011441_D010493 CID Propylthiouracil_0\NNP| (r_npadvmod) induced_2\VBN|propylthiouracil|- (r_amod) vasculitis_11\NN|induced|staining|antineutrophil|cytoplasmic|positive|in|. (l_prep) in_12\IN|conjunction (l_pobj) conjunction_13\NN|with (l_prep) with_14\IN|pericarditis (l_pobj) pericarditis_15\NN|
D011441_D010493 CID propylthiouracil_5\NN| (r_npadvmod) induced_7\VBN|propylthiouracil|- (r_amod) vasculitis_8\NN|induced|manifesting (l_acl) manifesting_9\VBG|with (l_prep) with_10\IN|pericarditis (l_pobj) pericarditis_11\NN|
D011441_D010493 CID propylthiouracil_13\NN|developed (l_relcl) developed_25\VBD|in|syndrome (l_nsubj) syndrome_17\NN|a|of (l_prep) of_18\IN|pericarditis (l_pobj) pericarditis_19\NN|,|fever
D011441_D010493 CID uracil_20\NN| (r_compound) therapy_21\NN|propylthio-|uracil (r_pobj) with_18\IN|therapy (r_prep) associated_17\VBN|with (r_acl) vasculitis_16\NN|mpo|positive|associated (r_pobj) in_9\IN|vasculitis (r_prep) reports_6\NNS|no|prior|of|in (l_prep) of_7\IN|pericarditis (l_pobj) pericarditis_8\NN|
D011441_D010493 CID uracil_14\NN| (r_compound) therapy_15\NN|uracil (r_appos) propylthio-_13\VB|therapy (r_pobj) to_12\IN|propylthio- (r_prep) attributable_11\JJ|to (r_amod) manifestation_5\NN|the|initial|of|attributable (r_attr) be_2\VB|pericarditis|may|manifestation|. (l_nsubj) Pericarditis_0\NNP|
D011441_D006980 NONE propylthiouracil_13\NN|developed (r_pobj) with_12\IN|propylthiouracil (r_prep) treated_11\VBN|with (r_acl) report_5\NN|the|first|case|of|treated (l_prep) of_6\IN|woman (l_pobj) woman_8\NN|a|with (l_prep) with_9\IN|hyperthyroidism (l_pobj) hyperthyroidism_10\NN|
D011441_D005334 CID propylthiouracil_13\NN|developed (l_relcl) developed_25\VBD|in|syndrome (l_nsubj) syndrome_17\NN|a|of (l_prep) of_18\IN|pericarditis (l_pobj) pericarditis_19\NN|,|fever (l_conj) fever_21\NN|,|and|glomerulonephritis
D011441_D005921 CID propylthiouracil_13\NN|developed (l_relcl) developed_25\VBD|in|syndrome (l_nsubj) syndrome_17\NN|a|of (l_prep) of_18\IN|pericarditis (l_pobj) pericarditis_19\NN|,|fever (l_conj) fever_21\NN|,|and|glomerulonephritis (l_conj) glomerulonephritis_24\NN|
17242861
D010862_D012640 NONE pilocarpine_4\NN| (r_npadvmod) induced_6\VBN|pilocarpine|- (r_amod) seizures_7\NNS|induced|,|model|,
D010862_D012640 NONE pilocarpine_4\NN| (r_npadvmod) induced_6\VBN|pilocarpine|- (r_amod) seizures_7\NNS|induced|,|model|, (r_pobj) to_3\IN|seizures (r_prep) susceptibility_2\NN|to (r_pobj) for_1\IN|susceptibility (r_prep) QTLs_0\NNS|for (r_nsubjpass) reported_19\VBN|qtls|have|not|been|,|and|used (l_conj) used_27\VBN|css|have|not|previously|been|localize|. (l_xcomp) localize_29\VB|to|genes (l_dobj) genes_32\NNS|susceptibility (l_compound) susceptibility_31\NN|seizure (l_compound) seizure_30\NN|
D010862_D012640 NONE pilocarpine_9\NN| (r_npadvmod) induced_11\VBN|pilocarpine|- (r_amod) seizures_12\NNS|induced
D010862_D012640 NONE pilocarpine_23\NN| (r_npadvmod) induced_25\VBN|pilocarpine|- (r_amod) seizures_26\NNS|induced
D010862_D004833 CID pilocarpine_4\NN| (r_npadvmod) induced_6\VBN|pilocarpine|- (r_amod) seizures_7\NNS|induced|,|model|, (l_appos) model_10\NN|a|of (l_prep) of_11\IN|epilepsy (l_pobj) epilepsy_14\NN|temporal|lobe
19803309
D013390_D009224 NONE suxamethonium_29\NN|intravenous (r_pobj) of_27\IN|suxamethonium (r_prep) dose_26\NN|a|standard|of|for (r_pobj) following_23\VBG|dose (r_prep) threatening_20\VBG|life|spasm|following (r_ccomp) developed_18\VBD|who|threatening (r_relcl) primigravida_15\NN|a|old|healthy|,|developed (r_pobj) in_8\IN|primigravida (r_prep) case_4\NN|an|undiagnosed|of|in (l_prep) of_5\IN|congenita (l_pobj) congenita_7\NN|myotonia
D013390_D014313 CID suxamethonium_29\NN|intravenous (r_pobj) of_27\IN|suxamethonium (r_prep) dose_26\NN|a|standard|of|for (r_pobj) following_23\VBG|dose (r_prep) threatening_20\VBG|life|spasm|following (l_dobj) spasm_22\NN|masseter
19356307
D012601_D003704 NONE scopolamine_9\NN| (r_pobj) by_8\IN|scopolamine (r_agent) induced_7\VBN|components|by|. (l_nsubj) Components_0\NNS|of (l_prep) of_1\IN|dementia (l_pobj) dementia_6\NN|attenuate
C008281_D003704 NONE limonene_8\NN|s|-|and|perillyl (r_nmod) alcohol_13\NN|limonene (r_pobj) of_5\IN|alcohol (r_prep) effects_4\NNS|the|dementia|of (l_compound) dementia_3\NN|anti|-
C032208_D003704 NONE alcohol_13\NN|limonene (r_pobj) of_5\IN|alcohol (r_prep) effects_4\NNS|the|dementia|of (l_compound) dementia_3\NN|anti|-
D012601_D008569 CID scopolamine_12\NN| (r_pobj) by_11\IN|scopolamine (r_agent) impaired_10\VBN|by
D012601_D008569 CID scopolamine_12\NN| (r_pobj) by_11\IN|scopolamine (r_agent) impaired_10\VBN|by (r_amod) memory_9\NN|impaired (r_dobj) improve_8\VB|to|memory (r_acl) ability_6\NN|strong|improve (r_dobj) showed_4\VBD|oils|ability (r_ccomp) relieved_20\VBD|showed|;|however|,|alcohol|deficit|only|,|and|improve|. (l_dobj) deficit_22\NN|the|of|in (l_prep) of_23\IN|memory (l_pobj) memory_25\NN|associative
C032208_D008569 NONE alcohol_19\NN|perillyl (r_nsubj) relieved_20\VBD|showed|;|however|,|alcohol|deficit|only|,|and|improve|. (l_ccomp) showed_4\VBD|oils|ability (l_dobj) ability_6\NN|strong|improve (l_acl) improve_8\VB|to|memory (l_dobj) memory_9\NN|impaired (l_amod) impaired_10\VBN|by
C032208_D008569 NONE alcohol_19\NN|perillyl (r_nsubj) relieved_20\VBD|showed|;|however|,|alcohol|deficit|only|,|and|improve|. (l_dobj) deficit_22\NN|the|of|in (l_prep) of_23\IN|memory (l_pobj) memory_25\NN|associative
10706004
D012964_D006973 NONE sodium_2\NN|and|atp (r_nmod) affinities_5\NNS|sodium|of (r_pobj) of_1\IN|affinities (r_prep) Changes_0\NNS|of|during|. (l_prep) during_13\IN|and|after (l_conj) after_15\IN|hypertension (l_pobj) hypertension_19\NN|nitric|deficient
D012964_D006973 NONE Na_10\UH| (r_nmod) K)-ATPase_12\NNP|the|cardiac|(|na|, (r_pobj) of_6\IN|k)-atpase (r_prep) affinities_5\NNS|sodium|of (r_pobj) of_1\IN|affinities (r_prep) Changes_0\NNS|of|during|. (l_prep) during_13\IN|and|after (l_conj) after_15\IN|hypertension (l_pobj) hypertension_19\NN|nitric|deficient
D012964_D006973 NONE sodium_9\NN| (r_compound) level_10\NN|intracellular|sodium (r_pobj) of_7\IN|level (r_prep) elevation_6\NN|of (r_nsubjpass) documented_12\VBN|in|,|elevation|was|in|. (l_prep) In_0\IN|models (l_pobj) models_2\NNS|several|of (l_prep) of_3\IN|hypertension (l_pobj) hypertension_4\NN|
D012964_D006973 NONE Na+_11\NNP| (r_pobj) of_10\IN|na+ (r_prep) transport_9\NN|transmembraneous|of (r_pobj) in_7\IN|transport (r_prep) disturbances_6\NNS|in (r_pobj) of_5\IN|disturbances (r_prep) basis_4\NN|the|molecular|of (r_dobj) assess_1\VB|to|basis (r_advcl) studied_14\VBD|assess|,|we|response|induced|. (l_dobj) response_16\NN|the|of (l_prep) of_17\IN|k)-atpase (l_pobj) K)-ATPase_22\NNP|cardiac|(|na|,|to (l_prep) to_23\IN|hypertension (l_pobj) hypertension_27\NN|deficient
D012964_D006973 NONE Na_20\UH| (r_nmod) K)-ATPase_22\NNP|cardiac|(|na|,|to (l_prep) to_23\IN|hypertension (l_pobj) hypertension_27\NN|deficient
D012964_D006973 NONE Na_9\NNP| (r_npadvmod) increased_12\VBD|(|na|,|k)-atpase|,|due|, (r_parataxis) activity_6\NN|after|,|the|of|increased|revealed|. (l_prep) After_0\IN|recovery (l_pobj) recovery_1\NN|from (l_prep) from_2\IN|hypertension (l_pobj) hypertension_3\NN|
D012964_D006973 NONE Na+-extrusion_12\NN|depressed (r_pobj) by_10\IN|na+-extrusion (r_agent) accompanied_9\VBN|by|from|as (r_acl) hypertension_8\NN|a|reversible|accompanied
D012964_D006973 NONE Na+-binding_21\NN| (r_compound) properties_22\NNS|deteriorated|na+-binding|of (r_pobj) of_19\IN|properties (r_prep) consequence_18\NN|a|of (r_pobj) as_16\IN|consequence (r_prep) accompanied_9\VBN|by|from|as (r_acl) hypertension_8\NN|a|reversible|accompanied
D012964_D006973 NONE Na_26\UH| (r_nmod) K)-ATPase_28\NNP|the|(|na|, (r_pobj) of_23\IN|k)-atpase (r_prep) properties_22\NNS|deteriorated|na+-binding|of (r_pobj) of_19\IN|properties (r_prep) consequence_18\NN|a|of (r_pobj) as_16\IN|consequence (r_prep) accompanied_9\VBN|by|from|as (r_acl) hypertension_8\NN|a|reversible|accompanied
D000255_D006973 NONE ATP_4\NNP| (r_conj) sodium_2\NN|and|atp (r_nmod) affinities_5\NNS|sodium|of (r_pobj) of_1\IN|affinities (r_prep) Changes_0\NNS|of|during|. (l_prep) during_13\IN|and|after (l_conj) after_15\IN|hypertension (l_pobj) hypertension_19\NN|nitric|deficient
D000255_D006973 NONE ATP_20\NNP| (r_npadvmod) binding_22\VBG|atp|- (r_amod) site_23\NN|the|binding (r_pobj) of_18\IN|site (r_prep) affinity_17\NN|higher|of (r_pobj) due_14\IN|to|affinity (r_prep) increased_12\VBD|(|na|,|k)-atpase|,|due|, (r_parataxis) activity_6\NN|after|,|the|of|increased|revealed|. (l_prep) After_0\IN|recovery (l_pobj) recovery_1\NN|from (l_prep) from_2\IN|hypertension (l_pobj) hypertension_3\NN|
D000255_D006973 NONE ATP_33\NNP| (r_pobj) for_32\IN|atp (r_prep) value_31\NN|the|lowered|km|for (r_pobj) from_27\IN|value (r_prep) revealed_26\VBN|as|from (r_advcl) activity_6\NN|after|,|the|of|increased|revealed|. (l_prep) After_0\IN|recovery (l_pobj) recovery_1\NN|from (l_prep) from_2\IN|hypertension (l_pobj) hypertension_3\NN|
D011188_D006973 NONE K)-ATPase_12\NNP|the|cardiac|(|na|, (r_pobj) of_6\IN|k)-atpase (r_prep) affinities_5\NNS|sodium|of (r_pobj) of_1\IN|affinities (r_prep) Changes_0\NNS|of|during|. (l_prep) during_13\IN|and|after (l_conj) after_15\IN|hypertension (l_pobj) hypertension_19\NN|nitric|deficient
D011188_D006973 NONE K)-ATPase_22\NNP|cardiac|(|na|,|to (l_prep) to_23\IN|hypertension (l_pobj) hypertension_27\NN|deficient
D011188_D006973 NONE K)-ATPase_11\NNP| (r_nsubj) increased_12\VBD|(|na|,|k)-atpase|,|due|, (r_parataxis) activity_6\NN|after|,|the|of|increased|revealed|. (l_prep) After_0\IN|recovery (l_pobj) recovery_1\NN|from (l_prep) from_2\IN|hypertension (l_pobj) hypertension_3\NN|
D011188_D006973 NONE K)-ATPase_28\NNP|the|(|na|, (r_pobj) of_23\IN|k)-atpase (r_prep) properties_22\NNS|deteriorated|na+-binding|of (r_pobj) of_19\IN|properties (r_prep) consequence_18\NN|a|of (r_pobj) as_16\IN|consequence (r_prep) accompanied_9\VBN|by|from|as (r_acl) hypertension_8\NN|a|reversible|accompanied
D009569_D006973 CID oxide_17\NN| (r_npadvmod) deficient_18\JJ|oxide (r_amod) hypertension_19\NN|nitric|deficient
D009569_D006973 CID NO_2\DT| (r_det) synthesis_3\NN|no (r_pobj) of_1\IN|synthesis (r_prep) Inhibition_0\NN|of (r_nsubj) induces_4\VBZ|inhibition|hypertension|. (l_dobj) hypertension_6\NN|sustained
D009569_D006973 CID NO_24\JJ| (r_npadvmod) deficient_26\JJ|no|- (r_amod) hypertension_27\NN|deficient
D009569_D006973 CID NO_32\JJ| (r_compound) synthase_34\NN|no|- (r_compound) inhibition_35\NN|synthase|with (r_pobj) by_31\IN|inhibition (r_prep) rats_30\NNS|by (r_pobj) in_29\IN|rats (r_prep) induced_28\VBN|in|for (r_advcl) studied_14\VBD|assess|,|we|response|induced|. (l_dobj) response_16\NN|the|of (l_prep) of_17\IN|k)-atpase (l_pobj) K)-ATPase_22\NNP|cardiac|(|na|,|to (l_prep) to_23\IN|hypertension (l_pobj) hypertension_27\NN|deficient
D009569_D006973 CID NO_2\JJ| (r_compound) synthase_4\NN|no|- (r_pobj) of_1\IN|synthase (r_prep) Inhibition_0\NN|of (r_nsubj) induced_5\VBD|inhibition|hypertension|. (l_dobj) hypertension_8\NN|a|reversible|accompanied
D019331_D006973 NONE ester_49\NN|arginine|methyl|name|) (r_appos) kg_40\NNS|40|mg|/|/|day|ester (r_pobj) with_36\IN|kg (r_prep) inhibition_35\NN|synthase|with (r_pobj) by_31\IN|inhibition (r_prep) rats_30\NNS|by (r_pobj) in_29\IN|rats (r_prep) induced_28\VBN|in|for (r_advcl) studied_14\VBD|assess|,|we|response|induced|. (l_dobj) response_16\NN|the|of (l_prep) of_17\IN|k)-atpase (l_pobj) K)-ATPase_22\NNP|cardiac|(|na|,|to (l_prep) to_23\IN|hypertension (l_pobj) hypertension_27\NN|deficient
D019331_D006973 NONE NAME_53\NNP|(|l|- (r_appos) ester_49\NN|arginine|methyl|name|) (r_appos) kg_40\NNS|40|mg|/|/|day|ester (r_pobj) with_36\IN|kg (r_prep) inhibition_35\NN|synthase|with (r_pobj) by_31\IN|inhibition (r_prep) rats_30\NNS|by (r_pobj) in_29\IN|rats (r_prep) induced_28\VBN|in|for (r_advcl) studied_14\VBD|assess|,|we|response|induced|. (l_dobj) response_16\NN|the|of (l_prep) of_17\IN|k)-atpase (l_pobj) K)-ATPase_22\NNP|cardiac|(|na|,|to (l_prep) to_23\IN|hypertension (l_pobj) hypertension_27\NN|deficient
D009569_D003866 NONE NO_2\JJ| (r_compound) synthase_4\NN|no|- (r_pobj) of_1\IN|synthase (r_prep) Inhibition_0\NN|of (r_nsubj) induced_5\VBD|inhibition|hypertension|. (l_dobj) hypertension_8\NN|a|reversible|accompanied (l_acl) accompanied_9\VBN|by|from|as (l_agent) by_10\IN|na+-extrusion (l_pobj) Na+-extrusion_12\NN|depressed (l_amod) depressed_11\JJ|
D012964_D003866 NONE Na+-extrusion_12\NN|depressed (l_amod) depressed_11\JJ|
D012964_D003866 NONE Na+-binding_21\NN| (r_compound) properties_22\NNS|deteriorated|na+-binding|of (r_pobj) of_19\IN|properties (r_prep) consequence_18\NN|a|of (r_pobj) as_16\IN|consequence (r_prep) accompanied_9\VBN|by|from|as (l_agent) by_10\IN|na+-extrusion (l_pobj) Na+-extrusion_12\NN|depressed (l_amod) depressed_11\JJ|
D012964_D003866 NONE Na_26\UH| (r_nmod) K)-ATPase_28\NNP|the|(|na|, (r_pobj) of_23\IN|k)-atpase (r_prep) properties_22\NNS|deteriorated|na+-binding|of (r_pobj) of_19\IN|properties (r_prep) consequence_18\NN|a|of (r_pobj) as_16\IN|consequence (r_prep) accompanied_9\VBN|by|from|as (l_agent) by_10\IN|na+-extrusion (l_pobj) Na+-extrusion_12\NN|depressed (l_amod) depressed_11\JJ|
D011188_D003866 NONE K)-ATPase_28\NNP|the|(|na|, (r_pobj) of_23\IN|k)-atpase (r_prep) properties_22\NNS|deteriorated|na+-binding|of (r_pobj) of_19\IN|properties (r_prep) consequence_18\NN|a|of (r_pobj) as_16\IN|consequence (r_prep) accompanied_9\VBN|by|from|as (l_agent) by_10\IN|na+-extrusion (l_pobj) Na+-extrusion_12\NN|depressed (l_amod) depressed_11\JJ|
3437726
D013034_D064420 NONE sparteine_11\NN| (r_nmod) debrisoquine_13\JJ|sparteine|/ (r_compound) polymorphism_14\NN|debrisoquine|in|,|constitutes|, (r_pobj) of_10\IN|polymorphism (r_prep) phenotype_9\NN|the|metabolizer|of (r_pobj) to_4\IN|phenotype (r_prep) belonging_3\VBG|to (r_acl) patients_2\NNS|belonging (r_nsubj) experience_29\VB|therefore|,|patients|may|reactions|treated|. (l_dobj) reactions_32\NNS|adverse|drug
D003647_D064420 NONE debrisoquine_13\JJ|sparteine|/ (r_compound) polymorphism_14\NN|debrisoquine|in|,|constitutes|, (r_pobj) of_10\IN|polymorphism (r_prep) phenotype_9\NN|the|metabolizer|of (r_pobj) to_4\IN|phenotype (r_prep) belonging_3\VBG|to (r_acl) patients_2\NNS|belonging (r_nsubj) experience_29\VB|therefore|,|patients|may|reactions|treated|. (l_dobj) reactions_32\NNS|adverse|drug
9293063
D003613_D001650 CID danazol_12\NN| (r_pobj) with_11\IN|danazol (r_prep) treatment_10\NN|term|with (r_pobj) with_6\IN|treatment (r_prep) association_5\NN|with (r_pobj) in_4\IN|association (r_prep) occurring_3\VBG|in (r_acl) hamartoma_2\NN|duct|occurring|.
D003613_D001650 CID danazol_20\NN| (r_compound) treatment_21\NN|term|danazol (r_pobj) on_16\IN|treatment (r_prep) been_15\VBN|who|had|on (r_relcl) patient_12\NN|a|been (r_pobj) in_10\IN|patient (r_prep) developed_9\VBD|which|in (r_relcl) hamartoma_7\NN|duct|developed
D003613_D006222 CID danazol_12\NN| (r_pobj) with_11\IN|danazol (r_prep) treatment_10\NN|term|with (r_pobj) with_6\IN|treatment (r_prep) association_5\NN|with (r_pobj) in_4\IN|association (r_prep) occurring_3\VBG|in (r_acl) hamartoma_2\NN|duct|occurring|.
D003613_D006222 CID danazol_20\NN| (r_compound) treatment_21\NN|term|danazol (r_pobj) on_16\IN|treatment (r_prep) been_15\VBN|who|had|on (r_relcl) patient_12\NN|a|been (r_pobj) in_10\IN|patient (r_prep) developed_9\VBD|which|in (r_relcl) hamartoma_7\NN|duct|developed
3371379
D014700_D020258 CID Verapamil_0\NNP| (r_npadvmod) induced_2\VBN|verapamil|-|neurotoxicity|. (l_dobj) neurotoxicity_4\NN|carbamazepine
D014700_D020258 CID verapamil_11\NN| (r_pobj) with_10\IN|verapamil (r_prep) treatment_9\NN|combined|with (r_pobj) after_7\IN|treatment (r_prep) signs_3\NNS|of|after (l_prep) of_4\IN|neurotoxicity (l_pobj) neurotoxicity_6\NN|carbamazepine
D002220_D020258 CID carbamazepine_3\NN| (r_compound) neurotoxicity_4\NN|carbamazepine
D002220_D020258 CID carbamazepine_5\JJ| (r_compound) neurotoxicity_6\NN|carbamazepine
D002118_D020258 NONE calcium_19\NN| (r_compound) entry_20\NN|calcium (r_compound) blocker_21\NN|the|entry (r_pobj) of_17\IN|blocker (r_prep) discontinuation_16\NN|of (r_pobj) after_15\IN|discontinuation (r_prep) recovery_14\NN|complete|after (r_dobj) showed_12\VBD|patients|recovery|. (l_nsubj) patients_1\NNS|two|with (l_prep) with_2\IN|signs (l_pobj) signs_3\NNS|of|after (l_prep) of_4\IN|neurotoxicity (l_pobj) neurotoxicity_6\NN|carbamazepine
7083920
D000638_D006327 CID amiodarone_13\NN| (r_compound) treatment_14\NN|amiodarone|for (r_pobj) under_12\IN|treatment (r_prep) occurring_11\VBG|under|in|without (r_acl) block_10\NN|a|reversible|hisian|occurring
D000638_D013617 NONE amiodarone_13\NN| (r_compound) treatment_14\NN|amiodarone|for (l_prep) for_15\IN|tachycardia (l_pobj) tachycardia_17\NNS|atrial
D000638_D006345 NONE amiodarone_13\NN| (r_compound) treatment_14\NN|amiodarone|for (r_pobj) under_12\IN|treatment (r_prep) occurring_11\VBG|under|in|without (l_prep) without_21\IN|abnormalities (l_pobj) abnormalities_25\NNS|clear|intraventricular|conduction
D000638_D001282 NONE amiodarone_3\NN| (r_compound) discontinuation_4\NN|amiodarone (r_pobj) after_2\IN|days|discontinuation (r_prep) showed_9\VBD|after|,|electrograms|flutter|. (l_dobj) flutter_11\NN|atrial|without
230316
D006912_D020258 NONE hydroxyquinolines_3\NNS|halogenated (r_pobj) of_1\IN|hydroxyquinolines (r_prep) Neurotoxicity_0\NN|of|:|analysis
D006912_D020258 NONE hydroxyquinolines_13\NNS|halogenated|reported (r_pobj) to_11\IN|hydroxyquinolines (r_prep) reactions_10\NNS|possible|neurotoxic|to (l_amod) neurotoxic_9\JJ|
D007464_D009422 NONE clioquinol_25\NN| (r_pobj) of_24\IN|clioquinol (r_prep) dose_23\NN|a|high|of|over (r_pobj) of_20\IN|dose (r_prep) ingestion_19\NN|the|of (r_pobj) to_17\IN|ingestion (r_prep) related_16\VBN|usually|to (r_acl) encephalopathy_14\NN|an|acute|reversible|related (r_pobj) of_10\IN|encephalopathy (r_prep) consisted_9\VBD|disturbance|of (l_nsubj) disturbance_8\NN|the|neurological
D007464_D001927 CID clioquinol_25\NN| (r_pobj) of_24\IN|clioquinol (r_prep) dose_23\NN|a|high|of|over (r_pobj) of_20\IN|dose (r_prep) ingestion_19\NN|the|of (r_pobj) to_17\IN|ingestion (r_prep) related_16\VBN|usually|to (r_acl) encephalopathy_14\NN|an|acute|reversible|related
D007464_C538178 NONE clioquinol_13\NN|as (l_prep) as_14\IN|treatment (l_pobj) treatment_15\NN|for (l_prep) for_16\IN|enteropathica (l_pobj) enteropathica_18\NN|acrodermatitis
11875660
D001374_D009436 NONE 5-azacytidine_6\NN| (r_pobj) by_5\IN|5-azacytidine (r_agent) induced_4\VBN|by|at (r_acl) exencephaly_3\NNS|the|induced
603022
D005702_D062787 NONE hydrobromide_1\RB|galanthamine|,|drug|, (r_nsubjpass) used_16\VBN|hydrobromide|was|in|. (l_prep) in_17\IN|patient (l_pobj) patient_19\JJ|a|demonstrating (l_acl) demonstrating_20\NN|effects (l_dobj) effects_22\NNS|central|of (l_prep) of_23\IN|overdosage (l_pobj) overdosage_28\NN|scopolamine|(|hyoscine|)
D012601_D062787 CID scopolamine_24\NN| (r_nmod) overdosage_28\NN|scopolamine|(|hyoscine|)
D012601_D062787 CID hyoscine_26\NN| (r_nmod) overdosage_28\NN|scopolamine|(|hyoscine|)
20880751
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|-|dyskinesias|:|filling|. (l_dobj) dyskinesias_3\NNS|in
D007980_D004409 CID levodopa_17\NN| (r_npadvmod) induced_19\VBN|levodopa|- (r_amod) dyskinesias_20\NNS|underlying|induced
D007980_D004409 CID levodopa_41\NN| (r_npadvmod) induced_43\VBN|levodopa|- (r_amod) dyskinesias_44\NNS|induced
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|-|dyskinesias|:|filling|. (l_dobj) dyskinesias_3\NNS|in (l_prep) in_4\IN|patients (l_pobj) patients_5\NNS|with (l_prep) with_6\IN|disease (l_pobj) disease_9\NN|parkinson
D007980_D010300 NONE Levodopa_0\NNP| (r_nsubj) is_1\VBZ|levodopa|drug|. (l_attr) drug_5\NN|the|effective|for (l_prep) for_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|disease (l_pobj) disease_12\NN|parkinson
D004298_D004409 NONE dopamine_9\NN| (r_compound) precursor_10\NN|this|dopamine (r_pobj) of_7\IN|precursor (r_prep) use_6\NN|the|term|of (r_nsubjpass) complicated_12\VBN|however|,|use|is|by|. (l_agent) by_13\IN|fluctuations (l_pobj) fluctuations_16\NNS|disabling|and|dyskinesias (l_conj) dyskinesias_18\NNS|
D004298_D004409 NONE dopamine_21\NN| (r_compound) subtypes_23\NNS|dopamine|receptor|,|receptors (l_conj) receptors_29\NNS|ionotropic|glutamate|,|and|systems (l_conj) systems_36\NNS|dopaminergic|neurotransmitter|in (l_prep) in_37\IN|pathophysiology (l_pobj) pathophysiology_39\NN|the|of (l_prep) of_40\IN|dyskinesias (l_pobj) dyskinesias_44\NNS|induced
D018698_D004409 NONE glutamate_28\NN| (r_compound) receptors_29\NNS|ionotropic|glutamate|,|and|systems (l_conj) systems_36\NNS|dopaminergic|neurotransmitter|in (l_prep) in_37\IN|pathophysiology (l_pobj) pathophysiology_39\NN|the|of (l_prep) of_40\IN|dyskinesias (l_pobj) dyskinesias_44\NNS|induced
6861444
D009638_D006973 CID noradrenaline_3\NN| (r_pobj) of_2\IN|noradrenaline (r_prep) infusion_1\NN|intrarenal|of (r_nsubj) caused_4\VBD|infusion|hypertension|at|. (l_dobj) hypertension_5\NN|
D009638_D006973 CID noradrenaline_8\NN| (r_amod) infusion_9\NN|chronic|intrarenal|noradrenaline (r_pobj) after_5\IN|infusion (r_prep) hypertension_4\NN|after
D009638_D006973 CID noradrenaline_18\NN| (r_dobj) circulating_17\VBG|noradrenaline (r_pcomp) of_16\IN|circulating (r_prep) levels_15\NNS|higher|of (r_pobj) by_12\IN|levels|and|by (r_agent) produced_11\VBN|that|hypertension|is|by (l_nsubjpass) hypertension_4\NN|after
3192036
18186898
D019259_D006509 NONE Lamivudine_0\NNP| (r_nsubjpass) added_2\VBN|lamivudine|was|because|. (l_prep) because_3\IN|of|infection (l_pobj) infection_9\NN|de|b|during
D016559_D000138 NONE tacrolimus_1\NN| (r_nsubjpass) suspected_3\VBN|although|tacrolimus|was|be|and|replaced (l_xcomp) be_5\VB|to|cause (l_attr) cause_7\NN|the|of (l_prep) of_8\IN|acidosis (l_pobj) acidosis_14\NN|transplant|renal
D016559_D000138 NONE tacrolimus_1\NN| (r_nsubjpass) suspected_3\VBN|although|tacrolimus|was|be|and|replaced (l_conj) replaced_17\VBN|was|by (l_agent) by_18\IN|sirolimus (l_pobj) sirolimus_19\NN|,|acidosis (l_conj) acidosis_21\NN|,|and|got
D020123_D000138 NONE sirolimus_19\NN|,|acidosis (r_pobj) by_18\IN|sirolimus (r_agent) replaced_17\VBN|was|by (r_conj) suspected_3\VBN|although|tacrolimus|was|be|and|replaced (l_xcomp) be_5\VB|to|cause (l_attr) cause_7\NN|the|of (l_prep) of_8\IN|acidosis (l_pobj) acidosis_14\NN|transplant|renal
D020123_D000138 NONE sirolimus_19\NN|,|acidosis (l_conj) acidosis_21\NN|,|and|got
D016559_D005198 CID tacrolimus_20\NN| (r_pobj) by_19\IN|tacrolimus (r_agent) triggered_18\VBN|which|is|by|and|augmented (r_relcl) dysfunction_15\NN|mitochondrial|triggered (r_pobj) from_13\IN|dysfunction (r_prep) resulted_12\VBN|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN|patient|tubular|and|myopathy
D016559_D009135 CID tacrolimus_20\NN| (r_pobj) by_19\IN|tacrolimus (r_agent) triggered_18\VBN|which|is|by|and|augmented (r_relcl) dysfunction_15\NN|mitochondrial|triggered (r_pobj) from_13\IN|dysfunction (r_prep) resulted_12\VBN|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN|patient|tubular|and|myopathy (l_conj) myopathy_9\NNS|
D016559_D028361 NONE tacrolimus_20\NN| (r_pobj) by_19\IN|tacrolimus (r_agent) triggered_18\VBN|which|is|by|and|augmented (r_relcl) dysfunction_15\NN|mitochondrial|triggered
D019259_D005198 CID lamivudine_24\NN| (r_pobj) by_23\IN|lamivudine (r_agent) augmented_22\VBN|by (r_conj) triggered_18\VBN|which|is|by|and|augmented (r_relcl) dysfunction_15\NN|mitochondrial|triggered (r_pobj) from_13\IN|dysfunction (r_prep) resulted_12\VBN|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN|patient|tubular|and|myopathy
D019259_D009135 CID lamivudine_24\NN| (r_pobj) by_23\IN|lamivudine (r_agent) augmented_22\VBN|by (r_conj) triggered_18\VBN|which|is|by|and|augmented (r_relcl) dysfunction_15\NN|mitochondrial|triggered (r_pobj) from_13\IN|dysfunction (r_prep) resulted_12\VBN|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN|patient|tubular|and|myopathy (l_conj) myopathy_9\NNS|
D019259_D028361 NONE lamivudine_24\NN| (r_pobj) by_23\IN|lamivudine (r_agent) augmented_22\VBN|by (r_conj) triggered_18\VBN|which|is|by|and|augmented (r_relcl) dysfunction_15\NN|mitochondrial|triggered
3125768
D015760_D009127 CID alfentanil_4\NN| (r_npadvmod) induced_6\VBN|alfentanil|- (r_amod) rigidity_7\NN|induced
D015760_D009127 CID alfentanil_8\NN| (r_npadvmod) induced_10\VBN|alfentanil|- (r_amod) rigidity_11\NN|induced|in
D015760_D009127 CID alfentanil_9\NN|when (r_advcl) prevented_7\VBN|that|rigidity|should|be|alfentanil|,|and|,|used (l_nsubjpass) rigidity_4\NN|
C032943_D009127 NONE metocurine_10\NN| (r_pobj) with_9\IN|metocurine (r_prep) abolished_8\VBN|when|rigidity|was|with (l_nsubjpass) rigidity_6\NN|
12615818
D017373_D054556 CID acetate_9\NN|in (r_oprd) prescribed_7\VBD|cyproterone|acetate (r_acl) women_6\NNS|prescribed (r_pobj) in_5\IN|women (r_prep) thromboembolism_4\NN|venous|in
D017373_D054556 CID CPA_15\NNP| (r_nmod) EE_17\NNP|cpa|/ (r_pobj) with_14\IN|ee (r_prep) associated_13\VBN|with (r_acl) thromboembolism_9\NN|venous|(|vte|)|associated
D017373_D054556 CID CPA_15\NNP| (r_nmod) EE_17\NNP|cpa|/ (r_pobj) with_14\IN|ee (r_prep) associated_13\VBN|with (r_acl) thromboembolism_9\NN|venous|(|vte|)|associated (l_appos) VTE_11\NNP|
D017373_D054556 CID CPA_42\NNP| (r_nmod) EE_44\NNP|cpa|/ (r_pobj) with_41\IN|ee (r_prep) associated_40\VBN|with (r_acl) VTE_39\NNP|associated
D017373_D054556 CID CPA_13\NNP| (r_nmod) EE_15\NNP|cpa|/ (r_pobj) of_12\IN|ee (r_prep) use_11\NN|the|of|in (r_pobj) with_9\IN|use (r_prep) associated_8\VBN|with|confounding (r_acl) risk_5\NN|an|increased|of|associated (l_prep) of_6\IN|vte (l_pobj) VTE_7\NNP|
D004997_D054556 CID estradiol_14\NN|:|analysis (r_appos) risk_1\NN|the|of|estradiol|. (l_prep) of_2\IN|thromboembolism (l_pobj) thromboembolism_4\NN|venous|in
D004997_D054556 CID EE_17\NNP|cpa|/ (r_pobj) with_14\IN|ee (r_prep) associated_13\VBN|with (r_acl) thromboembolism_9\NN|venous|(|vte|)|associated
D004997_D054556 CID EE_17\NNP|cpa|/ (r_pobj) with_14\IN|ee (r_prep) associated_13\VBN|with (r_acl) thromboembolism_9\NN|venous|(|vte|)|associated (l_appos) VTE_11\NNP|
D004997_D054556 CID EE_44\NNP|cpa|/ (r_pobj) with_41\IN|ee (r_prep) associated_40\VBN|with (r_acl) VTE_39\NNP|associated
D004997_D054556 CID EE_15\NNP|cpa|/ (r_pobj) of_12\IN|ee (r_prep) use_11\NN|the|of|in (r_pobj) with_9\IN|use (r_prep) associated_8\VBN|with|confounding (r_acl) risk_5\NN|an|increased|of|associated (l_prep) of_6\IN|vte (l_pobj) VTE_7\NNP|
D017373_D000152 NONE acetate_1\NN|cyproterone|combined (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|women (l_pobj) women_20\NNS|with (l_prep) with_21\IN|acne (l_pobj) acne_22\NN|and|hirsutism
D017373_D000152 NONE CPA_7\NNP| (r_nmod) EE_9\NNP|cpa|/ (r_appos) estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|women (l_pobj) women_20\NNS|with (l_prep) with_21\IN|acne (l_pobj) acne_22\NN|and|hirsutism
D017373_D000152 NONE CPA_42\NNP| (r_nmod) EE_44\NNP|cpa|/ (r_pobj) with_41\IN|ee (r_prep) associated_40\VBN|with (r_acl) VTE_39\NNP|associated (r_pobj) of_38\IN|vte (r_prep) risk_37\NN|the|of (r_dobj) estimate_35\VB|to|risk (r_advcl) conducted_7\VBD|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS|15|with (l_prep) with_28\IN|acne (l_pobj) acne_29\NN|,|hirsutism
D017373_D000152 NONE CPA_13\NNP| (r_nmod) EE_15\NNP|cpa|/ (r_pobj) of_12\IN|ee (r_prep) use_11\NN|the|of|in (l_prep) in_16\IN|women (l_pobj) women_17\NNS|with (l_prep) with_18\IN|acne (l_pobj) acne_19\NN|,|hirsutism
D017373_D006628 NONE acetate_1\NN|cyproterone|combined (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|women (l_pobj) women_20\NNS|with (l_prep) with_21\IN|acne (l_pobj) acne_22\NN|and|hirsutism (l_conj) hirsutism_24\NN|
D017373_D006628 NONE CPA_7\NNP| (r_nmod) EE_9\NNP|cpa|/ (r_appos) estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|women (l_pobj) women_20\NNS|with (l_prep) with_21\IN|acne (l_pobj) acne_22\NN|and|hirsutism (l_conj) hirsutism_24\NN|
D017373_D006628 NONE CPA_42\NNP| (r_nmod) EE_44\NNP|cpa|/ (r_pobj) with_41\IN|ee (r_prep) associated_40\VBN|with (r_acl) VTE_39\NNP|associated (r_pobj) of_38\IN|vte (r_prep) risk_37\NN|the|of (r_dobj) estimate_35\VB|to|risk (r_advcl) conducted_7\VBD|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS|15|with (l_prep) with_28\IN|acne (l_pobj) acne_29\NN|,|hirsutism (l_conj) hirsutism_31\NN|or|pcos
D017373_D006628 NONE CPA_13\NNP| (r_nmod) EE_15\NNP|cpa|/ (r_pobj) of_12\IN|ee (r_prep) use_11\NN|the|of|in (l_prep) in_16\IN|women (l_pobj) women_17\NNS|with (l_prep) with_18\IN|acne (l_pobj) acne_19\NN|,|hirsutism (l_conj) hirsutism_21\NN|or|pcos
D017373_D011085 NONE acetate_1\NN|cyproterone|combined (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ|also|option (l_attr) option_30\NN|a|treatment|for (l_prep) for_31\IN|syndrome (l_pobj) syndrome_34\NN|polycystic|ovary|(|pcos|)
D017373_D011085 NONE acetate_1\NN|cyproterone|combined (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ|also|option (l_attr) option_30\NN|a|treatment|for (l_prep) for_31\IN|syndrome (l_pobj) syndrome_34\NN|polycystic|ovary|(|pcos|) (l_appos) PCOS_36\NNP|
D017373_D011085 NONE CPA_7\NNP| (r_nmod) EE_9\NNP|cpa|/ (r_appos) estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ|also|option (l_attr) option_30\NN|a|treatment|for (l_prep) for_31\IN|syndrome (l_pobj) syndrome_34\NN|polycystic|ovary|(|pcos|)
D017373_D011085 NONE CPA_7\NNP| (r_nmod) EE_9\NNP|cpa|/ (r_appos) estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ|also|option (l_attr) option_30\NN|a|treatment|for (l_prep) for_31\IN|syndrome (l_pobj) syndrome_34\NN|polycystic|ovary|(|pcos|) (l_appos) PCOS_36\NNP|
D017373_D011085 NONE CPA_42\NNP| (r_nmod) EE_44\NNP|cpa|/ (r_pobj) with_41\IN|ee (r_prep) associated_40\VBN|with (r_acl) VTE_39\NNP|associated (r_pobj) of_38\IN|vte (r_prep) risk_37\NN|the|of (r_dobj) estimate_35\VB|to|risk (r_advcl) conducted_7\VBD|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS|15|with (l_prep) with_28\IN|acne (l_pobj) acne_29\NN|,|hirsutism (l_conj) hirsutism_31\NN|or|pcos (l_conj) PCOS_33\NNP|
D017373_D011085 NONE CPA_13\NNP| (r_nmod) EE_15\NNP|cpa|/ (r_pobj) of_12\IN|ee (r_prep) use_11\NN|the|of|in (l_prep) in_16\IN|women (l_pobj) women_17\NNS|with (l_prep) with_18\IN|acne (l_pobj) acne_19\NN|,|hirsutism (l_conj) hirsutism_21\NN|or|pcos (l_conj) PCOS_23\NNP|
D004997_D000152 NONE estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|women (l_pobj) women_20\NNS|with (l_prep) with_21\IN|acne (l_pobj) acne_22\NN|and|hirsutism
D004997_D000152 NONE EE_9\NNP|cpa|/ (r_appos) estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|women (l_pobj) women_20\NNS|with (l_prep) with_21\IN|acne (l_pobj) acne_22\NN|and|hirsutism
D004997_D000152 NONE EE_44\NNP|cpa|/ (r_pobj) with_41\IN|ee (r_prep) associated_40\VBN|with (r_acl) VTE_39\NNP|associated (r_pobj) of_38\IN|vte (r_prep) risk_37\NN|the|of (r_dobj) estimate_35\VB|to|risk (r_advcl) conducted_7\VBD|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS|15|with (l_prep) with_28\IN|acne (l_pobj) acne_29\NN|,|hirsutism
D004997_D000152 NONE EE_15\NNP|cpa|/ (r_pobj) of_12\IN|ee (r_prep) use_11\NN|the|of|in (l_prep) in_16\IN|women (l_pobj) women_17\NNS|with (l_prep) with_18\IN|acne (l_pobj) acne_19\NN|,|hirsutism
D004997_D006628 NONE estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|women (l_pobj) women_20\NNS|with (l_prep) with_21\IN|acne (l_pobj) acne_22\NN|and|hirsutism (l_conj) hirsutism_24\NN|
D004997_D006628 NONE EE_9\NNP|cpa|/ (r_appos) estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|women (l_pobj) women_20\NNS|with (l_prep) with_21\IN|acne (l_pobj) acne_22\NN|and|hirsutism (l_conj) hirsutism_24\NN|
D004997_D006628 NONE EE_44\NNP|cpa|/ (r_pobj) with_41\IN|ee (r_prep) associated_40\VBN|with (r_acl) VTE_39\NNP|associated (r_pobj) of_38\IN|vte (r_prep) risk_37\NN|the|of (r_dobj) estimate_35\VB|to|risk (r_advcl) conducted_7\VBD|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS|15|with (l_prep) with_28\IN|acne (l_pobj) acne_29\NN|,|hirsutism (l_conj) hirsutism_31\NN|or|pcos
D004997_D006628 NONE EE_15\NNP|cpa|/ (r_pobj) of_12\IN|ee (r_prep) use_11\NN|the|of|in (l_prep) in_16\IN|women (l_pobj) women_17\NNS|with (l_prep) with_18\IN|acne (l_pobj) acne_19\NN|,|hirsutism (l_conj) hirsutism_21\NN|or|pcos
D004997_D011085 NONE estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ|also|option (l_attr) option_30\NN|a|treatment|for (l_prep) for_31\IN|syndrome (l_pobj) syndrome_34\NN|polycystic|ovary|(|pcos|)
D004997_D011085 NONE estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ|also|option (l_attr) option_30\NN|a|treatment|for (l_prep) for_31\IN|syndrome (l_pobj) syndrome_34\NN|polycystic|ovary|(|pcos|) (l_appos) PCOS_36\NNP|
D004997_D011085 NONE EE_9\NNP|cpa|/ (r_appos) estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ|also|option (l_attr) option_30\NN|a|treatment|for (l_prep) for_31\IN|syndrome (l_pobj) syndrome_34\NN|polycystic|ovary|(|pcos|)
D004997_D011085 NONE EE_9\NNP|cpa|/ (r_appos) estradiol_5\NN|(|ee|) (r_nsubjpass) licensed_12\VBN|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ|also|option (l_attr) option_30\NN|a|treatment|for (l_prep) for_31\IN|syndrome (l_pobj) syndrome_34\NN|polycystic|ovary|(|pcos|) (l_appos) PCOS_36\NNP|
D004997_D011085 NONE EE_44\NNP|cpa|/ (r_pobj) with_41\IN|ee (r_prep) associated_40\VBN|with (r_acl) VTE_39\NNP|associated (r_pobj) of_38\IN|vte (r_prep) risk_37\NN|the|of (r_dobj) estimate_35\VB|to|risk (r_advcl) conducted_7\VBD|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS|15|with (l_prep) with_28\IN|acne (l_pobj) acne_29\NN|,|hirsutism (l_conj) hirsutism_31\NN|or|pcos (l_conj) PCOS_33\NNP|
D004997_D011085 NONE EE_15\NNP|cpa|/ (r_pobj) of_12\IN|ee (r_prep) use_11\NN|the|of|in (l_prep) in_16\IN|women (l_pobj) women_17\NNS|with (l_prep) with_18\IN|acne (l_pobj) acne_19\NN|,|hirsutism (l_conj) hirsutism_21\NN|or|pcos (l_conj) PCOS_23\NNP|
D003276_D054556 NONE contraceptives_23\NNS|conventional|combined|oral|(|cocs|) (r_pobj) with_19\IN|contraceptives (r_prep) compared_18\VBN|with (r_prep) demonstrated_3\VBN|studies|have|risk|compared|. (l_dobj) risk_6\NN|an|increased|of (l_prep) of_7\IN|thromboembolism (l_pobj) thromboembolism_9\NN|venous|(|vte|)|associated
D003276_D054556 NONE contraceptives_23\NNS|conventional|combined|oral|(|cocs|) (r_pobj) with_19\IN|contraceptives (r_prep) compared_18\VBN|with (r_prep) demonstrated_3\VBN|studies|have|risk|compared|. (l_dobj) risk_6\NN|an|increased|of (l_prep) of_7\IN|thromboembolism (l_pobj) thromboembolism_9\NN|venous|(|vte|)|associated (l_appos) VTE_11\NNP|
2008831
D008755_D000788 NONE methylergonovine_6\NN| (r_pobj) of_5\IN|methylergonovine (r_prep) administration_4\NN|direct|intracoronary|of|in (l_prep) in_7\IN|patients (l_pobj) patients_8\NNS|with (l_prep) with_9\IN|and|without (l_conj) without_11\IN|angina (l_pobj) angina_13\NN|variant
D008755_D000788 NONE methylergonovine_6\NN| (r_pobj) of_5\IN|methylergonovine (r_prep) administration_4\NN|intracoronary|of (r_pobj) of_2\IN|administration (r_prep) effects_1\NNS|the|of (r_nsubjpass) studied_8\VBN|effects|were|in|without|. (l_prep) in_9\IN|patients (l_pobj) patients_11\NNS|21|with (l_prep) with_12\IN|angina (l_pobj) angina_14\NN|variant|and|patients
D008755_D000788 NONE methylergonovine_19\NN| (r_pobj) of_18\IN|methylergonovine (r_prep) dose_17\NN|a|low|of (r_pobj) of_13\IN|dose (r_prep) injection_12\NN|an|intracoronary|of (r_dobj) use_9\VBP|which|injection (r_relcl) tests_6\NNS|spasm|provocation|,|use|, (r_nsubj) have_21\VBP|that|tests|sensitivity|and|be (l_dobj) sensitivity_24\NN|a|high|in (l_prep) in_25\IN|angina (l_pobj) angina_27\NN|variant
D008755_D002637 NONE methylergonovine_6\NN| (r_pobj) of_5\IN|methylergonovine (r_prep) administration_4\NN|intracoronary|of (r_pobj) of_2\IN|administration (r_prep) effects_1\NNS|the|of (r_nsubjpass) studied_8\VBN|effects|were|in|without|. (l_prep) in_9\IN|patients (l_pobj) patients_11\NNS|21|with (l_prep) with_12\IN|angina (l_pobj) angina_14\NN|variant|and|patients (l_conj) patients_17\NNS|22|with (l_prep) with_18\IN|pain|and|in (l_pobj) pain_21\NN|atypical|chest
D008755_D000787 NONE methylergonovine_6\NN| (r_pobj) of_5\IN|methylergonovine (r_prep) administration_4\NN|intracoronary|of (r_pobj) of_2\IN|administration (r_prep) effects_1\NNS|the|of (r_nsubjpass) studied_8\VBN|effects|were|in|without|. (l_prep) without_25\IN|angina (l_pobj) angina_26\NN|pectoris (l_appos) pectoris_27\NN|group
D008755_D013035 NONE methylergonovine_19\NN| (r_pobj) of_18\IN|methylergonovine (r_prep) dose_17\NN|a|low|of (r_pobj) of_13\IN|dose (r_prep) injection_12\NN|an|intracoronary|of (r_dobj) use_9\VBP|which|injection (r_relcl) tests_6\NNS|spasm|provocation|,|use|, (l_compound) spasm_4\NN|
3780846
D009020_D009127 CID morphine_14\NN| (r_pobj) by_13\IN|morphine (r_agent) produced_12\VBN|by|in (r_acl) rigidity_11\NN|the|muscular|produced
D009020_D009127 CID morphine_10\NN| (r_pobj) by_9\IN|morphine (r_agent) produced_8\VBN|by (r_acl) rigidity_7\NN|the|muscular|produced
D009020_D009127 CID morphine_9\NN| (r_pobj) of_8\IN|morphine (r_prep) dose_7\NN|a|test|of|(|mg/kg|) (r_dobj) given_4\VBN|controls|dose (r_csubj) showed_15\VBD|given|rigidity|. (l_dobj) rigidity_18\NN|a|pronounced|recorded
D009020_D009127 CID morphine_6\NN| (r_pobj) with_5\IN|morphine (r_prep) treated_1\VBD|rats|for|with|and|withdrawn|h|showed|showed|. (l_conj) showed_27\VBD|half|rigidity|after (l_dobj) rigidity_29\NN|a
D009020_D009127 CID morphine_35\NN| (r_pobj) of_34\IN|morphine (r_prep) dose_33\NN|the|test|of|was|group (r_pobj) after_30\IN|dose (r_prep) showed_27\VBD|half|rigidity|after (l_dobj) rigidity_29\NN|a
D009020_D009127 CID morphine_16\NN| (r_pobj) of_15\IN|morphine (r_prep) action_14\NN|an|of|in (r_pobj) to_12\IN|action (r_prep) due_11\JJ|to (r_acomp) be_10\VB|to|due (r_xcomp) assumed_8\VBN|which|is|be (r_relcl) rigidity_4\NN|,|assumed|,
D009020_D018476 CID morphine_6\NN| (r_pobj) with_5\IN|morphine (r_prep) treated_1\VBD|rats|for|with|and|withdrawn|h|showed|showed|. (l_conj) showed_27\VBD|half|rigidity|after (l_prep) after_30\IN|dose (l_pobj) dose_33\NN|the|test|of|was|group (l_relcl) was_37\VBD|that|not|less|and|were (l_conj) were_46\VBD|akinetic (l_acomp) akinetic_47\JJ|
D009020_D018476 CID morphine_35\NN| (r_pobj) of_34\IN|morphine (r_prep) dose_33\NN|the|test|of|was|group (l_relcl) was_37\VBD|that|not|less|and|were (l_conj) were_46\VBD|akinetic (l_acomp) akinetic_47\JJ|
D006220_D009127 CID haloperidol_7\NN|(|mg/kg|i.p.|) (r_nsubjpass) used_14\VBN|in|,|haloperidol|was|in|. (l_prep) in_15\IN|order (l_pobj) order_16\NN|block (l_acl) block_18\VB|to|activation|and|estimate (l_conj) estimate_24\VB|to|degree (l_dobj) degree_27\NN|the|real|of (l_prep) of_28\IN|tolerance (l_pobj) tolerance_30\NN|the|to (l_prep) to_31\IN|rigidity (l_pobj) rigidity_33\NN|the|without
D006220_D009127 CID Haloperidol_0\NNP| (r_nsubj) enhanced_1\VBD|haloperidol|rigidity|. (l_dobj) rigidity_3\NN|the|in
2887062
D004967_D015175 CID estrogen_8\NN| (r_npadvmod) induced_10\VBN|estrogen|- (r_amod) prolactinomas_12\NNS|induced|rat|after
D004967_D015175 CID estrogen_21\NN| (r_npadvmod) induced_23\VBN|estrogen|- (r_amod) cells_26\NNS|induced|rat|prolactinoma|h|and (r_pobj) to_20\IN|cells (r_prep) applied_19\VBN|clarify|analyses|were|to|h|. (l_advcl) clarify_1\VB|to|effects (l_dobj) effects_3\NNS|the|of|on (l_prep) on_6\IN|cells (l_pobj) cells_8\NNS|prolactinoma|in (l_compound) prolactinoma_7\NN|
D004967_D015175 CID estrogen_21\NN| (r_npadvmod) induced_23\VBN|estrogen|- (r_amod) cells_26\NNS|induced|rat|prolactinoma|h|and (l_compound) prolactinoma_25\NN|
D001971_D015175 NONE bromocriptine_14\NN| (r_amod) treatment_15\NN|bromocriptine (r_pobj) after_13\IN|treatment (r_prep) prolactinomas_12\NNS|induced|rat|after
D001971_D015175 NONE bromocriptine_5\NN| (r_pobj) of_4\IN|bromocriptine (r_prep) effects_3\NNS|the|of|on (l_prep) on_6\IN|cells (l_pobj) cells_8\NNS|prolactinoma|in (l_compound) prolactinoma_7\NN|
D001971_D015175 NONE bromocriptine_5\NN| (r_pobj) of_4\IN|bromocriptine (r_prep) effects_3\NNS|the|of|on (r_dobj) clarify_1\VB|to|effects (r_advcl) applied_19\VBN|clarify|analyses|were|to|h|. (l_prep) to_20\IN|cells (l_pobj) cells_26\NNS|induced|rat|prolactinoma|h|and (l_compound) prolactinoma_25\NN|
D001971_D015175 NONE bromocriptine_35\NN| (r_pobj) of_34\IN|bromocriptine (r_prep) injection_33\NN|of (r_pobj) after_32\IN|injection (r_prep) h_31\NN|6|after|mg/kg (r_conj) applied_19\VBN|clarify|analyses|were|to|h|. (l_advcl) clarify_1\VB|to|effects (l_dobj) effects_3\NNS|the|of|on (l_prep) on_6\IN|cells (l_pobj) cells_8\NNS|prolactinoma|in (l_compound) prolactinoma_7\NN|
D001971_D015175 NONE bromocriptine_35\NN| (r_pobj) of_34\IN|bromocriptine (r_prep) injection_33\NN|of (r_pobj) after_32\IN|injection (r_prep) h_31\NN|6|after|mg/kg (r_conj) applied_19\VBN|clarify|analyses|were|to|h|. (l_prep) to_20\IN|cells (l_pobj) cells_26\NNS|induced|rat|prolactinoma|h|and (l_compound) prolactinoma_25\NN|
D001971_D000236 NONE bromocriptine_15\JJ| (r_amod) treatment_16\NN|bromocriptine|of (l_prep) of_17\IN|cells (l_pobj) cells_20\NNS|the|adenoma (l_compound) adenoma_19\NN|
11532387
D018967_D013375 CID risperidone_9\NN| (r_pobj) of_8\IN|risperidone (r_prep) reduction_7\NN|dose|of (r_pobj) during_5\IN|reduction (r_prep) syndrome_4\NN|emergent|rabbit|during|.
D018967_D013375 CID risperidone_21\NN|,|antagonist (r_pobj) of_20\IN|risperidone (r_prep) profile_19\NN|the|pharmacological|of (r_pobj) to_16\IN|profile (r_prep) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN|the|underlying|of|in (l_prep) of_3\IN|rs (l_pobj) RS_7\NN|emergent
D018967_D001480 CID risperidone_9\NN| (r_pobj) of_8\IN|risperidone (r_prep) reduction_7\NN|dose|of (r_pobj) during_5\IN|reduction (r_prep) syndrome_4\NN|emergent|rabbit|during|.
D018967_D001480 CID risperidone_8\NN| (r_pobj) of_7\IN|risperidone (r_prep) reduction_6\NN|dose|of (r_pobj) during_4\IN|reduction (r_prep) developed_2\VBN|patient|rs|during|. (l_dobj) RS_3\NN|
D018967_D001480 CID risperidone_21\NN|,|antagonist (r_pobj) of_20\IN|risperidone (r_prep) profile_19\NN|the|pharmacological|of (r_pobj) to_16\IN|profile (r_prep) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN|the|underlying|of|in (l_prep) of_3\IN|rs (l_pobj) RS_7\NN|emergent
D018967_D001480 CID risperidone_21\NN|,|antagonist (r_pobj) of_20\IN|risperidone (r_prep) profile_19\NN|the|pharmacological|of (r_pobj) to_16\IN|profile (r_prep) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_advcl) suggesting_29\VBG|influence (l_dobj) influence_32\NN|the|pathophysiologic|of|in (l_prep) in_37\IN|development (l_pobj) development_39\NN|the|of (l_prep) of_40\IN|rs (l_pobj) RS_41\NN|
D012701_D013375 NONE serotonin_24\NN| (r_compound) dopamine_26\NN|serotonin|- (r_compound) antagonist_27\NN|a|dopamine (r_appos) risperidone_21\NN|,|antagonist (r_pobj) of_20\IN|risperidone (r_prep) profile_19\NN|the|pharmacological|of (r_pobj) to_16\IN|profile (r_prep) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN|the|underlying|of|in (l_prep) of_3\IN|rs (l_pobj) RS_7\NN|emergent
D012701_D013375 NONE serotonin_35\NN| (r_compound) system_36\NN|the|serotonin (r_pobj) of_33\IN|system (r_prep) influence_32\NN|the|pathophysiologic|of|in (r_dobj) suggesting_29\VBG|influence (r_advcl) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN|the|underlying|of|in (l_prep) of_3\IN|rs (l_pobj) RS_7\NN|emergent
D012701_D001480 NONE serotonin_24\NN| (r_compound) dopamine_26\NN|serotonin|- (r_compound) antagonist_27\NN|a|dopamine (r_appos) risperidone_21\NN|,|antagonist (r_pobj) of_20\IN|risperidone (r_prep) profile_19\NN|the|pharmacological|of (r_pobj) to_16\IN|profile (r_prep) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN|the|underlying|of|in (l_prep) of_3\IN|rs (l_pobj) RS_7\NN|emergent
D012701_D001480 NONE serotonin_24\NN| (r_compound) dopamine_26\NN|serotonin|- (r_compound) antagonist_27\NN|a|dopamine (r_appos) risperidone_21\NN|,|antagonist (r_pobj) of_20\IN|risperidone (r_prep) profile_19\NN|the|pharmacological|of (r_pobj) to_16\IN|profile (r_prep) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_advcl) suggesting_29\VBG|influence (l_dobj) influence_32\NN|the|pathophysiologic|of|in (l_prep) in_37\IN|development (l_pobj) development_39\NN|the|of (l_prep) of_40\IN|rs (l_pobj) RS_41\NN|
D012701_D001480 NONE serotonin_35\NN| (r_compound) system_36\NN|the|serotonin (r_pobj) of_33\IN|system (r_prep) influence_32\NN|the|pathophysiologic|of|in (r_dobj) suggesting_29\VBG|influence (r_advcl) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN|the|underlying|of|in (l_prep) of_3\IN|rs (l_pobj) RS_7\NN|emergent
D012701_D001480 NONE serotonin_35\NN| (r_compound) system_36\NN|the|serotonin (r_pobj) of_33\IN|system (r_prep) influence_32\NN|the|pathophysiologic|of|in (l_prep) in_37\IN|development (l_pobj) development_39\NN|the|of (l_prep) of_40\IN|rs (l_pobj) RS_41\NN|
D004298_D013375 NONE dopamine_26\NN|serotonin|- (r_compound) antagonist_27\NN|a|dopamine (r_appos) risperidone_21\NN|,|antagonist (r_pobj) of_20\IN|risperidone (r_prep) profile_19\NN|the|pharmacological|of (r_pobj) to_16\IN|profile (r_prep) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN|the|underlying|of|in (l_prep) of_3\IN|rs (l_pobj) RS_7\NN|emergent
D004298_D001480 NONE dopamine_26\NN|serotonin|- (r_compound) antagonist_27\NN|a|dopamine (r_appos) risperidone_21\NN|,|antagonist (r_pobj) of_20\IN|risperidone (r_prep) profile_19\NN|the|pharmacological|of (r_pobj) to_16\IN|profile (r_prep) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN|the|underlying|of|in (l_prep) of_3\IN|rs (l_pobj) RS_7\NN|emergent
D004298_D001480 NONE dopamine_26\NN|serotonin|- (r_compound) antagonist_27\NN|a|dopamine (r_appos) risperidone_21\NN|,|antagonist (r_pobj) of_20\IN|risperidone (r_prep) profile_19\NN|the|pharmacological|of (r_pobj) to_16\IN|profile (r_prep) related_15\VBN|mechanism|may|have|been|to|,|suggesting|. (l_advcl) suggesting_29\VBG|influence (l_dobj) influence_32\NN|the|pathophysiologic|of|in (l_prep) in_37\IN|development (l_pobj) development_39\NN|the|of (l_prep) of_40\IN|rs (l_pobj) RS_41\NN|
16005948
-1_D062787 NONE GNC92H2_6\NNP|the|anticocaine|monoclonal|antibody (r_pobj) of_1\IN|gnc92h2 (r_prep) Evaluation_0\NN|of|as|. (l_prep) as_7\IN|immunotherapy (l_pobj) immunotherapy_9\NN|an|for (l_prep) for_10\IN|overdose (l_pobj) overdose_12\NN|cocaine
-1_D062787 NONE GNC92H2_7\NNP|the|anticocaine|antibody (r_pobj) of_3\IN|gnc92h2 (r_prep) potential_2\NN|the|therapeutic|of (r_nsubjpass) examined_9\VBN|potential|was|using|. (l_advcl) using_10\VBG|model (l_dobj) model_12\NN|a|of (l_prep) of_13\IN|overdose (l_pobj) overdose_15\NN|cocaine
-1_D062787 NONE GNC92H2_7\NNP| (r_pobj) of_6\IN|gnc92h2 (r_prep) potential_5\NN|the|important|of|as (l_prep) as_8\IN|tool (l_pobj) tool_11\NN|a|therapeutic|against (l_prep) against_12\IN|overdose (l_pobj) overdose_14\NN|cocaine
D003042_D062787 NONE cocaine_4\NN| (r_pobj) of_3\IN|cocaine (r_prep) use_2\NN|the|illicit|of (r_nsubj) continues_5\VBZ|use|in (l_prep) in_6\IN|proportions (l_pobj) proportions_8\NNS|epidemic|and|treatment (l_conj) treatment_10\NN|for (l_prep) for_11\IN|overdose (l_pobj) overdose_13\NN|cocaine
D003042_D064420 NONE cocaine_3\NN| (r_compound) toxicity_4\NN|cocaine
D003042_D012640 CID cocaine_3\NN| (r_compound) toxicity_4\NN|cocaine (r_pobj) of_2\IN|toxicity (r_prep) blockade_1\NN|significant|of (r_nsubjpass) observed_6\VBN|blockade|was|with|. (l_prep) with_7\IN|dose (l_pobj) dose_10\NN|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS|up|by
D003042_D003643 NONE cocaine_3\NN| (r_compound) toxicity_4\NN|cocaine (r_pobj) of_2\IN|toxicity (r_prep) blockade_1\NN|significant|of (r_nsubjpass) observed_6\VBN|blockade|was|with|. (l_prep) with_7\IN|dose (l_pobj) dose_10\NN|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS|up|by (l_prt) up_29\IN|to (l_prep) to_30\TO|% (l_pobj) %_32\NN|77|and|death (l_conj) death_34\NN|
D003042_D003643 NONE cocaine_8\NN|post|- (r_compound) injection_9\NN|even|cocaine (r_dobj) prevented_3\VBD|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN|
-1_D064420 NONE GNC92H2_12\NNP| (r_pobj) of_11\IN|gnc92h2 (r_prep) dose_10\NN|the|higher|of|mg/kg|)|,|reduced|,|seizures (r_pobj) with_7\IN|dose (r_prep) observed_6\VBN|blockade|was|with|. (l_nsubjpass) blockade_1\NN|significant|of (l_prep) of_2\IN|toxicity (l_pobj) toxicity_4\NN|cocaine
-1_D012640 NONE GNC92H2_12\NNP| (r_pobj) of_11\IN|gnc92h2 (r_prep) dose_10\NN|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS|up|by
-1_D003643 NONE GNC92H2_12\NNP| (r_pobj) of_11\IN|gnc92h2 (r_prep) dose_10\NN|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS|up|by (l_prt) up_29\IN|to (l_prep) to_30\TO|% (l_pobj) %_32\NN|77|and|death (l_conj) death_34\NN|
-1_D003643 NONE GNC92H2_2\NNP| (r_nsubj) prevented_3\VBD|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN|
1867351
D015767_D008288 NONE mefloquine_10\NN| (r_pobj) with_9\IN|mefloquine (r_prep) treatment_8\NN|with (r_conj) prophylaxis_6\NN|malaria|and|treatment (l_compound) malaria_5\NN|
11027905
D007649_D009369 NONE ketamine_4\NN|intravenous|in (l_prep) in_5\IN|patients (l_pobj) patients_7\NNS|cancer|on (l_compound) cancer_6\NN|
D007649_D009369 NONE ketamine_7\NN| (r_pobj) of_6\IN|ketamine (r_prep) doses_5\NNS|subhypnotic|of|(|0.25|) (r_pobj) of_3\IN|doses (r_prep) bolus_2\NN|a|slow|of (r_nsubjpass) given_16\VBN|bolus|was|to|. (l_dative) to_17\IN|patients (l_pobj) patients_20\NNS|10|cancer|was (l_compound) cancer_19\NN|
D009020_D009369 NONE morphine_9\NN| (r_compound) therapy_10\NN|morphine (r_pobj) on_8\IN|therapy (r_prep) patients_7\NNS|cancer|on (l_compound) cancer_6\NN|
D009020_D009369 NONE morphine_26\NN| (r_pobj) by_25\IN|morphine (r_prep) unrelieved_24\JJ|by (r_acomp) was_23\VBD|pain|unrelieved|in (r_relcl) patients_20\NNS|10|cancer|was (l_compound) cancer_19\NN|
D009020_D010146 NONE morphine_4\NN| (r_pobj) to_3\IN|morphine (r_prep) responsive_2\JJ|not|to (r_amod) Pain_0\NN|responsive
D009020_D010146 NONE morphine_26\NN| (r_pobj) by_25\IN|morphine (r_prep) unrelieved_24\JJ|by (r_acomp) was_23\VBD|pain|unrelieved|in (l_nsubj) pain_22\NN|whose
D009020_D010146 NONE morphine_3\NN| (r_compound) analgesia_4\NN|morphine|in (l_prep) in_5\IN|syndromes (l_pobj) syndromes_8\NNS|difficult|pain|,|as (l_compound) pain_7\NN|
D016202_D010146 NONE aspartate_13\NNP|methyl|-|d|- (r_nmod) antagonists_17\NNS|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB|that|antagonists|,|may|effective (l_acomp) effective_25\JJ|in (l_prep) in_26\IN|improving (l_pcomp) improving_27\VBG|analgesia (l_dobj) analgesia_29\NN|opioid|in (l_prep) in_30\IN|syndromes (l_pobj) syndromes_33\NNS|difficult|pain|,|as (l_compound) pain_32\NN|
D016202_D010146 NONE NMDA_15\NNP| (r_nmod) antagonists_17\NNS|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB|that|antagonists|,|may|effective (l_acomp) effective_25\JJ|in (l_prep) in_26\IN|improving (l_pcomp) improving_27\VBG|analgesia (l_dobj) analgesia_29\NN|opioid|in (l_prep) in_30\IN|syndromes (l_pobj) syndromes_33\NNS|difficult|pain|,|as (l_compound) pain_32\NN|
D016202_D009437 NONE aspartate_13\NNP|methyl|-|d|- (r_nmod) antagonists_17\NNS|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB|that|antagonists|,|may|effective (l_acomp) effective_25\JJ|in (l_prep) in_26\IN|improving (l_pcomp) improving_27\VBG|analgesia (l_dobj) analgesia_29\NN|opioid|in (l_prep) in_30\IN|syndromes (l_pobj) syndromes_33\NNS|difficult|pain|,|as (l_prep) as_36\IN|such|pain (l_pobj) pain_38\NN|neuropathic
D016202_D009437 NONE NMDA_15\NNP| (r_nmod) antagonists_17\NNS|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB|that|antagonists|,|may|effective (l_acomp) effective_25\JJ|in (l_prep) in_26\IN|improving (l_pcomp) improving_27\VBG|analgesia (l_dobj) analgesia_29\NN|opioid|in (l_prep) in_30\IN|syndromes (l_pobj) syndromes_33\NNS|difficult|pain|,|as (l_prep) as_36\IN|such|pain (l_pobj) pain_38\NN|neuropathic
D007649_D010146 NONE ketamine_21\NN| (r_pobj) as_20\IN|such|ketamine (r_prep) antagonists_17\NNS|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB|that|antagonists|,|may|effective (l_acomp) effective_25\JJ|in (l_prep) in_26\IN|improving (l_pcomp) improving_27\VBG|analgesia (l_dobj) analgesia_29\NN|opioid|in (l_prep) in_30\IN|syndromes (l_pobj) syndromes_33\NNS|difficult|pain|,|as (l_compound) pain_32\NN|
D007649_D010146 NONE ketamine_7\NN| (r_pobj) of_6\IN|ketamine (r_prep) doses_5\NNS|subhypnotic|of|(|0.25|) (r_pobj) of_3\IN|doses (r_prep) bolus_2\NN|a|slow|of (r_nsubjpass) given_16\VBN|bolus|was|to|. (l_dative) to_17\IN|patients (l_pobj) patients_20\NNS|10|cancer|was (l_relcl) was_23\VBD|pain|unrelieved|in (l_nsubj) pain_22\NN|whose
D007649_D010146 NONE Ketamine_0\NN|,|but|solution (r_nsubj) reduced_8\VBD|ketamine|significantly|intensity|in|. (l_dobj) intensity_11\NN|the|pain (l_compound) pain_10\NN|
D007649_D010146 NONE Ketamine_0\NNP| (r_nsubj) improve_2\VB|ketamine|can|analgesia|. (l_dobj) analgesia_4\NN|morphine|in (l_prep) in_5\IN|syndromes (l_pobj) syndromes_8\NNS|difficult|pain|,|as (l_compound) pain_7\NN|
D007649_D009437 NONE ketamine_21\NN| (r_pobj) as_20\IN|such|ketamine (r_prep) antagonists_17\NNS|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB|that|antagonists|,|may|effective (l_acomp) effective_25\JJ|in (l_prep) in_26\IN|improving (l_pcomp) improving_27\VBG|analgesia (l_dobj) analgesia_29\NN|opioid|in (l_prep) in_30\IN|syndromes (l_pobj) syndromes_33\NNS|difficult|pain|,|as (l_prep) as_36\IN|such|pain (l_pobj) pain_38\NN|neuropathic
D007649_D009437 NONE Ketamine_0\NNP| (r_nsubj) improve_2\VB|ketamine|can|analgesia|. (l_dobj) analgesia_4\NN|morphine|in (l_prep) in_5\IN|syndromes (l_pobj) syndromes_8\NNS|difficult|pain|,|as (l_prep) as_11\IN|such|pain (l_pobj) pain_13\NN|neuropathic
D009020_D009437 NONE morphine_3\NN| (r_compound) analgesia_4\NN|morphine|in (l_prep) in_5\IN|syndromes (l_pobj) syndromes_8\NNS|difficult|pain|,|as (l_prep) as_11\IN|such|pain (l_pobj) pain_13\NN|neuropathic
8558192
C030852_C562729 NONE vinorelbine_4\NN| (r_pobj) of_3\IN|vinorelbine (r_prep) trial_2\NN|ii|of|in|. (l_prep) in_5\IN|carcinoma (l_pobj) carcinoma_10\NN|metastatic|esophageal
C030852_C562729 NONE vinorelbine_9\NN|(|vnb|) (r_pobj) of_8\IN|vinorelbine (r_prep) effects_7\NNS|toxic|of (r_conj) rate_4\NN|the|response|and|effects|administered (l_acl) administered_13\VBN|as (l_prep) as_14\IN|agent (l_pobj) agent_17\NN|a|single|in (l_prep) in_18\IN|carcinoma (l_pobj) carcinoma_23\NN|metastatic|esophageal
C030852_C562729 NONE VNB_11\NNP| (r_appos) vinorelbine_9\NN|(|vnb|) (r_pobj) of_8\IN|vinorelbine (r_prep) effects_7\NNS|toxic|of (r_conj) rate_4\NN|the|response|and|effects|administered (l_acl) administered_13\VBN|as (l_prep) as_14\IN|agent (l_pobj) agent_17\NN|a|single|in (l_prep) in_18\IN|carcinoma (l_pobj) carcinoma_23\NN|metastatic|esophageal
C030852_C562729 NONE VNB_4\NNP| (r_nsubj) is_5\VBZ|that|vnb|agent (l_attr) agent_8\NN|an|active|in (l_prep) in_9\IN|carcinoma (l_pobj) carcinoma_14\NN|metastatic|cell
D002945_D064420 NONE cisplatin_9\NN| (r_npadvmod) based_11\VBN|cisplatin|- (r_amod) chemotherapy_12\NN|based (r_pobj) with_8\IN|chemotherapy (r_prep) pretreated_7\VBN|patients|with (r_csubj) were_13\VBD|pretreated|assessable|. (l_acomp) assessable_14\JJ|for (l_prep) for_15\IN|toxicity (l_pobj) toxicity_16\NN|and|response
C030852_D064420 NONE VNB_0\NNP| (r_nsubjpass) tolerated_3\VBN|vnb|was|well|and|occurred (l_conj) occurred_13\VBD|instances|toxicity|. (l_nsubj) toxicity_12\NN|nonhematologic
C030852_D064420 NONE VNB_12\NNP| (r_pobj) of_11\IN|vnb (r_prep) evaluation_10\NN|further|of|in (r_nsubjpass) warranted_17\VBN|given|,|evaluation|is|. (l_prep) Given_0\VBN|profile (l_pobj) profile_4\NN|its|tolerance|and|toxicity (l_conj) toxicity_7\NN|low
1639466
D002118_D009400 NONE calcium_4\NN| (r_compound) channel_5\NN|the|calcium (r_pobj) of_2\IN|channel (r_prep) effect_1\NN|adverse|of|nitrendipine|. (l_appos) nitrendipine_7\NN|blocker|on (l_prep) on_8\IN|nephrosclerosis (l_pobj) nephrosclerosis_9\NN|in
D002118_D006978 NONE calcium_4\NN| (r_compound) channel_5\NN|the|calcium (r_pobj) of_2\IN|channel (r_prep) effect_1\NN|adverse|of|nitrendipine|. (l_appos) nitrendipine_7\NN|blocker|on (l_prep) on_8\IN|nephrosclerosis (l_pobj) nephrosclerosis_9\NN|in (l_prep) in_10\IN|rats (l_pobj) rats_11\NNS|with (l_prep) with_12\IN|hypertension (l_pobj) hypertension_14\NN|renovascular
D002118_D006978 NONE calcium_8\NN| (r_compound) channel_9\NN|the|calcium|nitrendipine (r_pobj) with_6\IN|channel (r_prep) treatment_5\NN|a|6-week|with (r_pobj) of_2\IN|treatment (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_35\VBN|effect|was|in|. (l_prep) in_36\IN|rats (l_pobj) rats_37\NNS|with (l_prep) with_38\IN|kidney (l_pobj) kidney_41\NN|two|-|,|hypertension (l_appos) hypertension_46\NN|one|renovascular
D009568_D009400 CID nitrendipine_7\NN|blocker|on (l_prep) on_8\IN|nephrosclerosis (l_pobj) nephrosclerosis_9\NN|in
D009568_D006978 NONE nitrendipine_7\NN|blocker|on (l_prep) on_8\IN|nephrosclerosis (l_pobj) nephrosclerosis_9\NN|in (l_prep) in_10\IN|rats (l_pobj) rats_11\NNS|with (l_prep) with_12\IN|hypertension (l_pobj) hypertension_14\NN|renovascular
D009568_D006978 NONE nitrendipine_11\NN|blocker|or|angiotensin (r_appos) channel_9\NN|the|calcium|nitrendipine (r_pobj) with_6\IN|channel (r_prep) treatment_5\NN|a|6-week|with (r_pobj) of_2\IN|treatment (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_35\VBN|effect|was|in|. (l_prep) in_36\IN|rats (l_pobj) rats_37\NNS|with (l_prep) with_38\IN|kidney (l_pobj) kidney_41\NN|two|-|,|hypertension (l_appos) hypertension_46\NN|one|renovascular
D002118_D000419 NONE calcium_8\NN| (r_compound) channel_9\NN|the|calcium|nitrendipine (l_appos) nitrendipine_11\NN|blocker|or|angiotensin (l_conj) angiotensin_14\NN|the|converting (l_acl) converting_15\VBG|enalapril|on (l_prep) on_19\IN|pressure (l_pobj) pressure_21\NN|blood|,|albuminuria (l_conj) albuminuria_23\NN|,|hemodynamics
D009568_D000419 CID nitrendipine_11\NN|blocker|or|angiotensin (l_conj) angiotensin_14\NN|the|converting (l_acl) converting_15\VBG|enalapril|on (l_prep) on_19\IN|pressure (l_pobj) pressure_21\NN|blood|,|albuminuria (l_conj) albuminuria_23\NN|,|hemodynamics
D009568_D000419 CID nitrendipine_5\NN| (r_npadvmod) treated_7\VBN|nitrendipine|- (r_amod) albuminuria_9\NN|the|treated|group
D000809_D000419 NONE angiotensin_14\NN|the|converting (l_acl) converting_15\VBG|enalapril|on (l_prep) on_19\IN|pressure (l_pobj) pressure_21\NN|blood|,|albuminuria (l_conj) albuminuria_23\NN|,|hemodynamics
D000809_D006978 NONE angiotensin_14\NN|the|converting (r_conj) nitrendipine_11\NN|blocker|or|angiotensin (r_appos) channel_9\NN|the|calcium|nitrendipine (r_pobj) with_6\IN|channel (r_prep) treatment_5\NN|a|6-week|with (r_pobj) of_2\IN|treatment (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_35\VBN|effect|was|in|. (l_prep) in_36\IN|rats (l_pobj) rats_37\NNS|with (l_prep) with_38\IN|kidney (l_pobj) kidney_41\NN|two|-|,|hypertension (l_appos) hypertension_46\NN|one|renovascular
D004656_D000419 NONE enalapril_18\NN|inhibitor (r_dobj) converting_15\VBG|enalapril|on (l_prep) on_19\IN|pressure (l_pobj) pressure_21\NN|blood|,|albuminuria (l_conj) albuminuria_23\NN|,|hemodynamics
D004656_D006978 NONE enalapril_18\NN|inhibitor (r_dobj) converting_15\VBG|enalapril|on (r_acl) angiotensin_14\NN|the|converting (r_conj) nitrendipine_11\NN|blocker|or|angiotensin (r_appos) channel_9\NN|the|calcium|nitrendipine (r_pobj) with_6\IN|channel (r_prep) treatment_5\NN|a|6-week|with (r_pobj) of_2\IN|treatment (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_35\VBN|effect|was|in|. (l_prep) in_36\IN|rats (l_pobj) rats_37\NNS|with (l_prep) with_38\IN|kidney (l_pobj) kidney_41\NN|two|-|,|hypertension (l_appos) hypertension_46\NN|one|renovascular
D004656_D006973 NONE enalapril_33\NN| (r_npadvmod) treated_35\VBN|enalapril|- (r_amod) 8)_39\CD|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS|untreated|hypertensive|(|8)|8) (r_appos) groups_23\NNS|three|:|controls (r_pobj) to_21\IN|groups (r_prep) assigned_20\VBN|after|were|randomly|to|. (l_prep) after_2\IN|weeks|clipping (l_pobj) clipping_3\VBG|of (l_prep) of_4\IN|artery (l_pobj) artery_7\NN|one|renal|,|rats|(|hg|) (l_appos) rats_10\NNS|hypertensive (l_amod) hypertensive_9\JJ|
D004656_D006973 NONE enalapril_33\NN| (r_npadvmod) treated_35\VBN|enalapril|- (r_amod) 8)_39\CD|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS|untreated|hypertensive|(|8)|8) (l_amod) hypertensive_26\JJ|
D004656_D006973 NONE enalapril_25\NN| (r_npadvmod) treated_27\VBN|enalapril|- (r_amod) group_28\NN|the|treated (r_pobj) in_23\IN|group (r_prep) lower_22\JJR|in|(|+/-|compared (l_prep) compared_37\VBN|with (l_prep) with_38\IN|controls (l_pobj) controls_41\NNS|the|hypertensive|(|+/-|) (l_amod) hypertensive_40\JJ|
D009568_D006973 NONE nitrendipine_42\NN| (r_advmod) treated_44\VBN|nitrendipine|-|n (r_conj) 8)_39\CD|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS|untreated|hypertensive|(|8)|8) (r_appos) groups_23\NNS|three|:|controls (r_pobj) to_21\IN|groups (r_prep) assigned_20\VBN|after|were|randomly|to|. (l_prep) after_2\IN|weeks|clipping (l_pobj) clipping_3\VBG|of (l_prep) of_4\IN|artery (l_pobj) artery_7\NN|one|renal|,|rats|(|hg|) (l_appos) rats_10\NNS|hypertensive (l_amod) hypertensive_9\JJ|
D009568_D006973 NONE nitrendipine_42\NN| (r_advmod) treated_44\VBN|nitrendipine|-|n (r_conj) 8)_39\CD|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS|untreated|hypertensive|(|8)|8) (l_amod) hypertensive_26\JJ|
D009568_D006973 NONE nitrendipine_5\NN| (r_npadvmod) treated_7\VBN|nitrendipine|- (r_amod) albuminuria_9\NN|the|treated|group (r_pobj) in_3\IN|albuminuria (r_prep) increased_10\VBD|in|,|in|from|progressively|to|compared|. (l_prep) compared_20\VBN|with (l_prep) with_21\IN|hr (l_pobj) hr_26\NN|mg/24|in (l_prep) in_27\IN|controls (l_pobj) controls_30\NNS|the|hypertensive (l_amod) hypertensive_29\JJ|
D009568_D006973 NONE nitrendipine_9\NN| (r_npadvmod) treated_11\VBN|nitrendipine|- (r_amod) group_12\NN|the|treated (r_pobj) in_7\IN|group (r_prep) increased_6\VBN|furthermore|,|index|was|significantly|in|compared|. (l_prep) compared_13\VBN|with (l_prep) with_14\IN|controls (l_pobj) controls_17\NNS|the|hypertensive|(|0.38|) (l_amod) hypertensive_16\JJ|
D009568_D006973 NONE nitrendipine_9\NN| (r_npadvmod) treated_11\VBN|nitrendipine|- (r_amod) group_12\NN|the|treated|(|+/-|) (r_pobj) in_7\IN|group (r_prep) was_5\VBD|in|,|size|higher|in|but|lower|. (l_conj) lower_22\JJR|in|(|+/-|compared (l_prep) compared_37\VBN|with (l_prep) with_38\IN|controls (l_pobj) controls_41\NNS|the|hypertensive|(|+/-|) (l_amod) hypertensive_40\JJ|
D004656_D005921 NONE enalapril_14\JJ| (r_compound) treatment_15\NN|enalapril (r_pobj) after_13\IN|treatment (r_prep) change_12\VB|excretion|did|not|after|. (l_nsubj) excretion_7\NN|albumin|and|glomerulosclerosis (l_conj) glomerulosclerosis_9\NN|
D009568_D005921 NONE nitrendipine_9\NN| (r_npadvmod) treated_11\VBN|nitrendipine|- (r_amod) group_12\NN|the|treated (r_pobj) in_7\IN|group (r_prep) increased_6\VBN|furthermore|,|index|was|significantly|in|compared|. (l_nsubjpass) index_3\NN|glomerulosclerosis (l_compound) glomerulosclerosis_2\NN|
7977601
16330766
C040029_D009437 NONE gabapentin_11\NN|,|drug (l_appos) drug_14\NN|a|effective (l_amod) effective_15\JJ|in (l_prep) in_16\IN|patients (l_pobj) patients_19\NNS|neuropathic|pain (l_compound) pain_18\NN|
C040029_D006930 NONE gabapentin_15\NN| (r_npadvmod) induced_17\VBN|gabapentin|- (r_amod) modulation_18\NN|the|induced|of|in (l_prep) in_22\IN|response (l_pobj) response_23\NN|to (l_prep) to_24\IN|stimulation (l_pobj) stimulation_27\NN|nociceptive|mechanical|of (l_prep) of_28\IN|skin (l_pobj) skin_30\NN|normal|and|hyperalgesia (l_conj) hyperalgesia_36\NN|induced|secondary
D002211_D006930 CID capsaicin_32\NN| (r_npadvmod) induced_34\VBN|capsaicin|- (r_amod) hyperalgesia_36\NN|induced|secondary
11206082
C036150_D012640 CID carboline_10\NN|beta|- (r_npadvmod) induced_12\VBN|carboline|- (r_amod) seizures_13\NNS|induced
C036150_D012640 CID carboline-3-carboxylate_32\NN|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN|carboline-3-carboxylate (r_prep) injection_27\NN|a|single|i.p.|of (r_pobj) by_23\IN|injection (r_agent) induced_22\VBN|by (r_acl) seizures_21\NNS|induced
C036150_D012640 CID CCM_36\NNP|(|beta|- (r_appos) carboline-3-carboxylate_32\NN|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN|carboline-3-carboxylate (r_prep) injection_27\NN|a|single|i.p.|of (r_pobj) by_23\IN|injection (r_agent) induced_22\VBN|by (r_acl) seizures_21\NNS|induced
D005680_D012640 NONE GABA(A_24\NNP| (r_nmod) ligands_27\NNS|other|gaba(a|)|receptor (r_pobj) of_22\IN|ligands (r_prep) effects_21\NNS|various|pharmacological|of (r_pobj) to_18\IN|effects (r_prep) sensitive_17\JJ|differentially|to (r_acomp) are_14\VBP|lines|also|sensitive|. (l_nsubj) lines_2\NNS|two|mouse|selected (l_acl) selected_3\VBN|for (l_prep) for_4\IN|sensitivities (l_pobj) sensitivities_6\NNS|differential|to (l_prep) to_7\IN|seizures (l_pobj) seizures_13\NNS|induced
D005680_D012640 NONE GABA(A_44\NNP| (r_nmod) site_48\NN|the|gaba(a|receptor|benzodiazepine (r_pobj) of_42\IN|site (r_prep) agonist_41\NN|an|inverse|of (r_appos) carboline-3-carboxylate_32\NN|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN|carboline-3-carboxylate (r_prep) injection_27\NN|a|single|i.p.|of (r_pobj) by_23\IN|injection (r_agent) induced_22\VBN|by (r_acl) seizures_21\NNS|induced
D001569_D012640 NONE benzodiazepine_47\NN| (r_amod) site_48\NN|the|gaba(a|receptor|benzodiazepine (r_pobj) of_42\IN|site (r_prep) agonist_41\NN|an|inverse|of (r_appos) carboline-3-carboxylate_32\NN|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN|carboline-3-carboxylate (r_prep) injection_27\NN|a|single|i.p.|of (r_pobj) by_23\IN|injection (r_agent) induced_22\VBN|by (r_acl) seizures_21\NNS|induced
D003975_D012640 NONE diazepam_2\NN| (r_npadvmod) induced_4\VBN|diazepam|- (r_amod) anxiolysis_5\NN|induced (r_dobj) measured_1\VBD|we|anxiolysis|with|,|sedation|. (l_dobj) sedation_17\NN|induced|by (l_prep) by_18\IN|recording (l_pcomp) recording_19\VBG|states (l_dobj) states_22\NNS|the|vigilance|,|and|seizures (l_conj) seizures_30\NNS|picrotoxin-|after
D003975_D012640 NONE diazepam_14\NN| (r_npadvmod) induced_16\VBN|diazepam|- (r_amod) sedation_17\NN|induced|by (l_prep) by_18\IN|recording (l_pcomp) recording_19\VBG|states (l_dobj) states_22\NNS|the|vigilance|,|and|seizures (l_conj) seizures_30\NNS|picrotoxin-|after
D010852_D012640 CID picrotoxin-_25\NN|and|induced (r_amod) seizures_30\NNS|picrotoxin-|after
D010433_D012640 CID pentylenetetrazol_27\NN| (r_npadvmod) induced_29\VBN|pentylenetetrazol|- (r_conj) picrotoxin-_25\NN|and|induced (r_amod) seizures_30\NNS|picrotoxin-|after
20067456
D016642_D012735 NONE bupropion_5\NN|the|adjunctive|on (l_prep) on_6\IN|dysfunction (l_pobj) dysfunction_9\NN|male|sexual|induced
D016642_D012735 NONE bupropion_8\NN|adjunctive|sr|on (l_prep) on_15\IN|dysfunction (l_pobj) dysfunction_18\NN|male|sexual|(|sd|)
D016642_D012735 NONE bupropion_8\NN|adjunctive|sr|on (l_prep) on_15\IN|dysfunction (l_pobj) dysfunction_18\NN|male|sexual|(|sd|) (l_appos) SD_20\NN|
D016642_D012735 NONE bupropion_8\NN|adjunctive|sr|on (r_pobj) of_6\IN|bupropion (r_prep) safety_3\NN|the|and|efficacy|of (r_dobj) determine_1\VB|to|safety (r_csubj) induced_22\VBN|determine|by|,|is|. (l_advcl) is_35\VBZ|as|sd|effect|have (l_nsubj) SD_34\NN|
D016642_D012735 NONE Bupropion_0\NN| (r_nsubj) is_1\VBZ|bupropion|treatment|. (l_attr) treatment_4\NN|an|effective|for|induced (l_prep) for_5\IN|sd (l_pobj) SD_7\NN|male
D017367_D012735 NONE inhibitor_16\NN|a|selective|serotonin|reuptake|:|study (r_pobj) by_11\IN|inhibitor (r_agent) induced_10\VBN|by (r_acl) dysfunction_9\NN|male|sexual|induced
D017367_D012735 NONE inhibitor_28\NN|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN|inhibitor (r_agent) induced_22\VBN|determine|by|,|is|. (l_csubj) determine_1\VB|to|safety (l_dobj) safety_3\NN|the|and|efficacy|of (l_prep) of_6\IN|bupropion (l_pobj) bupropion_8\NN|adjunctive|sr|on (l_prep) on_15\IN|dysfunction (l_pobj) dysfunction_18\NN|male|sexual|(|sd|)
D017367_D012735 NONE inhibitor_28\NN|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN|inhibitor (r_agent) induced_22\VBN|determine|by|,|is|. (l_csubj) determine_1\VB|to|safety (l_dobj) safety_3\NN|the|and|efficacy|of (l_prep) of_6\IN|bupropion (l_pobj) bupropion_8\NN|adjunctive|sr|on (l_prep) on_15\IN|dysfunction (l_pobj) dysfunction_18\NN|male|sexual|(|sd|) (l_appos) SD_20\NN|
D017367_D012735 NONE inhibitor_28\NN|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN|inhibitor (r_agent) induced_22\VBN|determine|by|,|is|. (l_advcl) is_35\VBZ|as|sd|effect|have (l_nsubj) SD_34\NN|
D017367_D012735 NONE SSRI_30\NNP| (r_appos) inhibitor_28\NN|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN|inhibitor (r_agent) induced_22\VBN|determine|by|,|is|. (l_csubj) determine_1\VB|to|safety (l_dobj) safety_3\NN|the|and|efficacy|of (l_prep) of_6\IN|bupropion (l_pobj) bupropion_8\NN|adjunctive|sr|on (l_prep) on_15\IN|dysfunction (l_pobj) dysfunction_18\NN|male|sexual|(|sd|)
D017367_D012735 NONE SSRI_30\NNP| (r_appos) inhibitor_28\NN|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN|inhibitor (r_agent) induced_22\VBN|determine|by|,|is|. (l_csubj) determine_1\VB|to|safety (l_dobj) safety_3\NN|the|and|efficacy|of (l_prep) of_6\IN|bupropion (l_pobj) bupropion_8\NN|adjunctive|sr|on (l_prep) on_15\IN|dysfunction (l_pobj) dysfunction_18\NN|male|sexual|(|sd|) (l_appos) SD_20\NN|
D017367_D012735 NONE SSRI_30\NNP| (r_appos) inhibitor_28\NN|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN|inhibitor (r_agent) induced_22\VBN|determine|by|,|is|. (l_advcl) is_35\VBZ|as|sd|effect|have (l_nsubj) SD_34\NN|
D017367_D012735 NONE SSRIs_42\NNS|and|treatments (r_pobj) of_41\IN|ssris (r_prep) effect_40\NN|a|common|side|-|of (r_attr) is_35\VBZ|as|sd|effect|have (r_advcl) induced_22\VBN|determine|by|,|is|. (l_csubj) determine_1\VB|to|safety (l_dobj) safety_3\NN|the|and|efficacy|of (l_prep) of_6\IN|bupropion (l_pobj) bupropion_8\NN|adjunctive|sr|on (l_prep) on_15\IN|dysfunction (l_pobj) dysfunction_18\NN|male|sexual|(|sd|)
D017367_D012735 NONE SSRIs_42\NNS|and|treatments (r_pobj) of_41\IN|ssris (r_prep) effect_40\NN|a|common|side|-|of (r_attr) is_35\VBZ|as|sd|effect|have (r_advcl) induced_22\VBN|determine|by|,|is|. (l_csubj) determine_1\VB|to|safety (l_dobj) safety_3\NN|the|and|efficacy|of (l_prep) of_6\IN|bupropion (l_pobj) bupropion_8\NN|adjunctive|sr|on (l_prep) on_15\IN|dysfunction (l_pobj) dysfunction_18\NN|male|sexual|(|sd|) (l_appos) SD_20\NN|
D017367_D012735 NONE SSRIs_42\NNS|and|treatments (r_pobj) of_41\IN|ssris (r_prep) effect_40\NN|a|common|side|-|of (r_attr) is_35\VBZ|as|sd|effect|have (l_nsubj) SD_34\NN|
D017367_D012735 NONE SSRI_21\NNP| (r_pobj) of_20\IN|ssri (r_prep) type_19\NN|of (r_appos) SD_17\NN|,|type
D017367_D012735 NONE SSRIs_10\NNS| (r_pobj) by_9\IN|ssris (r_agent) induced_8\VBN|by (r_acl) treatment_4\NN|an|effective|for|induced (l_prep) for_5\IN|sd (l_pobj) SD_7\NN|male
2632720
D007654_D006973 CID ketoconazole_7\JJ| (r_compound) treatment_8\NN|prolonged|ketoconazole (r_pobj) of_5\IN|treatment (r_prep) complication_4\NN|a|of (r_pobj) as_2\IN|complication (r_prep) hypertension_1\NN|arterial|as|.
D007654_D006973 CID ketoconazole_16\JJ| (r_pobj) with_15\IN|ketoconazole (r_prep) basis_14\NN|a|term|with (r_pobj) on_9\IN|basis (r_prep) treated_8\VBN|patients|on|developed|. (l_advcl) developed_17\VBN|hypertension (l_dobj) hypertension_19\NN|sustained
D007654_D006973 CID ketoconazole_14\JJ| (r_compound) therapy_15\NN|ketoconazole|,|yet|monitoring (r_dobj) following_13\VBG|therapy (r_prep) achieved_12\VBN|in|levels|had|been|following|demonstrated|. (l_conj) demonstrated_22\VBD|hypertension (l_dobj) hypertension_23\NN|31|patient
D007654_D006973 CID ketoconazole_12\NN| (r_pobj) of_11\IN|ketoconazole (r_prep) doses_10\NNS|high|of (r_pobj) with_8\IN|doses (r_prep) treatment_7\NN|term|with (r_nsubj) induce_14\VB|that|treatment|may|blockade (l_dobj) blockade_16\NN|enzyme|leading (l_acl) leading_17\VBG|to (l_prep) to_18\IN|hypertension (l_pobj) hypertension_22\NN|related
D007654_D003480 NONE ketoconazole_16\JJ| (r_pobj) with_15\IN|ketoconazole (r_prep) basis_14\NN|a|term|with (r_pobj) on_9\IN|basis (r_prep) treated_8\VBN|patients|on|developed|. (l_nsubj) patients_3\NNS|14|with (l_prep) with_4\IN|syndrome (l_pobj) syndrome_7\NN|cushing
D006854_D006973 NONE cortisol_8\NN|free (r_compound) levels_9\NNS|plasma|urinary|cortisol (r_nsubjpass) achieved_12\VBN|in|levels|had|been|following|demonstrated|. (l_conj) demonstrated_22\VBD|hypertension (l_dobj) hypertension_23\NN|31|patient
1664218
D000677_D002289 NONE amsacrine_5\NN| (r_compound) analogue_6\NN|the|amsacrine (r_pobj) of_3\IN|analogue (r_prep) study_2\NN|ii|of|nsc|in|. (l_prep) in_12\IN|cancer (l_pobj) cancer_18\NN|small|lung
C042315_D002289 NONE CI-921_7\NNP| (r_punct) (_8\-LRB-|ci-921 (r_punct) NSC_9\NNP|(|343499|) (r_appos) study_2\NN|ii|of|nsc|in|. (l_prep) in_12\IN|cancer (l_pobj) cancer_18\NN|small|lung
C042315_D002289 NONE 343499_10\CD| (r_nummod) NSC_9\NNP|(|343499|) (r_appos) study_2\NN|ii|of|nsc|in|. (l_prep) in_12\IN|cancer (l_pobj) cancer_18\NN|small|lung
6386793
D004308_D003866 NONE hydrochloride_12\NN|dothiepin (r_pobj) of_10\IN|hydrochloride (r_prep) efficacy_7\NN|the|and|safety|of (r_pobj) of_5\IN|efficacy (r_prep) study_4\NN|a|blind|of|in|. (l_prep) in_13\IN|treatment (l_pobj) treatment_15\NN|the|of (l_prep) of_16\IN|disorder (l_pobj) disorder_19\NN|major|depressive
D004308_D003866 NONE dothiepin_10\JJ|and|amitriptyline (r_nsubjpass) compared_14\VBN|in|,|dothiepin|were|to|. (l_prep) to_15\IN|placebo (l_pobj) placebo_16\NN|in (l_prep) in_17\IN|treatment (l_pobj) treatment_19\NN|the|of (l_prep) of_20\IN|outpatients (l_pobj) outpatients_23\NNS|33|depressed (l_amod) depressed_22\JJ|
D004308_D003866 NONE Dothiepin_0\JJ|and|amitriptyline (r_nsubj) were_3\VBD|dothiepin|effective|,|and|were (l_acomp) effective_5\JJ|equally|in (l_prep) in_6\IN|alleviating (l_pcomp) alleviating_7\VBG|symptoms (l_dobj) symptoms_9\NNS|the|of (l_prep) of_10\IN|illness (l_pobj) illness_12\NN|depressive
D004308_D003866 NONE Dothiepin_0\NNP| (r_nsubjpass) found_3\VBN|dothiepin|thus|was|be|. (l_xcomp) be_5\VB|to|drug (l_attr) drug_9\NN|an|effective|antidepressant|associated (l_acl) associated_10\VBN|with (l_prep) with_11\IN|effects (l_pobj) effects_14\NNS|fewer|side|than (l_prep) than_15\IN|amitriptyline (l_pobj) amitriptyline_16\NN|in (l_prep) in_17\IN|treatment (l_pobj) treatment_19\NN|the|of (l_prep) of_20\IN|outpatients (l_pobj) outpatients_22\NNS|depressed (l_amod) depressed_21\JJ|
D000639_D003866 NONE amitriptyline_12\NN| (r_conj) dothiepin_10\JJ|and|amitriptyline (r_nsubjpass) compared_14\VBN|in|,|dothiepin|were|to|. (l_prep) to_15\IN|placebo (l_pobj) placebo_16\NN|in (l_prep) in_17\IN|treatment (l_pobj) treatment_19\NN|the|of (l_prep) of_20\IN|outpatients (l_pobj) outpatients_23\NNS|33|depressed (l_amod) depressed_22\JJ|
D000639_D003866 NONE amitriptyline_2\NN| (r_conj) Dothiepin_0\JJ|and|amitriptyline (r_nsubj) were_3\VBD|dothiepin|effective|,|and|were (l_acomp) effective_5\JJ|equally|in (l_prep) in_6\IN|alleviating (l_pcomp) alleviating_7\VBG|symptoms (l_dobj) symptoms_9\NNS|the|of (l_prep) of_10\IN|illness (l_pobj) illness_12\NN|depressive
D000639_D003866 NONE amitriptyline_16\NN|in (l_prep) in_17\IN|treatment (l_pobj) treatment_19\NN|the|of (l_prep) of_20\IN|outpatients (l_pobj) outpatients_22\NNS|depressed (l_amod) depressed_21\JJ|
D004308_D014786 NONE dothiepin_24\JJ| (r_pobj) with_23\IN|dothiepin (r_prep) less_22\JJR|significantly|with|than (r_acomp) were_20\VBD|incidence|less|. (l_nsubj) incidence_2\NN|the|overall|of (l_prep) of_3\IN|effects (l_pobj) effects_5\NNS|side|and|frequency (l_conj) frequency_8\NN|the|and|severity|of (l_prep) of_11\IN|vision (l_pobj) vision_13\NN|blurred|,|mouth
D004308_D014987 NONE dothiepin_24\JJ| (r_pobj) with_23\IN|dothiepin (r_prep) less_22\JJR|significantly|with|than (r_acomp) were_20\VBD|incidence|less|. (l_nsubj) incidence_2\NN|the|overall|of (l_prep) of_3\IN|effects (l_pobj) effects_5\NNS|side|and|frequency (l_conj) frequency_8\NN|the|and|severity|of (l_prep) of_11\IN|vision (l_pobj) vision_13\NN|blurred|,|mouth (l_conj) mouth_16\NN|dry|,|and|drowsiness
D000639_D014786 CID amitriptyline_27\NN| (r_pobj) with_26\IN|amitriptyline (r_prep) than_25\IN|with (r_prep) less_22\JJR|significantly|with|than (r_acomp) were_20\VBD|incidence|less|. (l_nsubj) incidence_2\NN|the|overall|of (l_prep) of_3\IN|effects (l_pobj) effects_5\NNS|side|and|frequency (l_conj) frequency_8\NN|the|and|severity|of (l_prep) of_11\IN|vision (l_pobj) vision_13\NN|blurred|,|mouth
D000639_D014987 CID amitriptyline_27\NN| (r_pobj) with_26\IN|amitriptyline (r_prep) than_25\IN|with (r_prep) less_22\JJR|significantly|with|than (r_acomp) were_20\VBD|incidence|less|. (l_nsubj) incidence_2\NN|the|overall|of (l_prep) of_3\IN|effects (l_pobj) effects_5\NNS|side|and|frequency (l_conj) frequency_8\NN|the|and|severity|of (l_prep) of_11\IN|vision (l_pobj) vision_13\NN|blurred|,|mouth (l_conj) mouth_16\NN|dry|,|and|drowsiness
D000928_D003866 NONE antidepressant_8\NN| (r_amod) drug_9\NN|an|effective|antidepressant|associated (l_acl) associated_10\VBN|with (l_prep) with_11\IN|effects (l_pobj) effects_14\NNS|fewer|side|than (l_prep) than_15\IN|amitriptyline (l_pobj) amitriptyline_16\NN|in (l_prep) in_17\IN|treatment (l_pobj) treatment_19\NN|the|of (l_prep) of_20\IN|outpatients (l_pobj) outpatients_22\NNS|depressed (l_amod) depressed_21\JJ|
6103707
D005445_D010146 CID flunitrazepam_7\NN| (r_pobj) of_6\IN|flunitrazepam (r_prep) injection_5\NN|i.m.|of (r_pobj) on_3\IN|injection (r_prep) pain_2\NN|on
17244258
D003520_D003556 CID cyclophosphamide_9\NN| (r_npadvmod) induced_11\VBN|cyclophosphamide|- (r_amod) cystitis_12\NN|induced|in
D003520_D003556 CID cyclophosphamide_1\NN| (r_npadvmod) induced_3\VBN|cyclophosphamide|- (r_amod) cystitis_4\NN|induced|in
3173179
D014700_D009203 CID Verapamil_0\NNP| (r_compound) withdrawal_1\NN|verapamil|as|. (l_prep) as_2\IN|cause (l_pobj) cause_5\NN|a|possible|of (l_prep) of_6\IN|infarction (l_pobj) infarction_8\NN|myocardial|in|with
D014700_D009203 CID verapamil_18\NN| (r_pobj) of_17\IN|verapamil (r_prep) withdrawal_16\NN|the|of|in (r_conj) introduction_11\NN|the|of|and|withdrawal (r_pobj) with_9\IN|introduction (r_prep) coincided_8\VBD|in|infarction|with (l_nsubj) infarction_7\NN|myocardial
D014700_D006973 NONE Verapamil_0\NNP| (r_compound) withdrawal_1\NN|verapamil|as|. (l_prep) as_2\IN|cause (l_pobj) cause_5\NN|a|possible|of (l_prep) of_6\IN|infarction (l_pobj) infarction_8\NN|myocardial|in|with (l_prep) in_9\IN|woman (l_pobj) woman_12\NN|a|hypertensive (l_amod) hypertensive_11\JJ|
D014700_D006973 NONE verapamil_18\NN| (r_pobj) of_17\IN|verapamil (r_prep) withdrawal_16\NN|the|of|in (l_prep) in_19\IN|woman (l_pobj) woman_23\NN|a|asymptomatic|with (l_prep) with_24\IN|hypertension (l_pobj) hypertension_26\NN|severe
D002216_D009203 NONE captopril_13\NN| (r_pobj) of_12\IN|captopril (r_prep) introduction_11\NN|the|of|and|withdrawal (r_pobj) with_9\IN|introduction (r_prep) coincided_8\VBD|in|infarction|with (l_nsubj) infarction_7\NN|myocardial
D002216_D006973 NONE captopril_13\NN| (r_pobj) of_12\IN|captopril (r_prep) introduction_11\NN|the|of|and|withdrawal (l_conj) withdrawal_16\NN|the|of|in (l_prep) in_19\IN|woman (l_pobj) woman_23\NN|a|asymptomatic|with (l_prep) with_24\IN|hypertension (l_pobj) hypertension_26\NN|severe
8170551
D000086_D053040 NONE Acetazolamide_0\RB| (r_npadvmod) induced_2\VBN|acetazolamide|- (r_amod) nephrolithiasis_3\NN|induced|:|implications|.
D000086_D053040 NONE acetazolamide_5\NN| (r_pobj) of_4\IN|acetazolamide (r_prep) complication_3\NN|a|of (r_attr) is_1\VBZ|nephrolithiasis|complication|but|preclude|. (l_nsubj) Nephrolithiasis_0\NNP|
D000086_D009468 NONE Acetazolamide_0\RB| (r_npadvmod) induced_2\VBN|acetazolamide|- (r_amod) nephrolithiasis_3\NN|induced|:|implications|. (l_appos) implications_5\NNS|for (l_prep) for_6\IN|treatment (l_pobj) treatment_7\NN|of (l_prep) of_8\IN|disorders (l_pobj) disorders_10\NNS|neuromuscular
D000086_D007669 CID acetazolamide_3\NN|% (r_pobj) on_2\IN|acetazolamide (r_prep) patients_1\NNS|three|on (r_nsubj) developed_8\VBN|patients|calculi|. (l_dobj) calculi_10\NNS|renal
19759529
D004298_D012559 NONE dopamine_8\NN| (r_compound) neurotransmission_9\NN|dopamine (r_pobj) in_7\IN|neurotransmission (r_prep) dysfunction_6\NN|in (r_pobj) with_5\IN|dysfunction (r_prep) associated_4\VBN|schizophrenia|has|been|initially|with|. (l_nsubjpass) Schizophrenia_0\NNP|
D018698_D012559 NONE glutamate_8\NN| (r_nmod) receptor_19\NN|the|glutamate|methyl|(|nmda|) (r_pobj) of_6\IN|receptor (r_prep) antagonists_5\NNS|of (r_nsubj) produce_20\VBP|that|antagonists|symptoms (l_dobj) symptoms_24\NNS|like|in (l_amod) like_23\JJ|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ|
D016202_D012559 NONE aspartate_15\NNP|d|- (r_appos) methyl_11\NN|n|-|aspartate (r_nmod) receptor_19\NN|the|glutamate|methyl|(|nmda|) (r_pobj) of_6\IN|receptor (r_prep) antagonists_5\NNS|of (r_nsubj) produce_20\VBP|that|antagonists|symptoms (l_dobj) symptoms_24\NNS|like|in (l_amod) like_23\JJ|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ|
D016202_D012559 NONE NMDA_17\NNP| (r_nmod) receptor_19\NN|the|glutamate|methyl|(|nmda|) (r_pobj) of_6\IN|receptor (r_prep) antagonists_5\NNS|of (r_nsubj) produce_20\VBP|that|antagonists|symptoms (l_dobj) symptoms_24\NNS|like|in (l_amod) like_23\JJ|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ|
D016202_D012559 NONE NMDA_41\NNP| (r_compound) receptor_42\NN|its|nmda (r_pobj) via_39\IN|receptor (r_prep) dysfunctioning_34\NN|a|of|via (r_pobj) of_32\IN|dysfunctioning (r_prep) idea_31\NN|the|of (r_pobj) to_29\IN|idea (r_prep) led_28\VBN|however|,|observation|has|to|. (l_nsubj) observation_3\NN|the|produce (l_relcl) produce_20\VBP|that|antagonists|symptoms (l_dobj) symptoms_24\NNS|like|in (l_amod) like_23\JJ|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ|
-1_D006948 NONE SSR103800_12\NNP| (r_pobj) of_11\IN|ssr103800 (r_prep) properties_10\NNS|the|potential|like|of|involving (r_dobj) investigating_4\VBG|properties|,|with (l_prep) with_14\IN|focus (l_pobj) focus_17\NN|a|particular|on|, (l_prep) on_18\IN|models (l_pobj) models_19\NNS|of (l_prep) of_20\IN|hyperactivity (l_pobj) hyperactivity_21\NN|
-1_D006948 NONE SSR103800_3\NNP| (r_nmod) hyperactivity_12\NN|ssr103800|(|mg/kg|p.o.|)|blocked|induced
-1_D006948 NONE SSR103800_3\NNP| (r_nmod) hyperactivity_12\NN|ssr103800|(|mg/kg|p.o.|)|blocked|induced (r_punct) that_2\IN|hyperactivity (r_dobj) showed_1\VBD|results|that|and|reversed|. (l_conj) reversed_26\VBD|partially|hyperactivity (l_dobj) hyperactivity_28\NN|spontaneous|of
-1_D006948 NONE SSR103800_3\NNP| (r_nsubj) failed_4\VBD|in|,|ssr103800|affect|or|observed|) (l_xcomp) affect_6\VB|to|hyperactivity (l_dobj) hyperactivity_7\NN|induced
D000661_D006948 CID amphetamine_30\NN|(|ie|,|and|) (r_appos) challenge_26\NN|either|drug|amphetamine|or|mice (r_dobj) involving_23\VBG|challenge (r_prep) properties_10\NNS|the|potential|like|of|involving (r_dobj) investigating_4\VBG|properties|,|with (l_prep) with_14\IN|focus (l_pobj) focus_17\NN|a|particular|on|, (l_prep) on_18\IN|models (l_pobj) models_19\NNS|of (l_prep) of_20\IN|hyperactivity (l_pobj) hyperactivity_21\NN|
D000661_D006948 CID amphetamine_10\NN| (r_pobj) by_9\IN|amphetamine (r_agent) induced_8\VBN|by (r_acl) hyperactivity_7\NN|induced
D016291_D006948 CID MK-801_32\NNP| (r_punct) )_33\-RRB-|mk-801 (r_punct) amphetamine_30\NN|(|ie|,|and|) (r_appos) challenge_26\NN|either|drug|amphetamine|or|mice (r_dobj) involving_23\VBG|challenge (r_prep) properties_10\NNS|the|potential|like|of|involving (r_dobj) investigating_4\VBG|properties|,|with (l_prep) with_14\IN|focus (l_pobj) focus_17\NN|a|particular|on|, (l_prep) on_18\IN|models (l_pobj) models_19\NNS|of (l_prep) of_20\IN|hyperactivity (l_pobj) hyperactivity_21\NN|
D016291_D006948 CID MK-801_23\NNP| (r_punct) and_24\CC|mk-801 (r_cc) showed_1\VBD|results|that|and|reversed|. (l_dobj) that_2\IN|hyperactivity (l_punct) hyperactivity_12\NN|ssr103800|(|mg/kg|p.o.|)|blocked|induced
D016291_D006948 CID MK-801_23\NNP| (r_punct) and_24\CC|mk-801 (r_cc) showed_1\VBD|results|that|and|reversed|. (l_conj) reversed_26\VBD|partially|hyperactivity (l_dobj) hyperactivity_28\NN|spontaneous|of
D016202_D006948 NONE NMDA_40\NNP| (r_compound) Nr1(neo-/-_41\NNP|(|ie|,|nmda|)|and|dat(-/- (r_appos) mice_36\NNS|transgenic|nr1(neo-/-|) (r_conj) challenge_26\NN|either|drug|amphetamine|or|mice (r_dobj) involving_23\VBG|challenge (r_prep) properties_10\NNS|the|potential|like|of|involving (r_dobj) investigating_4\VBG|properties|,|with (l_prep) with_14\IN|focus (l_pobj) focus_17\NN|a|particular|on|, (l_prep) on_18\IN|models (l_pobj) models_19\NNS|of (l_prep) of_20\IN|hyperactivity (l_pobj) hyperactivity_21\NN|
D016202_D006948 NONE NMDA_19\NNP| (r_compound) antagonist_21\NN|the|competitive|nmda|receptor|, (r_pobj) by_14\IN|antagonist (r_agent) induced_13\VBN|by (r_acl) hyperactivity_12\NN|ssr103800|(|mg/kg|p.o.|)|blocked|induced
D016202_D006948 NONE NMDA_19\NNP| (r_compound) antagonist_21\NN|the|competitive|nmda|receptor|, (r_pobj) by_14\IN|antagonist (r_agent) induced_13\VBN|by (r_acl) hyperactivity_12\NN|ssr103800|(|mg/kg|p.o.|)|blocked|induced (r_punct) that_2\IN|hyperactivity (r_dobj) showed_1\VBD|results|that|and|reversed|. (l_conj) reversed_26\VBD|partially|hyperactivity (l_dobj) hyperactivity_28\NN|spontaneous|of
D016202_D006948 NONE NMDA_30\NNP| (r_nmod) mice_33\NNS|nmda|nr1(neo-/-|) (r_pobj) of_29\IN|mice (r_prep) hyperactivity_28\NN|spontaneous|of (r_dobj) reversed_26\VBD|partially|hyperactivity (r_conj) showed_1\VBD|results|that|and|reversed|. (l_dobj) that_2\IN|hyperactivity (l_punct) hyperactivity_12\NN|ssr103800|(|mg/kg|p.o.|)|blocked|induced
D016202_D006948 NONE NMDA_30\NNP| (r_nmod) mice_33\NNS|nmda|nr1(neo-/-|) (r_pobj) of_29\IN|mice (r_prep) hyperactivity_28\NN|spontaneous|of
D004298_D006948 NONE dopamine_15\NN| (r_compound) transporter_16\NN|dopamine|(|dat(-/-|) (r_pobj) in_14\IN|transporter (r_prep) observed_13\VBN|naturally|in (r_conj) failed_4\VBD|in|,|ssr103800|affect|or|observed|) (l_xcomp) affect_6\VB|to|hyperactivity (l_dobj) hyperactivity_7\NN|induced
D006220_D006948 NONE haloperidol_5\NN|importantly|,|both|classical|(|)|and|atypical (r_nmod) antipsychotics_16\NNS|haloperidol|clozapine (r_nsubj) were_17\VBD|antipsychotics|effective|. (l_acomp) effective_18\JJ|in (l_prep) in_19\IN|models (l_pobj) models_22\NNS|all|these|of (l_prep) of_23\IN|hyperactivity (l_pobj) hyperactivity_24\NN|
C076029_D006948 NONE olanzapine_10\NN| (r_nmod) clozapine_12\NN|(|olanzapine|,|and|aripiprazole|) (r_nmod) antipsychotics_16\NNS|haloperidol|clozapine (r_nsubj) were_17\VBD|antipsychotics|effective|. (l_acomp) effective_18\JJ|in (l_prep) in_19\IN|models (l_pobj) models_22\NNS|all|these|of (l_prep) of_23\IN|hyperactivity (l_pobj) hyperactivity_24\NN|
D003024_D006948 NONE clozapine_12\NN|(|olanzapine|,|and|aripiprazole|) (r_nmod) antipsychotics_16\NNS|haloperidol|clozapine (r_nsubj) were_17\VBD|antipsychotics|effective|. (l_acomp) effective_18\JJ|in (l_prep) in_19\IN|models (l_pobj) models_22\NNS|all|these|of (l_prep) of_23\IN|hyperactivity (l_pobj) hyperactivity_24\NN|
C094645_D006948 NONE aripiprazole_14\NN| (r_conj) clozapine_12\NN|(|olanzapine|,|and|aripiprazole|) (r_nmod) antipsychotics_16\NNS|haloperidol|clozapine (r_nsubj) were_17\VBD|antipsychotics|effective|. (l_acomp) effective_18\JJ|in (l_prep) in_19\IN|models (l_pobj) models_22\NNS|all|these|of (l_prep) of_23\IN|hyperactivity (l_pobj) hyperactivity_24\NN|
-1_D002375 NONE SSR103800_6\NNP| (r_nsubj) produce_9\VB|however|,|unlike|,|ssr103800|did|not|catalepsy|retention|up|together (l_dobj) catalepsy_10\NN|
9653867
D013974_D013971 CID Thyroxine_0\NNP| (r_compound) abuse_1\NN|thyroxine|:|case|. (l_appos) case_5\NN|an|unusual|of (l_prep) of_6\IN|thyrotoxicosis (l_pobj) thyrotoxicosis_7\NN|in
D013974_D013971 CID thyroxine_28\NN| (r_compound) abuse_29\NN|thyroxine (r_nsubjpass) considered_32\VBN|that|remains|,|abuse|should|be|and|explored (l_advcl) remains_25\VBZ|when|cause|obscure (l_nsubj) cause_22\NN|a|for (l_prep) for_23\IN|thyrotoxicosis (l_pobj) thyrotoxicosis_24\NN|
D013974_D001068 NONE thyroxine_28\NN| (r_compound) abuse_29\NN|thyroxine (r_nsubjpass) considered_32\VBN|that|remains|,|abuse|should|be|and|explored (r_ccomp) reminds_17\VBZ|us|considered (r_conj) illustrates_3\VBZ|in|it|derangements|and|reminds|. (l_dobj) derangements_5\NNS|the|of (l_prep) of_6\IN|function (l_pobj) function_8\NN|thyroid|seen (l_acl) seen_9\VBN|in|with (l_prep) with_13\IN|eating (l_pcomp) eating_14\VBG|disorders (l_dobj) disorders_15\NNS|
10807237
D003042_D000783 NONE cocaine_12\NN| (r_npadvmod) related_14\VBN|cocaine|- (r_amod) aneurysms_15\NNS|related
D003042_D000783 NONE cocaine_25\NN| (r_npadvmod) related_27\VBN|cocaine|- (r_amod) aneurysms_28\NNS|related
D003042_D000783 NONE Cocaine_0\NN| (r_compound) use_1\NN|cocaine (r_nsubj) predisposed_2\VBN|use|rupture|at|. (l_prep) at_5\IN|age|and|in (l_conj) in_11\IN|aneurysms (l_pobj) aneurysms_14\NNS|smaller
D003042_D017542 CID Cocaine_0\NN| (r_compound) use_1\NN|cocaine (r_nsubj) predisposed_2\VBN|use|rupture|at|. (l_dobj) rupture_4\NN|aneurysmal
7269015
D002066_D006470 CID Busulfan_0\NNS| (r_npadvmod) induced_2\VBN|busulfan|- (r_amod) cystitis_4\NN|induced|hemorrhagic|.
D002066_D006470 CID busulfan_4\NNS| (r_npadvmod) induced_6\VBN|busulfan|- (r_amod) cystitis_8\NN|a|induced|hemorrhage
D002066_D003556 CID Busulfan_0\NNS| (r_npadvmod) induced_2\VBN|busulfan|- (r_amod) cystitis_4\NN|induced|hemorrhagic|.
D002066_D003556 CID busulfan_4\NNS| (r_npadvmod) induced_6\VBN|busulfan|- (r_amod) cystitis_8\NN|a|induced|hemorrhage
D002066_D003556 CID busulfan_7\NNS| (r_amod) cystitis_8\NN|busulfan|and|cystitis
D002066_D003556 CID busulfan_7\NNS| (r_amod) cystitis_8\NN|busulfan|and|cystitis (l_conj) cystitis_16\NN|radiation
D003520_D003556 NONE cyclophosphamide_13\NN| (r_npadvmod) induced_15\VBN|cyclophosphamide|- (r_conj) radiation_11\NN|both|and|induced (r_nmod) cystitis_16\NN|radiation (r_conj) cystitis_8\NN|busulfan|and|cystitis
D003520_D003556 NONE cyclophosphamide_13\NN| (r_npadvmod) induced_15\VBN|cyclophosphamide|- (r_conj) radiation_11\NN|both|and|induced (r_nmod) cystitis_16\NN|radiation
D002066_D002277 NONE busulfan_7\NNS| (r_pobj) of_6\IN|busulfan (r_prep) tendency_5\NN|the|known|of (r_pobj) of_2\IN|tendency (r_prep) view_1\NN|of (r_pobj) In_0\IN|view|induce (l_advcl) induce_9\VB|to|atypia (l_dobj) atypia_11\NN|cellular|and|carcinoma|in (l_conj) carcinoma_13\NN|
15737522
D002443_D001660 CID Ceftriaxone_0\NN| (r_npadvmod) associated_2\VBN|ceftriaxone|- (r_amod) pseudolithiasis_4\NN|associated|biliary|in|.
D002443_D001660 CID ceftriaxone_5\NN| (r_nsubj) leads_6\VBZ|that|ceftriaxone|pseudolithiasis (l_xcomp) pseudolithiasis_8\NN|to|in
D002443_D001660 CID ceftriaxone_19\CD| (r_compound) treatment_20\NN|ceftriaxone|,|had (r_dobj) receiving_18\VBG|treatment (r_acl) patients_17\NNS|paediatric|surgical|receiving (r_pobj) in_14\IN|patients (r_prep) pseudolithiasis_13\NN|in
11587867
D014750_D001927 NONE vincristin_6\NN| (r_compound) administration_7\NN|accidental|intrathecal|vincristin|:|report (r_pobj) due_2\IN|to|administration (r_prep) myeloencephalopathy_1\NN|fatal|due|.
D014750_D054198 NONE vincristine_9\NN| (r_compound) instillation_10\NN|accidental|intrathecal|vincristine|in (l_prep) in_11\IN|girl (l_pobj) girl_15\NN|a|5-year|old|with (l_prep) with_16\IN|leucemia (l_pobj) leucemia_20\NN|recurrent|acute|lymphoblastic|and|man
D014750_D054198 NONE vincristine_9\NN| (r_compound) instillation_10\NN|accidental|intrathecal|vincristine|in (l_prep) in_11\IN|girl (l_pobj) girl_15\NN|a|5-year|old|with (l_prep) with_16\IN|leucemia (l_pobj) leucemia_20\NN|recurrent|acute|lymphoblastic|and|man (l_conj) man_25\NN|a|57-year|old|with (l_prep) with_26\IN|lymphoma (l_pobj) lymphoma_28\NN|lymphoblastic
D014750_D003711 CID vincristine_28\NN| (r_pobj) to_27\IN|vincristine (r_prep) exposed_26\VBN|to (r_acl) areas_25\NNS|exposed (r_pobj) in_24\IN|areas (r_prep) transformation_23\NN|pseudocystic|in|,|accompanied (r_conj) degeneration_14\NN|of|as|transformation (l_prep) of_15\IN|myelin (l_pobj) myelin_16\NN|and|axons (l_conj) axons_18\NNS|
D014750_D009410 CID vincristine_28\NN| (r_pobj) to_27\IN|vincristine (r_prep) exposed_26\VBN|to (r_acl) areas_25\NNS|exposed (r_pobj) in_24\IN|areas (r_prep) transformation_23\NN|pseudocystic|in|,|accompanied (r_conj) degeneration_14\NN|of|as|transformation (l_prep) of_15\IN|myelin (l_pobj) myelin_16\NN|and|axons (l_conj) axons_18\NNS|
D014750_-1 NONE vincristine_28\NN| (r_pobj) to_27\IN|vincristine (r_prep) exposed_26\VBN|to (r_acl) areas_25\NNS|exposed (r_pobj) in_24\IN|areas (r_prep) transformation_23\NN|pseudocystic|in|,|accompanied
3031535
D013759_D002375 CID 9-tetrahydrocannabinol_7\NN|delta (r_pobj) by_5\IN|9-tetrahydrocannabinol (r_agent) induced_4\VBN|involvement|by|. (l_nsubj) involvement_1\NN|noradrenergic|in (l_prep) in_2\IN|catalepsy (l_pobj) catalepsy_3\NN|
D013759_D002375 CID THC_17\NNP| (r_pobj) by_16\IN|thc (r_agent) induced_15\VBN|by (r_acl) manifestation_12\NN|the|of|induced (l_prep) of_13\IN|catalepsy (l_pobj) catalepsy_14\NN|
D013759_D002375 CID THC_17\NNP| (r_pobj) by_16\IN|thc (r_agent) induced_15\VBN|by (r_acl) manifestation_12\NN|the|of|induced (r_pobj) in_10\IN|manifestation (r_prep) role_9\NN|an|important|in (r_dobj) have_6\VBP|that|neurons|role|,|are (l_advcl) are_22\VBP|whereas|neurons|important|in|induced (l_prep) in_24\IN|catalepsy (l_pobj) catalepsy_25\NN|
D006220_D002375 CID haloperidol_28\NN| (r_pobj) by_27\IN|haloperidol (r_agent) induced_26\VBN|by (r_advcl) are_22\VBP|whereas|neurons|important|in|induced (r_advcl) have_6\VBP|that|neurons|role|,|are (l_dobj) role_9\NN|an|important|in (l_prep) in_10\IN|manifestation (l_pobj) manifestation_12\NN|the|of|induced (l_prep) of_13\IN|catalepsy (l_pobj) catalepsy_14\NN|
D006220_D002375 CID haloperidol_28\NN| (r_pobj) by_27\IN|haloperidol (r_agent) induced_26\VBN|by (r_advcl) are_22\VBP|whereas|neurons|important|in|induced (l_prep) in_24\IN|catalepsy (l_pobj) catalepsy_25\NN|
8682684
D000082_D007022 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|acetaminophen|- (r_amod) hypotension_3\NN|induced|.
D000082_D007022 CID acetaminophen_2\RB| (r_nsubjpass) demonstrated_5\VBN|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB|to|symptoms (l_dobj) symptoms_8\NNS|of|,|including|,|in (l_prep) including_12\VBG|hypotension (l_pobj) hypotension_13\NN|
D000082_D007022 CID acetaminophen_18\NN| (r_pobj) of_17\IN|acetaminophen (r_prep) administration_16\NN|of (r_pobj) after_15\IN|administration (r_prep) developed_14\VBN|in|episodes|reproducibly|after (l_nsubj) episodes_10\NNS|transient|of (l_prep) of_11\IN|hypotension (l_pobj) hypotension_12\NN|
D000082_D007022 CID acetaminophen_9\NN| (r_dobj) consider_8\VB|for|clinicians|to|acetaminophen|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|hypotension (l_pobj) hypotension_13\NN|of
D000082_D002318 NONE acetaminophen_3\NN| (r_pobj) for_2\IN|acetaminophen (r_prep) potential_1\NN|the|for|produce (l_acl) produce_5\VB|to|toxicities (l_dobj) toxicities_7\NNS|cardiovascular
D000082_D000707 NONE acetaminophen_2\RB| (r_nsubjpass) demonstrated_5\VBN|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB|to|symptoms (l_dobj) symptoms_8\NNS|of|,|including|,|in (l_prep) of_9\IN|anaphylaxis (l_pobj) anaphylaxis_10\NN|
D000082_D016638 NONE acetaminophen_18\NN| (r_pobj) of_17\IN|acetaminophen (r_prep) administration_16\NN|of (r_pobj) after_15\IN|administration (r_prep) developed_14\VBN|in|episodes|reproducibly|after (r_relcl) patients_6\NNS|two|ill|developed (l_amod) ill_5\JJ|critically
1616457
D010424_D000647 CID pentobarbital_7\NN| (r_pobj) by_6\IN|pentobarbital (r_agent) caused_5\VBN|by (r_acl) amnesia_4\NN|caused
D010424_D000647 CID pentobarbital_15\NN| (r_nmod) ip_20\NNP|pentobarbital|(|mg/kg|, (r_pobj) by_14\IN|ip (r_agent) produced_13\VBN|by (r_acl) amnesia_12\NN|produced
15863244
C106876_D064420 NONE DFU_17\NNP|and|study (r_appos) inhibitors_11\NNS|selective|cyclooxygenase-2|in|--|dfu (r_pobj) of_4\IN|inhibitors (r_prep) toxicity_3\NN|developmental|of
C106876_D064420 NONE DFU_22\NNP|selective|( (r_conj) toxicity_10\NN|the|developmental|of|dfu
C106876_D064420 NONE phenyl-2(5H)-furanon_26\XX|was|;|5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl|)|) (l_ccomp) was_5\VBD|aim|evaluate (l_xcomp) evaluate_7\VB|to|toxicity (l_dobj) toxicity_10\NN|the|developmental|of|dfu
C106876_D064420 NONE DFU_10\NNP| (r_nmod) toxicity_12\NN|the|dfu|developmental|observed
D010894_D064420 NONE piroxicam_19\NN| (r_compound) study_20\NN|piroxicam (r_conj) DFU_17\NNP|and|study (r_appos) inhibitors_11\NNS|selective|cyclooxygenase-2|in|--|dfu (r_pobj) of_4\IN|inhibitors (r_prep) toxicity_3\NN|developmental|of
D010894_D064420 NONE piroxicam_17\NN|the|selective|(|)|and (r_pobj) of_11\IN|piroxicam (r_prep) toxicity_10\NN|the|developmental|of|dfu
D010894_D064420 NONE piroxicam_24\NN| (r_pobj) of_23\IN|piroxicam (r_prep) dose_22\NN|the|highest|of (r_pobj) with_19\IN|dose (r_prep) treated_18\VBN|with (r_acl) rats_17\NNS|treated (r_pobj) in_16\IN|rats (r_prep) found_15\VBN|toxicity|were|in|. (l_nsubjpass) toxicity_1\NN|maternal|,|retardation
D010894_D006345 NONE piroxicam_23\NN|, (r_nmod) inhibitor_31\NN|piroxicam|selective|cox-2|based (r_pobj) to_22\IN|inhibitor (r_prep) exposed_21\VBN|to (r_acl) fetuses_20\NNS|rat|exposed (r_pobj) for_18\IN|fetuses (r_prep) performed_17\VBN|analysis|was|for|. (l_nsubjpass) analysis_3\NN|the|pooled|statistical|for (l_prep) for_4\IN|defects (l_pobj) defects_15\NNS|vsd|(|md|)
D010894_D009436 NONE piroxicam_23\NN|, (r_nmod) inhibitor_31\NN|piroxicam|selective|cox-2|based (r_pobj) to_22\IN|inhibitor (r_prep) exposed_21\VBN|to (r_acl) fetuses_20\NNS|rat|exposed (r_pobj) for_18\IN|fetuses (r_prep) performed_17\VBN|analysis|was|for|. (l_nsubjpass) analysis_3\NN|the|pooled|statistical|for (l_prep) for_4\IN|defects (l_pobj) defects_15\NNS|vsd|(|md|)
D010894_D005317 CID piroxicam_24\NN| (r_pobj) of_23\IN|piroxicam (r_prep) dose_22\NN|the|highest|of (r_pobj) with_19\IN|dose (r_prep) treated_18\VBN|with (r_acl) rats_17\NNS|treated (r_pobj) in_16\IN|rats (r_prep) found_15\VBN|toxicity|were|in|. (l_nsubjpass) toxicity_1\NN|maternal|,|retardation (l_appos) retardation_5\NN|intrauterine|growth|,|and|increase
D010894_D009139 CID piroxicam_24\NN| (r_pobj) of_23\IN|piroxicam (r_prep) dose_22\NN|the|highest|of (r_pobj) with_19\IN|dose (r_prep) treated_18\VBN|with (r_acl) rats_17\NNS|treated (r_pobj) in_16\IN|rats (r_prep) found_15\VBN|toxicity|were|in|. (l_nsubjpass) toxicity_1\NN|maternal|,|retardation (l_appos) retardation_5\NN|intrauterine|growth|,|and|increase (l_conj) increase_8\NN|of (l_prep) of_9\IN|variations (l_pobj) variations_13\NNS|external
2266990
D008454_D020388 NONE mazindol_7\NN|in (l_prep) in_8\IN|dystrophy (l_pobj) dystrophy_10\NN|duchenne
D008454_D020388 NONE mazindol_7\NN| (r_pobj) of_6\IN|mazindol (r_prep) trial_5\NN|a|12-month|controlled|of|,|inhibitor|, (r_dobj) conducted_1\VBD|we|trial|in|. (l_prep) in_16\IN|boys (l_pobj) boys_18\NNS|83|with (l_prep) with_19\IN|dystrophy (l_pobj) dystrophy_21\NN|duchenne
D008454_D020388 NONE Mazindol_0\JJ| (r_compound) doses_1\NNS|mazindol (r_nsubj) slow_3\VBP|doses|not|progression|. (l_dobj) progression_5\NN|the|of (l_prep) of_6\IN|weakness (l_pobj) weakness_7\NN|in (l_prep) in_8\IN|dystrophy (l_pobj) dystrophy_10\NN|duchenne
D008454_D001068 CID mazindol_4\NN| (r_pobj) to_3\IN|mazindol (r_prep) attributable_2\JJ|to (r_amod) effects_1\NNS|side|attributable (r_nsubj) included_5\VBN|effects|appetite (l_dobj) appetite_7\NN|decreased|(|%|)|,|mouth|,|change
D008454_D001068 CID mazindol_35\NN| (r_amod) dosage_36\NN|mazindol (r_nsubjpass) reduced_38\VBN|included|;|dosage|was|in|. (l_ccomp) included_5\VBN|effects|appetite (l_dobj) appetite_7\NN|decreased|(|%|)|,|mouth|,|change
D008454_D014987 CID mazindol_4\NN| (r_pobj) to_3\IN|mazindol (r_prep) attributable_2\JJ|to (r_amod) effects_1\NNS|side|attributable (r_nsubj) included_5\VBN|effects|appetite (l_dobj) appetite_7\NN|decreased|(|%|)|,|mouth|,|change (l_appos) mouth_14\NN|dry|(|%|)
D008454_D014987 CID mazindol_35\NN| (r_amod) dosage_36\NN|mazindol (r_nsubjpass) reduced_38\VBN|included|;|dosage|was|in|. (l_ccomp) included_5\VBN|effects|appetite (l_dobj) appetite_7\NN|decreased|(|%|)|,|mouth|,|change (l_appos) mouth_14\NN|dry|(|%|)
D008454_D012817 CID mazindol_4\NN| (r_pobj) to_3\IN|mazindol (r_prep) attributable_2\JJ|to (r_amod) effects_1\NNS|side|attributable (r_nsubj) included_5\VBN|effects|appetite (l_dobj) appetite_7\NN|decreased|(|%|)|,|mouth|,|change (l_appos) change_21\NN|behavioral|(|%|)|,|and|symptoms (l_conj) symptoms_29\NNS|gastrointestinal|(|%|)
D008454_D012817 CID mazindol_35\NN| (r_amod) dosage_36\NN|mazindol (r_nsubjpass) reduced_38\VBN|included|;|dosage|was|in|. (l_ccomp) included_5\VBN|effects|appetite (l_dobj) appetite_7\NN|decreased|(|%|)|,|mouth|,|change (l_appos) change_21\NN|behavioral|(|%|)|,|and|symptoms (l_conj) symptoms_29\NNS|gastrointestinal|(|%|)
D008454_D018908 NONE Mazindol_0\JJ| (r_compound) doses_1\NNS|mazindol (r_nsubj) slow_3\VBP|doses|not|progression|. (l_dobj) progression_5\NN|the|of (l_prep) of_6\IN|weakness (l_pobj) weakness_7\NN|in
16428221
D008774_D020293 CID methylphenidate_4\NN| (r_compound) intake_5\NN|oral|methylphenidate|in (r_dobj) following_2\VBG|intake (r_prep) vasculitis_1\NNS|cerebral|following|:|report|.
D008774_D020293 CID methylphenidate_20\NN| (r_compound) intake_21\NN|methylphenidate|in (r_pobj) after_19\IN|intake (r_prep) reported_18\VBN|in|stroke|has|been|after|. (r_conj) documented_8\VBN|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN|cerebral|associated
D008774_D019969 NONE methylphenidate_20\NN| (r_compound) intake_21\NN|methylphenidate|in (r_pobj) after_19\IN|intake (r_prep) reported_18\VBN|in|stroke|has|been|after|. (r_conj) documented_8\VBN|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN|cerebral|associated (l_acl) associated_2\VBN|with (l_prep) with_3\IN|abuse (l_pobj) abuse_5\NN|amphetamine
D008774_D002544 NONE methylphenidate_20\NN| (r_compound) intake_21\NN|methylphenidate|in (r_pobj) after_19\IN|intake (r_prep) reported_18\VBN|in|stroke|has|been|after|. (l_nsubjpass) stroke_15\NN|ischaemic
D008774_D002544 NONE methylphenidate_14\NN| (r_pobj) with_13\IN|methylphenidate (r_prep) treated_12\VBN|who|was|with|due|and|suffered (l_conj) suffered_19\VBD|from (l_prep) from_20\IN|strokes (l_pobj) strokes_23\NNS|multiple|ischaemic
D008774_D006948 NONE methylphenidate_14\NN| (r_pobj) with_13\IN|methylphenidate (r_prep) treated_12\VBN|who|was|with|due|and|suffered (l_prep) due_15\IN|to|hyperactivity (l_pobj) hyperactivity_17\NN|
D008774_D014657 NONE methylphenidate_3\NN|vasculitis (l_dobj) vasculitis_5\NN|mediated
D008774_D014657 NONE methylphenidate_18\NN| (r_compound) therapy_19\NN|methylphenidate (r_pobj) of_17\IN|therapy (r_prep) history_16\NN|a|of (r_conj) symptoms_13\NNS|neurological|and|history (r_pobj) with_11\IN|symptoms (r_prep) patients_10\NNS|with (r_pobj) in_9\IN|patients (r_prep) considered_8\VBN|that|methylphenidate|should|be|in (l_nsubjpass) methylphenidate_3\NN|vasculitis (l_dobj) vasculitis_5\NN|mediated
3985451
D014859_D006470 NONE Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|warfarin|- (r_amod) hemorrhage_4\NN|induced|iliopsoas|with|.
D014859_D020428 CID Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|warfarin|- (r_amod) hemorrhage_4\NN|induced|iliopsoas|with|. (l_prep) with_5\IN|palsy (l_pobj) palsy_9\JJ|subsequent|femoral|nerve
D014859_D020428 CID warfarin_12\RB| (r_npadvmod) induced_14\VBN|warfarin|- (r_amod) neuropathy_16\NN|induced|peripheral (r_pobj) of_11\IN|neuropathy (r_prep) form_10\NN|the|common|of (r_dobj) represents_6\VBZ|palsy|form (l_nsubj) palsy_5\JJ|induced|femoral|nerve
D014859_D009135 CID warfarin_12\NN| (r_compound) therapy_13\NN|chronic|warfarin (r_pobj) on_10\IN|therapy (r_prep) man_9\NN|a|old|on|sustained (l_relcl) sustained_15\VBD|who|tear|and|developed (l_dobj) tear_19\NN|a|muscle
D014859_D010146 NONE warfarin_12\NN| (r_compound) therapy_13\NN|chronic|warfarin (r_pobj) on_10\IN|therapy (r_prep) man_9\NN|a|old|on|sustained (l_relcl) sustained_15\VBD|who|tear|and|developed (l_conj) developed_21\VBD|pain (l_dobj) pain_23\NN|increasing|and|contracture
D014859_D010146 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|warfarin|- (r_amod) neuropathy_16\NN|induced|peripheral (r_pobj) of_11\IN|neuropathy (r_prep) form_10\NN|the|common|of (r_dobj) represents_6\VBZ|palsy|form (r_ccomp) characterized_20\VBN|represents|;|it|is|by|. (l_agent) by_21\IN|pain (l_pobj) pain_23\NN|severe|in|,|degrees
D014859_D003286 NONE warfarin_12\NN| (r_compound) therapy_13\NN|chronic|warfarin (r_pobj) on_10\IN|therapy (r_prep) man_9\NN|a|old|on|sustained (l_relcl) sustained_15\VBD|who|tear|and|developed (l_conj) developed_21\VBD|pain (l_dobj) pain_23\NN|increasing|and|contracture (l_conj) contracture_27\NN|a|flexure|of
D014859_D003286 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|warfarin|- (r_amod) neuropathy_16\NN|induced|peripheral (r_pobj) of_11\IN|neuropathy (r_prep) form_10\NN|the|common|of (r_dobj) represents_6\VBZ|palsy|form (r_ccomp) characterized_20\VBN|represents|;|it|is|by|. (l_agent) by_21\IN|pain (l_pobj) pain_23\NN|severe|in|,|degrees (l_conj) degrees_30\NNS|varying|of|,|and|contracture (l_conj) contracture_39\NN|flexure|of
D014859_D010523 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|warfarin|- (r_amod) neuropathy_16\NN|induced|peripheral
D014859_D015417 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|warfarin|- (r_amod) neuropathy_16\NN|induced|peripheral (r_pobj) of_11\IN|neuropathy (r_prep) form_10\NN|the|common|of (r_dobj) represents_6\VBZ|palsy|form (r_ccomp) characterized_20\VBN|represents|;|it|is|by|. (l_agent) by_21\IN|pain (l_pobj) pain_23\NN|severe|in|,|degrees (l_conj) degrees_30\NNS|varying|of|,|and|contracture (l_prep) of_31\IN|impairment (l_pobj) impairment_35\NN|motor
1468485
D010100_D006470 NONE oxygen_1\NN| (r_compound) therapy_2\NN|hyperbaric|oxygen|for|. (l_prep) for_3\IN|control (l_pobj) control_4\NN|of (l_prep) of_5\IN|cystitis (l_pobj) cystitis_11\NN|intractable|induced|hemorrhagic
D010100_D003556 NONE oxygen_1\NN| (r_compound) therapy_2\NN|hyperbaric|oxygen|for|. (l_prep) for_3\IN|control (l_pobj) control_4\NN|of (l_prep) of_5\IN|cystitis (l_pobj) cystitis_11\NN|intractable|induced|hemorrhagic
D003520_D006470 CID cyclophosphamide_7\NN| (r_npadvmod) induced_9\VBN|cyclophosphamide|- (r_amod) cystitis_11\NN|intractable|induced|hemorrhagic
D003520_D006470 CID cyclophosphamide_10\NN| (r_compound) therapy_11\NN|cyclophosphamide|for (r_pobj) due_8\IN|to|therapy (r_prep) report_1\VBP|we|case|due|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|cystitis (l_pobj) cystitis_7\NN|intractable|hemorrhagic
D003520_D006470 CID cyclophosphamide_16\NN| (r_pobj) of_15\IN|cyclophosphamide (r_prep) treatment_14\NN|the|of (r_pobj) in_12\IN|treatment (r_prep) alternative_11\NN|a|safe|in (r_dobj) offer_8\VB|in|,|form|can|alternative|cystitis|. (l_dobj) cystitis_20\NN|induced|hemorrhagic
D003520_D003556 CID cyclophosphamide_7\NN| (r_npadvmod) induced_9\VBN|cyclophosphamide|- (r_amod) cystitis_11\NN|intractable|induced|hemorrhagic
D003520_D003556 CID cyclophosphamide_10\NN| (r_compound) therapy_11\NN|cyclophosphamide|for (r_pobj) due_8\IN|to|therapy (r_prep) report_1\VBP|we|case|due|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|cystitis (l_pobj) cystitis_7\NN|intractable|hemorrhagic
D003520_D003556 CID cyclophosphamide_16\NN| (r_pobj) of_15\IN|cyclophosphamide (r_prep) treatment_14\NN|the|of (r_pobj) in_12\IN|treatment (r_prep) alternative_11\NN|a|safe|in (r_dobj) offer_8\VB|in|,|form|can|alternative|cystitis|. (l_dobj) cystitis_20\NN|induced|hemorrhagic
D003520_D014890 NONE cyclophosphamide_10\NN| (r_compound) therapy_11\NN|cyclophosphamide|for (l_prep) for_12\IN|granulomatosis (l_pobj) granulomatosis_15\NN|wegener
D015237_D006470 NONE alpha_14\NN|prostaglandin|f2 (r_pobj) of_11\IN|alpha (r_prep) saline_8\NN|physiological|and|instillation|of (r_pobj) with_6\IN|saline (r_prep) irrigation_5\NN|bladder|with (r_pobj) including_3\VBG|irrigation (r_prep) treatment_1\NN|conservative|,|including|, (r_nsubj) failed_16\VBD|treatment|control|. (l_xcomp) control_19\VB|to|totally|hemorrhage (l_dobj) hemorrhage_20\NN|
2445283
D012254_D006478 NONE ribavirin_5\NN| (r_pobj) of_4\IN|ribavirin (r_prep) effect_3\NN|antiviral|of (r_conj) Tolerance_0\NN|and|effect|in|. (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|with (l_prep) with_8\IN|fever (l_pobj) fever_11\NN|argentine|hemorrhagic
D012254_D006478 NONE ribavirin_5\NN| (r_pobj) of_4\IN|ribavirin (r_prep) effect_3\NN|antiviral|of (r_conj) Tolerance_0\NN|and|effect (r_nsubjpass) studied_7\VBN|tolerance|was|in|. (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|6|with (l_prep) with_11\IN|fever (l_pobj) fever_14\NN|argentine|hemorrhagic|(|ahf|)|of
D012254_D006478 NONE ribavirin_5\NN| (r_pobj) of_4\IN|ribavirin (r_prep) effect_3\NN|antiviral|of (r_conj) Tolerance_0\NN|and|effect (r_nsubjpass) studied_7\VBN|tolerance|was|in|. (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|6|with (l_prep) with_11\IN|fever (l_pobj) fever_14\NN|argentine|hemorrhagic|(|ahf|)|of (l_appos) AHF_16\NNP|
D012254_D006478 NONE ribavirin_7\NN| (r_nsubj) has_8\VBZ|that|ribavirin|effect|,|and|managed (l_dobj) effect_11\NN|an|antiviral|in (l_prep) in_12\IN|cases (l_pobj) cases_14\NNS|advanced|of (l_prep) of_15\IN|ahf (l_pobj) AHF_16\NNP|
D012254_D006478 NONE ribavirin_5\RB| (r_pobj) of_4\IN|ribavirin (r_prep) effect_3\NN|the|possible|beneficial|of|during (l_prep) during_6\IN|days (l_pobj) days_9\NNS|the|initial|of (l_prep) of_10\IN|ahf (l_pobj) AHF_11\NNP|
D012254_D014766 NONE ribavirin_2\RB| (r_pobj) of_1\IN|ribavirin (r_prep) Administration_0\NN|of (r_nsubj) resulted_3\VBD|administration|in|. (l_prep) in_4\IN|neutralization (l_pobj) neutralization_6\NN|a|of|and|drop (l_prep) of_7\IN|viremia (l_pobj) viremia_8\NN|
D012254_D000740 CID ribavirin_7\NN| (r_nsubj) has_8\VBZ|that|ribavirin|effect|,|and|managed (l_conj) managed_31\VBN|anemia|can|be|easily|. (l_nsubjpass) anemia_20\NN|that|,|observed|,
20084309
D008874_D020521 NONE MZ_38\NNP| (r_compound) dose_39\NN|the|mz (r_conj) MR_34\NNP|)|and|dose (r_appos) regurgitation_32\NN|mitral|(|mr (r_conj) duration_26\NN|of|,|regurgitation (r_dobj) test_7\VB|to|influence|duration (l_dobj) influence_9\NN|the|of (l_prep) of_10\IN|variables (l_pobj) variables_13\NNS|the|clinical|:|age|, (l_appos) age_15\NN|,|sex (l_conj) sex_17\NN|,|stroke (l_conj) stroke_19\UH|,|mp
D008874_D009202 NONE MZ_38\NNP| (r_compound) dose_39\NN|the|mz (r_conj) MR_34\NNP|)|and|dose (r_appos) regurgitation_32\NN|mitral|(|mr (r_conj) duration_26\NN|of|,|regurgitation (r_dobj) test_7\VB|to|influence|duration (l_dobj) influence_9\NN|the|of (l_prep) of_10\IN|variables (l_pobj) variables_13\NNS|the|clinical|:|age|, (l_appos) age_15\NN|,|sex (l_conj) sex_17\NN|,|stroke (l_conj) stroke_19\UH|,|mp (l_conj) MP_23\NNP|myocardiopathy|(|) (l_amod) myocardiopathy_21\NN|
D008874_D009202 NONE MZ_38\NNP| (r_compound) dose_39\NN|the|mz (r_conj) MR_34\NNP|)|and|dose (r_appos) regurgitation_32\NN|mitral|(|mr (r_conj) duration_26\NN|of|,|regurgitation (r_dobj) test_7\VB|to|influence|duration (l_dobj) influence_9\NN|the|of (l_prep) of_10\IN|variables (l_pobj) variables_13\NNS|the|clinical|:|age|, (l_appos) age_15\NN|,|sex (l_conj) sex_17\NN|,|stroke (l_conj) stroke_19\UH|,|mp (l_conj) MP_23\NNP|myocardiopathy|(|)
D008874_D009202 NONE MZ_17\NNP| (r_pobj) of_16\IN|mz (r_prep) doses_15\NNS|high|of (r_appos) MP_8\NNP|severe|mr|,|(|%|doses|associated
D008874_D008944 NONE MZ_38\NNP| (r_compound) dose_39\NN|the|mz (r_conj) MR_34\NNP|)|and|dose (r_appos) regurgitation_32\NN|mitral|(|mr
D008874_D008944 NONE MZ_38\NNP| (r_compound) dose_39\NN|the|mz (r_conj) MR_34\NNP|)|and|dose
D008874_D008944 NONE MZ_17\NNP| (r_pobj) of_16\IN|mz (r_prep) doses_15\NNS|high|of (r_appos) MP_8\NNP|severe|mr|,|(|%|doses|associated (l_nmod) MR_6\NNP|
D008874_D000860 CID MZ_42\NNP| (r_compound) use_43\NN|mz (r_pobj) by_41\IN|use (r_agent) caused_40\VBN|by (r_acl) hypoxia_39\NN|caused (r_pobj) due_37\JJ|to|hypoxia (r_prep) presented_20\VBD|was|;|patients|hypoxia|due|due|. (l_dobj) hypoxia_22\NN|transient
D008874_D000860 CID MZ_42\NNP| (r_compound) use_43\NN|mz (r_pobj) by_41\IN|use (r_agent) caused_40\VBN|by (r_acl) hypoxia_39\NN|caused
D008874_D000402 NONE MZ_42\NNP| (r_compound) use_43\NN|mz (r_pobj) by_41\IN|use (r_agent) caused_40\VBN|by (r_acl) hypoxia_39\NN|caused (r_pobj) due_37\JJ|to|hypoxia (r_prep) presented_20\VBD|was|;|patients|hypoxia|due|due|. (l_prep) due_23\IN|to|obstruction (l_pobj) obstruction_27\NN|upper|airway|by
17439425
D019820_D006973 NONE xanthine_2\NN| (r_compound) oxidase_3\NN|xanthine (r_pobj) of_1\IN|oxidase (r_prep) Role_0\NN|of|in|. (l_prep) in_4\IN|hypertension (l_pobj) hypertension_8\NN|induced|in
D019820_D006973 NONE xanthine_5\NN| (r_compound) oxidase_6\NN|xanthine|xo|,|implicated|, (r_pobj) of_4\IN|oxidase (r_prep) role_3\NN|the|of|in (l_prep) in_22\IN|hypertension (l_pobj) hypertension_26\NN|induced|ht
D019820_D006973 NONE xanthine_5\NN| (r_compound) oxidase_6\NN|xanthine|xo|,|implicated|, (r_pobj) of_4\IN|oxidase (r_prep) role_3\NN|the|of|in (l_prep) in_22\IN|hypertension (l_pobj) hypertension_26\NN|induced|ht (l_appos) HT_30\NNP|(|dex|-|)
D003907_D006973 CID dexamethasone_5\NN| (r_npadvmod) induced_7\VBN|dexamethasone|- (r_amod) hypertension_8\NN|induced|in
D003907_D006973 CID dexamethasone_23\NN| (r_npadvmod) induced_25\VBN|dexamethasone|- (r_amod) hypertension_26\NN|induced|ht
D003907_D006973 CID dexamethasone_23\NN| (r_npadvmod) induced_25\VBN|dexamethasone|- (r_amod) hypertension_26\NN|induced|ht (l_appos) HT_30\NNP|(|dex|-|)
D003907_D006973 CID dex_28\NN| (r_compound) HT_30\NNP|(|dex|-|) (r_appos) hypertension_26\NN|induced|ht
D003907_D006973 CID dex_28\NN| (r_compound) HT_30\NNP|(|dex|-|)
D003907_D006973 CID Dex_0\NNP| (r_nsubj) increased_1\VBD|dex|sbp|+/-|mmhg|;|p|. (l_dobj) SBP_2\NNP|
D003907_D006973 CID dex_4\NN| (r_compound) HT_6\NNP|dex|-
D009569_D006973 NONE oxide_16\NN| (r_compound) redox_18\NN|oxide|- (r_compound) imbalance_19\NN|nitric|redox (r_pobj) with_14\IN|imbalance (r_prep) associated_13\VBN|hypertension|is|with|. (l_nsubjpass) hypertension_3\NN|induced|ht|in
D009569_D006973 NONE oxide_16\NN| (r_compound) redox_18\NN|oxide|- (r_compound) imbalance_19\NN|nitric|redox (r_pobj) with_14\IN|imbalance (r_prep) associated_13\VBN|hypertension|is|with|. (l_nsubjpass) hypertension_3\NN|induced|ht|in (l_appos) HT_7\NNP|(|gc|-|)
D003907_D015431 CID Dex_0\NNP| (r_nsubj) increased_1\VBD|dex|sbp|+/-|mmhg|;|p|. (l_dep) P_13\NN|0.001|)|and|decreased (l_conj) decreased_18\VBN|thymus (l_dobj) thymus_19\NN|(|p|)|and|bodyweights (l_conj) bodyweights_26\NNS|(|p
D000493_D006973 NONE Allopurinol_0\NNP| (r_nsubj) prevent_3\VB|allopurinol|did|not|ht|. (l_dobj) HT_6\NNP|dex|-
D000493_D006973 NONE allopurinol_8\NN| (r_nsubj) failed_9\VBD|that|allopurinol|prevent (r_acl) findings_6\NNS|our|previous|failed (r_pobj) with_3\IN|together|findings (r_prep) induced_14\VBN|this|,|with|hypertension (l_dobj) hypertension_15\NN|
D000493_D006973 NONE allopurinol_8\NN| (r_nsubj) failed_9\VBD|that|allopurinol|prevent (r_acl) findings_6\NNS|our|previous|failed (r_pobj) with_3\IN|together|findings (r_prep) induced_14\VBN|this|,|with|hypertension (r_ccomp) suggests_17\VBZ|induced|,|is|. (l_ccomp) is_21\VBZ|that|activity|not|determinant (l_attr) determinant_25\NN|a|major|of|in (l_prep) of_26\IN|ht (l_pobj) HT_29\NNP|gc|-
18329269
D006220_D002375 CID haloperidol_36\NN| (r_npadvmod) induced_38\VBN|haloperidol|- (r_amod) model_40\NN|rat|induced|catalepsy|for (l_compound) catalepsy_39\NN|
D006220_D010300 NONE haloperidol_36\NN| (r_npadvmod) induced_38\VBN|haloperidol|- (r_amod) model_40\NN|rat|induced|catalepsy|for (l_prep) for_41\IN|disease (l_pobj) disease_44\NN|parkinson
1436384
D000661_D020258 CID amphetamine_2\NN| (r_npadvmod) induced_4\VBN|amphetamine|- (r_amod) neurotoxicity_5\NN|induced|toward
D000661_D020258 CID amphetamine_10\NN|and (r_nmod) compounds_13\NNS|amphetamine|related|toward (r_pobj) of_9\IN|compounds (r_prep) effect_8\NN|the|neurotoxic|of (l_amod) neurotoxic_7\JJ|
D004298_D020258 NONE dopamine_8\NN| (r_compound) neurons_9\NNS|striatal|dopamine|in (r_pobj) toward_6\IN|neurons (r_prep) neurotoxicity_5\NN|induced|toward
D004298_D020258 NONE dopamine_16\NN| (r_compound) neurons_17\NNS|nigrostriatal|dopamine (r_pobj) toward_14\IN|neurons (r_prep) compounds_13\NNS|amphetamine|related|toward (r_pobj) of_9\IN|compounds (r_prep) effect_8\NN|the|neurotoxic|of (l_amod) neurotoxic_7\JJ|
C070935_D020258 NONE LY274614_13\NNP|,|antagonist (r_pobj) by_12\IN|ly274614 (r_prep) rodents_11\NNS|by (r_pobj) in_10\IN|rodents (r_prep) neurons_9\NNS|striatal|dopamine|in (r_pobj) toward_6\IN|neurons (r_prep) neurotoxicity_5\NN|induced|toward
C070935_D020258 NONE LY274614_23\NNP| (r_nsubj) is_24\VBZ|that|ly274614|antagonist (r_conj) involves_18\VBZ|that|effect|receptors|and|is (l_nsubj) effect_8\NN|the|neurotoxic|of (l_amod) neurotoxic_7\JJ|
D000596_D020258 NONE acid_18\NN|amino (r_compound) antagonist_19\NN|an|excitatory|acid (r_appos) LY274614_13\NNP|,|antagonist (r_pobj) by_12\IN|ly274614 (r_prep) rodents_11\NNS|by (r_pobj) in_10\IN|rodents (r_prep) neurons_9\NNS|striatal|dopamine|in (r_pobj) toward_6\IN|neurons (r_prep) neurotoxicity_5\NN|induced|toward
D016202_D020258 NONE NMDA_19\NNP| (r_compound) receptors_20\NNS|nmda (r_dobj) involves_18\VBZ|that|effect|receptors|and|is (l_nsubj) effect_8\NN|the|neurotoxic|of (l_amod) neurotoxic_7\JJ|
D016202_D020258 NONE NMDA_26\NNP| (r_compound) antagonist_28\NN|an|nmda|receptor|with (r_attr) is_24\VBZ|that|ly274614|antagonist (r_conj) involves_18\VBZ|that|effect|receptors|and|is (l_nsubj) effect_8\NN|the|neurotoxic|of (l_amod) neurotoxic_7\JJ|
18020536
D001569_D004244 CID BZDs_4\NNP| (r_nmod) RDs_6\NNS|bzds|/ (r_pobj) of_3\IN|rds (r_prep) use_2\NN|of (r_nsubjpass) associated_8\VBN|however|,|use|was|with|,|inability|. (l_prep) with_9\IN|dizziness (l_pobj) dizziness_10\NN|
D001569_D007319 CID BZDs_4\NNP| (r_nmod) RDs_6\NNS|bzds|/ (r_pobj) of_3\IN|rds (r_prep) use_2\NN|of (r_nsubjpass) associated_8\VBN|however|,|use|was|with|,|inability|. (l_npadvmod) inability_12\NN|sleep (l_acl) sleep_14\VB|to|after
D001569_D005221 CID BZDs_4\NNP| (r_nmod) RDs_6\NNS|bzds|/ (r_pobj) of_3\IN|rds (r_prep) use_2\NN|of (r_nsubjpass) associated_8\VBN|however|,|use|was|with|,|inability|. (l_npadvmod) inability_12\NN|sleep (l_acl) sleep_14\VB|to|after (l_prep) after_15\IN|awaking|and|with (l_pcomp) awaking_16\VBG|at|in|during (l_prep) at_17\IN|night (l_pobj) night_18\NN|and|tiredness (l_conj) tiredness_20\NN|
D001569_D003866 CID BZDs_4\NNP| (r_nmod) RDs_6\NNS|bzds|/ (r_pobj) of_3\IN|rds (r_prep) use_2\NN|of (r_nsubjpass) associated_8\VBN|however|,|use|was|with|,|inability|. (l_npadvmod) inability_12\NN|sleep (l_acl) sleep_14\VB|to|after (l_prep) after_15\IN|awaking|and|with (l_conj) with_31\IN|symptoms (l_pobj) symptoms_34\NNS|stronger|depressive|measured
7453952
D008094_D003919 CID lithium_3\NN| (r_npadvmod) induced_5\VBN|lithium|- (r_amod) syndrome_11\NN|the|induced|like|by|in
D008094_D003919 CID lithium_9\NN| (r_npadvmod) induced_11\VBN|lithium|- (r_amod) syndrome_17\NN|the|induced|like|by
D008094_D003919 CID lithium_30\NN| (r_compound) concentration_31\NN|the|lithium|in|and|elevation (r_pobj) between_28\IN|concentration (r_prep) ratio_27\NN|the|between (r_pobj) of_25\IN|ratio (r_prep) reduction_24\NN|a|of (r_pobj) by_22\IN|reduction (r_agent) accompanied_21\VBN|in|,|attenuation|was|by|. (l_nsubjpass) attenuation_6\NN|the|of (l_prep) of_7\IN|syndrome (l_pobj) syndrome_17\NN|the|induced|like|by
D000584_D003919 NONE amiloride_13\NN| (r_pobj) by_12\IN|amiloride (r_prep) syndrome_11\NN|the|induced|like|by|in
D000584_D003919 NONE amiloride_19\NN| (r_pobj) by_18\IN|amiloride (r_prep) syndrome_17\NN|the|induced|like|by
D000584_D059606 NONE amiloride_3\NN| (r_pobj) of_2\IN|amiloride (r_prep) effect_1\NN|the|of|on (l_prep) on_4\IN|polydipsia|and|on (l_pobj) polydipsia_8\NN|induced|and|polyuria
D000584_D059606 NONE amiloride_5\NN| (r_compound) administration_6\NN|acute|amiloride|to (l_prep) to_7\IN|patients (l_pobj) patients_11\NNS|treated|suffering (l_acl) suffering_12\VBG|from (l_prep) from_13\IN|polydipsia (l_pobj) polydipsia_14\NN|and|polyuria
D000584_D059606 NONE amiloride_23\JJ| (r_compound) supplementation_24\NN|prolonged|amiloride (r_nsubj) result_26\VB|supplementation|would|in|and|be (r_conj) relieve_18\VB|that|administration|might|patients|but|result (l_nsubj) administration_6\NN|acute|amiloride|to (l_prep) to_7\IN|patients (l_pobj) patients_11\NNS|treated|suffering (l_acl) suffering_12\VBG|from (l_prep) from_13\IN|polydipsia (l_pobj) polydipsia_14\NN|and|polyuria
D000584_D011141 NONE amiloride_3\NN| (r_pobj) of_2\IN|amiloride (r_prep) effect_1\NN|the|of|on (l_prep) on_4\IN|polydipsia|and|on (l_pobj) polydipsia_8\NN|induced|and|polyuria (l_conj) polyuria_10\NN|
D000584_D011141 NONE amiloride_5\NN| (r_compound) administration_6\NN|acute|amiloride|to (l_prep) to_7\IN|patients (l_pobj) patients_11\NNS|treated|suffering (l_acl) suffering_12\VBG|from (l_prep) from_13\IN|polydipsia (l_pobj) polydipsia_14\NN|and|polyuria (l_conj) polyuria_16\NN|
D000584_D011141 NONE amiloride_23\JJ| (r_compound) supplementation_24\NN|prolonged|amiloride (r_nsubj) result_26\VB|supplementation|would|in|and|be (r_conj) relieve_18\VB|that|administration|might|patients|but|result (l_nsubj) administration_6\NN|acute|amiloride|to (l_prep) to_7\IN|patients (l_pobj) patients_11\NNS|treated|suffering (l_acl) suffering_12\VBG|from (l_prep) from_13\IN|polydipsia (l_pobj) polydipsia_14\NN|and|polyuria (l_conj) polyuria_16\NN|
D008094_D059606 NONE lithium_5\NN| (r_npadvmod) induced_7\VBN|lithium|- (r_amod) polydipsia_8\NN|induced|and|polyuria
D008094_D059606 NONE lithium_14\NN| (r_compound) concentration_15\NN|the|lithium|in (r_pobj) on_12\IN|concentration (r_conj) on_4\IN|polydipsia|and|on (l_pobj) polydipsia_8\NN|induced|and|polyuria
D008094_D059606 NONE lithium_8\NN| (r_npadvmod) treated_10\VBN|lithium|- (r_amod) patients_11\NNS|treated|suffering (l_acl) suffering_12\VBG|from (l_prep) from_13\IN|polydipsia (l_pobj) polydipsia_14\NN|and|polyuria
D008094_D059606 NONE lithium_29\NN| (r_compound) levels_30\NNS|elevated|lithium (r_pobj) in_27\IN|levels (r_prep) result_26\VB|supplementation|would|in|and|be (r_conj) relieve_18\VB|that|administration|might|patients|but|result (l_nsubj) administration_6\NN|acute|amiloride|to (l_prep) to_7\IN|patients (l_pobj) patients_11\NNS|treated|suffering (l_acl) suffering_12\VBG|from (l_prep) from_13\IN|polydipsia (l_pobj) polydipsia_14\NN|and|polyuria
D008094_D011141 NONE lithium_5\NN| (r_npadvmod) induced_7\VBN|lithium|- (r_amod) polydipsia_8\NN|induced|and|polyuria (l_conj) polyuria_10\NN|
D008094_D011141 NONE lithium_14\NN| (r_compound) concentration_15\NN|the|lithium|in (r_pobj) on_12\IN|concentration (r_conj) on_4\IN|polydipsia|and|on (l_pobj) polydipsia_8\NN|induced|and|polyuria (l_conj) polyuria_10\NN|
D008094_D011141 NONE lithium_8\NN| (r_npadvmod) treated_10\VBN|lithium|- (r_amod) patients_11\NNS|treated|suffering (l_acl) suffering_12\VBG|from (l_prep) from_13\IN|polydipsia (l_pobj) polydipsia_14\NN|and|polyuria (l_conj) polyuria_16\NN|
D008094_D011141 NONE lithium_29\NN| (r_compound) levels_30\NNS|elevated|lithium (r_pobj) in_27\IN|levels (r_prep) result_26\VB|supplementation|would|in|and|be (r_conj) relieve_18\VB|that|administration|might|patients|but|result (l_nsubj) administration_6\NN|acute|amiloride|to (l_prep) to_7\IN|patients (l_pobj) patients_11\NNS|treated|suffering (l_acl) suffering_12\VBG|from (l_prep) from_13\IN|polydipsia (l_pobj) polydipsia_14\NN|and|polyuria (l_conj) polyuria_16\NN|
D018021_D059606 NONE LiCl_37\NNP| (r_pobj) with_36\IN|licl (r_prep) treated_35\VBN|chronically|with (r_conj) investigated_30\VBN|effect|was|in|,|treated|. (l_nsubjpass) effect_1\NN|the|of|on (l_prep) on_4\IN|polydipsia|and|on (l_pobj) polydipsia_8\NN|induced|and|polyuria
D018021_D011141 NONE LiCl_37\NNP| (r_pobj) with_36\IN|licl (r_prep) treated_35\VBN|chronically|with (r_conj) investigated_30\VBN|effect|was|in|,|treated|. (l_nsubjpass) effect_1\NN|the|of|on (l_prep) on_4\IN|polydipsia|and|on (l_pobj) polydipsia_8\NN|induced|and|polyuria (l_conj) polyuria_10\NN|
D011188_D003919 NONE potassium_48\NN|plasma (r_compound) level_49\NN|the|potassium (r_pobj) in_45\IN|level (r_prep) elevation_44\NN|an|in (r_conj) concentration_31\NN|the|lithium|in|and|elevation (r_pobj) between_28\IN|concentration (r_prep) ratio_27\NN|the|between (r_pobj) of_25\IN|ratio (r_prep) reduction_24\NN|a|of (r_pobj) by_22\IN|reduction (r_agent) accompanied_21\VBN|in|,|attenuation|was|by|. (l_nsubjpass) attenuation_6\NN|the|of (l_prep) of_7\IN|syndrome (l_pobj) syndrome_17\NN|the|induced|like|by
10193204
C009438_D013927 NONE tetrandrine_2\NN|and|fangchinoline (r_pobj) of_1\IN|tetrandrine (r_prep) Effects_0\NNS|of|on|. (l_prep) on_5\IN|thrombosis (l_pobj) thrombosis_7\NN|experimental|in
C009438_D013927 NONE TET_10\NNP|and|fan (r_pobj) of_9\IN|tet (r_prep) effects_8\NNS|the|of|on (l_prep) on_13\IN|thrombosis (l_pobj) thrombosis_16\NN|the|experimental|induced
C009438_D013927 NONE TET_15\NNP|and|fan (r_pobj) of_14\IN|tet (r_prep) administration_7\NN|the|(|mg/kg|i.p.|)|of (r_nsubj) showed_20\VBD|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN|the|of|by|,|respectively (l_prep) of_23\IN|thrombosis (l_pobj) thrombosis_24\NN|
C009438_D001791 NONE tetrandrine_2\NN|and|fangchinoline (r_pobj) of_1\IN|tetrandrine (r_prep) Effects_0\NNS|of|on|. (l_prep) on_5\IN|thrombosis (l_pobj) thrombosis_7\NN|experimental|in (l_prep) in_8\IN|mice (l_pobj) mice_9\NNS|and|aggregation (l_conj) aggregation_13\NN|platelet
C009438_D001791 NONE TET_10\NNP|and|fan (r_pobj) of_9\IN|tet (r_prep) effects_8\NNS|the|of|on (r_dobj) investigate_6\VB|to|effects (r_advcl) undertaken_4\VBN|study|was|investigate|,|and|in (l_conj) in_34\IN|aggregation|vitro|. (l_nsubj) aggregation_30\NN|platelet|and|coagulation
C009438_D001791 NONE TET_14\NNP|and|fan (r_nsubj) showed_17\VBD|in|,|tet|dose|dependently|. (l_prep) In_0\IN|aggregations (l_pobj) aggregations_5\NNS|the|vitro|platelet|induced
C060802_D013927 NONE fangchinoline_4\NN| (r_conj) tetrandrine_2\NN|and|fangchinoline (r_pobj) of_1\IN|tetrandrine (r_prep) Effects_0\NNS|of|on|. (l_prep) on_5\IN|thrombosis (l_pobj) thrombosis_7\NN|experimental|in
C060802_D013927 NONE FAN_12\NNP| (r_conj) TET_10\NNP|and|fan (r_pobj) of_9\IN|tet (r_prep) effects_8\NNS|the|of|on (l_prep) on_13\IN|thrombosis (l_pobj) thrombosis_16\NN|the|experimental|induced
C060802_D013927 NONE FAN_17\NNP|in (r_conj) TET_15\NNP|and|fan (r_pobj) of_14\IN|tet (r_prep) administration_7\NN|the|(|mg/kg|i.p.|)|of (r_nsubj) showed_20\VBD|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN|the|of|by|,|respectively (l_prep) of_23\IN|thrombosis (l_pobj) thrombosis_24\NN|
C060802_D001791 NONE fangchinoline_4\NN| (r_conj) tetrandrine_2\NN|and|fangchinoline (r_pobj) of_1\IN|tetrandrine (r_prep) Effects_0\NNS|of|on|. (l_prep) on_5\IN|thrombosis (l_pobj) thrombosis_7\NN|experimental|in (l_prep) in_8\IN|mice (l_pobj) mice_9\NNS|and|aggregation (l_conj) aggregation_13\NN|platelet
C060802_D001791 NONE FAN_12\NNP| (r_conj) TET_10\NNP|and|fan (r_pobj) of_9\IN|tet (r_prep) effects_8\NNS|the|of|on (r_dobj) investigate_6\VB|to|effects (r_advcl) undertaken_4\VBN|study|was|investigate|,|and|in (l_conj) in_34\IN|aggregation|vitro|. (l_nsubj) aggregation_30\NN|platelet|and|coagulation
C060802_D001791 NONE FAN_16\NNP| (r_conj) TET_14\NNP|and|fan (r_nsubj) showed_17\VBD|in|,|tet|dose|dependently|. (l_prep) In_0\IN|aggregations (l_pobj) aggregations_5\NNS|the|vitro|platelet|induced
C009438_D001778 NONE TET_10\NNP|and|fan (r_pobj) of_9\IN|tet (r_prep) effects_8\NNS|the|of|on (r_dobj) investigate_6\VB|to|effects (r_advcl) undertaken_4\VBN|study|was|investigate|,|and|in (l_conj) in_34\IN|aggregation|vitro|. (l_nsubj) aggregation_30\NN|platelet|and|coagulation (l_conj) coagulation_33\NN|blood
C060802_D001778 NONE FAN_12\NNP| (r_conj) TET_10\NNP|and|fan (r_pobj) of_9\IN|tet (r_prep) effects_8\NNS|the|of|on (r_dobj) investigate_6\VB|to|effects (r_advcl) undertaken_4\VBN|study|was|investigate|,|and|in (l_conj) in_34\IN|aggregation|vitro|. (l_nsubj) aggregation_30\NN|platelet|and|coagulation (l_conj) coagulation_33\NN|blood
D004837_D013927 CID epinephrine_21\NN|ep (r_conj) collagen_19\NN|plus|epinephrine (r_pobj) by_18\IN|collagen (r_agent) induced_17\VBN|by|in (r_acl) thrombosis_16\NN|the|experimental|induced
D004837_D013927 CID EP_23\NN|(|) (r_appos) epinephrine_21\NN|ep (r_conj) collagen_19\NN|plus|epinephrine (r_pobj) by_18\IN|collagen (r_agent) induced_17\VBN|by|in (r_acl) thrombosis_16\NN|the|experimental|induced
D004837_D001791 NONE epinephrine_21\NN|ep (r_conj) collagen_19\NN|plus|epinephrine (r_pobj) by_18\IN|collagen (r_agent) induced_17\VBN|by|in (r_acl) thrombosis_16\NN|the|experimental|induced (r_pobj) on_13\IN|thrombosis (r_prep) effects_8\NNS|the|of|on (r_dobj) investigate_6\VB|to|effects (r_advcl) undertaken_4\VBN|study|was|investigate|,|and|in (l_conj) in_34\IN|aggregation|vitro|. (l_nsubj) aggregation_30\NN|platelet|and|coagulation
D004837_D001791 NONE EP_23\NN|(|) (r_appos) epinephrine_21\NN|ep (r_conj) collagen_19\NN|plus|epinephrine (r_pobj) by_18\IN|collagen (r_agent) induced_17\VBN|by|in (r_acl) thrombosis_16\NN|the|experimental|induced (r_pobj) on_13\IN|thrombosis (r_prep) effects_8\NNS|the|of|on (r_dobj) investigate_6\VB|to|effects (r_advcl) undertaken_4\VBN|study|was|investigate|,|and|in (l_conj) in_34\IN|aggregation|vitro|. (l_nsubj) aggregation_30\NN|platelet|and|coagulation
D004837_D001778 NONE epinephrine_21\NN|ep (r_conj) collagen_19\NN|plus|epinephrine (r_pobj) by_18\IN|collagen (r_agent) induced_17\VBN|by|in (r_acl) thrombosis_16\NN|the|experimental|induced (r_pobj) on_13\IN|thrombosis (r_prep) effects_8\NNS|the|of|on (r_dobj) investigate_6\VB|to|effects (r_advcl) undertaken_4\VBN|study|was|investigate|,|and|in (l_conj) in_34\IN|aggregation|vitro|. (l_nsubj) aggregation_30\NN|platelet|and|coagulation (l_conj) coagulation_33\NN|blood
D004837_D001778 NONE EP_23\NN|(|) (r_appos) epinephrine_21\NN|ep (r_conj) collagen_19\NN|plus|epinephrine (r_pobj) by_18\IN|collagen (r_agent) induced_17\VBN|by|in (r_acl) thrombosis_16\NN|the|experimental|induced (r_pobj) on_13\IN|thrombosis (r_prep) effects_8\NNS|the|of|on (r_dobj) investigate_6\VB|to|effects (r_advcl) undertaken_4\VBN|study|was|investigate|,|and|in (l_conj) in_34\IN|aggregation|vitro|. (l_nsubj) aggregation_30\NN|platelet|and|coagulation (l_conj) coagulation_33\NN|blood
D001241_D013927 NONE acid_36\NN|asa (r_dobj) acetylsalicylic_35\JJ|while|acid|mg/kg|,|control|,|showed (r_advcl) showed_20\VBD|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN|the|of|by|,|respectively (l_prep) of_23\IN|thrombosis (l_pobj) thrombosis_24\NN|
D001241_D013927 NONE ASA_38\NNP|(|, (r_appos) acid_36\NN|asa (r_dobj) acetylsalicylic_35\JJ|while|acid|mg/kg|,|control|,|showed (r_advcl) showed_20\VBD|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN|the|of|by|,|respectively (l_prep) of_23\IN|thrombosis (l_pobj) thrombosis_24\NN|
1549199
D007980_D064420 NONE levodopa_9\NN| (r_compound) therapy_10\NN|levodopa (r_pobj) for_8\IN|therapy (r_prep) dose_7\NN|for (r_dobj) starting_6\NN|dose (r_acl) correct_5\JJ|no|single|starting (r_attr) is_2\VBZ|while|there|correct (r_advcl) started_16\VBN|is|,|individuals|can|be|on|,|following|. (l_prep) following_27\VBG|rule (l_pobj) rule_30\NN|the|general|attempt (l_relcl) attempt_33\VB|not|to|titrate (l_xcomp) titrate_35\VB|to|levodopa (l_dobj) levodopa_38\NN|carbidopa|-|to|,|"|lead (l_relcl) lead_49\VB|which|can|to (l_prep) to_50\IN|toxicity (l_pobj) toxicity_51\NN|
D007980_D064420 NONE levodopa_38\NN|carbidopa|-|to|,|"|lead (l_relcl) lead_49\VB|which|can|to (l_prep) to_50\IN|toxicity (l_pobj) toxicity_51\NN|
D002230_D064420 NONE carbidopa_36\NN| (r_compound) levodopa_38\NN|carbidopa|-|to|,|"|lead (l_relcl) lead_49\VB|which|can|to (l_prep) to_50\IN|toxicity (l_pobj) toxicity_51\NN|
D007980_D005767 CID levodopa_13\RB| (r_npadvmod) induced_15\VBN|levodopa|- (r_amod) psychosis_16\NN|induced|,|disturbances (r_conj) hypotension_11\NN|orthostatic|,|psychosis (r_conj) disorders_8\NNS|gastrointestinal|,|hypotension
D007980_D007024 CID levodopa_13\RB| (r_npadvmod) induced_15\VBN|levodopa|- (r_amod) psychosis_16\NN|induced|,|disturbances (r_conj) hypotension_11\NN|orthostatic|,|psychosis
D007980_D011618 NONE levodopa_13\RB| (r_npadvmod) induced_15\VBN|levodopa|- (r_amod) psychosis_16\NN|induced|,|disturbances
D007980_D012893 NONE levodopa_13\RB| (r_npadvmod) induced_15\VBN|levodopa|- (r_amod) psychosis_16\NN|induced|,|disturbances (l_conj) disturbances_19\NNS|sleep|or|parasomnias
D007980_D020447 CID levodopa_13\RB| (r_npadvmod) induced_15\VBN|levodopa|- (r_amod) psychosis_16\NN|induced|,|disturbances (l_conj) disturbances_19\NNS|sleep|or|parasomnias (l_conj) parasomnias_21\NNS|,|or|interactions
11773892
D016572_D007674 CID cyclosporine_3\VBP|and|tacrolimus (r_appos) inhibitors_2\NNS|the|calcineurin|cyclosporine (r_nsubjpass) known_8\VBN|inhibitors|are|both|be|. (l_xcomp) be_10\VB|to|nephrotoxic (l_acomp) nephrotoxic_11\JJ|
D016559_D007674 CID tacrolimus_5\NN| (r_conj) cyclosporine_3\VBP|and|tacrolimus (r_appos) inhibitors_2\NNS|the|calcineurin|cyclosporine (r_nsubjpass) known_8\VBN|inhibitors|are|both|be|. (l_xcomp) be_10\VB|to|nephrotoxic (l_acomp) nephrotoxic_11\JJ|
D003404_D007676 NONE creatinine_20\NN|sustained|serum (r_conj) CRF_16\NNP|,|creatinine (r_conj) Controls_7\NNS|,|crf|;|crf (l_conj) CRF_10\NNP|no|or|esrd
D003404_D007676 NONE creatinine_20\NN|sustained|serum (r_conj) CRF_16\NNP|,|creatinine (r_conj) Controls_7\NNS|,|crf|;|crf (l_conj) CRF_10\NNP|no|or|esrd (l_conj) ESRD_12\NNP|,|n=748
D003404_D007676 NONE creatinine_20\NN|sustained|serum (r_conj) CRF_16\NNP|,|creatinine
D003404_D007676 NONE creatinine_20\NN|sustained|serum (r_conj) CRF_16\NNP|,|creatinine (r_conj) Controls_7\NNS|,|crf|;|crf (r_appos) groups_5\NNS|three|:|controls|>|;|and|n=45 (l_conj) n=45_32\JJ|esrd|. (l_nmod) ESRD_30\NNS|,
D003404_D007676 NONE creatinine_13\NN|serum (r_compound) levels_14\NNS|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD|compared|,|patients|levels|. (l_nsubj) patients_8\NNS|crf|esrd (l_nmod) CRF_5\NNP|and
D003404_D007676 NONE creatinine_13\NN|serum (r_compound) levels_14\NNS|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD|compared|,|patients|levels|. (l_nsubj) patients_8\NNS|crf|esrd (l_compound) ESRD_7\NNP|
D003404_D007676 NONE creatinine_42\NN|a|higher|1-year|serum (r_conj) requirement_27\NN|higher|percentage|for|in|,|and|creatinine (r_appos) levels_14\NNS|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD|compared|,|patients|levels|. (l_nsubj) patients_8\NNS|crf|esrd (l_nmod) CRF_5\NNP|and
D003404_D007676 NONE creatinine_42\NN|a|higher|1-year|serum (r_conj) requirement_27\NN|higher|percentage|for|in|,|and|creatinine (r_appos) levels_14\NNS|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD|compared|,|patients|levels|. (l_nsubj) patients_8\NNS|crf|esrd (l_compound) ESRD_7\NNP|
D003404_D007676 NONE creatinine_16\NN|serum (r_pobj) of_14\IN|creatinine (r_prep) increase_13\NN|an|of|compared|,|and (r_nsubj) were_31\VBD|that|increase|postoperatively|factors|respectively (l_attr) factors_34\NNS|independent|risk|for|with (l_prep) for_35\IN|development (l_pobj) development_37\NN|the|of (l_prep) of_38\IN|crf (l_pobj) CRF_39\NNP|or|esrd
D003404_D007676 NONE creatinine_16\NN|serum (r_pobj) of_14\IN|creatinine (r_prep) increase_13\NN|an|of|compared|,|and (r_nsubj) were_31\VBD|that|increase|postoperatively|factors|respectively (l_attr) factors_34\NNS|independent|risk|for|with (l_prep) for_35\IN|development (l_pobj) development_37\NN|the|of (l_prep) of_38\IN|crf (l_pobj) CRF_39\NNP|or|esrd (l_conj) ESRD_41\NNP|
D003404_D007676 NONE creatinine_11\NN|a|higher|preoperative (r_dobj) have_4\VBP|patients|creatinine|and|are|. (l_nsubj) Patients_0\NNS|develop (l_relcl) develop_2\VBP|who|esrd (l_dobj) ESRD_3\NNS|
D003404_D007676 NONE creatinine_6\NN|serum (r_pobj) of_4\IN|creatinine (r_prep) increase_3\NN|an|of|at|postoperatively (r_nsubj) is_11\VBZ|however|,|increase|predictive|. (l_acomp) predictive_13\JJ|more|of (l_prep) of_14\IN|development (l_pobj) development_16\NN|the|of (l_prep) of_17\IN|crf (l_pobj) CRF_18\NNP|or|esrd
D003404_D007676 NONE creatinine_6\NN|serum (r_pobj) of_4\IN|creatinine (r_prep) increase_3\NN|an|of|at|postoperatively (r_nsubj) is_11\VBZ|however|,|increase|predictive|. (l_acomp) predictive_13\JJ|more|of (l_prep) of_14\IN|development (l_pobj) development_16\NN|the|of (l_prep) of_17\IN|crf (l_pobj) CRF_18\NNP|or|esrd (l_conj) ESRD_20\NNP|
D003404_D006530 NONE creatinine_13\NN|serum (r_compound) levels_14\NNS|higher|preoperative|creatinine|,|percentage|,|requirement (l_appos) percentage_18\NN|a|greater|of (l_prep) of_19\IN|patients (l_pobj) patients_20\NNS|with (l_prep) with_21\IN|syndrome (l_pobj) syndrome_23\NN|hepatorenal
D003404_D006530 NONE creatinine_42\NN|a|higher|1-year|serum (r_conj) requirement_27\NN|higher|percentage|for|in|,|and|creatinine (r_appos) levels_14\NNS|higher|preoperative|creatinine|,|percentage|,|requirement (l_appos) percentage_18\NN|a|greater|of (l_prep) of_19\IN|patients (l_pobj) patients_20\NNS|with (l_prep) with_21\IN|syndrome (l_pobj) syndrome_23\NN|hepatorenal
D003404_D006530 NONE creatinine_11\NN|a|higher|preoperative (r_dobj) have_4\VBP|patients|creatinine|and|are|. (l_conj) are_13\VBP|likely (l_acomp) likely_15\JJ|more|have (l_xcomp) have_17\VB|to|syndrome (l_dobj) syndrome_19\NN|hepatorenal
2375138
D008874_D006323 CID midazolam_2\RB| (r_npadvmod) associated_4\VBN|midazolam|- (r_amod) arrest_6\NN|possible|intramuscular|associated|cardiorespiratory|and|death|.
D008874_D006323 CID midazolam_17\NN| (r_pobj) of_16\IN|midazolam (r_prep) administration_15\NN|intramuscular|of (r_pobj) with_13\IN|administration (r_prep) associated_12\VBN|with (r_acl) case_6\NN|the|first|published|of|associated (l_prep) of_7\IN|arrest (l_pobj) arrest_9\NN|cardiorespiratory|and|death
D008874_D003643 NONE midazolam_2\RB| (r_npadvmod) associated_4\VBN|midazolam|- (r_amod) arrest_6\NN|possible|intramuscular|associated|cardiorespiratory|and|death|. (l_conj) death_8\NN|
D008874_D003643 NONE midazolam_17\NN| (r_pobj) of_16\IN|midazolam (r_prep) administration_15\NN|intramuscular|of (r_pobj) with_13\IN|administration (r_prep) associated_12\VBN|with (r_acl) case_6\NN|the|first|published|of|associated (l_prep) of_7\IN|arrest (l_pobj) arrest_9\NN|cardiorespiratory|and|death (l_conj) death_11\NN|
9406968
D014667_D003919 NONE vasopressin_5\NN| (r_compound) gene_6\NN|vasopressin|in (l_prep) in_7\IN|nuclei (l_pobj) nuclei_12\NNS|the|paraventricular|of (l_prep) of_13\IN|rat (l_pobj) rat_20\NN|the|diabetes|insipidus (l_compound) insipidus_19\NN|
D008094_D003919 NONE lithium_15\NN| (r_npadvmod) induced_17\VBN|lithium|- (r_amod) diabetes_18\NN|induced (r_compound) rat_20\NN|the|diabetes|insipidus (l_compound) insipidus_19\NN|
D008094_D003919 NONE Li_35\NNP| (r_npadvmod) induced_37\VBN|li|- (r_amod) diabetes_38\NN|induced (r_compound) rat_40\NN|the|diabetes|insipidus (l_compound) insipidus_39\NN|
D001127_D011141 NONE vasopressin_4\NN|arginine (r_pobj) of_2\IN|vasopressin (r_prep) expression_1\NN|the|of (r_nsubjpass) investigated_22\VBN|expression|gene|was|in|polyuria|using|. (l_parataxis) polyuria_29\NN|(|li)-induced|,
D001127_D011141 NONE AVP_6\NNP| (r_nmod) gene_8\NN|(|avp|)|in (r_nsubjpass) investigated_22\VBN|expression|gene|was|in|polyuria|using|. (l_parataxis) polyuria_29\NN|(|li)-induced|,
D008094_D011141 NONE lithium_26\NN| (r_pobj) with_25\IN|lithium (r_prep) rats_24\NNS|with (r_pobj) in_23\IN|rats (r_prep) investigated_22\VBN|expression|gene|was|in|polyuria|using|. (l_parataxis) polyuria_29\NN|(|li)-induced|,
D008094_D011141 NONE Li)-induced_28\JJ| (r_amod) polyuria_29\NN|(|li)-induced|,
D018021_D011141 CID LiCl_9\NNP|(|kg|) (r_dobj) contained_8\VBD|that|licl|for (r_relcl) diet_6\NN|a|contained (r_dobj) consuming_4\VBG|diet (r_acl) rats_3\NNS|the|male|wistar|consuming (r_nsubj) developed_19\VBN|rats|polyuria|. (l_dobj) polyuria_21\NN|marked
D001127_D003681 NONE AVP_19\NNP|plasma|and (r_pobj) of_17\IN|avp (r_prep) elevation_16\NN|the|of|upregulation (r_pobj) to_14\IN|elevation (r_prep) contribute_13\VB|that|dehydration|may|to (l_nsubj) dehydration_4\NN|and/or|activation
D001127_D003681 NONE AVP_24\NNP| (r_compound) expression_26\NN|avp|gene|in (r_pobj) of_23\IN|expression (r_prep) upregulation_22\NN|the|of (r_conj) elevation_16\NN|the|of|upregulation (r_pobj) to_14\IN|elevation (r_prep) contribute_13\VB|that|dehydration|may|to (l_nsubj) dehydration_4\NN|and/or|activation
D001127_D003919 NONE AVP_19\NNP|plasma|and (r_pobj) of_17\IN|avp (r_prep) elevation_16\NN|the|of|upregulation (l_conj) upregulation_22\NN|the|of (l_prep) of_23\IN|expression (l_pobj) expression_26\NN|avp|gene|in (l_prep) in_27\IN|pvn (l_pobj) PVN_29\NN|the|and|son (l_conj) SON_32\NN|the|of (l_prep) of_33\IN|rat (l_pobj) rat_40\NN|the|diabetes|insipidus (l_compound) insipidus_39\NN|
D001127_D003919 NONE AVP_24\NNP| (r_compound) expression_26\NN|avp|gene|in (l_prep) in_27\IN|pvn (l_pobj) PVN_29\NN|the|and|son (l_conj) SON_32\NN|the|of (l_prep) of_33\IN|rat (l_pobj) rat_40\NN|the|diabetes|insipidus (l_compound) insipidus_39\NN|
D008094_D003681 NONE Li_35\NNP| (r_npadvmod) induced_37\VBN|li|- (r_amod) diabetes_38\NN|induced (r_compound) rat_40\NN|the|diabetes|insipidus (r_pobj) of_33\IN|rat (r_prep) SON_32\NN|the|of (r_conj) PVN_29\NN|the|and|son (r_pobj) in_27\IN|pvn (r_prep) expression_26\NN|avp|gene|in (r_pobj) of_23\IN|expression (r_prep) upregulation_22\NN|the|of (r_conj) elevation_16\NN|the|of|upregulation (r_pobj) to_14\IN|elevation (r_prep) contribute_13\VB|that|dehydration|may|to (l_nsubj) dehydration_4\NN|and/or|activation
4071154
D007213_D051437 NONE Indomethacin_0\NNP| (r_npadvmod) induced_2\VBN|indomethacin|- (r_amod) insufficiency_4\NN|induced|renal|:|recurrence|.
D007213_D051437 NONE indomethacin_24\NN|therapy (r_advcl) reported_2\VBN|we|have|case|indomethacin|. (l_dobj) case_4\NN|a|of|in (l_prep) of_5\IN|failure (l_pobj) failure_9\NN|acute|oliguric|renal|with
D007213_D006947 CID indomethacin_24\NN|therapy (r_advcl) reported_2\VBN|we|have|case|indomethacin|. (l_dobj) case_4\NN|a|of|in (l_prep) of_5\IN|failure (l_pobj) failure_9\NN|acute|oliguric|renal|with (l_prep) with_10\IN|hyperkalemia (l_pobj) hyperkalemia_11\NN|
D007213_D005355 CID indomethacin_24\NN|therapy (r_advcl) reported_2\VBN|we|have|case|indomethacin|. (l_dobj) case_4\NN|a|of|in (l_prep) in_12\IN|patient (l_pobj) patient_14\NN|a|with (l_prep) with_15\IN|cirrhosis (l_pobj) cirrhosis_16\NN|,|ascites
D007213_D001201 CID indomethacin_24\NN|therapy (r_advcl) reported_2\VBN|we|have|case|indomethacin|. (l_dobj) case_4\NN|a|of|in (l_prep) in_12\IN|patient (l_pobj) patient_14\NN|a|with (l_prep) with_15\IN|cirrhosis (l_pobj) cirrhosis_16\NN|,|ascites (l_conj) ascites_18\NNS|,|and|pulmonale
D007213_D011660 CID indomethacin_24\NN|therapy (r_advcl) reported_2\VBN|we|have|case|indomethacin|. (l_dobj) case_4\NN|a|of|in (l_prep) in_12\IN|patient (l_pobj) patient_14\NN|a|with (l_prep) with_15\IN|cirrhosis (l_pobj) cirrhosis_16\NN|,|ascites (l_conj) ascites_18\NNS|,|and|pulmonale (l_conj) pulmonale_22\NN|cor|after
D007213_D009846 CID indomethacin_18\NN| (r_pobj) of_17\IN|indomethacin (r_prep) dose_16\NN|a|single|of (r_pobj) to_13\IN|exposure|dose (r_punct) caused_19\VBD|to|recurrence (l_dobj) recurrence_20\NN|of (l_prep) of_21\IN|oliguria (l_pobj) oliguria_24\NN|acute|reversible
9660111
D014299_D007035 NONE TRI_4\NNP|(|given|) (r_nsubj) antagonize_11\VB|in|tri|does|not|hypothermia|in|and|potentiate|. (l_dobj) hypothermia_14\VBN|the|reserpine
D012110_D007035 CID reserpine_13\NN| (r_compound) hypothermia_14\VBN|the|reserpine
D006916_D007035 NONE 5-hydroxytryptophan_22\JJ| (r_poss) head_23\NN|the|5-hydroxytryptophan (r_compound) twitches_24\NNS|head|in (r_dobj) potentiate_20\VB|does|not|twitches (r_conj) antagonize_11\VB|in|tri|does|not|hypothermia|in|and|potentiate|. (l_dobj) hypothermia_14\VBN|the|reserpine
D014299_D006948 CID TRI_0\NNP|given (r_nsubj) increases_5\VBZ|tri|hyperactivity|. (l_dobj) hyperactivity_8\NN|the|locomotor|induced
D003913_D006948 CID amphetamine_13\NN|d|-|,|quinpirole (r_pobj) by_10\IN|amphetamine (r_agent) induced_9\VBN|by (r_acl) hyperactivity_8\NN|the|locomotor|induced
D019257_D006948 CID quinpirole_15\NN|and|(|+|dipropyloaminotetralin (r_conj) amphetamine_13\NN|d|-|,|quinpirole (r_pobj) by_10\IN|amphetamine (r_agent) induced_9\VBN|by (r_acl) hyperactivity_8\NN|the|locomotor|induced
D004298_D006948 NONE dopamine_24\NN| (r_compound) D2_25\NN|dopamine|and|effects (r_appos) dipropyloaminotetralin_22\NN|)|-7-hydroxy|-|(|d2|) (r_conj) quinpirole_15\NN|and|(|+|dipropyloaminotetralin (r_conj) amphetamine_13\NN|d|-|,|quinpirole (r_pobj) by_10\IN|amphetamine (r_agent) induced_9\VBN|by (r_acl) hyperactivity_8\NN|the|locomotor|induced
D010656_D010554 NONE phenylephrine_7\NN|given|evaluated (l_acl) evaluated_15\VBN|in|as|aggressiveness (l_conj) aggressiveness_25\NN|the|evoked
D003000_D010554 NONE clonidine_28\NN| (r_pobj) by_27\IN|clonidine (r_agent) evoked_26\VBN|by|in (r_acl) aggressiveness_25\NN|the|evoked
17879945
D019438_D050197 CID ritonavir_5\VBZ| (r_compound) treatment_6\NN|ritonavir (r_nsubj) increases_7\VBZ|that|treatment|formation|to (l_dobj) formation_10\NN|atherosclerotic|lesion|in (l_compound) lesion_9\NN|
7802851
D000525_D016584 NONE alprazolam_3\NN|and|placebo (r_pobj) of_2\IN|alprazolam (r_prep) efficacy_1\NN|the|of|in|,|and|effect (l_prep) in_6\IN|disorder (l_pobj) disorder_8\NN|panic|with
D000525_D016584 NONE alprazolam_20\NN|to|or|placebo (r_xcomp) randomised_18\VBN|in|were|alprazolam|. (l_prep) In_0\IN|london (l_pobj) London_1\NNP|and|patients (l_conj) patients_5\NNS|toronto|154|met (l_relcl) met_7\VBD|who|criteria (l_dobj) criteria_11\NNS|iii|for (l_prep) for_12\IN|disorder (l_pobj) disorder_14\NN|panic|with
D000525_D000379 NONE alprazolam_3\NN|and|placebo (r_pobj) of_2\IN|alprazolam (r_prep) efficacy_1\NN|the|of|in|,|and|effect (l_prep) in_6\IN|disorder (l_pobj) disorder_8\NN|panic|with (l_prep) with_9\IN|agoraphobia (l_pobj) agoraphobia_10\NNP|
D000525_D000379 NONE alprazolam_20\NN|to|or|placebo (r_xcomp) randomised_18\VBN|in|were|alprazolam|. (l_prep) In_0\IN|london (l_pobj) London_1\NNP|and|patients (l_conj) patients_5\NNS|toronto|154|met (l_relcl) met_7\VBD|who|criteria (l_dobj) criteria_11\NNS|iii|for (l_prep) for_12\IN|disorder (l_pobj) disorder_14\NN|panic|with (l_prep) with_15\IN|agoraphobia (l_pobj) agoraphobia_16\NNP|
D000525_D003866 CID alprazolam_5\NN| (r_compound) patients_6\NNS|alprazolam (r_nsubj) developed_7\VBD|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS|adverse|(|%|)|of|;|and|effects (l_prep) of_18\IN|depression (l_pobj) depression_19\NN|,|enuresis
D000525_D004775 CID alprazolam_5\NN| (r_compound) patients_6\NNS|alprazolam (r_nsubj) developed_7\VBD|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS|adverse|(|%|)|of|;|and|effects (l_prep) of_18\IN|depression (l_pobj) depression_19\NN|,|enuresis (l_conj) enuresis_21\NN|,|disinhibition
D000525_D001523 NONE alprazolam_5\NN| (r_compound) patients_6\NNS|alprazolam (r_nsubj) developed_7\VBD|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS|adverse|(|%|)|of|;|and|effects (l_prep) of_18\IN|depression (l_pobj) depression_19\NN|,|enuresis (l_conj) enuresis_21\NN|,|disinhibition (l_conj) disinhibition_23\NN|and|aggression (l_conj) aggression_25\NN|
D000525_D001523 NONE alprazolam_5\NN| (r_compound) patients_6\NNS|alprazolam (r_nsubj) developed_7\VBD|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS|more|side|-|,|sedation (l_appos) sedation_34\NN|particularly|,|irritability (l_conj) irritability_36\NN|,|memory
D000525_D008569 CID alprazolam_5\NN| (r_compound) patients_6\NNS|alprazolam (r_nsubj) developed_7\VBD|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS|more|side|-|,|sedation (l_appos) sedation_34\NN|particularly|,|irritability (l_conj) irritability_36\NN|,|memory (l_conj) memory_39\NN|impaired|,|loss
D000525_D015431 CID alprazolam_5\NN| (r_compound) patients_6\NNS|alprazolam (r_nsubj) developed_7\VBD|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS|more|side|-|,|sedation (l_appos) sedation_34\NN|particularly|,|irritability (l_conj) irritability_36\NN|,|memory (l_conj) memory_39\NN|impaired|,|loss (l_conj) loss_42\NN|weight|and|ataxia
D000525_D001259 CID alprazolam_5\NN| (r_compound) patients_6\NNS|alprazolam (r_nsubj) developed_7\VBD|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS|more|side|-|,|sedation (l_appos) sedation_34\NN|particularly|,|irritability (l_conj) irritability_36\NN|,|memory (l_conj) memory_39\NN|impaired|,|loss (l_conj) loss_42\NN|weight|and|ataxia (l_conj) ataxia_44\NN|
15572383
D004317_D007674 NONE adriamycin_12\NNS| (r_advmod) induced_14\VBN|adriamycin|- (r_amod) damage_16\NN|induced|renal
D004317_D007674 NONE adriamycin_23\NNS| (r_pobj) of_22\IN|adriamycin (r_prep) injection_21\NN|a|single|of|in (r_pobj) by_18\IN|injection (r_agent) induced_17\VBN|by (r_acl) severity_13\NN|the|of|induced (l_prep) of_14\IN|damage (l_pobj) damage_16\NN|renal
D004317_D007674 NONE adriamycin_3\NNS|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN|elicited|nephrotic|range|,|damage (l_conj) damage_11\NN|renal|interstitial|and|glomerulosclerosis
D004317_D007674 NONE adriamycin_10\NNS| (r_advmod) induced_12\VBN|adriamycin|- (r_amod) damage_14\NN|induced|renal|in
D004317_D011507 CID adriamycin_10\NNS|[|intravenously (r_pobj) by_9\IN|adriamycin (r_agent) induced_8\VBN|after|,|proteinuria|was|by|. (l_nsubjpass) proteinuria_6\NN|
D004317_D011507 CID adriamycin_3\NNS|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN|elicited|nephrotic|range|,|damage
D004317_D011507 CID adriamycin_12\NNS|after|0.62|,|actin (r_advcl) correlated_4\VBD|ace|positively|with|adriamycin (l_prep) with_5\IN|rise (l_pobj) rise_8\NN|the|relative|in (l_prep) in_9\IN|proteinuria (l_pobj) proteinuria_10\NN|
D004317_D009404 NONE adriamycin_3\NNS|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN|elicited|nephrotic|range|,|damage (l_amod) nephrotic_5\JJ|
D004317_D005923 NONE adriamycin_3\NNS|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN|elicited|nephrotic|range|,|damage (l_conj) damage_11\NN|renal|interstitial|and|glomerulosclerosis (l_conj) glomerulosclerosis_15\NN|mild|focal
10342929
D000806_D000799 CID inhibitors_4\NNS|ace|:|common (r_pobj) to_2\IN|inhibitors (r_pcomp) due_1\IN|to (r_prep) Angioedema_0\NNP|due|.
D000806_D000799 CID inhibitor_13\NN| (r_compound) treatment_14\NN|ace|)|inhibitor (r_nsubj) is_15\VBZ|incidence|(|treatment|patients|. (l_nsubj) incidence_2\NN|the|estimated|of|during (l_prep) of_3\IN|angioedema (l_pobj) angioedema_4\NN|
9245658
D009538_D002318 CID nicotine_3\NN| (r_pobj) of_2\IN|nicotine (r_prep) role_1\NN|the|of|in|. (l_prep) in_4\IN|disease (l_pobj) disease_9\NN|related|cardiovascular
D009538_D002318 CID Nicotine_0\NNP| (r_nsubj) activates_1\VBZ|nicotine|system|and|contribute (l_conj) contribute_11\VB|in|could|to|. (l_prep) to_12\IN|disease (l_pobj) disease_14\NN|cardiovascular
D009538_D050197 CID nicotine_7\NN| (r_nsubj) play_9\VB|that|nicotine|could|role|, (l_dobj) role_11\NN|a|in (l_prep) in_12\IN|accelerating (l_pcomp) accelerating_13\VBG|atherosclerosis (l_dobj) atherosclerosis_14\NN|
D009538_D013927 NONE Nicotine_0\NN| (r_nsubj) appear_3\VB|nicotine|does|not|enhance|. (l_xcomp) enhance_5\VB|to|thrombosis (l_dobj) thrombosis_6\NN|among
2440413
D001556_D012640 NONE hexachlorocyclohexane_5\NN|gamma|-|lindane (r_pobj) of_2\IN|hexachlorocyclohexane (r_prep) effects_1\NNS|differential|of|on|. (l_prep) on_9\IN|seizures (l_pobj) seizures_13\NNS|induced
D001556_D012640 NONE lindane_7\NN|(|) (r_appos) hexachlorocyclohexane_5\NN|gamma|-|lindane (r_pobj) of_2\IN|hexachlorocyclohexane (r_prep) effects_1\NNS|differential|of|on|. (l_prep) on_9\IN|seizures (l_pobj) seizures_13\NNS|induced
D001556_D012640 NONE hexachlorocyclohexane_2\NN|gamma|-|(|hch|)|,|ingredient|, (r_nsubjpass) shown_19\VBN|hexachlorocyclohexane|has|been|decrease|) (l_xcomp) decrease_21\VB|to|threshold|to (l_dobj) threshold_23\NN|seizure (l_compound) seizure_22\NN|
D001556_D012640 NONE HCH_6\NNP|gamma|- (r_appos) hexachlorocyclohexane_2\NN|gamma|-|(|hch|)|,|ingredient|, (r_nsubjpass) shown_19\VBN|hexachlorocyclohexane|has|been|decrease|) (l_xcomp) decrease_21\VB|to|threshold|to (l_dobj) threshold_23\NN|seizure (l_compound) seizure_22\NN|
D001556_D012640 NONE lindane_15\NN|the|insecticide (r_pobj) of_12\IN|lindane (r_prep) ingredient_11\NN|the|active|of (r_appos) hexachlorocyclohexane_2\NN|gamma|-|(|hch|)|,|ingredient|, (r_nsubjpass) shown_19\VBN|hexachlorocyclohexane|has|been|decrease|) (l_xcomp) decrease_21\VB|to|threshold|to (l_dobj) threshold_23\NN|seizure (l_compound) seizure_22\NN|
D001556_D012640 NONE HCH_7\NNP|gamma|- (r_pobj) to_4\IN|hch (r_prep) exposure_3\NN|to (r_pobj) after_2\IN|exposure (r_prep) h_1\NN|3|after|and|increase (l_conj) increase_10\VB|conversely|threshold|to (l_prep) to_12\IN|seizures (l_pobj) seizures_16\NNS|induced
D001556_D012640 NONE HCH_24\NNP|gamma|-|al (r_pobj) to_21\IN|hch (r_prep) exposure_20\NN|to (r_pobj) after_19\IN|exposure (r_prep) h_18\NN|h|24|after|)|. (l_dep) h_1\NN|3|after|and|increase (l_conj) increase_10\VB|conversely|threshold|to (l_prep) to_12\IN|seizures (l_pobj) seizures_16\NNS|induced
D001556_D012640 NONE HCH_30\NNP|mg/kg|gamma|- (r_pobj) of_25\IN|hch (r_prep) administration_24\NN|intraperitoneal|of (r_pobj) after_22\IN|administration (r_prep) tested_15\VBN|in|,|severity|was|in|h|after|. (l_nsubjpass) severity_5\NN|the|of (l_prep) of_6\IN|response (l_pobj) response_7\NN|to (l_prep) to_8\IN|agents (l_pobj) agents_13\NNS|other|inducing (l_amod) inducing_12\VBG|seizure|- (l_npadvmod) seizure_10\NN|
D001556_D012640 NONE HCH_8\NNP|gamma|- (r_pobj) of_5\IN|hch (r_prep) administration_4\NN|the|of (r_pobj) after_2\IN|administration (r_prep) increased_18\VBN|hour|after|,|activity|was (l_nsubjpass) activity_11\NN|the|of (l_prep) of_12\IN|agents (l_pobj) agents_16\NNS|inducing (l_amod) inducing_15\VBG|seizure|- (l_npadvmod) seizure_13\NN|
D001556_D012640 NONE HCH_31\NNP|- (r_appos) h_27\NN|24|after|hch (r_dep) observed_36\VBN|increased|,|regardless|,|while|h|response|was|. (l_advcl) increased_18\VBN|hour|after|,|activity|was (l_nsubjpass) activity_11\NN|the|of (l_prep) of_12\IN|agents (l_pobj) agents_16\NNS|inducing (l_amod) inducing_15\VBG|seizure|- (l_npadvmod) seizure_13\NN|
D001556_D012640 NONE HCH_22\NNP|gamma|- (r_pobj) after_19\IN|hch (r_prep) h_18\NN|24|after (r_npadvmod) occur_8\VB|that|tolerance|may|to|h|,|decreased (l_prep) to_9\IN|activity (l_pobj) activity_11\NN|seizure|induced (l_compound) seizure_10\NN|
D001556_D012640 NONE HCH_22\NNP|gamma|- (r_pobj) after_19\IN|hch (r_prep) h_18\NN|24|after (r_npadvmod) occur_8\VB|that|tolerance|may|to|h|,|decreased (l_advcl) decreased_36\VBN|since|response|is (l_nsubjpass) response_26\NN|the|to (l_prep) to_27\IN|agents (l_pobj) agents_34\NNS|only|these|two|inducing (l_amod) inducing_33\VBG|seizure|- (l_npadvmod) seizure_31\NN|
D001556_D012640 NONE HCH_20\NNP|gamma|- (r_nsubj) be_22\VB|that|site|hch|may|channel (l_nsubj) site_7\NN|the|responsible|h (l_amod) responsible_8\JJ|for (l_prep) for_9\IN|decrease (l_pobj) decrease_11\NN|the|in (l_prep) in_12\IN|activity (l_pobj) activity_14\NN|seizure (l_compound) seizure_13\NN|
D010433_D012640 CID PTZ_27\NNP|pentylenetrazol|( (r_pobj) to_24\TO|ptz (r_prep) decrease_21\VB|to|threshold|to (l_dobj) threshold_23\NN|seizure (l_compound) seizure_22\NN|
D010433_D012640 CID PTZ_13\NNP| (r_npadvmod) induced_15\VBN|ptz|- (r_amod) seizures_16\NNS|induced
D010433_D012640 CID PTZ_4\NNP|and|picrotoxin|ptx (r_pobj) due_2\IN|to|ptz (r_amod) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
D010433_D012640 CID PTZ_4\NNP|and|picrotoxin|ptx (r_pobj) due_2\IN|to|ptz (r_amod) activity_1\NN|seizure|due (r_nsubjpass) decreased_12\VBN|activity|was|significantly (r_ccomp) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_nsubj) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
D010433_D012640 CID PTZ_14\NNP|and|ptx (r_pobj) by_13\IN|ptz (r_agent) induced_12\VBN|by (r_acl) activity_11\NN|seizure|induced (l_compound) seizure_10\NN|
D010433_D012640 CID PTZ_14\NNP|and|ptx (r_pobj) by_13\IN|ptz (r_agent) induced_12\VBN|by (r_acl) activity_11\NN|seizure|induced (r_pobj) to_9\IN|activity (r_prep) occur_8\VB|that|tolerance|may|to|h|,|decreased (l_advcl) decreased_36\VBN|since|response|is (l_nsubjpass) response_26\NN|the|to (l_prep) to_27\IN|agents (l_pobj) agents_34\NNS|only|these|two|inducing (l_amod) inducing_33\VBG|seizure|- (l_npadvmod) seizure_31\NN|
D010852_D012640 CID picrotoxin_6\NN| (r_conj) PTZ_4\NNP|and|picrotoxin|ptx (r_pobj) due_2\IN|to|ptz (r_amod) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
D010852_D012640 CID picrotoxin_6\NN| (r_conj) PTZ_4\NNP|and|picrotoxin|ptx (r_pobj) due_2\IN|to|ptz (r_amod) activity_1\NN|seizure|due (r_nsubjpass) decreased_12\VBN|activity|was|significantly (r_ccomp) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_nsubj) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
D010852_D012640 CID PTX_8\NNP|(|) (r_appos) PTZ_4\NNP|and|picrotoxin|ptx (r_pobj) due_2\IN|to|ptz (r_amod) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
D010852_D012640 CID PTX_8\NNP|(|) (r_appos) PTZ_4\NNP|and|picrotoxin|ptx (r_pobj) due_2\IN|to|ptz (r_amod) activity_1\NN|seizure|due (r_nsubjpass) decreased_12\VBN|activity|was|significantly (r_ccomp) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_nsubj) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
D010852_D012640 CID PTX_16\NNP| (r_conj) PTZ_14\NNP|and|ptx (r_pobj) by_13\IN|ptz (r_agent) induced_12\VBN|by (r_acl) activity_11\NN|seizure|induced (l_compound) seizure_10\NN|
D010852_D012640 CID PTX_16\NNP| (r_conj) PTZ_14\NNP|and|ptx (r_pobj) by_13\IN|ptz (r_agent) induced_12\VBN|by (r_acl) activity_11\NN|seizure|induced (r_pobj) to_9\IN|activity (r_prep) occur_8\VB|that|tolerance|may|to|h|,|decreased (l_advcl) decreased_36\VBN|since|response|is (l_nsubjpass) response_26\NN|the|to (l_prep) to_27\IN|agents (l_pobj) agents_34\NNS|only|these|two|inducing (l_amod) inducing_33\VBG|seizure|- (l_npadvmod) seizure_31\NN|
D015097_D012640 CID acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (r_nsubj) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN|activity|was|significantly (l_nsubjpass) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
D015097_D012640 CID acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
D015097_D012640 CID MPA_23\NNP|(|) (r_appos) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (r_nsubj) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN|activity|was|significantly (l_nsubjpass) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
D015097_D012640 CID MPA_23\NNP|(|) (r_appos) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
D001640_D012640 CID bicuculline_26\NN| (r_conj) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (r_nsubj) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN|activity|was|significantly (l_nsubjpass) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
D001640_D012640 CID bicuculline_26\NN| (r_conj) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
D001640_D012640 CID BCC_28\NNP|(|) (r_appos) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (r_nsubj) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN|activity|was|significantly (l_nsubjpass) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
D001640_D012640 CID BCC_28\NNP|(|) (r_appos) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
C034818_D012640 CID carboline-3-carboxylate_36\NNP|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (r_nsubj) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN|activity|was|significantly (l_nsubjpass) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
C034818_D012640 CID carboline-3-carboxylate_36\NNP|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
C034818_D012640 CID DMCM_38\NNP| (r_appos) carboline-3-carboxylate_36\NNP|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (r_nsubj) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN|activity|was|significantly (l_nsubjpass) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
C034818_D012640 CID DMCM_38\NNP| (r_appos) carboline-3-carboxylate_36\NNP|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
D013331_D012640 CID strychnine_42\NN| (r_conj) carboline-3-carboxylate_36\NNP|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (r_nsubj) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN|activity|was|significantly (l_nsubjpass) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
D013331_D012640 CID strychnine_42\NN| (r_conj) carboline-3-carboxylate_36\NNP|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
D013331_D012640 CID STR_44\NNP| (r_appos) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (r_nsubj) was_46\VBD|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN|activity|was|significantly (l_nsubjpass) activity_1\NN|seizure|due (l_compound) Seizure_0\NN|
D013331_D012640 CID STR_44\NNP| (r_appos) acid_21\NN|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN|acid (r_pcomp) due_18\IN|to (r_prep) activity_17\NN|seizure|due (l_compound) seizure_16\NN|
D005680_D012640 NONE GABA_24\NNP| (r_compound) A_26\NNP|gaba|- (r_nmod) channel_31\NN|the|a|linked|chloride (r_attr) be_22\VB|that|site|hch|may|channel (l_nsubj) site_7\NN|the|responsible|h (l_amod) responsible_8\JJ|for (l_prep) for_9\IN|decrease (l_pobj) decrease_11\NN|the|in (l_prep) in_12\IN|activity (l_pobj) activity_14\NN|seizure (l_compound) seizure_13\NN|
18417364
D009538_D009759 CID Nicotine_0\NN| (r_npadvmod) induced_2\VBN|nicotine|- (r_amod) nystagmus_3\NN|induced
D009538_D009759 CID nicotine_3\NN| (r_npadvmod) induced_5\VBN|nicotine|- (r_amod) nystagmus_6\NN|induced|(|nin|)
D009538_D009759 CID nicotine_3\NN| (r_npadvmod) induced_5\VBN|nicotine|- (r_amod) nystagmus_6\NN|induced|(|nin|) (l_appos) NIN_8\NNP|
D010100_D009759 NONE oxygen_4\NN|blood (r_nmod) levels_12\NNS|oxygen|dependent|(|bold|)|activity|in (r_pobj) with_2\IN|levels (r_prep) correlated_1\VBD|nin|with|. (l_nsubj) NIN_0\NNP|
2559236
D004317_D007674 NONE adriamycin_9\NNS| (r_npadvmod) induced_11\VBN|adriamycin|- (r_amod) nephropathy_12\NN|induced
D004317_D007674 NONE adriamycin_24\JJ| (r_amod) nephrosis_25\NN|adriamycin (r_pobj) in_23\IN|nephrosis (r_prep) injury_22\NN|renal|in
D004656_D009401 NONE enalapril_10\NN|(|cei|) (r_appos) inhibitor_6\NN|enzyme|enalapril (r_pobj) of_2\IN|inhibitor (r_prep) effect_1\NN|the|of (r_nsubjpass) assessed_12\VBN|effect|was|in|with|. (l_prep) with_18\IN|nephrosis (l_pobj) nephrosis_21\NN|established|adriamycin
D004656_D009401 NONE enalapril_17\NN| (r_pobj) of_16\IN|enalapril (r_prep) effect_15\NN|the|of|on (l_prep) on_18\IN|progression (l_pobj) progression_19\NN|of (l_prep) of_20\IN|injury (l_pobj) injury_22\NN|renal|in (l_prep) in_23\IN|nephrosis (l_pobj) nephrosis_25\NN|adriamycin
D004317_D009401 CID adriamycin_20\NNS| (r_amod) nephrosis_21\NN|established|adriamycin
D004317_D009401 CID adriamycin_24\JJ| (r_amod) nephrosis_25\NN|adriamycin
D004317_D000419 CID adriamycin_7\NNS| (r_pobj) of_6\IN|adriamycin (r_prep) dose_5\NN|a|single|of|and (r_dobj) given_2\VBN|rats|were|dose|divided|. (l_advcl) divided_12\VBD|later|into (l_prep) into_13\IN|groups (l_pobj) groups_15\NNS|four|matched (l_acl) matched_16\VBN|for (l_prep) for_17\IN|albuminuria (l_pobj) albuminuria_18\NN|,|pressure
D004656_D000419 NONE enalapril_7\DT| (r_nsubj) reduced_8\JJ|that|enalapril|pressure|2|vs. (l_prep) vs._16\IN|hg (l_pobj) Hg_21\NNP|mm|,|group|,|p|)|and|pressure (l_conj) pressure_36\NN|glomerular|capillary|(|+/-|(|+/-|)|or|gfr (l_appos) +/-_39\SYM|54|1|vs.|without (l_prep) without_53\IN|reducing (l_pcomp) reducing_54\VBG|albuminuria (l_dobj) albuminuria_55\NN|
D004656_D000419 NONE enalapril_1\NN|chronic (r_compound) treatment_2\NN|enalapril (r_nsubj) reduced_3\VBN|treatment (r_amod) pressure_5\NN|reduced|blood|without|. (l_prep) without_6\IN|reducing (l_pcomp) reducing_7\VBG|albuminuria|in (l_dobj) albuminuria_8\NN|
D004656_D007674 NONE enalapril_17\NN| (r_pobj) of_16\IN|enalapril (r_prep) effect_15\NN|the|of|on (l_prep) on_18\IN|progression (l_pobj) progression_19\NN|of (l_prep) of_20\IN|injury (l_pobj) injury_22\NN|renal|in
12464714
C093622_D008881 NONE rizatriptan_7\JJ| (r_pobj) for_6\IN|rizatriptan (r_prep) preference_5\NN|for (r_conj) efficacy_3\NN|and|preference (r_pobj) of_2\IN|efficacy (r_prep) comparison_1\NN|crossover|of|caffeine|. (l_conj) caffeine_13\NN|mg|ergotamine|/|in (l_prep) in_14\IN|migraine (l_pobj) migraine_15\NN|
C093622_D008881 NONE Rizatriptan_0\NNP| (r_nsubj) is_1\VBZ|rizatriptan|agonist|. (l_attr) agonist_7\NN|a|selective|receptor|with (l_prep) with_8\IN|absorption (l_pobj) absorption_11\NN|rapid|oral|and|onset (l_conj) onset_14\NN|early|of|in (l_prep) in_17\IN|treatment (l_pobj) treatment_20\NN|the|acute|of (l_prep) of_21\IN|migraine (l_pobj) migraine_22\NN|
C093622_D008881 NONE rizatriptan_12\JJ|1|tablet (r_pobj) for_10\IN|rizatriptan (r_prep) preference_9\NN|the|for (r_dobj) assessed_7\VBD|study|preference|tablets|in|. (l_prep) in_26\IN|patients (l_pobj) patients_28\NNS|439|treating (l_acl) treating_29\VBG|attack (l_dobj) attack_33\NN|a|single|migraine|with (l_compound) migraine_32\JJ|
D004878_D008881 NONE ergotamine_11\NN| (r_nmod) caffeine_13\NN|mg|ergotamine|/|in (l_prep) in_14\IN|migraine (l_pobj) migraine_15\NN|
D004878_D008881 NONE ergotamine_18\NN|2|caffeine (r_pobj) to_16\IN|ergotamine (r_prep) tablet_15\NN|mg|to (r_amod) rizatriptan_12\JJ|1|tablet (r_pobj) for_10\IN|rizatriptan (r_prep) preference_9\NN|the|for (r_dobj) assessed_7\VBD|study|preference|tablets|in|. (l_prep) in_26\IN|patients (l_pobj) patients_28\NNS|439|treating (l_acl) treating_29\VBG|attack (l_dobj) attack_33\NN|a|single|migraine|with (l_compound) migraine_32\JJ|
D002110_D008881 NONE caffeine_13\NN|mg|ergotamine|/|in (l_prep) in_14\IN|migraine (l_pobj) migraine_15\NN|
D002110_D008881 NONE caffeine_22\NN|1|mg|/ (r_appos) ergotamine_18\NN|2|caffeine (r_pobj) to_16\IN|ergotamine (r_prep) tablet_15\NN|mg|to (r_amod) rizatriptan_12\JJ|1|tablet (r_pobj) for_10\IN|rizatriptan (r_prep) preference_9\NN|the|for (r_dobj) assessed_7\VBD|study|preference|tablets|in|. (l_prep) in_26\IN|patients (l_pobj) patients_28\NNS|439|treating (l_acl) treating_29\VBG|attack (l_dobj) attack_33\NN|a|single|migraine|with (l_compound) migraine_32\JJ|
D012701_D008881 NONE 5-HT(1B/1D_4\CD| (r_nummod) receptor_6\NN|5-ht(1b/1d|) (r_compound) agonist_7\NN|a|selective|receptor|with (l_prep) with_8\IN|absorption (l_pobj) absorption_11\NN|rapid|oral|and|onset (l_conj) onset_14\NN|early|of|in (l_prep) in_17\IN|treatment (l_pobj) treatment_20\NN|the|acute|of (l_prep) of_21\IN|migraine (l_pobj) migraine_22\NN|
C093622_D006261 NONE rizatriptan_19\JJ|and|% (r_dobj) preferring_18\VBG|rizatriptan (r_acl) patients_17\NNS|preferring (r_pobj) of_16\IN|patients (r_prep) %_15\NN|67.3|of (r_pobj) by_13\IN|% (r_agent) cited_12\VBN|by (r_acl) reason_8\NN|the|important|for|,|cited (r_attr) was_4\VBD|relief|reason|. (l_nsubj) relief_1\NN|faster|of (l_prep) of_2\IN|headache (l_pobj) headache_3\NN|
D004878_D006261 NONE ergotamine_27\NN| (r_nmod) caffeine_29\NN|ergotamine|/ (r_dobj) preferred_26\VBD|who|caffeine (r_relcl) patients_24\NNS|preferred (r_pobj) of_23\IN|patients (r_prep) %_22\NN|54.2|of (r_conj) rizatriptan_19\JJ|and|% (r_dobj) preferring_18\VBG|rizatriptan (r_acl) patients_17\NNS|preferring (r_pobj) of_16\IN|patients (r_prep) %_15\NN|67.3|of (r_pobj) by_13\IN|% (r_agent) cited_12\VBN|by (r_acl) reason_8\NN|the|important|for|,|cited (r_attr) was_4\VBD|relief|reason|. (l_nsubj) relief_1\NN|faster|of (l_prep) of_2\IN|headache (l_pobj) headache_3\NN|
D002110_D006261 NONE caffeine_29\NN|ergotamine|/ (r_dobj) preferred_26\VBD|who|caffeine (r_relcl) patients_24\NNS|preferred (r_pobj) of_23\IN|patients (r_prep) %_22\NN|54.2|of (r_conj) rizatriptan_19\JJ|and|% (r_dobj) preferring_18\VBG|rizatriptan (r_acl) patients_17\NNS|preferring (r_pobj) of_16\IN|patients (r_prep) %_15\NN|67.3|of (r_pobj) by_13\IN|% (r_agent) cited_12\VBN|by (r_acl) reason_8\NN|the|important|for|,|cited (r_attr) was_4\VBD|relief|reason|. (l_nsubj) relief_1\NN|faster|of (l_prep) of_2\IN|headache (l_pobj) headache_3\NN|
C093622_D010146 NONE rizatriptan_12\NN| (r_pobj) after_11\IN|rizatriptan (r_prep) h_10\NN|2|after (r_npadvmod) were_6\VBD|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ|pain (l_npadvmod) pain_7\NN|
C093622_D010146 NONE rizatriptan_31\JJ| (r_nsubj) being_32\VBG|rizatriptan|superior|within (r_advcl) were_6\VBD|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ|pain (l_npadvmod) pain_7\NN|
C093622_D010146 NONE rizatriptan_6\NN| (r_dobj) taking_5\VBG|rizatriptan (r_acl) patients_4\NNS|taking (r_pobj) of_3\IN|patients (r_prep) %_2\NN|36|of (r_nsubj) were_7\VBD|%|free|at|and|had|,|compared|. (l_acomp) free_9\JJ|pain (l_npadvmod) pain_8\NN|
D004878_D010146 NONE ergotamine_20\NN| (r_nmod) caffeine_22\NN|ergotamine|/|0.001 (r_pobj) with_19\IN|caffeine (r_prep) treated_18\VBN|with (r_acl) %_17\NN|24.3|treated (r_pobj) with_15\IN|% (r_prep) compared_14\VBN|with (r_prep) were_6\VBD|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ|pain (l_npadvmod) pain_7\NN|
D004878_D010146 NONE ergotamine_33\NNP| (r_nmod) caffeine_35\NN|ergotamine|/|0.001 (r_pobj) on_32\IN|caffeine (r_prep) patients_31\NNS|on (r_pobj) of_30\IN|patients (r_prep) %_29\NN|20|of (r_pobj) to_27\IN|% (r_prep) compared_26\VBN|to (r_prep) were_7\VBD|%|free|at|and|had|,|compared|. (l_acomp) free_9\JJ|pain (l_npadvmod) pain_8\NN|
D002110_D010146 NONE caffeine_22\NN|ergotamine|/|0.001 (r_pobj) with_19\IN|caffeine (r_prep) treated_18\VBN|with (r_acl) %_17\NN|24.3|treated (r_pobj) with_15\IN|% (r_prep) compared_14\VBN|with (r_prep) were_6\VBD|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ|pain (l_npadvmod) pain_7\NN|
D002110_D010146 NONE caffeine_35\NN|ergotamine|/|0.001 (r_pobj) on_32\IN|caffeine (r_prep) patients_31\NNS|on (r_pobj) of_30\IN|patients (r_prep) %_29\NN|20|of (r_pobj) to_27\IN|% (r_prep) compared_26\VBN|to (r_prep) were_7\VBD|%|free|at|and|had|,|compared|. (l_acomp) free_9\JJ|pain (l_npadvmod) pain_8\NN|
C093622_D009325 CID Rizatriptan_0\NNP| (r_nsubj) was_1\VBD|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ|to (l_prep) to_4\IN|caffeine (l_pobj) caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting
C093622_D009325 CID rizatriptan_17\NN|and|caffeine (r_pobj) after_16\IN|rizatriptan (r_prep) >_7\XX|incidence|or|%|after (r_appos) events_4\NNS|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN|(|4.2|)|and|somnolence
C093622_D014839 NONE Rizatriptan_0\NNP| (r_nsubj) was_1\VBD|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ|to (l_prep) to_4\IN|caffeine (l_pobj) caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting (l_conj) vomiting_17\VBG|,|phonophobia|and|for
C093622_D012001 NONE Rizatriptan_0\NNP| (r_nsubj) was_1\VBD|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ|to (l_prep) to_4\IN|caffeine (l_pobj) caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting (l_conj) vomiting_17\VBG|,|phonophobia|and|for (l_conj) phonophobia_19\NNS|or|photophobia
C093622_D020795 NONE Rizatriptan_0\NNP| (r_nsubj) was_1\VBD|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ|to (l_prep) to_4\IN|caffeine (l_pobj) caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting (l_conj) vomiting_17\VBG|,|phonophobia|and|for (l_conj) phonophobia_19\NNS|or|photophobia (l_conj) photophobia_21\NNS|
D004878_D009325 NONE ergotamine_5\NN| (r_nmod) caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting
D004878_D009325 NONE ergotamine_19\NNP| (r_nmod) caffeine_21\NN|ergotamine|/ (r_conj) rizatriptan_17\NN|and|caffeine (r_pobj) after_16\IN|rizatriptan (r_prep) >_7\XX|incidence|or|%|after (r_appos) events_4\NNS|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN|(|4.2|)|and|somnolence
D004878_D014839 NONE ergotamine_5\NN| (r_nmod) caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting (l_conj) vomiting_17\VBG|,|phonophobia|and|for
D004878_D012001 NONE ergotamine_5\NN| (r_nmod) caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting (l_conj) vomiting_17\VBG|,|phonophobia|and|for (l_conj) phonophobia_19\NNS|or|photophobia
D004878_D020795 NONE ergotamine_5\NN| (r_nmod) caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting (l_conj) vomiting_17\VBG|,|phonophobia|and|for (l_conj) phonophobia_19\NNS|or|photophobia (l_conj) photophobia_21\NNS|
D002110_D009325 NONE caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting
D002110_D009325 NONE caffeine_21\NN|ergotamine|/ (r_conj) rizatriptan_17\NN|and|caffeine (r_pobj) after_16\IN|rizatriptan (r_prep) >_7\XX|incidence|or|%|after (r_appos) events_4\NNS|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN|(|4.2|)|and|somnolence
D002110_D014839 NONE caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting (l_conj) vomiting_17\VBG|,|phonophobia|and|for
D002110_D012001 NONE caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting (l_conj) vomiting_17\VBG|,|phonophobia|and|for (l_conj) phonophobia_19\NNS|or|photophobia
D002110_D020795 NONE caffeine_7\NN|ergotamine|/|in (l_prep) in_8\IN|proportions (l_pobj) proportions_10\NNS|the|of (l_prep) of_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|nausea (l_pobj) nausea_15\NN|no|,|vomiting (l_conj) vomiting_17\VBG|,|phonophobia|and|for (l_conj) phonophobia_19\NNS|or|photophobia (l_conj) photophobia_21\NNS|
C093622_D004244 CID rizatriptan_17\NN|and|caffeine (r_pobj) after_16\IN|rizatriptan (r_prep) >_7\XX|incidence|or|%|after (r_appos) events_4\NNS|the|common|adverse|(|>|,|nausea (r_nsubj) were_25\VBD|events|respectively|,|dizziness|,|. (l_attr) dizziness_26\NN|(|6.7|)
C093622_D006970 NONE rizatriptan_17\NN|and|caffeine (r_pobj) after_16\IN|rizatriptan (r_prep) >_7\XX|incidence|or|%|after (r_appos) events_4\NNS|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN|(|4.2|)|and|somnolence (l_conj) somnolence_42\NN|(|5.5|)
D004878_D004244 NONE ergotamine_19\NNP| (r_nmod) caffeine_21\NN|ergotamine|/ (r_conj) rizatriptan_17\NN|and|caffeine (r_pobj) after_16\IN|rizatriptan (r_prep) >_7\XX|incidence|or|%|after (r_appos) events_4\NNS|the|common|adverse|(|>|,|nausea (r_nsubj) were_25\VBD|events|respectively|,|dizziness|,|. (l_attr) dizziness_26\NN|(|6.7|)
D004878_D006970 NONE ergotamine_19\NNP| (r_nmod) caffeine_21\NN|ergotamine|/ (r_conj) rizatriptan_17\NN|and|caffeine (r_pobj) after_16\IN|rizatriptan (r_prep) >_7\XX|incidence|or|%|after (r_appos) events_4\NNS|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN|(|4.2|)|and|somnolence (l_conj) somnolence_42\NN|(|5.5|)
D002110_D004244 NONE caffeine_21\NN|ergotamine|/ (r_conj) rizatriptan_17\NN|and|caffeine (r_pobj) after_16\IN|rizatriptan (r_prep) >_7\XX|incidence|or|%|after (r_appos) events_4\NNS|the|common|adverse|(|>|,|nausea (r_nsubj) were_25\VBD|events|respectively|,|dizziness|,|. (l_attr) dizziness_26\NN|(|6.7|)
D002110_D006970 NONE caffeine_21\NN|ergotamine|/ (r_conj) rizatriptan_17\NN|and|caffeine (r_pobj) after_16\IN|rizatriptan (r_prep) >_7\XX|incidence|or|%|after (r_appos) events_4\NNS|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN|(|4.2|)|and|somnolence (l_conj) somnolence_42\NN|(|5.5|)
3827439
D000666_D058186 CID amphotericin_6\JJ| (r_pobj) from_5\IN|amphotericin (r_prep) failure_4\NN|recurrent|reversible|acute|renal|from|.
D000666_D058186 CID B_18\NNP|amphotericin (r_pobj) of_16\IN|b (r_prep) administration_15\NN|the|of (r_dobj) following_13\VBG|immediately|administration|on (r_acl) failure_11\NN|acute|renal|following
D000666_D058186 CID amphotericin_3\JJ| (r_advmod) propose_1\VBP|we|that|amphotericin|activate|. (l_conj) activate_15\VB|,|in|,|may|feedback|,|contributing (l_advcl) contributing_20\VBG|thereby|to (l_prep) to_21\IN|failure (l_pobj) failure_24\NN|acute|renal
D000666_D005355 NONE B_18\NNP|amphotericin (r_pobj) of_16\IN|b (r_prep) administration_15\NN|the|of (r_dobj) following_13\VBG|immediately|administration|on (r_acl) failure_11\NN|acute|renal|following (r_dobj) developed_8\VBD|patient|failure|. (l_nsubj) patient_1\NN|a|with|and|disseminated (l_prep) with_2\IN|cirrhosis (l_pobj) cirrhosis_4\NN|cryptogenic
D000666_D013174 NONE B_18\NNP|amphotericin (r_pobj) of_16\IN|b (r_prep) administration_15\NN|the|of (r_dobj) following_13\VBG|immediately|administration|on (r_acl) failure_11\NN|acute|renal|following (r_dobj) developed_8\VBD|patient|failure|. (l_nsubj) patient_1\NN|a|with|and|disseminated (l_conj) disseminated_6\VBN|sporotrichosis (l_dobj) sporotrichosis_7\NN|
20003049
C031942_D013921 NONE argatroban_4\NN|elevation|in|. (l_prep) in_5\IN|patient (l_pobj) patient_9\NN|a|transplant|with (l_prep) with_10\IN|history (l_pobj) history_13\NN|a|suspected|of (l_prep) of_14\IN|thrombocytopenia (l_pobj) thrombocytopenia_18\NN|induced|with
C031942_D013921 NONE argatroban_20\NN|for (r_oprd) administered_19\VBN|in|,|patient|was|argatroban|during|. (l_nsubjpass) patient_11\JJ|a|old|ill|with (l_prep) with_12\IN|history (l_pobj) history_15\NN|a|suspected|of (l_prep) of_16\IN|hitt (l_pobj) HITT_17\NNP|
C031942_D013927 NONE argatroban_4\NN|elevation|in|. (l_prep) in_5\IN|patient (l_pobj) patient_9\NN|a|transplant|with (l_prep) with_10\IN|history (l_pobj) history_13\NN|a|suspected|of (l_prep) of_14\IN|thrombocytopenia (l_pobj) thrombocytopenia_18\NN|induced|with (l_prep) with_19\IN|thrombosis (l_pobj) thrombosis_20\NN|
C031942_D013927 NONE argatroban_20\NN|for (r_oprd) administered_19\VBN|in|,|patient|was|argatroban|during|. (l_nsubjpass) patient_11\JJ|a|old|ill|with (l_prep) with_12\IN|history (l_pobj) history_15\NN|a|suspected|of (l_prep) of_16\IN|hitt (l_pobj) HITT_17\NNP|
D006493_D013921 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|heparin|- (r_amod) thrombocytopenia_18\NN|induced|with
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|heparin|- (r_amod) thrombocytopenia_21\NN|induced|(|hit
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|heparin|- (r_amod) thrombocytopenia_21\NN|induced|(|hit (l_appos) HIT_23\NNP|)
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|heparin|- (r_amod) thrombocytopenia_21\NN|induced|(|hit (r_pobj) of_17\IN|thrombocytopenia (r_prep) history_16\NN|a|of (r_pobj) with_14\IN|history (r_prep) patients_13\NNS|with (r_pobj) for_12\IN|patients (r_prep) anticoagulation_11\NN|for (r_pobj) of_10\IN|anticoagulation (r_prep) method_9\NN|an|alternative|of (r_dobj) provide_6\VBP|inhibitors|method|or|hit|. (l_conj) HIT_26\VB|with|undergoing
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|heparin|- (r_amod) thrombocytopenia_21\NN|induced|(|hit (r_pobj) of_17\IN|thrombocytopenia (r_prep) history_16\NN|a|of (r_pobj) with_14\IN|history (r_prep) patients_13\NNS|with (r_pobj) for_12\IN|patients (r_prep) anticoagulation_11\NN|for (r_pobj) of_10\IN|anticoagulation (r_prep) method_9\NN|an|alternative|of (r_dobj) provide_6\VBP|inhibitors|method|or|hit|. (l_conj) HIT_26\VB|with|undergoing (l_prep) with_27\IN|thrombosis (l_pobj) thrombosis_28\NN|hitt (l_appos) HITT_30\NNP|(|)
D006493_D013927 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|heparin|- (r_amod) thrombocytopenia_18\NN|induced|with (l_prep) with_19\IN|thrombosis (l_pobj) thrombosis_20\NN|
D006493_D013927 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|heparin|- (r_amod) thrombocytopenia_21\NN|induced|(|hit (r_pobj) of_17\IN|thrombocytopenia (r_prep) history_16\NN|a|of (r_pobj) with_14\IN|history (r_prep) patients_13\NNS|with (r_pobj) for_12\IN|patients (r_prep) anticoagulation_11\NN|for (r_pobj) of_10\IN|anticoagulation (r_prep) method_9\NN|an|alternative|of (r_dobj) provide_6\VBP|inhibitors|method|or|hit|. (l_conj) HIT_26\VB|with|undergoing (l_prep) with_27\IN|thrombosis (l_pobj) thrombosis_28\NN|hitt
D006493_D013927 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|heparin|- (r_amod) thrombocytopenia_21\NN|induced|(|hit (r_pobj) of_17\IN|thrombocytopenia (r_prep) history_16\NN|a|of (r_pobj) with_14\IN|history (r_prep) patients_13\NNS|with (r_pobj) for_12\IN|patients (r_prep) anticoagulation_11\NN|for (r_pobj) of_10\IN|anticoagulation (r_prep) method_9\NN|an|alternative|of (r_dobj) provide_6\VBP|inhibitors|method|or|hit|. (l_conj) HIT_26\VB|with|undergoing (l_prep) with_27\IN|thrombosis (l_pobj) thrombosis_28\NN|hitt (l_appos) HITT_30\NNP|(|)
C031942_D016638 NONE argatroban_20\NN|for (r_oprd) administered_19\VBN|in|,|patient|was|argatroban|during|. (l_nsubjpass) patient_11\JJ|a|old|ill|with (l_amod) ill_10\JJ|critically
C031942_D008107 NONE argatroban_4\NN| (r_pobj) of_3\IN|argatroban (r_prep) concentrations_2\NNS|high|of (r_nsubjpass) measured_6\VBN|concentrations|were|in|,|and|observed|is|. (l_conj) is_42\VBZ|minutes|) (l_attr) minutes_46\NNS|39|51|[|minutes|] (l_appos) minutes_52\NNS|<|=|181|with (l_prep) with_53\IN|impairment (l_pobj) impairment_55\NN|hepatic
C031942_D008107 NONE argatroban_25\JJ| (r_amod) life_27\NN|argatroban|half|t(1/2 (r_npadvmod) plasma_24\NN|a|prolonged|life|)|of (r_nsubjpass) observed_36\VBN|plasma|was|published (r_conj) measured_6\VBN|concentrations|were|in|,|and|observed|is|. (l_conj) is_42\VBZ|minutes|) (l_attr) minutes_46\NNS|39|51|[|minutes|] (l_appos) minutes_52\NNS|<|=|181|with (l_prep) with_53\IN|impairment (l_pobj) impairment_55\NN|hepatic
C031942_D001778 NONE argatroban_3\JJ| (r_amod) concentration_4\NN|correlation|argatroban|versus (r_nsubj) suggest_14\VBP|concentration|contributed|. (l_ccomp) contributed_24\VBN|that|levels|may|have|to (l_prep) to_25\IN|coagulopathy (l_pobj) coagulopathy_30\NN|patient|extended
C031942_D001778 NONE argatroban_21\NN| (r_amod) levels_18\NNS|prolonged|elevated|of|argatroban (r_nsubj) contributed_24\VBN|that|levels|may|have|to (l_prep) to_25\IN|coagulopathy (l_pobj) coagulopathy_30\NN|patient|extended
C031942_D001778 NONE argatroban_8\JJ| (r_amod) concentration_9\NN|argatroban|in (r_dobj) measure_6\VB|to|plasma|concentration|and|extended (l_conj) extended_16\VBN|coagulopathy (l_dobj) coagulopathy_17\NN|
7265370
D014223_D053040 CID Triamterene_0\JJ| (r_compound) nephrolithiasis_1\JJ|triamterene
D014223_D053040 CID triamterene_3\JJ| (r_compound) nephrolithiasis_4\NN|triamterene
D014223_D053040 CID triamterene_2\JJ| (r_compound) nephrolithiasis_3\NN|triamterene
C020743_D053040 NONE dyazide_3\RB| (r_compound) therapy_4\NN|dyazide (r_dobj) complicating_2\VBG|nephrolithiasis|therapy|. (l_nsubj) nephrolithiasis_1\JJ|triamterene
C020743_D053040 NONE triamterene_16\JJ|hydrochlorothiazide|- (r_compound) therapy_17\NN|triamterene (r_pobj) of_13\IN|therapy (r_prep) years_12\NNS|4|of|for (r_pobj) after_10\IN|years (r_prep) reported_6\VBN|case|is|in|after|. (l_nsubjpass) case_1\NN|a|of (l_prep) of_2\IN|nephrolithiasis (l_pobj) nephrolithiasis_4\NN|triamterene
D014223_D006973 NONE triamterene_3\JJ| (r_compound) nephrolithiasis_4\NN|triamterene (r_pobj) of_2\IN|nephrolithiasis (r_prep) case_1\NN|a|of (r_nsubjpass) reported_6\VBN|case|is|in|after|. (l_prep) after_10\IN|years (l_pobj) years_12\NNS|4|of|for (l_prep) for_18\IN|hypertension (l_pobj) hypertension_19\NN|
C020743_D006973 NONE triamterene_16\JJ|hydrochlorothiazide|- (r_compound) therapy_17\NN|triamterene (r_pobj) of_13\IN|therapy (r_prep) years_12\NNS|4|of|for (l_prep) for_18\IN|hypertension (l_pobj) hypertension_19\NN|
9522152
D002045_D009461 NONE bupivacaine_11\NN|%|hyperbaric|for (r_pobj) of_7\IN|bupivacaine (r_prep) injection_6\NN|intrathecal|of (r_dobj) following_4\VBG|injection (r_acl) deficit_3\NN|a|transient|neurological|following|.
D002045_D009461 NONE bupivacaine_21\NN|%|hyperbaric (r_pobj) with_14\IN|bupivacaine (r_prep) anaesthesia_13\NN|unilateral|spinal|with (r_pobj) after_10\IN|anaesthesia (r_prep) occurred_9\VBD|that|after (r_relcl) deficit_7\NN|transient|neurological|occurred
10901305
D007649_D050723 NONE Ketamine_0\NN|sedation|. (l_dobj) sedation_1\NN|for (l_prep) for_2\IN|reduction (l_pobj) reduction_4\NN|the|of (l_prep) of_5\IN|fractures (l_pobj) fractures_8\NNS|children|in
D007649_D050723 NONE ketamine_14\NN|for (l_prep) for_15\IN|sedation (l_pobj) sedation_16\NN|in (l_prep) in_17\IN|treatment (l_pobj) treatment_19\NN|the|of (l_prep) of_20\IN|fractures (l_pobj) fractures_23\NNS|children|in
D007649_D050723 NONE ketamine_7\NN|to (l_prep) to_8\IN|manipulation (l_pobj) manipulation_9\NN|of (l_prep) of_10\IN|fracture (l_pobj) fracture_12\NN|the|or|dislocation
D007649_D050723 NONE Ketamine_0\NNP| (r_nsubj) provided_7\VBD|ketamine|reliably|quickly|sedation|. (l_dobj) sedation_9\NN|adequate|facilitate (l_acl) facilitate_12\VB|to|effectively|reduction (l_dobj) reduction_14\NN|the|of (l_prep) of_15\IN|fractures (l_pobj) fractures_18\NNS|children|in
D007649_D004204 NONE ketamine_7\NN|to (l_prep) to_8\IN|manipulation (l_pobj) manipulation_9\NN|of (l_prep) of_10\IN|fracture (l_pobj) fracture_12\NN|the|or|dislocation (l_conj) dislocation_14\NN|
8231633
D002118_D064420 NONE calcium_2\NN| (r_compound) channel_3\NN|calcium (r_compound) blockers_4\NNS|channel|on (l_prep) on_5\IN|toxicity (l_pobj) toxicity_9\NN|induced
D002118_D064420 NONE calcium_11\NN| (r_compound) channel_12\NN|calcium (r_compound) blockers_13\NNS|channel|on (l_prep) on_14\IN|toxicity (l_pobj) toxicity_19\NN|induced|acute
D002045_D064420 NONE bupivacaine_6\NN| (r_npadvmod) induced_8\VBN|bupivacaine|- (r_amod) toxicity_9\NN|induced
D002045_D064420 NONE bupivacaine_15\NN| (r_npadvmod) induced_17\VBN|bupivacaine|- (r_amod) toxicity_19\NN|induced|acute
D002045_D012640 CID bupivacaine_4\NN| (r_pobj) of_3\IN|bupivacaine (r_prep) activity_2\NN|the|convulsant|of (r_nsubj) was_5\VBD|activity (r_auxpass) modified_8\VBN|was|not|significantly|but|decreased (l_conj) decreased_13\VBD|blockers|time (l_dobj) time_15\NN|the|of|obtain (l_relcl) obtain_19\VB|to|convulsions (l_dobj) convulsions_23\NNS|induced
D002045_D012640 CID bupivacaine_20\NN| (r_npadvmod) induced_22\VBN|bupivacaine|- (r_amod) convulsions_23\NNS|induced
D002118_D012640 NONE calcium_10\NN| (r_compound) channel_11\NN|calcium (r_compound) blockers_12\NNS|channel (r_nsubj) decreased_13\VBD|blockers|time (l_dobj) time_15\NN|the|of|obtain (l_relcl) obtain_19\VB|to|convulsions (l_dobj) convulsions_23\NNS|induced
D015764_D012640 NONE bepridil_31\NN| (r_pcomp) with_30\IN|bepridil (r_prep) pronounced_29\VBN|less|with (r_acomp) was_27\VBD|modified|;|effect|pronounced|. (l_ccomp) modified_8\VBN|was|not|significantly|but|decreased (l_conj) decreased_13\VBD|blockers|time (l_dobj) time_15\NN|the|of|obtain (l_relcl) obtain_19\VB|to|convulsions (l_dobj) convulsions_23\NNS|induced
6666578
D010396_D001018 CID penicillamine_2\NN|d|- (r_compound) induced_4\VBN|penicillamine|-|angiopathy|in|. (l_advmod) angiopathy_5\NN|
14659530
D009569_D008881 NONE NO_0\RB| (r_intj) induced_2\VBN|no|- (r_amod) attack_4\NN|induced|migraine|:|increase|. (l_compound) migraine_3\JJ|
D015740_D008881 NONE peptide_14\NN|plasma|calcitonin|related|concentration (r_pobj) in_8\IN|peptide (r_prep) increase_7\NN|strong|in (r_appos) attack_4\NN|induced|migraine|:|increase|. (l_compound) migraine_3\JJ|
D015740_D008881 NONE CGRP_16\NN| (r_nmod) concentration_18\NN|(|cgrp|)|and|correlation (r_appos) peptide_14\NN|plasma|calcitonin|related|concentration (r_pobj) in_8\IN|peptide (r_prep) increase_7\NN|strong|in (r_appos) attack_4\NN|induced|migraine|:|increase|. (l_compound) migraine_3\JJ|
D015740_D008881 NONE peptide_17\NN|the|plasma|calcitonin|related (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (r_dobj) investigate_8\VB|to|changes|and|attack (l_conj) attack_40\NN|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ|
D015740_D008881 NONE CGRP_19\NN| (r_nmod) concentration_21\NN|(|cgrp|)|and (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (r_dobj) investigate_8\VB|to|changes|and|attack (l_conj) attack_40\NN|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ|
D015740_D008881 NONE CGRP_1\NN| (r_compound) concentration_2\NN|plasma|cgrp (r_nsubj) increased_3\VBD|concentration|significantly|p<0.01|during|and|returned|. (l_prep) during_8\IN|attack (l_pobj) attack_11\NN|the|migraine (l_compound) migraine_10\JJ|
D015740_D008881 NONE CGRP_1\NN| (r_compound) concentration_2\NN|plasma|cgrp (r_nsubj) increased_3\VBD|concentration|significantly|p<0.01|during|and|returned|. (l_conj) returned_13\VBD|to|after (l_prep) after_16\IN|cessation (l_pobj) cessation_18\NN|the|of (l_prep) of_19\IN|migraine (l_pobj) migraine_21\NN|the
D015740_D008881 NONE CGRP_3\NNP| (r_compound) concentrations_4\NNS|plasma|cgrp (r_nsubj) failed_5\VBD|however|,|concentrations|change|. (l_xcomp) change_7\VB|to|during (l_prep) during_8\IN|headache|and|in (l_conj) in_12\IN|subjects (l_pobj) subjects_14\NNS|the|with (l_prep) with_15\IN|attack (l_pobj) attack_18\NN|no|migraine (l_compound) migraine_17\JJ|
D015740_D008881 NONE CGRP_1\NNP| (r_compound) concentration_2\NN|basal|cgrp (r_nsubj) was_3\VBD|concentration|higher|and|platelet|. (l_conj) platelet_7\NN|tended (l_ccomp) tended_10\VBD|content|be (l_xcomp) be_12\VB|to|lower|in (l_prep) in_14\IN|subjects (l_pobj) subjects_15\NNS|experienced (l_relcl) experienced_17\VBD|who|attack (l_dobj) attack_20\NN|a|migraine (l_compound) migraine_19\JJ|
D015740_D008881 NONE CGRP_7\NN| (r_compound) concentration_8\NN|plasma|cgrp (r_nsubj) correlates_9\VBZ|that|concentration|with (l_prep) with_10\IN|timing (l_pobj) timing_12\NN|the|and|severity|of (l_prep) of_15\IN|headache (l_pobj) headache_18\NN|a|migraine (l_compound) migraine_17\JJ|
D015740_D008881 NONE CGRP_7\NN| (r_compound) concentration_8\NN|plasma|cgrp (r_nsubj) correlates_9\VBZ|that|concentration|with (r_acl) fact_4\NN|the|correlates (r_nsubj) suggests_19\VBZ|in|,|fact|relationship|. (l_dobj) relationship_22\NN|a|direct|between (l_prep) between_23\IN|cgrp (l_pobj) CGRP_24\NN|and|migraine (l_conj) migraine_26\NN|
D015740_D008881 NONE CGRP_24\NN|and|migraine (r_pobj) between_23\IN|cgrp (r_prep) relationship_22\NN|a|direct|between (r_dobj) suggests_19\VBZ|in|,|fact|relationship|. (l_nsubj) fact_4\NN|the|correlates (l_acl) correlates_9\VBZ|that|concentration|with (l_prep) with_10\IN|timing (l_pobj) timing_12\NN|the|and|severity|of (l_prep) of_15\IN|headache (l_pobj) headache_18\NN|a|migraine (l_compound) migraine_17\JJ|
D015740_D008881 NONE CGRP_24\NN|and|migraine (l_conj) migraine_26\NN|
D015740_D008881 NONE CGRP_21\NN| (r_compound) release_22\NN|the|concomitant|cgrp|in (r_conj) headache_17\NN|the|and|release (r_dobj) counteract_15\VB|provoke|,|it|may|even|headache|. (l_ccomp) provoke_9\VB|in|,|release|does|not|migraine (l_dobj) migraine_10\NN|
D012701_D008881 NONE serotonin_24\NN|platelet (r_compound) release_25\NN|serotonin (r_pobj) with_22\IN|release (r_prep) correlation_21\NN|negative|with (r_conj) concentration_18\NN|(|cgrp|)|and|correlation (r_appos) peptide_14\NN|plasma|calcitonin|related|concentration (r_pobj) in_8\IN|peptide (r_prep) increase_7\NN|strong|in (r_appos) attack_4\NN|induced|migraine|:|increase|. (l_compound) migraine_3\JJ|
D012701_D008881 NONE serotonin_24\NN|platelet (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (r_dobj) investigate_8\VB|to|changes|and|attack (l_conj) attack_40\NN|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ|
D012701_D008881 NONE 5-hydroxytriptamine_26\NN|( (r_punct) ,_27\,|5-hydroxytriptamine (r_punct) 5-HT_28\CD|, (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (r_dobj) investigate_8\VB|to|changes|and|attack (l_conj) attack_40\NN|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ|
D012701_D008881 NONE 5-HT_28\CD|, (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (r_dobj) investigate_8\VB|to|changes|and|attack (l_conj) attack_40\NN|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ|
D012701_D008881 NONE 5-HT_8\CD| (r_nummod) content_9\NN|5-ht (r_nsubj) tended_10\VBD|content|be (l_xcomp) be_12\VB|to|lower|in (l_prep) in_14\IN|subjects (l_pobj) subjects_15\NNS|experienced (l_relcl) experienced_17\VBD|who|attack (l_dobj) attack_20\NN|a|migraine (l_compound) migraine_19\JJ|
D012701_D008881 NONE serotonin_1\NN|platelet (r_compound) content_2\NN|serotonin (r_nsubj) decreased_3\VBD|content|significantly|p<0.01|after|but|observed (l_prep) after_8\IN|nitroglycerin (l_pobj) nitroglycerin_9\NN|in (l_prep) in_10\IN|subjects (l_pobj) subjects_11\NNS|with (l_prep) with_12\IN|attack (l_pobj) attack_15\NN|no|migraine (l_compound) migraine_14\JJ|
D012701_D008881 NONE serotonin_1\NN|platelet (r_compound) content_2\NN|serotonin (r_nsubj) decreased_3\VBD|content|significantly|p<0.01|after|but|observed (l_conj) observed_21\VBN|change|was|in|. (l_prep) in_22\IN|patients (l_pobj) patients_23\NNS|with (l_prep) with_24\IN|attack (l_pobj) attack_26\NN|migraine (l_compound) migraine_25\JJ|
D012701_D008881 NONE serotonin_3\NN| (r_compound) release_4\NN|serotonin|from (r_nsubj) provoke_9\VB|in|,|release|does|not|migraine (l_dobj) migraine_10\NN|
D015740_D006261 NONE peptide_17\NN|the|plasma|calcitonin|related (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (l_prep) during_31\IN|headache (l_pobj) headache_34\NN|the|immediate
D015740_D006261 NONE CGRP_19\NN| (r_nmod) concentration_21\NN|(|cgrp|)|and (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (l_prep) during_31\IN|headache (l_pobj) headache_34\NN|the|immediate
D015740_D006261 NONE CGRP_3\NNP| (r_compound) concentrations_4\NNS|plasma|cgrp (r_nsubj) failed_5\VBD|however|,|concentrations|change|. (l_xcomp) change_7\VB|to|during (l_prep) during_8\IN|headache|and|in (l_pobj) headache_10\NN|immediate
D015740_D006261 NONE CGRP_7\NN| (r_compound) concentration_8\NN|plasma|cgrp (r_nsubj) correlates_9\VBZ|that|concentration|with (l_prep) with_10\IN|timing (l_pobj) timing_12\NN|the|and|severity|of (l_prep) of_15\IN|headache (l_pobj) headache_18\NN|a|migraine
D015740_D006261 NONE CGRP_24\NN|and|migraine (r_pobj) between_23\IN|cgrp (r_prep) relationship_22\NN|a|direct|between (r_dobj) suggests_19\VBZ|in|,|fact|relationship|. (l_nsubj) fact_4\NN|the|correlates (l_acl) correlates_9\VBZ|that|concentration|with (l_prep) with_10\IN|timing (l_pobj) timing_12\NN|the|and|severity|of (l_prep) of_15\IN|headache (l_pobj) headache_18\NN|a|migraine
D015740_D006261 NONE CGRP_21\NN| (r_compound) release_22\NN|the|concomitant|cgrp|in (r_conj) headache_17\NN|the|and|release
D012701_D006261 NONE serotonin_24\NN|platelet (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (l_prep) during_31\IN|headache (l_pobj) headache_34\NN|the|immediate
D012701_D006261 NONE 5-hydroxytriptamine_26\NN|( (r_punct) ,_27\,|5-hydroxytriptamine (r_punct) 5-HT_28\CD|, (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (l_prep) during_31\IN|headache (l_pobj) headache_34\NN|the|immediate
D012701_D006261 NONE 5-HT_28\CD|, (r_nmod) content_30\NN|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN|content (r_prep) changes_9\NNS|in|during (l_prep) during_31\IN|headache (l_pobj) headache_34\NN|the|immediate
D012701_D006261 NONE serotonin_3\NN| (r_compound) release_4\NN|serotonin|from (r_nsubj) provoke_9\VB|in|,|release|does|not|migraine (r_ccomp) counteract_15\VB|provoke|,|it|may|even|headache|. (l_dobj) headache_17\NN|the|and|release
D005996_D006261 NONE nitroglycerin_43\NN| (r_pobj) by_42\IN|nitroglycerin (r_agent) provoked_41\VBN|by (r_acl) attack_40\NN|the|delayed|genuine|migraine|provoked (r_conj) investigate_8\VB|to|changes|and|attack (l_dobj) changes_9\NNS|in|during (l_prep) during_31\IN|headache (l_pobj) headache_34\NN|the|immediate
D005996_D008881 NONE nitroglycerin_43\NN| (r_pobj) by_42\IN|nitroglycerin (r_agent) provoked_41\VBN|by (r_acl) attack_40\NN|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ|
D005996_D008881 NONE nitroglycerin_16\NN| (r_compound) application_17\NN|the|nitroglycerin (r_pobj) after_14\IN|application (r_conj) before_12\RB|min|and|after (r_advmod) collected_2\VBN|blood|was|from|times|before|,|and|min (l_conj) min_23\NN|60|after|;|subjects|. (l_prep) after_24\IN|beginning (l_pobj) beginning_26\NN|the|of (l_prep) of_27\IN|attack (l_pobj) attack_30\NN|the|migraine|mean (l_compound) migraine_29\JJ|
D005996_D008881 NONE nitroglycerin_9\NN|in (l_prep) in_10\IN|subjects (l_pobj) subjects_11\NNS|with (l_prep) with_12\IN|attack (l_pobj) attack_15\NN|no|migraine (l_compound) migraine_14\JJ|
D005996_D008881 NONE nitroglycerin_9\NN|in (r_pobj) after_8\IN|nitroglycerin (r_prep) decreased_3\VBD|content|significantly|p<0.01|after|but|observed (l_conj) observed_21\VBN|change|was|in|. (l_prep) in_22\IN|patients (l_pobj) patients_23\NNS|with (l_prep) with_24\IN|attack (l_pobj) attack_26\NN|migraine (l_compound) migraine_25\JJ|
17241784
D019821_D009135 CID statin_12\NN| (r_compound) therapy_13\NN|statin (r_pobj) with_11\IN|therapy (r_prep) associated_10\VBD|with (r_acl) myopathy_1\NNS|progressive|with|associated|.
D019821_D009135 CID Statins_0\NNS| (r_nsubj) cause_2\VB|statins|can|necrotizing|myopathy|. (l_ccomp) myopathy_5\NN|and|hyperckaemia
D019821_D009135 CID statins_9\NNS| (r_nsubj) induce_11\VB|whereby|statins|may|myopathy (l_dobj) myopathy_13\NN|a
D019821_D009135 CID statins_4\NNS| (r_nsubj) initiate_6\VB|that|statins|may|myopathy (l_dobj) myopathy_11\NN|an|mediated|persists
D019821_D009135 CID statins_13\NNS|of (r_pobj) by_12\IN|statins (r_prep) induction_11\NN|the|by (r_dobj) involve_9\VB|may|induction (r_conj) is_5\VBZ|mechanism|uncertain|but|involve|. (l_nsubj) mechanism_1\NN|the|of (l_prep) of_2\IN|myopathy (l_pobj) myopathy_4\NN|this
D019821_-1 NONE Statins_0\NNS| (r_nsubj) cause_2\VB|statins|can|necrotizing|myopathy|. (l_ccomp) myopathy_5\NN|and|hyperckaemia (l_conj) hyperCKaemia_7\NN|
15602202
D017963_D009395 CID azithromycin_6\PRP| (r_pobj) by_5\IN|azithromycin (r_prep) induced_4\VBN|nephritis|by|. (l_nsubj) nephritis_3\NN|recurrent|acute|interstitial
D017963_D009395 CID azithromycin_10\RB| (r_advmod) induced_12\VBN|azithromycin|- (r_amod) nephritis_16\NN|induced|,|acute|interstitial
7444978
D013307_D020258 NONE streptomycin_11\NNS| (r_pobj) of_10\IN|streptomycin (r_prep) effects_9\NNS|neurotoxic|of (l_amod) neurotoxic_8\JJ|
D013307_D004409 CID streptomycin_48\NNS|than (r_pobj) to_47\IN|streptomycin (r_prep) sensitive_46\JJ|more|to (r_acomp) is_44\VBZ|that|cochlea|sensitive (r_ccomp) indicating_40\VBG|is (r_advcl) occurred_23\VBD|occurred|;|within|sensitivities|from|,|indicating|. (l_ccomp) occurred_4\VBD|movements|in (l_nsubj) movements_1\NNS|abnormal|and|deafness
D013307_D004409 CID streptomycin_48\NNS|than (l_prep) than_49\IN|site (l_pobj) site_51\NN|the|(|vestibular|)|responsible (l_amod) responsible_57\JJ|for (l_prep) for_58\IN|dyskinesias (l_pobj) dyskinesias_60\NNS|the
D013307_D003638 CID streptomycin_48\NNS|than (r_pobj) to_47\IN|streptomycin (r_prep) sensitive_46\JJ|more|to (r_acomp) is_44\VBZ|that|cochlea|sensitive (r_ccomp) indicating_40\VBG|is (r_advcl) occurred_23\VBD|occurred|;|within|sensitivities|from|,|indicating|. (l_ccomp) occurred_4\VBD|movements|in (l_nsubj) movements_1\NNS|abnormal|and|deafness (l_conj) deafness_3\NN|
8437969
D002927_D054138 CID cimetidine_7\NN|infusion (r_pobj) with_3\IN|cimetidine (r_prep) associated_2\VBN|with (r_acl) arrest_1\NN|sinus|associated|.
D002927_D054138 CID cimetidine_27\NN|infusion (r_dobj) receiving_23\VBG|while|cimetidine|hour (r_advcl) recurrent_14\JJ|developed|,|episodes|receiving (l_appos) episodes_17\NNS|brief|of (l_prep) of_18\IN|arrest (l_pobj) arrest_21\NN|apparent|sinus
D002927_D054138 CID cimetidine_14\NN|infusion (r_pobj) with_10\IN|cimetidine (r_prep) associated_9\VBN|with (r_acl) case_5\NN|the|first|reported|of|associated (l_prep) of_6\IN|arrest (l_pobj) arrest_8\NN|sinus
D002927_D001919 CID cimetidine_7\NN| (r_pobj) of_6\IN|cimetidine (r_prep) infusions_5\NNS|intermittent|intravenous|of (r_pobj) of_2\IN|infusions (r_prep) administration_1\NN|the|of (r_nsubjpass) associated_10\VBN|administration|is|infrequently|with|. (l_prep) with_11\IN|development (l_pobj) development_13\NN|the|of (l_prep) of_14\IN|bradyarrhythmias (l_pobj) bradyarrhythmias_15\NNS|
D002927_D007938 NONE cimetidine_27\NN|infusion (r_dobj) receiving_23\VBG|while|cimetidine|hour (r_advcl) recurrent_14\JJ|developed|,|episodes|receiving (r_appos) man_4\NN|a|old|with|and|history|recurrent|. (l_prep) with_5\IN|leukemia (l_pobj) leukemia_6\NN|
D002927_D006331 NONE cimetidine_27\NN|infusion (r_dobj) receiving_23\VBG|while|cimetidine|hour (r_advcl) recurrent_14\JJ|developed|,|episodes|receiving (r_appos) man_4\NN|a|old|with|and|history|recurrent|. (l_conj) history_9\NN|no|of (l_prep) of_10\IN|disease (l_pobj) disease_12\NN|cardiac
D002927_D001145 NONE cimetidine_6\NN| (r_compound) administration_7\NN|cimetidine (r_pobj) to_5\IN|administration (r_prep) related_4\VBN|arrhythmias|were|temporally|to (l_nsubjpass) arrhythmias_1\NNS|the
D011899_D001145 NONE ranitidine_18\NN| (r_compound) treatment_19\NN|ranitidine (r_pobj) during_17\IN|treatment (r_prep) recur_16\VB|did|not|during (r_conj) disappeared_9\VBD|related|,|after|,|and|recur|. (l_ccomp) related_4\VBN|arrhythmias|were|temporally|to (l_nsubjpass) arrhythmias_1\NNS|the
19843802
D004837_D006973 CID epinephrine_5\NN| (r_pobj) of_4\IN|epinephrine (r_prep) bolus_3\NN|a|of|injected (r_nsubj) provoked_11\VBD|however|,|bolus|crisis|. (l_dobj) crisis_14\NN|a|hypertensive (l_amod) hypertensive_13\JJ|
17344566
D019821_D003161 CID Simvastatin_0\NNP| (r_npadvmod) induced_2\VBN|simvastatin|- (r_amod) syndrome_6\NN|induced|compartment|and|myonecrosis|associated|.
D019821_D003161 CID simvastatin_9\NN| (r_conj) thyroxine_7\NN|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD|thyroxine|with|. (l_prep) with_11\IN|syndrome (l_pobj) syndrome_15\NN|compartment|and|myonecrosis
D019821_D009135 NONE Simvastatin_0\NNP| (r_npadvmod) induced_2\VBN|simvastatin|- (r_amod) syndrome_6\NN|induced|compartment|and|myonecrosis|associated|. (l_conj) myonecrosis_8\NN|
D019821_D009135 NONE simvastatin_9\NN| (r_conj) thyroxine_7\NN|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD|thyroxine|with|. (l_prep) with_11\IN|syndrome (l_pobj) syndrome_15\NN|compartment|and|myonecrosis (l_conj) myonecrosis_17\NN|
D019821_D007037 NONE Simvastatin_0\NNP| (r_npadvmod) induced_2\VBN|simvastatin|- (r_amod) syndrome_6\NN|induced|compartment|and|myonecrosis|associated|. (l_acl) associated_9\VBN|with (l_prep) with_10\IN|hypothyroidism (l_pobj) hypothyroidism_11\NN|
D019821_D007037 NONE simvastatin_9\NN| (r_conj) thyroxine_7\NN|a|old|taking|and|simvastatin (l_compound) taking_6\VBG|male (l_nsubj) male_5\NN|hypothyroid (l_amod) hypothyroid_4\JJ|
D013974_D007037 NONE thyroxine_7\NN|a|old|taking|and|simvastatin (l_compound) taking_6\VBG|male (l_nsubj) male_5\NN|hypothyroid (l_amod) hypothyroid_4\JJ|
D013974_D003161 NONE thyroxine_7\NN|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD|thyroxine|with|. (l_prep) with_11\IN|syndrome (l_pobj) syndrome_15\NN|compartment|and|myonecrosis
D013974_D009135 NONE thyroxine_7\NN|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD|thyroxine|with|. (l_prep) with_11\IN|syndrome (l_pobj) syndrome_15\NN|compartment|and|myonecrosis (l_conj) myonecrosis_17\NN|
3173180
D008795_D006463 CID metronidazole_7\NN| (r_pobj) with_6\IN|metronidazole (r_prep) treatment_5\NN|with (r_pobj) after_4\IN|treatment (r_prep) syndrome_3\NN|uraemic|after|.
D008795_D006463 CID metronidazole_19\NN| (r_pobj) with_18\IN|metronidazole (r_prep) treatment_17\NN|with (r_pobj) after_16\IN|treatment (r_prep) developed_10\VBD|who|syndrome|after (l_dobj) syndrome_15\NN|the|uraemic
D008795_D006463 CID metronidazole_4\NN| (r_pobj) of_3\IN|metronidazole (r_prep) involvement_2\NN|the|of|in (l_prep) in_5\IN|aetiology (l_pobj) aetiology_7\NN|the|of (l_prep) of_8\IN|syndrome (l_pobj) syndrome_13\NN|the|uraemic
D008795_D006463 CID metronidazole_4\NN| (r_pobj) of_3\IN|metronidazole (r_prep) involvement_2\NN|the|of|in (r_nsubjpass) established_16\VBN|while|involvement|is|not|firmly (r_advcl) suggest_43\VBP|established|,|action|link|. (l_nsubj) action_20\NN|the|of|in|evidence (l_conj) evidence_33\NN|the|reported|of (l_prep) of_34\IN|changes (l_pobj) changes_36\NNS|oxidation|in (l_prep) in_37\IN|syndrome (l_pobj) syndrome_42\NN|the|uraemic
D008795_D006463 CID metronidazole_4\NN| (r_pobj) of_3\IN|metronidazole (r_prep) involvement_2\NN|the|of|in (r_nsubjpass) established_16\VBN|while|involvement|is|not|firmly (r_advcl) suggest_43\VBP|established|,|action|link|. (l_dobj) link_46\NN|a|possible|between (l_prep) between_47\IN|treatment (l_pobj) treatment_49\NN|metronidazole|and|cases (l_conj) cases_52\NNS|some|of (l_prep) of_53\IN|syndrome (l_pobj) syndrome_58\NN|the|uraemic
D008795_D006463 CID metronidazole_48\NN| (r_amod) treatment_49\NN|metronidazole|and|cases (r_pobj) between_47\IN|treatment (r_prep) link_46\NN|a|possible|between (r_dobj) suggest_43\VBP|established|,|action|link|. (l_advcl) established_16\VBN|while|involvement|is|not|firmly (l_nsubjpass) involvement_2\NN|the|of|in (l_prep) in_5\IN|aetiology (l_pobj) aetiology_7\NN|the|of (l_prep) of_8\IN|syndrome (l_pobj) syndrome_13\NN|the|uraemic
D008795_D006463 CID metronidazole_48\NN| (r_amod) treatment_49\NN|metronidazole|and|cases (r_pobj) between_47\IN|treatment (r_prep) link_46\NN|a|possible|between (r_dobj) suggest_43\VBP|established|,|action|link|. (l_nsubj) action_20\NN|the|of|in|evidence (l_conj) evidence_33\NN|the|reported|of (l_prep) of_34\IN|changes (l_pobj) changes_36\NNS|oxidation|in (l_prep) in_37\IN|syndrome (l_pobj) syndrome_42\NN|the|uraemic
D008795_D006463 CID metronidazole_48\NN| (r_amod) treatment_49\NN|metronidazole|and|cases (l_conj) cases_52\NNS|some|of (l_prep) of_53\IN|syndrome (l_pobj) syndrome_58\NN|the|uraemic
20621845
D002122_D017545 CID CaCl2-induced_14\VBN| (r_amod) aneurysm_17\NN|cacl2-induced|thoracic|aortic|in
D002122_D017545 CID chloride_18\NN|calcium|injury (r_pobj) by_16\IN|chloride (r_prep) establish_5\VB|to|model|by|and|explore (l_dobj) model_8\NN|a|rat|of (l_prep) of_9\IN|aneurysm (l_pobj) aneurysm_12\NN|thoracic|aortic|(|taa|)
D002122_D017545 CID chloride_18\NN|calcium|injury (r_pobj) by_16\IN|chloride (r_prep) establish_5\VB|to|model|by|and|explore (l_dobj) model_8\NN|a|rat|of (l_prep) of_9\IN|aneurysm (l_pobj) aneurysm_12\NN|thoracic|aortic|(|taa|) (l_appos) TAA_14\NNP|
D002122_D017545 CID chloride_18\NN|calcium|injury (r_pobj) by_16\IN|chloride (r_prep) establish_5\VB|to|model|by|and|explore (r_xcomp) designed_3\VBN|study|was|establish|,|metalloproteinases|. (l_conj) metalloproteinases_39\NNS|matrix|(|mmps|)|and|inhibitors (l_conj) inhibitors_46\NNS|their|endogenous|(|timps|)|in (l_prep) in_50\IN|formation (l_pobj) formation_52\NN|taa (l_compound) TAA_51\NNP|
D002122_D017545 CID CaCl(2))-induced_20\VBN| (r_amod) injury_22\NN|(|cacl(2))-induced|arterial (r_appos) chloride_18\NN|calcium|injury (r_pobj) by_16\IN|chloride (r_prep) establish_5\VB|to|model|by|and|explore (l_dobj) model_8\NN|a|rat|of (l_prep) of_9\IN|aneurysm (l_pobj) aneurysm_12\NN|thoracic|aortic|(|taa|)
D002122_D017545 CID CaCl(2))-induced_20\VBN| (r_amod) injury_22\NN|(|cacl(2))-induced|arterial (r_appos) chloride_18\NN|calcium|injury (r_pobj) by_16\IN|chloride (r_prep) establish_5\VB|to|model|by|and|explore (l_dobj) model_8\NN|a|rat|of (l_prep) of_9\IN|aneurysm (l_pobj) aneurysm_12\NN|thoracic|aortic|(|taa|) (l_appos) TAA_14\NNP|
D002122_D017545 CID CaCl(2))-induced_20\VBN| (r_amod) injury_22\NN|(|cacl(2))-induced|arterial (r_appos) chloride_18\NN|calcium|injury (r_pobj) by_16\IN|chloride (r_prep) establish_5\VB|to|model|by|and|explore (r_xcomp) designed_3\VBN|study|was|establish|,|metalloproteinases|. (l_conj) metalloproteinases_39\NNS|matrix|(|mmps|)|and|inhibitors (l_conj) inhibitors_46\NNS|their|endogenous|(|timps|)|in (l_prep) in_50\IN|formation (l_pobj) formation_52\NN|taa (l_compound) TAA_51\NNP|
D002122_D017545 CID )_9\-RRB-| (r_punct) establishes_2\VBZ|study|model|by|) (l_dobj) model_5\NN|a|taa (l_compound) TAA_4\NNP|
D002122_D014652 NONE chloride_18\NN|calcium|injury (l_appos) injury_22\NN|(|cacl(2))-induced|arterial
D002122_D014652 NONE CaCl(2))-induced_20\VBN| (r_amod) injury_22\NN|(|cacl(2))-induced|arterial
567256
D004054_D006394 CID diethylstilbestrol_6\NN| (r_pobj) with_5\IN|diethylstilbestrol (r_prep) associated_4\VBN|with (r_acl) liver_3\NN|the|associated
D004054_D006394 CID diethylstilbestrol_25\NN| (r_pobj) with_24\IN|diethylstilbestrol (r_prep) liver_23\NN|the|with (r_pobj) of_21\IN|liver (r_prep) adenocarcinoma_20\NN|a|differentiated|of (r_pobj) for_15\IN|adenocarcinoma (r_prep) treated_14\VBN|who|had|been|for|for (r_relcl) man_10\NN|a|old|treated (r_pobj) in_5\IN|man (r_prep) occurred_4\VBD|angiosarcoma|in|. (l_nsubj) Angiosarcoma_0\NNP|of (l_prep) of_1\IN|liver (l_pobj) liver_3\NN|the
D004054_D008113 CID diethylstilbestrol_6\NN| (r_pobj) with_5\IN|diethylstilbestrol (r_prep) associated_4\VBN|with (r_acl) liver_3\NN|the|associated
D004054_D008113 CID diethylstilbestrol_25\NN| (r_pobj) with_24\IN|diethylstilbestrol (r_prep) liver_23\NN|the|with (r_pobj) of_21\IN|liver (r_prep) adenocarcinoma_20\NN|a|differentiated|of (r_pobj) for_15\IN|adenocarcinoma (r_prep) treated_14\VBN|who|had|been|for|for (r_relcl) man_10\NN|a|old|treated (r_pobj) in_5\IN|man (r_prep) occurred_4\VBD|angiosarcoma|in|. (l_nsubj) Angiosarcoma_0\NNP|of (l_prep) of_1\IN|liver (l_pobj) liver_3\NN|the
D004054_D008113 NONE diethylstilbestrol_25\NN| (r_pobj) with_24\IN|diethylstilbestrol (r_prep) liver_23\NN|the|with
D004054_D000230 NONE diethylstilbestrol_25\NN| (r_pobj) with_24\IN|diethylstilbestrol (r_prep) liver_23\NN|the|with
2870085
C047847_D013610 NONE Flestolol_0\NNP| (r_nsubj) produced_1\VBD|flestolol|attenuation|. (l_dobj) attenuation_6\NN|a|dependent|of (l_prep) of_7\IN|tachycardia (l_pobj) tachycardia_11\NN|induced
D007545_D013610 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|isoproterenol|- (r_amod) tachycardia_11\NN|induced
C047847_D013617 NONE Flestolol_0\NNP| (r_nsubj) reduced_2\VBD|flestolol|effectively|rate|in|. (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|tachyarrhythmia (l_pobj) tachyarrhythmia_9\NN|supraventricular
C047847_D000789 NONE flestolol_6\NN| (r_compound) infusion_7\NN|flestolol (r_nsubjpass) found_9\VBN|in|,|infusion|was|be|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|angina (l_pobj) angina_4\NN|unstable
C047847_D002637 NONE flestolol_6\NN| (r_compound) infusion_7\NN|flestolol (r_nsubjpass) found_9\VBN|in|,|infusion|was|be|. (l_xcomp) be_11\VB|to|safe (l_acomp) safe_12\JJ|and|effective (l_conj) effective_14\JJ|in (l_prep) in_15\IN|controlling (l_pcomp) controlling_16\VBG|pain (l_dobj) pain_18\NN|chest
17020434
D014859_D020521 NONE warfarin_12\NN| (r_nsubj) reduces_13\VBZ|that|warfarin|risk|by|,|and|reduces (l_dobj) risk_15\NN|the|of (l_prep) of_16\IN|stroke (l_pobj) stroke_17\NN|
D014859_D020521 NONE warfarin_8\VB| (r_nsubj) is_9\VBZ|overall|,|in|,|warfarin|superior|,|with|. (l_acomp) superior_10\JJ|to (l_prep) to_11\IN|aspirin (l_pobj) aspirin_12\NN|in (l_prep) in_13\IN|preventing (l_pcomp) preventing_14\VBG|strokes (l_dobj) strokes_15\NNS|
D001241_D020521 NONE aspirin_24\NN|alone (r_nsubj) reduces_26\VBZ|that|aspirin|risk|by (r_conj) reduces_13\VBZ|that|warfarin|risk|by|,|and|reduces (l_dobj) risk_15\NN|the|of (l_prep) of_16\IN|stroke (l_pobj) stroke_17\NN|
D001241_D020521 NONE aspirin_12\NN|in (l_prep) in_13\IN|preventing (l_pcomp) preventing_14\VBG|strokes (l_dobj) strokes_15\NNS|
C426686_D004617 NONE Ximelagatran_0\NN|,|inhibitor|, (r_nsubjpass) found_9\VBN|ximelagatran|was|be|,|but|withdrawn|. (l_xcomp) be_11\VB|to|efficient (l_acomp) efficient_13\JJ|as|as|in (l_prep) in_19\IN|prevention (l_pobj) prevention_21\NN|the|of (l_prep) of_22\IN|events (l_pobj) events_24\NNS|embolic
C426686_D056486 CID Ximelagatran_0\NN|,|inhibitor|, (r_nsubjpass) found_9\VBN|ximelagatran|was|be|,|but|withdrawn|. (l_conj) withdrawn_30\VBN|has|been|recently|because (l_prep) because_31\IN|of|tests (l_pobj) tests_36\NNS|abnormal|function (l_compound) function_35\NN|liver
D014812_D004617 NONE K_16\NNP|vitamin (r_compound) drugs_18\NNS|k|antagonist (r_pobj) as_14\IN|drugs (r_prep) efficient_13\JJ|as|as|in (l_prep) in_19\IN|prevention (l_pobj) prevention_21\NN|the|of (l_prep) of_22\IN|events (l_pobj) events_24\NNS|embolic
D014812_D056486 NONE K_16\NNP|vitamin (r_compound) drugs_18\NNS|k|antagonist (r_pobj) as_14\IN|drugs (r_prep) efficient_13\JJ|as|as|in (r_acomp) be_11\VB|to|efficient (r_xcomp) found_9\VBN|ximelagatran|was|be|,|but|withdrawn|. (l_conj) withdrawn_30\VBN|has|been|recently|because (l_prep) because_31\IN|of|tests (l_pobj) tests_36\NNS|abnormal|function (l_compound) function_35\NN|liver
C055162_D001281 NONE Clopidogrel_7\NNP|fibrillation (l_compound) Fibrillation_6\NNP|
C055162_D001281 NONE clopidogrel_28\JJ|plus|aspirin (r_dobj) platelet_25\NN|to|therapy|clopidogrel|)|in (r_xcomp) superior_23\JJ|platelet (r_acomp) is_22\VBZ|that|warfarin|superior (r_ccomp) demonstrated_19\VBN|trial|has|is|. (l_nsubj) Trial_8\NN|the|w|(|atrial|clopidogrel|with|)|study (l_compound) Clopidogrel_7\NNP|fibrillation (l_compound) Fibrillation_6\NNP|
C055162_D004617 NONE Clopidogrel_7\NNP|fibrillation (r_compound) Trial_8\NN|the|w|(|atrial|clopidogrel|with|)|study (r_nsubj) demonstrated_19\VBN|trial|has|is|. (l_ccomp) is_22\VBZ|that|warfarin|superior (l_acomp) superior_23\JJ|platelet (l_xcomp) platelet_25\NN|to|therapy|clopidogrel|)|in (l_prep) in_32\IN|prevention|events (l_pobj) events_37\NNS|af|embolic
C055162_D004617 NONE clopidogrel_28\JJ|plus|aspirin (r_dobj) platelet_25\NN|to|therapy|clopidogrel|)|in (l_prep) in_32\IN|prevention|events (l_pobj) events_37\NNS|af|embolic
C081309_D001281 NONE Irbesartan_10\NNP|for (r_pobj) with_9\IN|irbesartan (r_prep) Trial_8\NN|the|w|(|atrial|clopidogrel|with|)|study (l_compound) Clopidogrel_7\NNP|fibrillation (l_compound) Fibrillation_6\NNP|
C081309_D004617 NONE Irbesartan_10\NNP|for (r_pobj) with_9\IN|irbesartan (r_prep) Trial_8\NN|the|w|(|atrial|clopidogrel|with|)|study (r_nsubj) demonstrated_19\VBN|trial|has|is|. (l_ccomp) is_22\VBZ|that|warfarin|superior (l_acomp) superior_23\JJ|platelet (l_xcomp) platelet_25\NN|to|therapy|clopidogrel|)|in (l_prep) in_32\IN|prevention|events (l_pobj) events_37\NNS|af|embolic
D014859_D001281 NONE warfarin_21\NN| (r_nsubj) is_22\VBZ|that|warfarin|superior (r_ccomp) demonstrated_19\VBN|trial|has|is|. (l_nsubj) Trial_8\NN|the|w|(|atrial|clopidogrel|with|)|study (l_compound) Clopidogrel_7\NNP|fibrillation (l_compound) Fibrillation_6\NNP|
D014859_D004617 NONE warfarin_21\NN| (r_nsubj) is_22\VBZ|that|warfarin|superior (l_acomp) superior_23\JJ|platelet (l_xcomp) platelet_25\NN|to|therapy|clopidogrel|)|in (l_prep) in_32\IN|prevention|events (l_pobj) events_37\NNS|af|embolic
D001241_D001281 NONE aspirin_30\NN| (r_conj) clopidogrel_28\JJ|plus|aspirin (r_dobj) platelet_25\NN|to|therapy|clopidogrel|)|in (r_xcomp) superior_23\JJ|platelet (r_acomp) is_22\VBZ|that|warfarin|superior (r_ccomp) demonstrated_19\VBN|trial|has|is|. (l_nsubj) Trial_8\NN|the|w|(|atrial|clopidogrel|with|)|study (l_compound) Clopidogrel_7\NNP|fibrillation (l_compound) Fibrillation_6\NNP|
D001241_D004617 NONE aspirin_30\NN| (r_conj) clopidogrel_28\JJ|plus|aspirin (r_dobj) platelet_25\NN|to|therapy|clopidogrel|)|in (l_prep) in_32\IN|prevention|events (l_pobj) events_37\NNS|af|embolic
C479958_D001281 NONE Idraparinux_0\NNP|,|inhibitor|, (r_nsubjpass) evaluated_9\VBN|idraparinux|is|being|in|. (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial
D000809_D001281 NONE Angiotensin_0\NN| (r_npadvmod) converting_2\VBG|angiotensin|- (r_amod) inhibitors_4\NNS|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP|inhibitors|promise|. (l_dobj) promise_13\NN|in (l_prep) in_14\IN|fibrillation (l_pobj) fibrillation_16\NN|atrial|through
D000809_D020257 NONE Angiotensin_0\NN| (r_npadvmod) converting_2\VBG|angiotensin|- (r_amod) inhibitors_4\NNS|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP|inhibitors|promise|. (l_dobj) promise_13\NN|in (l_prep) in_14\IN|fibrillation (l_pobj) fibrillation_16\NN|atrial|through (l_prep) through_17\IN|remodelling (l_pobj) remodelling_19\NN|cardiac
D000804_D001281 NONE II_7\CD| (r_nummod) drugs_11\NNS|angiotensin|ii|blocking (r_conj) inhibitors_4\NNS|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP|inhibitors|promise|. (l_dobj) promise_13\NN|in (l_prep) in_14\IN|fibrillation (l_pobj) fibrillation_16\NN|atrial|through
D000804_D020257 NONE II_7\CD| (r_nummod) drugs_11\NNS|angiotensin|ii|blocking (r_conj) inhibitors_4\NNS|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP|inhibitors|promise|. (l_dobj) promise_13\NN|in (l_prep) in_14\IN|fibrillation (l_pobj) fibrillation_16\NN|atrial|through (l_prep) through_17\IN|remodelling (l_pobj) remodelling_19\NN|cardiac
3970039
D000477_D015470 CID agents_4\NNS|alkylating (r_pobj) with_2\IN|agents (r_prep) treated_1\VBN|patients|with (r_csubj) have_5\VBP|treated|risk|,|and|associated (l_dobj) risk_8\NN|an|increased|of (l_prep) of_9\IN|development (l_pobj) development_10\NN|of (l_prep) of_11\IN|leukemia (l_pobj) leukemia_14\NN|acute|nonlymphocytic
D000477_D015470 CID agents_19\NNS|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN|agents|are|with|. (r_conj) have_5\VBP|treated|risk|,|and|associated (l_dobj) risk_8\NN|an|increased|of (l_prep) of_9\IN|development (l_pobj) development_10\NN|of (l_prep) of_11\IN|leukemia (l_pobj) leukemia_14\NN|acute|nonlymphocytic
D000477_D008228 CID agents_4\NNS|alkylating (r_pobj) with_2\IN|agents (r_prep) treated_1\VBN|patients|with (r_csubj) have_5\VBP|treated|risk|,|and|associated (l_conj) associated_23\VBN|agents|are|with|. (l_prep) with_24\IN|development (l_pobj) development_26\NN|the|of (l_prep) of_27\IN|lymphoma (l_pobj) lymphoma_32\NN|hodgkin
D000477_D008228 CID agents_19\NNS|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN|agents|are|with|. (l_prep) with_24\IN|development (l_pobj) development_26\NN|the|of (l_prep) of_27\IN|lymphoma (l_pobj) lymphoma_32\NN|hodgkin
D001379_D015470 NONE azathioprine_21\NN| (r_conj) agents_19\NNS|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN|agents|are|with|. (r_conj) have_5\VBP|treated|risk|,|and|associated (l_dobj) risk_8\NN|an|increased|of (l_prep) of_9\IN|development (l_pobj) development_10\NN|of (l_prep) of_11\IN|leukemia (l_pobj) leukemia_14\NN|acute|nonlymphocytic
D001379_D008228 CID azathioprine_21\NN| (r_conj) agents_19\NNS|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN|agents|are|with|. (l_prep) with_24\IN|development (l_pobj) development_26\NN|the|of (l_prep) of_27\IN|lymphoma (l_pobj) lymphoma_32\NN|hodgkin
D003520_D001749 CID Cyclophosphamide_0\NNP| (r_compound) therapy_1\NN|cyclophosphamide (r_nsubj) increases_2\VBZ|therapy|risk|. (l_dobj) risk_4\NN|the|of (l_prep) of_5\IN|carcinoma (l_pobj) carcinoma_6\NN|of (l_prep) of_7\IN|bladder (l_pobj) bladder_9\NN|the
D003520_D002277 CID Cyclophosphamide_0\NNP| (r_compound) therapy_1\NN|cyclophosphamide (r_nsubj) increases_2\VBZ|therapy|risk|. (l_dobj) risk_4\NN|the|of (l_prep) of_5\IN|carcinoma (l_pobj) carcinoma_6\NN|of (l_prep) of_7\IN|bladder (l_pobj) bladder_9\NN|the
D001379_D001172 NONE azathioprine_15\NN|and|cyclophosphamide (r_pobj) with_14\IN|azathioprine (r_prep) treated_13\VBN|with (r_acl) studies_7\NNS|several|term|of|treated|and (l_prep) of_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|arthritis (l_pobj) arthritis_12\NN|rheumatoid
D001379_D009369 NONE azathioprine_15\NN|and|cyclophosphamide (r_pobj) with_14\IN|azathioprine (r_prep) treated_13\VBN|with (r_acl) studies_7\NNS|several|term|of|treated|and (r_attr) been_2\VBN|there|have|studies|increased|. (l_conj) increased_29\VBN|incidence|is|not (l_nsubjpass) incidence_20\NN|the|of (l_prep) of_21\IN|most (l_pobj) most_22\JJS|of (l_prep) of_23\IN|cancers (l_pobj) cancers_26\NNS|the|common
D003520_D001172 NONE cyclophosphamide_17\NN| (r_conj) azathioprine_15\NN|and|cyclophosphamide (r_pobj) with_14\IN|azathioprine (r_prep) treated_13\VBN|with (r_acl) studies_7\NNS|several|term|of|treated|and (l_prep) of_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|arthritis (l_pobj) arthritis_12\NN|rheumatoid
D003520_D009369 NONE cyclophosphamide_17\NN| (r_conj) azathioprine_15\NN|and|cyclophosphamide (r_pobj) with_14\IN|azathioprine (r_prep) treated_13\VBN|with (r_acl) studies_7\NNS|several|term|of|treated|and (r_attr) been_2\VBN|there|have|studies|increased|. (l_conj) increased_29\VBN|incidence|is|not (l_nsubjpass) incidence_20\NN|the|of (l_prep) of_21\IN|most (l_pobj) most_22\JJS|of (l_prep) of_23\IN|cancers (l_pobj) cancers_26\NNS|the|common
D000477_D009369 NONE agents_31\NNS|particularly|alkylating (r_appos) drugs_27\NNS|immunosuppressive|,|agents|, (r_pobj) of_25\IN|drugs (r_prep) use_24\NN|the|of|in (r_nsubjpass) reserved_41\VBN|is|,|use|should|be|for|. (r_conj) collected_14\VBN|data|are|still|being|,|and|reserved (l_nsubjpass) Data_0\NNS|on (l_prep) on_1\IN|risk (l_pobj) risk_5\NN|the|possible|increased|of (l_prep) of_6\IN|malignancy (l_pobj) malignancy_7\NN|in
D000477_D001172 NONE agents_31\NNS|particularly|alkylating (r_appos) drugs_27\NNS|immunosuppressive|,|agents|, (r_pobj) of_25\IN|drugs (r_prep) use_24\NN|the|of|in (r_nsubjpass) reserved_41\VBN|is|,|use|should|be|for|. (r_conj) collected_14\VBN|data|are|still|being|,|and|reserved (l_nsubjpass) Data_0\NNS|on (l_prep) on_1\IN|risk (l_pobj) risk_5\NN|the|possible|increased|of (l_prep) of_6\IN|malignancy (l_pobj) malignancy_7\NN|in (l_prep) in_8\IN|arthritis (l_pobj) arthritis_10\NN|rheumatoid
D000477_D001172 NONE agents_31\NNS|particularly|alkylating (r_appos) drugs_27\NNS|immunosuppressive|,|agents|, (r_pobj) of_25\IN|drugs (r_prep) use_24\NN|the|of|in (l_prep) in_33\IN|treatment (l_pobj) treatment_35\NN|the|of (l_prep) of_36\IN|arthritis (l_pobj) arthritis_38\NN|rheumatoid
7516729
D014700_D001919 CID verapamil_6\NN| (r_pobj) by_5\IN|verapamil (r_agent) induced_4\VBN|by (r_acl) bradycardia_3\NNS|dependent|induced
18081909
C026098_D001927 CID levetiracetam_3\NN| (r_pcomp) by_2\IN|levetiracetam (r_prep) induced_1\VBN|encephalopathy|by|added|. (l_nsubj) Encephalopathy_0\JJ|
C026098_D001927 CID levetiracetam_7\FW| (r_amod) encephalopathy_10\JJ|a|levetiracetam|(|lev)-induced
C026098_D001927 CID LEV)-induced_9\VBN| (r_amod) encephalopathy_10\JJ|a|levetiracetam|(|lev)-induced
D014635_D001927 CID valproate_6\VB|to (r_xcomp) added_4\VBN|valproate (r_conj) induced_1\VBN|encephalopathy|by|added|. (l_nsubj) Encephalopathy_0\JJ|
C026098_C562694 NONE LEV_15\NNP|mg (r_pobj) with_14\IN|lev (r_prep) treated_13\VBN|man|was|with|)|added|. (l_nsubjpass) man_4\NN|a|old|suffering (l_acl) suffering_5\VBG|from|with (l_prep) from_6\IN|epilepsy (l_pobj) epilepsy_8\NN|idiopathic
C026098_D012640 NONE LEV_15\NNP|mg (r_pobj) with_14\IN|lev (r_prep) treated_13\VBN|man|was|with|)|added|. (l_nsubjpass) man_4\NN|a|old|suffering (l_acl) suffering_5\VBG|from|with (l_prep) with_9\IN|seizures (l_pobj) seizures_11\NNS|generalized
C026098_D012640 NONE LEV_3\NNP|,|eeg (r_pobj) of_2\IN|lev (r_prep) discontinuation_1\NN|of (r_pobj) Following_0\VBG|discontinuation|improved (l_preconj) improved_9\VBN|and|decreased (l_conj) decreased_13\VBD|frequency|. (l_nsubj) frequency_12\NN|seizure (l_compound) seizure_11\NN|
D014635_C562694 NONE valproate_22\VB|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN|valproate (r_conj) treated_13\VBN|man|was|with|)|added|. (l_nsubjpass) man_4\NN|a|old|suffering (l_acl) suffering_5\VBG|from|with (l_prep) from_6\IN|epilepsy (l_pobj) epilepsy_8\NN|idiopathic
D014635_C562694 NONE VPA_24\NNP| (r_dobj) valproate_22\VB|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN|valproate (r_conj) treated_13\VBN|man|was|with|)|added|. (l_nsubjpass) man_4\NN|a|old|suffering (l_acl) suffering_5\VBG|from|with (l_prep) from_6\IN|epilepsy (l_pobj) epilepsy_8\NN|idiopathic
D014635_D012640 NONE valproate_22\VB|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN|valproate (r_conj) treated_13\VBN|man|was|with|)|added|. (l_nsubjpass) man_4\NN|a|old|suffering (l_acl) suffering_5\VBG|from|with (l_prep) with_9\IN|seizures (l_pobj) seizures_11\NNS|generalized
D014635_D012640 NONE VPA_24\NNP| (r_dobj) valproate_22\VB|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN|valproate (r_conj) treated_13\VBN|man|was|with|)|added|. (l_nsubjpass) man_4\NN|a|old|suffering (l_acl) suffering_5\VBG|from|with (l_prep) with_9\IN|seizures (l_pobj) seizures_11\NNS|generalized
2515254
D005996_D008881 CID nitroglycerin_11\NN|(|patients (r_pobj) of_10\IN|nitroglycerin (r_prep) application_9\NN|a|one|sided|frontotemporal|of (r_dobj) received_4\VBD|patients|application|. (l_nsubj) patients_3\NNS|twenty|common|migraine (l_compound) migraine_2\NN|
D005996_D008881 CID nitroglycerin_7\NN| (r_pobj) by_6\IN|nitroglycerin (r_agent) induced_5\VBN|attacks|were|by|in|. (l_nsubjpass) attacks_3\NNS|early|onset|migraine (l_compound) migraine_2\NN|
D005996_D008881 CID nitroglycerin_13\NN|frontotemporal (r_pobj) with_11\IN|nitroglycerin (r_prep) attack_10\NN|an|early|onset|with (r_dobj) developed_6\VBD|who|attack (r_relcl) patients_3\NNS|20|migraine|,|developed|, (l_compound) migraine_2\NN|
D005996_D008881 CID nitroglycerin_7\NN| (r_pobj) of_6\IN|nitroglycerin (r_prep) effect_5\NN|the|inducing|of (l_amod) inducing_4\VBG|migraine|- (l_npadvmod) migraine_2\NN|
D005996_D008881 CID nitroglycerin_7\NN| (r_pobj) of_6\IN|nitroglycerin (r_prep) effect_5\NN|the|inducing|of (r_nsubj) seems_8\VBZ|thus|effect|depend|,|suggesting|. (l_advcl) suggesting_21\VBG|is (l_ccomp) is_26\VBZ|that|region|of (l_prep) of_27\IN|importance (l_pobj) importance_29\NN|crucial|in (l_prep) in_30\IN|development (l_pobj) development_32\NN|the|of (l_prep) of_33\IN|crisis (l_pobj) crisis_36\NN|a|migraine (l_compound) migraine_35\JJ|
D005996_D010146 NONE nitroglycerin_7\NN| (r_pobj) of_6\IN|nitroglycerin (r_prep) effect_5\NN|the|inducing|of (r_nsubj) seems_8\VBZ|thus|effect|depend|,|suggesting|. (l_xcomp) depend_10\VB|to|on (l_prep) on_11\IN|stimulation (l_pobj) stimulation_13\NN|direct|of (l_prep) of_14\IN|site (l_pobj) site_17\NN|the|habitual|of (l_prep) of_18\IN|pain (l_pobj) pain_19\NN|
18752389
C492458_D017093 NONE ezetimibe_2\NN|simvastatin|- (r_npadvmod) induced_4\VBN|ezetimibe|- (r_amod) failure_6\NN|induced|hepatic|necessitating|.
C492458_D017093 NONE ezetimibe_13\NN|simvastatin|- (r_npadvmod) induced_15\VBN|ezetimibe|- (r_amod) failure_17\NN|induced|liver|resulted
C108606_D056486 NONE ezetimibe_10\NN|or|agent (r_pobj) with_9\IN|ezetimibe (r_prep) published_8\VBN|however|,|events|have|not|been|widely|with|. (l_nsubjpass) events_3\NNS|hepatotoxic (l_amod) hepatotoxic_2\JJ|
C108606_D056486 NONE Ezetimibe_0\NNP| (r_nsubj) undergoes_1\VBZ|ezetimibe|glucuronidation|and|inhibited|. (l_conj) inhibited_19\VBN|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG|in (l_prep) in_28\IN|exposure (l_pobj) exposure_31\NN|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN|subsequent
C108606_D056486 NONE ezetimibe_17\NN| (r_compound) inhibition_18\NN|ezetimibe|of (r_pobj) by_16\IN|inhibition (r_prep) exposure_15\NN|the|increased|simvastatin|by (r_attr) is_11\VBZ|that|mechanism|exposure (l_nsubj) mechanism_4\NN|the|of (l_prep) of_5\IN|hepatotoxicity (l_pobj) hepatotoxicity_10\NN|the|induced
C492458_D056486 CID ezetimibe_17\NN|simvastatin|- (r_appos) agent_14\NN|the|combination|ezetimibe (r_conj) ezetimibe_10\NN|or|agent (r_pobj) with_9\IN|ezetimibe (r_prep) published_8\VBN|however|,|events|have|not|been|widely|with|. (l_nsubjpass) events_3\NNS|hepatotoxic (l_amod) hepatotoxic_2\JJ|
C492458_D056486 CID Simvastatinezetimibe_0\NNP|and|escitalopram|(|taking|) (r_nsubjpass) discontinued_12\VBN|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN|causes|were|. (l_nsubjpass) causes_17\NNS|other|potential|of (l_prep) of_18\IN|hepatotoxicity (l_pobj) hepatotoxicity_19\NN|
C492458_D056486 CID simvastatinezetimibe_7\NN| (r_npadvmod) induced_9\VBN|simvastatinezetimibe|- (r_amod) hepatotoxicity_10\NN|the|induced
C492458_D056486 CID ezetimibe_10\NN|simvastatin|-|in (r_pobj) with_7\IN|ezetimibe (r_prep) hepatotoxicity_6\NN|potential|with
D019821_D017114 NONE simvastatin_21\NN| (r_nmod) day_25\NN|simvastatin|40|mg|/ (r_pobj) from_20\IN|day (r_prep) conversion_19\NN|from (r_pobj) after_18\IN|weeks|conversion (r_prep) necessitating_13\VBG|transplantation|after|simvastatin (r_acl) failure_12\NN|fulminant|hepatic|necessitating
C492458_D017114 CID mg_33\NN|40 (r_nummod) day_35\NN|mg|/ (r_npadvmod) ezetimibe_31\NN|10|mg|-|day (r_dobj) simvastatin_27\NN|to|ezetimibe (r_advcl) necessitating_13\VBG|transplantation|after|simvastatin (r_acl) failure_12\NN|fulminant|hepatic|necessitating
D019821_D056486 NONE simvastatin_9\NN| (r_pobj) with_8\IN|simvastatin (r_prep) maintained_7\VBN|panel|had|been|with|for|. (l_prep) for_10\IN|months (l_pobj) months_12\NNS|18|before (l_prep) before_13\IN|conversion (l_pobj) conversion_15\NN|the|without (l_prep) without_16\IN|evidence (l_pobj) evidence_17\NN|of (l_prep) of_18\IN|hepatotoxicity (l_pobj) hepatotoxicity_19\NN|
D019821_D056486 NONE simvastatin_30\NN| (r_amod) exposure_31\NN|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN|subsequent
D019821_D056486 NONE simvastatin_14\NN| (r_amod) exposure_15\NN|the|increased|simvastatin|by (r_attr) is_11\VBZ|that|mechanism|exposure (l_nsubj) mechanism_4\NN|the|of (l_prep) of_5\IN|hepatotoxicity (l_pobj) hepatotoxicity_10\NN|the|induced
C492458_D003866 NONE Simvastatinezetimibe_0\NNP|and|escitalopram|(|taking|) (l_relcl) taking_7\VBG|which|she|was|for (l_prep) for_8\IN|depression (l_pobj) depression_9\NN|
D015283_D003866 NONE escitalopram_2\NNP| (r_conj) Simvastatinezetimibe_0\NNP|and|escitalopram|(|taking|) (l_relcl) taking_7\VBG|which|she|was|for (l_prep) for_8\IN|depression (l_pobj) depression_9\NN|
D015283_D056486 NONE escitalopram_2\NNP| (r_conj) Simvastatinezetimibe_0\NNP|and|escitalopram|(|taking|) (r_nsubjpass) discontinued_12\VBN|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN|causes|were|. (l_nsubjpass) causes_17\NNS|other|potential|of (l_prep) of_18\IN|hepatotoxicity (l_pobj) hepatotoxicity_19\NN|
D014530_D056486 NONE diphosphate_6\NN|uridine (r_compound) glucoronosyltransferases_7\NNS|diphosphate|ugt|in (r_pobj) by_4\IN|glucoronosyltransferases (r_prep) glucuronidation_3\NN|extensive|by (r_dobj) undergoes_1\VBZ|ezetimibe|glucuronidation|and|inhibited|. (l_conj) inhibited_19\VBN|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG|in (l_prep) in_28\IN|exposure (l_pobj) exposure_31\NN|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN|subsequent
C532833_D056486 NONE acid_25\NN|simvastatin|hydroxy (r_pobj) of_22\IN|acid (r_prep) glucuronidation_21\NN|the|of (r_dobj) inhibited_19\VBN|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG|in (l_prep) in_28\IN|exposure (l_pobj) exposure_31\NN|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN|subsequent
10743446
D007649_D006930 NONE ketamine_5\NN|administered|and|lidocaine|on (l_prep) on_8\IN|hyperalgesia (l_pobj) hyperalgesia_12\NN|dynamic
D007649_D006930 NONE ketamine_9\NN|and|lidocaine (r_pobj) of_8\IN|ketamine (r_prep) administration_7\NN|systemic|of|on (l_prep) on_12\IN|hyperalgesia (l_pobj) hyperalgesia_27\NN|pain|evoked|(|static|)
D007649_D006930 NONE Ketamine_0\NN| (r_nsubj) reduced_1\VBD|ketamine|area|significantly|and|tended (l_dobj) area_4\NN|both|the|of (l_prep) of_5\IN|hyperalgesia (l_pobj) hyperalgesia_13\NN|evoked
D007649_D006930 NONE ketamine_4\NN|and|lidocaine (r_pobj) of_3\IN|ketamine (r_prep) effects_2\NNS|the|differential|of|on (l_prep) on_7\IN|hyperalgesia (l_pobj) hyperalgesia_11\NN|static
D007649_D006930 NONE ketamine_4\NN|and|lidocaine (r_pobj) of_3\IN|ketamine (r_prep) effects_2\NNS|the|differential|of|on (r_nsubj) suggest_12\VBP|effects|mediated|. (l_ccomp) mediated_20\VBN|that|types|are|by|and|have (l_nsubjpass) types_16\NNS|the|two|of (l_prep) of_17\IN|hyperalgesia (l_pobj) hyperalgesia_18\NN|
D008012_D006930 NONE lidocaine_7\NN| (r_conj) ketamine_5\NN|administered|and|lidocaine|on (l_prep) on_8\IN|hyperalgesia (l_pobj) hyperalgesia_12\NN|dynamic
D008012_D006930 NONE lidocaine_11\NN| (r_conj) ketamine_9\NN|and|lidocaine (r_pobj) of_8\IN|ketamine (r_prep) administration_7\NN|systemic|of|on (l_prep) on_12\IN|hyperalgesia (l_pobj) hyperalgesia_27\NN|pain|evoked|(|static|)
D008012_D006930 NONE Lidocaine_0\NN| (r_nsubj) reduced_1\VBD|lidocaine|area|significantly|. (l_dobj) area_3\NN|the|of (l_prep) of_4\IN|hyperalgesia (l_pobj) hyperalgesia_8\NN|evoked
D008012_D006930 NONE lidocaine_6\NN| (r_conj) ketamine_4\NN|and|lidocaine (r_pobj) of_3\IN|ketamine (r_prep) effects_2\NNS|the|differential|of|on (l_prep) on_7\IN|hyperalgesia (l_pobj) hyperalgesia_11\NN|static
D008012_D006930 NONE lidocaine_6\NN| (r_conj) ketamine_4\NN|and|lidocaine (r_pobj) of_3\IN|ketamine (r_prep) effects_2\NNS|the|differential|of|on (r_nsubj) suggest_12\VBP|effects|mediated|. (l_ccomp) mediated_20\VBN|that|types|are|by|and|have (l_nsubjpass) types_16\NNS|the|two|of (l_prep) of_17\IN|hyperalgesia (l_pobj) hyperalgesia_18\NN|
D002211_D006930 CID capsaicin_16\NN|intradermal|in (r_pobj) by_14\IN|capsaicin (r_agent) induced_13\VBN|by (r_acl) effects_1\NNS|differential|of|induced|. (l_prep) of_2\IN|ketamine (l_pobj) ketamine_5\NN|administered|and|lidocaine|on (l_prep) on_8\IN|hyperalgesia (l_pobj) hyperalgesia_12\NN|dynamic
D002211_D006930 CID capsaicin_30\NN| (r_pobj) by_29\IN|capsaicin (r_agent) induced_28\VBN|by (r_acl) effect_4\NN|the|of|induced (l_prep) of_5\IN|administration (l_pobj) administration_7\NN|systemic|of|on (l_prep) on_12\IN|hyperalgesia (l_pobj) hyperalgesia_27\NN|pain|evoked|(|static|)
D007649_D010146 NONE ketamine_9\NN|and|lidocaine (r_pobj) of_8\IN|ketamine (r_prep) administration_7\NN|systemic|of|on (l_prep) on_12\IN|hyperalgesia (l_pobj) hyperalgesia_27\NN|pain|evoked|(|static|) (l_nmod) pain_19\NN|evoked|(|dynamic|)|and
D007649_D010146 NONE Ketamine_0\NN| (r_nsubj) reduced_1\VBD|ketamine|area|significantly|and|tended (l_conj) tended_17\VBD|it|reduce|. (l_xcomp) reduce_19\VB|to|pain (l_dobj) pain_23\NN|evoked
D008012_D010146 NONE lidocaine_11\NN| (r_conj) ketamine_9\NN|and|lidocaine (r_pobj) of_8\IN|ketamine (r_prep) administration_7\NN|systemic|of|on (l_prep) on_12\IN|hyperalgesia (l_pobj) hyperalgesia_27\NN|pain|evoked|(|static|) (l_nmod) pain_19\NN|evoked|(|dynamic|)|and
D002211_D010146 CID capsaicin_30\NN| (r_pobj) by_29\IN|capsaicin (r_agent) induced_28\VBN|by (r_acl) effect_4\NN|the|of|induced (l_prep) of_5\IN|administration (l_pobj) administration_7\NN|systemic|of|on (l_prep) on_12\IN|hyperalgesia (l_pobj) hyperalgesia_27\NN|pain|evoked|(|static|) (l_nmod) pain_19\NN|evoked|(|dynamic|)|and
16938416
D013739_D050197 CID testosterone_3\NN|dose (r_nsubjpass) associated_5\VBN|testosterone|is|with|. (l_prep) with_6\IN|atherosclerosis (l_pobj) atherosclerosis_7\NN|in
D013739_D050197 CID testosterone_32\NN|estrogen|- (r_compound) therapy_33\NN|reported|administered|dose|testosterone|esters|)|and|atherosclerosis (l_conj) atherosclerosis_42\NN|aortic
D013739_D050197 CID testosterone_7\NN| (r_compound) therapy_8\NN|dose|testosterone (r_nsubj) affect_11\VB|that|therapy|may|adversely|atherosclerosis|and|indicate (l_dobj) atherosclerosis_12\NN|in
D004967_D050197 NONE estrogen_30\NN| (r_compound) testosterone_32\NN|estrogen|- (r_compound) therapy_33\NN|reported|administered|dose|testosterone|esters|)|and|atherosclerosis (l_conj) atherosclerosis_42\NN|aortic
C032109_D050197 NONE esters_38\NNS|estradiol- (r_appos) therapy_33\NN|reported|administered|dose|testosterone|esters|)|and|atherosclerosis (l_conj) atherosclerosis_42\NN|aortic
D002784_D003920 NONE cholesterol_9\NN| (r_compound) level_10\NN|cholesterol|,|pressure (r_conj) diabetes_7\NNS|,|level
D000431_D003920 NONE alcohol_17\NN| (r_compound) use_18\NN|alcohol (r_conj) pressure_14\NN|systolic|blood|,|or|use (r_conj) level_10\NN|cholesterol|,|pressure (r_conj) diabetes_7\NNS|,|level
3496378
D014217_D002779 CID troleandomycin_3\NN| (r_npadvmod) induced_5\VBN|troleandomycin|- (r_amod) hepatitis_7\NN|induced|acute (r_pobj) after_2\IN|hepatitis (r_prep) cholestasis_1\NN|prolonged|after|.
D014217_D002779 CID troleandomycin_9\NN| (r_npadvmod) induced_11\VBN|in|troleandomycin|- (r_relcl) patient_6\NN|a|induced (r_pobj) of_4\IN|patient (r_prep) case_3\NN|the|of (r_dobj) report_1\VBP|we|case|followed|. (l_ccomp) followed_14\VBN|hepatitis|was|by (l_agent) by_15\IN|cholestasis (l_pobj) cholestasis_18\NN|prolonged|anicteric
D014217_D002779 CID troleandomycin_8\NN| (r_npadvmod) induced_10\VBN|troleandomycin|- (r_amod) hepatitis_12\NN|induced|acute (r_dobj) follow_7\VB|that|cholestasis|can|hepatitis (l_nsubj) cholestasis_5\NN|prolonged
D014217_D056486 CID troleandomycin_3\NN| (r_npadvmod) induced_5\VBN|troleandomycin|- (r_amod) hepatitis_7\NN|induced|acute
D014217_D056486 CID troleandomycin_9\NN| (r_npadvmod) induced_11\VBN|in|troleandomycin|- (r_relcl) patient_6\NN|a|induced (r_pobj) of_4\IN|patient (r_prep) case_3\NN|the|of (r_dobj) report_1\VBP|we|case|followed|. (l_ccomp) followed_14\VBN|hepatitis|was|by (l_nsubjpass) hepatitis_12\NN|
D014217_D056486 CID troleandomycin_8\NN| (r_npadvmod) induced_10\VBN|troleandomycin|- (r_amod) hepatitis_12\NN|induced|acute
D014217_D007565 CID troleandomycin_5\NN| (r_pobj) of_4\IN|troleandomycin (r_prep) administration_3\NN|of (r_pobj) after_2\IN|administration (r_prep) occurred_1\VBD|jaundice|after|for|and|associated|. (l_nsubj) Jaundice_0\NN|
D014217_D004802 CID troleandomycin_5\NN| (r_pobj) of_4\IN|troleandomycin (r_prep) administration_3\NN|of (r_pobj) after_2\IN|administration (r_prep) occurred_1\VBD|jaundice|after|for|and|associated|. (l_conj) associated_11\VBN|was|with (l_prep) with_12\IN|hypereosinophilia (l_pobj) hypereosinophilia_13\NNS|
7199841
C004616_D010243 CID CE_11\NN|2-chloroprocaine|- (r_nmod) %_15\NN|ce|seven|35 (r_pobj) of_8\IN|% (r_prep) injection_7\NN|subarachnoid|of (r_dobj) received_5\VBD|that|injection (r_relcl) animals_3\NNS|the|20|received|) (r_pobj) Of_0\IN|animals (r_prep) paralysis_21\NN|of|developed|limb|.
D002045_D010243 NONE bupivacaine_6\NN| (r_dobj) received_5\VBD|that|bupivacaine (r_relcl) animals_3\NNS|the|received (r_pobj) of_1\IN|animals (r_prep) None_0\NN|of|,|saline (r_nsubj) titrated_14\VBN|none|to|. (l_prep) to_15\IN|paralysis (l_pobj) paralysis_23\NN|a|ph|3.0|developed|limb
C004616_D013118 CID CE_12\NNP|2-chloroprocaine|- (r_dobj) received_9\VBD|that|ce (r_relcl) animals_7\NNS|the|received (r_pobj) of_5\IN|animals (r_prep) cords_4\NNS|the|15|spinal|of (r_pobj) Of_0\IN|cords (r_prep) 13_14\CD|of (r_nsubj) showed_15\VBD|,|13|necrosis (l_dobj) necrosis_17\NN|subpial
8387218
D016049_D064420 NONE didanosine_5\NN|ddi|in (r_pobj) of_4\IN|didanosine (r_prep) use_1\NN|the|and|toxicity|of|) (l_conj) toxicity_3\NN|
D016049_D064420 NONE ddI_7\NN|(|) (r_appos) didanosine_5\NN|ddi|in (r_pobj) of_4\IN|didanosine (r_prep) use_1\NN|the|and|toxicity|of|) (l_conj) toxicity_3\NN|
D016049_D015658 NONE didanosine_5\NN|ddi|in (l_prep) in_9\IN|individuals (l_pobj) individuals_14\NNS|hiv|positive|intolerant|azt (l_amod) positive_13\JJ|antibody|-
D016049_D015658 NONE ddI_7\NN|(|) (r_appos) didanosine_5\NN|ddi|in (l_prep) in_9\IN|individuals (l_pobj) individuals_14\NNS|hiv|positive|intolerant|azt (l_amod) positive_13\JJ|antibody|-
D015215_D064420 NONE zidovudine_17\NNP| (r_pobj) to_16\IN|zidovudine (r_prep) intolerant_15\JJ|to (r_amod) individuals_14\NNS|hiv|positive|intolerant|azt (r_pobj) in_9\IN|individuals (r_prep) didanosine_5\NN|ddi|in (r_pobj) of_4\IN|didanosine (r_prep) use_1\NN|the|and|toxicity|of|) (l_conj) toxicity_3\NN|
D015215_D064420 NONE AZT_19\NNP|( (r_appos) individuals_14\NNS|hiv|positive|intolerant|azt (r_pobj) in_9\IN|individuals (r_prep) didanosine_5\NN|ddi|in (r_pobj) of_4\IN|didanosine (r_prep) use_1\NN|the|and|toxicity|of|) (l_conj) toxicity_3\NN|
D015215_D015658 NONE zidovudine_17\NNP| (r_pobj) to_16\IN|zidovudine (r_prep) intolerant_15\JJ|to (r_amod) individuals_14\NNS|hiv|positive|intolerant|azt (l_amod) positive_13\JJ|antibody|-
D015215_D015658 NONE AZT_19\NNP|( (r_appos) individuals_14\NNS|hiv|positive|intolerant|azt (l_amod) positive_13\JJ|antibody|-
D016049_D018149 CID didanosine_24\NN| (r_dobj) ceasing_23\VBG|didanosine (r_pcomp) on_22\IN|ceasing (r_prep) returned_19\VBN|to|on (r_conj) require_16\VB|,|did|not|treatment|and|returned|. (r_conj) developed_2\VBD|patients|curves|but|were|require (l_dobj) curves_5\VBZ|tolerance|characteristic
D016049_D003920 NONE didanosine_24\NN| (r_dobj) ceasing_23\VBG|didanosine (r_pcomp) on_22\IN|ceasing (r_prep) returned_19\VBN|to|on (r_conj) require_16\VB|,|did|not|treatment|and|returned|. (r_conj) developed_2\VBD|patients|curves|but|were|require (l_dobj) curves_5\VBZ|tolerance|characteristic (l_amod) characteristic_6\JJ|of (l_prep) of_7\IN|diabetes (l_pobj) diabetes_8\NNS|
6888657
D004967_D010911 NONE estrogen_2\NN| (r_npadvmod) induced_4\VBN|estrogen|- (r_amod) tumors_6\NNS|induced|adenohypophyseal|in
D004054_D010911 CID diethylstilbestrol_12\NN| (r_pobj) with_11\IN|diethylstilbestrol (r_prep) treatment_10\NN|chronic|with (r_pobj) by_8\IN|treatment (r_agent) induced_3\VBN|tumors|were|in|by|implanted|. (l_nsubjpass) tumors_1\NNS|pituitary
D004054_D010911 CID DES_14\NNP| (r_npadvmod) implanted_21\VBN|(|des|,|subcutaneously|in (r_parataxis) induced_3\VBN|tumors|were|in|by|implanted|. (l_nsubjpass) tumors_1\NNS|pituitary
D004054_D009369 NONE DES_12\NNP| (r_npadvmod) induced_14\VBN|des|- (r_amod) tumor_15\NN|the|induced
8092427
D000658_D004342 CID amoxicillin_4\NNP| (r_pobj) to_3\IN|amoxicillin (r_prep) reactions_2\NNS|immediate|allergic|to|.
D000658_D004342 CID amoxicillin_39\NNP|ax (r_pobj) to_38\IN|amoxicillin (r_prep) responses_37\NNS|selective|immediate|allergic|to (r_dobj) had_33\VBD|responses|or|were (r_conj) used_22\VBN|history|,|with|,|rast|was|establish|had|. (l_xcomp) establish_24\VB|to|allergic (l_ccomp) allergic_27\JJ|whether|patients|to
D000658_D004342 CID amoxicillin_39\NNP|ax (r_pobj) to_38\IN|amoxicillin (r_prep) responses_37\NNS|selective|immediate|allergic|to (l_amod) allergic_36\JJ|
D000658_D004342 CID AX_41\NN|(|) (r_appos) amoxicillin_39\NNP|ax (r_pobj) to_38\IN|amoxicillin (r_prep) responses_37\NNS|selective|immediate|allergic|to (r_dobj) had_33\VBD|responses|or|were (r_conj) used_22\VBN|history|,|with|,|rast|was|establish|had|. (l_xcomp) establish_24\VB|to|allergic (l_ccomp) allergic_27\JJ|whether|patients|to
D000658_D004342 CID AX_41\NN|(|) (r_appos) amoxicillin_39\NNP|ax (r_pobj) to_38\IN|amoxicillin (r_prep) responses_37\NNS|selective|immediate|allergic|to (l_amod) allergic_36\JJ|
D000658_D004342 CID AX_11\NNP| (r_compound) allergy_12\NN|immediate|ax|with
D000658_D004342 CID AX_3\NN| (r_pobj) with_2\IN|ax (r_prep) tests_1\NNS|challenge|with (r_nsubjpass) performed_5\VBN|tests|were|in|establish|and|were (l_advcl) establish_14\VB|to|diagnosis|, (l_dobj) diagnosis_16\NN|the|of (l_prep) of_17\IN|reaction (l_pobj) reaction_20\NN|immediate|allergic|to
D000658_D004342 CID AX_22\NN| (r_pobj) to_21\IN|ax (r_prep) reaction_20\NN|immediate|allergic|to
D000658_D004342 CID AX_38\NN| (r_pobj) for_37\IN|ax (r_prep) RAST_36\NNP|for (r_conj) test_34\NN|both|skin|and|rast (r_appos) %_30\NN|28|)|test (r_nsubj) were_39\VBD|in|(|%|negative|. (r_conj) performed_5\VBN|tests|were|in|establish|and|were (l_advcl) establish_14\VB|to|diagnosis|, (l_dobj) diagnosis_16\NN|the|of (l_prep) of_17\IN|reaction (l_pobj) reaction_20\NN|immediate|allergic|to
D000658_D004342 CID AX_6\NN| (r_npadvmod) allergic_8\JJ|ax|-
D047090_D004342 NONE lactam_12\NN|beta|- (r_amod) antibiotics_13\NNS|lactam (r_pobj) to_9\IN|antibiotics (r_prep) reactions_8\NNS|suspected|allergic|to
D047090_D004342 NONE lactam_31\NN|beta|- (r_amod) antibiotics_32\NNS|lactam (r_pobj) to_28\IN|antibiotics (r_prep) allergic_27\JJ|whether|patients|to
D047090_D004342 NONE lactam_31\NN|beta|- (r_amod) antibiotics_32\NNS|lactam (r_pobj) to_28\IN|antibiotics (r_prep) allergic_27\JJ|whether|patients|to (r_ccomp) establish_24\VB|to|allergic (r_xcomp) used_22\VBN|history|,|with|,|rast|was|establish|had|. (l_conj) had_33\VBD|responses|or|were (l_dobj) responses_37\NNS|selective|immediate|allergic|to (l_amod) allergic_36\JJ|
D047090_D004342 NONE lactam_12\NN|beta|- (r_amod) antibiotics_13\NNS|lactam (r_pobj) to_9\IN|antibiotics (r_prep) allergic_8\JJ|to
D010406_D004342 NONE penicillin_50\NN| (r_compound) derivatives_51\NNS|other|penicillin (r_pobj) with_48\IN|derivatives (r_prep) reacting_47\VBG|cross|-|with (r_acomp) were_44\VBD|reacting (r_conj) had_33\VBD|responses|or|were (r_conj) used_22\VBN|history|,|with|,|rast|was|establish|had|. (l_xcomp) establish_24\VB|to|allergic (l_ccomp) allergic_27\JJ|whether|patients|to
D010406_D004342 NONE penicillin_50\NN| (r_compound) derivatives_51\NNS|other|penicillin (r_pobj) with_48\IN|derivatives (r_prep) reacting_47\VBG|cross|-|with (r_acomp) were_44\VBD|reacting (r_conj) had_33\VBD|responses|or|were (l_dobj) responses_37\NNS|selective|immediate|allergic|to (l_amod) allergic_36\JJ|
D010400_D004342 NONE PG_17\NNP| (r_pobj) of_16\IN|pg (r_prep) tolerance_15\NN|good|of (r_pobj) with_13\IN|tolerance (r_prep) allergy_12\NN|immediate|ax|with
D010400_D004342 NONE PG_13\NNP| (r_dobj) tolerated_12\VBN|who|have|pg (r_relcl) patients_9\NNS|allergic|tolerated (l_amod) allergic_8\JJ|ax|-
-1_D007645 NONE BPO_8\NNP| (r_pobj) to_7\IN|bpo (r_prep) negative_6\JJ|to (r_amod) test_5\NN|skin|negative (r_attr) were_3\VBD|patients|test (r_ccomp) were_17\VBD|were|;|49|also|negative|,|and|44|. (l_acomp) negative_19\JJ|to (l_prep) to_20\IN|mdm (l_pobj) MDM_21\NNP|
D010400_D007645 NONE PG_32\NNP| (r_pobj) to_31\IN|pg (r_prep) 44_24\CD|of|%|)|to (r_conj) were_17\VBD|were|;|49|also|negative|,|and|44|. (l_acomp) negative_19\JJ|to (l_prep) to_20\IN|mdm (l_pobj) MDM_21\NNP|
2505783
C004656_D006470 CID chloroacetaldehyde_7\NN|caa (r_nsubj) is_11\VBZ|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN|an|important|of|,|carried (l_relcl) carried_23\VBN|study|was|out|in (l_prep) in_25\IN|order (l_pobj) order_26\NN|elucidate (l_acl) elucidate_28\VB|to|role|in (l_prep) in_33\IN|development (l_pobj) development_35\NN|the|of (l_prep) of_36\IN|cystitis (l_pobj) cystitis_38\NN|hemorrhagic
C004656_D006470 CID CAA_9\NNP|(|) (r_appos) chloroacetaldehyde_7\NN|caa (r_nsubj) is_11\VBZ|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN|an|important|of|,|carried (l_relcl) carried_23\VBN|study|was|out|in (l_prep) in_25\IN|order (l_pobj) order_26\NN|elucidate (l_acl) elucidate_28\VB|to|role|in (l_prep) in_33\IN|development (l_pobj) development_35\NN|the|of (l_prep) of_36\IN|cystitis (l_pobj) cystitis_38\NN|hemorrhagic
C004656_D006470 CID CAA_32\NNP| (r_pobj) of_31\IN|caa (r_prep) role_30\NN|the|of (r_dobj) elucidate_28\VB|to|role|in (l_prep) in_33\IN|development (l_pobj) development_35\NN|the|of (l_prep) of_36\IN|cystitis (l_pobj) cystitis_38\NN|hemorrhagic
C004656_D003556 CID chloroacetaldehyde_7\NN|caa (r_nsubj) is_11\VBZ|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN|an|important|of|,|carried (l_relcl) carried_23\VBN|study|was|out|in (l_prep) in_25\IN|order (l_pobj) order_26\NN|elucidate (l_acl) elucidate_28\VB|to|role|in (l_prep) in_33\IN|development (l_pobj) development_35\NN|the|of (l_prep) of_36\IN|cystitis (l_pobj) cystitis_38\NN|hemorrhagic
C004656_D003556 CID CAA_9\NNP|(|) (r_appos) chloroacetaldehyde_7\NN|caa (r_nsubj) is_11\VBZ|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN|an|important|of|,|carried (l_relcl) carried_23\VBN|study|was|out|in (l_prep) in_25\IN|order (l_pobj) order_26\NN|elucidate (l_acl) elucidate_28\VB|to|role|in (l_prep) in_33\IN|development (l_pobj) development_35\NN|the|of (l_prep) of_36\IN|cystitis (l_pobj) cystitis_38\NN|hemorrhagic
C004656_D003556 CID CAA_32\NNP| (r_pobj) of_31\IN|caa (r_prep) role_30\NN|the|of (r_dobj) elucidate_28\VB|to|role|in (l_prep) in_33\IN|development (l_pobj) development_35\NN|the|of (l_prep) of_36\IN|cystitis (l_pobj) cystitis_38\NN|hemorrhagic
C004656_D001745 NONE CAA_4\NNP| (r_nsubj) contribute_10\VB|that|caa|after|administration|does|not|to (l_prep) to_11\IN|damage (l_pobj) damage_13\NN|bladder
12617329
D006170_D007674 NONE Arabic_6\JJ|gum (r_pobj) with_4\IN|arabic (r_prep) treatment_3\NN|with|on (l_prep) on_7\IN|nephrotoxicity (l_pobj) nephrotoxicity_9\NN|gentamicin|in
D006170_D007674 NONE Arabic_14\JJ|gum (r_pobj) with_12\IN|arabic (r_prep) rats_11\NNS|with (r_pobj) of_10\IN|rats (r_prep) treatment_9\NN|of|on (l_prep) on_15\IN|failure (l_pobj) failure_18\NN|acute|renal|induced (l_acl) induced_19\VBN|by (l_agent) by_20\IN|nephrotoxicity (l_pobj) nephrotoxicity_25\NN|gentamicin|(|gm|)
D006170_D007674 NONE Arabic_6\JJ| (r_amod) treatment_7\NN|gum|arabic (r_nsubj) induced_9\VBN|that|treatment|has|amelioration (l_dobj) amelioration_12\NN|a|modest|of (l_prep) of_13\IN|some (l_pobj) some_14\DT|of (l_prep) of_15\IN|indices (l_pobj) indices_20\NNS|the|histological|of (l_prep) of_21\IN|nephrotoxicity (l_pobj) nephrotoxicity_23\NN|gm
D005839_D007674 NONE gentamicin_8\NN| (r_amod) nephrotoxicity_9\NN|gentamicin|in
D005839_D007674 NONE gentamicin_21\NN| (r_nmod) nephrotoxicity_25\NN|gentamicin|(|gm|)
D005839_D007674 NONE GM_23\NNP| (r_nmod) nephrotoxicity_25\NN|gentamicin|(|gm|)
D005839_D007674 NONE GM_22\NNP| (r_compound) nephrotoxicity_23\NN|gm
D006170_D058186 CID Arabic_14\JJ|gum (r_pobj) with_12\IN|arabic (r_prep) rats_11\NNS|with (r_pobj) of_10\IN|rats (r_prep) treatment_9\NN|of|on (l_prep) on_15\IN|failure (l_pobj) failure_18\NN|acute|renal|induced
D005839_D058186 CID gentamicin_21\NN| (r_nmod) nephrotoxicity_25\NN|gentamicin|(|gm|) (r_pobj) by_20\IN|nephrotoxicity (r_agent) induced_19\VBN|by (r_acl) failure_18\NN|acute|renal|induced
D005839_D058186 CID GM_23\NNP| (r_nmod) nephrotoxicity_25\NN|gentamicin|(|gm|) (r_pobj) by_20\IN|nephrotoxicity (r_agent) induced_19\VBN|by (r_acl) failure_18\NN|acute|renal|induced
D003404_D007674 NONE creatinine_8\NN|and|urea (r_pobj) of_7\IN|creatinine (r_prep) concentrations_6\NNS|the|of|in (r_dobj) measuring_4\VBG|concentrations|and|glutathione (r_pcomp) by_3\IN|measuring|and|by (r_prep) assessed_2\VBN|nephrotoxicity|was|by|. (l_nsubjpass) Nephrotoxicity_0\NN|
D014508_D007674 NONE urea_10\NN| (r_conj) creatinine_8\NN|and|urea (r_pobj) of_7\IN|creatinine (r_prep) concentrations_6\NNS|the|of|in (r_dobj) measuring_4\VBG|concentrations|and|glutathione (r_pcomp) by_3\IN|measuring|and|by (r_prep) assessed_2\VBN|nephrotoxicity|was|by|. (l_nsubjpass) Nephrotoxicity_0\NN|
D005978_D007674 NONE glutathione_16\NN|reduced|gsh|in|, (r_conj) measuring_4\VBG|concentrations|and|glutathione (r_pcomp) by_3\IN|measuring|and|by (r_prep) assessed_2\VBN|nephrotoxicity|was|by|. (l_nsubjpass) Nephrotoxicity_0\NN|
D005978_D007674 NONE GSH_18\NNP|(|) (r_appos) glutathione_16\NN|reduced|gsh|in|, (r_conj) measuring_4\VBG|concentrations|and|glutathione (r_pcomp) by_3\IN|measuring|and|by (r_prep) assessed_2\VBN|nephrotoxicity|was|by|. (l_nsubjpass) Nephrotoxicity_0\NN|
D005839_D007683 NONE GM_1\NNP| (r_npadvmod) induced_3\VBN|gm|- (r_amod) necrosis_6\NN|the|induced|proximal|tubular
D005839_D007683 NONE GM_16\NNP| (r_dobj) given_15\VBN|gm|with|than (r_acl) rats_14\NNS|given (r_pobj) in_13\IN|rats (r_prep) severe_12\JJ|less|in (r_acomp) be_9\VB|to|severe (r_xcomp) appeared_7\VBD|necrosis|be|. (l_nsubj) necrosis_6\NN|the|induced|proximal|tubular
D005839_D007683 NONE GM_25\NNP|and|cellulose (r_pobj) given_24\VBN|gm (r_acl) those_23\DT|given (r_pobj) in_22\IN|those (r_prep) than_21\IN|in (r_prep) given_15\VBN|gm|with|than (r_acl) rats_14\NNS|given (r_pobj) in_13\IN|rats (r_prep) severe_12\JJ|less|in (r_acomp) be_9\VB|to|severe (r_xcomp) appeared_7\VBD|necrosis|be|. (l_nsubj) necrosis_6\NN|the|induced|proximal|tubular
D006170_D007683 NONE Arabic_20\JJ|gum (r_pobj) with_18\IN|together|arabic (r_prep) given_15\VBN|gm|with|than (r_acl) rats_14\NNS|given (r_pobj) in_13\IN|rats (r_prep) severe_12\JJ|less|in (r_acomp) be_9\VB|to|severe (r_xcomp) appeared_7\VBD|necrosis|be|. (l_nsubj) necrosis_6\NN|the|induced|proximal|tubular
17491223
D004280_D017202 CID dobutamine_14\NN| (r_npadvmod) induced_16\VBN|dobutamine|- (r_amod) ischemia_18\NN|induced|myocardial
D004280_D017202 CID dobutamine_8\NN| (r_npadvmod) induced_10\VBN|dobutamine|- (r_amod) ischemia_12\NN|induced|myocardial
D004280_D017202 CID dobutamine_37\NN| (r_npadvmod) induced_39\VBN|dobutamine|- (r_amod) ischemia_41\NN|induced|myocardial
D004280_D007511 NONE dobutamine_37\NN| (r_npadvmod) induced_39\VBN|dobutamine|- (r_amod) ischemia_41\NN|induced|myocardial (r_dobj) detecting_36\VBG|ischemia|,|using (r_pcomp) for_35\IN|detecting (r_prep) assess_3\VB|to|value|,|compared|,|for|computed (l_conj) computed_51\VBD|tomography|assess (l_advcl) assess_60\VB|to|presence (l_dobj) presence_62\NN|the|or|absence|of (l_prep) of_65\IN|ischemia (l_pobj) ischemia_66\NN|
D017256_D017202 NONE Sestamibi_46\NNP|tc99m|- (r_nmod) emission_50\NN|sestamibi|photon (r_dobj) using_43\VBG|emission (r_conj) detecting_36\VBG|ischemia|,|using (l_dobj) ischemia_41\NN|induced|myocardial
D017256_D007511 NONE Sestamibi_46\NNP|tc99m|- (r_nmod) emission_50\NN|sestamibi|photon (r_dobj) using_43\VBG|emission (r_conj) detecting_36\VBG|ischemia|,|using (r_pcomp) for_35\IN|detecting (r_prep) assess_3\VB|to|value|,|compared|,|for|computed (l_conj) computed_51\VBD|tomography|assess (l_advcl) assess_60\VB|to|presence (l_dobj) presence_62\NN|the|or|absence|of (l_prep) of_65\IN|ischemia (l_pobj) ischemia_66\NN|
2348231
D010431_D006940 NONE Pentoxifylline_0\NNP|(|trental|) (r_nsubj) inhibit_6\VB|pentoxifylline|does|not|hyperemia|. (l_dobj) hyperemia_11\NN|induced|coronary|:|implications
D010431_D006940 NONE Trental_2\NNP| (r_appos) Pentoxifylline_0\NNP|(|trental|) (r_nsubj) inhibit_6\VB|pentoxifylline|does|not|hyperemia|. (l_dobj) hyperemia_11\NN|induced|coronary|:|implications
D010431_D006940 NONE pentoxifylline_1\NN|whether (r_nsubj) inhibits_2\VBZ|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_7\NN|induced|coronary|like
D010431_D006940 NONE pentoxifylline_3\NN| (r_pobj) of_2\IN|pentoxifylline (r_prep) dose_1\NN|neither|of (r_nsubj) decreased_5\VBD|dose|significantly|hyperemia|,|peak|less|)|. (l_dobj) hyperemia_10\NN|the|induced
D010431_D006940 NONE pentoxyifylline_3\NN| (r_nsubj) inhibit_6\VB|that|pentoxyifylline|does|not|hyperemia|at (l_dobj) hyperemia_11\NN|induced|coronary
D004176_D006940 CID dipyridamole_7\NN| (r_npadvmod) induced_9\VBN|dipyridamole|- (r_amod) hyperemia_11\NN|induced|coronary|:|implications
D004176_D006940 CID dipyridamole_15\JJ| (r_npadvmod) thallium-201_17\NN|dipyridamole|- (r_nmod) imaging_19\NN|thallium-201|myocardial (r_pobj) for_14\IN|imaging (r_prep) implications_13\NNS|for (r_appos) hyperemia_11\NN|induced|coronary|:|implications
D004176_D006940 CID dipyridamole_3\NN| (r_dep) induced_5\VBN|dipyridamole|- (r_amod) hyperemia_7\NN|induced|coronary|like
D004176_D006940 CID dipyridamole_20\NN| (r_compound) thallium-201_22\NN|dipyridamole|- (r_compound) imaging_23\NN|thallium-201 (r_pobj) to_19\IN|imaging (r_prep) prior_18\RB|to (r_advmod) stopped_17\VBN|should|be|prior (r_conj) inhibits_2\VBZ|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_7\NN|induced|coronary|like
D004176_D006940 CID dipyridamole_7\NN| (r_npadvmod) induced_9\VBN|dipyridamole|- (r_amod) hyperemia_10\NN|the|induced
D004176_D006940 CID dipyridamole_7\NN| (r_npadvmod) induced_9\VBN|dipyridamole|- (r_amod) hyperemia_11\NN|induced|coronary
D013793_D006940 NONE thallium-201_17\NN|dipyridamole|- (r_nmod) imaging_19\NN|thallium-201|myocardial (r_pobj) for_14\IN|imaging (r_prep) implications_13\NNS|for (r_appos) hyperemia_11\NN|induced|coronary|:|implications
D013793_D006940 NONE thallium-201_22\NN|dipyridamole|- (r_compound) imaging_23\NN|thallium-201 (r_pobj) to_19\IN|imaging (r_prep) prior_18\RB|to (r_advmod) stopped_17\VBN|should|be|prior (r_conj) inhibits_2\VBZ|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_7\NN|induced|coronary|like
D010431_D007383 CID pentoxifylline_6\NN| (r_dobj) taking_5\VBG|many|are|pentoxifylline|(|trental|)|,|derivative|. (l_conj) derivative_13\NN|a|methylxanthine|improve (l_relcl) improve_16\VB|which|may|claudication (l_dobj) claudication_18\NN|intermittent
D010431_D007383 CID Trental_8\NNP| (r_npadvmod) taking_5\VBG|many|are|pentoxifylline|(|trental|)|,|derivative|. (l_conj) derivative_13\NN|a|methylxanthine|improve (l_relcl) improve_16\VB|which|may|claudication (l_dobj) claudication_18\NN|intermittent
C008514_D007383 NONE methylxanthine_12\NN| (r_compound) derivative_13\NN|a|methylxanthine|improve (l_relcl) improve_16\VB|which|may|claudication (l_dobj) claudication_18\NN|intermittent
C008514_D006940 NONE methylxanthines_10\NNS|other|as (r_pobj) like_8\IN|methylxanthines (r_prep) hyperemia_7\NN|induced|coronary|like
D013806_D006940 NONE theophylline_13\NN| (r_pobj) as_12\IN|such|theophylline (r_prep) methylxanthines_10\NNS|other|as (r_pobj) like_8\IN|methylxanthines (r_prep) hyperemia_7\NN|induced|coronary|like
D013806_D006940 NONE theophylline_21\NN| (r_pobj) after_20\IN|theophylline (r_prep) was_17\VBD|flow|lower|after (r_ccomp) peak_13\JJ|while|was (r_advcl) decreased_5\VBD|dose|significantly|hyperemia|,|peak|less|)|. (l_dobj) hyperemia_10\NN|the|induced
19473225
D018698_D010523 NONE glutamate_3\NN| (r_compound) supplementation_4\NN|term|glutamate (r_nsubj) failed_5\VBD|supplementation|protect|. (l_xcomp) protect_7\VB|to|against (l_prep) against_8\IN|neurotoxicity (l_pobj) neurotoxicity_10\NN|peripheral|of
D018698_D010523 NONE glutamate_18\NN|and|glutamine (r_nsubjpass) claimed_27\VBN|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN|toxic|peripheral
D018698_D010523 NONE glutamine_25\NN|its|related|acid (r_conj) glutamate_18\NN|and|glutamine (r_nsubjpass) claimed_27\VBN|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN|toxic|peripheral
D018698_D010523 NONE glutamate_9\NN| (r_compound) supplementation_10\NN|glutamate|for (l_prep) for_11\IN|preventing (l_pcomp) preventing_12\VBG|neuropathy|in (l_dobj) neuropathy_17\NN|induced|peripheral
D018698_D010523 NONE glutamate_8\NN| (r_compound) supplementation_9\NN|glutamate|at (r_nsubj) fails_14\VBZ|that|supplementation|protect (l_xcomp) protect_16\VB|to|against (l_prep) against_17\IN|neurotoxicity (l_pobj) neurotoxicity_19\NN|peripheral|of
D017239_D010523 CID paclitaxel_12\NN| (r_pobj) of_11\IN|paclitaxel (r_prep) neurotoxicity_10\NN|peripheral|of
D017239_D010523 CID paclitaxel_12\NN| (r_pobj) with_11\IN|paclitaxel (r_prep) chemotherapy_10\NN|with|pac (r_pobj) for_9\IN|chemotherapy (r_prep) factor_8\NN|a|significant|limiting|for (r_attr) is_3\VBZ|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN|toxic|peripheral
D017239_D010523 CID PAC_14\NNP|(|) (r_appos) chemotherapy_10\NN|with|pac (r_pobj) for_9\IN|chemotherapy (r_prep) factor_8\NN|a|significant|limiting|for (r_attr) is_3\VBZ|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN|toxic|peripheral
D017239_D010523 CID PAC_30\NNP| (r_compound) neurotoxicity_31\NN|pac (r_dobj) ameliorate_29\VB|to|neurotoxicity (r_xcomp) claimed_27\VBN|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN|toxic|peripheral
D017239_D010523 CID PAC_13\NNP| (r_npadvmod) induced_15\VBN|pac|- (r_amod) neuropathy_17\NN|induced|peripheral
D017239_D010523 CID PAC_21\NNP| (r_pobj) of_20\IN|pac (r_prep) neurotoxicity_19\NN|peripheral|of
D017239_D020258 NONE paclitaxel_12\NN| (r_pobj) with_11\IN|paclitaxel (r_prep) chemotherapy_10\NN|with|pac (r_pobj) for_9\IN|chemotherapy (r_prep) factor_8\NN|a|significant|limiting|for (r_attr) is_3\VBZ|neuropathy|still|factor|,|claimed|. (l_advcl) claimed_27\VBN|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB|to|neurotoxicity (l_dobj) neurotoxicity_31\NN|pac
D017239_D020258 NONE PAC_14\NNP|(|) (r_appos) chemotherapy_10\NN|with|pac (r_pobj) for_9\IN|chemotherapy (r_prep) factor_8\NN|a|significant|limiting|for (r_attr) is_3\VBZ|neuropathy|still|factor|,|claimed|. (l_advcl) claimed_27\VBN|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB|to|neurotoxicity (l_dobj) neurotoxicity_31\NN|pac
D017239_D020258 NONE PAC_30\NNP| (r_compound) neurotoxicity_31\NN|pac
D018698_D020258 NONE glutamate_18\NN|and|glutamine (r_nsubjpass) claimed_27\VBN|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB|to|neurotoxicity (l_dobj) neurotoxicity_31\NN|pac
D018698_D020258 NONE glutamine_25\NN|its|related|acid (r_conj) glutamate_18\NN|and|glutamine (r_nsubjpass) claimed_27\VBN|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB|to|neurotoxicity (l_dobj) neurotoxicity_31\NN|pac
D000596_D010523 NONE acid_24\NN|amino (r_compound) glutamine_25\NN|its|related|acid (r_conj) glutamate_18\NN|and|glutamine (r_nsubjpass) claimed_27\VBN|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN|toxic|peripheral
D000596_D020258 NONE acid_24\NN|amino (r_compound) glutamine_25\NN|its|related|acid (r_conj) glutamate_18\NN|and|glutamine (r_nsubjpass) claimed_27\VBN|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB|to|neurotoxicity (l_dobj) neurotoxicity_31\NN|pac
D017239_D010051 NONE PAC_16\NNP| (r_npadvmod) containing_18\VBG|pac|- (r_amod) regimen_19\NN|the|same|containing (r_pobj) of_13\IN|regimen (r_prep) cycles_12\NNS|six|of (r_pobj) following_10\VBG|cycles (r_prep) analysis_9\NN|following (r_pobj) for_8\IN|analysis (r_prep) available_7\JJ|for (r_acomp) were_6\VBD|patients|available (l_nsubj) patients_5\NNS|three|ovarian|cancer (l_compound) cancer_4\NN|
D018698_D010051 NONE glutamate_26\NN|along (r_pobj) by_25\IN|glutamate (r_agent) supplemented_24\VBN|were|:|23|had|been|by|,|at|,|and|received|. (l_ccomp) were_6\VBD|patients|available (l_nsubj) patients_5\NNS|three|ovarian|cancer (l_compound) cancer_4\NN|
8690168
D006497_D003928 NONE sulphate_3\NN| (r_npadvmod) associated_5\VBN|sulphate|- (r_amod) sites_7\NNS|heparan|associated|anionic|in (l_prep) in_8\IN|membrane (l_pobj) membrane_12\NN|the|glomerular|basement|of (l_prep) of_13\IN|rats (l_pobj) rats_14\NNS|with (l_prep) with_15\IN|nephropathy (l_pobj) nephropathy_20\NN|induced|diabetic
D013311_D003928 CID streptozotocin_16\NNS| (r_npadvmod) induced_18\VBN|streptozotocin|- (r_amod) nephropathy_20\NN|induced|diabetic
D006497_D003920 NONE sulphate_1\NN| (r_npadvmod) associated_3\VBN|sulphate|- (r_amod) sites_5\NNS|heparan|associated|anionic|in (r_nsubjpass) studied_12\VBN|sites|were|in|after|,|employing|. (l_prep) after_17\IN|months|induction (l_pobj) induction_18\NN|of|by (l_prep) of_19\IN|diabetes (l_pobj) diabetes_20\NNS|
D006497_D003920 NONE sulphate_18\NN| (r_compound) charge_19\NN|sulphate (r_compound) density_22\NN|a|reduced|heparan|charge|barrier|/ (r_nsubjpass) found_24\VBN|that|in|density|is|at (l_prep) in_3\IN|rats (l_pobj) rats_7\NNS|diabetic|with (l_amod) diabetic_6\JJ|streptozotocin|-
D013311_D003920 NONE streptozotocin_22\NNS| (r_pobj) by_21\IN|streptozotocin|and|in (r_prep) induction_18\NN|of|by (l_prep) of_19\IN|diabetes (l_pobj) diabetes_20\NNS|
D013311_D003920 NONE streptozotocin_4\JJ| (r_amod) diabetic_6\JJ|streptozotocin|-
C015445_D003920 NONE blue_38\JJ|the|cationic|dye|cuprolinic (r_dobj) employing_33\VBG|blue (r_advcl) studied_12\VBN|sites|were|in|after|,|employing|. (l_prep) after_17\IN|months|induction (l_pobj) induction_18\NN|of|by (l_prep) of_19\IN|diabetes (l_pobj) diabetes_20\NNS|
7468724
D013726_D002318 CID terbutaline_4\JJ| (r_compound) treatment_5\NN|terbutaline|for (r_pobj) with_3\IN|treatment (r_prep) associated_2\VBN|with (r_acl) complications_1\NNS|cardiovascular|associated|.
D013726_D002318 CID terbutaline_11\NN|for (r_pobj) with_10\IN|terbutaline (r_prep) treated_9\VBN|with (r_acl) patients_8\NNS|160|treated (r_pobj) in_4\IN|patients (r_prep) occurred_3\VBD|complications|in|. (l_nsubj) complications_2\NNS|severe|cardiovascular
D013726_D007752 NONE terbutaline_4\JJ| (r_compound) treatment_5\NN|terbutaline|for (l_prep) for_6\IN|labor (l_pobj) labor_8\NN|preterm
D013726_D007752 NONE terbutaline_11\NN|for (l_prep) for_12\IN|labor (l_pobj) labor_14\NN|preterm
11007689
D016572_D057049 CID Cyclosporine_0\NN|and|microangiopathy|. (l_conj) microangiopathy_6\NN|associated|thrombotic
D016572_D057049 CID cyclosporine_13\NN| (r_pobj) of_12\IN|cyclosporine (r_prep) use_11\NN|the|of (r_pobj) with_9\IN|use (r_prep) associated_8\VBN|with (r_acl) microangiopathy_4\NN|thrombotic|tma|associated
D016572_D057049 CID cyclosporine_13\NN| (r_pobj) of_12\IN|cyclosporine (r_prep) use_11\NN|the|of (r_pobj) with_9\IN|use (r_prep) associated_8\VBN|with (r_acl) microangiopathy_4\NN|thrombotic|tma|associated (l_appos) TMA_6\NNP|(|)
D016572_D057049 CID cyclosporine_20\NN| (r_npadvmod) induced_22\VBN|cyclosporine|- (r_amod) TMA_23\NNP|induced
D016572_D057049 CID cyclosporine_16\NN|and|tacrolimus (r_pobj) to_15\IN|cyclosporine (r_prep) exposed_13\VBN|sequentially|to (r_acl) patients_12\NNS|exposed (r_pobj) in_11\IN|patients (r_prep) recurrence_8\NN|the|of|in (l_prep) of_9\IN|tma (l_pobj) TMA_10\NNP|
D016572_D057049 CID cyclosporine_13\NN| (r_npadvmod) induced_15\VBN|cyclosporine|- (r_amod) TMA_16\NNP|induced|responded
D016572_D057049 CID cyclosporine_23\NN| (r_pobj) of_22\IN|cyclosporine (r_prep) withdrawal_21\NN|the|of|in (r_pobj) to_19\IN|withdrawal (r_prep) responded_18\VBD|that|to (r_relcl) TMA_16\NNP|induced|responded
D016572_D057049 CID cyclosporine_5\NN| (r_pobj) from_4\IN|cyclosporine (r_prep) switched_3\VBN|who|are|from|to (r_relcl) Patients_0\NNS|switched (r_nsubjpass) monitored_14\VBN|patients|should|be|closely|for|. (l_prep) for_15\IN|signs (l_pobj) signs_17\NNS|the|and|symptoms|of (l_prep) of_20\IN|tma (l_pobj) TMA_22\NNP|recurrent
D016559_D057049 CID tacrolimus_2\NN| (r_npadvmod) associated_4\VBN|tacrolimus|- (r_amod) microangiopathy_6\NN|associated|thrombotic
D016559_D057049 CID tacrolimus_6\NN| (r_pobj) to_5\IN|tacrolimus (r_prep) switching_4\VBG|to (r_nsubjpass) reported_9\VBN|as|,|switching|has|been|be|. (l_xcomp) be_11\VB|to|option (l_attr) option_15\NN|a|viable|therapeutic|in (l_prep) in_16\IN|setting (l_pobj) setting_18\NN|the|of (l_prep) of_19\IN|tma (l_pobj) TMA_23\NNP|induced
D016559_D057049 CID tacrolimus_6\NN|in (r_pobj) of_5\IN|tacrolimus (r_prep) application_4\NN|the|widespread|of (r_pobj) With_0\IN|application (r_prep) recognized_18\VBN|with|,|tma|has|also|been|. (l_nsubjpass) TMA_14\NNP|associated
D016559_D057049 CID tacrolimus_11\NN| (r_npadvmod) associated_13\VBN|tacrolimus|- (r_amod) TMA_14\NNP|associated
D016559_D057049 CID tacrolimus_18\NN| (r_conj) cyclosporine_16\NN|and|tacrolimus (r_pobj) to_15\IN|cyclosporine (r_prep) exposed_13\VBN|sequentially|to (r_acl) patients_12\NNS|exposed (r_pobj) in_11\IN|patients (r_prep) recurrence_8\NN|the|of|in (l_prep) of_9\IN|tma (l_pobj) TMA_10\NNP|
D016559_D057049 CID tacrolimus_2\NN|as (r_pobj) of_1\IN|tacrolimus (r_prep) Introduction_0\NN|of (r_nsubj) resulted_8\VBD|introduction|in|. (l_prep) in_9\IN|recurrence (l_pobj) recurrence_11\NN|the|of|and|loss (l_prep) of_12\IN|tma (l_pobj) TMA_13\NNP|
D016559_D057049 CID tacrolimus_7\NN|or|versa (r_pobj) to_6\IN|tacrolimus (r_prep) switched_3\VBN|who|are|from|to (r_relcl) Patients_0\NNS|switched (r_nsubjpass) monitored_14\VBN|patients|should|be|closely|for|. (l_prep) for_15\IN|signs (l_pobj) signs_17\NNS|the|and|symptoms|of (l_prep) of_20\IN|tma (l_pobj) TMA_22\NNP|recurrent
15632880
D013148_D051437 CID Spironolactone_0\NNP| (r_npadvmod) induced_2\VBN|spironolactone|-|insufficiency|. (l_dobj) insufficiency_4\NN|renal|and|hyperkalemia|in
D013148_D051437 CID spironolactone_9\NN|in (r_pobj) of_8\IN|spironolactone (r_prep) use_7\NN|the|of (r_dobj) evaluating_5\VBG|use (r_acl) trial_4\NN|a|previous|randomized|controlled|evaluating (r_nsubj) reported_14\VBD|trial|risk|. (l_dobj) risk_17\NN|a|low|of (l_prep) of_18\IN|hyperkalemia (l_pobj) hyperkalemia_19\NN|(|%|)|and|insufficiency (l_conj) insufficiency_26\NN|renal|(|%|)
D013148_D051437 CID spironolactone_21\NN| (r_pobj) with_20\IN|spironolactone (r_prep) treated_19\VBN|with (r_acl) patients_18\NNS|failure|treated (r_pobj) in_15\IN|patients (r_prep) insufficiency_14\NN|renal|in
D013148_D051437 CID spironolactone_13\NN| (r_pobj) of_12\IN|spironolactone (r_prep) discontinuation_11\NN|of (r_dobj) required_10\VBD|seven|discontinuation|due|. (l_prep) due_14\IN|to|hyperkalemia (l_pobj) hyperkalemia_16\NN|(|n|)|or|failure (l_conj) failure_24\NN|renal|(|34|)
D013148_D051437 CID Spironolactone_0\NNP| (r_npadvmod) induced_2\VBN|spironolactone|- (r_amod) hyperkalemia_3\NN|induced|and (r_nmod) insufficiency_6\NN|hyperkalemia|renal
D013148_D006947 CID Spironolactone_0\NNP| (r_npadvmod) induced_2\VBN|spironolactone|-|insufficiency|. (l_dobj) insufficiency_4\NN|renal|and|hyperkalemia|in (l_conj) hyperkalemia_6\NN|
D013148_D006947 CID spironolactone_9\NN|in (r_pobj) of_8\IN|spironolactone (r_prep) use_7\NN|the|of (r_dobj) evaluating_5\VBG|use (r_acl) trial_4\NN|a|previous|randomized|controlled|evaluating (r_nsubj) reported_14\VBD|trial|risk|. (l_dobj) risk_17\NN|a|low|of (l_prep) of_18\IN|hyperkalemia (l_pobj) hyperkalemia_19\NN|(|%|)|and|insufficiency
D013148_D006947 CID spironolactone_21\NN| (r_pobj) with_20\IN|spironolactone (r_prep) treated_19\VBN|with (r_acl) patients_18\NNS|failure|treated (r_pobj) in_15\IN|patients (r_prep) insufficiency_14\NN|renal|in (r_conj) hyperkalemia_11\NN|and|insufficiency
D013148_D006947 CID spironolactone_13\NN| (r_pobj) of_12\IN|spironolactone (r_prep) discontinuation_11\NN|of (r_dobj) required_10\VBD|seven|discontinuation|due|. (l_prep) due_14\IN|to|hyperkalemia (l_pobj) hyperkalemia_16\NN|(|n|)|or|failure
D013148_D006947 CID Spironolactone_0\NNP| (r_npadvmod) induced_2\VBN|spironolactone|- (r_amod) hyperkalemia_3\NN|induced|and
D013148_D006333 NONE Spironolactone_0\NNP| (r_npadvmod) induced_2\VBN|spironolactone|-|insufficiency|. (l_dobj) insufficiency_4\NN|renal|and|hyperkalemia|in (l_prep) in_7\IN|patients (l_pobj) patients_8\NNS|with (l_prep) with_9\IN|failure (l_pobj) failure_11\NN|heart
D013148_D006333 NONE spironolactone_9\NN|in (l_prep) in_10\IN|patients (l_pobj) patients_13\NNS|failure (l_compound) failure_12\NN|heart
D013148_D006333 NONE spironolactone_11\NN| (r_pobj) of_10\IN|spironolactone (r_prep) benefits_9\NNS|the|of (r_nsubjpass) reported_13\VBN|since|benefits|were (r_advcl) changed_6\VBN|because|treatments|have|reported (l_nsubj) treatments_1\NNS|for (l_prep) for_2\IN|failure (l_pobj) failure_4\NN|heart
D013148_D006333 NONE spironolactone_21\NN| (r_pobj) with_20\IN|spironolactone (r_prep) treated_19\VBN|with (r_acl) patients_18\NNS|failure|treated (l_compound) failure_17\NN|heart
D013148_D006333 NONE spironolactone_12\NN|in (r_pobj) with_11\IN|spironolactone (r_prep) treated_10\VBN|with (r_acl) patients_9\NNS|failure|treated (l_compound) failure_8\NN|heart
D011188_D006947 NONE K(+_7\NNP|(|) (r_appos) hyperkalemia_5\NN|k(+
D011188_D006947 NONE potassium_17\NN|serum (r_compound) levels_18\NNS|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD|levels|,|and|were (r_conj) were_4\VBD|patients|older|,|had|. (l_nsubj) Patients_0\NNS|developed (l_relcl) developed_2\VBD|who|hyperkalemia (l_dobj) hyperkalemia_3\NN|
D011188_D006947 NONE potassium_22\NN| (r_compound) supplement_23\NN|potassium (r_compound) doses_24\NNS|lower|baseline|supplement (r_conj) levels_18\NNS|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD|levels|,|and|were (r_conj) were_4\VBD|patients|older|,|had|. (l_nsubj) Patients_0\NNS|developed (l_relcl) developed_2\VBD|who|hyperkalemia (l_dobj) hyperkalemia_3\NN|
D011188_D051437 NONE K(+_7\NNP|(|) (r_appos) hyperkalemia_5\NN|k(+ (r_dobj) developed_4\VBD|who|hyperkalemia (r_relcl) patients_2\NNS|developed (r_attr) were_1\VBD|cases|patients|( (l_nsubj) Cases_0\NNS|l (l_appos) L_13\NN|>|meq|/|)|or|insufficiency (l_conj) insufficiency_17\NN|renal
D011188_D003920 NONE potassium_17\NN|serum (r_compound) levels_18\NNS|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD|levels|,|and|were (r_conj) were_4\VBD|patients|older|,|had|. (l_acomp) older_5\JJR|and|likely (l_conj) likely_8\JJ|more|have (l_xcomp) have_10\VB|to|diabetes (l_dobj) diabetes_11\NNS|
D011188_D003920 NONE potassium_22\NN| (r_compound) supplement_23\NN|potassium (r_compound) doses_24\NNS|lower|baseline|supplement (r_conj) levels_18\NNS|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD|levels|,|and|were (r_conj) were_4\VBD|patients|older|,|had|. (l_acomp) older_5\JJR|and|likely (l_conj) likely_8\JJ|more|have (l_xcomp) have_10\VB|to|diabetes (l_dobj) diabetes_11\NNS|
D003404_D051437 NONE creatinine_14\NN|higher|serum (r_conj) weight_9\NN|lower|baseline|body|and|creatinine (r_dobj) had_5\VBD|patients|weight|,|required|. (l_nsubj) Patients_0\NNS|developed (l_relcl) developed_2\VBD|who|insufficiency (l_dobj) insufficiency_4\NN|renal
D049971_D051437 NONE thiazide_31\NN| (r_amod) diuretics_32\NNS|thiazide|than (r_pobj) with_30\IN|diuretics (r_prep) treated_29\VBN|to|be|with (r_xcomp) likely_26\JJ|more|treated (r_acomp) were_24\VBD|likely (r_conj) required_16\VBD|doses|,|and|were (r_conj) had_5\VBD|patients|weight|,|required|. (l_nsubj) Patients_0\NNS|developed (l_relcl) developed_2\VBD|who|insufficiency (l_dobj) insufficiency_4\NN|renal
20528871
C104457_D015458 NONE nelarabine_3\NN|,|etoposide|in (l_prep) in_9\IN|leukaemia (l_pobj) leukaemia_18\NN|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN|
C104457_D015458 NONE nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
C104457_D015458 NONE AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
C104457_D016399 NONE nelarabine_3\NN|,|etoposide|in (l_prep) in_9\IN|leukaemia (l_pobj) leukaemia_18\NN|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN|
C104457_D016399 NONE nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
C104457_D016399 NONE AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
D005047_D015458 NONE etoposide_5\RB|,|and|cyclophosphamide (r_conj) nelarabine_3\NN|,|etoposide|in (l_prep) in_9\IN|leukaemia (l_pobj) leukaemia_18\NN|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN|
D005047_D015458 NONE etoposide_14\NN| (r_pobj) of_13\IN|etoposide (r_prep) d_12\SYM|5|of|vp (r_pobj) with_10\IN|d (r_prep) AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
D005047_D015458 NONE VP_16\NNP|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM|5|of|vp (r_pobj) with_10\IN|d (r_prep) AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
D005047_D016399 NONE etoposide_5\RB|,|and|cyclophosphamide (r_conj) nelarabine_3\NN|,|etoposide|in (l_prep) in_9\IN|leukaemia (l_pobj) leukaemia_18\NN|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN|
D005047_D016399 NONE etoposide_14\NN| (r_pobj) of_13\IN|etoposide (r_prep) d_12\SYM|5|of|vp (r_pobj) with_10\IN|d (r_prep) AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
D005047_D016399 NONE VP_16\NNP|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM|5|of|vp (r_pobj) with_10\IN|d (r_prep) AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
D003520_D015458 NONE cyclophosphamide_8\NN| (r_conj) etoposide_5\RB|,|and|cyclophosphamide (r_conj) nelarabine_3\NN|,|etoposide|in (l_prep) in_9\IN|leukaemia (l_pobj) leukaemia_18\NN|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN|
D003520_D015458 NONE cyclophosphamide_19\NN| (r_conj) VP_16\NNP|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM|5|of|vp (r_pobj) with_10\IN|d (r_prep) AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
D003520_D015458 NONE CPM_21\NNP|(|) (r_appos) VP_16\NNP|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM|5|of|vp (r_pobj) with_10\IN|d (r_prep) AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
D003520_D016399 NONE cyclophosphamide_8\NN| (r_conj) etoposide_5\RB|,|and|cyclophosphamide (r_conj) nelarabine_3\NN|,|etoposide|in (l_prep) in_9\IN|leukaemia (l_pobj) leukaemia_18\NN|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN|
D003520_D016399 NONE cyclophosphamide_19\NN| (r_conj) VP_16\NNP|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM|5|of|vp (r_pobj) with_10\IN|d (r_prep) AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
D003520_D016399 NONE CPM_21\NNP|(|) (r_appos) VP_16\NNP|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM|5|of|vp (r_pobj) with_10\IN|d (r_prep) AraG_8\NNP|(|)|with (r_appos) nelarabine_6\JJ|arag (r_pobj) of_5\IN|nelarabine (r_prep) d_4\SYM|5|of (r_pobj) of_2\IN|d (r_prep) combination_1\NN|a|of (r_nsubjpass) used_28\VBN|combination|was|as|in|. (l_prep) in_32\IN|children (l_pobj) children_34\NNS|seven|with (l_prep) with_35\IN|leukaemia (l_pobj) leukaemia_42\NN|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN|
C104457_D009422 CID AraG_8\NNP|the (r_pobj) to_6\IN|arag (r_prep) attributable_5\JJ|to (r_amod) effects_4\NNS|the|common|side|attributable (r_nsubj) included_9\VBD|effects|neuropathy|. (l_dobj) neuropathy_17\NN|grade|sensory|and|pain
C104457_D009422 CID AraG_7\NN| (r_dobj) giving_6\VBG|arag|as (r_pcomp) of_5\IN|giving (r_prep) safety_4\NN|the|of (r_dobj) supports_2\VBZ|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN|neurological
C104457_D059352 CID AraG_8\NNP|the (r_pobj) to_6\IN|arag (r_prep) attributable_5\JJ|to (r_amod) effects_4\NNS|the|common|side|attributable (r_nsubj) included_9\VBD|effects|neuropathy|. (l_dobj) neuropathy_17\NN|grade|sensory|and|pain (l_conj) pain_20\NN|musculoskeletal
C104457_D006402 CID AraG_8\NNP|alone (r_pobj) than_7\IN|arag (r_prep) combination_6\NN|the|than (r_pobj) for_4\IN|combination (r_prep) greater_3\JJR|for (r_acomp) was_2\VBD|toxicity|greater|,|was|. (l_nsubj) toxicity_1\NN|haematological
D005047_D009422 NONE etoposide_14\NN|and|cyclophosphamide (r_pobj) with_13\IN|etoposide (r_prep) synchrony_12\NN|with (r_pobj) in_11\IN|synchrony (r_prep) therapy_10\NN|salvage|in (r_pobj) as_8\IN|therapy (r_prep) giving_6\VBG|arag|as (r_pcomp) of_5\IN|giving (r_prep) safety_4\NN|the|of (r_dobj) supports_2\VBZ|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN|neurological
D003520_D009422 NONE cyclophosphamide_16\NN| (r_conj) etoposide_14\NN|and|cyclophosphamide (r_pobj) with_13\IN|etoposide (r_prep) synchrony_12\NN|with (r_pobj) in_11\IN|synchrony (r_prep) therapy_10\NN|salvage|in (r_pobj) as_8\IN|therapy (r_prep) giving_6\VBG|arag|as (r_pcomp) of_5\IN|giving (r_prep) safety_4\NN|the|of (r_dobj) supports_2\VBZ|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN|neurological
17175308
D020123_D011507 CID sirolimus_4\VB| (r_pobj) to_3\TO|sirolimus (r_prep) conversion_2\NN|to|in (r_pobj) after_1\IN|conversion (r_prep) Proteinuria_0\NNP|after|.
D020123_D011507 CID sirolimus_11\NN| (r_compound) therapy_12\NN|sirolimus (r_pobj) of_10\IN|therapy (r_prep) consequence_9\NN|a|of (r_pobj) as_7\IN|consequence (r_prep) reported_6\VBN|recently|,|proteinuria|has|been|as|,|remained|. (l_nsubjpass) proteinuria_3\NN|
D020123_D011507 CID SRL_18\NN| (r_compound) conversion_19\NN|srl (r_pobj) after_17\IN|conversion (r_prep) displayed_14\VBD|proteinuria|after (l_dobj) proteinuria_16\NN|increased
D020123_D011507 CID SRL_8\NN| (r_pobj) of_7\IN|srl (r_prep) use_6\NN|the|of|as (r_pobj) after_4\IN|use (r_prep) was_2\VBD|proteinuria|common|after|. (l_nsubj) proteinuria_1\NN|heavy
D020123_D051436 NONE SRL_13\NNP| (r_pobj) with_12\IN|srl (r_prep) treated_11\VBN|cohort|was|with|as|,|due|) (l_prep) due_18\IN|to|nephropathy (l_pobj) nephropathy_22\NN|chronic|allograft|(|can|(|n
D020123_D007674 NONE SRL_13\NNP| (r_pobj) with_12\IN|srl (r_prep) treated_11\VBN|cohort|was|with|as|,|due|) (l_prep) due_18\IN|to|nephropathy (l_pobj) nephropathy_22\NN|chronic|allograft|(|can|(|n (l_advmod) CAN_24\VB|)
2265898
C009265_D004827 CID carbidopa_6\NN|epilepsy|/|administration|in|. (l_nsubj) epilepsy_1\NN|serial|caused
C009265_D007676 NONE levodopa_38\JJ|/ (r_compound) preparation_39\NN|a|carbidopa|levodopa (r_dobj) receiving_34\VBG|had|;|both|had|been|preparation|;|and|had|. (l_ccomp) had_11\VBD|presented|:|patients|failure|,|on|but|begun (l_dobj) failure_14\NN|chronic|renal
C009265_D001523 NONE levodopa_38\JJ|/ (r_compound) preparation_39\NN|a|carbidopa|levodopa (r_dobj) receiving_34\VBG|had|;|both|had|been|preparation|;|and|had|. (l_conj) had_43\VBD|both|onset (l_dobj) onset_45\NN|the|of (l_prep) of_46\IN|seizures (l_pobj) seizures_50\NNS|hallucinosis|,|were (l_nmod) hallucinosis_47\NN|and|recurrent
C009265_D012640 NONE levodopa_38\JJ|/ (r_compound) preparation_39\NN|a|carbidopa|levodopa (r_dobj) receiving_34\VBG|had|;|both|had|been|preparation|;|and|had|. (l_conj) had_43\VBD|both|onset (l_dobj) onset_45\NN|the|of (l_prep) of_46\IN|seizures (l_pobj) seizures_50\NNS|hallucinosis|,|were
18503483
D016559_D020968 CID tacrolimus_2\NN| (r_npadvmod) associated_4\VBN|tacrolimus|- (r_amod) neuritis_6\NN|associated|brachial
C107135_D020968 NONE everolimus_10\NN| (r_pobj) to_9\TO|everolimus (r_prep) conversion_8\NN|to|in (r_pobj) after_7\IN|conversion (r_prep) Recovery_0\NN|of|after|--|report|. (l_prep) of_1\IN|neuritis (l_pobj) neuritis_6\NN|associated|brachial
3629586
D015790_D006402 NONE cefonicid_4\NN|and|cefazedone (r_pobj) of_3\IN|cefonicid (r_prep) effects_2\NNS|the|hematologic|of|:|model|. (l_appos) model_13\NN|a|potential|of (l_prep) of_14\IN|hematotoxicity (l_pobj) hematotoxicity_16\NN|cephalosporin|in
D015790_D006402 NONE cefonicid_23\NN|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG|cefonicid (r_acl) dogs_17\NNS|receiving (r_pobj) of_16\IN|dogs (r_prep) %_15\NN|50|of (r_pobj) in_12\IN|% (r_prep) occurred_11\VBD|in (r_conj) was_3\VBD|anemia|compromising|and|occurred|. (l_attr) compromising_6\NN|the|most|of (l_prep) of_7\IN|cytopenias (l_pobj) cytopenias_9\NNS|the
D015790_D006402 NONE cefonicid_16\NN| (r_amod) dogs_21\NNS|cefonicid|(|cefazedone)-treated (r_nsubj) showed_22\VBD|reproduced|;|dogs|period|compared|. (l_ccomp) reproduced_10\VBN|upon|,|syndrome|was|in (l_nsubjpass) syndrome_8\NN|the|hematologic
D015790_D006402 NONE cefonicid_9\NN|or|cefazedone (r_pobj) of_8\IN|cefonicid (r_prep) doses_7\NNS|high|of (r_pobj) of_5\IN|doses (r_prep) administration_4\NN|the|of|to (r_nsubj) induce_15\VB|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN|similar
D015790_D006402 NONE cefonicid_9\NN|or|cefazedone (r_pobj) of_8\IN|cefonicid (r_prep) doses_7\NNS|high|of (r_pobj) of_5\IN|doses (r_prep) administration_4\NN|the|of|to (r_nsubj) induce_15\VB|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN|similar (l_amod) similar_17\JJ|to (l_prep) to_18\IN|dyscrasias (l_pobj) dyscrasias_24\NNS|the|induced|blood|described
C021341_D006402 NONE cefazedone_6\NN|in (r_conj) cefonicid_4\NN|and|cefazedone (r_pobj) of_3\IN|cefonicid (r_prep) effects_2\NNS|the|hematologic|of|:|model|. (l_appos) model_13\NN|a|potential|of (l_prep) of_14\IN|hematotoxicity (l_pobj) hematotoxicity_16\NN|cephalosporin|in
C021341_D006402 NONE cefazedone_29\NN|540|840|mg/kg (r_conj) cefonicid_23\NN|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG|cefonicid (r_acl) dogs_17\NNS|receiving (r_pobj) of_16\IN|dogs (r_prep) %_15\NN|50|of (r_pobj) in_12\IN|% (r_prep) occurred_11\VBD|in (r_conj) was_3\VBD|anemia|compromising|and|occurred|. (l_attr) compromising_6\NN|the|most|of (l_prep) of_7\IN|cytopenias (l_pobj) cytopenias_9\NNS|the
C021341_D006402 NONE cefazedone)-treated_20\VBN|but|not (r_amod) dogs_21\NNS|cefonicid|(|cefazedone)-treated (r_nsubj) showed_22\VBD|reproduced|;|dogs|period|compared|. (l_ccomp) reproduced_10\VBN|upon|,|syndrome|was|in (l_nsubjpass) syndrome_8\NN|the|hematologic
C021341_D006402 NONE cefazedone_11\NN| (r_conj) cefonicid_9\NN|or|cefazedone (r_pobj) of_8\IN|cefonicid (r_prep) doses_7\NNS|high|of (r_pobj) of_5\IN|doses (r_prep) administration_4\NN|the|of|to (r_nsubj) induce_15\VB|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN|similar
C021341_D006402 NONE cefazedone_11\NN| (r_conj) cefonicid_9\NN|or|cefazedone (r_pobj) of_8\IN|cefonicid (r_prep) doses_7\NNS|high|of (r_pobj) of_5\IN|doses (r_prep) administration_4\NN|the|of|to (r_nsubj) induce_15\VB|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN|similar (l_amod) similar_17\JJ|to (l_prep) to_18\IN|dyscrasias (l_pobj) dyscrasias_24\NNS|the|induced|blood|described
D002511_D006402 NONE cephalosporin_15\JJ| (r_amod) hematotoxicity_16\NN|cephalosporin|in
D002511_D006402 NONE Cephalosporin_0\JJ| (r_amod) antibiotics_1\NNS|cephalosporin (r_nsubj) cause_2\VBP|antibiotics|variety|characterized|. (l_dobj) variety_4\NN|a|of|, (l_prep) of_5\IN|disturbances (l_pobj) disturbances_7\NNS|hematologic|in
D002511_D006402 NONE cephalosporin_4\NN|either (r_pobj) with_2\IN|cephalosporin (r_prep) rechallenge_1\VB|with (r_pobj) Upon_0\IN|rechallenge (r_prep) reproduced_10\VBN|upon|,|syndrome|was|in (l_nsubjpass) syndrome_8\NN|the|hematologic
D002511_D006402 NONE cephalosporin_20\NN| (r_advmod) induced_22\VBN|cephalosporin|- (r_amod) dyscrasias_24\NNS|the|induced|blood|described (r_pobj) to_18\IN|dyscrasias (r_prep) similar_17\JJ|to (r_amod) hematotoxicity_16\NN|similar
D002511_D006402 NONE cephalosporin_20\NN| (r_advmod) induced_22\VBN|cephalosporin|- (r_amod) dyscrasias_24\NNS|the|induced|blood|described
D015790_D064420 NONE cefonicid_10\NN|or|cefazedone (r_pobj) of_9\IN|cefonicid (r_prep) administration_8\NN|the|intravenous|of|to (r_nsubj) caused_16\VBD|in|,|administration|incidence|thrombocytopenia|. (l_prep) In_0\IN|studies (l_pobj) studies_4\NNS|four|subacute|toxicity (l_compound) toxicity_3\NN|
D015790_D000740 CID cefonicid_10\NN|or|cefazedone (r_pobj) of_9\IN|cefonicid (r_prep) administration_8\NN|the|intravenous|of|to (r_nsubj) caused_16\VBD|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN|a|dependent|of (l_prep) of_22\IN|anemia (l_pobj) anemia_23\NN|,|neutropenia
D015790_D000740 CID cefonicid_23\NN|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG|cefonicid (r_acl) dogs_17\NNS|receiving (r_pobj) of_16\IN|dogs (r_prep) %_15\NN|50|of (r_pobj) in_12\IN|% (r_prep) occurred_11\VBD|in (r_conj) was_3\VBD|anemia|compromising|and|occurred|. (l_nsubj) anemia_2\NN|a|nonregenerative
D015790_D009503 CID cefonicid_10\NN|or|cefazedone (r_pobj) of_9\IN|cefonicid (r_prep) administration_8\NN|the|intravenous|of|to (r_nsubj) caused_16\VBD|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN|a|dependent|of (l_prep) of_22\IN|anemia (l_pobj) anemia_23\NN|,|neutropenia (l_conj) neutropenia_25\NN|,|and
D015790_D013921 CID cefonicid_10\NN|or|cefazedone (r_pobj) of_9\IN|cefonicid (r_prep) administration_8\NN|the|intravenous|of|to (r_nsubj) caused_16\VBD|in|,|administration|incidence|thrombocytopenia|. (l_ccomp) thrombocytopenia_28\NN|after
C021341_D064420 NONE cefazedone_12\NN| (r_conj) cefonicid_10\NN|or|cefazedone (r_pobj) of_9\IN|cefonicid (r_prep) administration_8\NN|the|intravenous|of|to (r_nsubj) caused_16\VBD|in|,|administration|incidence|thrombocytopenia|. (l_prep) In_0\IN|studies (l_pobj) studies_4\NNS|four|subacute|toxicity (l_compound) toxicity_3\NN|
C021341_D000740 CID cefazedone_12\NN| (r_conj) cefonicid_10\NN|or|cefazedone (r_pobj) of_9\IN|cefonicid (r_prep) administration_8\NN|the|intravenous|of|to (r_nsubj) caused_16\VBD|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN|a|dependent|of (l_prep) of_22\IN|anemia (l_pobj) anemia_23\NN|,|neutropenia
C021341_D000740 CID cefazedone_29\NN|540|840|mg/kg (r_conj) cefonicid_23\NN|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG|cefonicid (r_acl) dogs_17\NNS|receiving (r_pobj) of_16\IN|dogs (r_prep) %_15\NN|50|of (r_pobj) in_12\IN|% (r_prep) occurred_11\VBD|in (r_conj) was_3\VBD|anemia|compromising|and|occurred|. (l_nsubj) anemia_2\NN|a|nonregenerative
C021341_D009503 CID cefazedone_12\NN| (r_conj) cefonicid_10\NN|or|cefazedone (r_pobj) of_9\IN|cefonicid (r_prep) administration_8\NN|the|intravenous|of|to (r_nsubj) caused_16\VBD|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN|a|dependent|of (l_prep) of_22\IN|anemia (l_pobj) anemia_23\NN|,|neutropenia (l_conj) neutropenia_25\NN|,|and
C021341_D013921 CID cefazedone_12\NN| (r_conj) cefonicid_10\NN|or|cefazedone (r_pobj) of_9\IN|cefonicid (r_prep) administration_8\NN|the|intravenous|of|to (r_nsubj) caused_16\VBD|in|,|administration|incidence|thrombocytopenia|. (l_ccomp) thrombocytopenia_28\NN|after
11706060
D019344_D009202 NONE lactate_8\NN|plasma (r_dobj) elevates_6\VBZ|lactate|in (r_conj) causes_3\VBZ|combined|therapy|cardiomyopathy|and|elevates|. (l_advmod) cardiomyopathy_4\NN|
D019344_D009202 NONE lactate_18\NN|elevated|plasma|(|la|)|in (r_pobj) in_15\IN|lactate (r_conj) in_9\IN|cm|and|in (l_pobj) CM_12\NNP|cardiomyopathy|(|) (l_amod) cardiomyopathy_10\NN|
D019344_D009202 NONE lactate_18\NN|elevated|plasma|(|la|)|in (r_pobj) in_15\IN|lactate (r_conj) in_9\IN|cm|and|in (l_pobj) CM_12\NNP|cardiomyopathy|(|)
D019344_D009202 NONE LA_20\NNP| (r_appos) lactate_18\NN|elevated|plasma|(|la|)|in (r_pobj) in_15\IN|lactate (r_conj) in_9\IN|cm|and|in (l_pobj) CM_12\NNP|cardiomyopathy|(|) (l_amod) cardiomyopathy_10\NN|
D019344_D009202 NONE LA_20\NNP| (r_appos) lactate_18\NN|elevated|plasma|(|la|)|in (r_pobj) in_15\IN|lactate (r_conj) in_9\IN|cm|and|in (l_pobj) CM_12\NNP|cardiomyopathy|(|)
D019344_D009202 NONE LA_41\NNP|plasma (r_pobj) of_39\IN|la (r_prep) determination_38\NN|of (r_conj) underwent_7\VBD|at|,|mice|echocardiography|,|and|determination|. (l_dobj) echocardiography_8\RB|,|quantitation (l_appos) quantitation_10\NN|of|encoding (l_prep) of_11\IN|abundance (l_pobj) abundance_12\NN|of (l_prep) of_13\IN|markers (l_pobj) markers_15\NNS|molecular|of (l_prep) of_16\IN|cm (l_pobj) CM_17\NNP|
D019344_D009202 NONE LA_10\NNP|elevated|in (r_pobj) with_8\IN|la (r_prep) CM_7\NNP|mitochondrial|with
D019344_D000163 NONE lactate_8\NN|plasma (r_dobj) elevates_6\VBZ|lactate|in (l_prep) in_9\IN|mice (l_pobj) mice_12\NNS|transgenic|aids (l_compound) AIDS_11\NNP|
D019344_D000163 NONE lactate_18\NN|elevated|plasma|(|la|)|in (l_prep) in_22\IN|aids (l_pobj) AIDS_23\NNP|
D019344_D000163 NONE LA_20\NNP| (r_appos) lactate_18\NN|elevated|plasma|(|la|)|in (l_prep) in_22\IN|aids (l_pobj) AIDS_23\NNP|
D019344_D000163 NONE LA_10\NNP|elevated|in (l_prep) in_11\IN|mice (l_pobj) mice_14\NNS|transgenic (l_compound) transgenic_13\JJ|aids (l_compound) AIDS_12\NNP|
D019344_D028361 NONE lactate_18\NN|elevated|plasma|(|la|)|in (r_pobj) in_15\IN|lactate (r_conj) in_9\IN|cm|and|in (r_prep) implicated_8\VBN|therapy|is|in|through|. (l_prep) through_24\IN|mechanisms (l_pobj) mechanisms_25\NNS|of (l_prep) of_26\IN|dysfunction (l_pobj) dysfunction_28\NN|mitochondrial
D019344_D028361 NONE LA_20\NNP| (r_appos) lactate_18\NN|elevated|plasma|(|la|)|in (r_pobj) in_15\IN|lactate (r_conj) in_9\IN|cm|and|in (r_prep) implicated_8\VBN|therapy|is|in|through|. (l_prep) through_24\IN|mechanisms (l_pobj) mechanisms_25\NNS|of (l_prep) of_26\IN|dysfunction (l_pobj) dysfunction_28\NN|mitochondrial
D015215_D000163 NONE zidovudine_41\NN| (r_nmod) lamivudine_43\NN|zidovudine|,|,|and|indinavir (r_pobj) of_40\IN|lamivudine (r_prep) combination_39\NN|the|haart|of (r_pobj) with_36\IN|combination (r_prep) treated_35\VBN|determine|,|mice|were|with|. (l_nsubjpass) mice_15\NNS|old|hemizygous|transgenic|aids|pol (l_compound) AIDS_14\NNP|
D019259_D000163 NONE lamivudine_43\NN|zidovudine|,|,|and|indinavir (r_pobj) of_40\IN|lamivudine (r_prep) combination_39\NN|the|haart|of (r_pobj) with_36\IN|combination (r_prep) treated_35\VBN|determine|,|mice|were|with|. (l_nsubjpass) mice_15\NNS|old|hemizygous|transgenic|aids|pol (l_compound) AIDS_14\NNP|
D019469_D000163 NONE indinavir_46\NNS|or|control|for (r_conj) lamivudine_43\NN|zidovudine|,|,|and|indinavir (r_pobj) of_40\IN|lamivudine (r_prep) combination_39\NN|the|haart|of (r_pobj) with_36\IN|combination (r_prep) treated_35\VBN|determine|,|mice|were|with|. (l_nsubjpass) mice_15\NNS|old|hemizygous|transgenic|aids|pol (l_compound) AIDS_14\NNP|
D002118_D009202 NONE calcium_30\NN| (r_compound) ATPase_31\NNP|sarcoplasmic|calcium|[|serca2|]|) (r_conj) encoding_21\VBG|(|ventricular|mrna|factor|and|atpase (r_parataxis) quantitation_10\NN|of|encoding (l_prep) of_11\IN|abundance (l_pobj) abundance_12\NN|of (l_prep) of_13\IN|markers (l_pobj) markers_15\NNS|molecular|of (l_prep) of_16\IN|cm (l_pobj) CM_17\NNP|
9754849
D008691_D002819 CID methadone_7\NN| (r_pobj) to_6\IN|methadone (r_prep) adjustment_5\NN|rapid|to (r_pobj) with_3\IN|adjustment (r_prep) associated_2\VBN|with (r_acl) movements_1\NNS|choreoathetoid|associated|.
D008691_D002819 CID methadone_24\NN|the|selective|opioid|agonist (r_pobj) to_16\IN|methadone (r_prep) adjustment_15\NN|rapid|to|in (r_pobj) by_13\IN|adjustment (r_agent) induced_12\VBN|both|transiently|by (r_xcomp) choreoathetoid_8\JJ|movements|induced (l_dobj) movements_9\NNS|
D003042_D002819 CID cocaine_12\NN|but|opiates (r_pobj) with_11\IN|cocaine (r_prep) intoxications_10\NNS|with (r_pobj) during_9\IN|intoxications (r_prep) be_5\VB|to|abnormalities|during (r_xcomp) known_3\VBN|hyperkinesias|are|be|. (l_nsubjpass) hyperkinesias_1\NNS|choreatiform
D003042_D002819 CID cocaine_32\NN| (r_conj) heroine_30\NN|and|cocaine (r_dobj) abusing_29\VBG|previously|heroine (r_acl) inpatient_27\NN|an|abusing (r_pobj) in_25\IN|inpatient (r_prep) adjustment_15\NN|rapid|to|in (r_pobj) by_13\IN|adjustment (r_agent) induced_12\VBN|both|transiently|by (r_xcomp) choreoathetoid_8\JJ|movements|induced (l_dobj) movements_9\NNS|
D003042_D006948 CID cocaine_12\NN|but|opiates (r_pobj) with_11\IN|cocaine (r_prep) intoxications_10\NNS|with (r_pobj) during_9\IN|intoxications (r_prep) be_5\VB|to|abnormalities|during (r_xcomp) known_3\VBN|hyperkinesias|are|be|. (l_nsubjpass) hyperkinesias_1\NNS|choreatiform
D003042_D020820 NONE cocaine_12\NN|but|opiates (r_pobj) with_11\IN|cocaine (r_prep) intoxications_10\NNS|with (r_pobj) during_9\IN|intoxications (r_prep) be_5\VB|to|abnormalities|during (l_attr) abnormalities_8\NNS|occasional|movement
D003932_D002819 NONE heroine_30\NN|and|cocaine (r_dobj) abusing_29\VBG|previously|heroine (r_acl) inpatient_27\NN|an|abusing (r_pobj) in_25\IN|inpatient (r_prep) adjustment_15\NN|rapid|to|in (r_pobj) by_13\IN|adjustment (r_agent) induced_12\VBN|both|transiently|by (r_xcomp) choreoathetoid_8\JJ|movements|induced (l_dobj) movements_9\NNS|
18004067
D000431_D017114 NONE alcohol_8\NN| (r_compound) consumption_9\NN|regular|alcohol|ingesting (r_pobj) with_6\IN|consumption (r_prep) patients_5\NNS|two|with (r_pobj) in_3\IN|patients (r_prep) failure_2\NN|acute|liver|in|.
D000082_D017114 NONE paracetamol_11\NN| (r_dobj) ingesting_10\VBG|paracetamol|at (r_acl) consumption_9\NN|regular|alcohol|ingesting (r_pobj) with_6\IN|consumption (r_prep) patients_5\NNS|two|with (r_pobj) in_3\IN|patients (r_prep) failure_2\NN|acute|liver|in|.
D000431_D056486 NONE alcohol_4\NN| (r_pobj) of_3\IN|alcohol (r_prep) role_2\NN|the|possible|of|in (l_prep) in_5\IN|development (l_pobj) development_7\NN|the|of (l_prep) of_8\IN|hepatotoxicity (l_pobj) hepatotoxicity_9\NN|associated
D000082_D056486 CID paracetamol_15\JJ|(|acetaminophen|) (r_pobj) of_14\IN|paracetamol (r_prep) doses_13\NNS|therapeutic|of (r_pobj) with_11\IN|doses (r_prep) associated_10\VBN|with (r_acl) hepatotoxicity_9\NN|associated
D000082_D056486 CID acetaminophen_17\NN| (r_appos) paracetamol_15\JJ|(|acetaminophen|) (r_pobj) of_14\IN|paracetamol (r_prep) doses_13\NNS|therapeutic|of (r_pobj) with_11\IN|doses (r_prep) associated_10\VBN|with (r_acl) hepatotoxicity_9\NN|associated
D000082_D056486 CID paracetamol_15\NN| (r_pobj) of_14\IN|paracetamol (r_prep) doses_13\NNS|therapeutic|of (r_pobj) with_11\IN|doses (r_prep) treated_10\VBN|with (r_acl) patients_9\NNS|treated (r_pobj) in_8\IN|patients (r_prep) development_5\NN|the|of|in (l_prep) of_6\IN|hepatotoxicity (l_pobj) hepatotoxicity_7\NN|
D000431_D017093 NONE alcohol_9\NN| (r_pobj) of_8\IN|alcohol (r_prep) consumers_7\NNS|regular|of (r_attr) were_5\VBD|who|consumers|and|developed (l_conj) developed_12\VBD|who|failure|within|and|stopping (l_dobj) failure_14\NN|liver
D000431_D017093 NONE alcohol_24\NN| (r_compound) consumption_25\NN|alcohol (r_dobj) stopping_23\VBG|consumption|treated (r_conj) developed_12\VBD|who|failure|within|and|stopping (l_dobj) failure_14\NN|liver
D000431_D017093 NONE alcohol_10\NN| (r_pobj) of_9\IN|alcohol (r_prep) consumption_8\NN|e.g.|regular|of (r_appos) factors_4\NNS|risk|,|consumption (r_pobj) with_2\IN|factors (r_prep) patients_1\NNS|with (r_pobj) In_0\IN|patients (r_prep) is_14\VBZ|in|,|failure|possible|ingested|. (l_nsubj) failure_13\NN|liver
D000082_D017093 CID paracetamol_32\JJ|g (r_advmod) 4_30\CD|paracetamol (r_nummod) day_34\NN|4|/ (r_pobj) with_29\IN|day (r_prep) treated_28\VBN|while|being|with (r_advcl) stopping_23\VBG|consumption|treated (r_conj) developed_12\VBD|who|failure|within|and|stopping (l_dobj) failure_14\NN|liver
9495837
C087567_D000647 NONE /-)-PG-9_2\.|mg|kg-1|) (r_nsubj) was_11\VBD|(|+|/-)-pg-9|able|. (l_acomp) able_12\JJ|prevent (l_xcomp) prevent_14\VB|to|amnesia (l_dobj) amnesia_15\NN|induced
C087567_D000647 NONE /-)-PG-9_5\NFP|for|, (r_conj) of_2\IN|(|+|/-)-pg-9 (r_prep) profiles_1\NNS|affinity|of|determined|deferens (r_nsubj) shown_44\VBN|profiles|,|have|ratio|+|/-)-pg-9|. (l_dobj) ratio_48\NN|an|m4/m1|selectivity|of|be (l_relcl) be_53\VB|that|might|responsible (l_acomp) responsible_54\JJ|for (l_prep) for_55\IN|antinociception (l_pobj) antinociception_57\NN|the|and|effect|induced (l_conj) effect_63\NN|the|amnesic (l_amod) amnesic_62\JJ|anti|-
C087567_D000647 NONE /-)-PG-9_68\NFP|through (r_punct) shown_44\VBN|profiles|,|have|ratio|+|/-)-pg-9|. (l_dobj) ratio_48\NN|an|m4/m1|selectivity|of|be (l_relcl) be_53\VB|that|might|responsible (l_acomp) responsible_54\JJ|for (l_prep) for_55\IN|antinociception (l_pobj) antinociception_57\NN|the|and|effect|induced (l_conj) effect_63\NN|the|amnesic (l_amod) amnesic_62\JJ|anti|-
D012601_D000647 CID scopolamine_18\NN|(|kg-1|in (r_pobj) by_17\IN|scopolamine (r_agent) induced_16\VBN|by (r_acl) amnesia_15\NN|induced
D004025_D000647 CID dicyclomine_26\NN|(|kg-1|) (r_conj) kg-1_22\NNP|mg|i.p.|)|and|dicyclomine (r_appos) scopolamine_18\NN|(|kg-1|in (r_pobj) by_17\IN|scopolamine (r_agent) induced_16\VBN|by (r_acl) amnesia_15\NN|induced
D000109_D000647 NONE acetylcholine_73\NN| (r_amod) levels_75\NNS|acetylcholine|extracellular (r_pobj) in_72\IN|levels (r_prep) increase_71\NN|an|in (r_pobj) through_69\IN|increase (r_prep) /-)-PG-9_68\NFP|through (r_punct) shown_44\VBN|profiles|,|have|ratio|+|/-)-pg-9|. (l_dobj) ratio_48\NN|an|m4/m1|selectivity|of|be (l_relcl) be_53\VB|that|might|responsible (l_acomp) responsible_54\JJ|for (l_prep) for_55\IN|antinociception (l_pobj) antinociception_57\NN|the|and|effect|induced (l_conj) effect_63\NN|the|amnesic (l_amod) amnesic_62\JJ|anti|-
16403073
D007654_D016171 CID Ketoconazole_0\NNP| (r_nsubj) induced_1\VBD|ketoconazole|pointes|without|. (l_dobj) pointes_4\FW|torsades|de
D007654_D016171 CID ketoconazole_24\RB| (r_dobj) taking_23\VBG|ketoconazole|for (r_pcomp) after_22\IN|taking (r_prep) torsades_16\NNS|pointes|after (l_dobj) pointes_18\FW|de|(|tdp|)
D007654_D016171 CID ketoconazole_24\RB| (r_dobj) taking_23\VBG|ketoconazole|for (r_pcomp) after_22\IN|taking (r_prep) torsades_16\NNS|pointes|after (l_dobj) pointes_18\FW|de|(|tdp|) (l_appos) TdP_20\NN|
D007654_D016171 CID ketoconazole_13\RB|alone (r_nsubj) prolong_16\VB|that|by|,|ketoconazole|may|interval|and|induce (l_conj) induce_20\VB|tdp. (l_dobj) TdP._21\NN|
D007654_D003324 NONE ketoconazole_24\RB| (r_dobj) taking_23\VBG|ketoconazole|for (r_pcomp) after_22\IN|taking (r_prep) torsades_16\NNS|pointes|after (r_conj) developed_9\VBD|who|interval|and|torsades (r_relcl) woman_3\NN|a|with|developed (l_prep) with_4\IN|disease (l_pobj) disease_7\NN|coronary|artery
D007654_D008133 CID ketoconazole_24\RB| (r_dobj) taking_23\VBG|ketoconazole|for (r_pcomp) after_22\IN|taking (r_prep) torsades_16\NNS|pointes|after (r_conj) developed_9\VBD|who|interval|and|torsades (l_dobj) interval_14\NN|a|prolonged|qt
D007654_D008133 CID ketoconazole_5\JJ| (r_nsubjpass) administered_7\VBN|when|ketoconazole|is|to (l_prep) to_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|factors (l_pobj) factors_12\NNS|risk|for (l_prep) for_13\IN|syndrome (l_pobj) syndrome_17\NN|acquired|long|qt
D007654_D009181 NONE ketoconazole_24\RB| (r_dobj) taking_23\VBG|ketoconazole|for (l_prep) for_25\IN|treatment (l_pobj) treatment_26\NN|of (l_prep) of_27\IN|infection (l_pobj) infection_29\NN|fungal
12757899
D004958_D012640 NONE Estradiol_0\NN| (r_nsubj) reduces_1\VBZ|estradiol|injury|but|in|. (l_dobj) injury_6\NN|induced|hippocampal|in (l_amod) induced_4\VBN|seizure|- (l_npadvmod) seizure_2\NN|
D004958_D012640 NONE estradiol_7\NN| (r_pobj) of_6\IN|estradiol (r_prep) effects_5\NNS|the|of|on (l_prep) on_8\IN|threshold (l_pobj) threshold_10\NN|seizure|and|damage (l_compound) seizure_9\NN|
D004958_D001930 NONE Estradiol_0\NN| (r_nsubj) reduces_1\VBZ|estradiol|injury|but|in|. (l_dobj) injury_6\NN|induced|hippocampal|in
D007608_D001930 NONE acid_10\NN| (r_npadvmod) induced_12\VBN|acid|- (r_amod) status_13\NN|kainic|induced|se (r_pobj) by_8\IN|status (r_agent) induced_7\VBN|by (r_advcl) protect_1\VBP|estrogens|rats|induced|)|. (l_dobj) rats_3\NNS|ovariectomized|from (l_prep) from_4\IN|injury (l_pobj) injury_6\NN|hippocampal
D007608_D013226 NONE acid_10\NN| (r_npadvmod) induced_12\VBN|acid|- (r_amod) status_13\NN|kainic|induced|se (l_appos) SE_16\NNP|epilepticus|( (l_amod) epilepticus_14\NN|
D007608_D013226 NONE acid_10\NN| (r_npadvmod) induced_12\VBN|acid|- (r_amod) status_13\NN|kainic|induced|se (l_appos) SE_16\NNP|epilepticus|(
D004958_D013226 NONE estradiol_7\NN|17beta|- (r_pobj) of_4\IN|estradiol (r_prep) effects_3\NNS|the|of|in|and|rats (l_conj) rats_14\NNS|ovariectomized|female|subjected (l_acl) subjected_15\VBN|to (l_prep) to_16\IN|se (l_pobj) SE_22\NNP|induced
D008094_D013226 CID lithium_17\NN| (r_compound) pilocarpine_19\NN|lithium|- (r_npadvmod) induced_21\VBN|pilocarpine|- (r_amod) SE_22\NNP|induced
D010862_D013226 CID pilocarpine_19\NN|lithium|- (r_npadvmod) induced_21\VBN|pilocarpine|- (r_amod) SE_22\NNP|induced
D012834_D013226 NONE silver_3\NN| (r_npadvmod) stained_5\VBN|silver|- (r_amod) CA3_6\NN|stained|and|neurons (r_pobj) of_2\IN|ca3 (r_prep) extent_1\NN|the|of (r_nsubjpass) evaluated_12\VBN|extent|was|after|. (l_prep) after_15\IN|days|se (l_pobj) SE_16\NNP|
15275829
D000109_D012640 NONE acetylcholine_5\NN| (r_compound) subunits_7\NNS|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) are_8\VBP|subunits|necessary|for|. (l_prep) for_10\IN|seizures (l_pobj) seizures_14\NNS|induced|and|hypolocomotion
D000109_D012640 NONE acetylcholine_5\NN| (r_compound) receptors_6\NNS|nicotinic|acetylcholine|(|nachrs|) (r_pobj) to_3\IN|receptors (r_prep) Binding_0\NN|of|to (r_nsubj) elicits_10\VBZ|binding|series|. (l_dobj) series_12\NN|a|of (l_prep) of_13\IN|behaviors (l_pobj) behaviors_17\NNS|dependent|go (l_relcl) go_19\VBP|that|from|,|to (l_prep) to_29\IN|seizures (l_pobj) seizures_30\NNS|and|death
D000109_D006948 NONE acetylcholine_5\NN| (r_compound) subunits_7\NNS|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) are_8\VBP|subunits|necessary|for|. (l_prep) for_10\IN|seizures (l_pobj) seizures_14\NNS|induced|and|hypolocomotion (l_conj) hypolocomotion_16\NN|in
D009538_D012640 CID nicotine_11\NN| (r_npadvmod) induced_13\VBN|nicotine|- (r_amod) seizures_14\NNS|induced|and|hypolocomotion
D009538_D012640 CID nicotine_2\NN| (r_pobj) of_1\IN|nicotine (r_prep) Binding_0\NN|of|to (r_nsubj) elicits_10\VBZ|binding|series|. (l_dobj) series_12\NN|a|of (l_prep) of_13\IN|behaviors (l_pobj) behaviors_17\NNS|dependent|go (l_relcl) go_19\VBP|that|from|,|to (l_prep) to_29\IN|seizures (l_pobj) seizures_30\NNS|and|death
D009538_D012640 CID nicotine_9\NN| (r_npadvmod) induced_11\VBN|nicotine|- (r_amod) seizures_12\NNS|induced
D009538_D012640 CID nicotine_10\NN| (r_pobj) of_9\IN|nicotine (r_prep) effects_8\NNS|the|of|at (r_pobj) to_6\IN|effects (r_prep) sensitive_5\JJ|less|to (r_acomp) were_3\VBD|mice|sensitive|,|measured|. (l_advcl) measured_16\VBN|as|,|and|at|measured (l_conj) measured_30\VBN|as (l_prep) as_31\IN|sensitivity (l_pobj) sensitivity_32\NN|to (l_prep) to_33\IN|seizures (l_pobj) seizures_37\NNS|induced
D009538_D012640 CID nicotine_34\NN| (r_npadvmod) induced_36\VBN|nicotine|- (r_amod) seizures_37\NNS|induced
D009538_D012640 CID nicotine_7\NN| (r_npadvmod) induced_9\VBN|nicotine|- (r_amod) seizures_10\NNS|induced
D009538_D012640 CID nicotine_15\NN| (r_npadvmod) induced_17\VBN|nicotine|- (r_amod) seizures_18\NNS|induced|and|hypolocomotion
D009538_D006948 NONE nicotine_11\NN| (r_npadvmod) induced_13\VBN|nicotine|- (r_amod) seizures_14\NNS|induced|and|hypolocomotion (l_conj) hypolocomotion_16\NN|in
D009538_D006948 NONE nicotine_9\NN| (r_npadvmod) induced_11\VBN|nicotine|- (r_amod) seizures_12\NNS|induced (r_pobj) in_8\IN|seizures (r_prep) subunits_7\NNS|the|beta4|in|and|hypolocomotion (l_conj) hypolocomotion_14\NN|in
D009538_D006948 NONE nicotine_15\NN| (r_npadvmod) induced_17\VBN|nicotine|- (r_amod) seizures_18\NNS|induced|and|hypolocomotion (l_conj) hypolocomotion_20\NN|
D009538_D014202 NONE nicotine_2\NN| (r_pobj) of_1\IN|nicotine (r_prep) Binding_0\NN|of|to (r_nsubj) elicits_10\VBZ|binding|series|. (l_dobj) series_12\NN|a|of (l_prep) of_13\IN|behaviors (l_pobj) behaviors_17\NNS|dependent|go (l_relcl) go_19\VBP|that|from|,|to (l_prep) from_20\IN|exploration (l_pobj) exploration_22\NN|altered|,|sedation (l_conj) sedation_24\NN|,|and|tremors (l_conj) tremors_27\NNS|
D009538_D003643 NONE nicotine_2\NN| (r_pobj) of_1\IN|nicotine (r_prep) Binding_0\NN|of|to (r_nsubj) elicits_10\VBZ|binding|series|. (l_dobj) series_12\NN|a|of (l_prep) of_13\IN|behaviors (l_pobj) behaviors_17\NNS|dependent|go (l_relcl) go_19\VBP|that|from|,|to (l_prep) to_29\IN|seizures (l_pobj) seizures_30\NNS|and|death (l_conj) death_32\NN|
D000109_D014202 NONE acetylcholine_5\NN| (r_compound) receptors_6\NNS|nicotinic|acetylcholine|(|nachrs|) (r_pobj) to_3\IN|receptors (r_prep) Binding_0\NN|of|to (r_nsubj) elicits_10\VBZ|binding|series|. (l_dobj) series_12\NN|a|of (l_prep) of_13\IN|behaviors (l_pobj) behaviors_17\NNS|dependent|go (l_relcl) go_19\VBP|that|from|,|to (l_prep) from_20\IN|exploration (l_pobj) exploration_22\NN|altered|,|sedation (l_conj) sedation_24\NN|,|and|tremors (l_conj) tremors_27\NNS|
D000109_D003643 NONE acetylcholine_5\NN| (r_compound) receptors_6\NNS|nicotinic|acetylcholine|(|nachrs|) (r_pobj) to_3\IN|receptors (r_prep) Binding_0\NN|of|to (r_nsubj) elicits_10\VBZ|binding|series|. (l_dobj) series_12\NN|a|of (l_prep) of_13\IN|behaviors (l_pobj) behaviors_17\NNS|dependent|go (l_relcl) go_19\VBP|that|from|,|to (l_prep) to_29\IN|seizures (l_pobj) seizures_30\NNS|and|death (l_conj) death_32\NN|
3676049
D007530_D007022 CID isoflurane_6\RB| (r_npadvmod) induced_8\VBN|isoflurane|- (r_amod) hypotension_9\NN|induced|in
D007530_D007022 CID isoflurane_12\RB| (r_npadvmod) induced_14\VBN|isoflurane|- (r_amod) hypotension_15\NN|induced|in
D007530_D007022 CID isoflurane_19\NN| (r_pobj) of_18\IN|isoflurane (r_prep) dose_17\NN|the|of (r_dobj) increasing_15\VBG|dose (r_pcomp) by_14\IN|increasing (r_prep) induced_13\VBN|hypotension|was|by|,|and|maintained|. (l_nsubjpass) hypotension_1\NN|controlled|to
D007530_D002532 NONE isoflurane_6\RB| (r_npadvmod) induced_8\VBN|isoflurane|- (r_amod) hypotension_9\NN|induced|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|subjected (l_acl) subjected_12\VBN|to|for (l_prep) for_15\IN|aneurysms (l_pobj) aneurysms_17\NNS|cerebral
D007530_D002532 NONE isoflurane_12\RB| (r_npadvmod) induced_14\VBN|isoflurane|- (r_amod) hypotension_15\NN|induced|in (l_prep) in_16\IN|patients (l_pobj) patients_18\NNS|10|subjected (l_acl) subjected_19\VBN|to (l_prep) to_20\IN|craniotomy (l_pobj) craniotomy_21\NN|for (l_prep) for_22\IN|clipping (l_pobj) clipping_23\NN|of (l_prep) of_24\IN|aneurysm (l_pobj) aneurysm_27\NN|a|cerebral
D010100_D007022 NONE oxygen_8\NN| (r_pobj) for_7\IN|oxygen (r_prep) rate_6\NN|cerebral|metabolic|for (r_conj) flow_2\NN|cerebral|blood|and|rate (r_nsubjpass) measured_10\VBN|flow|were|during|. (l_prep) during_11\IN|hypotension (l_pobj) hypotension_15\NN|induced|in
D010100_D002532 NONE oxygen_8\NN| (r_pobj) for_7\IN|oxygen (r_prep) rate_6\NN|cerebral|metabolic|for (r_conj) flow_2\NN|cerebral|blood|and|rate (r_nsubjpass) measured_10\VBN|flow|were|during|. (l_prep) during_11\IN|hypotension (l_pobj) hypotension_15\NN|induced|in (l_prep) in_16\IN|patients (l_pobj) patients_18\NNS|10|subjected (l_acl) subjected_19\VBN|to (l_prep) to_20\IN|craniotomy (l_pobj) craniotomy_21\NN|for (l_prep) for_22\IN|clipping (l_pobj) clipping_23\NN|of (l_prep) of_24\IN|aneurysm (l_pobj) aneurysm_27\NN|a|cerebral
D014978_D013345 NONE xenon-133_24\.| (r_punct) measured_4\VBN|flow|were|after|by|xenon-133 (l_prep) after_9\IN|days|haemorrhage (l_pobj) haemorrhage_12\NN|the|subarachnoid
D008628_D007022 NONE Hg_11\NNP|mm (r_pobj) of_6\IN|hg (r_prep) MAP_5\NNP|an|average|of (r_pobj) to_2\IN|map (r_prep) hypotension_1\NN|controlled|to
D007530_D000783 NONE isoflurane_7\JJ| (r_amod) concentration_8\NN|the|isoflurane (r_nsubjpass) reduced_10\VBN|after|concentration|was|to|. (l_prep) After_0\IN|clipping (l_pobj) clipping_2\NN|the|of (l_prep) of_3\IN|aneurysm (l_pobj) aneurysm_5\NN|the
12536034
D002220_D004832 CID carbamazepine_13\NN|and|vigabatrin (r_pobj) of_12\IN|carbamazepine (r_prep) administration_11\NN|of (r_pobj) after_10\IN|administration (r_prep) present_2\VBP|authors|patients|after|. (l_dobj) patients_4\NNS|three|with (l_prep) with_5\IN|epilepsy (l_pobj) epilepsy_9\NN|absence
D020888_D004832 CID vigabatrin_15\NN| (r_conj) carbamazepine_13\NN|and|vigabatrin (r_pobj) of_12\IN|carbamazepine (r_prep) administration_11\NN|of (r_pobj) after_10\IN|administration (r_prep) present_2\VBP|authors|patients|after|. (l_dobj) patients_4\NNS|three|with (l_prep) with_5\IN|epilepsy (l_pobj) epilepsy_9\NN|absence
D005680_D004832 NONE acid_4\NN| (r_npadvmod) transmitted_6\VBN|acid|- (r_amod) circuitry_8\NN|transmitted|thalamocortical (r_compound) accounts_9\VBZ|the|aminobutyric|circuitry|for|. (l_prep) for_10\IN|part (l_pobj) part_13\NN|a|major|of (l_prep) of_14\IN|neurophysiology (l_pobj) neurophysiology_17\NN|the|underlying|of (l_prep) of_18\IN|epilepsy (l_pobj) epilepsy_21\NN|the|absence
19308880
D014635_D003221 CID acid_10\NN|valproic (r_pobj) with_8\IN|acid (r_prep) reaction_7\NN|a|serious|adverse|drug|with (r_appos) Confusion_0\NN|,|reaction|:|review|.
D014635_D003221 CID acid_10\NN|valproic (r_pobj) with_8\IN|acid (r_prep) observed_7\VBD|frequently|with (r_acl) reaction_5\NN|an|adverse|drug|observed (r_attr) is_1\VBZ|confusion|reaction|. (l_nsubj) Confusion_0\NN|
D014635_D003221 CID acid_17\NN|valproic (r_pobj) with_15\IN|acid (r_prep) reported_12\VBN|since|with (r_acl) confusion_11\NN|reported
D014635_D003221 CID acid_9\NN|valproic|:|women (r_pobj) with_7\IN|acid (r_prep) reported_6\VBN|:|cases|were|with|. (l_nsubjpass) cases_2\NNS|272|of (l_prep) of_3\IN|confusion (l_pobj) confusion_4\NN|
D014635_D003221 CID acid_10\NN|valproic (r_compound) exposure_11\NN|acid|(|%|) (r_pobj) following_8\VBG|exposure (r_prep) weeks_7\NNS|the|two|first|following (r_pobj) during_3\IN|weeks (r_prep) occurred_2\VBD|confusion|mostly|during|. (l_nsubj) Confusion_0\NN|
D014635_D003221 CID acid_7\NN|valproic (r_pobj) with_5\IN|acid (r_prep) confusion_4\NN|with
20477932
D003042_D008569 CID Cocaine_0\NN| (r_nsubj) causes_1\VBZ|cocaine|memory|. (l_dobj) memory_2\NN|and|learning|:|involvement (l_conj) learning_4\VBG|impairments (l_dobj) impairments_5\NNS|in
D003042_D007859 CID Cocaine_0\NN| (r_nsubj) causes_1\VBZ|cocaine|memory|. (l_dobj) memory_2\NN|and|learning|:|involvement (l_conj) learning_4\VBG|impairments (l_dobj) impairments_5\NNS|in
C052342_D008569 NONE topiramate_22\NN| (r_pobj) by_21\IN|topiramate (r_prep) prevention_20\NN|by (r_conj) involvement_9\NN|of|,|and|prevention (r_appos) memory_2\NN|and|learning|:|involvement (l_conj) learning_4\VBG|impairments (l_dobj) impairments_5\NNS|in
C052342_D007859 NONE topiramate_22\NN| (r_pobj) by_21\IN|topiramate (r_prep) prevention_20\NN|by (r_conj) involvement_9\NN|of|,|and|prevention (r_appos) memory_2\NN|and|learning|:|involvement (l_conj) learning_4\VBG|impairments (l_dobj) impairments_5\NNS|in
D003042_D064420 NONE cocaine_6\NN| (r_compound) toxicity_7\NN|cocaine|including
D003042_D064420 NONE cocaine_24\NN| (r_conj) brain_22\NN|the|and|cocaine (r_nmod) behaviour_27\NN|brain|induced|- (r_pobj) in_20\IN|behaviour (r_prep) status_19\NN|oxidative|in (r_pobj) between_17\IN|status (r_prep) association_16\NN|the|between (r_conj) increase_10\NN|an|in|but|association (r_pobj) including_8\VBG|increase (r_prep) toxicity_7\NN|cocaine|including
D009569_D019970 NONE oxide_9\NN| (r_compound) synthase_10\NN|neuronal|nitric|oxide|(|activity|,|therapy (l_conj) therapy_31\NN|a|proposed|for (l_prep) for_32\IN|addiction (l_pobj) addiction_34\NN|cocaine
C052342_D019970 NONE topiramate_26\NN| (r_pobj) of_25\IN|topiramate (r_prep) effect_24\NN|the|of (r_conj) learning_17\NN|spatial|and|memory|as|effect (r_conj) activity_14\NN|nnos|)|,|learning (r_conj) synthase_10\NN|neuronal|nitric|oxide|(|activity|,|therapy (l_conj) therapy_31\NN|a|proposed|for (l_prep) for_32\IN|addiction (l_pobj) addiction_34\NN|cocaine
D003042_D019970 NONE cocaine_43\NN| (r_compound) administration_44\NN|cocaine (r_pobj) of_42\IN|administration (r_prep) model_41\NN|an|experimental|of|in (r_pobj) in_38\IN|model (r_prep) evaluated_37\VBN|therefore|activity|were|in|. (l_nsubjpass) activity_2\NN|nfkappab|,|stress|, (l_appos) stress_5\NN|oxidative|,|synthase (l_conj) synthase_10\NN|neuronal|nitric|oxide|(|activity|,|therapy (l_conj) therapy_31\NN|a|proposed|for (l_prep) for_32\IN|addiction (l_pobj) addiction_34\NN|cocaine
84204
D002927_D003221 CID cimetidine_7\NN| (r_npadvmod) associated_9\VBN|cimetidine|- (r_amod) confusion_11\NN|associated|mental
D002927_D003221 CID cimetidine_3\NN| (r_npadvmod) associated_5\VBN|cimetidine|- (r_amod) confusion_7\NN|associated|mental
D002927_D051437 NONE cimetidine_19\FW|concentrations (r_conj) dysfunction_8\NN|both|renal|(|p|)|,|as|cimetidine
D002927_D008107 NONE cimetidine_19\FW|concentrations (r_conj) dysfunction_8\NN|both|renal|(|p|)|,|as|cimetidine
8372922
2673163
D003042_D020521 NONE cocaine_3\NN| (r_compound) use_4\NN|cocaine (r_pobj) with_2\IN|use (r_prep) associated_1\VBN|with (r_acl) Stroke_0\NN|associated|.
D003042_D020521 NONE cocaine_6\NN| (r_compound) use_7\NN|cocaine (r_nsubjpass) related_9\VBN|in|use|was|to|and|review (l_prep) to_10\IN|stroke (l_pobj) stroke_11\NN|
D003042_D020521 NONE cocaine_2\NN| (r_compound) use_3\NN|cocaine|by (r_dobj) followed_1\VBD|stroke|use|. (l_nsubj) Stroke_0\NN|
D003042_D020521 NONE cocaine_14\NN| (r_compound) use_15\NN|cocaine (r_pobj) to_13\IN|use (r_prep) related_12\VBN|to (r_acl) stroke_11\NN|related
D003042_D020521 NONE cocaine_14\NN| (r_compound) use_15\NN|cocaine (r_pobj) to_13\IN|use (r_prep) related_12\VBN|to (r_acl) stroke_11\NN|related (r_pobj) of_10\IN|stroke (r_prep) incidence_9\NN|the|apparent|of (r_nsubj) increasing_17\VBG|that|incidence|is (r_ccomp) indicate_2\VBP|data|increasing (r_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN|2|)|associated
D003042_D020521 NONE cocaine_14\NN| (r_compound) use_15\NN|cocaine (r_pobj) to_13\IN|use (r_prep) related_12\VBN|to (r_acl) stroke_11\NN|related (r_pobj) of_10\IN|stroke (r_prep) incidence_9\NN|the|apparent|of (r_nsubj) increasing_17\VBG|that|incidence|is (r_ccomp) indicate_2\VBP|data|increasing (r_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN|3
D003042_D020521 NONE cocaine_14\NN| (r_compound) use_15\NN|cocaine (r_pobj) to_13\IN|use (r_prep) related_12\VBN|to (r_acl) stroke_11\NN|related (r_pobj) of_10\IN|stroke (r_prep) incidence_9\NN|the|apparent|of (r_nsubj) increasing_17\VBG|that|incidence|is (r_ccomp) indicate_2\VBP|data|increasing (r_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5
D003042_D020521 NONE cocaine_14\NN| (r_compound) use_15\NN|cocaine (r_pobj) to_13\IN|use (r_prep) related_12\VBN|to (r_acl) stroke_11\NN|related (r_pobj) of_10\IN|stroke (r_prep) incidence_9\NN|the|apparent|of (r_nsubj) increasing_17\VBG|that|incidence|is (r_ccomp) indicate_2\VBP|data|increasing (r_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5 (l_conj) 5_63\CD|(|)|in|, (l_prep) in_65\IN|stroke (l_pobj) stroke_69\NN|associated
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|cocaine|- (r_amod) stroke_25\NN|2|)|associated (r_nsubj) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP|data|increasing (l_ccomp) increasing_17\VBG|that|incidence|is (l_nsubj) incidence_9\NN|the|apparent|of (l_prep) of_10\IN|stroke (l_pobj) stroke_11\NN|related
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|cocaine|- (r_amod) stroke_25\NN|2|)|associated
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|cocaine|- (r_amod) stroke_25\NN|2|)|associated (r_nsubj) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN|3
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|cocaine|- (r_amod) stroke_25\NN|2|)|associated (r_nsubj) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|cocaine|- (r_amod) stroke_25\NN|2|)|associated (r_nsubj) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5 (l_conj) 5_63\CD|(|)|in|, (l_prep) in_65\IN|stroke (l_pobj) stroke_69\NN|associated
D003042_D020521 NONE cocaine_41\NN| (r_compound) administration_42\NN|cocaine (r_pobj) of_40\IN|administration (r_prep) route_39\NN|any|of (r_dobj) follow_37\VB|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP|data|increasing (l_ccomp) increasing_17\VBG|that|incidence|is (l_nsubj) incidence_9\NN|the|apparent|of (l_prep) of_10\IN|stroke (l_pobj) stroke_11\NN|related
D003042_D020521 NONE cocaine_41\NN| (r_compound) administration_42\NN|cocaine (r_pobj) of_40\IN|administration (r_prep) route_39\NN|any|of (r_dobj) follow_37\VB|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN|2|)|associated
D003042_D020521 NONE cocaine_41\NN| (r_compound) administration_42\NN|cocaine (r_pobj) of_40\IN|administration (r_prep) route_39\NN|any|of (r_dobj) follow_37\VB|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN|3
D003042_D020521 NONE cocaine_41\NN| (r_compound) administration_42\NN|cocaine (r_pobj) of_40\IN|administration (r_prep) route_39\NN|any|of (r_dobj) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5
D003042_D020521 NONE cocaine_41\NN| (r_compound) administration_42\NN|cocaine (r_pobj) of_40\IN|administration (r_prep) route_39\NN|any|of (r_dobj) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5 (l_conj) 5_63\CD|(|)|in|, (l_prep) in_65\IN|stroke (l_pobj) stroke_69\NN|associated
D003042_D020521 NONE cocaine_49\NN| (r_compound) use_50\NN|cocaine (r_nsubjpass) associated_53\VBN|after|use|is|frequently|with (r_advcl) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (r_nsubj) exceeds_76\VBZ|follow|;|frequency|that|. (l_ccomp) follow_37\VB|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP|data|increasing (l_ccomp) increasing_17\VBG|that|incidence|is (l_nsubj) incidence_9\NN|the|apparent|of (l_prep) of_10\IN|stroke (l_pobj) stroke_11\NN|related
D003042_D020521 NONE cocaine_49\NN| (r_compound) use_50\NN|cocaine (r_nsubjpass) associated_53\VBN|after|use|is|frequently|with (r_advcl) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (r_nsubj) exceeds_76\VBZ|follow|;|frequency|that|. (l_ccomp) follow_37\VB|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN|2|)|associated
D003042_D020521 NONE cocaine_49\NN| (r_compound) use_50\NN|cocaine (r_nsubjpass) associated_53\VBN|after|use|is|frequently|with (r_advcl) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (r_nsubj) exceeds_76\VBZ|follow|;|frequency|that|. (l_ccomp) follow_37\VB|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN|3
D003042_D020521 NONE cocaine_49\NN| (r_compound) use_50\NN|cocaine (r_nsubjpass) associated_53\VBN|after|use|is|frequently|with (r_advcl) stroke_47\NN|4|associated|;|and|5
D003042_D020521 NONE cocaine_49\NN| (r_compound) use_50\NN|cocaine (r_nsubjpass) associated_53\VBN|after|use|is|frequently|with (r_advcl) stroke_47\NN|4|associated|;|and|5 (l_conj) 5_63\CD|(|)|in|, (l_prep) in_65\IN|stroke (l_pobj) stroke_69\NN|associated
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|cocaine|- (r_amod) stroke_69\NN|associated (r_pobj) in_65\IN|stroke (r_prep) 5_63\CD|(|)|in|, (r_conj) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (r_nsubj) exceeds_76\VBZ|follow|;|frequency|that|. (l_ccomp) follow_37\VB|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP|data|increasing (l_ccomp) increasing_17\VBG|that|incidence|is (l_nsubj) incidence_9\NN|the|apparent|of (l_prep) of_10\IN|stroke (l_pobj) stroke_11\NN|related
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|cocaine|- (r_amod) stroke_69\NN|associated (r_pobj) in_65\IN|stroke (r_prep) 5_63\CD|(|)|in|, (r_conj) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (r_nsubj) exceeds_76\VBZ|follow|;|frequency|that|. (l_ccomp) follow_37\VB|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN|2|)|associated
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|cocaine|- (r_amod) stroke_69\NN|associated (r_pobj) in_65\IN|stroke (r_prep) 5_63\CD|(|)|in|, (r_conj) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (r_nsubj) exceeds_76\VBZ|follow|;|frequency|that|. (l_ccomp) follow_37\VB|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN|3
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|cocaine|- (r_amod) stroke_69\NN|associated (r_pobj) in_65\IN|stroke (r_prep) 5_63\CD|(|)|in|, (r_conj) stroke_47\NN|4|associated|;|and|5
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|cocaine|- (r_amod) stroke_69\NN|associated
D003042_D002532 NONE cocaine_14\NN| (r_compound) use_15\NN|cocaine (r_pobj) to_13\IN|use (r_prep) related_12\VBN|to (r_acl) stroke_11\NN|related (r_pobj) of_10\IN|stroke (r_prep) incidence_9\NN|the|apparent|of (r_nsubj) increasing_17\VBG|that|incidence|is (r_ccomp) indicate_2\VBP|data|increasing (r_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5 (l_advcl) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations
D003042_D002532 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|cocaine|- (r_amod) stroke_25\NN|2|)|associated (r_nsubj) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5 (l_advcl) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations
D003042_D002532 NONE cocaine_41\NN| (r_compound) administration_42\NN|cocaine (r_pobj) of_40\IN|administration (r_prep) route_39\NN|any|of (r_dobj) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5 (l_advcl) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations
D003042_D002532 NONE cocaine_49\NN| (r_compound) use_50\NN|cocaine (r_nsubjpass) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations
D003042_D002532 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|cocaine|- (r_amod) stroke_69\NN|associated (r_pobj) in_65\IN|stroke (r_prep) 5_63\CD|(|)|in|, (r_conj) stroke_47\NN|4|associated|;|and|5 (l_advcl) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations
D003042_D001165 NONE cocaine_14\NN| (r_compound) use_15\NN|cocaine (r_pobj) to_13\IN|use (r_prep) related_12\VBN|to (r_acl) stroke_11\NN|related (r_pobj) of_10\IN|stroke (r_prep) incidence_9\NN|the|apparent|of (r_nsubj) increasing_17\VBG|that|incidence|is (r_ccomp) indicate_2\VBP|data|increasing (r_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5 (l_advcl) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations (l_conj) malformations_59\NNS|arteriovenous
D003042_D001165 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|cocaine|- (r_amod) stroke_25\NN|2|)|associated (r_nsubj) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5 (l_advcl) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations (l_conj) malformations_59\NNS|arteriovenous
D003042_D001165 NONE cocaine_41\NN| (r_compound) administration_42\NN|cocaine (r_pobj) of_40\IN|administration (r_prep) route_39\NN|any|of (r_dobj) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_nmod) stroke_47\NN|4|associated|;|and|5 (l_advcl) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations (l_conj) malformations_59\NNS|arteriovenous
D003042_D001165 NONE cocaine_49\NN| (r_compound) use_50\NN|cocaine (r_nsubjpass) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations (l_conj) malformations_59\NNS|arteriovenous
D003042_D001165 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|cocaine|- (r_amod) stroke_69\NN|associated (r_pobj) in_65\IN|stroke (r_prep) 5_63\CD|(|)|in|, (r_conj) stroke_47\NN|4|associated|;|and|5 (l_advcl) associated_53\VBN|after|use|is|frequently|with (l_prep) with_54\IN|aneurysms (l_pobj) aneurysms_56\NNS|intracranial|and|malformations (l_conj) malformations_59\NNS|arteriovenous
D003042_D020300 NONE cocaine_14\NN| (r_compound) use_15\NN|cocaine (r_pobj) to_13\IN|use (r_prep) related_12\VBN|to (r_acl) stroke_11\NN|related (r_pobj) of_10\IN|stroke (r_prep) incidence_9\NN|the|apparent|of (r_nsubj) increasing_17\VBG|that|incidence|is (r_ccomp) indicate_2\VBP|data|increasing (r_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_prep) of_73\IN|hemorrhage (l_pobj) hemorrhage_75\NN|intracranial
D003042_D020300 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN|cocaine|- (r_amod) stroke_25\NN|2|)|associated (r_nsubj) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_prep) of_73\IN|hemorrhage (l_pobj) hemorrhage_75\NN|intracranial
D003042_D020300 NONE cocaine_41\NN| (r_compound) administration_42\NN|cocaine (r_pobj) of_40\IN|administration (r_prep) route_39\NN|any|of (r_dobj) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_nsubj) frequency_72\NN|stroke|the|of (l_prep) of_73\IN|hemorrhage (l_pobj) hemorrhage_75\NN|intracranial
D003042_D020300 NONE cocaine_49\NN| (r_compound) use_50\NN|cocaine (r_nsubjpass) associated_53\VBN|after|use|is|frequently|with (r_advcl) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (l_prep) of_73\IN|hemorrhage (l_pobj) hemorrhage_75\NN|intracranial
D003042_D020300 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|cocaine|- (r_amod) stroke_69\NN|associated (r_pobj) in_65\IN|stroke (r_prep) 5_63\CD|(|)|in|, (r_conj) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (l_prep) of_73\IN|hemorrhage (l_pobj) hemorrhage_75\NN|intracranial
D003042_D002544 CID cocaine_14\NN| (r_compound) use_15\NN|cocaine (r_pobj) to_13\IN|use (r_prep) related_12\VBN|to (r_acl) stroke_11\NN|related (r_pobj) of_10\IN|stroke (r_prep) incidence_9\NN|the|apparent|of (r_nsubj) increasing_17\VBG|that|incidence|is (r_ccomp) indicate_2\VBP|data|increasing (r_ccomp) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_dobj) that_77\DT|of (l_prep) of_78\IN|infarction (l_pobj) infarction_80\NN|cerebral
D003042_D002544 CID cocaine_22\NN| (r_npadvmod) associated_24\VBN|cocaine|- (r_amod) stroke_25\NN|2|)|associated (r_nsubj) occurs_26\VBZ|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_dobj) that_77\DT|of (l_prep) of_78\IN|infarction (l_pobj) infarction_80\NN|cerebral
D003042_D002544 CID cocaine_41\NN| (r_compound) administration_42\NN|cocaine (r_pobj) of_40\IN|administration (r_prep) route_39\NN|any|of (r_dobj) follow_37\VB|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ|follow|;|frequency|that|. (l_dobj) that_77\DT|of (l_prep) of_78\IN|infarction (l_pobj) infarction_80\NN|cerebral
D003042_D002544 CID cocaine_49\NN| (r_compound) use_50\NN|cocaine (r_nsubjpass) associated_53\VBN|after|use|is|frequently|with (r_advcl) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (r_nsubj) exceeds_76\VBZ|follow|;|frequency|that|. (l_dobj) that_77\DT|of (l_prep) of_78\IN|infarction (l_pobj) infarction_80\NN|cerebral
D003042_D002544 CID cocaine_66\NN| (r_npadvmod) associated_68\VBN|cocaine|- (r_amod) stroke_69\NN|associated (r_pobj) in_65\IN|stroke (r_prep) 5_63\CD|(|)|in|, (r_conj) stroke_47\NN|4|associated|;|and|5 (r_nmod) frequency_72\NN|stroke|the|of (r_nsubj) exceeds_76\VBZ|follow|;|frequency|that|. (l_dobj) that_77\DT|of (l_prep) of_78\IN|infarction (l_pobj) infarction_80\NN|cerebral
7423039
D004317_D066126 CID adriamycin_3\JJ| (r_amod) cardiotoxicity_4\NN|adriamycin
D004317_D066126 CID adriamycin_4\NNS| (r_pobj) of_3\IN|adriamycin (r_prep) effects_2\NNS|the|cardiotoxic|of (l_amod) cardiotoxic_1\JJ|
3070035
D002216_D051437 NONE captopril_2\NN| (r_npadvmod) induced_4\VBN|captopril|- (r_amod) insufficiency_6\NN|induced|renal
D002216_D051437 NONE captopril_4\NN| (r_npadvmod) induced_6\VBN|captopril|- (r_amod) failure_8\NN|induced|renal
D002216_D006978 NONE captopril_2\NN| (r_npadvmod) induced_4\VBN|captopril|- (r_amod) insufficiency_6\NN|induced|renal (r_pobj) of_1\IN|insufficiency (r_prep) Reversibility_0\NN|of|after|. (l_prep) after_7\IN|use (l_pobj) use_9\NN|prolonged|in (l_prep) in_10\IN|case (l_pobj) case_13\NN|an|unusual|of (l_prep) of_14\IN|hypertension (l_pobj) hypertension_16\NN|renovascular
D002216_D006973 NONE captopril_27\NN| (r_pobj) with_26\IN|captopril (r_prep) treatment_25\NN|with (r_pobj) following_24\VBG|treatment (r_prep) deterioration_20\NN|sudden|of|following (r_dobj) developed_18\VBD|who|deterioration (r_relcl) kidney_15\NN|a|solitary|,|developed (r_pobj) to_12\IN|kidney (r_prep) artery_11\NN|an|occluded|renal|to (r_pobj) with_7\IN|artery (r_prep) hypertension_6\NN|severe|with
D002216_D058186 CID captopril_27\NN| (r_pobj) with_26\IN|captopril (r_prep) treatment_25\NN|with (r_pobj) following_24\VBG|treatment (r_prep) deterioration_20\NN|sudden|of|following (l_prep) of_21\IN|function (l_pobj) function_23\NN|renal
3865016
D005047_D054218 NONE etoposide_4\NN|and|cyclosporin (r_nmod) A_7\NNP|etoposide (r_pobj) of_3\IN|a (r_prep) effect_2\NN|a|synergistic|of (r_nsubjpass) observed_9\VBN|effect|was|in|in|. (l_prep) in_10\IN|patient (l_pobj) patient_12\NN|a|with (l_prep) with_13\IN|leukemia (l_pobj) leukemia_18\NN|acute|lymphocytic
D016572_D054218 NONE A_7\NNP|etoposide (r_pobj) of_3\IN|a (r_prep) effect_2\NN|a|synergistic|of (r_nsubjpass) observed_9\VBN|effect|was|in|in|. (l_prep) in_10\IN|patient (l_pobj) patient_12\NN|a|with (l_prep) with_13\IN|leukemia (l_pobj) leukemia_18\NN|acute|lymphocytic
D005047_D017254 NONE etoposide_4\NN|and|cyclosporin (r_nmod) A_7\NNP|etoposide (r_pobj) of_3\IN|a (r_prep) administration_2\NN|the|concomitant|of (r_nsubj) resulted_8\VBD|administration|in|. (l_prep) in_9\IN|eradication (l_pobj) eradication_10\NN|of (l_prep) of_11\IN|infiltration (l_pobj) infiltration_15\NN|hitherto|refractory|leukemic|of
D016572_D017254 NONE A_7\NNP|etoposide (r_pobj) of_3\IN|a (r_prep) administration_2\NN|the|concomitant|of (r_nsubj) resulted_8\VBD|administration|in|. (l_prep) in_9\IN|eradication (l_pobj) eradication_10\NN|of (l_prep) of_11\IN|infiltration (l_pobj) infiltration_15\NN|hitherto|refractory|leukemic|of
17532790
D007980_D004409 CID DOPA_12\NNP| (r_npadvmod) induced_14\VBN|l|-|dopa|- (r_amod) dyskinesia_15\NN|induced
D007980_D004409 CID DOPA_2\NNP| (r_npadvmod) induced_4\VBN|l|-|dopa|- (r_amod) dyskinesia_5\NN|induced|lid
D007980_D004409 CID DOPA_2\NNP| (r_npadvmod) induced_4\VBN|l|-|dopa|- (r_amod) dyskinesia_5\NN|induced|lid (l_appos) LID_7\NNP|(|)
D007980_D004409 CID DOPA_31\NNP|l|- (r_pobj) with_28\IN|dopa (r_prep) treatment_27\NN|a|prolonged|with (r_pobj) after_24\IN|treatment (r_prep) arise_15\VBP|that|in|after (r_relcl) complications_13\NNS|the|motor|arise (r_pobj) among_10\IN|complications (r_prep) is_9\VBZ|dyskinesia|among|. (l_nsubj) dyskinesia_5\NN|induced|lid
D007980_D004409 CID DOPA_31\NNP|l|- (r_pobj) with_28\IN|dopa (r_prep) treatment_27\NN|a|prolonged|with (r_pobj) after_24\IN|treatment (r_prep) arise_15\VBP|that|in|after (r_relcl) complications_13\NNS|the|motor|arise (r_pobj) among_10\IN|complications (r_prep) is_9\VBZ|dyskinesia|among|. (l_nsubj) dyskinesia_5\NN|induced|lid (l_appos) LID_7\NNP|(|)
D007980_D004409 CID DOPA_5\NNP|l|- (r_pobj) with_2\IN|dopa (r_prep) treated_1\VBD|rats|with|allocated|. (l_conj) allocated_7\VBN|were|to (l_prep) to_8\IN|groups (l_pobj) groups_10\NNS|two|based (l_acl) based_11\VBN|on (l_prep) on_12\IN|presence (l_pobj) presence_14\NN|the|or|absence (l_conj) absence_16\NN|of (l_prep) of_17\IN|lid (l_pobj) LID_18\NNP|
D007980_D010300 NONE DOPA_2\NNP| (r_npadvmod) induced_4\VBN|l|-|dopa|- (r_amod) dyskinesia_5\NN|induced|lid (r_nsubj) is_9\VBZ|dyskinesia|among|. (l_prep) among_10\IN|complications (l_pobj) complications_13\NNS|the|motor|arise (l_relcl) arise_15\VBP|that|in|after (l_prep) in_16\IN|patients (l_pobj) patients_23\NNS|disease|(|pd|) (l_nmod) disease_19\NN|parkinson
D007980_D010300 NONE DOPA_2\NNP| (r_npadvmod) induced_4\VBN|l|-|dopa|- (r_amod) dyskinesia_5\NN|induced|lid (r_nsubj) is_9\VBZ|dyskinesia|among|. (l_prep) among_10\IN|complications (l_pobj) complications_13\NNS|the|motor|arise (l_relcl) arise_15\VBP|that|in|after (l_prep) in_16\IN|patients (l_pobj) patients_23\NNS|disease|(|pd|) (l_nmod) PD_21\NNP|
D007980_D010300 NONE DOPA_31\NNP|l|- (r_pobj) with_28\IN|dopa (r_prep) treatment_27\NN|a|prolonged|with (r_pobj) after_24\IN|treatment (r_prep) arise_15\VBP|that|in|after (l_prep) in_16\IN|patients (l_pobj) patients_23\NNS|disease|(|pd|) (l_nmod) disease_19\NN|parkinson
D007980_D010300 NONE DOPA_31\NNP|l|- (r_pobj) with_28\IN|dopa (r_prep) treatment_27\NN|a|prolonged|with (r_pobj) after_24\IN|treatment (r_prep) arise_15\VBP|that|in|after (l_prep) in_16\IN|patients (l_pobj) patients_23\NNS|disease|(|pd|) (l_nmod) PD_21\NNP|
D007980_D010300 NONE DOPA_34\NNP|l|-|or|bromocriptine (r_appos) changes_8\NNS|the|occurring|,|dopa|using (l_acl) occurring_9\VBG|at (l_prep) at_10\IN|level (l_pobj) level_13\NN|the|protein|in|obtained (l_acl) obtained_17\VBN|from (l_prep) from_18\IN|model (l_pobj) model_25\NN|the|unilaterally|rat|of|treated (l_prep) of_26\IN|pd (l_pobj) PD_27\NNP|
D016627_D010300 NONE 6-hydroxydopamine_21\CD| (r_compound) lesion_23\NN|6-hydroxydopamine|- (r_compound) rat_24\NN|lesion (r_compound) model_25\NN|the|unilaterally|rat|of|treated (l_prep) of_26\IN|pd (l_pobj) PD_27\NNP|
D001971_D010300 NONE bromocriptine_36\NN| (r_conj) DOPA_34\NNP|l|-|or|bromocriptine (r_appos) changes_8\NNS|the|occurring|,|dopa|using (l_acl) occurring_9\VBG|at (l_prep) at_10\IN|level (l_pobj) level_13\NN|the|protein|in|obtained (l_acl) obtained_17\VBN|from (l_prep) from_18\IN|model (l_pobj) model_25\NN|the|unilaterally|rat|of|treated (l_prep) of_26\IN|pd (l_pobj) PD_27\NNP|
1085609
D011736_D012640 NONE pyridoxine_1\NN| (r_nmod) convulsions_3\NNS|neonatal|pyridoxine|responsive|due|.
D011736_D012640 NONE pyridoxine_9\NN|intramuscular (r_dobj) administering_7\VBG|pyridoxine (r_pcomp) of_6\IN|administering (r_prep) hours_5\NNS|4|of (r_pobj) within_3\IN|hours (r_prep) ceased_2\VBD|fits|within|,|suggesting|. (l_nsubj) fits_1\NNS|the
D011736_D012640 NONE pyridoxine_15\JJ| (r_compound) deficiency_16\NN|pyridoxine|secondary (r_pobj) of_14\IN|deficiency (r_prep) aetiology_13\NN|an|of|isoniazid (r_dobj) suggesting_11\VBG|aetiology (r_advcl) ceased_2\VBD|fits|within|,|suggesting|. (l_nsubj) fits_1\NNS|the
D007538_D012640 CID isoniazid_6\NN| (r_amod) therapy_7\NN|isoniazid (r_pobj) due_4\IN|to|therapy (r_amod) convulsions_3\NNS|neonatal|pyridoxine|responsive|due|.
D007538_D012640 CID isoniazid_6\NN| (r_pobj) on_5\IN|isoniazid|therapy (r_prep) infant_4\NN|a|old|on|daily|because (r_nsubjpass) admitted_18\VBN|infant|was|after|. (l_prep) after_19\IN|days (l_pobj) days_21\NNS|4|of (l_prep) of_22\IN|fits (l_pobj) fits_24\NNS|clonic
D007538_D012640 CID isoniazid_19\NN|to|medication (r_relcl) aetiology_13\NN|an|of|isoniazid (r_dobj) suggesting_11\VBG|aetiology (r_advcl) ceased_2\VBD|fits|within|,|suggesting|. (l_nsubj) fits_1\NNS|the
D007538_D014376 NONE isoniazid_6\NN| (r_pobj) on_5\IN|isoniazid|therapy (r_prep) infant_4\NN|a|old|on|daily|because (l_prep) because_13\IN|of|tuberculosis (l_pobj) tuberculosis_16\NN|maternal
11897407
C067171_D009203 NONE glucarate_2\NN|99mtc|-|for|. (l_prep) for_3\IN|detection (l_pobj) detection_4\NN|of (l_prep) of_5\IN|infarction (l_pobj) infarction_10\NN|induced|myocardial|in
C067171_D009203 NONE glucarate_2\NN|99mtc|- (r_nsubj) was_3\VBD|glucarate|easy|,|stable|and|used|. (l_conj) used_14\VBN|was|study (l_xcomp) study_16\VB|to|biodistribution (l_dobj) biodistribution_18\NN|its|in (l_prep) in_19\IN|rats (l_pobj) rats_20\NNS|with (l_prep) with_21\IN|infarction (l_pobj) infarction_27\NN|induced|acute|myocardial
D007545_D009203 CID isoproterenol_6\NN| (r_npadvmod) induced_8\VBN|isoproterenol|- (r_amod) infarction_10\NN|induced|myocardial|in
D007545_D009203 CID isoproterenol_22\NN| (r_npadvmod) induced_24\VBN|isoproterenol|- (r_amod) infarction_27\NN|induced|acute|myocardial
D007545_D007238 NONE isoproterenol_18\NN| (r_pobj) with_17\IN|isoproterenol (r_prep) obtained_16\VBN|can|be|easily|with (r_conj) implies_7\VBZ|model|ligation|obtained|. (l_nsubj) model_2\NN|the|animal|used (l_acl) used_3\VBN|produce (l_xcomp) produce_5\VB|to|infarction (l_dobj) infarction_6\NN|
D007545_D007238 NONE isoproterenol_12\JJ| (r_compound) administration_13\NN|isoproterenol (r_pobj) after_11\IN|administration (r_prep) h_10\NN|18|after (r_npadvmod) developed_6\VBD|that|rats|infarct|h (l_dobj) infarct_8\NN|an
D005937_D007238 NONE acid_9\NN|glucaric (r_pobj) on_7\IN|acid (r_prep) based_6\VBN|on (r_acl) radiopharmaceutical_5\NN|a|new|avid|based (l_amod) avid_4\JJ|infarct|- (l_npadvmod) infarct_2\NN|
7919560
D000667_D004892 CID ampicillin_7\NN| (r_pobj) by_6\IN|ampicillin (r_agent) caused_5\VBN|multiforme|by|. (l_nsubj) multiforme_1\NN|erythema|and|myocarditis
D000667_D004892 CID ampicillin_12\NN| (r_pobj) by_11\IN|ampicillin (r_agent) caused_10\VBN|by (r_acl) case_3\NN|a|of|caused (l_prep) of_4\IN|multiforme (l_pobj) multiforme_6\NNS|erythema|and|myocarditis
D000667_D009205 CID ampicillin_7\NN| (r_pobj) by_6\IN|ampicillin (r_agent) caused_5\VBN|multiforme|by|. (l_nsubj) multiforme_1\NN|erythema|and|myocarditis (l_conj) myocarditis_4\NN|hypersensitivity
D000667_D009205 CID ampicillin_12\NN| (r_pobj) by_11\IN|ampicillin (r_agent) caused_10\VBN|by (r_acl) case_3\NN|a|of|caused (l_prep) of_4\IN|multiforme (l_pobj) multiforme_6\NNS|erythema|and|myocarditis (l_conj) myocarditis_9\NN|hypersensitivity
D000667_D018805 NONE ampicillin_8\NN| (r_pobj) with_7\IN|ampicillin (r_prep) treated_6\VBN|boy|was|with|and|gentamicin|. (l_conj) gentamicin_10\NN|because (l_prep) because_11\IN|of|septicemia (l_pobj) septicemia_14\NN|suspected
D005839_D018805 NONE gentamicin_10\NN|because (l_prep) because_11\IN|of|septicemia (l_pobj) septicemia_14\NN|suspected
D010406_D009205 NONE penicillins_11\NNS| (r_pobj) to_10\IN|penicillins (r_prep) is_2\VBZ|myocarditis|manifestation|to|. (l_nsubj) myocarditis_1\NN|hypersensitivity
D010406_D004342 NONE penicillins_11\NNS| (r_pobj) to_10\IN|penicillins (r_prep) is_2\VBZ|myocarditis|manifestation|to|. (l_attr) manifestation_7\NN|a|rare|of (l_prep) of_8\IN|allergy (l_pobj) allergy_9\NN|
18809400
D008063_D028361 NONE acid_3\NN|lipoic (r_nsubj) prevents_4\VBZ|acid|damage|. (l_dobj) damage_6\NN|mitochondrial|and|neurotoxicity|in
D008063_D028361 NONE acid_7\NN|lipoic (r_nsubj) is_8\VBZ|if|acid|neuroprotective|induced|,|plays (l_advcl) plays_18\VBZ|if|damage|role|,|and|depend (l_nsubj) damage_17\NN|mitochondrial
D008063_D028361 NONE acid_35\NN|lipoic (r_pobj) of_31\IN|acid (r_prep) effects_30\NNS|neuroprotective|of (r_nsubj) depend_36\VBP|if|effects|on (r_conj) plays_18\VBZ|if|damage|role|,|and|depend (l_nsubj) damage_17\NN|mitochondrial
D008063_D028361 NONE acid_3\NN|lipoic (r_nsubj) exerts_4\VBZ|acid|effects|induced (r_ccomp) rescues_16\VBZ|exerts|:|it|toxicity|and|induces|. (l_dobj) toxicity_19\NN|the|mitochondrial
D008063_D020258 NONE acid_3\NN|lipoic (r_nsubj) prevents_4\VBZ|acid|damage|. (l_dobj) damage_6\NN|mitochondrial|and|neurotoxicity|in (l_conj) neurotoxicity_8\NN|
D008063_D020258 NONE acid_7\NN|lipoic (r_nsubj) is_8\VBZ|if|acid|neuroprotective|induced|,|plays (l_advcl) induced_12\VBN|neurotoxicity (l_dobj) neurotoxicity_13\NN|
D008063_D020258 NONE acid_35\NN|lipoic (r_pobj) of_31\IN|acid (r_prep) effects_30\NNS|neuroprotective|of (r_nsubj) depend_36\VBP|if|effects|on (r_conj) plays_18\VBZ|if|damage|role|,|and|depend (r_advcl) is_8\VBZ|if|acid|neuroprotective|induced|,|plays (l_advcl) induced_12\VBN|neurotoxicity (l_dobj) neurotoxicity_13\NN|
D008063_D020258 NONE acid_3\NN|lipoic (r_nsubj) exerts_4\VBZ|acid|effects|induced (l_conj) induced_9\VBN|neurotoxicity (l_dobj) neurotoxicity_10\NN|in
D008063_D009422 NONE acid_3\NN|lipoic (r_nsubj) prevents_4\VBZ|acid|damage|. (l_dobj) damage_6\NN|mitochondrial|and|neurotoxicity|in (l_prep) in_9\IN|neuropathy (l_pobj) neuropathy_12\NN|experimental|chemotherapy
D008063_D009410 NONE acid_7\NN|lipoic (r_nsubj) is_8\VBZ|if|acid|neuroprotective|induced|,|plays (l_advcl) plays_18\VBZ|if|damage|role|,|and|depend (l_dobj) role_21\NN|a|critical|in (l_prep) in_22\IN|cascade (l_pobj) cascade_25\NN|toxic|neurodegenerative
D008063_D009410 NONE acid_35\NN|lipoic (r_pobj) of_31\IN|acid (r_prep) effects_30\NNS|neuroprotective|of (r_nsubj) depend_36\VBP|if|effects|on (r_conj) plays_18\VBZ|if|damage|role|,|and|depend (l_dobj) role_21\NN|a|critical|in (l_prep) in_22\IN|cascade (l_pobj) cascade_25\NN|toxic|neurodegenerative
D017239_D010523 CID paclitaxel_32\NN|and|cisplatin (r_pobj) to_31\IN|paclitaxel (r_prep) neurons_30\NNS|(|drg|)|sensory|to (r_appos) ganglion_25\NN|dorsal|root|neurons (r_pobj) of_22\IN|ganglion (r_prep) cultures_21\NNS|primary|of (r_dobj) exposing_19\VBG|cultures (r_pcomp) by_18\IN|exposing (r_prep) mimic_13\VBP|that|closely|in|by|drugs (r_relcl) model_5\NN|an|in|vitro|of|mimic (r_dobj) used_1\VBD|we|model|induced|. (l_xcomp) induced_8\VBD|neuropathy (l_dobj) neuropathy_10\NN|peripheral
D002945_D010523 CID cisplatin_34\NN| (r_conj) paclitaxel_32\NN|and|cisplatin (r_pobj) to_31\IN|paclitaxel (r_prep) neurons_30\NNS|(|drg|)|sensory|to (r_appos) ganglion_25\NN|dorsal|root|neurons (r_pobj) of_22\IN|ganglion (r_prep) cultures_21\NNS|primary|of (r_dobj) exposing_19\VBG|cultures (r_pcomp) by_18\IN|exposing (r_prep) mimic_13\VBP|that|closely|in|by|drugs (r_relcl) model_5\NN|an|in|vitro|of|mimic (r_dobj) used_1\VBD|we|model|induced|. (l_xcomp) induced_8\VBD|neuropathy (l_dobj) neuropathy_10\NN|peripheral
D008063_D001480 NONE acid_10\NN|lipoic (r_pobj) of_6\IN|acid (r_prep) efficacy_5\NN|the|of|in (l_prep) in_11\IN|preventing (l_pcomp) preventing_12\VBG|damage (l_dobj) damage_14\NN|axonal
D008063_D001480 NONE acid_34\NN|lipoic (r_conj) agents_29\NNS|toxic|and|acid (r_pobj) to_27\IN|agents (r_prep) exposure_26\NN|to (r_pobj) after_25\IN|exposure (r_prep) function_19\NN|the|and|morphology|of|after (r_conj) apoptosis_16\NN|and|function (r_conj) investigating_3\VBG|efficacy|and|apoptosis (l_dobj) efficacy_5\NN|the|of|in (l_prep) in_11\IN|preventing (l_pcomp) preventing_12\VBG|damage (l_dobj) damage_14\NN|axonal
D002945_D028361 NONE cisplatin_5\NN|both|and|paclitaxel (r_nsubj) cause_8\VBP|that|cisplatin|impairment (l_dobj) impairment_11\NN|early|mitochondrial|with
D002945_D028361 NONE cisplatin_13\NN| (r_conj) in_10\IN|both|paclitaxel|and|cisplatin (r_prep) event_8\NN|an|early|common|in (r_attr) is_4\VBZ|in|toxicity|event|induced|. (l_nsubj) toxicity_3\NN|mitochondrial
D017239_D028361 NONE paclitaxel_7\NN| (r_conj) cisplatin_5\NN|both|and|paclitaxel (r_nsubj) cause_8\VBP|that|cisplatin|impairment (l_dobj) impairment_11\NN|early|mitochondrial|with
D017239_D028361 NONE paclitaxel_11\NN| (r_pobj) in_10\IN|both|paclitaxel|and|cisplatin (r_prep) event_8\NN|an|early|common|in (r_attr) is_4\VBZ|in|toxicity|event|induced|. (l_nsubj) toxicity_3\NN|mitochondrial
D017239_D020258 NONE paclitaxel_11\NN| (r_pobj) in_10\IN|both|paclitaxel|and|cisplatin (r_prep) event_8\NN|an|early|common|in (r_attr) is_4\VBZ|in|toxicity|event|induced|. (l_advcl) induced_14\VBN|neurotoxicity (l_dobj) neurotoxicity_15\NN|
D002945_D020258 NONE cisplatin_13\NN| (r_conj) in_10\IN|both|paclitaxel|and|cisplatin (r_prep) event_8\NN|an|early|common|in (r_attr) is_4\VBZ|in|toxicity|event|induced|. (l_advcl) induced_14\VBN|neurotoxicity (l_dobj) neurotoxicity_15\NN|
D008063_D010523 NONE acid_7\NN|lipoic (r_nsubj) reduce_9\VB|that|acid|might|risk|and|encourage (l_dobj) risk_11\NN|the|of (l_prep) of_12\IN|developing (l_pcomp) developing_13\VBG|toxicity (l_dobj) toxicity_16\NN|nerve|in
9746003
D002220_D004832 CID carbamazepine_3\NN|and|vigabatrin (l_conj) vigabatrin_5\VBP|in (l_prep) in_6\IN|seizures (l_pobj) seizures_9\NNS|typical|absence
D002220_D004832 CID Carbamazepine_0\NNP|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN|carbamazepine|are|in|. (l_prep) in_5\IN|seizures (l_pobj) seizures_8\NNS|typical|absence
D020888_D004832 CID vigabatrin_5\VBP|in (l_prep) in_6\IN|seizures (l_pobj) seizures_9\NNS|typical|absence
D020888_D004832 CID vigabatrin_2\NN| (r_conj) Carbamazepine_0\NNP|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN|carbamazepine|are|in|. (l_prep) in_5\IN|seizures (l_pobj) seizures_8\NNS|typical|absence
D002220_D009207 CID carbamazepine_9\NN|and|two (l_conj) two_11\CD|of (l_prep) of_12\IN|jerks (l_pobj) jerks_16\NNS|these|developed|myoclonic|,|resolved
D002220_D009207 CID carbamazepine_23\NN| (r_pobj) of_22\IN|carbamazepine (r_prep) withdrawal_21\NN|of (r_pobj) on_20\IN|withdrawal (r_prep) resolved_19\VBD|which|on (r_relcl) jerks_16\NNS|these|developed|myoclonic|,|resolved
8829025
D016559_D006973 CID tacrolimus_5\NNS| (r_dobj) receiving_4\VBG|tacrolimus (r_acl) patients_3\NNS|receiving (r_pobj) of_2\IN|patients (r_prep) groups_1\NNS|two|of (r_nsubjpass) compared_7\VBN|groups|were|over|,|group|. (l_appos) group_16\NN|one|comprising|,|and|other (l_acl) comprising_17\VBG|patients (l_dobj) patients_19\NNS|hypertensive|receiving (l_amod) hypertensive_18\JJ|
D016559_D006973 CID tacrolimus_12\NN|in (r_pobj) with_11\IN|tacrolimus (r_prep) associated_10\VBN|with (r_acl) nephrotoxicity_9\NN|the|associated (r_dobj) reducing_7\VBG|nephrotoxicity (r_pcomp) on_6\IN|reducing (r_prep) impact_3\NN|the|observed|positive|of|on (r_nsubj) be_18\VB|impact|should|factor|. (l_attr) factor_21\NN|an|important|in (l_prep) in_22\IN|selecting (l_pcomp) selecting_23\VBG|agent|treat (l_xcomp) treat_27\VB|to|hypertension (l_dobj) hypertension_28\NN|in
D009543_D006973 NONE nifedipine_23\NN| (r_dobj) receiving_22\VBG|who|were|nifedipine (r_relcl) patients_19\NNS|hypertensive|receiving (l_amod) hypertensive_18\JJ|
D009543_D006973 NONE nifedipine_33\NN| (r_dobj) receiving_32\VBG|not|nifedipine (r_acl) patients_30\NNS|nonhypertensive|receiving (r_dobj) comprising_28\VBG|patients (r_acl) other_27\JJ|the|comprising (r_conj) group_16\NN|one|comprising|,|and|other (l_acl) comprising_17\VBG|patients (l_dobj) patients_19\NNS|hypertensive|receiving (l_amod) hypertensive_18\JJ|
D009543_D006973 NONE nifedipine_5\NN| (r_pobj) of_4\IN|nifedipine (r_prep) impact_3\NN|the|observed|positive|of|on (r_nsubj) be_18\VB|impact|should|factor|. (l_attr) factor_21\NN|an|important|in (l_prep) in_22\IN|selecting (l_pcomp) selecting_23\VBG|agent|treat (l_xcomp) treat_27\VB|to|hypertension (l_dobj) hypertension_28\NN|in
D009543_D007674 NONE nifedipine_5\NN| (r_pobj) of_4\IN|nifedipine (r_prep) impact_3\NN|the|observed|positive|of|on (l_prep) on_6\IN|reducing (l_pcomp) reducing_7\VBG|nephrotoxicity (l_dobj) nephrotoxicity_9\NN|the|associated
D016559_D007674 NONE tacrolimus_12\NN|in (r_pobj) with_11\IN|tacrolimus (r_prep) associated_10\VBN|with (r_acl) nephrotoxicity_9\NN|the|associated
11334364
D000082_D009336 CID acetaminophen_13\RB| (r_advmod) induced_15\VBN|acetaminophen|- (r_amod) nephrotoxicity_16\NN|induced|,|toxicity (r_pobj) during_12\IN|nephrotoxicity (r_prep) deaths_11\NNS|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ|and|necrotic (l_conj) necrotic_9\JJ|
D000082_D009336 CID AAP_9\NNP|,|ami (r_appos) drugs_4\NNS|all|the|,|as|aap (r_nsubj) induced_14\VBD|interestingly|,|drugs|death|in|. (l_prep) in_17\IN|addition (l_pobj) addition_18\NN|to (l_prep) to_19\IN|necrosis (l_pobj) necrosis_20\NN|in|blocked
D000082_D007674 CID acetaminophen_13\RB| (r_advmod) induced_15\VBN|acetaminophen|- (r_amod) nephrotoxicity_16\NN|induced|,|toxicity
D000082_D007674 CID acetaminophen_16\RB| (r_advmod) prevent_15\VB|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone
D000082_D007674 CID AAP)-induced_18\VBN| (r_compound) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone
D000082_D008171 NONE acetaminophen_13\RB| (r_advmod) induced_15\VBN|acetaminophen|- (r_amod) nephrotoxicity_16\NN|induced|,|toxicity (l_conj) toxicity_22\NN|induced|lung|and|cardiotoxicity
D000082_D008171 NONE acetaminophen_16\RB| (r_advmod) prevent_15\VB|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000082_D008171 NONE AAP)-induced_18\VBN| (r_compound) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000082_D066126 NONE acetaminophen_13\RB| (r_advmod) induced_15\VBN|acetaminophen|- (r_amod) nephrotoxicity_16\NN|induced|,|toxicity (l_conj) toxicity_22\NN|induced|lung|and|cardiotoxicity (l_conj) cardiotoxicity_27\NN|induced|by
D000082_D066126 NONE acetaminophen_16\RB| (r_advmod) prevent_15\VB|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN|cardiotoxicity (l_dobj) cardiotoxicity_31\NN|(|dox)-induced|in
D000082_D066126 NONE AAP)-induced_18\VBN| (r_compound) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN|cardiotoxicity (l_dobj) cardiotoxicity_31\NN|(|dox)-induced|in
D000638_D009336 CID amiodarone_18\NN| (r_npadvmod) induced_20\VBN|amiodarone|- (r_amod) toxicity_22\NN|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN|induced|,|toxicity (r_pobj) during_12\IN|nephrotoxicity (r_prep) deaths_11\NNS|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ|and|necrotic (l_conj) necrotic_9\JJ|
D000638_D009336 CID AMI_11\NNP|and|dox (r_conj) AAP_9\NNP|,|ami (r_appos) drugs_4\NNS|all|the|,|as|aap (r_nsubj) induced_14\VBD|interestingly|,|drugs|death|in|. (l_prep) in_17\IN|addition (l_pobj) addition_18\NN|to (l_prep) to_19\IN|necrosis (l_pobj) necrosis_20\NN|in|blocked
D000638_D007674 NONE amiodarone_18\NN| (r_npadvmod) induced_20\VBN|amiodarone|- (r_amod) toxicity_22\NN|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN|induced|,|toxicity
D000638_D007674 NONE amiodarone_21\NN| (r_appos) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone
D000638_D007674 NONE AMI)-induced_23\JJ| (r_amod) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone
D000638_D008171 CID amiodarone_18\NN| (r_npadvmod) induced_20\VBN|amiodarone|- (r_amod) toxicity_22\NN|induced|lung|and|cardiotoxicity
D000638_D008171 CID amiodarone_21\NN| (r_appos) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000638_D008171 CID AMI)-induced_23\JJ| (r_amod) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000638_D066126 NONE amiodarone_18\NN| (r_npadvmod) induced_20\VBN|amiodarone|- (r_amod) toxicity_22\NN|induced|lung|and|cardiotoxicity (l_conj) cardiotoxicity_27\NN|induced|by
D000638_D066126 NONE amiodarone_21\NN| (r_appos) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN|cardiotoxicity (l_dobj) cardiotoxicity_31\NN|(|dox)-induced|in
D000638_D066126 NONE AMI)-induced_23\JJ| (r_amod) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN|cardiotoxicity (l_dobj) cardiotoxicity_31\NN|(|dox)-induced|in
D004317_D009336 CID doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|doxorubicin|- (r_amod) cardiotoxicity_27\NN|induced|by (r_conj) toxicity_22\NN|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN|induced|,|toxicity (r_pobj) during_12\IN|nephrotoxicity (r_prep) deaths_11\NNS|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ|and|necrotic (l_conj) necrotic_9\JJ|
D004317_D009336 CID DOX_13\NNP| (r_conj) AMI_11\NNP|and|dox (r_conj) AAP_9\NNP|,|ami (r_appos) drugs_4\NNS|all|the|,|as|aap (r_nsubj) induced_14\VBD|interestingly|,|drugs|death|in|. (l_prep) in_17\IN|addition (l_pobj) addition_18\NN|to (l_prep) to_19\IN|necrosis (l_pobj) necrosis_20\NN|in|blocked
D004317_D007674 NONE doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|doxorubicin|- (r_amod) cardiotoxicity_27\NN|induced|by (r_conj) toxicity_22\NN|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN|induced|,|toxicity
D004317_D007674 NONE doxorubicin_28\NN|cardiotoxicity (r_conj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone
D004317_D007674 NONE DOX)-induced_30\JJ| (r_amod) cardiotoxicity_31\NN|(|dox)-induced|in (r_dobj) doxorubicin_28\NN|cardiotoxicity (r_conj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone
D004317_D008171 NONE doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|doxorubicin|- (r_amod) cardiotoxicity_27\NN|induced|by (r_conj) toxicity_22\NN|induced|lung|and|cardiotoxicity
D004317_D008171 NONE doxorubicin_28\NN|cardiotoxicity (r_conj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D004317_D008171 NONE DOX)-induced_30\JJ| (r_amod) cardiotoxicity_31\NN|(|dox)-induced|in (r_dobj) doxorubicin_28\NN|cardiotoxicity (r_conj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D004317_D066126 CID doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|doxorubicin|- (r_amod) cardiotoxicity_27\NN|induced|by
D004317_D066126 CID doxorubicin_28\NN|cardiotoxicity (l_dobj) cardiotoxicity_31\NN|(|dox)-induced|in
D004317_D066126 CID DOX)-induced_30\JJ| (r_amod) cardiotoxicity_31\NN|(|dox)-induced|in
C511402_D009336 NONE extract_35\NN|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN|extract (r_prep) cardiotoxicity_27\NN|induced|by (r_conj) toxicity_22\NN|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN|induced|,|toxicity (r_pobj) during_12\IN|nephrotoxicity (r_prep) deaths_11\NNS|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ|and|necrotic (l_conj) necrotic_9\JJ|
C511402_D009336 NONE GSPE_31\NNP| (r_pobj) by_30\IN|gspe (r_agent) blocked_29\VBN|which|was|effectively|by (r_relcl) necrosis_20\NN|in|blocked
C511402_D007674 NONE extract_35\NN|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN|extract (r_prep) cardiotoxicity_27\NN|induced|by (r_conj) toxicity_22\NN|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN|induced|,|toxicity
C511402_D007674 NONE extract_10\NN|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN|extract (r_prep) ability_4\NN|the|of|prevent (l_acl) prevent_15\VB|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone
C511402_D007674 NONE GSPE_12\NNP| (r_appos) extract_10\NN|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN|extract (r_prep) ability_4\NN|the|of|prevent (l_acl) prevent_15\VB|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN|(|aap)-induced|,|amiodarone
C511402_D008171 NONE extract_35\NN|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN|extract (r_prep) cardiotoxicity_27\NN|induced|by (r_conj) toxicity_22\NN|induced|lung|and|cardiotoxicity
C511402_D008171 NONE extract_10\NN|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN|extract (r_prep) ability_4\NN|the|of|prevent (l_acl) prevent_15\VB|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
C511402_D008171 NONE GSPE_12\NNP| (r_appos) extract_10\NN|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN|extract (r_prep) ability_4\NN|the|of|prevent (l_acl) prevent_15\VB|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
C511402_D066126 NONE extract_35\NN|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN|extract (r_prep) cardiotoxicity_27\NN|induced|by
C511402_D066126 NONE extract_10\NN|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN|extract (r_prep) ability_4\NN|the|of|prevent (l_acl) prevent_15\VB|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN|cardiotoxicity (l_dobj) cardiotoxicity_31\NN|(|dox)-induced|in
C511402_D066126 NONE GSPE_12\NNP| (r_appos) extract_10\NN|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN|extract (r_prep) ability_4\NN|the|of|prevent (l_acl) prevent_15\VB|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN|cardiotoxicity (l_dobj) cardiotoxicity_31\NN|(|dox)-induced|in
C511402_D017695 NONE GSPE_30\NNP| (r_compound) preexposure_31\NN|gspe|than (r_pobj) of_29\IN|preexposure (r_prep) absence_28\NN|the|of (r_pobj) in_26\IN|absence (r_prep) variety_17\NN|a|of|by|in (r_pobj) with_15\IN|variety (r_prep) damage_14\NN|massive|tissue|with
8643971
D017239_D006258 NONE paclitaxel_7\NN| (r_pobj) of_6\IN|paclitaxel (r_prep) study_5\NN|ii|of (r_dobj) phase_1\NN|a|study|plus|cisplatin|. (l_conj) cisplatin_9\NN|as (l_prep) as_10\IN|therapy (l_pobj) therapy_14\NN|line|for|:|results (l_prep) for_15\IN|cancers (l_pobj) cancers_19\NNS|head
D017239_D006258 NONE paclitaxel_13\NN|agent|taxol (r_pobj) of_9\IN|paclitaxel (r_prep) study_8\NN|an|group|of (r_pobj) of_2\IN|study (r_prep) results_1\NNS|preliminary|of (r_nsubj) reported_27\VBD|results|rate|used|. (l_dobj) rate_32\NN|a|%|response|in|,|and (l_prep) in_33\IN|patients (l_pobj) patients_34\NNS|with (l_prep) with_35\IN|cancer (l_pobj) cancer_39\NN|head
D017239_D006258 NONE Taxol_15\NNP|(|;|company|) (r_appos) paclitaxel_13\NN|agent|taxol (r_pobj) of_9\IN|paclitaxel (r_prep) study_8\NN|an|group|of (r_pobj) of_2\IN|study (r_prep) results_1\NNS|preliminary|of (r_nsubj) reported_27\VBD|results|rate|used|. (l_dobj) rate_32\NN|a|%|response|in|,|and (l_prep) in_33\IN|patients (l_pobj) patients_34\NNS|with (l_prep) with_35\IN|cancer (l_pobj) cancer_39\NN|head
D017239_D006258 NONE paclitaxel_43\NN| (r_nmod) combination_46\NN|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN|combination|has|been|successfully|and|improved (r_conj) reported_27\VBD|results|rate|used|. (l_dobj) rate_32\NN|a|%|response|in|,|and (l_prep) in_33\IN|patients (l_pobj) patients_34\NNS|with (l_prep) with_35\IN|cancer (l_pobj) cancer_39\NN|head
D017239_D006258 NONE paclitaxel_16\NN| (r_compound) doses_17\NNS|escalating|paclitaxel|combined (l_acl) combined_18\VBN|with|with (l_prep) with_24\IN|support (l_pobj) support_30\NN|granulocyte|factor|in (l_prep) in_31\IN|patients (l_pobj) patients_32\NNS|with (l_prep) with_33\IN|head (l_pobj) head_38\NN|untreated|advanced|inoperable|and|carcinoma (l_conj) carcinoma_41\NN|neck
D017239_D006258 NONE Paclitaxel_0\NNP| (r_nsubj) is_3\VBZ|paclitaxel|cisplatin|regimen|warranted (l_attr) regimen_9\NN|an|effective|line|for|and (l_prep) for_10\IN|head (l_pobj) head_13\NN|advanced|and|cancer (l_conj) cancer_16\NN|neck
D002945_D006258 NONE cisplatin_9\NN|as (l_prep) as_10\IN|therapy (l_pobj) therapy_14\NN|line|for|:|results (l_prep) for_15\IN|cancers (l_pobj) cancers_19\NNS|head
D002945_D006258 NONE cisplatin_45\NN|/ (r_compound) combination_46\NN|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN|combination|has|been|successfully|and|improved (r_conj) reported_27\VBD|results|rate|used|. (l_dobj) rate_32\NN|a|%|response|in|,|and (l_prep) in_33\IN|patients (l_pobj) patients_34\NNS|with (l_prep) with_35\IN|cancer (l_pobj) cancer_39\NN|head
D002945_D006258 NONE cisplatin_23\NN|dose (r_pobj) with_19\IN|cisplatin (r_prep) combined_18\VBN|with|with (l_prep) with_24\IN|support (l_pobj) support_30\NN|granulocyte|factor|in (l_prep) in_31\IN|patients (l_pobj) patients_32\NNS|with (l_prep) with_33\IN|head (l_pobj) head_38\NN|untreated|advanced|inoperable|and|carcinoma (l_conj) carcinoma_41\NN|neck
D002945_D006258 NONE cisplatin_2\NN|/ (r_advmod) is_3\VBZ|paclitaxel|cisplatin|regimen|warranted (l_attr) regimen_9\NN|an|effective|line|for|and (l_prep) for_10\IN|head (l_pobj) head_13\NN|advanced|and|cancer (l_conj) cancer_16\NN|neck
D017239_D010051 NONE paclitaxel_13\NN|agent|taxol (r_pobj) of_9\IN|paclitaxel (r_prep) study_8\NN|an|group|of (r_pobj) of_2\IN|study (r_prep) results_1\NNS|preliminary|of (r_nsubj) reported_27\VBD|results|rate|used|. (l_conj) used_49\VBN|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN|has|significantly|duration (l_dobj) duration_57\NN|median|response|in (l_prep) in_58\IN|patients (l_pobj) patients_61\NNS|ovarian|cancer (l_compound) cancer_60\NN|
D017239_D010051 NONE Taxol_15\NNP|(|;|company|) (r_appos) paclitaxel_13\NN|agent|taxol (r_pobj) of_9\IN|paclitaxel (r_prep) study_8\NN|an|group|of (r_pobj) of_2\IN|study (r_prep) results_1\NNS|preliminary|of (r_nsubj) reported_27\VBD|results|rate|used|. (l_conj) used_49\VBN|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN|has|significantly|duration (l_dobj) duration_57\NN|median|response|in (l_prep) in_58\IN|patients (l_pobj) patients_61\NNS|ovarian|cancer (l_compound) cancer_60\NN|
D017239_D010051 NONE paclitaxel_43\NN| (r_nmod) combination_46\NN|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN|has|significantly|duration (l_dobj) duration_57\NN|median|response|in (l_prep) in_58\IN|patients (l_pobj) patients_61\NNS|ovarian|cancer (l_compound) cancer_60\NN|
D002945_D010051 NONE cisplatin_45\NN|/ (r_compound) combination_46\NN|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN|has|significantly|duration (l_dobj) duration_57\NN|median|response|in (l_prep) in_58\IN|patients (l_pobj) patients_61\NNS|ovarian|cancer (l_compound) cancer_60\NN|
D017239_D064420 NONE paclitaxel_16\NN| (r_compound) doses_17\NNS|escalating|paclitaxel|combined (r_pobj) of_14\IN|doses (r_prep) response_11\NN|the|and|toxicity|of (l_conj) toxicity_13\NN|
D017239_D064420 NONE paclitaxel_5\NN| (r_compound) doses_6\NNS|escalating|paclitaxel (r_dobj) incorporate_3\VBP|levels|doses|,|and|permitted (l_conj) permitted_17\VBN|escalations|are|permits|. (l_advcl) permits_20\VBZ|if|toxicity (l_nsubj) toxicity_19\NN|
D002945_D064420 NONE cisplatin_23\NN|dose (r_pobj) with_19\IN|cisplatin (r_prep) combined_18\VBN|with|with (r_acl) doses_17\NNS|escalating|paclitaxel|combined (r_pobj) of_14\IN|doses (r_prep) response_11\NN|the|and|toxicity|of (l_conj) toxicity_13\NN|
20667451
D003474_D003072 NONE Curcumin_0\NN| (r_nsubj) ameliorates_1\VBZ|curcumin|dysfunction|. (l_dobj) dysfunction_3\NN|cognitive|and|damage|administered
D003474_D003072 NONE curcumin_14\NN| (r_compound) administration_15\NN|chronic|curcumin (r_pobj) of_12\IN|administration (r_prep) effect_11\NN|the|of|on (l_prep) on_16\IN|impairment (l_pobj) impairment_23\NN|phenobarbitone-|cognitive|and|stress
D003474_D003072 NONE curcumin_1\NN| (r_compound) administration_2\NN|concomitant|curcumin (r_nsubj) prevented_3\VBD|administration|impairment|and|decreased|. (l_dobj) impairment_6\NN|the|cognitive
D003474_D003072 NONE curcumin_4\NN| (r_nsubj) has_5\VBZ|that|curcumin|effect (l_dobj) effect_7\NN|beneficial|in (l_prep) in_8\IN|mitigating (l_pcomp) mitigating_9\VBG|deterioration (l_dobj) deterioration_11\NN|the|of (l_prep) of_12\IN|functions (l_pobj) functions_14\NNS|cognitive|and|damage
D003474_D003072 NONE curcumin_4\NN| (r_nsubjpass) considered_7\VBN|that|curcumin|can|be|as|phenobarbitone (l_advcl) phenobarbitone_16\NN|to|and|therapy|in (l_prep) in_20\IN|preventing (l_pcomp) preventing_21\VBG|impairment (l_dobj) impairment_23\NN|cognitive|associated
D010634_D003072 CID phenobarbitone_8\NN|and|carbamazepine (r_pobj) in_7\IN|phenobarbitone (r_prep) damage_6\NN|oxidative|in (r_conj) dysfunction_3\NN|cognitive|and|damage|administered
D010634_D003072 CID phenobarbitone_4\NN|and|carbamazepine (r_conj) drugs_2\NNS|the|antiepileptic|,|phenobarbitone (r_nsubj) are_7\VBP|drugs|known|. (l_acomp) known_9\JJ|well|cause (l_xcomp) cause_11\VB|to|impairment (l_dobj) impairment_13\NN|cognitive|on
D010634_D003072 CID phenobarbitone-_17\JJ|and|induced (r_nmod) impairment_23\NN|phenobarbitone-|cognitive|and|stress
D010634_D003072 CID phenobarbitone_3\NN|and|carbamazepine (r_pobj) of_2\IN|phenobarbitone (r_prep) administration_1\NN|the|of|for (r_nsubj) caused_8\VBD|administration|impairment|. (l_dobj) impairment_11\NN|a|significant|of (l_prep) of_12\IN|learning|stress (l_pobj) learning_13\NN|and|memory|as (l_conj) memory_15\NN|
D010634_D003072 CID phenobarbitone_22\NN|and|carbamazepine (r_pobj) with_21\IN|phenobarbitone (r_prep) treated_20\VBN|with|without (r_acl) rats_19\NNS|treated (r_pobj) in_18\IN|rats (r_prep) damage_17\NN|oxidative|in (r_conj) functions_14\NNS|cognitive|and|damage
D010634_D003072 CID phenobarbitone_16\NN|to|and|therapy|in (l_prep) in_20\IN|preventing (l_pcomp) preventing_21\VBG|impairment (l_dobj) impairment_23\NN|cognitive|associated
D002220_D003072 CID carbamazepine_10\NN| (r_conj) phenobarbitone_8\NN|and|carbamazepine (r_pobj) in_7\IN|phenobarbitone (r_prep) damage_6\NN|oxidative|in (r_conj) dysfunction_3\NN|cognitive|and|damage|administered
D002220_D003072 CID carbamazepine_6\NN| (r_conj) phenobarbitone_4\NN|and|carbamazepine (r_conj) drugs_2\NNS|the|antiepileptic|,|phenobarbitone (r_nsubj) are_7\VBP|drugs|known|. (l_acomp) known_9\JJ|well|cause (l_xcomp) cause_11\VB|to|impairment (l_dobj) impairment_13\NN|cognitive|on
D002220_D003072 CID carbamazepine_19\NN| (r_npadvmod) induced_21\VBN|carbamazepine|- (r_conj) phenobarbitone-_17\JJ|and|induced (r_nmod) impairment_23\NN|phenobarbitone-|cognitive|and|stress
D002220_D003072 CID carbamazepine_5\NN| (r_conj) phenobarbitone_3\NN|and|carbamazepine (r_pobj) of_2\IN|phenobarbitone (r_prep) administration_1\NN|the|of|for (r_nsubj) caused_8\VBD|administration|impairment|. (l_dobj) impairment_11\NN|a|significant|of (l_prep) of_12\IN|learning|stress (l_pobj) learning_13\NN|and|memory|as (l_conj) memory_15\NN|
D002220_D003072 CID carbamazepine_24\NN| (r_conj) phenobarbitone_22\NN|and|carbamazepine (r_pobj) with_21\IN|phenobarbitone (r_prep) treated_20\VBN|with|without (r_acl) rats_19\NNS|treated (r_pobj) in_18\IN|rats (r_prep) damage_17\NN|oxidative|in (r_conj) functions_14\NNS|cognitive|and|damage
D002220_D003072 CID carbamazepine_18\NN| (r_compound) therapy_19\NN|carbamazepine (r_conj) phenobarbitone_16\NN|to|and|therapy|in (l_prep) in_20\IN|preventing (l_pcomp) preventing_21\VBG|impairment (l_dobj) impairment_23\NN|cognitive|associated
7582165
D000305_D004342 NONE corticosteroids_5\NNS| (r_pobj) to_4\IN|corticosteroids (r_prep) reactions_3\NNS|allergic|to|:|diagnosis|.
D010248_D004342 NONE paramethasone_3\NN| (r_pobj) from_2\IN|paramethasone (r_prep) different_1\JJ|from (r_amod) Corticosteroids_0\NNS|different (r_nsubj) produced_5\VBD|corticosteroids|also|reactions (l_dobj) reactions_7\NNS|hypersensitivity|in (l_compound) hypersensitivity_6\NN|
D010248_D004342 NONE paramethasone_16\NN| (r_pobj) by_15\IN|paramethasone (r_agent) caused_14\VBN|by (r_acl) allergy_13\NN|a|pseudo|-|caused
8421099
D015282_D042882 CID octreotide_12\NN| (r_appos) analog_10\NN|somatostatin|(|octreotide|) (r_pobj) of_8\IN|analog (r_prep) effects_7\NNS|the|term|of|on (l_prep) on_14\IN|function (l_pobj) function_16\NN|gallbladder|and|formation|in (l_conj) formation_19\NN|gallstone (l_compound) gallstone_18\NN|
D015282_D042882 CID octreotide_3\NN| (r_pobj) with_2\IN|octreotide (r_prep) treatment_1\NN|with (r_pobj) During_0\IN|treatment (r_prep) developed_7\VBD|during|,|patients|sludge|had|. (l_conj) had_11\VBD|10|gallstones|,|and|developed (l_dobj) gallstones_12\NNS|
D015282_D042882 CID octreotide_3\NN| (r_pobj) of_2\IN|octreotide (r_prep) withdrawal_1\NN|of|in (l_prep) in_4\IN|patients (l_pobj) patients_6\NNS|10|without (l_prep) without_7\IN|gallstones (l_pobj) gallstones_8\NNS|
D015282_D042882 CID octreotide_25\NN| (r_compound) therapy_26\NN|octreotide|in (r_pobj) during_24\IN|therapy (r_prep) formation_15\NN|the|successive|of|during (l_prep) of_16\IN|sludge (l_pobj) sludge_18\NN|bile|,|gallstones (l_conj) gallstones_20\NNS|,|and|cholecystitis
D015282_D000172 NONE octreotide_12\NN| (r_appos) analog_10\NN|somatostatin|(|octreotide|) (r_pobj) of_8\IN|analog (r_prep) effects_7\NNS|the|term|of|on (l_prep) on_14\IN|function (l_pobj) function_16\NN|gallbladder|and|formation|in (l_prep) in_20\IN|patients (l_pobj) patients_23\NNS|chinese|acromegalic (l_compound) acromegalic_22\JJ|
D015282_D000172 NONE octreotide_26\NN| (r_appos) analog_25\NN|the|somatostatin|octreotide (r_pobj) of_22\IN|analog (r_prep) injection_21\NN|sc|of (r_pobj) with_19\IN|injection (r_prep) treated_18\VBN|with|in|day|for (r_acl) patients_14\NNS|20|chinese|with|treated (l_prep) with_15\IN|acromegaly (l_pobj) acromegaly_17\NNS|active
D015282_D000172 NONE octreotide_25\NN| (r_compound) therapy_26\NN|octreotide|in (l_prep) in_27\IN|patients (l_pobj) patients_30\NNS|chinese|acromegalic (l_compound) acromegalic_29\JJ|
D015282_D000172 NONE octreotide_16\NN| (r_compound) therapy_17\NN|term|octreotide|of (l_prep) of_18\IN|patients (l_pobj) patients_20\NNS|acromegalic (l_compound) acromegalic_19\JJ|
D015282_D041881 CID octreotide_3\NN| (r_pobj) with_2\IN|octreotide (r_prep) treatment_1\NN|with (r_pobj) During_0\IN|treatment (r_prep) developed_7\VBD|during|,|patients|sludge|had|. (l_conj) had_11\VBD|10|gallstones|,|and|developed (l_conj) developed_16\VBD|1|cholecystitis|requiring (l_dobj) cholecystitis_18\NN|acute
D015282_D002764 NONE octreotide_25\NN| (r_compound) therapy_26\NN|octreotide|in (r_pobj) during_24\IN|therapy (r_prep) formation_15\NN|the|successive|of|during (l_prep) of_16\IN|sludge (l_pobj) sludge_18\NN|bile|,|gallstones (l_conj) gallstones_20\NNS|,|and|cholecystitis (l_conj) cholecystitis_23\NN|
2385256
D008274_D009157 CID magnesium_6\NN| (r_compound) administration_7\NN|magnesium (r_pobj) after_5\IN|administration (r_prep) weakness_4\NN|after (r_pobj) as_3\IN|weakness (r_prep) presenting_2\VBG|as (r_acl) gravis_1\NN|myasthenia|presenting|.
D008274_D009157 CID magnesium_3\NN| (r_compound) administration_4\NN|magnesium (r_pobj) after_2\IN|administration (r_prep) paralysis_1\NN|after (r_nsubjpass) described_7\VBN|although|paralysis|has|been|in (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|gravis (l_pobj) gravis_13\NN|known|myasthenia
D008274_D009468 NONE magnesium_17\NN| (r_compound) administration_18\NN|parenteral|magnesium|for (r_pobj) after_15\IN|administration (r_prep) became_12\VBD|who|quadriplegic|after (r_relcl) disease_10\NN|neuromuscular|became
D008274_D011782 NONE magnesium_17\NN| (r_compound) administration_18\NN|parenteral|magnesium|for (r_pobj) after_15\IN|administration (r_prep) became_12\VBD|who|quadriplegic|after (l_acomp) quadriplegic_14\JJ|virtually
D008274_D011225 NONE magnesium_17\NN| (r_compound) administration_18\NN|parenteral|magnesium|for (l_prep) for_19\IN|preeclampsia (l_pobj) preeclampsia_20\NN|
D008274_D010243 NONE magnesium_3\NN| (r_compound) administration_4\NN|magnesium (r_pobj) after_2\IN|administration (r_prep) paralysis_1\NN|after
D008274_D020511 NONE magnesium_10\NN| (r_pobj) of_9\IN|magnesium (r_prep) effects_8\NNS|the|neuromuscular|of (r_pobj) to_5\IN|effects (r_prep) sensitive_4\JJ|unusually|to (r_acomp) are_2\VBP|who|sensitive (r_relcl) Patients_0\NNS|are (r_nsubjpass) suspected_13\VBN|patients|should|be|of|. (l_prep) of_14\IN|having (l_pcomp) having_15\VBG|disorder (l_dobj) disorder_18\NN|an|underlying|of (l_prep) of_19\IN|transmission (l_pobj) transmission_21\NN|neuromuscular
7988234
D008790_D000799 CID metoprolol_6\NN| (r_pobj) of_5\IN|metoprolol (r_prep) administration_4\NN|the|intravenous|of (r_dobj) following_1\VBG|administration (r_prep) Angioedema_0\NNP|following|.
D008790_D000799 CID metoprolol_12\NN|intravenous (r_nsubjpass) given_14\VBN|during|,|metoprolol|was|,|resulting|. (l_advcl) resulting_16\VBG|in (l_prep) in_17\IN|angioedema (l_pobj) angioedema_19\NN|severe
D017706_D000799 CID lisinopril_6\NN| (r_compound) therapy_7\NN|lisinopril (r_pobj) to_5\IN|therapy (r_prep) history_1\NN|a|of|to (l_prep) of_2\IN|angioedema (l_pobj) angioedema_3\NN|secondary
D013256_D000799 NONE steroids_7\NNS|intravenous|and|diphenhydramine (r_pobj) with_5\IN|steroids (r_prep) resolved_2\VBD|angioedema|after|with|. (l_nsubj) angioedema_1\NN|the
D004155_D000799 NONE diphenhydramine_9\NN|hydrochloride (r_conj) steroids_7\NNS|intravenous|and|diphenhydramine (r_pobj) with_5\IN|steroids (r_prep) resolved_2\VBD|angioedema|after|with|. (l_nsubj) angioedema_1\NN|the
2611118
D004008_D006521 NONE sodium_6\NN| (r_compound) therapy_7\NN|diclofenac|sodium (r_pobj) with_4\IN|therapy (r_prep) associated_3\VBN|with (r_acl) hepatitis_2\NN|chronic|active|associated|.
D004008_D006521 NONE sodium_13\NN|diclofenac (r_pobj) with_11\IN|sodium (r_prep) therapy_10\NN|months|with|progressed (r_pobj) after_7\IN|therapy (r_prep) developed_3\VBD|patient|hepatitis|after|,|finding|. (l_dobj) hepatitis_6\NN|chronic|active
D004008_D056486 CID diclofenac_23\NNP| (r_pobj) by_22\IN|diclofenac (r_agent) induced_21\VBN|,|commonly|,|hepatitis|by|. (r_conj) recorded_13\VBN|tolerated|,|abnormalities|have|been|and|induced (l_nsubjpass) abnormalities_7\NNS|asymptomatic|of (l_prep) of_8\IN|function (l_pobj) function_10\NN|liver
D004008_D056486 CID diclofenac_23\NNP| (r_pobj) by_22\IN|diclofenac (r_agent) induced_21\VBN|,|commonly|,|hepatitis|by|. (l_nsubj) hepatitis_20\NN|severe
10457883
11745184
D002945_D001943 NONE cisplatin_5\NN|plus (r_nmod) amifostine_9\NN|cisplatin|wr-2721|(|) (r_pobj) of_4\IN|amifostine (r_prep) trial_3\NN|a|ii|of|for|:|e8188|. (l_prep) for_11\IN|carcinoma (l_pobj) carcinoma_14\NN|metastatic|breast
D002945_D001943 NONE Cisplatin_0\NNP| (r_nsubj) has_1\VBZ|cisplatin|activity|used|. (l_advcl) used_6\VBN|when|as (l_prep) as_7\IN|treatment (l_pobj) treatment_13\NN|second-|line|of (l_prep) of_14\IN|carcinoma (l_pobj) carcinoma_17\NN|metastatic|breast
D002945_D001943 NONE cisplatin_10\NN| (r_pobj) with_9\IN|cisplatin (r_prep) observed_8\VBN|although|effect|has|been|with (r_advcl) limited_31\VBN|observed|,|toxicities|have|use|. (l_dobj) use_33\NN|its|as (l_prep) as_34\IN|treatment (l_pobj) treatment_36\NN|a|for (l_prep) for_37\IN|carcinoma (l_pobj) carcinoma_39\NN|breast
D002945_D001943 NONE cisplatin_19\NN|nephrotoxicity (r_pcomp) with_18\IN|cisplatin (r_prep) associated_17\VBN|with (r_acl) toxicities_16\NNS|the|limiting|associated (r_nsubj) limited_31\VBN|observed|,|toxicities|have|use|. (l_dobj) use_33\NN|its|as (l_prep) as_34\IN|treatment (l_pobj) treatment_36\NN|a|for (l_prep) for_37\IN|carcinoma (l_pobj) carcinoma_39\NN|breast
D002945_D001943 NONE cisplatin_8\NN|plus|amifostine (r_pobj) of_7\IN|cisplatin (r_prep) combination_6\NN|the|of (r_pobj) of_4\IN|combination (r_prep) study_3\NN|a|ii|of (r_nsubjpass) conducted_12\VBN|study|was|in|,|but|regimen (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|carcinoma (l_pobj) carcinoma_19\NN|progressive|metastatic|breast|received
D004999_D001943 NONE WR-2721_7\NNP| (r_nmod) amifostine_9\NN|cisplatin|wr-2721|(|) (r_pobj) of_4\IN|amifostine (r_prep) trial_3\NN|a|ii|of|for|:|e8188|. (l_prep) for_11\IN|carcinoma (l_pobj) carcinoma_14\NN|metastatic|breast
D004999_D001943 NONE amifostine_9\NN|cisplatin|wr-2721|(|) (r_pobj) of_4\IN|amifostine (r_prep) trial_3\NN|a|ii|of|for|:|e8188|. (l_prep) for_11\IN|carcinoma (l_pobj) carcinoma_14\NN|metastatic|breast
D004999_D001943 NONE amifostine_10\NN| (r_conj) cisplatin_8\NN|plus|amifostine (r_pobj) of_7\IN|cisplatin (r_prep) combination_6\NN|the|of (r_pobj) of_4\IN|combination (r_prep) study_3\NN|a|ii|of (r_nsubjpass) conducted_12\VBN|study|was|in|,|but|regimen (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|carcinoma (l_pobj) carcinoma_19\NN|progressive|metastatic|breast|received
D002945_D064420 NONE cisplatin_10\NN| (r_pobj) with_9\IN|cisplatin (r_prep) observed_8\VBN|although|effect|has|been|with (r_advcl) limited_31\VBN|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS|the|limiting|associated
D002945_D064420 NONE cisplatin_19\NN|nephrotoxicity (r_pcomp) with_18\IN|cisplatin (r_prep) associated_17\VBN|with (r_acl) toxicities_16\NNS|the|limiting|associated
D002945_D064420 NONE cisplatin_20\VB|to|in (r_acl) amifostine_18\NN|cisplatin (r_pobj) of_17\IN|amifostine (r_prep) addition_16\NN|the|of (r_pobj) with_14\IN|addition (r_prep) observed_13\VBN|effect|was|with|. (l_nsubjpass) effect_5\NN|neither|a|protective|nor|reduced (l_conj) reduced_7\VBN|toxicity|to (l_dobj) toxicity_8\NN|
D002945_D007674 CID cisplatin_10\NN| (r_pobj) with_9\IN|cisplatin (r_prep) observed_8\VBN|although|effect|has|been|with (r_advcl) limited_31\VBN|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS|the|limiting|associated (l_acl) associated_17\VBN|with (l_prep) with_18\IN|cisplatin (l_pcomp) cisplatin_19\NN|nephrotoxicity (l_preconj) nephrotoxicity_23\NN|(|e.g.|,|,|ototoxicity|)
D002945_D007674 CID cisplatin_19\NN|nephrotoxicity (l_preconj) nephrotoxicity_23\NN|(|e.g.|,|,|ototoxicity|)
D002945_D007674 CID cisplatin_3\NN|and|amifostine (r_pobj) of_2\IN|cisplatin (r_prep) trials_1\NNS|early|of (r_nsubj) suggested_7\VBD|trials|also|reduced|. (l_ccomp) reduced_24\VBN|that|incidence|were (l_nsubjpass) incidence_10\NN|the|and|severity|of (l_prep) of_13\IN|nephrotoxicity (l_pobj) nephrotoxicity_17\NN|induced|,|ototoxicity
D002945_D007674 CID cisplatin_14\NN| (r_advmod) induced_16\VBN|cisplatin|- (r_amod) nephrotoxicity_17\NN|induced|,|ototoxicity
D002945_D006311 CID cisplatin_10\NN| (r_pobj) with_9\IN|cisplatin (r_prep) observed_8\VBN|although|effect|has|been|with (r_advcl) limited_31\VBN|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS|the|limiting|associated (l_acl) associated_17\VBN|with (l_prep) with_18\IN|cisplatin (l_pcomp) cisplatin_19\NN|nephrotoxicity (l_preconj) nephrotoxicity_23\NN|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN|,|and|neurotoxicity
D002945_D006311 CID cisplatin_19\NN|nephrotoxicity (l_preconj) nephrotoxicity_23\NN|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN|,|and|neurotoxicity
D002945_D006311 CID cisplatin_3\NN|and|amifostine (r_pobj) of_2\IN|cisplatin (r_prep) trials_1\NNS|early|of (r_nsubj) suggested_7\VBD|trials|also|reduced|. (l_ccomp) reduced_24\VBN|that|incidence|were (l_nsubjpass) incidence_10\NN|the|and|severity|of (l_prep) of_13\IN|nephrotoxicity (l_pobj) nephrotoxicity_17\NN|induced|,|ototoxicity (l_conj) ototoxicity_19\NN|,|and|neuropathy
D002945_D006311 CID cisplatin_14\NN| (r_advmod) induced_16\VBN|cisplatin|- (r_amod) nephrotoxicity_17\NN|induced|,|ototoxicity (l_conj) ototoxicity_19\NN|,|and|neuropathy
D002945_D020258 NONE cisplatin_10\NN| (r_pobj) with_9\IN|cisplatin (r_prep) observed_8\VBN|although|effect|has|been|with (r_advcl) limited_31\VBN|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS|the|limiting|associated (l_acl) associated_17\VBN|with (l_prep) with_18\IN|cisplatin (l_pcomp) cisplatin_19\NN|nephrotoxicity (l_preconj) nephrotoxicity_23\NN|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN|,|and|neurotoxicity (l_conj) neurotoxicity_28\NN|
D002945_D020258 NONE cisplatin_19\NN|nephrotoxicity (l_preconj) nephrotoxicity_23\NN|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN|,|and|neurotoxicity (l_conj) neurotoxicity_28\NN|
D002945_D009422 CID cisplatin_3\NN|and|amifostine (r_pobj) of_2\IN|cisplatin (r_prep) trials_1\NNS|early|of (r_nsubj) suggested_7\VBD|trials|also|reduced|. (l_ccomp) reduced_24\VBN|that|incidence|were (l_nsubjpass) incidence_10\NN|the|and|severity|of (l_prep) of_13\IN|nephrotoxicity (l_pobj) nephrotoxicity_17\NN|induced|,|ototoxicity (l_conj) ototoxicity_19\NN|,|and|neuropathy (l_conj) neuropathy_22\NN|
D002945_D009422 CID cisplatin_14\NN| (r_advmod) induced_16\VBN|cisplatin|- (r_amod) nephrotoxicity_17\NN|induced|,|ototoxicity (l_conj) ototoxicity_19\NN|,|and|neuropathy (l_conj) neuropathy_22\NN|
D004999_D007674 NONE amifostine_5\NN| (r_conj) cisplatin_3\NN|and|amifostine (r_pobj) of_2\IN|cisplatin (r_prep) trials_1\NNS|early|of (r_nsubj) suggested_7\VBD|trials|also|reduced|. (l_ccomp) reduced_24\VBN|that|incidence|were (l_nsubjpass) incidence_10\NN|the|and|severity|of (l_prep) of_13\IN|nephrotoxicity (l_pobj) nephrotoxicity_17\NN|induced|,|ototoxicity
D004999_D006311 NONE amifostine_5\NN| (r_conj) cisplatin_3\NN|and|amifostine (r_pobj) of_2\IN|cisplatin (r_prep) trials_1\NNS|early|of (r_nsubj) suggested_7\VBD|trials|also|reduced|. (l_ccomp) reduced_24\VBN|that|incidence|were (l_nsubjpass) incidence_10\NN|the|and|severity|of (l_prep) of_13\IN|nephrotoxicity (l_pobj) nephrotoxicity_17\NN|induced|,|ototoxicity (l_conj) ototoxicity_19\NN|,|and|neuropathy
D004999_D009422 NONE amifostine_5\NN| (r_conj) cisplatin_3\NN|and|amifostine (r_pobj) of_2\IN|cisplatin (r_prep) trials_1\NNS|early|of (r_nsubj) suggested_7\VBD|trials|also|reduced|. (l_ccomp) reduced_24\VBN|that|incidence|were (l_nsubjpass) incidence_10\NN|the|and|severity|of (l_prep) of_13\IN|nephrotoxicity (l_pobj) nephrotoxicity_17\NN|induced|,|ototoxicity (l_conj) ototoxicity_19\NN|,|and|neuropathy (l_conj) neuropathy_22\NN|
D004999_D009369 NONE amifostine_18\NN|cisplatin (r_pobj) of_17\IN|amifostine (r_prep) addition_16\NN|the|of (r_pobj) with_14\IN|addition (r_prep) observed_13\VBN|effect|was|with|. (l_nsubjpass) effect_5\NN|neither|a|protective|nor|reduced (l_amod) protective_4\JJ|tumor|- (l_npadvmod) tumor_2\NN|
D004999_D064420 NONE amifostine_18\NN|cisplatin (r_pobj) of_17\IN|amifostine (r_prep) addition_16\NN|the|of (r_pobj) with_14\IN|addition (r_prep) observed_13\VBN|effect|was|with|. (l_nsubjpass) effect_5\NN|neither|a|protective|nor|reduced (l_conj) reduced_7\VBN|toxicity|to (l_dobj) toxicity_8\NN|
D002945_D009369 NONE cisplatin_20\VB|to|in (r_acl) amifostine_18\NN|cisplatin (r_pobj) of_17\IN|amifostine (r_prep) addition_16\NN|the|of (r_pobj) with_14\IN|addition (r_prep) observed_13\VBN|effect|was|with|. (l_nsubjpass) effect_5\NN|neither|a|protective|nor|reduced (l_amod) protective_4\JJ|tumor|- (l_npadvmod) tumor_2\NN|
3714122
C005238_D020258 NONE mipafox_7\NN| (r_npadvmod) induced_9\VBN|mipafox|- (r_amod) damage_11\NN|induced|neuropathic|in (r_conj) inhibition_5\NN|neurotoxic|esterase|and|damage (l_amod) neurotoxic_3\JJ|
C005238_D020258 NONE Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN|mipafox (r_prep) exposed_22\VBN|acutely|to (r_acl) rats_20\NNS|exposed (r_pobj) in_19\IN|rats (r_prep) examined_18\VBN|correlation|was|in|. (l_nsubjpass) correlation_1\NN|the|between (l_prep) between_2\IN|damage (l_pobj) damage_4\NN|neuropathic|and|inhibition|of (l_prep) of_7\IN|esterase (l_pobj) esterase_9\NN|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ|
C005238_D020258 NONE Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (l_appos) organophosphate_33\NN|a|neurotoxic (l_amod) neurotoxic_32\JJ|
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|(|n|, (r_appos) Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN|mipafox (r_prep) exposed_22\VBN|acutely|to (r_acl) rats_20\NNS|exposed (r_pobj) in_19\IN|rats (r_prep) examined_18\VBN|correlation|was|in|. (l_nsubjpass) correlation_1\NN|the|between (l_prep) between_2\IN|damage (l_pobj) damage_4\NN|neuropathic|and|inhibition|of (l_prep) of_7\IN|esterase (l_pobj) esterase_9\NN|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ|
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|(|n|, (r_appos) Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (l_appos) organophosphate_33\NN|a|neurotoxic (l_amod) neurotoxic_32\JJ|
C005238_D009422 NONE mipafox_7\NN| (r_npadvmod) induced_9\VBN|mipafox|- (r_amod) damage_11\NN|induced|neuropathic|in
C005238_D009422 NONE Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN|mipafox (r_prep) exposed_22\VBN|acutely|to (r_acl) rats_20\NNS|exposed (r_pobj) in_19\IN|rats (r_prep) examined_18\VBN|correlation|was|in|. (l_nsubjpass) correlation_1\NN|the|between (l_prep) between_2\IN|damage (l_pobj) damage_4\NN|neuropathic|and|inhibition|of
C005238_D009422 NONE Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN|mipafox (r_prep) exposed_22\VBN|acutely|to (r_acl) rats_20\NNS|exposed (r_pobj) in_19\IN|rats (r_prep) examined_18\VBN|correlation|was|in|. (l_nsubjpass) correlation_1\NN|the|between (l_prep) between_2\IN|damage (l_pobj) damage_4\NN|neuropathic|and|inhibition|of (l_prep) of_7\IN|esterase (l_pobj) esterase_9\NN|neurotoxic|or|enzyme (l_conj) enzyme_13\NN|target|(|nte|) (l_compound) target_12\NN|neuropathy (l_compound) neuropathy_11\NN|
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|(|n|, (r_appos) Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN|mipafox (r_prep) exposed_22\VBN|acutely|to (r_acl) rats_20\NNS|exposed (r_pobj) in_19\IN|rats (r_prep) examined_18\VBN|correlation|was|in|. (l_nsubjpass) correlation_1\NN|the|between (l_prep) between_2\IN|damage (l_pobj) damage_4\NN|neuropathic|and|inhibition|of
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|(|n|, (r_appos) Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN|mipafox (r_prep) exposed_22\VBN|acutely|to (r_acl) rats_20\NNS|exposed (r_pobj) in_19\IN|rats (r_prep) examined_18\VBN|correlation|was|in|. (l_nsubjpass) correlation_1\NN|the|between (l_prep) between_2\IN|damage (l_pobj) damage_4\NN|neuropathic|and|inhibition|of (l_prep) of_7\IN|esterase (l_pobj) esterase_9\NN|neurotoxic|or|enzyme (l_conj) enzyme_13\NN|target|(|nte|) (l_compound) target_12\NN|neuropathy (l_compound) neuropathy_11\NN|
C005238_D009422 NONE Mipafox_18\NNP| (r_compound) exposure_19\NN|mipafox (r_nsubj) predict_21\VB|shortly|after|exposure|can|damage|later (l_dobj) damage_23\NN|neuropathic|in
D010755_D009422 NONE organophosphate_33\NN|a|neurotoxic (r_appos) Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN|mipafox (r_prep) exposed_22\VBN|acutely|to (r_acl) rats_20\NNS|exposed (r_pobj) in_19\IN|rats (r_prep) examined_18\VBN|correlation|was|in|. (l_nsubjpass) correlation_1\NN|the|between (l_prep) between_2\IN|damage (l_pobj) damage_4\NN|neuropathic|and|inhibition|of
D010755_D009422 NONE organophosphate_33\NN|a|neurotoxic (r_appos) Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN|mipafox (r_prep) exposed_22\VBN|acutely|to (r_acl) rats_20\NNS|exposed (r_pobj) in_19\IN|rats (r_prep) examined_18\VBN|correlation|was|in|. (l_nsubjpass) correlation_1\NN|the|between (l_prep) between_2\IN|damage (l_pobj) damage_4\NN|neuropathic|and|inhibition|of (l_prep) of_7\IN|esterase (l_pobj) esterase_9\NN|neurotoxic|or|enzyme (l_conj) enzyme_13\NN|target|(|nte|) (l_compound) target_12\NN|neuropathy (l_compound) neuropathy_11\NN|
D010755_D020258 NONE organophosphate_33\NN|a|neurotoxic (r_appos) Mipafox_24\NNP|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN|mipafox (r_prep) exposed_22\VBN|acutely|to (r_acl) rats_20\NNS|exposed (r_pobj) in_19\IN|rats (r_prep) examined_18\VBN|correlation|was|in|. (l_nsubjpass) correlation_1\NN|the|between (l_prep) between_2\IN|damage (l_pobj) damage_4\NN|neuropathic|and|inhibition|of (l_prep) of_7\IN|esterase (l_pobj) esterase_9\NN|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ|
D010755_D020258 NONE organophosphate_33\NN|a|neurotoxic (l_amod) neurotoxic_32\JJ|
C005238_D013118 CID Mipafox_5\NNP| (r_pobj) of_4\IN|mipafox (r_prep) dosages_3\NNS|of|less|inhibited (r_nsubj) produced_39\VBN|in|,|dosages|degree|in|. (l_dobj) degree_41\NN|this|of (l_prep) of_42\IN|damage (l_pobj) damage_44\NN|cord
9195768
D018170_D010292 CID sumatriptan_7\NN|subcutaneous (r_pobj) of_5\IN|sumatriptan (r_prep) use_4\NN|the|of (r_dobj) following_2\VBG|use (r_prep) sensations_1\NNS|atypical|following
6387529
D003975_D016584 NONE diazepam_3\NN| (r_pobj) of_2\IN|diazepam (r_prep) effects_1\NNS|behavioral|of|and|propranolol|. (l_conj) propranolol_5\NN|in (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|with (l_prep) with_8\IN|disorder (l_pobj) disorder_10\NN|panic|and|agoraphobia
D003975_D016584 NONE diazepam_6\NN| (r_pobj) of_5\IN|diazepam (r_prep) doses_4\NNS|oral|of|(|dose|and (r_pobj) of_2\IN|doses (r_prep) effects_1\NNS|the|of (r_nsubj) propranolol_27\NN|effects|dose (r_advcl) investigated_58\VBN|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN|a|median|of|for|)|on (l_prep) on_47\IN|performance (l_pobj) performance_49\NN|psychological|of (l_prep) of_50\IN|patients (l_pobj) patients_51\NNS|with (l_prep) with_52\IN|disorders (l_pobj) disorders_54\NNS|panic|and|agoraphobia
D003975_D000379 NONE diazepam_3\NN| (r_pobj) of_2\IN|diazepam (r_prep) effects_1\NNS|behavioral|of|and|propranolol|. (l_conj) propranolol_5\NN|in (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|with (l_prep) with_8\IN|disorder (l_pobj) disorder_10\NN|panic|and|agoraphobia (l_conj) agoraphobia_12\NNP|
D003975_D000379 NONE diazepam_6\NN| (r_pobj) of_5\IN|diazepam (r_prep) doses_4\NNS|oral|of|(|dose|and (r_pobj) of_2\IN|doses (r_prep) effects_1\NNS|the|of (r_nsubj) propranolol_27\NN|effects|dose (r_advcl) investigated_58\VBN|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN|a|median|of|for|)|on (l_prep) on_47\IN|performance (l_pobj) performance_49\NN|psychological|of (l_prep) of_50\IN|patients (l_pobj) patients_51\NNS|with (l_prep) with_52\IN|disorders (l_pobj) disorders_54\NNS|panic|and|agoraphobia (l_conj) agoraphobia_56\NNP|
D011433_D016584 NONE propranolol_5\NN|in (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|with (l_prep) with_8\IN|disorder (l_pobj) disorder_10\NN|panic|and|agoraphobia
D011433_D016584 NONE propranolol_27\NN|effects|dose (r_advcl) investigated_58\VBN|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN|a|median|of|for|)|on (l_prep) on_47\IN|performance (l_pobj) performance_49\NN|psychological|of (l_prep) of_50\IN|patients (l_pobj) patients_51\NNS|with (l_prep) with_52\IN|disorders (l_pobj) disorders_54\NNS|panic|and|agoraphobia
D011433_D000379 NONE propranolol_5\NN|in (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|with (l_prep) with_8\IN|disorder (l_pobj) disorder_10\NN|panic|and|agoraphobia (l_conj) agoraphobia_12\NNP|
D011433_D000379 NONE propranolol_27\NN|effects|dose (r_advcl) investigated_58\VBN|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN|a|median|of|for|)|on (l_prep) on_47\IN|performance (l_pobj) performance_49\NN|psychological|of (l_prep) of_50\IN|patients (l_pobj) patients_51\NNS|with (l_prep) with_52\IN|disorders (l_pobj) disorders_54\NNS|panic|and|agoraphobia (l_conj) agoraphobia_56\NNP|
D003975_D008569 CID diazepam_12\NN|propranolol (r_pobj) for_11\IN|diazepam (r_prep) greater_10\JJR|for (r_acomp) was_9\VBD|decrease|greater|. (r_conj) impaired_2\VBD|drugs|recall|but|was (l_dobj) recall_5\NN|immediate|free
D011433_D008569 CID propranolol_14\NN|than (r_advcl) diazepam_12\NN|propranolol (r_pobj) for_11\IN|diazepam (r_prep) greater_10\JJR|for (r_acomp) was_9\VBD|decrease|greater|. (r_conj) impaired_2\VBD|drugs|recall|but|was (l_dobj) recall_5\NN|immediate|free
9034419
C047426_D012640 CID venlafaxine_4\NNP| (r_amod) overdose_5\NN|a|venlafaxine (r_pobj) from_2\IN|overdose (r_prep) resulting_1\VBG|from (r_acl) Seizure_0\NN|resulting|.
C047426_D012640 CID venlafaxine_5\NNP|26 (r_pobj) of_3\IN|venlafaxine (r_prep) ingestion_2\NN|the|of|tablets (r_pobj) After_0\IN|ingestion (r_prep) experienced_11\VBD|after|,|patient|seizure|. (l_dobj) seizure_15\NN|a|witnessed|generalized
C047426_D012640 CID venlafaxine_11\NNP| (r_amod) overdose_12\NN|venlafaxine (r_pobj) of_10\IN|overdose (r_prep) case_9\NN|the|first|reported|of|resulted (l_relcl) resulted_14\VBD|that|in (l_prep) in_15\IN|seizure (l_pobj) seizure_18\NN|a|generalized
C047426_D012640 CID venlafaxine_1\NNP| (r_amod) overdose_2\NN|the|venlafaxine|in (r_nsubj) resulted_6\VBD|overdose|in|but|elicited|. (l_prep) in_7\IN|episode (l_pobj) episode_10\NN|a|single|of (l_prep) of_11\IN|seizure (l_pobj) seizure_13\NN|generalized
C047426_D062787 CID venlafaxine_4\NNP| (r_amod) overdose_5\NN|a|venlafaxine
C047426_D062787 CID venlafaxine_5\NNP| (r_amod) overdose_6\NN|venlafaxine
C047426_D062787 CID venlafaxine_12\NN| (r_pobj) of_11\IN|venlafaxine (r_prep) overdose_10\NN|an|of
C047426_D062787 CID venlafaxine_11\NNP| (r_amod) overdose_12\NN|venlafaxine
C047426_D062787 CID venlafaxine_1\NNP| (r_amod) overdose_2\NN|the|venlafaxine|in
C047426_D003865 NONE venlafaxine_12\NN| (r_pobj) of_11\IN|venlafaxine (r_prep) overdose_10\NN|an|of (r_dobj) took_8\VBD|woman|overdose|in|. (l_nsubj) woman_4\NN|a|old|with (l_prep) with_5\IN|depression (l_pobj) depression_7\NN|major
14976857
D011405_-1 NONE propafenone_9\NN| (r_compound) overdose_10\NN|propafenone|in (r_pobj) by_8\IN|overdose (r_agent) induced_7\VBN|by (r_acl) syndrome_6\NN|transient|like|induced|.
D011405_D062787 NONE propafenone_9\NN| (r_compound) overdose_10\NN|propafenone|in
D011405_D062787 NONE propafenone_26\NN| (r_compound) overdose_27\NN|a|propafenone
D011405_D004437 NONE propafenone_9\NN| (r_compound) overdose_10\NN|propafenone|in (l_prep) in_11\IN|woman (l_pobj) woman_14\NN|a|young|with (l_prep) with_15\IN|anomaly (l_pobj) anomaly_18\NN|ebstein
D011405_D054092 NONE propafenone_26\NN| (r_compound) overdose_27\NN|a|propafenone (r_pobj) by_24\IN|overdose (r_agent) precipitated_23\VBN|was|probably|by (r_conj) occurred_9\VBD|shunt|in|,|and|precipitated|. (l_nsubj) shunt_1\NN|this|of|via (l_prep) via_4\IN|ovale (l_pobj) ovale_8\NN|a|foramen
9522143
D011318_D034381 CID prilocaine_2\NN| (r_dobj) given_1\VBN|prilocaine (r_acl) Patients_0\NNS|given|p (r_nsubj) were_3\VBD|patients|likely|. (l_acomp) likely_5\JJ|more|develop (l_xcomp) develop_7\VB|to|hearing (l_xcomp) hearing_8\VBG|loss (l_dobj) loss_9\NN|10|than
D011318_D034381 CID prilocaine_12\NN|and|db (r_pobj) after_11\IN|prilocaine (r_prep) was_7\VBD|loss|db|after|. (l_nsubj) loss_3\NN|the|average|hearing|for
D002045_D034381 CID bupivacaine_19\NN|those|given|4 (r_pobj) than_16\IN|bupivacaine (r_prep) loss_9\NN|10|than
D002045_D034381 CID bupivacaine_17\NN| (r_pobj) after_16\IN|bupivacaine (r_prep) dB_15\NN|15|after (r_conj) prilocaine_12\NN|and|db (r_pobj) after_11\IN|prilocaine (r_prep) was_7\VBD|loss|db|after|. (l_nsubj) loss_3\NN|the|average|hearing|for
1835291
D009241_D029424 NONE bromide_5\NN|ipratropium|and|theophylline (r_pobj) of_3\IN|bromide (r_prep) effects_2\NNS|acute|bronchodilating|of|in|. (l_prep) in_8\IN|disease (l_pobj) disease_12\NN|chronic|obstructive|pulmonary
D009241_D029424 NONE bromide_9\NN| (r_compound) aerosol_10\NN|ipratropium|bromide|(|micrograms|)|and|tablets (r_pobj) of_7\IN|aerosol (r_prep) dose_6\NN|a|single|of|titrated (r_pobj) of_3\IN|dose (r_prep) effects_2\NNS|the|bronchodilator|of (r_nsubjpass) compared_37\VBN|effects|were|in|. (l_prep) in_38\IN|study (l_pobj) study_48\NN|a|blind|,|controlled|crossover|in (l_prep) in_49\IN|patients (l_pobj) patients_51\NNS|21|with (l_prep) with_52\IN|disease (l_pobj) disease_58\NN|stable|,|chronic|obstructive|pulmonary
D009241_D029424 NONE ipratropium_4\NN| (r_nsubj) is_5\VBZ|that|ipratropium|bronchodilator|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|obstruction (l_pobj) obstruction_18\NN|chronic|airflow
D013806_D029424 NONE theophylline_7\NN| (r_conj) bromide_5\NN|ipratropium|and|theophylline (r_pobj) of_3\IN|bromide (r_prep) effects_2\NNS|acute|bronchodilating|of|in|. (l_prep) in_8\IN|disease (l_pobj) disease_12\NN|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_19\NN| (r_amod) tablets_20\NNS|acting|theophylline (r_conj) aerosol_10\NN|ipratropium|bromide|(|micrograms|)|and|tablets (r_pobj) of_7\IN|aerosol (r_prep) dose_6\NN|a|single|of|titrated (r_pobj) of_3\IN|dose (r_prep) effects_2\NNS|the|bronchodilator|of (r_nsubjpass) compared_37\VBN|effects|were|in|. (l_prep) in_38\IN|study (l_pobj) study_48\NN|a|blind|,|controlled|crossover|in (l_prep) in_49\IN|patients (l_pobj) patients_51\NNS|21|with (l_prep) with_52\IN|disease (l_pobj) disease_58\NN|stable|,|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_12\NN|oral (r_pobj) than_10\IN|theophylline (r_prep) bronchodilator_9\NN|a|potent|than (r_attr) is_5\VBZ|that|ipratropium|bronchodilator|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|obstruction (l_pobj) obstruction_18\NN|chronic|airflow
D013806_D002318 CID theophylline_9\JJ| (r_amod) use_10\NN|theophylline (r_pobj) after_8\IN|use (r_prep) experienced_7\VBN|after (r_acl) those_6\DT|experienced (r_nsubj) involve_12\VB|were|,|those|did|systems|. (l_dobj) systems_17\NNS|the|cardiovascular
D013806_D005767 CID theophylline_9\JJ| (r_amod) use_10\NN|theophylline (r_pobj) after_8\IN|use (r_prep) experienced_7\VBN|after (r_acl) those_6\DT|experienced (r_nsubj) involve_12\VB|were|,|those|did|systems|. (l_dobj) systems_17\NNS|the|cardiovascular
6287825
D013831_D010523 CID thiamine_7\NN|and|riboflavin (r_pobj) of_6\IN|thiamine (r_prep) deficiency_5\NN|nutritional|of (r_pobj) due_2\IN|to|deficiency (r_prep) neuropathy_1\NNS|peripheral|due
D013831_D010523 CID thiamine_7\NN|and|riboflavin (r_pobj) of_6\IN|thiamine (r_prep) deficiency_5\NN|nutritional|of (r_pobj) due_2\IN|to|deficiency (r_prep) neuropathy_1\NNS|peripheral|due (r_nsubj) was_10\VBD|neuropathy|common|%|and|presented|. (l_conj) presented_17\VBN|as (l_prep) as_19\IN|mainly|neuropathy (l_pobj) neuropathy_25\NN|sensory
D013831_D044342 NONE thiamine_7\NN|and|riboflavin (r_pobj) of_6\IN|thiamine (r_prep) deficiency_5\NN|nutritional|of
D012256_D010523 CID riboflavin_9\NN| (r_conj) thiamine_7\NN|and|riboflavin (r_pobj) of_6\IN|thiamine (r_prep) deficiency_5\NN|nutritional|of (r_pobj) due_2\IN|to|deficiency (r_prep) neuropathy_1\NNS|peripheral|due
D012256_D010523 CID riboflavin_9\NN| (r_conj) thiamine_7\NN|and|riboflavin (r_pobj) of_6\IN|thiamine (r_prep) deficiency_5\NN|nutritional|of (r_pobj) due_2\IN|to|deficiency (r_prep) neuropathy_1\NNS|peripheral|due (r_nsubj) was_10\VBD|neuropathy|common|%|and|presented|. (l_conj) presented_17\VBN|as (l_prep) as_19\IN|mainly|neuropathy (l_pobj) neuropathy_25\NN|sensory
D012256_D044342 NONE riboflavin_9\NN| (r_conj) thiamine_7\NN|and|riboflavin (r_pobj) of_6\IN|thiamine (r_prep) deficiency_5\NN|nutritional|of
D007538_D009422 NONE Isoniazid_0\NNP| (r_nsubj) was_1\VBD|isoniazid|agent|. (l_attr) agent_5\NN|the|frequent|in (l_prep) in_6\IN|neuropathy (l_pobj) neuropathy_10\NN|induced
19269743
D002211_D010146 CID capsaicin_9\NN| (r_npadvmod) induced_11\VBN|capsaicin|- (r_amod) pain_12\NN|induced
D002211_D010146 CID capsaicin_21\NN| (r_pobj) of_20\IN|capsaicin (r_prep) doses_19\NNS|three|of|microg (r_pobj) of_17\IN|doses (r_prep) injections_16\NNS|intradermal|of|separated (r_dobj) received_14\VBD|in|,|volunteers|injections|)|,|given|. (l_prep) In_0\IN|order (l_pobj) order_1\NN|address (l_acl) address_3\VB|to|memory (l_dobj) memory_8\NN|term|pain (l_compound) pain_7\NN|
D002211_D010146 CID capsaicin_11\NN| (r_compound) doses_12\NNS|capsaicin|(|p<0.001|) (r_pobj) across_10\IN|doses (r_prep) discriminate_5\VB|to|reliably|magnitude|across|,|regardless (l_dobj) magnitude_7\NN|pain|and|duration (l_compound) pain_6\NN|
15130900
D003520_D001749 CID cyclophosphamide_12\NN| (r_pobj) to_11\IN|cyclophosphamide (r_prep) risks_8\NNS|and|relation|to (r_appos) granulomatosis_6\NN|wegener|:|risks (r_pobj) in_3\IN|granulomatosis (r_prep) cancer_2\NN|urinary|bladder|in|.
D003520_D001749 CID cyclophosphamide_16\NN| (r_pobj) to_15\IN|cyclophosphamide (r_prep) relation_14\NN|its|to|,|in (r_conj) assess_3\VB|to|and|characterise|,|and|relation (l_conj) characterise_5\VB|risk (l_dobj) risk_7\NN|the|of (l_prep) of_8\IN|cancer (l_pobj) cancer_10\NN|bladder
D003520_D001749 CID cyclophosphamide_18\NN|and|cancer (l_conj) cancer_21\NN|bladder
D003520_D001749 CID cyclophosphamide_12\NN| (r_pobj) in_11\IN|cyclophosphamide (r_prep) increment_10\NN|every|10|g|in|(|or (r_pobj) for_6\IN|increment (r_prep) doubled_5\VBD|risk|for|. (l_nsubj) risk_1\NN|the|of (l_prep) of_2\IN|cancer (l_pobj) cancer_4\NN|bladder
D003520_D001749 CID cyclophosphamide_9\NN| (r_pobj) between_8\IN|cyclophosphamide (r_prep) relationship_7\NN|a|response|between|and|risk (l_conj) risk_12\NN|the|of|,|risks (l_prep) of_13\IN|cancer (l_pobj) cancer_15\NN|bladder
D003520_D014890 NONE cyclophosphamide_12\NN| (r_pobj) to_11\IN|cyclophosphamide (r_prep) risks_8\NNS|and|relation|to (r_appos) granulomatosis_6\NN|wegener|:|risks
D003520_D014890 NONE cyclophosphamide_16\NN| (r_pobj) to_15\IN|cyclophosphamide (r_prep) relation_14\NN|its|to|,|in (l_prep) in_18\IN|patients (l_pobj) patients_19\NNS|with (l_prep) with_20\IN|granulomatosis (l_pobj) granulomatosis_23\NN|wegener
D003520_D014890 NONE cyclophosphamide_9\NN| (r_pobj) between_8\IN|cyclophosphamide (r_prep) relationship_7\NN|a|response|between|and|risk (l_conj) risk_12\NN|the|of|,|risks (l_conj) risks_19\NNS|high|cumulative|in|,|and|possibility (l_conj) possibility_28\NN|the|of (l_prep) of_29\IN|factors (l_pobj) factors_31\NNS|risk|operating (l_acl) operating_32\VBG|before (l_prep) before_34\IN|even|granulomatosis (l_pobj) granulomatosis_37\NN|wegener
17612891
D003024_D009205 CID clozapine_4\NN| (r_pobj) with_3\IN|clozapine (r_prep) associated_2\VBN|with (r_acl) myocarditis_1\NN|acute|associated|.
D003024_D009205 CID clozapine_10\NN| (r_pobj) of_9\IN|clozapine (r_prep) commencement_8\NN|the|of (r_pobj) with_6\IN|commencement (r_prep) associated_5\VBN|with (r_acl) case_1\NN|a|of|associated (l_prep) of_2\IN|myocarditis (l_pobj) myocarditis_4\NN|acute
D003024_D009205 CID clozapine_16\NN| (r_pobj) of_15\IN|clozapine (r_prep) commencement_14\NN|of (r_pobj) after_13\IN|commencement (r_prep) developed_7\VBD|male|onset|after|. (l_dobj) onset_10\NN|a|sudden|of (l_prep) of_11\IN|myocarditis (l_pobj) myocarditis_12\NN|
D003024_D009205 CID clozapine_11\NN| (r_pobj) of_10\IN|clozapine (r_prep) use_9\NN|the|of (r_pobj) with_7\IN|use (r_prep) associated_6\VBN|with (r_acl) complication_5\NN|an|recognized|associated (r_attr) is_1\VBZ|myocarditis|complication|. (l_nsubj) Myocarditis_0\NNP|
D003024_D012559 NONE clozapine_16\NN| (r_pobj) of_15\IN|clozapine (r_prep) commencement_14\NN|of (r_pobj) after_13\IN|commencement (r_prep) developed_7\VBD|male|onset|after|. (l_nsubj) male_4\NN|a|old|with (l_prep) with_5\IN|schizophrenia (l_pobj) schizophrenia_6\NN|
D003024_D011618 NONE clozapine_2\NN|that (r_pobj) Considering_0\VBG|clozapine (r_csubj) remains_3\VBZ|considering|standard (l_attr) standard_6\NN|the|gold|in (l_prep) in_7\IN|treatment (l_pobj) treatment_8\NN|of (l_prep) of_9\IN|psychosis (l_pobj) psychosis_11\NN|resistant
1428568
D013999_D005901 NONE timolol_6\NN| (r_compound) 0.5%/12h_7\CD|timolol (r_pobj) with_5\IN|0.5%/12h (r_prep) treated_4\VBN|patients|chronically|with|,|suffering (l_nsubj) patients_2\NNS|eight|glaucomatous (l_amod) glaucomatous_1\JJ|
D013999_D003866 CID timolol_6\NN| (r_compound) 0.5%/12h_7\CD|timolol (r_pobj) with_5\IN|0.5%/12h (r_prep) treated_4\VBN|patients|chronically|with|,|suffering (l_advcl) suffering_9\VBG|from|diagnosed (l_prep) from_10\IN|depression (l_pobj) depression_11\NN|
D013999_D003866 CID timolol_15\NN| (r_compound) treatment_16\NN|timolol (r_pobj) under_14\IN|treatment (r_prep) patients_13\NNS|the|under (r_nsubj) presented_17\VBD|in|,|patients|values|. (l_dobj) values_20\NNS|higher|depression|measured|0.001 (l_compound) depression_19\NN|
D013999_D003866 CID timolol_14\NN|in (r_pobj) than_13\IN|timolol (r_prep) less_7\JJR|of|than (l_prep) of_8\IN|inducer (l_pobj) inducer_12\NN|a|depression|- (l_compound) depression_10\NN|
D015784_D003866 NONE betaxolol_4\NN| (r_nsubj) be_6\VB|that|betaxolol|could|less (l_attr) less_7\JJR|of|than (l_prep) of_8\IN|inducer (l_pobj) inducer_12\NN|a|depression|- (l_compound) depression_10\NN|
10721819
D007545_D013610 NONE isoproterenol_7\NN|on (l_prep) on_8\IN|tachycardia (l_pobj) tachycardia_12\NN|induced
D007545_D013610 NONE isoproterenol_10\NN| (r_pobj) with_9\IN|isoproterenol (r_prep) pretreatment_8\NN|prolonged|with (r_nsubj) abolish_12\VB|whether|pretreatment|could|tachycardia|in (l_dobj) tachycardia_16\NN|induced
D007545_D013610 NONE isoproterenol_7\JJ| (r_compound) pretreatment_8\NN|isoproterenol (r_pobj) by_6\IN|pretreatment (r_prep) unaffected_5\JJ|by (r_acomp) was_4\VBD|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN|while|tachycardia|was|to|,|effect (l_nsubjpass) tachycardia_11\NN|
D007545_D013610 NONE isoproterenol_5\JJ| (r_compound) pretreatment_6\NN|15-day|isoproterenol (r_nsubj) abolished_9\VBD|that|pretreatment|not|but|reversed (l_conj) reversed_11\VBD|tachycardia|to|,|effect (l_dobj) tachycardia_15\NN|induced
D001971_D013610 CID bromocriptine_9\NN| (r_npadvmod) induced_11\VBN|bromocriptine|- (r_amod) tachycardia_12\NN|induced
D001971_D013610 CID bromocriptine_5\NN| (r_npadvmod) induced_7\VBN|bromocriptine|- (r_amod) tachycardia_8\NN|induced|,|persisted|,
D001971_D013610 CID bromocriptine_13\NN| (r_npadvmod) induced_15\VBN|bromocriptine|- (r_amod) tachycardia_16\NN|induced
D001971_D013610 CID bromocriptine_5\NN|intravenous|(|kg|) (r_nsubj) induced_12\VBD|in|,|bromocriptine|hypotension|. (l_dobj) hypotension_14\NN|significant|and|tachycardia (l_conj) tachycardia_16\NN|
D001971_D013610 CID Bromocriptine_0\NNP| (r_npadvmod) induced_2\VBN|bromocriptine|- (r_amod) hypotension_3\NN|induced (r_nsubj) was_4\VBD|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN|while|tachycardia|was|to|,|effect (l_nsubjpass) tachycardia_11\NN|
D001971_D013610 CID bromocriptine_12\NN| (r_npadvmod) induced_14\VBN|bromocriptine|- (r_amod) tachycardia_15\NN|induced
D001971_D013610 CID bromocriptine_13\NN| (r_pobj) of_12\IN|bromocriptine (r_prep) tachycardia_11\NN|the|central|of
D007545_D006332 CID Isoproterenol_0\JJ| (r_compound) pretreatment_1\NN|isoproterenol|for (r_nsubj) caused_5\VBD|pretreatment|hypertrophy|without|. (l_dobj) hypertrophy_7\NN|cardiac
D001971_D007022 CID bromocriptine_5\NN|intravenous|(|kg|) (r_nsubj) induced_12\VBD|in|,|bromocriptine|hypotension|. (l_dobj) hypotension_14\NN|significant|and|tachycardia
D001971_D007022 CID Bromocriptine_0\NNP| (r_npadvmod) induced_2\VBN|bromocriptine|- (r_amod) hypotension_3\NN|induced
D001971_D001919 NONE Bromocriptine_0\NNP| (r_npadvmod) induced_2\VBN|bromocriptine|- (r_amod) hypotension_3\NN|induced (r_nsubj) was_4\VBD|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN|while|tachycardia|was|to|,|effect (l_prep) to_14\IN|bradycardia (l_pobj) bradycardia_16\NNS|significant
D001971_D001919 NONE bromocriptine_12\NN| (r_npadvmod) induced_14\VBN|bromocriptine|- (r_amod) tachycardia_15\NN|induced (r_dobj) reversed_11\VBD|tachycardia|to|,|effect (l_prep) to_16\IN|bradycardia (l_pobj) bradycardia_17\NNP|
D001971_D001919 NONE bromocriptine_13\NN| (r_pobj) of_12\IN|bromocriptine (r_prep) tachycardia_11\NN|the|central|of (r_nsubj) appears_14\VBZ|that|,|in|,|tachycardia|predominate (l_xcomp) predominate_16\VB|to|and|mask (l_conj) mask_19\VB|to|bradycardia (l_dobj) bradycardia_21\NN|the|of|at
D007545_D007022 NONE isoproterenol_7\JJ| (r_compound) pretreatment_8\NN|isoproterenol (r_pobj) by_6\IN|pretreatment (r_prep) unaffected_5\JJ|by (r_acomp) was_4\VBD|hypotension|unaffected|,|reversed|. (l_nsubj) hypotension_3\NN|induced
D007545_D001919 CID isoproterenol_7\JJ| (r_compound) pretreatment_8\NN|isoproterenol (r_pobj) by_6\IN|pretreatment (r_prep) unaffected_5\JJ|by (r_acomp) was_4\VBD|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN|while|tachycardia|was|to|,|effect (l_prep) to_14\IN|bradycardia (l_pobj) bradycardia_16\NNS|significant
D007545_D001919 CID isoproterenol_5\JJ| (r_compound) pretreatment_6\NN|15-day|isoproterenol (r_nsubj) abolished_9\VBD|that|pretreatment|not|but|reversed (l_conj) reversed_11\VBD|tachycardia|to|,|effect (l_prep) to_16\IN|bradycardia (l_pobj) bradycardia_17\NNP|
D004294_D007022 NONE domperidone_26\NN|i.v. (r_pobj) by_24\IN|domperidone (r_agent) reduced_23\VBN|that|was|partly|by (r_relcl) effect_19\NN|an|reduced|mg/kg|) (r_npadvmod) reversed_13\VBN|while|tachycardia|was|to|,|effect (r_advcl) was_4\VBD|hypotension|unaffected|,|reversed|. (l_nsubj) hypotension_3\NN|induced
D004294_D013610 NONE domperidone_26\NN|i.v. (r_pobj) by_24\IN|domperidone (r_agent) reduced_23\VBN|that|was|partly|by (r_relcl) effect_19\NN|an|reduced|mg/kg|) (r_npadvmod) reversed_13\VBN|while|tachycardia|was|to|,|effect (l_nsubjpass) tachycardia_11\NN|
D004294_D001919 CID domperidone_26\NN|i.v. (r_pobj) by_24\IN|domperidone (r_agent) reduced_23\VBN|that|was|partly|by (r_relcl) effect_19\NN|an|reduced|mg/kg|) (r_npadvmod) reversed_13\VBN|while|tachycardia|was|to|,|effect (l_prep) to_14\IN|bradycardia (l_pobj) bradycardia_16\NNS|significant
D004298_D013610 NONE dopamine_27\NN| (r_compound) D2_28\NN|dopamine (r_compound) receptors_29\NNS|peripheral|d2 (r_pobj) at_25\IN|receptors (r_prep) bradycardia_21\NN|the|of|at (r_dobj) mask_19\VB|to|bradycardia (r_conj) predominate_16\VB|to|and|mask (r_xcomp) appears_14\VBZ|that|,|in|,|tachycardia|predominate (l_nsubj) tachycardia_11\NN|the|central|of
D004298_D001919 NONE dopamine_27\NN| (r_compound) D2_28\NN|dopamine (r_compound) receptors_29\NNS|peripheral|d2 (r_pobj) at_25\IN|receptors (r_prep) bradycardia_21\NN|the|of|at
17854040
D019259_D006509 NONE lamivudine_3\NN| (r_compound) resistance_5\NN|lamivudine|-|in (r_pobj) with_2\IN|resistance (r_prep) associated_1\VBN|with (r_acl) Mutations_0\NNS|associated (r_nsubj) ve_10\VB|mutations|na|virus|. (l_dobj) virus_13\NN|b|(|hbv|)|patients (l_appos) patients_18\NNS|infected|with (l_amod) infected_17\JJ|
D019259_D006509 NONE lamivudine_3\NN| (r_compound) resistance_5\NN|lamivudine|-|in (r_pobj) with_2\IN|resistance (r_prep) associated_1\VBN|with (r_acl) Mutations_0\NNS|associated (r_nsubj) ve_10\VB|mutations|na|virus|. (l_dobj) virus_13\NN|b|(|hbv|)|patients (l_appos) patients_18\NNS|infected|with (l_prep) with_19\IN|and|without (l_conj) without_21\IN|implications (l_pobj) implications_27\NNS|:|for|patients (l_conj) patients_40\NNS|infected|african (l_amod) infected_37\VBN|-
D019259_D006509 NONE lamivudine_7\JJ| (r_npadvmod) resistant_9\JJ|lamivudine|- (r_amod) virus_12\NN|resistant|b (l_compound) B_11\NN|hepatitis
D019259_D006509 NONE lamivudine_19\NN| (r_compound) na_21\NN|selected|lamivudine|- (r_aux) ve_22\VB|na|carriers|with (r_acl) study_4\NN|an|exploratory|investigate|strains|ve (l_acl) investigate_6\VB|to|virus (l_dobj) virus_12\NN|resistant|b (l_compound) B_11\NN|hepatitis
D019259_D006509 NONE lamivudine_1\NN| (r_npadvmod) resistant_3\JJ|lamivudine|- (r_amod) strains_4\NNS|hbv|resistant (r_nsubjpass) detected_6\VBN|strains|were|in|and|patients|. (l_prep) in_7\IN|patients (l_pobj) patients_17\NNS|15|infected|chronic|b (l_compound) B_16\NNP|hepatitis
D019259_D006509 NONE lamivudine_1\NN| (r_npadvmod) resistant_3\JJ|lamivudine|- (r_amod) strains_4\NNS|hbv|resistant (r_nsubjpass) detected_6\VBN|strains|were|in|and|patients|. (l_conj) patients_28\NNS|20|infected (l_amod) infected_27\VBN|hiv|-
D019259_D006509 NONE lamivudine_14\NN| (r_npadvmod) resistant_16\JJ|lamivudine|- (r_amod) strains_17\NNS|hbv|resistant|in (l_prep) in_18\IN|ve (l_pcomp) ve_22\VB|na|patients (l_dobj) patients_29\NNS|infected (l_amod) infected_28\VBN|hiv|-
D019259_D006509 NONE lamivudine_22\NN| (r_npadvmod) containing_24\VBG|when|lamivudine|-|treatment (r_advcl) emergence_16\NN|widespread|of|containing (r_pobj) in_14\IN|emergence (r_prep) result_13\VB|whether|mutations|could|in|applied (l_conj) applied_38\VBN|regimens|become|widely|in|,|is (l_advcl) is_45\VBZ|as|this|likely (l_acomp) likely_46\JJ|have (l_xcomp) have_48\VB|to|implications (l_dobj) implications_50\NNS|potential|in (l_prep) in_51\IN|management (l_pobj) management_53\NN|the|of (l_prep) of_54\IN|patients (l_pobj) patients_61\NNS|infected (l_amod) infected_60\VBN|hiv|-
D019259_D015658 NONE lamivudine_3\NN| (r_compound) resistance_5\NN|lamivudine|-|in (r_pobj) with_2\IN|resistance (r_prep) associated_1\VBN|with (r_acl) Mutations_0\NNS|associated (r_nsubj) ve_10\VB|mutations|na|virus|. (l_dobj) virus_13\NN|b|(|hbv|)|patients (l_appos) patients_18\NNS|infected|with (l_prep) with_19\IN|and|without (l_conj) without_21\IN|implications (l_pobj) implications_27\NNS|:|for|patients (l_punct) :_26\:|infection (l_punct) infection_25\NN|hiv|-
D019259_D015658 NONE lamivudine_3\NN| (r_compound) resistance_5\NN|lamivudine|-|in (r_pobj) with_2\IN|resistance (r_prep) associated_1\VBN|with (r_acl) Mutations_0\NNS|associated (r_nsubj) ve_10\VB|mutations|na|virus|. (l_dobj) virus_13\NN|b|(|hbv|)|patients (l_appos) patients_18\NNS|infected|with (l_prep) with_19\IN|and|without (l_conj) without_21\IN|implications (l_pobj) implications_27\NNS|:|for|patients (l_conj) patients_40\NNS|infected|african (l_amod) infected_37\VBN|-
D019259_D015658 NONE lamivudine_7\JJ| (r_npadvmod) resistant_9\JJ|lamivudine|- (r_amod) virus_12\NN|resistant|b (r_dobj) investigate_6\VB|to|virus (r_acl) study_4\NN|an|exploratory|investigate|strains|ve (r_attr) was_1\VBD|this|study|. (l_punct) ._41\.|in (l_punct) in_37\IN|infection|patients (l_punct) infection_36\NN|-
D019259_D015658 NONE lamivudine_19\NN| (r_compound) na_21\NN|selected|lamivudine|- (r_aux) ve_22\VB|na|carriers|with (r_acl) study_4\NN|an|exploratory|investigate|strains|ve (r_attr) was_1\VBD|this|study|. (l_punct) ._41\.|in (l_punct) in_37\IN|infection|patients (l_punct) infection_36\NN|-
D019259_D015658 NONE lamivudine_1\NN| (r_npadvmod) resistant_3\JJ|lamivudine|- (r_amod) strains_4\NNS|hbv|resistant (r_nsubjpass) detected_6\VBN|strains|were|in|and|patients|. (l_conj) patients_28\NNS|20|infected (l_amod) infected_27\VBN|hiv|-
D019259_D015658 NONE lamivudine_14\NN| (r_npadvmod) resistant_16\JJ|lamivudine|- (r_amod) strains_17\NNS|hbv|resistant|in (l_prep) in_18\IN|ve (l_pcomp) ve_22\VB|na|patients (l_dobj) patients_29\NNS|infected (l_amod) infected_28\VBN|hiv|-
D019259_D015658 NONE lamivudine_22\NN| (r_npadvmod) containing_24\VBG|when|lamivudine|-|treatment (r_advcl) emergence_16\NN|widespread|of|containing (r_pobj) in_14\IN|emergence (r_prep) result_13\VB|whether|mutations|could|in|applied (l_conj) applied_38\VBN|regimens|become|widely|in|,|is (l_advcl) is_45\VBZ|as|this|likely (l_acomp) likely_46\JJ|have (l_xcomp) have_48\VB|to|implications (l_dobj) implications_50\NNS|potential|in (l_prep) in_51\IN|management (l_pobj) management_53\NN|the|of (l_prep) of_54\IN|patients (l_pobj) patients_61\NNS|infected (l_amod) infected_60\VBN|hiv|-
D012964_D006509 NONE na_9\TO|therapy|- (r_aux) ve_10\VB|mutations|na|virus|. (l_dobj) virus_13\NN|b|(|hbv|)|patients (l_appos) patients_18\NNS|infected|with (l_amod) infected_17\JJ|
D012964_D006509 NONE na_9\TO|therapy|- (r_aux) ve_10\VB|mutations|na|virus|. (l_dobj) virus_13\NN|b|(|hbv|)|patients (l_appos) patients_18\NNS|infected|with (l_prep) with_19\IN|and|without (l_conj) without_21\IN|implications (l_pobj) implications_27\NNS|:|for|patients (l_conj) patients_40\NNS|infected|african (l_amod) infected_37\VBN|-
D012964_D006509 NONE na_21\NN|selected|lamivudine|- (r_aux) ve_22\VB|na|carriers|with (r_acl) study_4\NN|an|exploratory|investigate|strains|ve (l_acl) investigate_6\VB|to|virus (l_dobj) virus_12\NN|resistant|b (l_compound) B_11\NN|hepatitis
D012964_D006509 NONE na_21\TO|therapy|- (r_aux) ve_22\VB|na|patients (l_dobj) patients_29\NNS|infected (l_amod) infected_28\VBN|hiv|-
D012964_D015658 NONE na_9\TO|therapy|- (r_aux) ve_10\VB|mutations|na|virus|. (l_dobj) virus_13\NN|b|(|hbv|)|patients (l_appos) patients_18\NNS|infected|with (l_prep) with_19\IN|and|without (l_conj) without_21\IN|implications (l_pobj) implications_27\NNS|:|for|patients (l_punct) :_26\:|infection (l_punct) infection_25\NN|hiv|-
D012964_D015658 NONE na_9\TO|therapy|- (r_aux) ve_10\VB|mutations|na|virus|. (l_dobj) virus_13\NN|b|(|hbv|)|patients (l_appos) patients_18\NNS|infected|with (l_prep) with_19\IN|and|without (l_conj) without_21\IN|implications (l_pobj) implications_27\NNS|:|for|patients (l_conj) patients_40\NNS|infected|african (l_amod) infected_37\VBN|-
D012964_D015658 NONE na_21\NN|selected|lamivudine|- (r_aux) ve_22\VB|na|carriers|with (r_acl) study_4\NN|an|exploratory|investigate|strains|ve (r_attr) was_1\VBD|this|study|. (l_punct) ._41\.|in (l_punct) in_37\IN|infection|patients (l_punct) infection_36\NN|-
D012964_D015658 NONE na_21\TO|therapy|- (r_aux) ve_22\VB|na|patients (l_dobj) patients_29\NNS|infected (l_amod) infected_28\VBN|hiv|-
9334596
D013739_D007172 NONE testosterone_6\NN|serum|and|determination (r_pobj) of_4\IN|testosterone (r_prep) results_3\NNS|the|of|in (l_prep) in_10\IN|patients (l_pobj) patients_12\NNS|1,022|referred (l_acl) referred_13\VBD|because (l_prep) because_14\IN|of|dysfunction (l_pobj) dysfunction_17\NN|erectile
D013739_D007172 NONE testosterone_5\NN| (r_compound) levels_6\NNS|the|other|low|testosterone (r_pobj) of_1\IN|levels (r_prep) Most_0\JJS|of (r_nsubj) seemed_7\VBD|most|result|. (l_xcomp) result_9\VB|to|from|because (l_prep) because_14\IN|of|hormone|and|have (l_conj) have_24\VB|to|role (l_dobj) role_28\NN|only|a|small|in (l_prep) in_29\IN|dysfunction (l_pobj) dysfunction_31\NN|erectile|(|improvement|)
D013739_D007172 NONE testosterone_6\NN|low|and|prolactin (r_pobj) of_4\IN|testosterone (r_prep) effects_3\NNS|of|in (l_prep) in_10\IN|dysfunction (l_pobj) dysfunction_12\NN|erectile
D013739_D020018 CID testosterone_5\NN|and|451 (r_pobj) for_4\IN|testosterone (r_prep) screened_3\VBN|patient|was|for|screened|. (l_conj) screened_9\VBN|were|for|on (l_prep) on_12\IN|basis (l_pobj) basis_14\NN|the|of (l_prep) of_15\IN|desire (l_pobj) desire_18\NN|low|sexual|,|gynecomastia
D013739_D020018 CID testosterone_22\NN|ng./ml (r_conj) gynecomastia_20\NN|or|testosterone (r_conj) desire_18\NN|low|sexual|,|gynecomastia
D013739_D020018 CID testosterone_1\NN| (r_dobj) Determining_0\VBG|testosterone|in (l_prep) in_3\IN|only|cases (l_pobj) cases_4\NNS|of (l_prep) of_5\IN|desire (l_pobj) desire_8\NN|low|sexual|or|examination
D013739_D020018 CID testosterone_23\NN|low|,|including (r_pobj) with_21\IN|testosterone (r_prep) cases_20\NNS|the|with (r_pobj) of_18\IN|cases (r_prep) %_17\NN|40|of (r_dobj) missed_15\VBN|determining|would|have|%|. (l_csubj) Determining_0\VBG|testosterone|in (l_prep) in_3\IN|only|cases (l_pobj) cases_4\NNS|of (l_prep) of_5\IN|desire (l_pobj) desire_8\NN|low|sexual|or|examination
D013739_D020018 CID testosterone_8\NN|years (r_nsubjpass) determined_10\VBN|that|before|testosterone|be|in|but|measured (l_prep) in_12\IN|only|cases (l_pobj) cases_13\NNS|of (l_prep) of_14\IN|desire (l_pobj) desire_17\NN|low|sexual|and|examination
D013739_D020018 CID testosterone_14\NN|ng./ml (r_conj) gynecomastia_12\NN|and/or|testosterone (r_conj) desire_10\NN|low|sexual|,|gynecomastia
D013739_D006177 NONE testosterone_5\NN|and|451 (r_pobj) for_4\IN|testosterone (r_prep) screened_3\VBN|patient|was|for|screened|. (l_conj) screened_9\VBN|were|for|on (l_prep) on_12\IN|basis (l_pobj) basis_14\NN|the|of (l_prep) of_15\IN|desire (l_pobj) desire_18\NN|low|sexual|,|gynecomastia (l_conj) gynecomastia_20\NN|or|testosterone
D013739_D006177 NONE testosterone_22\NN|ng./ml (r_conj) gynecomastia_20\NN|or|testosterone
D013739_D006177 NONE testosterone_14\NN|ng./ml (r_conj) gynecomastia_12\NN|and/or|testosterone
C004648_D007006 NONE heptylate_5\NN|testosterone|or|gonadotropin (l_conj) gonadotropin_9\NN|human|chorionic|for (l_prep) for_10\IN|hypogonadism (l_pobj) hypogonadism_11\NN|and|bromocriptine
C004648_D006966 NONE heptylate_5\NN|testosterone|or|gonadotropin (l_conj) gonadotropin_9\NN|human|chorionic|for (l_prep) for_10\IN|hypogonadism (l_pobj) hypogonadism_11\NN|and|bromocriptine (l_conj) bromocriptine_13\NN|for (l_prep) for_14\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_15\NN|
D001971_D007006 NONE bromocriptine_13\NN|for (r_conj) hypogonadism_11\NN|and|bromocriptine
D001971_D006966 NONE bromocriptine_13\NN|for (l_prep) for_14\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_15\NN|
D013739_D010911 NONE testosterone_6\NN| (r_compound) determination_7\NN|testosterone (r_pobj) after_5\IN|determination (r_prep) discovered_4\VBN|tumors|were|after|. (l_nsubjpass) tumors_2\NNS|two|pituitary
D013739_D007027 NONE testosterone_5\NN| (r_compound) levels_6\NNS|the|other|low|testosterone (r_pobj) of_1\IN|levels (r_prep) Most_0\JJS|of (r_nsubj) seemed_7\VBD|most|result|. (l_xcomp) result_9\VB|to|from|because (l_prep) from_10\IN|dysfunction (l_pobj) dysfunction_13\NN|nonorganic|hypothalamic
1987816
D008094_D011141 CID Lithium_0\NN| (r_npadvmod) induced_2\VBN|lithium|- (r_amod) polyuria_3\NN|induced
20619828
D002997_D001008 CID Clomipramine_0\NNP| (r_compound) exposure_1\NN|clomipramine|in (r_nsubj) produced_5\VBD|exposure|changes|inflexibility|. (l_dobj) changes_10\NNS|significant|behavioral|include (l_relcl) include_12\VBP|that|anxiety (l_dobj) anxiety_14\NN|enhanced|(|elevated|)
D002997_-1 NONE Clomipramine_0\NNP| (r_compound) exposure_1\NN|clomipramine|in (r_nsubj) produced_5\VBD|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN|,|behavioral|(|perseveration|,|impairment
D002997_-1 NONE Clomipramine_0\NNP| (r_compound) exposure_1\NN|clomipramine|in (r_nsubj) produced_5\VBD|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN|,|behavioral|(|perseveration|,|impairment (l_appos) impairment_41\NN|working|memory|(|paradigm|,|hoarding (l_conj) hoarding_51\NN|,|and|dysfunction (l_conj) dysfunction_55\NN|corticostriatal
D002997_D008569 CID Clomipramine_0\NNP| (r_compound) exposure_1\NN|clomipramine|in (r_nsubj) produced_5\VBD|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN|,|behavioral|(|perseveration|,|impairment (l_appos) impairment_41\NN|working|memory|(|paradigm|,|hoarding
D002997_D060845 CID Clomipramine_0\NNP| (r_compound) exposure_1\NN|clomipramine|in (r_nsubj) produced_5\VBD|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN|,|behavioral|(|perseveration|,|impairment (l_appos) impairment_41\NN|working|memory|(|paradigm|,|hoarding (l_conj) hoarding_51\NN|,|and|dysfunction
10704919
D013629_D006461 CID tamoxifen_6\NN| (r_pobj) by_5\IN|tamoxifen (r_agent) induced_4\VBN|hemolysis|by|related|. (l_nsubj) Hemolysis_0\NNP|of
D013629_D006461 CID TAM_0\NNP| (r_nsubj) induces_1\VBZ|tam|hemolysis|. (l_dobj) hemolysis_2\NN|of
D013629_D006461 CID TAM_13\NNP|12.5|microm (r_nsubj) induces_14\VBZ|tam|hemolysis|. (r_conj) is_4\VBZ|extension|variable|,|but|induces (l_nsubj) extension_1\NN|the|of (l_prep) of_2\IN|hemolysis (l_pobj) hemolysis_3\NN|
D013629_D006461 CID TAM_13\NNP|12.5|microm (r_nsubj) induces_14\VBZ|tam|hemolysis|. (l_dobj) hemolysis_16\NN|total|of
D013629_D006461 CID TAM_4\NNP| (r_pobj) of_3\IN|tam (r_prep) effect_2\NN|the|hemolytic|of (l_amod) hemolytic_1\JJ|
D013629_D006461 CID TAM_4\NNP| (r_pobj) of_3\IN|tam (r_prep) effect_2\NN|the|hemolytic|of (r_nsubjpass) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG|related (l_ccomp) related_42\VBN|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN|induced
D013629_D006461 CID TAM_36\NNP| (r_npadvmod) induced_38\VBN|tam|- (r_amod) hemolysis_39\NN|induced (r_nsubjpass) related_42\VBN|that|hemolysis|is|not|to (r_ccomp) indicating_34\VBG|related (r_advcl) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN|the|hemolytic|of (l_amod) hemolytic_1\JJ|
D013629_D006461 CID TAM_36\NNP| (r_npadvmod) induced_38\VBN|tam|- (r_amod) hemolysis_39\NN|induced
D013629_D006461 CID TAM_17\NNP| (r_npadvmod) induced_19\VBN|tam|- (r_amod) hemolysis_20\NN|induced
D013629_D006461 CID TAM_3\NNP| (r_pobj) by_2\IN|tam (r_agent) caused_1\VBN|by (r_acl) Hemolysis_0\NNP|caused
D013629_D006461 CID TAM_3\NNP| (r_pobj) by_2\IN|tam (r_agent) caused_1\VBN|by (r_acl) Hemolysis_0\NNP|caused (r_nsubjpass) preceded_6\VBN|hemolysis|was|not|by|,|excluding|,|according|. (l_prep) excluding_18\VBG|also|mechanism (l_pobj) mechanism_24\NN|a|osmotic|type|of (l_prep) of_25\IN|hemolysis (l_pobj) hemolysis_26\NN|
D013629_D006461 CID TAM_15\NNP| (r_compound) incorporation_16\NN|a|decreased|tam|in|and (r_pobj) to_12\IN|incorporation (r_prep) related_11\VBN|that|protection|is|to (l_nsubjpass) protection_5\NN|the|from|by (l_prep) from_6\IN|hemolysis (l_pobj) hemolysis_7\NN|
D013629_D006461 CID TAM_2\NNP| (r_npadvmod) induced_4\VBN|tam|- (r_amod) results_6\NNS|therefore|,|induced|hemolysis|from|,|leading|. (l_compound) hemolysis_5\NN|
D013629_D001943 NONE Tamoxifen_0\NNP|tam|, (r_nsubj) induces_18\VBZ|tamoxifen|drug|,|changes|. (l_nsubj) drug_7\NN|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN|widely|in (l_prep) in_11\IN|chemotherapy (l_pobj) chemotherapy_13\NN|the|of (l_prep) of_14\IN|cancer (l_pobj) cancer_16\NN|breast
D013629_D001943 NONE TAM_2\NNP|(|) (r_appos) Tamoxifen_0\NNP|tam|, (r_nsubj) induces_18\VBZ|tamoxifen|drug|,|changes|. (l_nsubj) drug_7\NN|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN|widely|in (l_prep) in_11\IN|chemotherapy (l_pobj) chemotherapy_13\NN|the|of (l_prep) of_14\IN|cancer (l_pobj) cancer_16\NN|breast
D013629_D000743 CID Tamoxifen_0\NNP|tam|, (r_nsubj) induces_18\VBZ|tamoxifen|drug|,|changes|. (l_dobj) changes_19\NNS|in (l_prep) in_20\IN|shape (l_pobj) shape_23\NN|normal|discoid|of (l_prep) of_24\IN|erythrocytes (l_pobj) erythrocytes_25\NNS|and|anemia (l_conj) anemia_28\NN|hemolytic
D013629_D000743 CID TAM_2\NNP|(|) (r_appos) Tamoxifen_0\NNP|tam|, (r_nsubj) induces_18\VBZ|tamoxifen|drug|,|changes|. (l_dobj) changes_19\NNS|in (l_prep) in_20\IN|shape (l_pobj) shape_23\NN|normal|discoid|of (l_prep) of_24\IN|erythrocytes (l_pobj) erythrocytes_25\NNS|and|anemia (l_conj) anemia_28\NN|hemolytic
D013629_D000743 CID TAM_6\NNP| (r_pobj) of_5\IN|tam (r_prep) effects_4\NNS|the|of|on (r_dobj) evaluates_2\VBZ|work|effects|,|attempting|. (l_advcl) attempting_12\VBG|identify (l_xcomp) identify_14\VB|to|mechanisms (l_dobj) mechanisms_17\NNS|the|underlying|on|and|involvement (l_prep) on_18\IN|anemia (l_pobj) anemia_23\NN|induced|hemolytic
D013629_D000743 CID TAM_19\NNP| (r_npadvmod) induced_21\VBN|tam|- (r_amod) anemia_23\NN|induced|hemolytic
D013629_D000743 CID TAM_13\NNP| (r_pobj) by_12\IN|tam (r_agent) promoted_11\VBN|by (r_acl) stability_10\NN|mechanical|promoted (r_dobj) decreased_8\VBD|stability|,|resulting (l_conj) resulting_15\VBG|in (l_prep) in_16\IN|anemia (l_pobj) anemia_18\NN|hemolytic
D024502_D006461 NONE tocopherol_13\NN|alpha|-|(|t|) (r_pobj) of_10\IN|tocopherol (r_prep) concentrations_9\NNS|low|of|and|acetate (r_pobj) by_7\IN|concentrations (r_agent) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN|the|hemolytic|of (l_amod) hemolytic_1\JJ|
D024502_D006461 NONE tocopherol_13\NN|alpha|-|(|t|) (r_pobj) of_10\IN|tocopherol (r_prep) concentrations_9\NNS|low|of|and|acetate (r_pobj) by_7\IN|concentrations (r_agent) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG|related (l_ccomp) related_42\VBN|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN|induced
D024502_D006461 NONE T_17\NNP|alpha|- (r_appos) tocopherol_13\NN|alpha|-|(|t|) (r_pobj) of_10\IN|tocopherol (r_prep) concentrations_9\NNS|low|of|and|acetate (r_pobj) by_7\IN|concentrations (r_agent) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN|the|hemolytic|of (l_amod) hemolytic_1\JJ|
D024502_D006461 NONE T_17\NNP|alpha|- (r_appos) tocopherol_13\NN|alpha|-|(|t|) (r_pobj) of_10\IN|tocopherol (r_prep) concentrations_9\NNS|low|of|and|acetate (r_pobj) by_7\IN|concentrations (r_agent) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG|related (l_ccomp) related_42\VBN|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN|induced
D024502_D006461 NONE acetate_23\NN|tocopherol|(|tac|) (r_conj) concentrations_9\NNS|low|of|and|acetate (r_pobj) by_7\IN|concentrations (r_agent) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN|the|hemolytic|of (l_amod) hemolytic_1\JJ|
D024502_D006461 NONE acetate_23\NN|tocopherol|(|tac|) (r_conj) concentrations_9\NNS|low|of|and|acetate (r_pobj) by_7\IN|concentrations (r_agent) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG|related (l_ccomp) related_42\VBN|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN|induced
D024502_D006461 NONE TAc_27\NNS|alpha|- (r_appos) acetate_23\NN|tocopherol|(|tac|) (r_conj) concentrations_9\NNS|low|of|and|acetate (r_pobj) by_7\IN|concentrations (r_agent) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN|the|hemolytic|of (l_amod) hemolytic_1\JJ|
D024502_D006461 NONE TAc_27\NNS|alpha|- (r_appos) acetate_23\NN|tocopherol|(|tac|) (r_conj) concentrations_9\NNS|low|of|and|acetate (r_pobj) by_7\IN|concentrations (r_agent) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG|related (l_ccomp) related_42\VBN|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN|induced
D017665_D006461 NONE hydroxyl_32\NN|functional (r_dobj) inactivated_30\VBN|(|hydroxyl|) (r_parataxis) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN|the|hemolytic|of (l_amod) hemolytic_1\JJ|
D017665_D006461 NONE hydroxyl_32\NN|functional (r_dobj) inactivated_30\VBN|(|hydroxyl|) (r_parataxis) prevented_6\VBN|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG|related (l_ccomp) related_42\VBN|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN|induced
D010100_D006461 NONE oxygen_7\NN| (r_compound) consumption_8\NN|oxygen|and|oxidation (r_pobj) of_6\IN|consumption (r_prep) absence_5\NN|of (r_pobj) by_4\IN|absence (r_agent) evidenced_3\VBN|this|was|further|by|determined|. (l_conj) determined_13\VBN|in (l_prep) in_14\IN|parallel (l_pobj) parallel_15\NN|with (l_prep) with_16\IN|hemolysis (l_pobj) hemolysis_20\NN|induced
D011188_D006461 NONE K(+_11\NNP| (r_pobj) of_10\IN|k(+ (r_prep) leakage_9\NN|the|of|)|from (r_pobj) by_7\IN|leakage (r_agent) preceded_6\VBN|hemolysis|was|not|by|,|excluding|,|according|. (l_nsubjpass) Hemolysis_0\NNP|caused
D011188_D006461 NONE K(+_11\NNP| (r_pobj) of_10\IN|k(+ (r_prep) leakage_9\NN|the|of|)|from (r_pobj) by_7\IN|leakage (r_agent) preceded_6\VBN|hemolysis|was|not|by|,|excluding|,|according|. (l_prep) excluding_18\VBG|also|mechanism (l_pobj) mechanism_24\NN|a|osmotic|type|of (l_prep) of_25\IN|hemolysis (l_pobj) hemolysis_26\NN|
D024505_D006461 NONE tocopherols_9\NNS| (r_pobj) by_8\IN|tocopherols (r_prep) protection_5\NN|the|from|by (l_prep) from_6\IN|hemolysis (l_pobj) hemolysis_7\NN|
8864707
D010672_D004827 NONE phenytoin_10\NNP| (r_compound) overdosages_11\NNS|phenytoin (r_pobj) after_9\IN|overdosages (r_prep) volumetry_2\NN|resonance|of|in|after|. (l_prep) in_6\IN|patients (l_pobj) patients_8\NNS|epileptic (l_amod) epileptic_7\JJ|
D010672_D062787 CID phenytoin_10\NNP| (r_compound) overdosages_11\NNS|phenytoin
D010672_D062787 CID phenytoin_3\JJ| (r_compound) overdosage_4\NN|phenytoin
D010672_D062787 CID phenytoin_17\JJ| (r_compound) medication_18\NN|phenytoin (r_nsubj) was_19\VBD|that|medication|cause (r_ccomp) is_14\VBZ|it|unlikely|was (r_conj) result_8\VB|that|overdosage|does|not|necessarily|in|and|is (l_nsubj) overdosage_4\NN|phenytoin
D010672_D002526 NONE phenytoin_11\JJ| (r_compound) medication_12\NN|phenytoin|and|atrophy (l_conj) atrophy_15\NN|cerebellar|in
D010672_D002526 NONE phenytoin_3\JJ| (r_compound) overdosage_4\NN|phenytoin (r_nsubj) result_8\VB|that|overdosage|does|not|necessarily|in|and|is (l_prep) in_9\IN|atrophy (l_pobj) atrophy_11\NN|cerebellar
D010672_D002526 NONE phenytoin_3\JJ| (r_compound) overdosage_4\NN|phenytoin (r_nsubj) result_8\VB|that|overdosage|does|not|necessarily|in|and|is (l_conj) is_14\VBZ|it|unlikely|was (l_ccomp) was_19\VBD|that|medication|cause (l_attr) cause_22\NN|the|only|of (l_prep) of_23\IN|atrophy (l_pobj) atrophy_25\NN|cerebellar|in
D010672_D002526 NONE phenytoin_17\JJ| (r_compound) medication_18\NN|phenytoin (r_nsubj) was_19\VBD|that|medication|cause (r_ccomp) is_14\VBZ|it|unlikely|was (r_conj) result_8\VB|that|overdosage|does|not|necessarily|in|and|is (l_prep) in_9\IN|atrophy (l_pobj) atrophy_11\NN|cerebellar
D010672_D002526 NONE phenytoin_17\JJ| (r_compound) medication_18\NN|phenytoin (r_nsubj) was_19\VBD|that|medication|cause (l_attr) cause_22\NN|the|only|of (l_prep) of_23\IN|atrophy (l_pobj) atrophy_25\NN|cerebellar|in
D010672_D012640 NONE phenytoin_15\JJ| (r_compound) levels_17\NNS|phenytoin|serum|and|volume (r_pobj) of_14\IN|levels (r_prep) elevation_13\NN|of (r_conj) duration_11\NN|seizure|,|elevation (l_compound) seizure_10\NN|
14765563
D011803_D020922 NONE quinine_23\NN| (r_nsubj) is_24\VBZ|banned|,|quinine|available|. (l_advcl) banned_8\VBD|although|administration|use|due (l_dobj) use_10\NN|its|for (l_prep) for_11\IN|cramps (l_pobj) cramps_14\NNS|nocturnal|leg
D011803_D002493 NONE quinine_7\NN| (r_dobj) containing_6\VBG|quinine (r_acl) products_5\NNS|containing (r_nsubj) produce_9\VB|that|products|may|complications|status|in (l_dobj) complications_11\NNS|neurological|,|including|,
D011803_D003221 CID quinine_7\NN| (r_dobj) containing_6\VBG|quinine (r_acl) products_5\NNS|containing (r_nsubj) produce_9\VB|that|products|may|complications|status|in (l_dobj) complications_11\NNS|neurological|,|including|, (l_prep) including_13\VBG|confusion (l_pobj) confusion_14\NN|
D011803_D012640 CID quinine_7\NN| (r_dobj) containing_6\VBG|quinine (r_acl) products_5\NNS|containing (r_nsubj) produce_9\VB|that|products|may|complications|status|in (l_dobj) status_18\NN|altered|mental|,|seizures|, (l_conj) seizures_20\NNS|,|and|coma
D011803_D003128 CID quinine_7\NN| (r_dobj) containing_6\VBG|quinine (r_acl) products_5\NNS|containing (r_nsubj) produce_9\VB|that|products|may|complications|status|in (l_dobj) status_18\NN|altered|mental|,|seizures|, (l_conj) seizures_20\NNS|,|and|coma (l_conj) coma_23\NN|
12369736
D003042_D009069 CID cocaine_14\NN| (r_npadvmod) induced_16\VBN|cocaine|- (r_amod) hyperactivity_18\NN|the|induced|locomotor|in
D003042_D009069 CID cocaine_34\NN|in (r_pobj) by_33\IN|cocaine (r_agent) induced_32\VBN|by (r_acl) hyperactivity_31\NN|the|locomotor|induced
D003042_D009069 CID cocaine_18\NN|, (r_pobj) to_17\IN|cocaine (r_prep) prior_16\RB|to (r_advmod) administered_11\VBN|gr|shell|prior|attenuated|. (l_conj) attenuated_23\VBD|dependently|hyperactivity (l_dobj) hyperactivity_29\NN|the|induced|locomotor
D003042_D009069 CID cocaine_4\NN| (r_nsubj) induced_5\VBN|that|cocaine (r_ccomp) indicate_2\VBP|findings|induced|modified (l_ccomp) modified_8\VBN|hyperlocomotion|is|by|. (l_nsubjpass) hyperlocomotion_6\NN|
C103477_D009069 NONE 55562_1\CD| (r_nummod) GR_0\NNP|55562|side|, (r_nsubj) administered_11\VBN|gr|shell|prior|attenuated|. (l_conj) attenuated_23\VBD|dependently|hyperactivity (l_dobj) hyperactivity_29\NN|the|induced|locomotor
C103477_D009069 NONE 55562_38\CD| (r_nummod) GR_37\NNP|55562 (r_appos) antagonist_35\NN|the|5-ht1b|receptor|(|gr|) (r_pobj) of_31\IN|antagonist (r_prep) effects_30\NNS|inhibitory|of (r_pobj) in_26\IN|effects (r_prep) consisting_25\VBG|in (r_acl) modification_24\NN|core|,|this|consisting|and|agonist|respectively (r_conj) shell_17\NN|the|accumbens|,|but|modification (r_pobj) into_14\IN|shell (r_prep) microinjected_13\VBN|into (r_acl) ligands_12\NNS|5-ht1b|receptor|microinjected (r_pobj) by_9\IN|ligands (r_agent) modified_8\VBN|hyperlocomotion|is|by|. (l_nsubjpass) hyperlocomotion_6\NN|
C065046_D009069 CID 93129_44\CD| (r_nummod) CP_43\NNP|(|93129|) (r_appos) agonist_41\NN|cp|, (r_conj) modification_24\NN|core|,|this|consisting|and|agonist|respectively (r_conj) shell_17\NN|the|accumbens|,|but|modification (r_pobj) into_14\IN|shell (r_prep) microinjected_13\VBN|into (r_acl) ligands_12\NNS|5-ht1b|receptor|microinjected (r_pobj) by_9\IN|ligands (r_agent) modified_8\VBN|hyperlocomotion|is|by|. (l_nsubjpass) hyperlocomotion_6\NN|
17261653
D003000_D001919 CID Clonidine_0\NNP| (r_npadvmod) induced_2\VBN|clonidine|-|bradycardia|in (l_dobj) bradycardia_3\NN|
1601297
D003042_D009202 NONE cocaine_8\NN| (r_compound) abusers_9\NNS|hospitalized|cocaine (r_pobj) in_5\IN|abusers (r_prep) injury_4\NN|myocardial|in
D003042_D009202 NONE cocaine_3\NN| (r_compound) abusers_4\NNS|the|cocaine (r_pobj) of_1\IN|abusers (r_prep) Eleven_0\CD|of|and|none (r_nsubj) had_10\VBD|eleven|evidence|. (l_dobj) evidence_12\NN|ecg|of (l_prep) of_13\IN|injury (l_pobj) injury_16\NN|significant|myocardial|defined
D003042_D012559 NONE cocaine_7\NN| (r_npadvmod) abusing_9\VBG|cocaine|- (r_amod) patients_10\NNS|99|abusing (r_pobj) of_5\IN|patients (r_prep) ECG_3\NNP|(|)|of (r_appos) electrocardiograms_1\NNS|the|ecg (r_nsubjpass) compared_12\VBN|electrocardiograms|were|with|. (l_prep) with_13\IN|ecgs (l_pobj) ECGs_15\NNS|the|of (l_prep) of_16\IN|controls (l_pobj) controls_19\NNS|50|schizophrenic (l_amod) schizophrenic_18\JJ|
D003042_D009203 CID cocaine_3\NN| (r_compound) abusers_4\NNS|the|cocaine (r_pobj) of_1\IN|abusers (r_prep) Eleven_0\CD|of|and|none (r_nsubj) had_10\VBD|eleven|evidence|. (l_dobj) evidence_12\NN|ecg|of (l_prep) of_13\IN|injury (l_pobj) injury_16\NN|significant|myocardial|defined (l_acl) defined_17\VBN|as (l_prep) as_18\IN|infarction (l_pobj) infarction_20\NN|myocardial|,|ischemia
D003042_D007511 NONE cocaine_3\NN| (r_compound) abusers_4\NNS|the|cocaine (r_pobj) of_1\IN|abusers (r_prep) Eleven_0\CD|of|and|none (r_nsubj) had_10\VBD|eleven|evidence|. (l_dobj) evidence_12\NN|ecg|of (l_prep) of_13\IN|injury (l_pobj) injury_16\NN|significant|myocardial|defined (l_acl) defined_17\VBN|as (l_prep) as_18\IN|infarction (l_pobj) infarction_20\NN|myocardial|,|ischemia (l_conj) ischemia_22\NN|,|and|block
D003042_D002037 CID cocaine_3\NN| (r_compound) abusers_4\NNS|the|cocaine (r_pobj) of_1\IN|abusers (r_prep) Eleven_0\CD|of|and|none (r_nsubj) had_10\VBD|eleven|evidence|. (l_dobj) evidence_12\NN|ecg|of (l_prep) of_13\IN|injury (l_pobj) injury_16\NN|significant|myocardial|defined (l_acl) defined_17\VBN|as (l_prep) as_18\IN|infarction (l_pobj) infarction_20\NN|myocardial|,|ischemia (l_conj) ischemia_22\NN|,|and|block (l_conj) block_27\NN|bundle|branch
11279304
D018943_D066126 NONE anthracycline_7\NN| (r_advmod) induced_9\VBN|anthracycline|- (r_amod) cardiotoxicity_10\NN|induced
D018943_D066126 NONE Anthracyclines_0\NNS| (r_nsubj) are_1\VBP|anthracyclines|drugs|,|but|cause (l_conj) cause_9\VBP|they|frequently|cardiotoxicity|. (l_dobj) cardiotoxicity_13\NN|related
D018943_D066126 NONE anthracycline_4\NN| (r_amod) therapy_5\NN|conventional|anthracycline (r_pobj) of_2\IN|therapy (r_prep) cardiotoxicity_1\NN|the|of
D018943_D066126 NONE anthracycline_24\NN| (r_advmod) induced_26\VBN|anthracycline|- (r_amod) cardiotoxicity_27\NN|induced|in
D018943_D066126 NONE anthracycline_16\NN| (r_advmod) induced_18\VBN|anthracycline|- (r_compound) cardiotoxicity_19\NN|induced
D018943_D006331 NONE anthracycline_4\NN| (r_amod) therapy_5\NN|conventional|anthracycline (r_pobj) of_2\IN|therapy (r_prep) cardiotoxicity_1\NN|the|of (r_nsubj) highlights_6\VBZ|cardiotoxicity|need|. (l_dobj) need_8\NN|a|search (l_acl) search_10\VB|to|for (l_prep) for_11\IN|methods (l_pobj) methods_12\NNS|are (l_relcl) are_14\VBP|that|sensitive (l_acomp) sensitive_16\JJ|highly|and|capable (l_conj) capable_18\JJ|of (l_prep) of_19\IN|predicting (l_pcomp) predicting_20\VBG|dysfunction (l_dobj) dysfunction_22\NN|cardiac
D018943_D015470 NONE anthracycline_24\NN| (r_advmod) induced_26\VBN|anthracycline|- (r_amod) cardiotoxicity_27\NN|induced|in (l_prep) in_28\IN|patients (l_pobj) patients_29\NNS|with (l_prep) with_30\IN|leukemia (l_pobj) leukemia_32\NN|acute|treated
D003630_D066126 NONE daunorubicin_36\NN|a|(|regimen (r_pobj) with_34\IN|daunorubicin (r_prep) treated_33\VBN|with (r_acl) leukemia_32\NN|acute|treated (r_pobj) with_30\IN|leukemia (r_prep) patients_29\NNS|with (r_pobj) in_28\IN|patients (r_prep) cardiotoxicity_27\NN|induced|in
D003630_D066126 NONE DNR)-containing_38\NN| (r_compound) regimen_39\NNS|dnr)-containing (r_appos) daunorubicin_36\NN|a|(|regimen (r_pobj) with_34\IN|daunorubicin (r_prep) treated_33\VBN|with (r_acl) leukemia_32\NN|acute|treated (r_pobj) with_30\IN|leukemia (r_prep) patients_29\NNS|with (r_pobj) in_28\IN|patients (r_prep) cardiotoxicity_27\NN|induced|in
D003630_D015470 NONE daunorubicin_36\NN|a|(|regimen (r_pobj) with_34\IN|daunorubicin (r_prep) treated_33\VBN|with (r_acl) leukemia_32\NN|acute|treated
D003630_D015470 NONE DNR)-containing_38\NN| (r_compound) regimen_39\NNS|dnr)-containing (r_appos) daunorubicin_36\NN|a|(|regimen (r_pobj) with_34\IN|daunorubicin (r_prep) treated_33\VBN|with (r_acl) leukemia_32\NN|acute|treated
D003630_D015470 NONE DNR_9\NNP| (r_npadvmod) containing_11\VBG|dnr|- (r_amod) regimen_12\NN|a|containing (r_pobj) with_7\IN|regimen (r_prep) treated_6\VBN|patients|were|with|. (l_nsubjpass) patients_1\NNS|thirteen|with (l_prep) with_2\IN|leukemia (l_pobj) leukemia_4\NN|acute
D003630_D006333 CID DNR_16\NNP| (r_pobj) given_15\VBN|dnr (r_acl) failure_14\NN|heart|given
3341566
D009599_D006470 NONE nitroprusside_10\RB| (r_advmod) induced_12\VBN|nitroprusside|- (r_amod) hypotension_13\NN|sodium|induced|in (r_pobj) during_8\IN|hypotension (r_prep) than_7\IN|during (r_prep) is_3\VBZ|variation|greater|during|than|. (l_prep) during_5\IN|hemorrhage (l_pobj) hemorrhage_6\NN|
D009599_D006470 NONE nitroprusside_28\NN|n (r_advcl) decreased_4\VBN|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN|minutes (l_pobj) minutes_11\NNS|30|by (l_prep) by_13\IN|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN|hem
D009599_D006470 NONE nitroprusside_28\NN|n (r_advcl) decreased_4\VBN|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN|minutes (l_pobj) minutes_11\NNS|30|by (l_prep) by_13\IN|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN|hem (l_appos) HEM_16\NNP|(|,|n|7|)
D009599_D006470 NONE SNP_30\NNP| (r_dep) n_32\CC|(|snp|,|7|) (r_npadvmod) nitroprusside_28\NN|n (r_advcl) decreased_4\VBN|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN|minutes (l_pobj) minutes_11\NNS|30|by (l_prep) by_13\IN|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN|hem
D009599_D006470 NONE SNP_30\NNP| (r_dep) n_32\CC|(|snp|,|7|) (r_npadvmod) nitroprusside_28\NN|n (r_advcl) decreased_4\VBN|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN|minutes (l_pobj) minutes_11\NNS|30|by (l_prep) by_13\IN|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN|hem (l_appos) HEM_16\NNP|(|,|n|7|)
D009599_D006470 NONE SNP_21\NNP| (r_compound) group_22\NN|the|snp (r_pobj) in_19\IN|group (r_prep) that_18\DT|in (r_pobj) with_17\IN|that (r_prep) compared_16\VBN|with (r_prep) higher_15\RBR|compared (r_acomp) was_8\VBD|during|output|lower|higher|. (l_prep) During_0\IN|hypotension (l_pobj) hypotension_4\NN|induced (l_amod) induced_3\VBN|hem|- (l_npadvmod) HEM_1\NNP|
D009599_D006470 NONE SNP_17\NNP| (r_compound) group_18\NN|the|snp (r_pobj) in_15\IN|group (r_prep) Hg_14\NNP|in (r_appos) mm_13\NN|+/-|2.0|hg|p (r_pobj) with_9\IN|mm (r_prep) compared_8\VBN|with (r_prep) Hg_2\NNP|mm|in|,|compared|. (l_prep) in_3\IN|group (l_pobj) group_6\NN|the|hem (l_compound) HEM_5\NNP|
D009599_D006470 NONE SNP_7\NNP| (r_compound) groups_8\NNS|hem|snp (l_nmod) HEM_5\NNP|the|and
D009599_D007022 CID nitroprusside_10\RB| (r_advmod) induced_12\VBN|nitroprusside|- (r_amod) hypotension_13\NN|sodium|induced|in
D009599_D007022 CID SNP_21\NNP| (r_compound) group_22\NN|the|snp (r_pobj) in_19\IN|group (r_prep) that_18\DT|in (r_pobj) with_17\IN|that (r_prep) compared_16\VBN|with (r_prep) higher_15\RBR|compared (r_acomp) was_8\VBD|during|output|lower|higher|. (l_prep) During_0\IN|hypotension (l_pobj) hypotension_4\NN|induced
D009599_D007022 CID SNP_7\NNP| (r_compound) groups_8\NNS|hem|snp (r_pobj) in_3\IN|groups (r_prep) Hg_2\NNP|mm|in|,|respectively|,|during|p|. (l_prep) during_12\IN|hypotension (l_pobj) hypotension_13\NN|
12695819
D016559_D020258 NONE tacrolimus_7\NN| (r_npadvmod) induced_9\VBN|tacrolimus|- (r_amod) neurotoxicity_10\NN|induced|in
D016559_D020258 NONE tacrolimus_15\NN| (r_npadvmod) induced_17\VBN|tacrolimus|- (r_amod) neurotoxicity_18\NN|induced
D016559_D009422 NONE tacrolimus_17\NNS|developed (l_relcl) developed_19\VBD|who|complications (l_dobj) complications_21\NNS|neurologic
1592014
D003042_D012640 CID cocaine_4\NN| (r_compound) metabolite_5\NN|cocaine (r_amod) benzoylecgonine_6\NN|the|metabolite|in (r_pobj) by_2\IN|benzoylecgonine (r_agent) induced_1\VBN|seizures|by|. (l_nsubj) Seizures_0\NNS|
D003042_D012640 CID cocaine_8\NN| (r_pobj) of_7\IN|cocaine (r_prep) t1/2_5\NN|(|)|of (r_appos) life_3\NN|half|-|t1/2 (r_nsubj) is_9\VBZ|the|life|short|,|but|occur (l_conj) occur_29\VB|some|can|hours|. (l_nsubj) some_14\DT|of (l_prep) of_15\IN|consequences (l_pobj) consequences_17\NNS|the|of (l_prep) of_18\IN|use (l_pobj) use_20\NN|its|,|as|, (l_prep) as_23\IN|such|seizures (l_pobj) seizures_24\NNS|and|strokes
D003042_D012640 CID cocaine_9\NN|, (r_pobj) of_8\IN|cocaine (r_prep) metabolite_7\NN|the|major|of|benzoylecgonine|be (r_pobj) of_4\IN|metabolite (r_prep) potential_3\NN|the|of (r_dobj) evaluated_1\VBD|we|potential|,|cause|. (l_advcl) cause_17\VB|to|seizures (l_dobj) seizures_18\NNS|
D003042_D012640 CID cocaine_19\NN| (r_pobj) of_18\IN|cocaine (r_prep) amounts_17\NNS|equimolar|of (r_pobj) by_15\IN|amounts (r_agent) induced_14\VBN|by (r_acl) those_13\DT|induced (r_pobj) than_12\IN|those (r_prep) latencies_11\NNS|longer|than (r_dobj) had_8\VBD|latencies (r_conj) occurred_4\VBD|seizures|frequently|and|had|. (l_nsubj) seizures_3\NNS|induced
D003042_D012640 CID cocaine_1\NN| (r_npadvmod) induced_3\VBN|cocaine|- (r_amod) seizures_4\NNS|induced
D003042_D012640 CID cocaine_15\NN| (r_npadvmod) injected_17\VBN|cocaine|- (r_amod) animals_18\NNS|injected (r_pobj) than_14\IN|animals (r_prep) activity_13\NN|more|locomotor|than (r_dobj) had_9\VBD|rats|activity|without|. (l_nsubj) rats_3\NNS|injected|have (l_relcl) have_7\VB|that|did|not|seizures (l_dobj) seizures_8\NNS|
D003042_D012640 CID cocaine_15\NN| (r_npadvmod) injected_17\VBN|cocaine|- (r_amod) animals_18\NNS|injected (r_pobj) than_14\IN|animals (r_prep) activity_13\NN|more|locomotor|than (r_dobj) had_9\VBD|rats|activity|without|. (l_prep) without_19\IN|seizures (l_pobj) seizures_20\NNS|
D003042_D012640 CID cocaine-_3\NN|and|induced (r_nmod) seizures_8\NNS|cocaine-
D003042_D012640 CID cocaine-_3\NN|and|induced (r_nmod) seizures_8\NNS|cocaine- (r_nsubj) differ_9\VBP|seizures|in (r_relcl) finding_1\NN|the|differ (r_nsubj) suggests_13\VBZ|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN|one|for (l_prep) for_18\IN|seizures (l_pobj) seizures_22\NNS|induced
D003042_D012640 CID cocaine_19\NN| (r_npadvmod) induced_21\VBN|cocaine|- (r_amod) seizures_22\NNS|induced (r_pobj) for_18\IN|seizures (r_prep) mechanism_17\NN|one|for (r_dobj) suggests_13\VBZ|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN|the|differ (l_relcl) differ_9\VBP|seizures|in (l_nsubj) seizures_8\NNS|cocaine-
D003042_D012640 CID cocaine_19\NN| (r_npadvmod) induced_21\VBN|cocaine|- (r_amod) seizures_22\NNS|induced
D003042_D012640 CID cocaine_29\NN| (r_compound) metabolite_30\NN|a|cocaine (r_pobj) of_27\IN|metabolite (r_prep) importance_26\NN|the|of (r_dobj) emphasizes_24\VBZ|importance|,|be (r_conj) suggests_13\VBZ|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN|the|differ (l_relcl) differ_9\VBP|seizures|in (l_nsubj) seizures_8\NNS|cocaine-
D003042_D012640 CID cocaine_29\NN| (r_compound) metabolite_30\NN|a|cocaine (r_pobj) of_27\IN|metabolite (r_prep) importance_26\NN|the|of (r_dobj) emphasizes_24\VBZ|importance|,|be (r_conj) suggests_13\VBZ|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN|one|for (l_prep) for_18\IN|seizures (l_pobj) seizures_22\NNS|induced
C005618_D012640 CID benzoylecgonine_6\NN|the|metabolite|in (r_pobj) by_2\IN|benzoylecgonine (r_agent) induced_1\VBN|seizures|by|. (l_nsubj) Seizures_0\NNS|
C005618_D012640 CID benzoylecgonine_11\NN| (r_appos) metabolite_7\NN|the|major|of|benzoylecgonine|be (r_pobj) of_4\IN|metabolite (r_prep) potential_3\NN|the|of (r_dobj) evaluated_1\VBD|we|potential|,|cause|. (l_advcl) cause_17\VB|to|seizures (l_dobj) seizures_18\NNS|
C005618_D012640 CID BE_13\VB|(|) (r_appos) metabolite_7\NN|the|major|of|benzoylecgonine|be (r_pobj) of_4\IN|metabolite (r_prep) potential_3\NN|the|of (r_dobj) evaluated_1\VBD|we|potential|,|cause|. (l_advcl) cause_17\VB|to|seizures (l_dobj) seizures_18\NNS|
C005618_D012640 CID BE_0\VB| (r_advmod) Induced_2\VBN|be|- (r_amod) seizures_3\NNS|induced
C005618_D012640 CID BE_23\NNP| (r_pobj) by_22\IN|be (r_agent) induced_21\VBN|by (r_acl) those_20\DT|induced (r_nsubj) were_24\VBD|characterized|,|those|multiple|,|and|resulted|. (l_advcl) characterized_7\VBN|whereas|seizures|were|best|as|and|resulted (l_nsubjpass) seizures_4\NNS|induced
C005618_D012640 CID BE_0\VB| (r_advmod) Injected_2\VBN|be|- (r_amod) rats_3\NNS|injected|have (l_relcl) have_7\VB|that|did|not|seizures (l_dobj) seizures_8\NNS|
C005618_D012640 CID BE_0\VB| (r_advmod) Injected_2\VBN|be|- (r_amod) rats_3\NNS|injected|have (r_nsubj) had_9\VBD|rats|activity|without|. (l_prep) without_19\IN|seizures (l_pobj) seizures_20\NNS|
C005618_D012640 CID BE_5\VB| (r_advmod) induced_7\VBN|be|- (r_conj) cocaine-_3\NN|and|induced (r_nmod) seizures_8\NNS|cocaine-
C005618_D012640 CID BE_5\VB| (r_advmod) induced_7\VBN|be|- (r_conj) cocaine-_3\NN|and|induced (r_nmod) seizures_8\NNS|cocaine- (r_nsubj) differ_9\VBP|seizures|in (r_relcl) finding_1\NN|the|differ (r_nsubj) suggests_13\VBZ|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN|one|for (l_prep) for_18\IN|seizures (l_pobj) seizures_22\NNS|induced
C005618_D012640 CID BE_32\VB| (r_conj) emphasizes_24\VBZ|importance|,|be (r_conj) suggests_13\VBZ|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN|the|differ (l_relcl) differ_9\VBP|seizures|in (l_nsubj) seizures_8\NNS|cocaine-
C005618_D012640 CID BE_32\VB| (r_conj) emphasizes_24\VBZ|importance|,|be (r_conj) suggests_13\VBZ|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN|one|for (l_prep) for_18\IN|seizures (l_pobj) seizures_22\NNS|induced
D003042_D020521 NONE cocaine_8\NN| (r_pobj) of_7\IN|cocaine (r_prep) t1/2_5\NN|(|)|of (r_appos) life_3\NN|half|-|t1/2 (r_nsubj) is_9\VBZ|the|life|short|,|but|occur (l_conj) occur_29\VB|some|can|hours|. (l_nsubj) some_14\DT|of (l_prep) of_15\IN|consequences (l_pobj) consequences_17\NNS|the|of (l_prep) of_18\IN|use (l_pobj) use_20\NN|its|,|as|, (l_prep) as_23\IN|such|seizures (l_pobj) seizures_24\NNS|and|strokes (l_conj) strokes_26\NNS|
D003042_D003643 NONE cocaine_1\NN| (r_npadvmod) induced_3\VBN|cocaine|- (r_amod) seizures_4\NNS|induced (r_nsubjpass) characterized_7\VBN|whereas|seizures|were|best|as|and|resulted (l_conj) resulted_16\VBD|in (l_prep) in_17\IN|death (l_pobj) death_18\NN|
D003042_D003643 NONE cocaine_1\NN| (r_npadvmod) induced_3\VBN|cocaine|- (r_amod) seizures_4\NNS|induced (r_nsubjpass) characterized_7\VBN|whereas|seizures|were|best|as|and|resulted (r_advcl) were_24\VBD|characterized|,|those|multiple|,|and|resulted|. (l_conj) resulted_36\VBD|rarely|in (l_prep) in_37\IN|death (l_pobj) death_38\NN|
C005618_D003643 NONE BE_23\NNP| (r_pobj) by_22\IN|be (r_agent) induced_21\VBN|by (r_acl) those_20\DT|induced (r_nsubj) were_24\VBD|characterized|,|those|multiple|,|and|resulted|. (l_advcl) characterized_7\VBN|whereas|seizures|were|best|as|and|resulted (l_conj) resulted_16\VBD|in (l_prep) in_17\IN|death (l_pobj) death_18\NN|
C005618_D003643 NONE BE_23\NNP| (r_pobj) by_22\IN|be (r_agent) induced_21\VBN|by (r_acl) those_20\DT|induced (r_nsubj) were_24\VBD|characterized|,|those|multiple|,|and|resulted|. (l_conj) resulted_36\VBD|rarely|in (l_prep) in_37\IN|death (l_pobj) death_38\NN|
18619688
D004317_D003643 NONE Adriamycin_0\NNP| (r_advmod) induced_2\VBN|adriamycin|- (r_amod) death_5\NN|induced|cardiomyocyte
D004317_D003643 NONE adriamycin_17\NNS| (r_pobj) by_16\IN|adriamycin (r_agent) induced_15\VBN|by (r_advcl) plays_3\VBZ|death|role|in|induced|. (l_nsubj) death_2\NN|autophagic|cardiomyocyte
D004317_D006333 CID Adriamycin_0\NNP| (r_advmod) induced_2\VBN|adriamycin|- (r_amod) death_5\NN|induced|cardiomyocyte (r_nsubj) plays_6\VBZ|death|role|in|. (l_prep) in_10\IN|model (l_pobj) model_13\NN|a|rat|of (l_prep) of_14\IN|failure (l_pobj) failure_16\NN|heart
D004317_D006333 CID adriamycin_7\NNS| (r_pobj) by_6\IN|adriamycin (r_agent) induced_5\VBN|by (r_acl) failure_4\NN|mechanisms|underlying|heart|induced
D004317_D006333 CID adriamycin_20\NNS| (r_pobj) by_19\IN|adriamycin (r_agent) induced_18\VBN|by (r_acl) progression_14\NN|the|of|induced (l_prep) of_15\IN|failure (l_pobj) failure_17\NN|heart
D004317_D006333 CID adriamycin_20\NNS| (r_pobj) by_19\IN|adriamycin (r_agent) induced_18\VBN|by (r_acl) progression_14\NN|the|of|induced (r_pobj) in_12\IN|progression (r_prep) involved_11\VBN|whether|autophagy|was|in (r_ccomp) investigate_7\VB|to|involved|,|develop (l_advcl) develop_26\VB|so|that|we|can|strategy (l_dobj) strategy_30\NN|a|novel|treatment|for (l_prep) for_31\IN|failure (l_pobj) failure_33\NN|heart
D004317_D006333 CID adriamycin_23\NNS| (r_pobj) by_22\IN|adriamycin (r_agent) induced_21\VBN|by (r_acl) model_18\NN|a|heart|failure|of|induced (l_compound) failure_17\NN|
D004317_D006333 CID adriamycin_17\NNS| (r_pobj) by_16\IN|adriamycin (r_agent) induced_15\VBN|by (r_advcl) plays_3\VBZ|death|role|in|induced|. (l_prep) in_7\IN|pathogenesis (l_pobj) pathogenesis_9\NN|the|of (l_prep) of_10\IN|failure (l_pobj) failure_12\NN|heart|in
D004317_D006333 CID adriamycin_13\NNS| (r_pobj) by_12\IN|adriamycin (r_agent) caused_11\VBN|by|via (r_acl) failure_10\NN|heart|caused
C025946_D006333 NONE 3-methyladenine_2\LS|3ma (r_appos) METHODS_0\NNS|:|3-methyladenine|, (r_nsubjpass) used_13\VBN|methods|inhibitor|was|in|. (l_prep) in_14\IN|model (l_pobj) model_18\NN|a|heart|failure|of|induced (l_compound) failure_17\NN|
C025946_D006333 NONE 3MA_4\VBN|(|) (r_appos) 3-methyladenine_2\LS|3ma (r_appos) METHODS_0\NNS|:|3-methyladenine|, (r_nsubjpass) used_13\VBN|methods|inhibitor|was|in|. (l_prep) in_14\IN|model (l_pobj) model_18\NN|a|heart|failure|of|induced (l_compound) failure_17\NN|
18221780
D016202_D010146 NONE NMDA_3\NNP| (r_compound) enhancement_5\NN|nmda|antagonist|of (r_pobj) in_2\IN|enhancement (r_prep) differences_1\NNS|sex|in|in|:|comparisons|. (l_prep) in_9\IN|model (l_pobj) model_12\NN|a|capsaicin|of (l_prep) of_13\IN|pain (l_pobj) pain_15\NN|persistent
D016202_D010146 NONE NMDA_9\NNP| (r_compound) antagonists_10\NNS|nmda|and|morphine (r_pobj) between_8\IN|antagonists (r_prep) interaction_7\NN|a|dimorphic|between|in (l_prep) in_13\IN|model (l_pobj) model_17\NN|a|persistent|pain|distinguished (l_compound) pain_16\NN|
D016202_D059787 NONE NMDA_3\NNP| (r_compound) enhancement_5\NN|nmda|antagonist|of (r_pobj) in_2\IN|enhancement (r_prep) differences_1\NNS|sex|in|in|:|comparisons|. (l_appos) comparisons_17\NNS|to (l_prep) to_18\IN|models (l_pobj) models_20\NNS|two|of (l_prep) of_21\IN|pain (l_pobj) pain_23\NN|acute
D016202_D059787 NONE aspartate_11\NNP|d|- (r_nmod) antagonists_15\NNS|methyl|aspartate|(|nmda|) (r_nsubj) enhance_16\VBP|in|antagonists|effects|to|. (l_prep) In_0\IN|models|, (l_pobj) models_3\NNS|acute|pain (l_compound) pain_2\NN|
D016202_D059787 NONE NMDA_13\NNP| (r_nmod) antagonists_15\NNS|methyl|aspartate|(|nmda|) (r_nsubj) enhance_16\VBP|in|antagonists|effects|to|. (l_prep) In_0\IN|models|, (l_pobj) models_3\NNS|acute|pain (l_compound) pain_2\NN|
D016202_D059787 NONE NMDA_9\NNP| (r_compound) antagonists_10\NNS|nmda|and|morphine (r_pobj) between_8\IN|antagonists (r_prep) interaction_7\NN|a|dimorphic|between|in (l_prep) in_13\IN|model (l_pobj) model_17\NN|a|persistent|pain|distinguished (l_relcl) distinguished_21\VBN|that|can|be|from (l_prep) from_22\IN|those (l_pobj) those_23\DT|observed (l_acl) observed_24\VBN|in (l_prep) in_25\IN|models (l_pobj) models_28\NNS|acute|pain (l_compound) pain_27\NN|
D009020_D010146 NONE morphine_7\NN| (r_compound) antihyperalgesia_8\NN|morphine (r_pobj) of_6\IN|antihyperalgesia (r_prep) enhancement_5\NN|nmda|antagonist|of (r_pobj) in_2\IN|enhancement (r_prep) differences_1\NNS|sex|in|in|:|comparisons|. (l_prep) in_9\IN|model (l_pobj) model_12\NN|a|capsaicin|of (l_prep) of_13\IN|pain (l_pobj) pain_15\NN|persistent
D009020_D010146 NONE morphine_12\NN| (r_conj) antagonists_10\NNS|nmda|and|morphine (r_pobj) between_8\IN|antagonists (r_prep) interaction_7\NN|a|dimorphic|between|in (l_prep) in_13\IN|model (l_pobj) model_17\NN|a|persistent|pain|distinguished (l_compound) pain_16\NN|
D009020_D059787 NONE morphine_7\NN| (r_compound) antihyperalgesia_8\NN|morphine (r_pobj) of_6\IN|antihyperalgesia (r_prep) enhancement_5\NN|nmda|antagonist|of (r_pobj) in_2\IN|enhancement (r_prep) differences_1\NNS|sex|in|in|:|comparisons|. (l_appos) comparisons_17\NNS|to (l_prep) to_18\IN|models (l_pobj) models_20\NNS|two|of (l_prep) of_21\IN|pain (l_pobj) pain_23\NN|acute
D009020_D059787 NONE morphine_21\NN| (r_pobj) of_20\IN|morphine (r_prep) effects_19\NNS|the|antinociceptive|of (r_dobj) enhance_16\VBP|in|antagonists|effects|to|. (l_prep) In_0\IN|models|, (l_pobj) models_3\NNS|acute|pain (l_compound) pain_2\NN|
D009020_D059787 NONE morphine_2\NN| (r_compound) antinociception_3\NN|morphine (r_pobj) of_1\IN|antinociception (r_prep) Enhancement_0\NN|of|by (r_nsubjpass) seen_7\VBN|enhancement|was|in|,|with|. (l_prep) in_8\IN|males (l_pobj) males_10\NNS|both|and|females|in (l_prep) in_13\IN|models (l_pobj) models_17\NNS|the|acute|pain (l_compound) pain_16\NN|
D009020_D059787 NONE morphine_12\NN| (r_conj) antagonists_10\NNS|nmda|and|morphine (r_pobj) between_8\IN|antagonists (r_prep) interaction_7\NN|a|dimorphic|between|in (l_prep) in_13\IN|model (l_pobj) model_17\NN|a|persistent|pain|distinguished (l_relcl) distinguished_21\VBN|that|can|be|from (l_prep) from_22\IN|those (l_pobj) those_23\DT|observed (l_acl) observed_24\VBN|in (l_prep) in_25\IN|models (l_pobj) models_28\NNS|acute|pain (l_compound) pain_27\NN|
D002211_D010146 NONE capsaicin_11\NN| (r_compound) model_12\NN|a|capsaicin|of (l_prep) of_13\IN|pain (l_pobj) pain_15\NN|persistent
D002211_D059787 NONE capsaicin_11\NN| (r_compound) model_12\NN|a|capsaicin|of (r_pobj) in_9\IN|model (r_prep) differences_1\NNS|sex|in|in|:|comparisons|. (l_appos) comparisons_17\NNS|to (l_prep) to_18\IN|models (l_pobj) models_20\NNS|two|of (l_prep) of_21\IN|pain (l_pobj) pain_23\NN|acute
D002211_D006930 CID capsaicin_11\NN| (r_pobj) of_10\IN|capsaicin (r_prep) administration_9\NN|of|in (r_pobj) by_8\IN|administration (r_agent) induced_7\VBN|to|,|hyperalgesia|was|by|,|immersed|. (l_nsubjpass) hyperalgesia_5\NN|persistent
D003915_D059787 NONE dextromethorphan_5\NNP| (r_pobj) by_4\IN|dextromethorphan (r_prep) Enhancement_0\NN|of|by (r_nsubjpass) seen_7\VBN|enhancement|was|in|,|with|. (l_prep) in_8\IN|males (l_pobj) males_10\NNS|both|and|females|in (l_prep) in_13\IN|models (l_pobj) models_17\NNS|the|acute|pain (l_compound) pain_16\NN|
11391224
D003042_D006974 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|cocaine|- (r_amod) failure_28\NN|related|acute|renal (r_conj) glomerulonephritis_20\NN|crescentic|,|and|failure (r_conj) nephritis_17\NN|schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN|,|nephritis (r_dobj) lupus_11\NN|microangiopathy|nephritis (r_conj) included_2\VBD|13|cases|,|lupus|. (l_dobj) cases_3\NNS|of (l_prep) of_4\IN|hypertension (l_pobj) hypertension_6\NN|malignant
D003042_D057049 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|cocaine|- (r_amod) failure_28\NN|related|acute|renal (r_conj) glomerulonephritis_20\NN|crescentic|,|and|failure (r_conj) nephritis_17\NN|schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN|,|nephritis (r_dobj) lupus_11\NN|microangiopathy|nephritis (l_nsubj) microangiopathy_9\NN|thrombotic|,
D003042_D008181 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|cocaine|- (r_amod) failure_28\NN|related|acute|renal (r_conj) glomerulonephritis_20\NN|crescentic|,|and|failure (r_conj) nephritis_17\NN|schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN|,|nephritis
D003042_D011695 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|cocaine|- (r_amod) failure_28\NN|related|acute|renal (r_conj) glomerulonephritis_20\NN|crescentic|,|and|failure (r_conj) nephritis_17\NN|schonlein|,|glomerulonephritis
D003042_D005921 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|cocaine|- (r_amod) failure_28\NN|related|acute|renal (r_conj) glomerulonephritis_20\NN|crescentic|,|and|failure
D003042_D058186 CID cocaine_23\NN| (r_npadvmod) related_25\VBN|cocaine|- (r_amod) failure_28\NN|related|acute|renal
10739826
D003276_D054556 CID contraceptives_5\NNS|newer|oral|and|risk (l_conj) risk_8\NN|the|of (l_prep) of_9\IN|thromboembolism (l_pobj) thromboembolism_11\NN|venous
D003276_D054556 CID contraceptives_17\NNS|newer|oral|oc (r_pobj) with_14\IN|contraceptives (r_prep) associated_13\VBN|with (r_acl) thromboembolism_9\NN|venous|(|vte|)|associated
D003276_D054556 CID contraceptives_17\NNS|newer|oral|oc (r_pobj) with_14\IN|contraceptives (r_prep) associated_13\VBN|with (r_acl) thromboembolism_9\NN|venous|(|vte|)|associated (l_appos) VTE_11\NNP|
D003276_D054556 CID OC_19\NNP|(|) (r_appos) contraceptives_17\NNS|newer|oral|oc (r_pobj) with_14\IN|contraceptives (r_prep) associated_13\VBN|with (r_acl) thromboembolism_9\NN|venous|(|vte|)|associated
D003276_D054556 CID OC_19\NNP|(|) (r_appos) contraceptives_17\NNS|newer|oral|oc (r_pobj) with_14\IN|contraceptives (r_prep) associated_13\VBN|with (r_acl) thromboembolism_9\NN|venous|(|vte|)|associated (l_appos) VTE_11\NNP|
D003276_D054556 CID OC_27\NNP| (r_compound) use_28\NN|oc|,|users (r_pobj) of_26\IN|use (r_prep) patterns_25\NNS|of (r_pobj) between_24\IN|patterns (r_prep) distinguish_23\VB|studies|did|not|between|. (l_nsubj) studies_2\NNS|the|epidemiological|assessed (l_relcl) assessed_4\VBD|that|risk (l_dobj) risk_6\NN|the|of (l_prep) of_7\IN|thromboembolism (l_pobj) thromboembolism_9\NN|venous|(|vte|)|associated
D003276_D054556 CID OC_27\NNP| (r_compound) use_28\NN|oc|,|users (r_pobj) of_26\IN|use (r_prep) patterns_25\NNS|of (r_pobj) between_24\IN|patterns (r_prep) distinguish_23\VB|studies|did|not|between|. (l_nsubj) studies_2\NNS|the|epidemiological|assessed (l_relcl) assessed_4\VBD|that|risk (l_dobj) risk_6\NN|the|of (l_prep) of_7\IN|thromboembolism (l_pobj) thromboembolism_9\NN|venous|(|vte|)|associated (l_appos) VTE_11\NNP|
D003276_D054556 CID OC_12\NNP|generation (r_pobj) of_9\IN|oc (r_prep) users_8\NNS|repeat|of (r_pobj) for_6\IN|users (r_prep) ratio_3\NN|the|adjusted|rate|of|for (l_prep) of_4\IN|vte (l_pobj) VTE_5\NN|
15145918
D004967_D007022 NONE estrogen_3\NN|of (l_prep) of_4\IN|hypotension (l_pobj) hypotension_11\NN|alpha2-adrenergic|in
D004967_D007022 NONE estrogen_5\NN| (r_nsubj) modulates_7\VBZ|that|estrogen|negatively|effect|and|implicates (l_dobj) effect_10\NN|the|hypotensive|of (l_amod) hypotensive_9\JJ|
D004967_D007022 NONE estrogen_4\NN| (r_nsubj) downregulates_5\VBZ|that|estrogen|alpha2-|but|hypotension|and|highlight (l_conj) hypotension_12\NN|not|mediated
D004967_D007022 NONE estrogen_27\NN|methyldopa|- (r_compound) interaction_28\NN|estrogen (r_pobj) in_22\IN|interaction (r_prep) control_21\NN|the|cardiac|autonomic|in (r_pobj) for_17\IN|control (r_prep) role_16\NN|a|for (r_dobj) highlight_14\VB|role (r_conj) downregulates_5\VBZ|that|estrogen|alpha2-|but|hypotension|and|highlight (l_conj) hypotension_12\NN|not|mediated
D048288_D007022 NONE I1-imidazoline_7\NNP| (r_punct) mediated_10\VBN|i1-imidazoline|receptor|- (r_conj) alpha2-adrenergic_5\JJ|and|mediated (r_amod) hypotension_11\NN|alpha2-adrenergic|in
D003000_D007022 NONE clonidine_12\NN|agonist (r_pobj) of_11\IN|clonidine (r_prep) effect_10\NN|the|hypotensive|of (l_amod) hypotensive_9\JJ|
C032302_D007022 CID rilmenidine_6\NN|or|methyldopa (r_amod) rats_4\NNS|operated|,|rilmenidine (r_pobj) In_0\IN|rats (r_prep) elicited_11\VBD|in|hypotension|. (l_dobj) hypotension_13\NN|similar|lasted
C032302_D007022 CID rilmenidine_17\JJ| (r_amod) hypotension_18\NN|rilmenidine (r_pobj) on_16\IN|hypotension (r_prep) effect_15\NN|no|on (r_pobj) to_13\IN|effect (r_prep) contrast_12\NN|to (r_pobj) in_11\IN|contrast (r_prep) enhanced_2\VBD|ovx|significantly|response|,|in|. (l_dobj) response_5\NN|the|hypotensive|to (l_amod) hypotensive_4\JJ|
C032302_D007022 CID rilmenidine_17\JJ| (r_amod) hypotension_18\NN|rilmenidine
D008750_D007022 CID methyldopa_10\NN|alpha|- (r_conj) rilmenidine_6\NN|or|methyldopa (r_amod) rats_4\NNS|operated|,|rilmenidine (r_pobj) In_0\IN|rats (r_prep) elicited_11\VBD|in|hypotension|. (l_dobj) hypotension_13\NN|similar|lasted
D008750_D007022 CID methyldopa_9\NN|alpha|- (r_pobj) to_6\IN|methyldopa (r_prep) response_5\NN|the|hypotensive|to (l_amod) hypotensive_4\JJ|
D008750_D007022 CID methyldopa_9\NN|alpha|- (r_pobj) to_6\IN|methyldopa (r_prep) response_5\NN|the|hypotensive|to (r_dobj) enhanced_2\VBD|ovx|significantly|response|,|in|. (l_prep) in_11\IN|contrast (l_pobj) contrast_12\NN|to (l_prep) to_13\IN|effect (l_pobj) effect_15\NN|no|on (l_prep) on_16\IN|hypotension (l_pobj) hypotension_18\NN|rilmenidine
D008750_D007022 CID methyldopa_4\NN|alpha|- (r_compound) hypotension_5\NN|the|enhanced|methyldopa|in
D008750_D007022 CID methyldopa_25\NN|alpha|- (r_compound) estrogen_27\NN|methyldopa|- (r_compound) interaction_28\NN|estrogen (r_pobj) in_22\IN|interaction (r_prep) control_21\NN|the|cardiac|autonomic|in (r_pobj) for_17\IN|control (r_prep) role_16\NN|a|for (r_dobj) highlight_14\VB|role (r_conj) downregulates_5\VBZ|that|estrogen|alpha2-|but|hypotension|and|highlight (l_conj) hypotension_12\NN|not|mediated
D008750_D001523 NONE methyldopa_4\NN|alpha|- (r_compound) hypotension_5\NN|the|enhanced|methyldopa|in (r_nsubjpass) paralleled_10\VBN|hypotension|was|with|. (l_prep) with_11\IN|reduction (l_pobj) reduction_13\NN|further|in|and|activity (l_conj) activity_20\NN|a|reduced|locomotor
20470218
D008727_D056784 NONE methotrexate_32\NN| (r_compound) toxicity_33\NN|dose|methotrexate|(|n|2|)|,|syndrome (r_conj) syndrome_6\NN|posterior|reversible|leukoencephalopathy|(|n|)|,|stroke|,|toxicity (l_compound) leukoencephalopathy_5\JJ|
D008727_D020521 NONE methotrexate_32\NN| (r_compound) toxicity_33\NN|dose|methotrexate|(|n|2|)|,|syndrome (r_conj) syndrome_6\NN|posterior|reversible|leukoencephalopathy|(|n|)|,|stroke|,|toxicity (l_conj) stroke_13\NN|(|n|5|)|,|epilepsy
D008727_D004833 NONE methotrexate_32\NN| (r_compound) toxicity_33\NN|dose|methotrexate|(|n|2|)|,|syndrome (r_conj) syndrome_6\NN|posterior|reversible|leukoencephalopathy|(|n|)|,|stroke|,|toxicity (l_conj) stroke_13\NN|(|n|5|)|,|epilepsy (l_conj) epilepsy_22\NN|temporal|lobe|(|n|)
D008727_D064420 NONE methotrexate_32\NN| (r_compound) toxicity_33\NN|dose|methotrexate|(|n|2|)|,|syndrome
D008727_D007177 NONE methotrexate_32\NN| (r_compound) toxicity_33\NN|dose|methotrexate|(|n|2|)|,|syndrome (l_conj) syndrome_40\NN|of|,|and|events (l_prep) of_41\IN|secretion (l_pobj) secretion_45\NN|inappropriate|antidiuretic|hormone|(|n|)
4008111
D000638_D012848 CID Amiodarone_0\NN| (r_npadvmod) induced_2\VBN|amiodarone|- (r_amod) block_4\NN|induced|sinoatrial|.
D000638_D012848 CID amiodarone_7\NN| (r_compound) administration_8\NN|chronic|amiodarone|in (r_pobj) due_4\JJ|to|administration (r_prep) observed_1\VBD|we|block|due|,|syndrome|. (l_dobj) block_3\NN|sinoatrial
D000638_D012848 CID amiodarone_5\NN| (r_pobj) of_4\IN|amiodarone (r_prep) dosage_3\NN|the|of (r_pobj) in_1\IN|dosage (r_prep) Reduction_0\NN|in (r_nsubj) resulted_6\VBD|reduction|in|. (l_prep) in_7\IN|disappearance (l_pobj) disappearance_9\NN|the|of|and|persistence (l_prep) of_10\IN|block (l_pobj) block_13\NN|the|sinoatrial
D000638_D009202 NONE amiodarone_7\NN| (r_compound) administration_8\NN|chronic|amiodarone|in (l_prep) in_9\IN|boy (l_pobj) boy_14\NN|a|old|with (l_prep) with_15\IN|cardiomyopathy (l_pobj) cardiomyopathy_17\NN|primary
D000638_D014927 NONE amiodarone_7\NN| (r_compound) administration_8\NN|chronic|amiodarone|in (r_pobj) due_4\JJ|to|administration (r_prep) observed_1\VBD|we|block|due|,|syndrome|. (l_dobj) syndrome_24\NN|white|and|tachycardia
D000638_D013617 NONE amiodarone_7\NN| (r_compound) administration_8\NN|chronic|amiodarone|in (r_pobj) due_4\JJ|to|administration (r_prep) observed_1\VBD|we|block|due|,|syndrome|. (l_dobj) syndrome_24\NN|white|and|tachycardia (l_conj) tachycardia_27\NN|supraventricular
D000638_D012804 NONE amiodarone_5\NN| (r_pobj) of_4\IN|amiodarone (r_prep) dosage_3\NN|the|of (r_pobj) in_1\IN|dosage (r_prep) Reduction_0\NN|in (r_nsubj) resulted_6\VBD|reduction|in|. (l_prep) in_7\IN|disappearance (l_pobj) disappearance_9\NN|the|of|and|persistence (l_conj) persistence_16\NN|the|of (l_prep) of_17\IN|bradycardia (l_pobj) bradycardia_20\NNP|asymptomatic|sinus
9390208
D008942_D001943 NONE mitoxantrone_8\NN|and (r_pobj) by_7\IN|mitoxantrone (r_prep) cancer_6\NN|treated|metastatic|breast|by
D008942_D001943 NONE mitoxantrone_20\NN| (r_pobj) by_19\IN|mitoxantrone (r_prep) treated_8\VBD|from|,|we|patients|by|,|m2|on|,|with|,|m2|for|. (l_dobj) patients_10\NNS|13|with (l_prep) with_11\IN|cancer (l_pobj) cancer_18\NN|treated|metastatic|breast
D008942_D064420 NONE mitoxantrone_8\NN|and (r_pobj) by_7\IN|mitoxantrone (r_prep) cancer_6\NN|treated|metastatic|breast|by (r_pobj) of_1\IN|cancer (r_prep) Treatment_0\NN|of|infusion|. (l_conj) infusion_12\NN|48-hour|continuous|of (l_prep) of_13\IN|5-fu (l_pobj) 5-FU_17\CD|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN|low|palliative|and|toxicity (l_conj) toxicity_32\NN|high|related
D005472_D001943 NONE 5-FU_17\CD|dose|and|leucovorin|(|mfl|)|:|benefit (r_pobj) of_13\IN|5-fu (r_prep) infusion_12\NN|48-hour|continuous|of (r_conj) Treatment_0\NN|of|infusion|. (l_prep) of_1\IN|cancer (l_pobj) cancer_6\NN|treated|metastatic|breast|by
D005472_D001943 NONE 5-FU_34\CD|,|m2 (r_pobj) of_33\IN|5-fu (r_prep) infusion_32\NN|continuous|of (r_conj) day_28\NN|1|and|infusion (r_pobj) on_27\IN|day (r_prep) treated_8\VBD|from|,|we|patients|by|,|m2|on|,|with|,|m2|for|. (l_dobj) patients_10\NNS|13|with (l_prep) with_11\IN|cancer (l_pobj) cancer_18\NN|treated|metastatic|breast
D005472_D064420 NONE 5-FU_17\CD|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN|low|palliative|and|toxicity (l_conj) toxicity_32\NN|high|related
D002955_D001943 NONE leucovorin_19\NN| (r_conj) 5-FU_17\CD|dose|and|leucovorin|(|mfl|)|:|benefit (r_pobj) of_13\IN|5-fu (r_prep) infusion_12\NN|48-hour|continuous|of (r_conj) Treatment_0\NN|of|infusion|. (l_prep) of_1\IN|cancer (l_pobj) cancer_6\NN|treated|metastatic|breast|by
D002955_D001943 NONE leucovorin_43\NN| (r_pobj) with_42\IN|together|leucovorin (r_prep) treated_8\VBD|from|,|we|patients|by|,|m2|on|,|with|,|m2|for|. (l_dobj) patients_10\NNS|13|with (l_prep) with_11\IN|cancer (l_pobj) cancer_18\NN|treated|metastatic|breast
D002955_D064420 NONE leucovorin_19\NN| (r_conj) 5-FU_17\CD|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN|low|palliative|and|toxicity (l_conj) toxicity_32\NN|high|related
C085788_D001943 NONE MFL_21\NNP| (r_appos) 5-FU_17\CD|dose|and|leucovorin|(|mfl|)|:|benefit (r_pobj) of_13\IN|5-fu (r_prep) infusion_12\NN|48-hour|continuous|of (r_conj) Treatment_0\NN|of|infusion|. (l_prep) of_1\IN|cancer (l_pobj) cancer_6\NN|treated|metastatic|breast|by
C085788_D064420 NONE MFL_21\NNP| (r_appos) 5-FU_17\CD|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN|low|palliative|and|toxicity (l_conj) toxicity_32\NN|high|related
C085788_D064420 NONE regimen_2\NN|the|mfl (r_nsubj) achieves_3\VBZ|regimen|benefit|and|induces|. (l_conj) induces_8\VBZ|toxicity|at (l_dobj) toxicity_10\NN|severe
12443032
D003042_D002637 CID Cocaine_0\NN| (r_nsubj) related_1\VBN|cocaine|pain (l_dobj) pain_3\NN|chest
D003042_D002637 CID cocaine_6\NN| (r_pobj) of_5\IN|cocaine (r_prep) tendency_4\NN|the|of|produce (l_acl) produce_8\VB|to|pain (l_dobj) pain_10\NN|chest
D003042_D002637 CID cocaine_6\NN| (r_pobj) of_5\IN|cocaine (r_prep) tendency_4\NN|the|of|produce (r_nsubj) ought_11\MD|in|,|tendency|be|. (l_xcomp) be_13\VB|to|in|faced (l_advcl) faced_22\VBN|when|with (l_prep) with_23\IN|victim (l_pobj) victim_26\NN|a|young|of|is (l_prep) of_27\IN|pain (l_pobj) pain_29\NN|chest
D003042_D002637 CID cocaine_7\NN| (r_compound) use_8\NN|cocaine (r_pobj) to_6\IN|use (r_prep) related_5\VBN|to (r_acl) mechanism_1\NN|the|of|related (l_prep) of_2\IN|pain (l_pobj) pain_4\NN|chest
19346865
D008795_D001927 CID metronidazole_5\NN| (r_npadvmod) induced_7\VBN|metronidazole|- (r_amod) encephalopathy_8\NN|induced (r_pobj) in_4\IN|encephalopathy (r_prep) lesion_3\NN|reversible|inferior|colliculus|in|:|findings|.
D008795_D001927 CID metronidazole_5\NN| (r_npadvmod) induced_7\VBN|metronidazole|- (r_amod) encephalopathy_8\NN|induced
D008795_D001927 CID metronidazole_9\NN| (r_npadvmod) induced_11\VBN|metronidazole|- (r_amod) encephalopathy_12\NN|induced (r_pobj) in_8\IN|encephalopathy (r_prep) lesions_7\NNS|reversible|inferior|colliculus|in
D008795_D001927 CID metronidazole_9\NN| (r_npadvmod) induced_11\VBN|metronidazole|- (r_amod) encephalopathy_12\NN|induced
D008795_D001927 CID metronidazole_20\NN| (r_npadvmod) induced_22\VBN|metronidazole|- (r_amod) encephalopathy_23\NN|induced|(|range|;|years
D008795_D001927 CID metronidazole_11\NN| (r_npadvmod) induced_13\VBN|metronidazole|- (r_amod) encephalopathy_14\NN|induced (r_pobj) for_10\IN|encephalopathy (r_prep) characteristic_9\NN|the|for (r_pobj) as_7\IN|characteristic (r_prep) considered_6\VBN|lesions|could|be|as|,|next|. (l_nsubjpass) lesions_3\NNS|reversible|inferior|colliculus
D008795_D001927 CID metronidazole_11\NN| (r_npadvmod) induced_13\VBN|metronidazole|- (r_amod) encephalopathy_14\NN|induced
D008795_D007239 NONE metronidazole_4\NN| (r_dobj) taking_3\VBG|they|had|been|metronidazole|(|dosage|)|treat|. (l_advcl) treat_23\VB|to|infection (l_dobj) infection_25\NN|the|in
3403780
D000082_D003128 NONE Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|paracetamol|- (r_amod) coma_3\NN|associated|,|acidosis|.
D000082_D000138 CID Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|paracetamol|- (r_amod) coma_3\NN|associated|,|acidosis|. (l_appos) acidosis_6\NN|metabolic|,|failure
D000082_D000138 CID paracetamol_13\JJ| (r_compound) ingestion_14\NN|paracetamol (r_pobj) following_12\VBG|ingestion (r_prep) failure_8\NN|acute|renal|and|failure|following (r_nsubjpass) presented_16\VBN|case|,|failure|is|. (l_nsubjpass) case_1\NN|a|of (l_prep) of_2\IN|acidosis (l_pobj) acidosis_4\NN|metabolic
D000082_D058186 CID paracetamol_13\JJ| (r_compound) ingestion_14\NN|paracetamol (r_pobj) following_12\VBG|ingestion (r_prep) failure_8\NN|acute|renal|and|failure|following (l_conj) failure_11\NN|hepatic
D000082_D058186 NONE Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|paracetamol|- (r_amod) coma_3\NN|associated|,|acidosis|. (l_appos) acidosis_6\NN|metabolic|,|failure (l_conj) failure_11\NN|renal
D000082_D017093 NONE Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|paracetamol|- (r_amod) coma_3\NN|associated|,|acidosis|. (l_appos) acidosis_6\NN|metabolic|,|failure (l_conj) failure_11\NN|renal
D000082_D017114 CID paracetamol_13\JJ| (r_compound) ingestion_14\NN|paracetamol (r_pobj) following_12\VBG|ingestion (r_prep) failure_8\NN|acute|renal|and|failure|following (l_conj) failure_11\NN|hepatic
8701950
D016559_D000743 CID FK506_4\NNP|(|therapy (r_dobj) complicating_3\VBG|anemia|fk506|. (l_nsubj) anemia_2\NN|microangiopathic|hemolytic
D016559_D000743 CID tacrolimus_6\NNP|) (r_nmod) therapy_8\NN|tacrolimus (r_appos) FK506_4\NNP|(|therapy (r_dobj) complicating_3\VBG|anemia|fk506|. (l_nsubj) anemia_2\NN|microangiopathic|hemolytic
D016559_D000743 CID FK506_17\NNP|( (r_nmod) therapy_21\NN|fk506|tacrolimus (r_pobj) under_16\IN|therapy (r_prep) recipients_15\NNS|2|solid|organ|under (r_pobj) in_11\IN|recipients (r_prep) episodes_3\NNS|3|of|in (l_prep) of_4\IN|anemia (l_pobj) anemia_7\NN|microangiopathic|hemolytic|(|maha|)
D016559_D000743 CID FK506_17\NNP|( (r_nmod) therapy_21\NN|fk506|tacrolimus (r_pobj) under_16\IN|therapy (r_prep) recipients_15\NNS|2|solid|organ|under (r_pobj) in_11\IN|recipients (r_prep) episodes_3\NNS|3|of|in (l_prep) of_4\IN|anemia (l_pobj) anemia_7\NN|microangiopathic|hemolytic|(|maha|) (l_appos) MAHA_9\NNP|
D016559_D000743 CID tacrolimus_19\NNP|) (r_nmod) therapy_21\NN|fk506|tacrolimus (r_pobj) under_16\IN|therapy (r_prep) recipients_15\NNS|2|solid|organ|under (r_pobj) in_11\IN|recipients (r_prep) episodes_3\NNS|3|of|in (l_prep) of_4\IN|anemia (l_pobj) anemia_7\NN|microangiopathic|hemolytic|(|maha|)
D016559_D000743 CID tacrolimus_19\NNP|) (r_nmod) therapy_21\NN|fk506|tacrolimus (r_pobj) under_16\IN|therapy (r_prep) recipients_15\NNS|2|solid|organ|under (r_pobj) in_11\IN|recipients (r_prep) episodes_3\NNS|3|of|in (l_prep) of_4\IN|anemia (l_pobj) anemia_7\NN|microangiopathic|hemolytic|(|maha|) (l_appos) MAHA_9\NNP|
D016559_D000743 CID FK506_6\NNP|and|treatment (r_pobj) of_5\IN|fk506 (r_prep) discontinuation_4\NN|of|,|replacement (r_nsubj) led_24\VBD|in|,|discontinuation|to|. (l_prep) to_25\IN|resolution (l_pobj) resolution_26\NN|of (l_prep) of_27\IN|maha (l_pobj) MAHA_28\NNP|
D016559_D000743 CID FK506_6\NNP| (r_pobj) of_5\IN|fk506 (r_prep) reintroduction_4\NN|of (r_nsubj) led_7\VBD|in|,|reintroduction|to|. (l_prep) to_8\IN|recurrence (l_pobj) recurrence_10\NN|rapid|of (l_prep) of_11\IN|maha (l_pobj) MAHA_12\NNP|
D016559_D000743 CID FK506-associated_0\VBN| (r_amod) MAHA_1\NNP|fk506-associated
D016559_D000743 CID FK506_9\NNP| (r_nsubj) seem_12\VB|in|,|fk506|does|not|a|. (l_oprd) A_19\NNP|react|with|cyclosporin|cya|,|drug (l_appos) drug_28\NN|an|suppressive|known (l_acl) known_30\VBN|already|induce (l_xcomp) induce_32\VB|to|maha (l_dobj) MAHA_33\NNP|
D000305_D000743 NONE corticosteroids_18\NNS|,|aspirin (r_conj) replacement_16\NN|fresh|plasma|,|corticosteroids (r_appos) discontinuation_4\NN|of|,|replacement (r_nsubj) led_24\VBD|in|,|discontinuation|to|. (l_prep) to_25\IN|resolution (l_pobj) resolution_26\NN|of (l_prep) of_27\IN|maha (l_pobj) MAHA_28\NNP|
D001241_D000743 NONE aspirin_20\NN|,|and|dipyridamole (r_conj) corticosteroids_18\NNS|,|aspirin (r_conj) replacement_16\NN|fresh|plasma|,|corticosteroids (r_appos) discontinuation_4\NN|of|,|replacement (r_nsubj) led_24\VBD|in|,|discontinuation|to|. (l_prep) to_25\IN|resolution (l_pobj) resolution_26\NN|of (l_prep) of_27\IN|maha (l_pobj) MAHA_28\NNP|
D004176_D000743 NONE dipyridamole_23\NN| (r_conj) aspirin_20\NN|,|and|dipyridamole (r_conj) corticosteroids_18\NNS|,|aspirin (r_conj) replacement_16\NN|fresh|plasma|,|corticosteroids (r_appos) discontinuation_4\NN|of|,|replacement (r_nsubj) led_24\VBD|in|,|discontinuation|to|. (l_prep) to_25\IN|resolution (l_pobj) resolution_26\NN|of (l_prep) of_27\IN|maha (l_pobj) MAHA_28\NNP|
D016572_D000743 NONE A_19\NNP|react|with|cyclosporin|cya|,|drug (l_appos) drug_28\NN|an|suppressive|known (l_acl) known_30\VBN|already|induce (l_xcomp) induce_32\VB|to|maha (l_dobj) MAHA_33\NNP|
D016572_D000743 NONE CyA_21\NN|(|) (r_appos) A_19\NNP|react|with|cyclosporin|cya|,|drug (l_appos) drug_28\NN|an|suppressive|known (l_acl) known_30\VBN|already|induce (l_xcomp) induce_32\VB|to|maha (l_dobj) MAHA_33\NNP|
12589964
D004317_D009202 CID doxorubicin_14\NN| (r_npadvmod) induced_16\VBN|doxorubicin|- (r_amod) rats_18\NNS|induced|cardiomyopathy (r_pobj) in_13\IN|rats (r_prep) damage_12\NN|myocardial|in
D004317_D009202 CID doxorubicin_14\NN| (r_npadvmod) induced_16\VBN|doxorubicin|- (r_amod) rats_18\NNS|induced|cardiomyopathy (l_amod) cardiomyopathy_17\NN|
D004317_D009202 CID doxorubicin_20\NN| (r_pobj) of_19\IN|doxorubicin (r_prep) model_18\NN|a|rat|of|cardiomyopathy (r_pobj) in_15\IN|model (r_prep) damage_14\NN|myocardial|in
D004317_D009202 CID doxorubicin_20\NN| (r_pobj) of_19\IN|doxorubicin (r_prep) model_18\NN|a|rat|of|cardiomyopathy (l_appos) cardiomyopathy_23\NN|(|dox)-induced
D004317_D009202 CID DOX)-induced_22\VBN| (r_amod) cardiomyopathy_23\NN|(|dox)-induced (r_appos) model_18\NN|a|rat|of|cardiomyopathy (r_pobj) in_15\IN|model (r_prep) damage_14\NN|myocardial|in
D004317_D009202 CID DOX)-induced_22\VBN| (r_amod) cardiomyopathy_23\NN|(|dox)-induced
D004317_D009202 CID DOX_6\NNP|in (r_pobj) after_5\IN|dox (r_prep) markers_1\NNS|of|after (r_pobj) Among_0\IN|markers (r_prep) showed_11\VBD|among|,|ctnt|ability|. (l_dobj) ability_14\NN|the|greatest|detect (l_acl) detect_16\VB|to|damage (l_dobj) damage_18\NN|myocardial|assessed
D004317_D006331 NONE doxorubicin_20\NN| (r_pobj) of_19\IN|doxorubicin (r_prep) model_18\NN|a|rat|of|cardiomyopathy (r_pobj) in_15\IN|model (r_prep) damage_14\NN|myocardial|in (r_pobj) of_12\IN|damage (r_prep) diagnosis_11\NN|the|of (r_pobj) for_9\IN|diagnosis (r_prep) investigated_1\VBD|we|value|for|,|and|examined (l_conj) examined_27\VBD|we|relationship|. (l_dobj) relationship_29\NN|the|between|with (l_prep) with_35\IN|development (l_pobj) development_37\NN|the|of (l_prep) of_38\IN|disorders (l_pobj) disorders_40\NNS|cardiac|monitored
D004317_D006331 NONE DOX)-induced_22\VBN| (r_amod) cardiomyopathy_23\NN|(|dox)-induced (r_appos) model_18\NN|a|rat|of|cardiomyopathy (r_pobj) in_15\IN|model (r_prep) damage_14\NN|myocardial|in (r_pobj) of_12\IN|damage (r_prep) diagnosis_11\NN|the|of (r_pobj) for_9\IN|diagnosis (r_prep) investigated_1\VBD|we|value|for|,|and|examined (l_conj) examined_27\VBD|we|relationship|. (l_dobj) relationship_29\NN|the|between|with (l_prep) with_35\IN|development (l_pobj) development_37\NN|the|of (l_prep) of_38\IN|disorders (l_pobj) disorders_40\NNS|cardiac|monitored
D004317_D064420 NONE DOX_3\NNP| (r_compound) rats_4\NNS|the|dox (r_pobj) of_1\IN|rats (r_prep) Eighteen_0\CD|of (r_nsubj) died_5\VBD|eighteen|prematurely|of|during|. (l_prep) of_7\IN|toxicity (l_pobj) toxicity_9\NN|general
D004317_D005355 NONE DOX_8\NNP| (r_pobj) given_7\VBN|dox (r_prep) rats_6\NNS|all|given (r_pobj) from_4\IN|rats (r_prep) hearts_3\NNS|from (r_pobj) of_2\IN|hearts (r_prep) evaluation_1\NN|histological|of (r_nsubj) revealed_9\VBD|evaluation|degrees|. (l_dobj) degrees_12\NNS|significant|slight|of (l_prep) of_13\IN|fibrosis (l_pobj) fibrosis_17\NN|perivascular
D004317_D017202 NONE DOX_6\NNP|in (r_pobj) after_5\IN|dox (r_prep) markers_1\NNS|of|after (l_prep) of_2\IN|injury (l_pobj) injury_4\NN|ischemic
D004317_D066126 NONE DOX_13\NNP| (r_pobj) after_12\IN|dox (r_prep) amount_7\NN|the|of|after|, (r_pobj) between_5\IN|amount (r_prep) discrepancy_4\NN|a|between (r_attr) was_2\VBD|although|there|discrepancy|due (r_advcl) is_33\VBZ|was|,|it|likely|. (l_acomp) likely_34\JJ|indicates (l_ccomp) indicates_41\VBZ|that|ctnt|after|dox|damage|induced|and|be (l_conj) be_55\VB|that|ctnt|should|marker (l_attr) marker_58\NN|a|useful|for (l_prep) for_59\IN|prediction (l_pobj) prediction_61\NN|the|of (l_prep) of_62\IN|cardiotoxicity (l_pobj) cardiotoxicity_65\NN|induced|and|for
D004317_D066126 NONE DOX_40\NNP| (r_nsubj) indicates_41\VBZ|that|ctnt|after|dox|damage|induced|and|be (l_conj) be_55\VB|that|ctnt|should|marker (l_attr) marker_58\NN|a|useful|for (l_prep) for_59\IN|prediction (l_pobj) prediction_61\NN|the|of (l_prep) of_62\IN|cardiotoxicity (l_pobj) cardiotoxicity_65\NN|induced|and|for
19037603
D019259_D012216 NONE lamivudine_3\NN| (r_pobj) of_2\IN|lamivudine (r_prep) use_1\NN|prophylactic|of|with|. (l_prep) with_4\IN|therapy (l_pobj) therapy_7\NN|chronic|immunosuppressive|for (l_prep) for_8\IN|disorders (l_pobj) disorders_10\NNS|rheumatologic
D019259_D012216 NONE lamivudine_18\NN| (r_pobj) of_17\IN|lamivudine (r_prep) administration_16\NN|the|prophylactic|of|in (r_pobj) of_13\IN|administration (r_prep) effectiveness_12\NN|the|of (r_pobj) concerning_10\VBG|effectiveness (r_prep) report_7\VB|to|experience|concerning (r_xcomp) was_5\VBD|objective|report|patients|. (l_attr) patients_30\NNS|)|positive|with (l_prep) with_31\IN|disease (l_pobj) disease_33\NN|rheumatologic
D019259_D012216 NONE lamivudine_23\JJ| (r_compound) therapies_24\NNS|immunosuppressive|lamivudine (r_pobj) on_18\IN|therapies (r_prep) were_17\VBD|who|on (r_relcl) diseases_14\NNS|rheumatologic|,|were
D006514_D012216 NONE antigen_24\NN|virus|surface|ag (r_pobj) in_19\IN|antigen (r_prep) administration_16\NN|the|prophylactic|of|in (r_pobj) of_13\IN|administration (r_prep) effectiveness_12\NN|the|of (r_pobj) concerning_10\VBG|effectiveness (r_prep) report_7\VB|to|experience|concerning (r_xcomp) was_5\VBD|objective|report|patients|. (l_attr) patients_30\NNS|)|positive|with (l_prep) with_31\IN|disease (l_pobj) disease_33\NN|rheumatologic
D006514_D012216 NONE Ag_27\NNP|(|hbs (r_appos) antigen_24\NN|virus|surface|ag (r_pobj) in_19\IN|antigen (r_prep) administration_16\NN|the|prophylactic|of|in (r_pobj) of_13\IN|administration (r_prep) effectiveness_12\NN|the|of (r_pobj) concerning_10\VBG|effectiveness (r_prep) report_7\VB|to|experience|concerning (r_xcomp) was_5\VBD|objective|report|patients|. (l_attr) patients_30\NNS|)|positive|with (l_prep) with_31\IN|disease (l_pobj) disease_33\NN|rheumatologic
D006514_D012216 NONE Ag_9\NNP|11|hbs (r_nmod) patients_11\NNS|ag|positive|with (l_prep) with_12\IN|diseases (l_pobj) diseases_14\NNS|rheumatologic|,|were
12653683
D012964_D009404 NONE sodium_1\NN| (r_compound) channel_2\NN|epithelial|sodium|(|enac|)|subunit|. (l_appos) subunit_6\NN|mrna (l_appos) mRNA_7\NN|and|expression (l_conj) expression_10\NN|protein|in (l_prep) in_11\IN|rats (l_pobj) rats_12\NNS|with (l_prep) with_13\IN|syndrome (l_pobj) syndrome_19\NN|puromycin|induced|nephrotic
D012964_D009404 NONE sodium_6\NN|urinary (r_compound) excretion_7\NN|sodium (r_nsubjpass) decreased_9\VBN|in|,|excretion|is|during|. (l_prep) In_0\IN|syndrome (l_pobj) syndrome_3\NN|experimental|nephrotic
D011692_D009404 CID aminonucleoside_15\RB| (r_advmod) induced_17\VBN|aminonucleoside|- (r_amod) syndrome_19\NN|puromycin|induced|nephrotic
D011692_D009404 CID aminonucleoside_12\NN|syndrome (l_pobj) syndrome_16\NN|pan)-induced|nephrotic
D011692_D009404 CID PAN)-induced_14\VBN|( (r_amod) syndrome_16\NN|pan)-induced|nephrotic
D011692_D009404 CID PAN_22\NNP| (r_npadvmod) induced_24\VBN|pan|- (r_amod) syndrome_26\NN|induced|nephrotic|in
D012964_D011507 NONE sodium_5\NN|urinary (r_compound) excretion_6\NN|sodium|,|concentration (l_conj) concentration_10\NN|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN|
D012964_D011507 NONE sodium_4\NN|urinary (r_compound) excretion_5\NN|sodium (r_pobj) of_2\IN|excretion (r_prep) kinetics_1\NNS|the|of|and|appearance (l_conj) appearance_8\NN|the|of (l_prep) of_9\IN|proteinuria (l_pobj) proteinuria_10\NN|
D000450_D011507 NONE aldosterone_9\NN|plasma (r_compound) concentration_10\NN|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN|
D011692_D011507 CID PAN_28\NNP|either|or|vehicle (r_pobj) of_26\IN|pan (r_prep) dose_25\NN|a|single|of (r_pobj) with_22\IN|dose (r_prep) treated_21\VBN|with (r_acl) rats_20\NNS|male|dawley|treated (r_pobj) in_15\IN|rats (r_prep) studied_14\VBN|courses|were|in|. (l_nsubjpass) courses_2\NNS|the|time|of (l_prep) of_3\IN|excretion (l_pobj) excretion_6\NN|sodium|,|concentration (l_conj) concentration_10\NN|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN|
D000450_D009404 NONE aldosterone_38\NN| (r_pobj) by_37\IN|aldosterone (r_prep) regulation_36\NN|the|by (r_pobj) from_34\IN|regulation (r_prep) escape_33\VB|to|from|after (r_xcomp) appears_31\VBZ|escape (r_conj) increased_11\VBN|in|,|expression|is|in|,|but|appears|. (l_prep) in_12\IN|phase (l_pobj) phase_16\NN|the|early|of (l_prep) of_17\IN|model (l_pobj) model_20\NN|the|experimental|of (l_prep) of_21\IN|syndrome (l_pobj) syndrome_26\NN|induced|nephrotic|in
12090760
D015215_D000740 CID azidothymidine_9\RB| (r_advmod) induced_11\VBN|azidothymidine|- (r_amod) anemia_12\NN|induced
D015215_D000740 CID Azidothymidine_0\NNP| (r_nsubjpass) reversed_8\VBN|azidothymidine|anemia|can|be|by|and|interleukin|. (l_nsubjpass) anemia_3\NN|(|azt)-induced|in
D015215_D000740 CID AZT)-induced_2\VBN| (r_compound) anemia_3\NN|(|azt)-induced|in
20080419
D010862_D004827 CID pilocarpine_24\NN| (r_pobj) by_23\IN|pilocarpine (r_agent) induced_22\VBN|by|in (r_acl) model_19\NN|a|of|induced (l_prep) of_20\IN|epilepsy (l_pobj) epilepsy_21\NN|
11419773
D002110_D001145 NONE Caffeine_0\NN| (r_nsubj) induced_2\VBN|caffeine|- (r_amod) arrhythmia_4\NN|induced|cardiac|:|danger|.
D002110_D008945 NONE caffeine_34\NN| (r_pobj) of_33\IN|caffeine (r_prep) concentration_32\NN|a|high|of (r_dobj) containing_29\VBG|concentration (r_acl) drink_28\NN|a|"|energy|"|guarana|health|containing (r_dobj) consuming_20\VBG|drink (r_pcomp) after_19\IN|consuming (r_prep) developed_15\VBD|who|fibrillation|after (r_relcl) woman_6\NN|a|old|with|developed (l_prep) with_7\IN|prolapse (l_pobj) prolapse_13\NN|existing|mitral|valve
D002110_D014693 CID caffeine_34\NN| (r_pobj) of_33\IN|caffeine (r_prep) concentration_32\NN|a|high|of (r_dobj) containing_29\VBG|concentration (r_acl) drink_28\NN|a|"|energy|"|guarana|health|containing (r_dobj) consuming_20\VBG|drink (r_pcomp) after_19\IN|consuming (r_prep) developed_15\VBD|who|fibrillation|after (l_dobj) fibrillation_18\NN|intractable|ventricular
12627929
C067311_D054556 CID docetaxel_9\NNS|and|thalidomide (r_pobj) of_8\IN|docetaxel (r_prep) combination_7\NN|the|of|in (r_pobj) with_5\IN|combination (r_prep) thromboembolism_4\NN|venous|with
C067311_D054556 CID docetaxel_26\NNS| (r_pobj) with_25\IN|docetaxel (r_prep) treated_24\VBN|who|were|with|alone (r_relcl) cancer_21\NN|advanced|independent|prostate|treated (r_pobj) with_15\IN|cancer (r_prep) patients_14\NNS|with (r_pobj) in_13\IN|patients (r_prep) frequency_6\NN|the|of|in (l_prep) of_7\IN|thromboembolism (l_pobj) thromboembolism_9\NN|venous|(|vte|)
C067311_D054556 CID docetaxel_26\NNS| (r_pobj) with_25\IN|docetaxel (r_prep) treated_24\VBN|who|were|with|alone (r_relcl) cancer_21\NN|advanced|independent|prostate|treated (r_pobj) with_15\IN|cancer (r_prep) patients_14\NNS|with (r_pobj) in_13\IN|patients (r_prep) frequency_6\NN|the|of|in (l_prep) of_7\IN|thromboembolism (l_pobj) thromboembolism_9\NN|venous|(|vte|) (l_appos) VTE_11\NNP|
C067311_D054556 CID docetaxel_6\NNS| (r_dobj) received_5\VBD|who|docetaxel|alone (r_relcl) patients_3\NNS|23|received (r_pobj) of_1\IN|patients (r_prep) None_0\NN|of (r_nsubj) developed_8\VBN|none|vte|,|developed|. (l_dobj) VTE_9\NNP|
C067311_D054556 CID docetaxel_6\NNS| (r_dobj) received_5\VBD|who|docetaxel|alone (r_relcl) patients_3\NNS|23|received (r_pobj) of_1\IN|patients (r_prep) None_0\NN|of (r_nsubj) developed_8\VBN|none|vte|,|developed|. (l_advcl) developed_25\VBD|whereas|9|vte (l_dobj) VTE_26\NNP|p=0.025
C067311_D054556 CID docetaxel_22\NNS| (r_dobj) received_21\VBD|who|docetaxel (r_relcl) patients_15\NNS|47|(|%|)|received (r_pobj) of_13\IN|patients (r_prep) 9_12\CD|of|plus|thalidomide (r_nsubj) developed_25\VBD|whereas|9|vte (r_advcl) developed_8\VBN|none|vte|,|developed|. (l_dobj) VTE_9\NNP|
C067311_D054556 CID docetaxel_22\NNS| (r_dobj) received_21\VBD|who|docetaxel (r_relcl) patients_15\NNS|47|(|%|)|received (r_pobj) of_13\IN|patients (r_prep) 9_12\CD|of|plus|thalidomide (r_nsubj) developed_25\VBD|whereas|9|vte (l_dobj) VTE_26\NNP|p=0.025
C067311_D054556 CID docetaxel_5\NNS|to|in (r_relcl) addition_1\NN|the|of|docetaxel (r_nsubj) increases_13\VBZ|addition|significantly|frequency|. (l_dobj) frequency_15\NN|the|of (l_prep) of_16\IN|vte (l_pobj) VTE_17\NNP|
C067311_D011471 NONE docetaxel_9\NNS|and|thalidomide (r_pobj) of_8\IN|docetaxel (r_prep) combination_7\NN|the|of|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|cancer (l_pobj) cancer_20\NN|metastatic|independent|prostate
C067311_D011471 NONE docetaxel_26\NNS| (r_pobj) with_25\IN|docetaxel (r_prep) treated_24\VBN|who|were|with|alone (r_relcl) cancer_21\NN|advanced|independent|prostate|treated
C067311_D011471 NONE docetaxel_5\NNS|to|in (l_prep) in_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|cancer (l_pobj) cancer_11\NN|prostate
D013792_D054556 CID thalidomide_11\NN| (r_conj) docetaxel_9\NNS|and|thalidomide (r_pobj) of_8\IN|docetaxel (r_prep) combination_7\NN|the|of|in (r_pobj) with_5\IN|combination (r_prep) thromboembolism_4\NN|venous|with
D013792_D054556 CID thalidomide_32\NN| (r_pobj) with_31\IN|thalidomide (r_prep) combination_30\NN|with (r_pobj) in_29\IN|combination (r_conj) alone_27\RB|or|in (r_advmod) treated_24\VBN|who|were|with|alone (r_relcl) cancer_21\NN|advanced|independent|prostate|treated (r_pobj) with_15\IN|cancer (r_prep) patients_14\NNS|with (r_pobj) in_13\IN|patients (r_prep) frequency_6\NN|the|of|in (l_prep) of_7\IN|thromboembolism (l_pobj) thromboembolism_9\NN|venous|(|vte|)
D013792_D054556 CID thalidomide_32\NN| (r_pobj) with_31\IN|thalidomide (r_prep) combination_30\NN|with (r_pobj) in_29\IN|combination (r_conj) alone_27\RB|or|in (r_advmod) treated_24\VBN|who|were|with|alone (r_relcl) cancer_21\NN|advanced|independent|prostate|treated (r_pobj) with_15\IN|cancer (r_prep) patients_14\NNS|with (r_pobj) in_13\IN|patients (r_prep) frequency_6\NN|the|of|in (l_prep) of_7\IN|thromboembolism (l_pobj) thromboembolism_9\NN|venous|(|vte|) (l_appos) VTE_11\NNP|
D013792_D054556 CID thalidomide_24\NN| (r_conj) 9_12\CD|of|plus|thalidomide (r_nsubj) developed_25\VBD|whereas|9|vte (r_advcl) developed_8\VBN|none|vte|,|developed|. (l_dobj) VTE_9\NNP|
D013792_D054556 CID thalidomide_24\NN| (r_conj) 9_12\CD|of|plus|thalidomide (r_nsubj) developed_25\VBD|whereas|9|vte (l_dobj) VTE_26\NNP|p=0.025
D013792_D054556 CID thalidomide_3\NN| (r_pobj) of_2\IN|thalidomide (r_prep) addition_1\NN|the|of|docetaxel (r_nsubj) increases_13\VBZ|addition|significantly|frequency|. (l_dobj) frequency_15\NN|the|of (l_prep) of_16\IN|vte (l_pobj) VTE_17\NNP|
D013792_D011471 NONE thalidomide_11\NN| (r_conj) docetaxel_9\NNS|and|thalidomide (r_pobj) of_8\IN|docetaxel (r_prep) combination_7\NN|the|of|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|cancer (l_pobj) cancer_20\NN|metastatic|independent|prostate
D013792_D011471 NONE thalidomide_32\NN| (r_pobj) with_31\IN|thalidomide (r_prep) combination_30\NN|with (r_pobj) in_29\IN|combination (r_conj) alone_27\RB|or|in (r_advmod) treated_24\VBN|who|were|with|alone (r_relcl) cancer_21\NN|advanced|independent|prostate|treated
D013792_D011471 NONE thalidomide_3\NN| (r_pobj) of_2\IN|thalidomide (r_prep) addition_1\NN|the|of|docetaxel (l_relcl) docetaxel_5\NNS|to|in (l_prep) in_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|cancer (l_pobj) cancer_11\NN|prostate
11256525
D019808_D001002 CID losartan_4\NN| (r_amod) administration_5\NN|losartan (r_dobj) following_3\VBG|administration|in (r_prep) anuria_2\NN|repeated|transient|following|.
D019808_D001002 CID losartan_27\NN| (r_amod) administration_28\NN|losartan (r_pobj) after_26\IN|administration (r_prep) developed_20\VBD|who|episodes|after (l_dobj) episodes_22\NNS|two|of (l_prep) of_23\IN|anuria (l_pobj) anuria_25\NN|transient
D019808_D001002 CID losartan_9\NN| (r_pobj) of_8\IN|losartan (r_prep) mg_7\NN|50|of (r_pobj) of_5\IN|mg (r_prep) dose_4\NN|the|first|of (r_nsubj) resulted_10\VBD|surprisingly|,|dose|in|. (l_prep) in_11\IN|anuria (l_pobj) anuria_14\NN|a|sudden|,|lasted
D019808_D001002 CID losartan_7\NN| (r_nsubjpass) prescribed_9\VBN|later|,|by|,|losartan|was|again|and|developed (l_conj) developed_22\VBD|after|,|patient|episode|. (l_dobj) episode_25\NN|a|second|of|lasting (l_prep) of_26\IN|anuria (l_pobj) anuria_28\NN|transient
D019808_D006973 NONE losartan_27\NN| (r_amod) administration_28\NN|losartan (r_pobj) after_26\IN|administration (r_prep) developed_20\VBD|who|episodes|after (r_relcl) kidney_14\NN|a|solitary|and|insufficiency|developed (r_pobj) with_11\IN|kidney (r_prep) man_10\NN|a|old|hypertensive|with (l_amod) hypertensive_9\JJ|
D019808_D051436 NONE losartan_27\NN| (r_amod) administration_28\NN|losartan (r_pobj) after_26\IN|administration (r_prep) developed_20\VBD|who|episodes|after (r_relcl) kidney_14\NN|a|solitary|and|insufficiency|developed (l_conj) insufficiency_18\NN|chronic|renal
D019808_D006331 NONE losartan_5\NN|dysfunction (l_compound) dysfunction_4\NN|severe|systolic
D005665_D001002 NONE furosemide_24\NN|and|amine (r_nmod) infusion_27\NN|dose|furosemide (r_pobj) despite_20\IN|infusion (r_prep) lasted_17\VBD|which|hours|despite (r_relcl) anuria_14\NN|a|sudden|,|lasted
D000588_D001002 NONE amine_26\NN| (r_conj) furosemide_24\NN|and|amine (r_nmod) infusion_27\NN|dose|furosemide (r_pobj) despite_20\IN|infusion (r_prep) lasted_17\VBD|which|hours|despite (r_relcl) anuria_14\NN|a|sudden|,|lasted
D000809_D012078 NONE angiotensin_24\NN|renin|- (r_compound) system_25\NN|the|angiotensin|(|ras|) (r_pobj) of_20\IN|system (r_prep) activation_19\NN|a|strong|of (r_pobj) in_16\IN|activation (r_prep) resulted_15\VBD|in|,|stenosis|certainly|in|. (l_nsubj) stenosis_6\NN|renal|artery|combined
D000809_D006333 NONE angiotensin_24\NN|renin|- (r_compound) system_25\NN|the|angiotensin|(|ras|) (r_pobj) of_20\IN|system (r_prep) activation_19\NN|a|strong|of (r_pobj) in_16\IN|activation (r_prep) resulted_15\VBD|in|,|stenosis|certainly|in|. (l_nsubj) stenosis_6\NN|renal|artery|combined (l_acl) combined_7\VBN|with (l_prep) with_8\IN|failure (l_pobj) failure_10\NN|heart|and|therapy
D000804_D014652 NONE II_9\NNP| (r_compound) antagonist_11\NN|ii|receptor (r_compound) losartan_12\NN|the|angiotensin|antagonist (r_nsubj) cause_14\VB|that|losartan|can|complications|and|used (l_dobj) complications_17\NNS|serious|unexpected|in (l_prep) in_18\IN|patients (l_pobj) patients_19\NNS|with (l_prep) with_20\IN|disease (l_pobj) disease_22\NN|renovascular
D019808_D014652 NONE losartan_12\NN|the|angiotensin|antagonist (r_nsubj) cause_14\VB|that|losartan|can|complications|and|used (l_dobj) complications_17\NNS|serious|unexpected|in (l_prep) in_18\IN|patients (l_pobj) patients_19\NNS|with (l_prep) with_20\IN|disease (l_pobj) disease_22\NN|renovascular
3358181
D012312_D014693 CID ritodrine_6\JJ| (r_compound) therapy_7\NN|ritodrine (r_pobj) after_5\IN|therapy (r_prep) section_4\NN|cesarean|after (r_pobj) during_2\IN|section (r_prep) tachyarrhythmias_1\NNS|ventricular|during|:|interaction|.
D012312_D007752 NONE ritodrine_6\RB|for (l_prep) for_7\IN|labor (l_pobj) labor_9\NN|preterm
D012312_D007752 NONE ritodrine_19\NN| (r_pobj) of_18\IN|ritodrine (r_prep) effects_17\NNS|the|residual|betamimetic|of|and|effects (r_pobj) between_13\IN|effects (r_prep) interactions_12\NNS|between (r_dobj) risk_11\VB|that|patients|may|interactions (l_nsubj) patients_4\NNS|receiving (l_acl) receiving_5\VBG|ritodrine (l_dobj) ritodrine_6\RB|for (l_prep) for_7\IN|labor (l_pobj) labor_9\NN|preterm
D012312_D002318 NONE ritodrine_15\NN| (r_pobj) of_14\IN|ritodrine (r_prep) infusion_13\NN|an|of (r_pobj) of_11\IN|infusion (r_prep) cessation_10\NN|of (r_pobj) after_9\IN|even|cessation (r_prep) complications_7\NNS|serious|cardiovascular|after
D010656_D007022 NONE phenylephrine_22\NN|treat (l_relcl) treat_24\VB|to|patients|with (l_dobj) patients_26\NNS|hypotensive (l_amod) hypotensive_25\JJ|
D010656_D013610 NONE phenylephrine_22\NN|treat (l_relcl) treat_24\VB|to|patients|with (l_prep) with_27\IN|tachycardia (l_pobj) tachycardia_28\NNS|
11581460
D005283_D016055 CID fentanyl_12\NN| (r_pobj) of_11\IN|fentanyl (r_prep) infusion_10\NN|continuous|intravenous|of (r_pobj) of_7\IN|infusion (r_prep) result_6\NN|a|of (r_pobj) as_4\IN|result (r_prep) retention_1\NN|bladder|of|as (l_prep) of_2\IN|urine (l_pobj) urine_3\NN|
D005283_D009127 NONE fentanyl_5\NN| (r_compound) administration_6\NN|fentanyl (r_pobj) of_4\IN|administration (r_prep) effects_3\NNS|various|reported|side|of (r_nsubj) include_7\VBP|effects|rigidity|. (l_dobj) rigidity_10\NN|chest|wall|,|hypotension
D005283_D007022 CID fentanyl_5\NN| (r_compound) administration_6\NN|fentanyl (r_pobj) of_4\IN|administration (r_prep) effects_3\NNS|various|reported|side|of (r_nsubj) include_7\VBP|effects|rigidity|. (l_dobj) rigidity_10\NN|chest|wall|,|hypotension (l_conj) hypotension_12\NN|,|depression
D005283_D012131 CID fentanyl_5\NN| (r_compound) administration_6\NN|fentanyl (r_pobj) of_4\IN|administration (r_prep) effects_3\NNS|various|reported|side|of (r_nsubj) include_7\VBP|effects|rigidity|. (l_dobj) rigidity_10\NN|chest|wall|,|hypotension (l_conj) hypotension_12\NN|,|depression (l_conj) depression_15\NN|respiratory|,|and|bradycardia
D005283_D001919 CID fentanyl_5\NN| (r_compound) administration_6\NN|fentanyl (r_pobj) of_4\IN|administration (r_prep) effects_3\NNS|various|reported|side|of (r_nsubj) include_7\VBP|effects|rigidity|. (l_dobj) rigidity_10\NN|chest|wall|,|hypotension (l_conj) hypotension_12\NN|,|depression (l_conj) depression_15\NN|respiratory|,|and|bradycardia (l_conj) bradycardia_18\NN|
D005283_D001745 CID fentanyl_22\NN| (r_pobj) of_21\IN|fentanyl (r_prep) infusion_20\NN|continuous|of (r_pobj) of_18\IN|infusion (r_prep) result_17\NN|a|of (r_pobj) as_15\IN|result (r_prep) mimicking_13\VBG|hydronephrosis|as (r_acl) dilatation_12\NN|renal|pelvocalyceal|mimicking (r_pobj) to_9\IN|dilatation (r_prep) leading_8\VBG|to (r_acl) cases_3\NNS|2|of|leading (l_prep) of_4\IN|retention (l_pobj) retention_7\NN|urinary|bladder
D005283_D006869 NONE fentanyl_22\NN| (r_pobj) of_21\IN|fentanyl (r_prep) infusion_20\NN|continuous|of (r_pobj) of_18\IN|infusion (r_prep) result_17\NN|a|of (r_pobj) as_15\IN|result (r_prep) mimicking_13\VBG|hydronephrosis|as (l_dobj) hydronephrosis_14\NN|
2396046
D002794_D006528 CID choline_13\NN| (r_npadvmod) supplemented_15\VBN|choline|- (r_amod) diet_16\NN|the|plain|supplemented (r_dobj) fed_10\VBD|nodules|diet|,|developed|fed|. (l_nsubj) nodules_3\NNS|no|hepatic|preneoplastic|or|carcinomas|developed (l_conj) carcinomas_6\NNS|hepatocellular
D002794_D006528 CID choline_13\NN| (r_npadvmod) supplemented_15\VBN|choline|- (r_amod) diet_16\NN|the|plain|supplemented (r_dobj) fed_10\VBD|nodules|diet|,|developed|fed|. (l_advcl) developed_26\VBN|while|nodule|in (l_nsubj) nodule_21\NN|one|preneoplastic|and|carcinoma (l_conj) carcinoma_25\NN|one|hepatocellular
D002794_D006528 CID choline_23\NN| (r_npadvmod) devoid_25\JJ|choline|- (r_amod) diet_26\NN|the|plain|devoid (r_dobj) fed_20\VBD|in|rats|diet|,|and|%|,|in (r_conj) was_9\VBD|incidence|%|,|respectively|,|fed|fed|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|nodules|and|of (l_conj) of_6\IN|carcinomas (l_pobj) carcinomas_8\NNS|hepatocellular
D002794_D006528 CID choline_42\NN| (r_npadvmod) devoid_44\JJ|choline|- (r_amod) diet_45\NN|the|containing|devoid (r_dobj) fed_37\VBD|diet (r_conj) was_9\VBD|incidence|%|,|respectively|,|fed|fed|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|nodules|and|of (l_conj) of_6\IN|carcinomas (l_pobj) carcinomas_8\NNS|hepatocellular
D010634_D006528 NONE phenobarbital_35\NN| (r_dobj) containing_34\VBG|phenobarbital (r_acl) diet_33\NN|the|same|containing (r_dobj) fed_30\VBD|diet (r_conj) fed_10\VBD|nodules|diet|,|developed|fed|. (l_nsubj) nodules_3\NNS|no|hepatic|preneoplastic|or|carcinomas|developed (l_conj) carcinomas_6\NNS|hepatocellular
D010634_D006528 NONE phenobarbital_35\NN| (r_dobj) containing_34\VBG|phenobarbital (r_acl) diet_33\NN|the|same|containing (r_dobj) fed_30\VBD|diet (r_conj) fed_10\VBD|nodules|diet|,|developed|fed|. (l_advcl) developed_26\VBN|while|nodule|in (l_nsubj) nodule_21\NN|one|preneoplastic|and|carcinoma (l_conj) carcinoma_25\NN|one|hepatocellular
D010634_D006528 NONE phenobarbital_39\RB| (r_npadvmod) containing_41\VBG|phenobarbital|- (r_amod) diet_45\NN|the|containing|devoid (r_dobj) fed_37\VBD|diet (r_conj) was_9\VBD|incidence|%|,|respectively|,|fed|fed|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|nodules|and|of (l_conj) of_6\IN|carcinomas (l_pobj) carcinomas_8\NNS|hepatocellular
18754075
D004164_D011507 NONE bisphosphonate_8\NN|oral (r_nmod) administration_12\NN|bisphosphonate|alendronate|in (r_pobj) after_6\IN|administration (r_prep) proteinuria_1\NN|massive|and|failure|after|.
D004164_D011507 NONE bisphosphonates_11\NNS|oral (r_nsubj) aggravate_13\VB|that|intravenous|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN|and|failure
D004164_D058186 NONE bisphosphonate_8\NN|oral (r_nmod) administration_12\NN|bisphosphonate|alendronate|in (r_pobj) after_6\IN|administration (r_prep) proteinuria_1\NN|massive|and|failure|after|. (l_conj) failure_5\NN|acute|renal
D004164_D058186 NONE bisphosphonate_6\NN|the|oral (r_pobj) of_3\IN|bisphosphonate (r_prep) days_2\NNS|14|of (r_pobj) Within_0\IN|days (r_prep) increased_19\VBD|within|administration|amount|rapidly|up|with|. (l_prep) with_25\IN|failure (l_pobj) failure_28\NN|acute|renal
D004164_D058186 NONE bisphosphonates_11\NNS|oral (r_nsubj) aggravate_13\VB|that|intravenous|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN|and|failure (l_conj) failure_18\NN|acute|renal
D004164_D005923 NONE bisphosphonate_8\NN|oral (r_nmod) administration_12\NN|bisphosphonate|alendronate|in (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_19\NN|focal|segmental
D019386_D011507 CID alendronate_10\JJ|(|) (r_nmod) administration_12\NN|bisphosphonate|alendronate|in (r_pobj) after_6\IN|administration (r_prep) proteinuria_1\NN|massive|and|failure|after|.
D019386_D058186 CID alendronate_10\JJ|(|) (r_nmod) administration_12\NN|bisphosphonate|alendronate|in (r_pobj) after_6\IN|administration (r_prep) proteinuria_1\NN|massive|and|failure|after|. (l_conj) failure_5\NN|acute|renal
D019386_D058186 CID sodium_9\NN|(|alendronate|) (r_nmod) administration_11\NN|sodium|, (r_nsubj) increased_19\VBD|within|administration|amount|rapidly|up|with|. (l_prep) with_25\IN|failure (l_pobj) failure_28\NN|acute|renal
D019386_D005923 NONE alendronate_10\JJ|(|) (r_nmod) administration_12\NN|bisphosphonate|alendronate|in (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_19\NN|focal|segmental
D013256_D009404 NONE steroid_19\NN| (r_compound) therapy_20\NN|steroid (r_pobj) to_18\IN|therapy (r_prep) responding_16\VBG|man|was|initially|well|to|. (l_nsubj) man_5\NN|a|old|japanese|with|due (l_prep) with_6\IN|syndrome (l_pobj) syndrome_8\NN|nephrotic
D013256_D005923 NONE steroid_19\NN| (r_compound) therapy_20\NN|steroid (r_pobj) to_18\IN|therapy (r_prep) responding_16\VBG|man|was|initially|well|to|. (l_nsubj) man_5\NN|a|old|japanese|with|due (l_amod) due_9\IN|to|glomerulosclerosis (l_pobj) glomerulosclerosis_13\NN|focal|segmental
10683478
D001058_D007035 CID Apomorphine_0\NNP|,|agonist|, (r_nsubjpass) selected_8\VBN|apomorphine|was|due|,|ability|. (l_dobj) ability_17\NN|its|induce (l_acl) induce_19\VB|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN|
D001058_D007035 CID apomorphine_11\NN|to|as (l_prep) as_13\IN|such|hypothermia (l_pobj) hypothermia_17\NN|induced
D018491_D007035 NONE agonist_5\NN|a|nonselective|dopamine (r_appos) Apomorphine_0\NNP|,|agonist|, (r_nsubjpass) selected_8\VBN|apomorphine|was|due|,|ability|. (l_dobj) ability_17\NN|its|induce (l_acl) induce_19\VB|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN|
D004298_D007035 NONE dopamine_28\NN|to|turnover (r_relcl) changes_26\NNS|distinct|dopamine (r_dobj) produce_24\VB|to|changes (r_conj) induce_19\VB|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN|
D001058_D006948 CID apomorphine_5\NN| (r_npadvmod) induced_7\VBN|apomorphine|- (r_amod) hyperactivity_8\NN|induced
15859940
D016572_D064420 NONE cyclosporine_7\NN|,|tacrolimus (r_nmod) toxicity_11\NN|related|(|cyclosporine|,|status
D016559_D064420 NONE tacrolimus_9\NN|) (r_conj) cyclosporine_7\NN|,|tacrolimus (r_nmod) toxicity_11\NN|related|(|cyclosporine|,|status
D016572_D057049 CID cyclosporine_18\NN| (r_pobj) to_17\IN|mainly|cyclosporine (r_prep) secondary_15\JJ|to (r_amod) related_13\VBN|drug|,|secondary (r_acomp) was_11\VBD|that|cause|related (l_nsubj) cause_7\NN|the|frequent|of (l_prep) of_8\IN|microangiopathy (l_pobj) microangiopathy_10\NN|thrombotic
18343374
D002996_D012170 CID clomiphene_6\NN| (r_npadvmod) induced_8\VBN|clomiphene|- (r_amod) ovulation_9\NN|induced (r_pobj) with_5\IN|ovulation (r_prep) associated_4\VBN|with (r_acl) occlusion_3\NN|central|vein|associated|.
D002996_D012170 CID citrate_12\NN|clomiphene|(|cc|) (r_pobj) with_10\IN|citrate (r_prep) associated_9\VBN|with (r_acl) occlusion_8\NN|central|vein|associated
D002996_D012170 CID CC_14\NN| (r_appos) citrate_12\NN|clomiphene|(|cc|) (r_pobj) with_10\IN|citrate (r_prep) associated_9\VBN|with (r_acl) occlusion_8\NN|central|vein|associated
D002996_D012170 CID CC_13\NN| (r_pobj) with_12\IN|cc (r_prep) induction_11\NN|ovulation|with (r_pobj) after_9\IN|induction (r_prep) occlusion_8\NN|central|vein|after
D002996_D012170 CID CC_18\NN| (r_pobj) of_17\IN|cc (r_prep) courses_16\NNS|eight|of (r_pobj) after_14\IN|courses (r_prep) developed_9\VBD|result(s|:|woman|occlusion|after|. (l_dobj) occlusion_13\NN|central|vein
D002996_D012170 CID CC_15\NN| (r_pobj) with_14\IN|cc (r_prep) treatment_13\NN|with (r_pobj) after_12\IN|treatment (r_prep) occlusion_11\NN|vein|after
D002996_D013923 NONE CC_10\NN| (r_pobj) of_9\IN|cc (r_prep) complications_8\NNS|the|thromboembolic|of (l_compound) thromboembolic_7\JJ|
D002996_D013923 NONE CC_24\NN| (r_compound) intake_25\NN|cc (r_pobj) after_23\IN|intake (r_prep) disturbance_22\NN|mild|visual|after (r_nsubj) is_26\VBZ|although|disturbance|not|uncommon (r_advcl) include_13\VB|search|does|not|complication|,|is|. (l_nsubj) search_1\NN|a|of|on (l_prep) on_5\IN|complications (l_pobj) complications_8\NNS|the|thromboembolic|of (l_compound) thromboembolic_7\JJ|
D002996_D014786 CID CC_10\NN| (r_pobj) of_9\IN|cc (r_prep) complications_8\NNS|the|thromboembolic|of (r_pobj) on_5\IN|complications (r_prep) search_1\NN|a|of|on (r_nsubj) include_13\VB|search|does|not|complication|,|is|. (l_advcl) is_26\VBZ|although|disturbance|not|uncommon (l_nsubj) disturbance_22\NN|mild|visual|after
D002996_D014786 CID CC_24\NN| (r_compound) intake_25\NN|cc (r_pobj) after_23\IN|intake (r_prep) disturbance_22\NN|mild|visual|after
D002996_D007247 NONE CC_9\NN| (r_pobj) with_8\IN|cc (r_prep) treating_5\VBG|patients|with (l_dobj) patients_7\NNS|infertility (l_compound) infertility_6\NN|
2425813
D011239_D006529 CID prednisolone_14\NN| (r_pobj) of_13\IN|prednisolone (r_prep) administration_12\NN|the|subcutaneous|of (r_pobj) following_9\VBG|administration (r_prep) occurred_5\VBD|enlargement|in|following|. (l_nsubj) enlargement_1\NN|liver|and|wastage
D011239_D009133 CID prednisolone_14\NN| (r_pobj) of_13\IN|prednisolone (r_prep) administration_12\NN|the|subcutaneous|of (r_pobj) following_9\VBG|administration (r_prep) occurred_5\VBD|enlargement|in|following|. (l_nsubj) enlargement_1\NN|liver|and|wastage (l_conj) wastage_4\NN|muscle
18726058
D010208_D020301 NONE hydrochloride_1\NN|papaverine (r_nsubj) is_2\VBZ|hydrochloride|vasodilator|. (l_attr) vasodilator_7\NN|a|acting|used (l_acl) used_8\VBD|manage (l_xcomp) manage_10\VB|to|vasospasm|during (l_dobj) vasospasm_11\NN|
D010208_D020301 NONE papaverine_18\NN|topical (r_dobj) received_16\VBD|who|papaverine|for (l_prep) for_19\IN|vasospasm (l_pobj) vasospasm_20\NN|
D010208_D020301 NONE papaverine_1\NN|topical (r_nsubjpass) used_3\VBN|papaverine|was|as|. (l_prep) as_4\IN|action (l_pobj) action_8\NN|a|direct|therapeutic|manage (l_acl) manage_10\VB|to|vasospasm|in (l_dobj) vasospasm_11\NN|
D010208_D020301 NONE papaverine_1\NN|topical|for (l_prep) for_2\IN|treatment (l_pobj) treatment_4\NN|the|of (l_prep) of_5\IN|vasospasm (l_pobj) vasospasm_6\NN|
D010208_D003389 NONE papaverine_13\NN|topical (r_pobj) with_11\IN|papaverine (r_prep) cases_10\NNS|a|few|with (r_pobj) in_7\IN|cases (r_prep) described_6\VBN|dysfunction|has|been|in|. (l_nsubjpass) dysfunction_3\NN|transient|cranial|nerve
D010208_D003389 NONE papaverine_8\NN| (r_pobj) from_7\IN|papaverine (r_prep) deficits_6\NNS|potential|nerve|from
11752354
D003276_D009203 CID contraceptives_1\NNS|oral|and|risk|. (l_conj) risk_4\NN|the|of (l_prep) of_5\IN|infarction (l_pobj) infarction_7\NN|myocardial
D003276_D009203 CID contraceptives_7\NNS|oral (r_pobj) of_5\IN|contraceptives (r_prep) use_4\NN|the|of|and|risk (l_conj) risk_10\NN|the|of (l_prep) of_11\IN|infarction (l_pobj) infarction_13\NN|myocardial
D003276_D009203 CID contraceptives_33\NNS|generation|oral (r_pobj) in_12\IN|contraceptives (r_prep) included_11\VBN|in (r_acl) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between
D003276_D009203 CID contraceptives_33\NNS|generation|oral (r_pobj) in_12\IN|contraceptives (r_prep) included_11\VBN|in (r_acl) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between (l_prep) between_82\IN|1990 (l_pobj) 1990_83\CD|and|1995|and|women (l_conj) women_89\NNS|925|control|had (l_relcl) had_93\VBN|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN|a|myocardial
D003276_D009203 CID contraceptive_39\NN|combined|oral (r_pobj) of_36\IN|contraceptive (r_prep) type_35\NN|any|of (r_dobj) used_33\VBD|who|type|,|compared (r_relcl) women_31\NNS|used (r_pobj) among_30\IN|women (r_prep) infarction_29\NN|myocardial|among
D003276_D009203 CID contraceptives_5\NNS|oral (r_dobj) used_3\VBD|who|contraceptives (r_relcl) women_1\NNS|used (r_pobj) Among_0\IN|women (r_prep) was_10\VBD|among|,|ratio|interval|for|: (r_ccomp) increased_53\VBN|was|risk|was|among|. (l_nsubjpass) risk_48\NN|the|of (l_prep) of_49\IN|infarction (l_pobj) infarction_51\NN|myocardial
D003276_D009203 CID contraceptives_62\NNS|generation|oral (r_dobj) used_57\VBD|who|contraceptives (r_relcl) women_55\NNS|used (r_pobj) among_54\IN|women (r_prep) increased_53\VBN|was|risk|was|among|. (l_nsubjpass) risk_48\NN|the|of (l_prep) of_49\IN|infarction (l_pobj) infarction_51\NN|myocardial
D003276_D009203 CID contraceptives_12\NNS|oral (r_dobj) used_10\VBD|who|contraceptives|had (r_relcl) women_8\NNS|used (r_pobj) among_7\IN|women (r_prep) similar_6\JJ|among (r_acomp) was_5\VBD|risk|similar|. (l_nsubj) risk_1\NN|the|of (l_prep) of_2\IN|infarction (l_pobj) infarction_4\NN|myocardial
D011372_D009203 NONE progestagen_10\NN| (r_pobj) of_9\IN|progestagen (r_prep) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between
D011372_D009203 NONE progestagen_10\NN| (r_pobj) of_9\IN|progestagen (r_prep) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between (l_prep) between_82\IN|1990 (l_pobj) 1990_83\CD|and|1995|and|women (l_conj) women_89\NNS|925|control|had (l_relcl) had_93\VBN|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN|a|myocardial
D017135_D009203 NONE desogestrel_19\NN|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN|third|-|desogestrel (r_nmod) contraceptives_33\NNS|generation|oral (r_pobj) in_12\IN|contraceptives (r_prep) included_11\VBN|in (r_acl) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between
D017135_D009203 NONE desogestrel_19\NN|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN|third|-|desogestrel (r_nmod) contraceptives_33\NNS|generation|oral (r_pobj) in_12\IN|contraceptives (r_prep) included_11\VBN|in (r_acl) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between (l_prep) between_82\IN|1990 (l_pobj) 1990_83\CD|and|1995|and|women (l_conj) women_89\NNS|925|control|had (l_relcl) had_93\VBN|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN|a|myocardial
C033273_D009203 NONE gestodene_21\NN| (r_conj) desogestrel_19\NN|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN|third|-|desogestrel (r_nmod) contraceptives_33\NNS|generation|oral (r_pobj) in_12\IN|contraceptives (r_prep) included_11\VBN|in (r_acl) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between
C033273_D009203 NONE gestodene_21\NN| (r_conj) desogestrel_19\NN|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN|third|-|desogestrel (r_nmod) contraceptives_33\NNS|generation|oral (r_pobj) in_12\IN|contraceptives (r_prep) included_11\VBN|in (r_acl) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between (l_prep) between_82\IN|1990 (l_pobj) 1990_83\CD|and|1995|and|women (l_conj) women_89\NNS|925|control|had (l_relcl) had_93\VBN|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN|a|myocardial
D016912_D009203 NONE levonorgestrel_30\JJ|generation|(|i.e.|,|) (r_conj) desogestrel_19\NN|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN|third|-|desogestrel (r_nmod) contraceptives_33\NNS|generation|oral (r_pobj) in_12\IN|contraceptives (r_prep) included_11\VBN|in (r_acl) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between
D016912_D009203 NONE levonorgestrel_30\JJ|generation|(|i.e.|,|) (r_conj) desogestrel_19\NN|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN|third|-|desogestrel (r_nmod) contraceptives_33\NNS|generation|oral (r_pobj) in_12\IN|contraceptives (r_prep) included_11\VBN|in (r_acl) type_8\NN|the|of|included (r_pobj) to_6\IN|type (r_prep) according_5\VBG|to (r_prep) investigated_1\VBD|we|association|,|according|identified (l_conj) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between (l_prep) between_82\IN|1990 (l_pobj) 1990_83\CD|and|1995|and|women (l_conj) women_89\NNS|925|control|had (l_relcl) had_93\VBN|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN|a|myocardial
D004967_D009203 NONE estrogen_38\NN| (r_pobj) of_37\IN|estrogen (r_prep) dose_36\NN|the|of|,|and|presence (r_dep) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between
D004967_D009203 NONE estrogen_38\NN| (r_pobj) of_37\IN|estrogen (r_prep) dose_36\NN|the|of|,|and|presence (r_dep) identified_64\VBD|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD|women|18|through|,|year (l_dobj) women_68\NNS|248|had (l_relcl) had_77\VBN|who|had|infarction (l_dobj) infarction_81\NN|a|first|myocardial|between (l_prep) between_82\IN|1990 (l_pobj) 1990_83\CD|and|1995|and|women (l_conj) women_89\NNS|925|control|had (l_relcl) had_93\VBN|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN|a|myocardial
9721172
D007052_D001649 NONE ibuprofen_30\JJ| (r_compound) use_31\NN|ibuprofen (r_pobj) with_29\IN|use (r_prep) associated_28\VBN|child|;|this|was|temporally|with|. (l_nsubjpass) child_3\NN|a|healthy|developed|described (l_relcl) developed_5\VBD|who|syndrome (l_dobj) syndrome_15\NN|acute|,|severe|,|progressive|duct
D007052_D013262 CID ibuprofen_30\JJ| (r_compound) use_31\NN|ibuprofen (r_pobj) with_29\IN|use (r_prep) associated_28\VBN|child|;|this|was|temporally|with|. (l_nsubjpass) child_3\NN|a|healthy|developed|described (l_relcl) described_23\VBN|after|syndrome|is (l_nsubjpass) syndrome_21\NN|johnson
D014580_D002779 NONE acid_4\NN|ursodeoxycholic|,|prednisone (l_conj) prednisone_6\NN|,|and|tacrolimus (l_conj) tacrolimus_10\VB|then|,|disease (l_conj) disease_14\NN|her|cholestatic
D014580_D005355 NONE acid_4\NN|ursodeoxycholic|,|prednisone (r_pobj) with_2\IN|acid (r_prep) therapy_1\NN|with (r_pobj) Despite_0\IN|therapy (r_prep) was_15\VBD|despite|unrelenting|,|with|. (l_prep) with_18\IN|cirrhosis (l_pobj) cirrhosis_19\NN|shown
D011241_D002779 NONE prednisone_6\NN|,|and|tacrolimus (l_conj) tacrolimus_10\VB|then|,|disease (l_conj) disease_14\NN|her|cholestatic
D011241_D005355 NONE prednisone_6\NN|,|and|tacrolimus (r_conj) acid_4\NN|ursodeoxycholic|,|prednisone (r_pobj) with_2\IN|acid (r_prep) therapy_1\NN|with (r_pobj) Despite_0\IN|therapy (r_prep) was_15\VBD|despite|unrelenting|,|with|. (l_prep) with_18\IN|cirrhosis (l_pobj) cirrhosis_19\NN|shown
D016559_D002779 NONE tacrolimus_10\VB|then|,|disease (l_conj) disease_14\NN|her|cholestatic
D016559_D005355 NONE tacrolimus_10\VB|then|,|disease (r_conj) prednisone_6\NN|,|and|tacrolimus (r_conj) acid_4\NN|ursodeoxycholic|,|prednisone (r_pobj) with_2\IN|acid (r_prep) therapy_1\NN|with (r_pobj) Despite_0\IN|therapy (r_prep) was_15\VBD|despite|unrelenting|,|with|. (l_prep) with_18\IN|cirrhosis (l_pobj) cirrhosis_19\NN|shown
9587734
D013390_D006323 CID Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|suxamethonium|- (r_amod) arrest_4\NN|induced|cardiac|and|death|following|.
D013390_D006323 CID suxamethonium_21\NN|in (r_pobj) of_20\IN|suxamethonium (r_prep) use_19\NN|the|of (r_pobj) following_17\VBG|use (r_prep) case_5\NN|a|of|following (l_prep) of_6\IN|arrest (l_pobj) arrest_8\NN|cardiac|and|death
D013390_D006323 CID suxamethonium_5\NN|,|arrest (l_appos) arrest_10\NN|bradycardia|cardiac
D013390_D003643 NONE Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|suxamethonium|- (r_amod) arrest_4\NN|induced|cardiac|and|death|following|. (l_conj) death_6\NN|
D013390_D003643 NONE suxamethonium_21\NN|in (r_pobj) of_20\IN|suxamethonium (r_prep) use_19\NN|the|of (r_pobj) following_17\VBG|use (r_prep) case_5\NN|a|of|following (l_prep) of_6\IN|arrest (l_pobj) arrest_8\NN|cardiac|and|death (l_conj) death_11\NN|subsequent|as
D013390_D003643 NONE suxamethonium_11\NN| (r_pobj) to_10\IN|suxamethonium (r_prep) hypersensitivity_9\NN|to (r_pobj) by_8\IN|hypersensitivity (r_agent) caused_7\VBN|that|death|was|by|,|associated (l_nsubjpass) death_5\NN|her
D013390_D006947 CID suxamethonium_21\NN|in (r_pobj) of_20\IN|suxamethonium (r_prep) use_19\NN|the|of (r_pobj) following_17\VBG|use (r_prep) case_5\NN|a|of|following (l_prep) of_6\IN|arrest (l_pobj) arrest_8\NN|cardiac|and|death (l_conj) death_11\NN|subsequent|as (l_prep) as_12\IN|result (l_pobj) result_14\NN|a|of (l_prep) of_15\IN|hyperkalaemia (l_pobj) hyperkalaemia_16\NN|
D013390_D006947 CID suxamethonium_35\NN| (r_pobj) of_34\IN|suxamethonium (r_prep) administration_33\NN|the|of (r_pobj) following_31\VBG|administration (r_prep) signs_15\NNS|no|of|following (l_prep) of_16\IN|damage|or|of (l_conj) of_21\IN|any (l_pobj) any_22\DT|of (l_prep) of_23\IN|conditions (l_pobj) conditions_28\NNS|the|other|known|predisposing|for (l_prep) for_29\IN|hyperkalaemia (l_pobj) hyperkalaemia_30\NN|
D013390_D001919 CID suxamethonium_5\NN|,|arrest (l_appos) arrest_10\NN|bradycardia|cardiac (l_amod) bradycardia_7\NN|and
D013390_D004342 CID suxamethonium_11\NN| (r_pobj) to_10\IN|suxamethonium (r_prep) hypersensitivity_9\NN|to
3856631
D008727_D008577 NONE methotrexate_10\NNP|dose|intravenous (r_pobj) with_5\IN|methotrexate (r_prep) leukemia_4\NN|meningeal|with
D008727_D054198 NONE methotrexate_18\NNP| (r_compound) regimen_19\NN|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN|regimen (r_prep) treated_11\VBN|children|were|with|. (l_nsubjpass) children_1\NNS|twenty|with|developed (l_prep) with_2\IN|leukemia (l_pobj) leukemia_5\NN|acute|lymphoblastic
D008727_D054198 NONE methotrexate_28\NNP| (r_compound) concentrations_29\NNS|csf|methotrexate|of (r_dobj) maintain_26\VB|concentrations|without (r_conj) achieve_24\VB|to|and|maintain (r_xcomp) designed_22\VBN|that|was|achieve (r_relcl) regimen_19\NN|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN|regimen (r_prep) treated_11\VBN|children|were|with|. (l_nsubjpass) children_1\NNS|twenty|with|developed (l_prep) with_2\IN|leukemia (l_pobj) leukemia_5\NN|acute|lymphoblastic
D008727_D054198 NONE methotrexate_4\NN|dose|intravenous (r_nsubj) is_5\VBZ|methotrexate|treatment|. (l_attr) treatment_8\NN|an|effective|for (l_prep) for_9\IN|induction (l_pobj) induction_11\NN|the|of|after (l_prep) after_14\IN|relapse (l_pobj) relapse_16\NN|meningeal|in (l_prep) in_17\IN|leukemia (l_pobj) leukemia_20\NN|acute|lymphoblastic
D008727_D002493 NONE methotrexate_18\NNP| (r_compound) regimen_19\NN|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN|regimen (r_prep) treated_11\VBN|children|were|with|. (l_nsubjpass) children_1\NNS|twenty|with|developed (l_relcl) developed_7\VBD|who|disease (l_dobj) disease_9\NN|meningeal
D008727_D002493 NONE methotrexate_28\NNP| (r_compound) concentrations_29\NNS|csf|methotrexate|of (r_dobj) maintain_26\VB|concentrations|without (r_conj) achieve_24\VB|to|and|maintain (r_xcomp) designed_22\VBN|that|was|achieve (r_relcl) regimen_19\NN|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN|regimen (r_prep) treated_11\VBN|children|were|with|. (l_nsubjpass) children_1\NNS|twenty|with|developed (l_relcl) developed_7\VBD|who|disease (l_dobj) disease_9\NN|meningeal
D001663_D064420 NONE bilirubin_10\NN| (r_amod) elevations_11\NNS|bilirubin (r_conj) transaminase_8\NN|transient|serum|and|elevations|,|neutropenia (r_attr) were_5\VBD|toxicities|transaminase|. (l_nsubj) toxicities_3\NNS|the|common|encountered
D001663_D009503 NONE bilirubin_10\NN| (r_amod) elevations_11\NNS|bilirubin (r_conj) transaminase_8\NN|transient|serum|and|elevations|,|neutropenia (l_appos) neutropenia_13\NN|,|and|mucositis
D001663_D052016 NONE bilirubin_10\NN| (r_amod) elevations_11\NNS|bilirubin (r_conj) transaminase_8\NN|transient|serum|and|elevations|,|neutropenia (l_appos) neutropenia_13\NN|,|and|mucositis (l_conj) mucositis_16\NN|
15804801
D017239_D003323 CID paclitaxel_6\NN| (r_compound) eluting_8\VBG|paclitaxel|- (r_amod) stent_9\NN|a|eluting (r_pobj) of_4\IN|stent (r_prep) implantation_3\NN|of (r_pobj) after_2\IN|implantation (r_prep) aneurysm_1\NN|coronary|after|.
D017239_D003323 CID paclitaxel_22\NN| (r_compound) eluting_24\VBG|paclitaxel|- (r_amod) stent_25\NN|a|eluting (r_dobj) receiving_20\VBG|stent (r_pcomp) after_19\IN|months|receiving (r_prep) developed_8\VBD|who|aneurysm|in|after (l_dobj) aneurysm_11\NN|a|coronary
6634932
C002616_D017180 NONE UM-272_0\NNP| (r_punct) dimethylpropranolol_6\NNP|um-272|(|n|,|n|-|)|,|agent (r_nsubjpass) administered_15\VBN|dimethylpropranolol|,|was|sublingually|to|. (l_prep) to_17\IN|dogs (l_pobj) dogs_18\NNS|with (l_prep) with_19\IN|tachycardias (l_pobj) tachycardias_24\NNS|induced|ventricular
C002616_D017180 NONE dimethylpropranolol_6\NNP|um-272|(|n|,|n|-|)|,|agent (r_nsubjpass) administered_15\VBN|dimethylpropranolol|,|was|sublingually|to|. (l_prep) to_17\IN|dogs (l_pobj) dogs_18\NNS|with (l_prep) with_19\IN|tachycardias (l_pobj) tachycardias_24\NNS|induced|ventricular
C002616_D017180 NONE UM-272_1\NNP| (r_punct) converted_2\VBD|sublingual|um-272|tachycardia|sinus|. (l_dobj) tachycardia_4\NN|ventricular
D010042_D017180 CID ouabain_20\RB| (r_npadvmod) induced_22\VBN|ouabain|- (r_amod) tachycardias_24\NNS|induced|ventricular
6640832
D004317_D001749 NONE adriamycin_2\NNS|in (l_prep) in_3\IN|carcinoma (l_pobj) carcinoma_6\NN|superficial|bladder
D004317_D001749 NONE Adriamycin_0\NNP|ml (r_nsubjpass) administered_7\VBN|adriamycin|was|intravesically|within|after|. (l_prep) after_12\IN|resection (l_pobj) resection_14\NN|transurethral|of (l_prep) of_15\IN|tumors (l_pobj) tumors_25\NNS|t1|(|a|)|bladder
D004317_D002277 NONE adriamycin_2\NNS|in (l_prep) in_3\IN|carcinoma (l_pobj) carcinoma_6\NN|superficial|bladder
8741744
D009538_D009069 NONE nicotine_29\NN| (r_pobj) by_28\IN|nicotine (r_agent) caused_27\VBN|by (r_acl) hypoactivity_26\NN|the|early|(|min|)|field|locomotor|caused|(|kg(-1|)|,|i.m.|)
D009538_D009069 NONE nicotine_48\NN| (r_npadvmod) induced_50\VBN|nicotine|- (r_amod) hyperactivity_51\NN|the|later|(|min|induced (r_dobj) enhanced_39\VBD|hyperactivity|,|and|raised (r_advcl) blunted_14\VBD|compared|,|lesions|hypoactivity|,|enhanced|. (l_dobj) hypoactivity_26\NN|the|early|(|min|)|field|locomotor|caused|(|kg(-1|)|,|i.m.|)
D009538_D006948 CID nicotine_29\NN| (r_pobj) by_28\IN|nicotine (r_agent) caused_27\VBN|by (r_acl) hypoactivity_26\NN|the|early|(|min|)|field|locomotor|caused|(|kg(-1|)|,|i.m.|) (r_dobj) blunted_14\VBD|compared|,|lesions|hypoactivity|,|enhanced|. (l_advcl) enhanced_39\VBD|hyperactivity|,|and|raised (l_dobj) hyperactivity_51\NN|the|later|(|min|induced
D009538_D006948 CID nicotine_48\NN| (r_npadvmod) induced_50\VBN|nicotine|- (r_amod) hyperactivity_51\NN|the|later|(|min|induced
1147734
D011441_D008107 NONE propylthiouracil_4\NN| (r_pobj) by_3\IN|propylthiouracil (r_agent) caused_2\VBN|by (r_acl) disease_1\NN|liver|caused|.
D011441_D006521 CID propylthiouracil_29\NN| (r_pobj) of_28\IN|propylthiouracil (r_prep) administration_27\NN|the|of (r_pobj) by_25\IN|administration (r_agent) caused_24\VBN|by (r_acl) hepatitis_23\NN|chronic|active|(|aggressive|)|caused
1720453
D007069_D007674 CID ifosfamide_7\JJ| (r_amod) toxicity_9\NN|ifosfamide|renal|in
D007069_C535700 NONE ifosfamide_7\JJ| (r_amod) toxicity_9\NN|ifosfamide|renal|in (r_pobj) of_6\IN|toxicity (r_prep) up_5\NN|term|follow|-|of (r_nsubj) treated_12\VBN|up|for|:|society|. (l_prep) for_13\IN|tumors (l_pobj) tumors_16\NNS|malignant|mesenchymal
D007069_C535700 NONE ifosfamide_19\JJ| (r_compound) protocol_21\NN|the|same|ifosfamide|chemotherapy|(|society|mmt|) (r_dobj) received_16\VBN|who|have|protocol (r_relcl) function_2\NN|the|renal|of|with|in|and|received (l_prep) with_6\IN|tumors (l_pobj) tumors_9\NNS|malignant|mesenchymal
D007069_C535700 NONE ifosfamide_19\JJ| (r_compound) protocol_21\NN|the|same|ifosfamide|chemotherapy|(|society|mmt|) (l_appos) Society_24\NNP|international|of (l_prep) of_25\IN|study (l_pobj) Study_31\NNP|oncology|malignant|mesenchymal|tumor (l_compound) Tumor_30\NNP|
D007069_C535700 NONE ifosfamide_18\NN| (r_pobj) of_17\IN|ifosfamide (r_prep) efficacy_16\NN|the|of|in (l_prep) in_19\IN|treatment (l_pobj) treatment_21\NN|the|of|in (l_prep) of_22\IN|tumors (l_pobj) tumors_24\NNS|mesenchymal
D003404_D006030 NONE creatinine_22\NN| (r_compound) clearance_23\NN|creatinine|,|reabsorption (r_conj) osmolarity_20\NN|,|clearance (r_conj) pH_18\NN|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ|,|ph (r_conj) proteinuria_13\NN|,|aminoaciduria (r_conj) glucosuria_11\NN|,|proteinuria
D003404_D011507 NONE creatinine_22\NN| (r_compound) clearance_23\NN|creatinine|,|reabsorption (r_conj) osmolarity_20\NN|,|clearance (r_conj) pH_18\NN|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ|,|ph (r_conj) proteinuria_13\NN|,|aminoaciduria
D003404_D000608 NONE creatinine_22\NN| (r_compound) clearance_23\NN|creatinine|,|reabsorption (r_conj) osmolarity_20\NN|,|clearance (r_conj) pH_18\NN|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ|,|ph
D010710_D006030 NONE phosphate_25\NN| (r_nmod) reabsorption_27\NN|phosphate|tubular (r_conj) clearance_23\NN|creatinine|,|reabsorption (r_conj) osmolarity_20\NN|,|clearance (r_conj) pH_18\NN|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ|,|ph (r_conj) proteinuria_13\NN|,|aminoaciduria (r_conj) glucosuria_11\NN|,|proteinuria
D010710_D011507 NONE phosphate_25\NN| (r_nmod) reabsorption_27\NN|phosphate|tubular (r_conj) clearance_23\NN|creatinine|,|reabsorption (r_conj) osmolarity_20\NN|,|clearance (r_conj) pH_18\NN|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ|,|ph (r_conj) proteinuria_13\NN|,|aminoaciduria
D010710_D000608 NONE phosphate_25\NN| (r_nmod) reabsorption_27\NN|phosphate|tubular (r_conj) clearance_23\NN|creatinine|,|reabsorption (r_conj) osmolarity_20\NN|,|clearance (r_conj) pH_18\NN|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ|,|ph
D010710_D064420 NONE phosphate_51\NN|low (r_compound) reabsorption_52\NN|phosphate (r_conj) microglobulinuria_48\NN|elevated|beta|2|and|reabsorption (r_pobj) with_44\IN|microglobulinuria (r_prep) patients_43\NNS|five|with (r_dobj) included_41\VBD|group|patients|. (r_conj) included_13\VBD|identified|:|first|patients|;|and|included (l_dobj) patients_15\NNS|four|(|%|)|developed (l_relcl) developed_25\VBD|who|toxicity (l_dobj) toxicity_27\NN|major|resulting
D010710_D005198 NONE phosphate_51\NN|low (r_compound) reabsorption_52\NN|phosphate (r_conj) microglobulinuria_48\NN|elevated|beta|2|and|reabsorption (r_pobj) with_44\IN|microglobulinuria (r_prep) patients_43\NNS|five|with (r_dobj) included_41\VBD|group|patients|. (r_conj) included_13\VBD|identified|:|first|patients|;|and|included (l_dobj) patients_15\NNS|four|(|%|)|developed (l_relcl) developed_25\VBD|who|toxicity (l_dobj) toxicity_27\NN|major|resulting (l_acl) resulting_28\VBG|in (l_prep) in_29\IN|syndrome (l_pobj) syndrome_32\NN|fanconi|(|tdfs|)
D010710_D005198 NONE phosphate_51\NN|low (r_compound) reabsorption_52\NN|phosphate (r_conj) microglobulinuria_48\NN|elevated|beta|2|and|reabsorption (r_pobj) with_44\IN|microglobulinuria (r_prep) patients_43\NNS|five|with (r_dobj) included_41\VBD|group|patients|. (r_conj) included_13\VBD|identified|:|first|patients|;|and|included (l_dobj) patients_15\NNS|four|(|%|)|developed (l_relcl) developed_25\VBD|who|toxicity (l_dobj) toxicity_27\NN|major|resulting (l_acl) resulting_28\VBG|in (l_prep) in_29\IN|syndrome (l_pobj) syndrome_32\NN|fanconi|(|tdfs|) (l_appos) TDFS_34\NNP|
D007069_D064420 NONE ifosfamide_15\NN| (r_pobj) of_14\IN|ifosfamide (r_prep) m2_13\NN|60|g|/|of (r_pobj) of_9\IN|m2 (r_prep) dose_8\NN|the|higher|cumulative|of|,|age|,|and|predominance (r_pobj) with_4\IN|dose (r_prep) correlated_3\VBN|toxicity|was|with|. (l_nsubjpass) toxicity_1\NN|severe
D007069_D009369 NONE ifosfamide_15\NN| (r_pobj) of_14\IN|ifosfamide (r_prep) m2_13\NN|60|g|/|of (r_pobj) of_9\IN|m2 (r_prep) dose_8\NN|the|higher|cumulative|of|,|age|,|and|predominance (l_conj) predominance_31\NN|a|of (l_prep) of_32\IN|involvement (l_pobj) involvement_35\NN|vesicoprostatic|tumor (l_compound) tumor_34\NN|
7352670
D009599_D006973 NONE nitroprusside_4\NN|after|sodium (r_advmod) hypertensive_1\JJ|rebound|nitroprusside|prevented|.
D009599_D006973 NONE SNP_2\NNP| (r_compound) infusion_3\NN|the|snp (r_pobj) During_0\IN|infusion (r_prep) demonstrated_7\VBD|during|animals|increase|,|showed|. (l_dobj) increase_10\NN|a|progressive|in|to (l_prep) in_11\IN|pressure (l_pobj) pressure_13\NN|blood
D012504_D006973 NONE saralasin_7\NN|in (r_pobj) by_6\IN|saralasin (r_agent) prevented_5\VBN|by (r_acl) hypertensive_1\JJ|rebound|nitroprusside|prevented|.
D012504_D006973 NONE saralasin_20\NN| (r_npadvmod) treated_22\VBN|saralasin|- (r_amod) animals_23\NNS|the|treated (r_nsubj) showed_24\VBD|whereas|animals|change (r_advcl) demonstrated_7\VBD|during|animals|increase|,|showed|. (l_dobj) increase_10\NN|a|progressive|in|to (l_prep) in_11\IN|pressure (l_pobj) pressure_13\NN|blood
D000809_D007022 NONE angiotensin_6\NN| (r_compound) system_7\NN|angiotensin|in (l_prep) in_8\IN|maintenance (l_pobj) maintenance_10\NN|the|of|during (l_prep) during_14\IN|anesthesia (l_pobj) anesthesia_16\NN|halothane|and|sodium|nitroprusside (l_conj) nitroprusside_19\NN|evaluated (l_parataxis) evaluated_24\VBN|(|hypotension|was (l_nsubjpass) hypotension_22\NN|snp)-induced
D000809_D007022 NONE angiotensin_8\NN| (r_compound) system_9\NN|angiotensin|in (l_prep) in_10\IN|antagonizing (l_pcomp) antagonizing_11\VBG|effects (l_dobj) effects_15\NNS|the|combined|hypotensive|of (l_amod) hypotensive_14\JJ|
D006221_D007022 CID halothane_15\NN| (r_compound) anesthesia_16\NN|halothane|and|sodium|nitroprusside (l_conj) nitroprusside_19\NN|evaluated (l_parataxis) evaluated_24\VBN|(|hypotension|was (l_nsubjpass) hypotension_22\NN|snp)-induced
D006221_D007022 CID halothane_17\NN|and|snp (r_pobj) of_16\IN|halothane (r_prep) effects_15\NNS|the|combined|hypotensive|of (l_amod) hypotensive_14\JJ|
D009599_D007022 CID nitroprusside_19\NN|evaluated (l_parataxis) evaluated_24\VBN|(|hypotension|was (l_nsubjpass) hypotension_22\NN|snp)-induced
D009599_D007022 CID SNP)-induced_21\VBN| (r_amod) hypotension_22\NN|snp)-induced
D009599_D007022 CID SNP_19\NNP| (r_conj) halothane_17\NN|and|snp (r_pobj) of_16\IN|halothane (r_prep) effects_15\NNS|the|combined|hypotensive|of (l_amod) hypotensive_14\JJ|
9100294
D002118_D018376 NONE calcium_7\NN| (r_compound) channel_8\NN|calcium (r_compound) blockers_9\NNS|channel (r_pobj) to_6\IN|blockers (r_prep) exposed_5\VBN|to (r_acl) alterations_1\NNS|cardiovascular|in|exposed|.
D002118_D018376 NONE calcium_7\NN| (r_compound) channel_8\NN|new|calcium (r_compound) blocker_9\NN|a|channel|,|ro (r_nsubj) induced_16\VBD|that|blocker|,|alterations (l_dobj) alterations_18\NNS|cardiovascular|in|exposed
D002118_D018376 NONE calcium_10\NN| (r_compound) channel_11\NN|calcium (r_compound) blockers_12\NNS|channel|in (r_nsubj) induce_15\VBP|that|blockers|malformations (l_dobj) malformations_17\NNS|cardiovascular|indicating
D002118_D018376 NONE calcium_7\NN| (r_compound) channel_8\NN|calcium (r_compound) blockers_9\NNS|these|channel (r_pobj) of_5\IN|blockers (r_prep) one_4\CD|of (r_dobj) administered_3\VBN|rats|were|one|during|. (l_prep) during_10\IN|period (l_pobj) period_12\NN|the|of (l_prep) of_13\IN|morphogenesis (l_pobj) morphogenesis_15\NN|cardiac|and|offspring (l_conj) offspring_18\NN|the|examined (l_acl) examined_19\VBD|on (l_prep) on_20\IN|day (l_pobj) day_21\NN|20|of (l_prep) of_23\IN|gestation (l_pobj) gestation_24\NN|for (l_prep) for_25\IN|malformations (l_pobj) malformations_27\NNS|cardiovascular
D002118_D018376 NONE calcium_15\NN| (r_compound) channel_16\NN|calcium (r_compound) blockers_17\NNS|the|four|channel (r_pobj) of_12\IN|blockers (r_prep) each_11\DT|of (r_pobj) to_10\IN|each (r_prep) exposure_9\NN|to (r_pobj) after_8\IN|exposure (r_prep) observed_7\VBN|incidence|was|after|,|but|was (l_nsubjpass) incidence_2\NN|a|low|of (l_prep) of_3\IN|malformations (l_pobj) malformations_5\NNS|cardiovascular
D020748_D018376 CID 5967_14\CD|- (r_prep) 40_12\CD|5967 (r_nummod) Ro_11\NNP|40 (r_appos) blocker_9\NN|a|channel|,|ro (r_nsubj) induced_16\VBD|that|blocker|,|alterations (l_dobj) alterations_18\NNS|cardiovascular|in|exposed
D014700_D018376 CID verapamil_27\NN|and|nifedipine (r_pobj) for_26\IN|only|verapamil (r_prep) significant_24\JJ|statistically|for (r_acomp) was_22\VBD|incidence|significant|. (r_conj) observed_7\VBN|incidence|was|after|,|but|was (l_nsubjpass) incidence_2\NN|a|low|of (l_prep) of_3\IN|malformations (l_pobj) malformations_5\NNS|cardiovascular
D009543_D018376 CID nifedipine_29\NN| (r_conj) verapamil_27\NN|and|nifedipine (r_pobj) for_26\IN|only|verapamil (r_prep) significant_24\JJ|statistically|for (r_acomp) was_22\VBD|incidence|significant|. (r_conj) observed_7\VBN|incidence|was|after|,|but|was (l_nsubjpass) incidence_2\NN|a|low|of (l_prep) of_3\IN|malformations (l_pobj) malformations_5\NNS|cardiovascular
18083142
D009638_D001008 NONE Norepinephrine_0\NN| (r_compound) signaling_1\VBG|norepinephrine|through (r_nsubj) is_7\VBZ|signaling|critical|. (l_acomp) critical_8\JJ|for (l_prep) for_9\IN|expression (l_pobj) expression_10\NN|of (l_prep) of_11\IN|anxiety (l_pobj) anxiety_15\NN|induced
D009638_D001008 NONE norepinephrine_22\NN|ne (r_dobj) lack_21\VBP|which|norepinephrine (r_relcl) mice_18\NNS|(|dbh|-/-|)|,|lack|, (r_appos) knockout_13\NN|dopamine|hydroxylase|mice (r_pobj) of_8\IN|knockout (r_prep) performance_7\NN|the|of (r_dobj) evaluated_5\VBD|in|,|we|performance|in|examine|. (l_advcl) examine_36\VB|to|contribution (l_dobj) contribution_38\NN|the|of (l_prep) of_39\IN|signaling (l_pobj) signaling_41\NN|noradrenergic|to (l_prep) to_42\IN|anxiety (l_pobj) anxiety_46\NN|induced
D009638_D001008 NONE NE_24\NNP|(|) (r_appos) norepinephrine_22\NN|ne (r_dobj) lack_21\VBP|which|norepinephrine (r_relcl) mice_18\NNS|(|dbh|-/-|)|,|lack|, (r_appos) knockout_13\NN|dopamine|hydroxylase|mice (r_pobj) of_8\IN|knockout (r_prep) performance_7\NN|the|of (r_dobj) evaluated_5\VBD|in|,|we|performance|in|examine|. (l_advcl) examine_36\VB|to|contribution (l_dobj) contribution_38\NN|the|of (l_prep) of_39\IN|signaling (l_pobj) signaling_41\NN|noradrenergic|to (l_prep) to_42\IN|anxiety (l_pobj) anxiety_46\NN|induced
D003042_D001008 CID cocaine_12\NN| (r_npadvmod) induced_14\VBN|cocaine|- (r_amod) anxiety_15\NN|induced
D003042_D001008 CID cocaine_4\NN|'s (r_poss) effects_7\NNS|underlying|cocaine|rewarding (r_nsubjpass) studied_10\VBN|while|mechanisms|effects|have|been|extensively (r_advcl) paid_17\VBN|studied|,|attention|has|been|to|. (l_dative) to_18\IN|states (l_pobj) states_22\NNS|the|unpleasant|behavioral|induced (l_acl) induced_23\VBN|by (l_agent) by_24\IN|cocaine (l_pobj) cocaine_25\NN|,|as (l_prep) as_28\IN|such|anxiety (l_pobj) anxiety_29\NN|
D003042_D001008 CID cocaine_25\NN|,|as (l_prep) as_28\IN|such|anxiety (l_pobj) anxiety_29\NN|
D003042_D001008 CID cocaine_43\NN| (r_npadvmod) induced_45\VBN|cocaine|- (r_amod) anxiety_46\NN|induced
D003042_D001008 CID cocaine_4\NN| (r_nsubj) increased_8\VBN|that|cocaine|dependently|behavior|,|measured (l_dobj) behavior_12\NN|like|in (l_amod) like_11\JJ|anxiety (l_npadvmod) anxiety_9\NN|-
D003042_D001008 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) anxiety_3\NN|induced
D003042_D001008 CID cocaine_20\NN| (r_npadvmod) induced_22\VBN|cocaine|- (r_amod) behavior_26\NN|blocked|induced|like (l_amod) like_25\JJ|anxiety|- (l_npadvmod) anxiety_23\NN|
D003042_D001008 CID cocaine_14\NN| (r_npadvmod) induced_16\VBN|cocaine|- (r_amod) anxiety_17\NN|induced|in
D004298_D001008 NONE dopamine_9\NN| (r_compound) knockout_13\NN|dopamine|hydroxylase|mice (r_pobj) of_8\IN|knockout (r_prep) performance_7\NN|the|of (r_dobj) evaluated_5\VBD|in|,|we|performance|in|examine|. (l_advcl) examine_36\VB|to|contribution (l_dobj) contribution_38\NN|the|of (l_prep) of_39\IN|signaling (l_pobj) signaling_41\NN|noradrenergic|to (l_prep) to_42\IN|anxiety (l_pobj) anxiety_46\NN|induced
D004298_D001008 NONE dopamine_17\NN| (r_nmod) hydroxylase_20\NN|a|dopamine|beta|- (r_nmod) inhibitor_24\NN|hydroxylase|(|dbh|) (r_appos) administration_12\NN|of|,|inhibitor (r_pobj) following_11\VBG|administration (r_prep) attenuated_6\VBN|anxiety|was|also|in|following|. (l_nsubjpass) anxiety_3\NN|induced
D004221_D001008 NONE disulfiram_14\NN| (r_pobj) of_13\IN|disulfiram (r_prep) administration_12\NN|of|,|inhibitor (r_pobj) following_11\VBG|administration (r_prep) attenuated_6\VBN|anxiety|was|also|in|following|. (l_nsubjpass) anxiety_3\NN|induced
D011433_D001008 NONE propranolol_18\NN|behavior|in (l_dobj) behavior_26\NN|blocked|induced|like (l_amod) like_25\JJ|anxiety|- (l_npadvmod) anxiety_23\NN|
D011224_D001008 NONE prazosin_42\NN|the|antagonist|and|antagonist (r_nsubj) had_49\VBD|while|prazosin|effect (r_advcl) pretreatment_10\NN|that|with|,|had (l_prep) with_11\IN|antagonist (l_pobj) antagonist_17\NN|the|adrenergic|receptor|propranolol (l_acl) propranolol_18\NN|behavior|in (l_dobj) behavior_26\NN|blocked|induced|like (l_amod) like_25\JJ|anxiety|- (l_npadvmod) anxiety_23\NN|
D015016_D001008 NONE yohimbine_48\NN| (r_appos) antagonist_47\NN|the|alpha(2|)|yohimbine (r_conj) prazosin_42\NN|the|antagonist|and|antagonist (r_nsubj) had_49\VBD|while|prazosin|effect (r_advcl) pretreatment_10\NN|that|with|,|had (l_prep) with_11\IN|antagonist (l_pobj) antagonist_17\NN|the|adrenergic|receptor|propranolol (l_acl) propranolol_18\NN|behavior|in (l_dobj) behavior_26\NN|blocked|induced|like (l_amod) like_25\JJ|anxiety|- (l_npadvmod) anxiety_23\NN|
2234245
D003676_D014786 NONE desferrioxamine_8\NN| (r_dobj) receiving_7\VBG|desferrioxamine (r_acl) patients_6\NNS|hemodialyzed|receiving (r_pobj) in_4\IN|patients (r_prep) toxicity_3\NN|ocular|in|.
D003676_D014786 NONE desferrioxamine_10\NN| (r_dobj) receiving_9\VBG|desferrioxamine (r_acl) patients_8\NNS|41|hemodialyzed|receiving|weekly (r_pobj) During_0\IN|period|patients (r_prep) monitored_25\VBN|during|for|were|for|. (l_prep) for_26\IN|detection (l_pobj) detection_27\NN|of (l_prep) of_28\IN|toxicity (l_pobj) toxicity_30\NN|audiovisual
D003676_D014786 NONE desferrioxamine_15\NN| (r_dobj) receiving_14\VBG|desferrioxamine (r_acl) patients_13\NNS|hemodialyzed|receiving (r_pobj) in_11\IN|patients (r_prep) complication_10\NN|an|infrequent|in (r_attr) is_6\VBZ|that|toxicity|not|complication (l_nsubj) toxicity_5\NN|audiovisual
D003676_D006311 NONE desferrioxamine_8\NN| (r_dobj) receiving_7\VBG|desferrioxamine (r_acl) patients_6\NNS|hemodialyzed|receiving (r_pobj) in_4\IN|patients (r_prep) toxicity_3\NN|ocular|in|.
D003676_D006311 NONE desferrioxamine_10\NN| (r_dobj) receiving_9\VBG|desferrioxamine (r_acl) patients_8\NNS|41|hemodialyzed|receiving|weekly (r_pobj) During_0\IN|period|patients (r_prep) monitored_25\VBN|during|for|were|for|. (l_prep) for_26\IN|detection (l_pobj) detection_27\NN|of (l_prep) of_28\IN|toxicity (l_pobj) toxicity_30\NN|audiovisual
D003676_D006311 NONE desferrioxamine_15\NN| (r_dobj) receiving_14\VBG|desferrioxamine (r_acl) patients_13\NNS|hemodialyzed|receiving (r_pobj) in_11\IN|patients (r_prep) complication_10\NN|an|infrequent|in (r_attr) is_6\VBZ|that|toxicity|not|complication (l_nsubj) toxicity_5\NN|audiovisual
D003676_D034381 NONE Desferrioxamine_0\NNP| (r_compound) withdrawal_1\NN|desferrioxamine (r_nsubj) resulted_2\VBD|withdrawal|in|,|and|reversal|. (l_conj) reversal_22\NN|a|complete|of (l_prep) of_23\IN|hearing (l_pcomp) hearing_24\NN|loss|in|in (l_dobj) loss_25\NN|
D003676_D064420 NONE desferrioxamine_10\NN| (r_pobj) of_9\IN|desferrioxamine (r_prep) doses_8\NNS|the|higher|of (r_dobj) receiving_5\VBG|doses (r_acl) patients_4\NNS|receiving (r_pobj) in_3\IN|patients (r_prep) appeared_2\VBD|toxicity|in|or|coincided|. (l_nsubj) toxicity_1\NN|this
-1_D064420 NONE aluminium_19\NN| (r_conj) ferritin_17\NN|or|aluminium (r_nmod) levels_21\NNS|ferritin|serum (r_pobj) of_16\IN|levels (r_prep) normalization_15\NN|the|of (r_pobj) with_13\IN|normalization (r_prep) coincided_12\VBD|with (r_conj) appeared_2\VBD|toxicity|in|or|coincided|. (l_nsubj) toxicity_1\NN|this
18217897
D013792_D008228 NONE Thalidomide_0\NNP| (r_nsubj) limited_2\VBN|thalidomide|has|activity|in (l_prep) in_7\IN|lymphomas (l_pobj) lymphomas_15\NNS|relapsed|indolent|hodgkin|:|trial
D013792_D009369 NONE Thalidomide_0\NNP| (r_nsubj) limited_2\VBN|thalidomide|has|activity|in (l_prep) in_7\IN|lymphomas (l_pobj) lymphomas_15\NNS|relapsed|indolent|hodgkin|:|trial (l_appos) trial_20\NN|a|phase|ii|of (l_prep) of_21\IN|cancer (l_pobj) Cancer_23\NNP|the|and|b.
D013792_D007938 NONE Thalidomide_0\NNP| (r_nsubj) limited_2\VBN|thalidomide|has|activity|in (l_prep) in_7\IN|lymphomas (l_pobj) lymphomas_15\NNS|relapsed|indolent|hodgkin|:|trial (l_appos) trial_20\NN|a|phase|ii|of (l_prep) of_21\IN|cancer (l_pobj) Cancer_23\NNP|the|and|b. (l_conj) B._27\NNP|leukemia|group (l_compound) Leukemia_25\NNP|
D013792_D009101 NONE Thalidomide_0\NNP| (r_nsubj) is_1\VBZ|thalidomide|agent|. (l_attr) agent_4\NN|an|immunomodulatory|with (l_prep) with_5\IN|activity (l_pobj) activity_7\NN|demonstrated|in (l_prep) in_8\IN|myeloma (l_pobj) myeloma_10\NN|multiple|,|lymphoma
D013792_D020522 NONE Thalidomide_0\NNP| (r_nsubj) is_1\VBZ|thalidomide|agent|. (l_attr) agent_4\NN|an|immunomodulatory|with (l_prep) with_5\IN|activity (l_pobj) activity_7\NN|demonstrated|in (l_prep) in_8\IN|myeloma (l_pobj) myeloma_10\NN|multiple|,|lymphoma (l_conj) lymphoma_14\NN|mantle|cell|and|lymphoma
D013792_D008223 NONE Thalidomide_0\NNP| (r_nsubj) is_1\VBZ|thalidomide|agent|. (l_attr) agent_4\NN|an|immunomodulatory|with (l_prep) with_5\IN|activity (l_pobj) activity_7\NN|demonstrated|in (l_prep) in_8\IN|myeloma (l_pobj) myeloma_10\NN|multiple|,|lymphoma (l_conj) lymphoma_14\NN|mantle|cell|and|lymphoma (l_conj) lymphoma_17\NN|lymphoplasmacytic
D013792_D008223 NONE thalidomide_16\NN| (r_dobj) received_15\VBD|between|,|patients|thalidomide|daily|with|tolerated|. (l_nsubj) patients_8\NNS|24|with (l_prep) with_9\IN|lymphomas (l_pobj) lymphomas_14\NNS|relapsed|/|refractory|indolent
D013792_D008223 NONE thalidomide_12\NN|agent (r_pobj) to_9\IN|thalidomide (r_prep) rate_8\NN|an|important|response|to|in (l_prep) in_13\IN|lymphomas (l_pobj) lymphomas_15\NNS|indolent
C467567_D008223 NONE lenalidomide_31\NN| (r_appos) agent_29\NN|the|generation|immunomodulatory|,|lenalidomide (r_pobj) with_24\IN|agent (r_prep) reported_23\VBN|with (r_acl) level_22\NN|the|higher|activity|reported (r_pobj) with_18\IN|level (r_prep) contrast_17\NN|with (r_conj) demonstrate_4\VB|to|rate|and|contrast (l_dobj) rate_8\NN|an|important|response|to|in (l_prep) in_13\IN|lymphomas (l_pobj) lymphomas_15\NNS|indolent
3101906
D007654_D003643 NONE ketoconazole_9\JJ| (r_compound) treatment_10\NN|ketoconazole (r_pobj) with_8\IN|treatment (r_prep) associated_7\VBN|probably|with (r_acl) deaths_5\NNS|the|three|associated
D007654_D007565 CID ketoconazole_9\JJ| (r_compound) treatment_10\NN|ketoconazole (r_pobj) with_8\IN|treatment (r_prep) associated_7\VBN|probably|with (r_acl) deaths_5\NNS|the|three|associated (r_pobj) of_2\IN|deaths (r_prep) two_1\CD|of (r_pobj) In_0\IN|two (r_prep) continued_15\VBN|in|drug|had|been|after|. (l_prep) after_16\IN|onset (l_pobj) onset_18\NN|the|of (l_prep) of_19\IN|jaundice (l_pobj) jaundice_20\NN|and|symptoms
D007654_D056486 CID ketoconazole_9\JJ| (r_compound) treatment_10\NN|ketoconazole (r_pobj) with_8\IN|treatment (r_prep) associated_7\VBN|probably|with (r_acl) deaths_5\NNS|the|three|associated (r_pobj) of_2\IN|deaths (r_prep) two_1\CD|of (r_pobj) In_0\IN|two (r_prep) continued_15\VBN|in|drug|had|been|after|. (l_prep) after_16\IN|onset (l_pobj) onset_18\NN|the|of (l_prep) of_19\IN|jaundice (l_pobj) jaundice_20\NN|and|symptoms (l_conj) symptoms_23\NNS|other|of (l_prep) of_24\IN|hepatitis (l_pobj) hepatitis_25\NN|
D007654_D056486 CID ketoconazole_18\NN| (r_pobj) with_17\IN|ketoconazole (r_prep) treatment_16\NN|term|with (r_pobj) during_13\IN|treatment (r_prep) advised_12\VBN|monitoring|is|during|prevent|. (l_nsubjpass) monitoring_3\NN|clinical|at|for (l_prep) for_7\IN|evidence (l_pobj) evidence_8\NN|of (l_prep) of_9\IN|hepatitis (l_pobj) hepatitis_10\NN|
D007654_D056486 CID ketoconazole_18\NN| (r_pobj) with_17\IN|ketoconazole (r_prep) treatment_16\NN|term|with (r_pobj) during_13\IN|treatment (r_prep) advised_12\VBN|monitoring|is|during|prevent|. (l_advcl) prevent_20\VB|to|injury (l_dobj) injury_24\NN|possible|serious|hepatic
2273650
D012601_D000647 CID scopolamine_3\NN|and|cycloheximide (r_pobj) by_2\IN|scopolamine (r_agent) produced_1\VBN|by (r_acl) Amnesia_0\NNP|produced
D012601_D000647 CID scopolamine_5\NN|test (r_nsubj) reversed_7\VBD|similarly|scopolamine|partially|amnesia|,|but|failed (l_dobj) amnesia_12\NN|the|induced
D012601_D000647 CID scopolamine_5\NN|test (r_nsubj) reversed_7\VBD|similarly|scopolamine|partially|amnesia|,|but|failed (l_conj) failed_23\VBD|significantly|cycloheximide|reverse|. (l_xcomp) reverse_25\VB|to|amnesia (l_dobj) amnesia_30\NN|the|induced
D012601_D000647 CID scopolamine_9\NN| (r_npadvmod) induced_11\VBN|scopolamine|- (r_amod) amnesia_12\NN|the|induced
D012601_D000647 CID scopolamine_9\NN| (r_npadvmod) induced_11\VBN|scopolamine|- (r_amod) amnesia_12\NN|the|induced (r_dobj) reversed_7\VBD|similarly|scopolamine|partially|amnesia|,|but|failed (l_conj) failed_23\VBD|significantly|cycloheximide|reverse|. (l_xcomp) reverse_25\VB|to|amnesia (l_dobj) amnesia_30\NN|the|induced
D003513_D000647 CID cycloheximide_5\NN| (r_conj) scopolamine_3\NN|and|cycloheximide (r_pobj) by_2\IN|scopolamine (r_agent) produced_1\VBN|by (r_acl) Amnesia_0\NNP|produced
D003513_D000647 CID cycloheximide_22\NN|test (r_nsubj) failed_23\VBD|significantly|cycloheximide|reverse|. (r_conj) reversed_7\VBD|similarly|scopolamine|partially|amnesia|,|but|failed (l_dobj) amnesia_12\NN|the|induced
D003513_D000647 CID cycloheximide_22\NN|test (r_nsubj) failed_23\VBD|significantly|cycloheximide|reverse|. (l_xcomp) reverse_25\VB|to|amnesia (l_dobj) amnesia_30\NN|the|induced
D003513_D000647 CID cycloheximide_27\RB| (r_advmod) induced_29\VBN|cycloheximide|- (r_amod) amnesia_30\NN|the|induced (r_dobj) reverse_25\VB|to|amnesia (r_xcomp) failed_23\VBD|significantly|cycloheximide|reverse|. (r_conj) reversed_7\VBD|similarly|scopolamine|partially|amnesia|,|but|failed (l_dobj) amnesia_12\NN|the|induced
D003513_D000647 CID cycloheximide_27\RB| (r_advmod) induced_29\VBN|cycloheximide|- (r_amod) amnesia_30\NN|the|induced
D009020_D000647 NONE morphine_9\NN| (r_pobj) by_8\IN|morphine (r_agent) reversed_7\VBN|amnesia|were|by|given|,|and|facilitated (l_nsubjpass) Amnesia_0\NNP|produced
D009020_D000647 NONE morphine_27\NN|test (r_nsubj) facilitated_29\VBD|morphine|also|retrieval|. (r_conj) reversed_7\VBN|amnesia|were|by|given|,|and|facilitated (l_nsubjpass) Amnesia_0\NNP|produced
D009270_D000647 NONE naloxone_37\NN| (r_dobj) administered_36\VBN|naloxone|during (r_acl) retrieval_32\NN|the|memory|in|administered (r_dobj) facilitated_29\VBD|morphine|also|retrieval|. (r_conj) reversed_7\VBN|amnesia|were|by|given|,|and|facilitated (l_nsubjpass) Amnesia_0\NNP|produced
6538499
D011092_D064420 NONE 400_4\CD|on (r_nummod) glycol_3\NN|effect|400|adriamycin|. (l_advcl) adriamycin_6\JJ|toxicity (l_dobj) toxicity_7\NN|in
D004317_D064420 NONE adriamycin_6\JJ|toxicity (l_dobj) toxicity_7\NN|in
D004317_D009202 CID ADR_8\NNP| (r_npadvmod) induced_10\VBN|adr|- (r_amod) alterations_13\NNS|induced|cardiac|morphological
D004317_D007939 NONE ADR_6\NNP| (r_compound) activity_8\NN|the|adr|antitumor|in|tumor (l_prep) in_9\IN|leukemia|and (l_pobj) leukemia_11\NN|l1210
D004317_D002286 NONE ADR_6\NNP| (r_compound) activity_8\NN|the|adr|antitumor|in|tumor (l_relcl) tumor_16\NN|in|ascites
9351491
D018967_D011618 NONE risperidone_6\NN|'s (r_poss) profile_9\NN|risperidone|pharmacologic (r_nsubj) produce_11\VB|that|profile|may|efficacy|and|decreased (l_dobj) efficacy_13\NN|improved|for (l_prep) for_14\IN|symptoms (l_pobj) symptoms_17\NNS|negative|psychotic
D018967_D010302 CID risperidone_10\NN|(|%|)|and|haloperidol (r_pobj) with_9\IN|risperidone (r_prep) treated_8\VBN|with (r_acl) subjects_7\NNS|treated (r_pobj) in_6\IN|subjects (r_prep) observed_5\VBN|parkinsonism|was|in|and|observed|. (l_nsubjpass) parkinsonism_3\NN|induced
D006220_D010302 CID haloperidol_16\NN|(|%|) (r_conj) risperidone_10\NN|(|%|)|and|haloperidol (r_pobj) with_9\IN|risperidone (r_prep) treated_8\VBN|with (r_acl) subjects_7\NNS|treated (r_pobj) in_6\IN|subjects (r_prep) observed_5\VBN|parkinsonism|was|in|and|observed|. (l_nsubjpass) parkinsonism_3\NN|induced
15120741
D010862_D013226 CID pilocarpine_5\NN| (r_compound) injection_6\NN|systemic|pilocarpine (r_nsubj) causes_7\VBZ|similar|,|injection|se|,|but|identified (l_dobj) SE_11\NNP|status|epilepticus|(|)|and|development (l_nmod) epilepticus_9\NN|
D010862_D013226 CID pilocarpine_5\NN| (r_compound) injection_6\NN|systemic|pilocarpine (r_nsubj) causes_7\VBZ|similar|,|injection|se|,|but|identified (l_dobj) SE_11\NNP|status|epilepticus|(|)|and|development
D010862_D013226 CID pilocarpine_34\NN| (r_npadvmod) treated_36\VBN|pilocarpine|- (r_amod) mice_37\NNS|treated (r_conj) mice_32\NNS|control|and|mice (r_pobj) from_30\IN|mice (r_prep) cells_29\NNS|granule|from (r_pobj) in_27\IN|cells (r_prep) spike_26\NN|a|single|population|in|experience (l_relcl) experience_41\VB|that|did|not|se (l_dobj) SE_42\NNP|
D010862_D012640 CID pilocarpine_5\NN| (r_compound) injection_6\NN|systemic|pilocarpine (r_nsubj) causes_7\VBZ|similar|,|injection|se|,|but|identified (l_dobj) SE_11\NNP|status|epilepticus|(|)|and|development (l_conj) development_16\NN|the|eventual|of (l_prep) of_17\IN|seizures (l_pobj) seizures_19\NNS|spontaneous|and|fiber|sprouting
D008274_D013226 NONE Mg(2+)-free_1\JJ| (r_pobj) In_0\IN|mg(2+)-free|bicuculline (r_prep) resulted_21\VBD|in|,|conditions|,|stimulation|in|. (l_prep) in_22\IN|spike (l_pobj) spike_26\NN|a|single|population|in|experience (l_relcl) experience_41\VB|that|did|not|se (l_dobj) SE_42\NNP|
D001640_D013226 NONE bicuculline_5\NN|bathing|containing (r_pobj) In_0\IN|mg(2+)-free|bicuculline (r_prep) resulted_21\VBD|in|,|conditions|,|stimulation|in|. (l_prep) in_22\IN|spike (l_pobj) spike_26\NN|a|single|population|in|experience (l_relcl) experience_41\VB|that|did|not|se (l_dobj) SE_42\NNP|
D018698_D013226 NONE glutamate_37\NN| (r_compound) receptor_38\NN|glutamate (r_compound) antagonists_39\NNS|ionotropic|receptor (r_pobj) by_35\IN|antagonists (r_agent) blocked_34\VBN|which|were|by (r_relcl) duration_30\NN|s|,|blocked (r_pobj) of_25\IN|duration (r_prep) afterdischarges_24\NNS|repetitive|of (r_conj) shifts_21\NNS|negative|dc|and|afterdischarges (r_pobj) by_18\IN|shifts (r_prep) followed_11\VBD|,|at|,|by (r_advcl) resulted_6\VBD|in|,|stimulation|in|followed|. (l_prep) In_0\IN|survivors (l_pobj) survivors_2\NNS|se (l_compound) SE_1\NNP|
D018698_D013226 NONE glutamate_1\NN| (r_compound) photostimulation_2\NN|focal|glutamate|of|at (r_nsubj) resulted_15\VBD|photostimulation|in|. (l_prep) in_16\IN|responses (l_pobj) responses_18\NNS|population|of (l_prep) of_19\IN|duration (l_pobj) duration_24\NN|s|in|but|groups (l_prep) in_25\IN|slices (l_pobj) slices_26\NNS|from (l_prep) from_27\IN|survivors (l_pobj) survivors_29\NNS|se (l_compound) SE_28\NNP|
2578334
D001374_D011230 CID 5-azacytidine_0\RB| (r_nsubj) potentiates_1\VBZ|5-azacytidine|initiation|. (l_dobj) initiation_2\NN|induced (l_acl) induced_3\VBN|by (l_agent) by_4\IN|carcinogens (l_pobj) carcinogens_5\NNS|in
D001374_D011230 CID 5-azacytidine_22\JJ| (r_punct) 5-AzC_24\CD|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB|to|validity (l_dobj) validity_3\NN|the|of (l_prep) of_4\IN|hypothesis (l_pobj) hypothesis_6\NN|the|plays (l_acl) plays_11\VBZ|that|hypomethylation|role|in (l_prep) in_15\IN|initiation (l_pobj) initiation_17\NN|the|of (l_prep) of_18\IN|process (l_pobj) process_20\NN|carcinogenic
D001374_D011230 CID 5-AzC_24\CD|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB|to|validity (l_dobj) validity_3\NN|the|of (l_prep) of_4\IN|hypothesis (l_pobj) hypothesis_6\NN|the|plays (l_acl) plays_11\VBZ|that|hypomethylation|role|in (l_prep) in_15\IN|initiation (l_pobj) initiation_17\NN|the|of (l_prep) of_18\IN|process (l_pobj) process_20\NN|carcinogenic
D001564_D011230 CID benzo[a]-pyrene_53\NN|(|mg/kg|) (r_appos) carcinogens_51\NNS|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN|carcinogens (r_agent) induced_47\VBN|by (r_acl) phase_43\NN|the|of|induced (r_pobj) during_41\IN|phase (r_prep) given_38\VBN|5-azc|was|to|during|. (l_nsubjpass) 5-AzC_24\CD|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB|to|validity (l_dobj) validity_3\NN|the|of (l_prep) of_4\IN|hypothesis (l_pobj) hypothesis_6\NN|the|plays (l_acl) plays_11\VBZ|that|hypomethylation|role|in (l_prep) in_15\IN|initiation (l_pobj) initiation_17\NN|the|of (l_prep) of_18\IN|process (l_pobj) process_20\NN|carcinogenic
D008770_D011230 CID nitrosourea_65\NN|methyl|-|n|-|60|1,2-dmh|mg/kg (r_appos) carcinogens_51\NNS|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN|carcinogens (r_agent) induced_47\VBN|by (r_acl) phase_43\NN|the|of|induced (r_pobj) during_41\IN|phase (r_prep) given_38\VBN|5-azc|was|to|during|. (l_nsubjpass) 5-AzC_24\CD|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB|to|validity (l_dobj) validity_3\NN|the|of (l_prep) of_4\IN|hypothesis (l_pobj) hypothesis_6\NN|the|plays (l_acl) plays_11\VBZ|that|hypomethylation|role|in (l_prep) in_15\IN|initiation (l_pobj) initiation_17\NN|the|of (l_prep) of_18\IN|process (l_pobj) process_20\NN|carcinogenic
D019813_D011230 CID 1,2-dimethylhydrazine_71\CD| (r_conj) 60_67\CD|(|mg/kg|)|and|1,2-dimethylhydrazine (r_appos) nitrosourea_65\NN|methyl|-|n|-|60|1,2-dmh|mg/kg (r_appos) carcinogens_51\NNS|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN|carcinogens (r_agent) induced_47\VBN|by (r_acl) phase_43\NN|the|of|induced (r_pobj) during_41\IN|phase (r_prep) given_38\VBN|5-azc|was|to|during|. (l_nsubjpass) 5-AzC_24\CD|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB|to|validity (l_dobj) validity_3\NN|the|of (l_prep) of_4\IN|hypothesis (l_pobj) hypothesis_6\NN|the|plays (l_acl) plays_11\VBZ|that|hypomethylation|role|in (l_prep) in_15\IN|initiation (l_pobj) initiation_17\NN|the|of (l_prep) of_18\IN|process (l_pobj) process_20\NN|carcinogenic
D019813_D011230 CID 1,2-DMH_73\NNP|(|) (r_appos) nitrosourea_65\NN|methyl|-|n|-|60|1,2-dmh|mg/kg (r_appos) carcinogens_51\NNS|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN|carcinogens (r_agent) induced_47\VBN|by (r_acl) phase_43\NN|the|of|induced (r_pobj) during_41\IN|phase (r_prep) given_38\VBN|5-azc|was|to|during|. (l_nsubjpass) 5-AzC_24\CD|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB|to|validity (l_dobj) validity_3\NN|the|of (l_prep) of_4\IN|hypothesis (l_pobj) hypothesis_6\NN|the|plays (l_acl) plays_11\VBZ|that|hypomethylation|role|in (l_prep) in_15\IN|initiation (l_pobj) initiation_17\NN|the|of (l_prep) of_18\IN|process (l_pobj) process_20\NN|carcinogenic
8410052
D019344_D001480 NONE lactate_10\NN| (r_pobj) of_9\IN|lactate (r_prep) infusion_8\NN|of|at (r_pobj) by_7\IN|infusion|or|by (r_agent) produced_6\VBN|injury|was|by|. (l_nsubjpass) injury_1\NN|focal|in (l_prep) in_2\IN|cortex (l_pobj) cortex_4\NN|the
D010862_D002544 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|pilocarpine|- (r_amod) status_13\NN|prolonged|induced (r_pobj) by_8\IN|status (r_agent) evoked_7\VBN|infarcts|were|by|epilepticus|. (l_nsubjpass) Infarcts_0\NNS|in (l_prep) in_1\IN|reticulata (l_pobj) reticulata_5\NNS|substantia|pars
D010862_D013226 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|pilocarpine|- (r_amod) status_13\NN|prolonged|induced (r_pobj) by_8\IN|status (r_agent) evoked_7\VBN|infarcts|were|by|epilepticus|. (l_advmod) epilepticus_14\NN|
11807648
D014148_D004827 NONE acid_10\NN|tranexamic (r_dobj) containing_8\VBG|acid|in (r_acl) sealants_7\NNS|fibrin|containing (r_pobj) of_5\IN|sealants (r_prep) application_4\NN|cortical|of (r_dobj) following_2\VBG|application (r_prep) seizures_1\NNS|epileptic|following|.
D014148_D004827 NONE tAMCA_2\NN| (r_nsubjpass) shown_5\VBN|however|,|tamca|has|been|cause|. (l_xcomp) cause_7\VB|to|seizures (l_dobj) seizures_9\NNS|epileptic
D014148_D012640 CID tAMCA_5\NN| (r_nsubj) retains_6\VBZ|whether|tamca|action|incorporated (l_dobj) action_9\NN|its|convulsive (l_amod) convulsive_8\JJ|
D014148_D012640 CID tAMCA_4\NN| (r_appos) FINDINGS_0\NNS|:|fs|tamca (r_nsubj) caused_5\VBD|findings|activity|. (l_dobj) activity_8\NN|paroxysmal|brain|associated (l_relcl) associated_11\VBN|which|was|with (l_prep) with_12\IN|behaviours (l_pobj) behaviours_15\NNS|distinct|convulsive (l_amod) convulsive_14\JJ|
D014148_D012640 CID tAMCA_10\CD| (r_pobj) of_9\IN|tamca (r_prep) concentration_8\NN|increasing|of (r_pobj) with_6\IN|concentration (r_prep) increased_5\VBD|degree|with|. (l_nsubj) degree_1\NN|the|of (l_prep) of_2\IN|seizures (l_pobj) seizures_4\NNS|these
D014148_D012640 CID tAMCA_0\NN| (r_advmod) evoked_1\VBD|tamca|seizures|evoked|. (l_dobj) seizures_3\NNS|generalized|in
D014148_D012640 CID tAMCA_0\NN| (r_advmod) evoked_1\VBD|tamca|seizures|evoked|. (l_advcl) evoked_24\VBD|while|concentration|)|only|episodes (l_dobj) episodes_26\NNS|brief|of (l_prep) of_27\IN|potentials (l_pobj) potentials_32\NNS|correlated|convulsive|in (l_amod) convulsive_31\JJ|
D014148_D012640 CID tAMCA_16\NN| (r_nmod) ml_21\NNS|tamca|(|0.5|mg|/ (r_pobj) of_15\IN|ml (r_prep) concentration_14\NN|the|lowest|of (r_nsubj) evoked_24\VBD|while|concentration|)|only|episodes (r_advcl) evoked_1\VBD|tamca|seizures|evoked|. (l_dobj) seizures_3\NNS|generalized|in
D014148_D012640 CID tAMCA_16\NN| (r_nmod) ml_21\NNS|tamca|(|0.5|mg|/ (r_pobj) of_15\IN|ml (r_prep) concentration_14\NN|the|lowest|of (r_nsubj) evoked_24\VBD|while|concentration|)|only|episodes (l_dobj) episodes_26\NNS|brief|of (l_prep) of_27\IN|potentials (l_pobj) potentials_32\NNS|correlated|convulsive|in (l_amod) convulsive_31\JJ|
D014148_D012640 CID acid_1\NN|tranexamic (r_nsubj) retains_2\VBZ|acid|action|. (l_dobj) action_5\NN|its|convulsive|within (l_amod) convulsive_4\JJ|
7234705
D011342_D017180 CID Procainamide_0\NNP| (r_npadvmod) induced_2\VBN|procainamide|-|tachycardia|. (l_dobj) tachycardia_5\NN|polymorphous|ventricular
D011342_D017180 CID procainamide_3\RB| (r_advmod) induced_5\VBN|procainamide|- (r_amod) tachycardia_8\NNS|induced|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN| (r_pobj) of_16\IN|procainamide (r_prep) mg_15\IN|400|of (r_pobj) of_11\IN|mg (r_prep) administration_10\NN|intravenous|of|for (r_pobj) after_8\IN|administration (r_prep) appeared_7\VBD|in|,|tachycardia|after|. (l_nsubj) tachycardia_6\NN|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN| (r_pobj) of_16\IN|procainamide (r_prep) mg_15\IN|400|of (r_pobj) of_11\IN|mg (r_prep) administration_10\NN|intravenous|of|for (l_prep) for_18\IN|treatment (l_pobj) treatment_20\NN|the|of (l_prep) of_21\IN|tachycardia (l_pobj) tachycardia_24\NN|sustained|ventricular
D011342_D017180 CID procainamide_16\NN| (r_amod) therapy_17\NN|procainamide (r_pobj) of_15\IN|therapy (r_prep) continuation_14\NN|of (r_pobj) despite_13\IN|continuation (r_prep) reoccur_24\VB|despite|,|tachycardia|did|not|. (l_nsubj) tachycardia_21\NN|polymorphous|ventricular
D011342_D017180 CID procainamide_5\NN| (r_nsubj) produce_7\VB|that|procainamide|can|syndrome|with (l_prep) with_15\IN|tachycardia (l_pobj) tachycardia_18\NN|polymorphous|ventricular
D011342_D018879 NONE procainamide_6\NN| (r_nsubjpass) administered_8\VBN|in|,|procainamide|was|orally|for|. (l_prep) for_10\IN|treatment (l_pobj) treatment_11\NN|of (l_prep) of_12\IN|contractions (l_pobj) contractions_16\NNS|chronic|premature|ventricular|or|flutter
D011342_D001282 NONE procainamide_6\NN| (r_nsubjpass) administered_8\VBN|in|,|procainamide|was|orally|for|. (l_prep) for_10\IN|treatment (l_pobj) treatment_11\NN|of (l_prep) of_12\IN|contractions (l_pobj) contractions_16\NNS|chronic|premature|ventricular|or|flutter (l_conj) flutter_19\NN|atrial
D011342_D008133 NONE procainamide_5\NN| (r_nsubj) produce_7\VB|that|procainamide|can|syndrome|with (l_dobj) syndrome_14\NN|an|acquired|prolonged|t
15278670
C009250_D012640 NONE sevoflurane_3\NN| (r_pobj) of_2\IN|sevoflurane (r_prep) effects_1\NNS|the|of|on|. (l_prep) on_4\IN|convulsions (l_pobj) convulsions_8\NNS|induced
C009250_D012640 NONE sevoflurane_3\NN|on (l_prep) on_4\IN|convulsions (l_pobj) convulsions_8\NNS|induced
C009250_D012640 NONE sevoflurane_40\NN| (r_pobj) of_39\IN|sevoflurane (r_prep) concentration_38\NN|the|tidal|of (r_nsubj) was_41\VBD|when|concentration|% (r_relcl) l(-1_31\NN|mg.|)|was (r_pobj) to_26\IN|l(-1 (r_prep) increasing_24\VBG|significantly|to (r_advcl) was_8\VBD|threshold|+/-|)|with|)|,|increasing|. (l_nsubj) threshold_2\NN|the|convulsive|(|mean|) (l_amod) convulsive_1\JJ|
C009250_D012640 NONE sevoflurane_10\NN|and|enflurane (r_pobj) between_9\IN|sevoflurane (r_prep) threshold_8\NN|the|convulsive|between (l_amod) convulsive_7\JJ|
C009250_D012640 NONE sevoflurane_12\NN|or|enflurane (r_pobj) of_11\IN|sevoflurane (r_prep) concentrations_10\NNS|higher|of (r_nsubjpass) administered_16\VBN|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN|the|blood|at (l_prep) at_21\IN|convulsions (l_pobj) convulsions_22\NNS|
C009250_D012640 NONE sevoflurane_28\NN|% (r_pobj) in_25\IN|sevoflurane (r_prep) decreased_23\VBD|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN|the|blood|at (l_prep) at_21\IN|convulsions (l_pobj) convulsions_22\NNS|
C009250_D012640 NONE sevoflurane_4\NN| (r_nsubj) reduces_5\VBZ|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN|the|convulsive|of (l_amod) convulsive_7\JJ|
D008012_D012640 CID lidocaine_5\NN| (r_npadvmod) induced_7\VBN|lidocaine|- (r_amod) convulsions_8\NNS|induced
D008012_D012640 CID lidocaine_5\NN| (r_npadvmod) induced_7\VBN|lidocaine|- (r_amod) convulsions_8\NNS|induced
D008012_D012640 CID lidocaine_16\NN| (r_compound) infusion_17\NN|lidocaine|(|mg.kg(-1).min(-1|) (r_pobj) with_15\IN|infusion (r_prep) was_8\VBD|threshold|+/-|)|with|)|,|increasing|. (l_nsubj) threshold_2\NN|the|convulsive|(|mean|) (l_amod) convulsive_1\JJ|
D008012_D012640 CID lidocaine_10\JJ| (r_compound) toxicity_11\NN|lidocaine (r_pobj) of_9\IN|toxicity (r_prep) effect_8\NN|the|convulsive|of (l_amod) convulsive_7\JJ|
D004737_D012640 NONE enflurane_12\NN| (r_conj) sevoflurane_10\NN|and|enflurane (r_pobj) between_9\IN|sevoflurane (r_prep) threshold_8\NN|the|convulsive|between (l_amod) convulsive_7\JJ|
D004737_D012640 NONE enflurane_14\NN| (r_conj) sevoflurane_12\NN|or|enflurane (r_pobj) of_11\IN|sevoflurane (r_prep) concentrations_10\NNS|higher|of (r_nsubjpass) administered_16\VBN|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN|the|blood|at (l_prep) at_21\IN|convulsions (l_pobj) convulsions_22\NNS|
D004737_D012640 NONE enflurane_37\NN|% (r_conj) %_33\NN|0.8|and|enflurane (r_pobj) in_31\IN|% (r_conj) decreased_23\VBD|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN|the|blood|at (l_prep) at_21\IN|convulsions (l_pobj) convulsions_22\NNS|
D001030_D012640 NONE Apamin_0\NNP|ng (r_nsubj) had_5\VBD|apamin|tendency|)|but|was (l_dobj) tendency_7\NN|a|decrease (l_acl) decrease_9\VB|to|threshold (l_dobj) threshold_12\NN|the|convulsive|(|+/-|) (l_amod) convulsive_11\JJ|
C009250_D064420 NONE sevoflurane_4\NN| (r_nsubj) reduces_5\VBZ|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN|the|convulsive|of (l_prep) of_9\IN|toxicity (l_pobj) toxicity_11\NN|lidocaine
C009250_D003866 NONE sevoflurane_4\NN| (r_nsubj) reduces_5\VBZ|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ|risk|due (l_prep) due_16\IN|to (l_pcomp) to_17\IN|depression (l_pobj) depression_19\NN|circulatory
D008012_D064420 NONE lidocaine_10\JJ| (r_compound) toxicity_11\NN|lidocaine
D008012_D003866 NONE lidocaine_10\JJ| (r_compound) toxicity_11\NN|lidocaine (r_pobj) of_9\IN|toxicity (r_prep) effect_8\NN|the|convulsive|of (r_dobj) reduces_5\VBZ|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ|risk|due (l_prep) due_16\IN|to (l_pcomp) to_17\IN|depression (l_pobj) depression_19\NN|circulatory
6209318
D008801_D001145 NONE mexiletine_1\NN|and|placebo (r_nmod) trial_6\NN|international|mexiletine|antiarrhythmic|coronary|:|report|. (l_appos) Report_9\NNP|i.|on (l_prep) on_10\IN|arrhythmia (l_pobj) arrhythmia_11\NN|and|findings
D008801_D009203 NONE mexiletine_9\NN| (r_pobj) of_8\IN|mexiletine|perlongets (r_prep) form_7\NN|the|sustained|release|of (r_pobj) of_3\IN|form (r_prep) effects_2\NNS|the|antiarrhythmic|of (r_nsubjpass) evaluated_16\VBN|effects|were|in|. (l_prep) in_17\IN|trial (l_pobj) trial_23\NN|a|blind|placebo|in (l_prep) in_24\IN|patients (l_pobj) patients_26\NNS|630|with (l_prep) with_27\IN|infarction (l_pobj) infarction_31\NN|recent|documented|myocardial
D008801_D009203 NONE Perlongets_13\NNP|(|mexitil|-|) (r_pobj) of_8\IN|mexiletine|perlongets (r_prep) form_7\NN|the|sustained|release|of (r_pobj) of_3\IN|form (r_prep) effects_2\NNS|the|antiarrhythmic|of (r_nsubjpass) evaluated_16\VBN|effects|were|in|. (l_prep) in_17\IN|trial (l_pobj) trial_23\NN|a|blind|placebo|in (l_prep) in_24\IN|patients (l_pobj) patients_26\NNS|630|with (l_prep) with_27\IN|infarction (l_pobj) infarction_31\NN|recent|documented|myocardial
D008801_D003643 NONE mexiletine_6\NN| (r_amod) group_7\NN|the|mexiletine|(|%|) (r_pobj) in_4\IN|group (r_prep) deaths_3\NNS|more|in|than
D008801_D014202 CID mexiletine_16\NN| (r_amod) group_17\NN|the|mexiletine (r_pobj) in_14\IN|group (r_prep) frequent_13\JJ|more|in|than (r_acomp) were_11\VBD|effects|frequent|. (l_nsubj) effects_3\NNS|recognized|side|,|tremor|, (l_appos) tremor_6\JJ|particularly|and|problems
D008801_D012817 CID mexiletine_16\NN| (r_amod) group_17\NN|the|mexiletine (r_pobj) in_14\IN|group (r_prep) frequent_13\JJ|more|in|than (r_acomp) were_11\VBD|effects|frequent|. (l_nsubj) effects_3\NNS|recognized|side|,|tremor|, (l_appos) tremor_6\JJ|particularly|and|problems (l_conj) problems_9\NNS|gastrointestinal
2071257
D005997_D000647 NONE phosphorylcholine_8\NN|glyceryl|- (r_pobj) of_1\IN|phosphorylcholine (r_prep) Effect_0\NN|of|on|. (l_prep) on_9\IN|amnesia (l_pobj) amnesia_10\NN|caused
D012601_D000647 NONE scopolamine_13\NN| (r_pobj) by_12\IN|scopolamine (r_agent) caused_11\VBN|by (r_acl) amnesia_10\NN|caused
D005997_D008569 NONE glycerylphosphorylcholine_15\NN|l|-|alpha|-|gfc (r_pobj) of_10\IN|glycerylphosphorylcholine (r_prep) effects_9\NNS|the|of|on (l_prep) on_23\IN|impairment (l_pobj) impairment_25\NN|memory|induced
D005997_D008569 NONE GFC_21\NNP|(|l|-|alpha|-|) (r_appos) glycerylphosphorylcholine_15\NN|l|-|alpha|-|gfc (r_pobj) of_10\IN|glycerylphosphorylcholine (r_prep) effects_9\NNS|the|of|on (l_prep) on_23\IN|impairment (l_pobj) impairment_25\NN|memory|induced
D012601_D008569 CID scopolamine_28\NN|in (r_pobj) by_27\IN|scopolamine (r_agent) induced_26\VBN|by (r_acl) impairment_25\NN|memory|induced
D012601_D008569 CID scopolamine_20\NN| (r_pobj) by_19\IN|scopolamine (r_agent) induced_18\VBN|by (r_acl) impairment_13\NN|of|induced (l_prep) of_14\IN|attention (l_pobj) attention_15\NN|and|memory (l_conj) memory_17\NN|
17437408
D010862_D012640 CID pilocarpine_11\NN| (r_npadvmod) induced_13\VBN|pilocarpine|- (r_amod) seizures_14\NNS|induced|in
4812392
D001379_D011565 NONE azathioprine_4\NN| (r_pobj) with_3\IN|azathioprine (r_prep) psoriasis_2\NN|with
D001379_D011565 NONE Azathioprine_0\JJ| (r_det) treatment_1\NN|azathioprine (r_nsubj) benefited_2\VBD|treatment|%|out|. (l_prep) out_8\IN|of (l_prep) of_9\IN|patients (l_pobj) patients_11\NNS|29|suffering (l_acl) suffering_12\VBG|from (l_prep) from_13\IN|psoriasis (l_pobj) psoriasis_15\NN|severe
D001379_D056486 NONE azathioprine_9\JJ| (r_amod) therapy_10\NN|azathioprine (r_nsubjpass) continued_12\VBN|if|therapy|is|detected (l_advcl) detected_20\VBN|so|that|damage|may|be|at (l_nsubjpass) damage_17\NN|structural|liver
1786266
D000928_D001480 NONE antidepressant_3\NN| (r_compound) use_4\NN|antidepressant|,|and|findings (r_conj) syndrome_1\NN|rabbit|,|use|.
12523465
C022189_D006212 CID zonisamide_4\NN| (r_pobj) with_3\IN|zonisamide (r_prep) associated_2\VBN|with (r_acl) hallucinations_1\NNS|visual|associated|.
C022189_D006212 CID zonisamide_29\NN| (r_amod) treatment_30\NN|zonisamide (r_pobj) after_28\IN|treatment (r_prep) altered_25\VBD|status|after (r_conj) experienced_20\VBD|who|hallucinations|and|altered (r_relcl) patients_18\NNS|three|experienced (r_dobj) describe_16\VBP|reported|,|we|patients|begun|. (l_advcl) reported_6\VBN|although|hallucinations|have|not|been|as (l_nsubjpass) hallucinations_2\NNS|visual
C022189_D006212 CID zonisamide_29\NN| (r_amod) treatment_30\NN|zonisamide (r_pobj) after_28\IN|treatment (r_prep) altered_25\VBD|status|after (r_conj) experienced_20\VBD|who|hallucinations|and|altered (l_dobj) hallucinations_23\NNS|complex|visual
C022189_D012640 NONE Zonisamide_0\NNP| (r_nsubj) is_1\VBZ|zonisamide|drug|. (l_attr) drug_7\NN|a|spectrum|antiepileptic|used (l_acl) used_8\VBN|treat (l_xcomp) treat_10\VB|to|types (l_dobj) types_12\NNS|various|of (l_prep) of_13\IN|seizures (l_pobj) seizures_14\NNS|
2355241
D007980_D002543 NONE levodopa_23\NN| (r_pobj) of_22\IN|levodopa (r_prep) effect_21\NN|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB|incidence|may|effect|. (l_nsubj) incidence_2\NN|the|low|of|as (l_prep) of_3\IN|haemorrhage (l_pobj) haemorrhage_5\NN|cerebral
D007980_D003643 NONE levodopa_23\NN| (r_pobj) of_22\IN|levodopa (r_prep) effect_21\NN|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB|incidence|may|effect|. (l_nsubj) incidence_2\NN|the|low|of|as (l_prep) as_6\IN|cause (l_pobj) cause_8\NN|a|of|in (l_prep) of_9\IN|death (l_pobj) death_10\NN|
D007980_D010300 NONE levodopa_23\NN| (r_pobj) of_22\IN|levodopa (r_prep) effect_21\NN|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB|incidence|may|effect|. (l_nsubj) incidence_2\NN|the|low|of|as (l_prep) as_6\IN|cause (l_pobj) cause_8\NN|a|of|in (l_prep) in_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|disease (l_pobj) disease_16\NN|parkinson
D007980_D010300 NONE levodopa_23\NN| (r_pobj) of_22\IN|levodopa (r_prep) effect_21\NN|the|hypotensive|of|and|mechanism (l_conj) mechanism_27\NN|a|hypotensive|due (l_amod) due_28\IN|to|levels (l_pobj) levels_32\NNS|reduced|noradrenaline|in (l_prep) in_33\IN|brain (l_pobj) brain_36\NN|the|parkinsonian (l_amod) parkinsonian_35\JJ|
D007980_D007022 CID levodopa_23\NN| (r_pobj) of_22\IN|levodopa (r_prep) effect_21\NN|the|hypotensive|of|and|mechanism (l_amod) hypotensive_20\JJ|
D007980_D007022 CID levodopa_23\NN| (r_pobj) of_22\IN|levodopa (r_prep) effect_21\NN|the|hypotensive|of|and|mechanism (l_conj) mechanism_27\NN|a|hypotensive|due (l_amod) hypotensive_26\JJ|
D009638_D002543 NONE noradrenaline_31\NN| (r_amod) levels_32\NNS|reduced|noradrenaline|in (r_pobj) due_28\IN|to|levels (r_amod) mechanism_27\NN|a|hypotensive|due (r_conj) effect_21\NN|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB|incidence|may|effect|. (l_nsubj) incidence_2\NN|the|low|of|as (l_prep) of_3\IN|haemorrhage (l_pobj) haemorrhage_5\NN|cerebral
D009638_D003643 NONE noradrenaline_31\NN| (r_amod) levels_32\NNS|reduced|noradrenaline|in (r_pobj) due_28\IN|to|levels (r_amod) mechanism_27\NN|a|hypotensive|due (r_conj) effect_21\NN|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB|incidence|may|effect|. (l_nsubj) incidence_2\NN|the|low|of|as (l_prep) as_6\IN|cause (l_pobj) cause_8\NN|a|of|in (l_prep) of_9\IN|death (l_pobj) death_10\NN|
D009638_D010300 NONE noradrenaline_31\NN| (r_amod) levels_32\NNS|reduced|noradrenaline|in (r_pobj) due_28\IN|to|levels (r_amod) mechanism_27\NN|a|hypotensive|due (r_conj) effect_21\NN|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB|incidence|may|effect|. (l_nsubj) incidence_2\NN|the|low|of|as (l_prep) as_6\IN|cause (l_pobj) cause_8\NN|a|of|in (l_prep) in_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|disease (l_pobj) disease_16\NN|parkinson
D009638_D010300 NONE noradrenaline_31\NN| (r_amod) levels_32\NNS|reduced|noradrenaline|in (l_prep) in_33\IN|brain (l_pobj) brain_36\NN|the|parkinsonian (l_amod) parkinsonian_35\JJ|
D009638_D007022 NONE noradrenaline_31\NN| (r_amod) levels_32\NNS|reduced|noradrenaline|in (r_pobj) due_28\IN|to|levels (r_amod) mechanism_27\NN|a|hypotensive|due (r_conj) effect_21\NN|the|hypotensive|of|and|mechanism (l_amod) hypotensive_20\JJ|
D009638_D007022 NONE noradrenaline_31\NN| (r_amod) levels_32\NNS|reduced|noradrenaline|in (r_pobj) due_28\IN|to|levels (r_amod) mechanism_27\NN|a|hypotensive|due (l_amod) hypotensive_26\JJ|
1378968
D008094_D007676 CID lithium_8\NN| (r_npadvmod) induced_10\VBN|lithium|- (r_amod) failure_13\NN|induced|chronic|renal|in
D008094_D007674 NONE lithium_2\NN| (r_npadvmod) induced_4\VBN|lithium|- (r_amod) nephropathy_5\NN|induced
D008094_D007674 NONE Li_4\NNP| (r_npadvmod) induced_6\VBN|li|- (r_amod) nephropathy_7\NN|induced|,|reduced|,
D008094_D051437 NONE lithium_2\NN| (r_npadvmod) induced_4\VBN|lithium|- (r_amod) nephropathy_5\NN|induced (r_pobj) with_1\IN|nephropathy (r_prep) Rats_0\NNS|with (r_nsubjpass) subjected_7\VBN|rats|were|to|,|in|. (l_prep) in_26\IN|attempt (l_pobj) attempt_28\NN|an|induce (l_acl) induce_30\VB|to|hyperfiltration (l_dobj) hyperfiltration_32\NN|glomerular|and|progression (l_conj) progression_35\NN|further|of (l_prep) of_36\IN|failure (l_pobj) failure_38\NN|renal
D008094_D051437 NONE lithium_21\NN| (r_nmod) rats_23\NNS|lithium|pretreated (r_pobj) in_20\IN|rats (r_prep) levels_19\NNS|plasma|creatinine|in (r_dobj) decrease_16\NN|levels (r_conj) increase_13\VB|to|gfr|decrease (r_xcomp) tended_11\VBD|in|increase|. (r_conj) failed_1\VBD|hp|accentuante|and|tended (l_xcomp) accentuante_3\NN|to|progression (l_dobj) progression_4\NN|of (l_prep) of_5\IN|failure (l_pobj) failure_7\NN|renal
D008094_D011507 CID Lithium_0\NN| (r_nsubj) caused_2\VBD|lithium|also|proteinuria|in|. (l_dobj) proteinuria_3\NN|and|hypertension
D008094_D011507 CID Li_4\NNP| (r_npadvmod) induced_6\VBN|li|- (r_amod) nephropathy_7\NN|induced|,|reduced|, (r_nsubjpass) associated_19\VBN|that|nephropathy|is|with (l_prep) with_20\IN|proteinuria (l_pobj) proteinuria_21\NN|and|hypertension
D008094_D006973 CID Lithium_0\NN| (r_nsubj) caused_2\VBD|lithium|also|proteinuria|in|. (l_dobj) proteinuria_3\NN|and|hypertension (l_conj) hypertension_6\NN|systolic
D008094_D006973 CID Li_4\NNP| (r_npadvmod) induced_6\VBN|li|- (r_amod) nephropathy_7\NN|induced|,|reduced|, (r_nsubjpass) associated_19\VBN|that|nephropathy|is|with (l_prep) with_20\IN|proteinuria (l_pobj) proteinuria_21\NN|and|hypertension (l_conj) hypertension_25\NN|arterial|systolic
D008094_D005921 NONE Lithium_0\NN| (r_nsubj) caused_2\VBD|lithium|also|proteinuria|in|. (l_prep) in_7\IN|absence (l_pobj) absence_8\NN|of (l_prep) of_9\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_10\NN|
D003404_D051437 NONE creatinine_18\NN| (r_compound) levels_19\NNS|plasma|creatinine|in (r_dobj) decrease_16\NN|levels (r_conj) increase_13\VB|to|gfr|decrease (r_xcomp) tended_11\VBD|in|increase|. (r_conj) failed_1\VBD|hp|accentuante|and|tended (l_xcomp) accentuante_3\NN|to|progression (l_dobj) progression_4\NN|of (l_prep) of_5\IN|failure (l_pobj) failure_7\NN|renal
9766615
D003024_D001480 NONE clozapine_40\NN|primarily (r_appos) threshold_37\NN|seizure|(|clozapine|) (r_dobj) lowered_35\VBD|effects|threshold|,|and|agranulocytosis (r_conj) associated_13\VBN|are|in|,|lowered (r_conj) have_4\VBP|agents|risk|,|but|associated|. (l_dobj) risk_7\NN|a|lower|of (l_prep) of_8\IN|eps (l_pobj) EPS_9\NNP|
D003024_D001480 NONE clozapine_46\NN|(|only|) (r_appos) agranulocytosis_44\NN|clozapine (r_conj) lowered_35\VBD|effects|threshold|,|and|agranulocytosis (r_conj) associated_13\VBN|are|in|,|lowered (r_conj) have_4\VBP|agents|risk|,|but|associated|. (l_dobj) risk_7\NN|a|lower|of (l_prep) of_8\IN|eps (l_pobj) EPS_9\NNP|
D003024_D015430 NONE clozapine_40\NN|primarily (r_appos) threshold_37\NN|seizure|(|clozapine|) (r_dobj) lowered_35\VBD|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS|cardiovascular|,|effects|, (l_conj) effects_24\NNS|anticholinergic|,|gain (l_conj) gain_27\NN|weight|,|dysfunction
D003024_D015430 NONE clozapine_46\NN|(|only|) (r_appos) agranulocytosis_44\NN|clozapine (r_conj) lowered_35\VBD|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS|cardiovascular|,|effects|, (l_conj) effects_24\NNS|anticholinergic|,|gain (l_conj) gain_27\NN|weight|,|dysfunction
D003024_D012735 NONE clozapine_40\NN|primarily (r_appos) threshold_37\NN|seizure|(|clozapine|) (r_dobj) lowered_35\VBD|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS|cardiovascular|,|effects|, (l_conj) effects_24\NNS|anticholinergic|,|gain (l_conj) gain_27\NN|weight|,|dysfunction (l_conj) dysfunction_30\NN|sexual|,|effects
D003024_D012735 NONE clozapine_46\NN|(|only|) (r_appos) agranulocytosis_44\NN|clozapine (r_conj) lowered_35\VBD|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS|cardiovascular|,|effects|, (l_conj) effects_24\NNS|anticholinergic|,|gain (l_conj) gain_27\NN|weight|,|dysfunction (l_conj) dysfunction_30\NN|sexual|,|effects
D003024_D012640 NONE clozapine_40\NN|primarily (r_appos) threshold_37\NN|seizure|(|clozapine|) (l_compound) seizure_36\NN|
D003024_D012640 NONE clozapine_46\NN|(|only|) (r_appos) agranulocytosis_44\NN|clozapine (r_conj) lowered_35\VBD|effects|threshold|,|and|agranulocytosis (l_dobj) threshold_37\NN|seizure|(|clozapine|) (l_compound) seizure_36\NN|
D003024_D000380 CID clozapine_40\NN|primarily (r_appos) threshold_37\NN|seizure|(|clozapine|) (r_dobj) lowered_35\VBD|effects|threshold|,|and|agranulocytosis (l_conj) agranulocytosis_44\NN|clozapine
D003024_D000380 CID clozapine_46\NN|(|only|) (r_appos) agranulocytosis_44\NN|clozapine
15899738
D003401_D001281 CID creatine_5\NN| (r_compound) supplementation_7\NN|creatine|monohydrate (r_pobj) with_4\IN|supplementation (r_prep) associated_3\VBN|with (r_acl) fibrillation_2\NN|lone|atrial|associated|.
D003401_D001145 NONE creatine_5\NN|to (l_prep) to_6\IN|development (l_pobj) development_8\NN|the|of (l_prep) of_9\IN|arrhythmia (l_pobj) arrhythmia_10\NN|
1992636
D009853_D000743 CID omeprazole_7\NN| (r_pobj) of_6\IN|omeprazole (r_prep) use_5\NN|the|of (r_pobj) with_3\IN|use (r_prep) associated_2\VBN|with (r_acl) anemia_1\NN|hemolytic|associated|.
D009853_D000743 CID omeprazole_17\NN| (r_pobj) of_16\IN|omeprazole (r_prep) use_15\NN|the|of (r_pobj) with_13\IN|use (r_prep) reaction_12\NN|a|serious|term|adverse|with (r_pobj) of_5\IN|reaction (r_prep) case_4\NN|the|first|of|:|anemia (l_appos) anemia_20\NN|hemolytic
D009853_D000743 CID omeprazole_4\NN| (r_nsubj) caused_5\VBD|by|omeprazole|is (l_ccomp) is_11\VBZ|anemia|uncertain (l_nsubj) anemia_10\NN|patient|hemolytic
D009853_D053609 CID omeprazole_17\NN| (r_pobj) with_16\IN|omeprazole (r_prep) starting_14\VBG|therapy|with (r_pcomp) after_13\IN|days|starting (r_prep) weakness_3\NN|developed|,|lethargy|after|. (l_conj) lethargy_5\NN|,|and|shortness
D009853_D004417 CID omeprazole_17\NN| (r_pobj) with_16\IN|omeprazole (r_prep) starting_14\VBG|therapy|with (r_pcomp) after_13\IN|days|starting (r_prep) weakness_3\NN|developed|,|lethargy|after|. (l_conj) lethargy_5\NN|,|and|shortness (l_conj) shortness_8\NN|of (l_prep) of_9\IN|breath (l_pobj) breath_10\NN|
2951327
D009638_D013610 NONE norepinephrine_76\NN| (r_amod) rate_78\NN|the|norepinephrine|release|( (r_pobj) of_74\IN|rate (r_prep) augmentation_73\NN|no|of (r_conj) tachycardia_70\NN|no|and|augmentation|min|)
D009638_D007022 NONE norepinephrine_76\NN| (r_amod) rate_78\NN|the|norepinephrine|release|( (r_pobj) of_74\IN|rate (r_prep) augmentation_73\NN|no|of (r_conj) tachycardia_70\NN|no|and|augmentation|min|) (r_conj) +/-_45\NN|93|1|p|,|or|%|but|tachycardia (r_appos) was_29\VBD|pressure|+/-|,|+/-|observed|. (l_conj) observed_90\VBN|were|,|is (l_advcl) is_93\VBZ|which|in (l_prep) in_94\IN|contrast (l_pobj) contrast_95\NN|to (l_prep) to_96\IN|hypotension (l_pobj) hypotension_98\NN|comparable|induced
D006830_D013610 NONE hydralazine_101\NN|or|nitroglycerin (r_pobj) by_100\IN|hydralazine (r_agent) induced_99\VBN|by (r_acl) hypotension_98\NN|comparable|induced (r_pobj) to_96\IN|hypotension (r_prep) contrast_95\NN|to (r_pobj) in_94\IN|contrast (r_prep) is_93\VBZ|which|in (r_advcl) observed_90\VBN|were|,|is (r_conj) was_29\VBD|pressure|+/-|,|+/-|observed|. (l_appos) +/-_45\NN|93|1|p|,|or|%|but|tachycardia (l_conj) tachycardia_70\NN|no|and|augmentation|min|)
D006830_D007022 CID hydralazine_101\NN|or|nitroglycerin (r_pobj) by_100\IN|hydralazine (r_agent) induced_99\VBN|by (r_acl) hypotension_98\NN|comparable|induced
D005996_D013610 NONE nitroglycerin_103\NN| (r_conj) hydralazine_101\NN|or|nitroglycerin (r_pobj) by_100\IN|hydralazine (r_agent) induced_99\VBN|by (r_acl) hypotension_98\NN|comparable|induced (r_pobj) to_96\IN|hypotension (r_prep) contrast_95\NN|to (r_pobj) in_94\IN|contrast (r_prep) is_93\VBZ|which|in (r_advcl) observed_90\VBN|were|,|is (r_conj) was_29\VBD|pressure|+/-|,|+/-|observed|. (l_appos) +/-_45\NN|93|1|p|,|or|%|but|tachycardia (l_conj) tachycardia_70\NN|no|and|augmentation|min|)
D005996_D007022 CID nitroglycerin_103\NN| (r_conj) hydralazine_101\NN|or|nitroglycerin (r_pobj) by_100\IN|hydralazine (r_agent) induced_99\VBN|by (r_acl) hypotension_98\NN|comparable|induced
10669626
D014859_D061205 CID Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|warfarin|- (r_amod) calcification_4\NN|induced|artery
D014859_D061205 CID Warfarin_22\NNP| (r_pobj) of_21\IN|warfarin (r_prep) doses_20\NNS|sufficient|of (r_dobj) given_18\VBN|doses|inhibit (r_prep) enhance_10\VB|that|treatment|extent|given (l_dobj) extent_12\NN|the|of (l_prep) of_13\IN|calcification (l_pobj) calcification_15\NN|artery|in
D014859_D061205 CID Warfarin_17\NNP| (r_npadvmod) treated_19\VBN|warfarin|- (r_amod) rats_20\NNS|treated (r_pobj) in_16\IN|rats (r_prep) calcification_15\NN|artery|in
D014859_D061205 CID Warfarin_5\NNP| (r_pobj) with_4\IN|warfarin (r_prep) Treatment_0\NN|for|with (r_nsubj) caused_6\VBD|treatment|calcification|. (l_dobj) calcification_9\NN|massive|focal|of|in|and|calcification (l_prep) of_10\IN|media (l_pobj) media_13\NNS|the|artery (l_compound) artery_12\NN|
D014859_D061205 CID Warfarin_20\NNP| (r_compound) treatment_21\NN|warfarin (r_pobj) of_19\IN|treatment (r_prep) weeks_18\NNS|4|of (r_pobj) after_16\IN|even|weeks (r_prep) detected_8\VBN|in|,|calcification|could|be|in|after|. (l_nsubjpass) calcification_5\NN|no|artery
D014859_D061205 CID Warfarin_8\NNP| (r_npadvmod) induced_10\VBN|warfarin|- (r_amod) calcification_12\NN|induced|artery|in
D014859_D061205 CID Warfarin_7\NNP| (r_pobj) with_6\IN|warfarin (r_prep) groups_5\NNS|both|dietary|with (r_pobj) of_2\IN|groups (r_prep) treatment_1\NN|concurrent|of (r_nsubj) produced_8\VBD|treatment|calcification|. (l_dobj) calcification_11\NN|massive|focal|of|in|but|calcification (l_prep) of_12\IN|media (l_pobj) media_15\NNS|the|artery (l_compound) artery_14\NN|
D014859_D061205 CID Warfarin_7\NNP| (r_pobj) with_6\IN|warfarin (r_prep) groups_5\NNS|both|dietary|with (r_pobj) of_2\IN|groups (r_prep) treatment_1\NN|concurrent|of (r_nsubj) produced_8\VBD|treatment|calcification|. (l_dobj) calcification_11\NN|massive|focal|of|in|but|calcification (l_conj) calcification_27\NN|no|detectable|artery|in
D014859_D061205 CID Warfarin_61\NNP| (r_npadvmod) induced_63\VBN|warfarin|- (r_amod) calcification_65\NN|induced|artery (r_pobj) to_60\IN|calcification (r_prep) resistant_59\JJ|to (r_acomp) was_58\VBD|that|resistant (r_relcl) groups_56\NNS|the|was (r_pobj) of_54\IN|groups (r_prep) either_53\DT|of (r_pobj) with_52\IN|either (r_prep) compared_51\VBN|with|rats (r_prep) rats_50\NNS|ad|fed|compared (r_appos) relationship_24\NN|a|between|,|with|,|rats (r_attr) was_22\VBD|determined|,|there|relationship|. (l_advcl) determined_15\VBN|although|explanation|can|not|be|from (l_nsubjpass) explanation_2\NN|the|for (l_prep) for_3\IN|association (l_pobj) association_5\NN|the|between (l_prep) between_6\IN|calcification (l_pobj) calcification_8\NN|artery|and|status
D014859_D061205 CID Warfarin_61\NNP| (r_npadvmod) induced_63\VBN|warfarin|- (r_amod) calcification_65\NN|induced|artery (r_pobj) to_60\IN|calcification (r_prep) resistant_59\JJ|to (r_acomp) was_58\VBD|that|resistant (r_relcl) groups_56\NNS|the|was (r_pobj) of_54\IN|groups (r_prep) either_53\DT|of (r_pobj) with_52\IN|either (r_prep) compared_51\VBN|with|rats (r_prep) rats_50\NNS|ad|fed|compared (r_appos) relationship_24\NN|a|between|,|with|,|rats (l_prep) between_25\IN|phosphate (l_pobj) phosphate_28\NN|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN|to (l_prep) to_31\IN|calcification (l_pobj) calcification_33\NN|artery
D014859_D061205 CID Warfarin_61\NNP| (r_npadvmod) induced_63\VBN|warfarin|- (r_amod) calcification_65\NN|induced|artery
D014859_D061205 CID Warfarin_7\NNP| (r_npadvmod) induced_9\VBN|warfarin|- (r_amod) calcification_11\NN|induced|artery
D014859_D061205 CID Warfarin_13\NNP| (r_conj) D_11\NN|vitamin|and|warfarin (r_pobj) between_9\IN|d (r_prep) synergy_8\NN|the|possible|between|in (l_prep) in_14\IN|calcification (l_pobj) calcification_16\NN|artery
D014859_D061205 CID Warfarin_0\NNP| (r_nsubjpass) known_3\VBN|warfarin|are|also|cause|,|but|at|. (l_xcomp) cause_5\VB|to|calcification (l_dobj) calcification_6\NN|of (l_prep) of_7\IN|media (l_pobj) media_10\NNS|the|artery (l_compound) artery_9\NN|
D014859_D061205 CID Warfarin_20\NNP| (r_conj) D_18\NNP|vitamin|plus|warfarin (r_pobj) with_16\IN|d (r_prep) treated_15\VBN|with (r_acl) rats_14\NNS|treated (r_pobj) in_13\IN|rats (r_prep) calcification_12\NN|artery|in
D014807_D061205 NONE D._11\NNP| (r_conj) growth_8\NN|and|vitamin|d. (r_pobj) by_7\IN|growth (r_agent) accelerated_6\VBN|calcification|is|by (l_nsubjpass) calcification_4\NN|induced|artery
D014807_D061205 NONE D_8\JJ|vitamin (r_conj) growth_5\NN|and|d (r_nmod) treatment_9\NN|growth (r_nsubj) enhance_10\VB|that|treatment|extent|given (l_dobj) extent_12\NN|the|of (l_prep) of_13\IN|calcification (l_pobj) calcification_15\NN|artery|in
D014807_D061205 NONE D_11\NN|vitamin|and|warfarin (r_pobj) between_9\IN|d (r_prep) synergy_8\NN|the|possible|between|in (l_prep) in_14\IN|calcification (l_pobj) calcification_16\NN|artery
D014807_D061205 NONE D_4\NNP|vitamin (r_pobj) of_2\IN|d (r_prep) doses_1\NNS|high|of (r_nsubjpass) known_6\VBN|doses|are|cause|. (l_xcomp) cause_8\VB|to|calcification|in (l_dobj) calcification_9\NN|of (l_prep) of_10\IN|media (l_pobj) media_13\NNS|the|artery (l_compound) artery_12\NN|
D014807_D061205 NONE D_10\NN|vitamin (r_compound) dose_11\NN|d|on (l_prep) on_12\IN|calcification (l_pobj) calcification_14\NN|artery
D014807_D061205 NONE D_10\NN|vitamin (r_compound) dose_11\NN|d|on (r_pobj) of_8\IN|dose (r_prep) effect_7\NN|the|of|and|effect (l_conj) effect_17\NN|the|of (l_prep) of_18\IN|dose (l_pobj) dose_21\NN|d|on (l_prep) on_22\IN|elevation (l_pobj) elevation_24\NN|the|of|,|suggests (l_relcl) suggests_30\VBZ|which|induce (l_ccomp) induce_35\VB|that|d|may|calcification|through (l_dobj) calcification_37\NN|artery
D014807_D061205 NONE D_20\NNP|vitamin (r_compound) dose_21\NN|d|on (r_pobj) of_18\IN|dose (r_prep) effect_17\NN|the|of (r_conj) effect_7\NN|the|of|and|effect (l_prep) of_8\IN|dose (l_pobj) dose_11\NN|d|on (l_prep) on_12\IN|calcification (l_pobj) calcification_14\NN|artery
D014807_D061205 NONE D_20\NNP|vitamin (r_compound) dose_21\NN|d|on (l_prep) on_22\IN|elevation (l_pobj) elevation_24\NN|the|of|,|suggests (l_relcl) suggests_30\VBZ|which|induce (l_ccomp) induce_35\VB|that|d|may|calcification|through (l_dobj) calcification_37\NN|artery
D014807_D061205 NONE D_33\NN|vitamin (r_nsubj) induce_35\VB|that|d|may|calcification|through (r_ccomp) suggests_30\VBZ|which|induce (r_relcl) elevation_24\NN|the|of|,|suggests (r_pobj) on_22\IN|elevation (r_prep) dose_21\NN|d|on (r_pobj) of_18\IN|dose (r_prep) effect_17\NN|the|of (r_conj) effect_7\NN|the|of|and|effect (l_prep) of_8\IN|dose (l_pobj) dose_11\NN|d|on (l_prep) on_12\IN|calcification (l_pobj) calcification_14\NN|artery
D014807_D061205 NONE D_33\NN|vitamin (r_nsubj) induce_35\VB|that|d|may|calcification|through (l_dobj) calcification_37\NN|artery
D014807_D061205 NONE D_18\NNP|vitamin|plus|warfarin (r_pobj) with_16\IN|d (r_prep) treated_15\VBN|with (r_acl) rats_14\NNS|treated (r_pobj) in_13\IN|rats (r_prep) calcification_12\NN|artery|in
D014807_D002114 NONE D_8\JJ|vitamin (r_conj) growth_5\NN|and|d (r_nmod) treatment_9\NN|growth (r_nsubj) enhance_10\VB|that|treatment|extent|given (l_prep) given_18\VBN|doses|inhibit (l_advcl) inhibit_24\VB|to|carboxylation (l_dobj) carboxylation_27\NN|gamma|-|of (l_prep) of_28\IN|protein (l_pobj) protein_31\NN|matrix|gla|,|inhibitor (l_appos) inhibitor_35\NN|calcification|known (l_compound) calcification_34\NN|a
D014807_D002114 NONE D_30\NN| (r_npadvmod) treated_32\VBN|d|- (r_amod) rats_33\NNS|vitamin|treated (r_pobj) of_28\IN|rats (r_prep) media_27\NNS|the|of (r_pobj) in_25\IN|media (r_prep) calcification_24\NN|in|at
D014807_D002114 NONE D_15\NN|vitamin|,|synergy (r_pobj) by_13\IN|d (r_agent) produced_12\VBN|by (r_acl) calcium_11\NN|serum|produced (r_pobj) in_9\IN|calcium (r_prep) elevation_8\NN|the|in (r_pobj) on_6\IN|elevation (r_prep) effect_5\NN|no|on (r_dobj) had_3\VBD|because|treatment|effect (r_advcl) explained_27\VBN|had|is|probably|best|by|. (l_agent) by_28\IN|hypothesis (l_pobj) hypothesis_30\NN|the|inhibits (l_acl) inhibits_33\VBZ|that|warfarin|activity|as (l_prep) as_40\IN|inhibitor (l_pobj) inhibitor_43\NN|a|calcification (l_compound) calcification_42\NN|
D014807_D002114 NONE D_23\NN|warfarin (r_pobj) between_19\IN|d (r_prep) synergy_18\NN|the|between (r_appos) D_15\NN|vitamin|,|synergy (r_pobj) by_13\IN|d (r_agent) produced_12\VBN|by (r_acl) calcium_11\NN|serum|produced (r_pobj) in_9\IN|calcium (r_prep) elevation_8\NN|the|in (r_pobj) on_6\IN|elevation (r_prep) effect_5\NN|no|on (r_dobj) had_3\VBD|because|treatment|effect (r_advcl) explained_27\VBN|had|is|probably|best|by|. (l_agent) by_28\IN|hypothesis (l_pobj) hypothesis_30\NN|the|inhibits (l_acl) inhibits_33\VBZ|that|warfarin|activity|as (l_prep) as_40\IN|inhibitor (l_pobj) inhibitor_43\NN|a|calcification (l_compound) calcification_42\NN|
D014859_D002114 NONE Warfarin_22\NNP| (r_pobj) of_21\IN|warfarin (r_prep) doses_20\NNS|sufficient|of (r_dobj) given_18\VBN|doses|inhibit (l_advcl) inhibit_24\VB|to|carboxylation (l_dobj) carboxylation_27\NN|gamma|-|of (l_prep) of_28\IN|protein (l_pobj) protein_31\NN|matrix|gla|,|inhibitor (l_appos) inhibitor_35\NN|calcification|known (l_compound) calcification_34\NN|a
D014859_D002114 NONE Warfarin_5\NNP| (r_pobj) with_4\IN|warfarin (r_prep) Treatment_0\NN|for|with (r_nsubj) caused_6\VBD|treatment|calcification|. (l_dobj) calcification_9\NN|massive|focal|of|in|and|calcification (l_conj) calcification_23\NN|less|extensive|focal|in
D014859_D002114 NONE Warfarin_17\NNP| (r_compound) administration_18\NN|concurrent|warfarin (r_nsubj) increased_20\VBD|that|administration|dramatically|extent (l_dobj) extent_22\NN|the|of (l_prep) of_23\IN|calcification (l_pobj) calcification_24\NN|in|at
D014859_D002114 NONE Warfarin_1\NNP| (r_compound) treatment_2\NN|warfarin (r_nsubj) had_3\VBD|because|treatment|effect (r_advcl) explained_27\VBN|had|is|probably|best|by|. (l_agent) by_28\IN|hypothesis (l_pobj) hypothesis_30\NN|the|inhibits (l_acl) inhibits_33\VBZ|that|warfarin|activity|as (l_prep) as_40\IN|inhibitor (l_pobj) inhibitor_43\NN|a|calcification (l_compound) calcification_42\NN|
D014859_D002114 NONE Warfarin_20\NNP|and|vitamin (r_nmod) D_23\NN|warfarin (r_pobj) between_19\IN|d (r_prep) synergy_18\NN|the|between (r_appos) D_15\NN|vitamin|,|synergy (r_pobj) by_13\IN|d (r_agent) produced_12\VBN|by (r_acl) calcium_11\NN|serum|produced (r_pobj) in_9\IN|calcium (r_prep) elevation_8\NN|the|in (r_pobj) on_6\IN|elevation (r_prep) effect_5\NN|no|on (r_dobj) had_3\VBD|because|treatment|effect (r_advcl) explained_27\VBN|had|is|probably|best|by|. (l_agent) by_28\IN|hypothesis (l_pobj) hypothesis_30\NN|the|inhibits (l_acl) inhibits_33\VBZ|that|warfarin|activity|as (l_prep) as_40\IN|inhibitor (l_pobj) inhibitor_43\NN|a|calcification (l_compound) calcification_42\NN|
D014859_D002114 NONE Warfarin_32\NNP| (r_nsubj) inhibits_33\VBZ|that|warfarin|activity|as (l_prep) as_40\IN|inhibitor (l_pobj) inhibitor_43\NN|a|calcification (l_compound) calcification_42\NN|
D010710_D061205 NONE phosphate_28\NN|higher|serum|and|susceptibility (r_pobj) between_25\IN|phosphate (r_prep) relationship_24\NN|a|between|,|with|,|rats (r_attr) was_22\VBD|determined|,|there|relationship|. (l_advcl) determined_15\VBN|although|explanation|can|not|be|from (l_nsubjpass) explanation_2\NN|the|for (l_prep) for_3\IN|association (l_pobj) association_5\NN|the|between (l_prep) between_6\IN|calcification (l_pobj) calcification_8\NN|artery|and|status
D010710_D061205 NONE phosphate_28\NN|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN|to (l_prep) to_31\IN|calcification (l_pobj) calcification_33\NN|artery
D010710_D061205 NONE phosphate_28\NN|higher|serum|and|susceptibility (r_pobj) between_25\IN|phosphate (r_prep) relationship_24\NN|a|between|,|with|,|rats (l_appos) rats_50\NNS|ad|fed|compared (l_prep) compared_51\VBN|with|rats (l_prep) with_52\IN|either (l_pobj) either_53\DT|of (l_prep) of_54\IN|groups (l_pobj) groups_56\NNS|the|was (l_relcl) was_58\VBD|that|resistant (l_acomp) resistant_59\JJ|to (l_prep) to_60\IN|calcification (l_pobj) calcification_65\NN|induced|artery
D010710_D061205 NONE phosphate_42\NN|serum (r_pobj) of_40\IN|phosphate (r_prep) levels_39\NNS|higher|of|in (r_pobj) with_35\IN|levels (r_prep) relationship_24\NN|a|between|,|with|,|rats (r_attr) was_22\VBD|determined|,|there|relationship|. (l_advcl) determined_15\VBN|although|explanation|can|not|be|from (l_nsubjpass) explanation_2\NN|the|for (l_prep) for_3\IN|association (l_pobj) association_5\NN|the|between (l_prep) between_6\IN|calcification (l_pobj) calcification_8\NN|artery|and|status
D010710_D061205 NONE phosphate_42\NN|serum (r_pobj) of_40\IN|phosphate (r_prep) levels_39\NNS|higher|of|in (r_pobj) with_35\IN|levels (r_prep) relationship_24\NN|a|between|,|with|,|rats (l_prep) between_25\IN|phosphate (l_pobj) phosphate_28\NN|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN|to (l_prep) to_31\IN|calcification (l_pobj) calcification_33\NN|artery
D010710_D061205 NONE phosphate_42\NN|serum (r_pobj) of_40\IN|phosphate (r_prep) levels_39\NNS|higher|of|in (r_pobj) with_35\IN|levels (r_prep) relationship_24\NN|a|between|,|with|,|rats (l_appos) rats_50\NNS|ad|fed|compared (l_prep) compared_51\VBN|with|rats (l_prep) with_52\IN|either (l_pobj) either_53\DT|of (l_prep) of_54\IN|groups (l_pobj) groups_56\NNS|the|was (l_relcl) was_58\VBD|that|resistant (l_acomp) resistant_59\JJ|to (l_prep) to_60\IN|calcification (l_pobj) calcification_65\NN|induced|artery
D010710_D061205 NONE phosphate_18\NN|serum (r_compound) levels_19\NNS|higher|phosphate (r_pobj) to_15\IN|levels (r_prep) related_14\VBN|that|susceptibility|could|be|to (l_nsubjpass) susceptibility_5\NN|increased|to (l_prep) to_6\IN|calcification (l_pobj) calcification_11\NN|induced|artery
D002118_D061205 NONE calcium_27\NN|serum (r_pobj) of_25\IN|calcium (r_prep) elevation_24\NN|the|of|,|suggests (r_pobj) on_22\IN|elevation (r_prep) dose_21\NN|d|on (r_pobj) of_18\IN|dose (r_prep) effect_17\NN|the|of (r_conj) effect_7\NN|the|of|and|effect (l_prep) of_8\IN|dose (l_pobj) dose_11\NN|d|on (l_prep) on_12\IN|calcification (l_pobj) calcification_14\NN|artery
D002118_D061205 NONE calcium_27\NN|serum (r_pobj) of_25\IN|calcium (r_prep) elevation_24\NN|the|of|,|suggests (l_relcl) suggests_30\VBZ|which|induce (l_ccomp) induce_35\VB|that|d|may|calcification|through (l_dobj) calcification_37\NN|artery
D002118_D061205 NONE calcium_43\NN|serum (r_pobj) on_41\IN|calcium (r_prep) effect_40\NN|its|on (r_pobj) through_38\IN|effect (r_prep) induce_35\VB|that|d|may|calcification|through (r_ccomp) suggests_30\VBZ|which|induce (r_relcl) elevation_24\NN|the|of|,|suggests (r_pobj) on_22\IN|elevation (r_prep) dose_21\NN|d|on (r_pobj) of_18\IN|dose (r_prep) effect_17\NN|the|of (r_conj) effect_7\NN|the|of|and|effect (l_prep) of_8\IN|dose (l_pobj) dose_11\NN|d|on (l_prep) on_12\IN|calcification (l_pobj) calcification_14\NN|artery
D002118_D061205 NONE calcium_43\NN|serum (r_pobj) on_41\IN|calcium (r_prep) effect_40\NN|its|on (r_pobj) through_38\IN|effect (r_prep) induce_35\VB|that|d|may|calcification|through (l_dobj) calcification_37\NN|artery
D002118_D002114 NONE calcium_11\NN|serum|produced (r_pobj) in_9\IN|calcium (r_prep) elevation_8\NN|the|in (r_pobj) on_6\IN|elevation (r_prep) effect_5\NN|no|on (r_dobj) had_3\VBD|because|treatment|effect (r_advcl) explained_27\VBN|had|is|probably|best|by|. (l_agent) by_28\IN|hypothesis (l_pobj) hypothesis_30\NN|the|inhibits (l_acl) inhibits_33\VBZ|that|warfarin|activity|as (l_prep) as_40\IN|inhibitor (l_pobj) inhibitor_43\NN|a|calcification (l_compound) calcification_42\NN|
D015055_D061205 NONE carboxylated_36\JJ|not|gamma|- (r_acomp) was_31\VBD|that|protein|indeed|carboxylated (r_ccomp) showed_25\VBD|analysis|was|. (r_conj) found_7\VBN|levels|are|at|,|and|showed (l_prep) at_8\IN|sites (l_pobj) sites_9\NNS|of (l_prep) of_10\IN|calcification (l_pobj) calcification_12\NN|artery|in
D015055_D002114 NONE carboxyglutamate_8\NN|gamma|- (r_compound) residues_9\NNS|the|carboxyglutamate|of (r_nsubjpass) required_16\VBN|although|residues|are|apparently|for|as (l_prep) as_20\IN|inhibitor (l_pobj) inhibitor_23\NN|a|calcification (l_compound) calcification_22\NN|
D015055_D002114 NONE carboxyglutamate_8\NN|gamma|- (r_compound) residues_9\NNS|the|carboxyglutamate|of (r_nsubjpass) required_16\VBN|although|residues|are|apparently|for|as (r_advcl) required_28\VBN|that|required|,|they|are|not|for (l_prep) for_29\IN|accumulation (l_pobj) accumulation_31\NN|its|at (l_prep) at_32\IN|sites (l_pobj) sites_34\NNS|calcification (l_compound) calcification_33\NN|
17147461
D020123_D011507 CID Sirolimus_0\NNP| (r_npadvmod) associated_2\VBN|sirolimus|- (r_amod) proteinuria_3\NN|associated|and|dysfunction|.
D020123_D011507 CID sirolimus_11\NN| (r_nsubjpass) associated_13\VBN|that|,|under|,|sirolimus|is|with (l_prep) with_14\IN|proteinuria (l_pobj) proteinuria_15\NN|and|dysfunction
D020123_D011507 CID sirolimus_3\NN| (r_npadvmod) associated_5\VBN|sirolimus|- (r_amod) proteinuria_6\NN|associated
D020123_D011507 CID sirolimus_21\NN| (r_pobj) of_20\IN|sirolimus (r_prep) effects_19\NNS|the|molecular|of|on (r_pobj) of_16\IN|effects (r_prep) knowledge_15\NN|of (r_pobj) by_14\IN|knowledge (r_agent) minimised_13\VBN|occur|,|occurrence|could|be|by|,|use|. (l_dep) use_27\NN|the|of|in|,|monitoring (l_appos) monitoring_36\NN|close|of|,|use|occurs (l_prep) of_37\IN|proteinuria (l_pobj) proteinuria_38\NN|and|function
D020123_D011507 CID sirolimus_21\NN| (r_pobj) of_20\IN|sirolimus (r_prep) effects_19\NNS|the|molecular|of|on (r_pobj) of_16\IN|effects (r_prep) knowledge_15\NN|of (r_pobj) by_14\IN|knowledge (r_agent) minimised_13\VBN|occur|,|occurrence|could|be|by|,|use|. (l_dep) use_27\NN|the|of|in|,|monitoring (l_appos) monitoring_36\NN|close|of|,|use|occurs (l_advcl) occurs_57\VBZ|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN|
D020123_D011507 CID sirolimus_29\NN| (r_pobj) of_28\IN|sirolimus (r_prep) use_27\NN|the|of|in|,|monitoring (l_appos) monitoring_36\NN|close|of|,|use|occurs (l_prep) of_37\IN|proteinuria (l_pobj) proteinuria_38\NN|and|function
D020123_D011507 CID sirolimus_29\NN| (r_pobj) of_28\IN|sirolimus (r_prep) use_27\NN|the|of|in|,|monitoring (l_appos) monitoring_36\NN|close|of|,|use|occurs (l_advcl) occurs_57\VBZ|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN|
D020123_D007674 CID Sirolimus_0\NNP| (r_npadvmod) associated_2\VBN|sirolimus|- (r_amod) proteinuria_3\NN|associated|and|dysfunction|. (l_conj) dysfunction_6\NN|renal
D020123_D007674 CID Sirolimus_0\NNP| (r_nsubj) represents_1\VBZ|sirolimus|advance|. (l_dobj) advance_5\NN|a|major|therapeutic|in (l_prep) in_6\IN|prevention (l_pobj) prevention_8\NN|the|of (l_prep) of_9\IN|rejection (l_pobj) rejection_13\NN|acute|allograft|and|nephropathy (l_conj) nephropathy_17\NN|chronic|allograft
D020123_D007674 CID sirolimus_1\NN| (r_nsubj) share_4\VB|because|sirolimus|does|not|vasomotor|effects (r_advcl) designated_18\VBN|share|,|it|has|been|drug|. (l_oprd) drug_24\NN|a|'|nephrotoxic|' (l_amod) nephrotoxic_23\JJ|-
D020123_D058186 NONE sirolimus_11\NN| (r_nsubjpass) associated_13\VBN|that|,|under|,|sirolimus|is|with (l_prep) with_14\IN|proteinuria (l_pobj) proteinuria_15\NN|and|dysfunction (l_conj) dysfunction_19\NN|acute|renal
D020123_D058186 NONE sirolimus_6\NN| (r_pobj) with_5\IN|sirolimus (r_prep) associated_4\VBN|with (r_acl) dysfunction_3\NN|the|acute|renal|associated|(|as|)
D000809_D011507 NONE angiotensin_45\NN| (r_npadvmod) converting_47\VBG|angiotensin|- (r_amod) inhibitors_49\NNS|converting|enzyme|or|blockers (r_pobj) of_44\IN|inhibitors (r_prep) use_43\NN|of (r_conj) monitoring_36\NN|close|of|,|use|occurs (l_prep) of_37\IN|proteinuria (l_pobj) proteinuria_38\NN|and|function
D000809_D011507 NONE angiotensin_45\NN| (r_npadvmod) converting_47\VBG|angiotensin|- (r_amod) inhibitors_49\NNS|converting|enzyme|or|blockers (r_pobj) of_44\IN|inhibitors (r_prep) use_43\NN|of (r_conj) monitoring_36\NN|close|of|,|use|occurs (l_advcl) occurs_57\VBZ|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN|
D000804_D011507 NONE II_52\CD| (r_compound) blockers_54\NNS|angiotensin|ii|receptor (r_conj) inhibitors_49\NNS|converting|enzyme|or|blockers (r_pobj) of_44\IN|inhibitors (r_prep) use_43\NN|of (r_conj) monitoring_36\NN|close|of|,|use|occurs (l_prep) of_37\IN|proteinuria (l_pobj) proteinuria_38\NN|and|function
D000804_D011507 NONE II_52\CD| (r_compound) blockers_54\NNS|angiotensin|ii|receptor (r_conj) inhibitors_49\NNS|converting|enzyme|or|blockers (r_pobj) of_44\IN|inhibitors (r_prep) use_43\NN|of (r_conj) monitoring_36\NN|close|of|,|use|occurs (l_advcl) occurs_57\VBZ|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN|
6308277
D002110_D064420 NONE caffeine_2\NN| (r_compound) toxicity_3\NN|caffeine
D002110_D064420 NONE caffeine_11\NN| (r_pobj) of_10\IN|caffeine (r_prep) effects_9\NNS|the|stimulatory|of|on (r_dobj) augment_6\VB|to|effects (r_xcomp) reported_4\VBN|because|salicylates|have|been|augment (r_advcl) focused_18\VBN|reported|,|attention|was|on|. (l_prep) on_19\IN|possibility (l_pobj) possibility_21\NN|the|reduced (l_acl) reduced_33\VBD|that|presence|(|micrograms|toxicity (l_dobj) toxicity_36\NN|the|cns|of
D002110_D064420 NONE caffeine_38\NN| (r_pobj) of_37\IN|caffeine (r_prep) toxicity_36\NN|the|cns|of
D000082_D064420 NONE acetaminophen_5\NN| (r_pobj) by_4\IN|acetaminophen (r_prep) Reduction_0\NN|in|by|. (l_prep) in_1\IN|toxicity (l_pobj) toxicity_3\NN|caffeine
D000082_D064420 NONE acetaminophen_26\NN| (r_pobj) of_25\IN|acetaminophen (r_prep) presence_24\NN|the|of (r_nsubj) reduced_33\VBD|that|presence|(|micrograms|toxicity (l_dobj) toxicity_36\NN|the|cns|of
D000082_D012640 NONE acetaminophen_11\NN|mg/kg (r_pobj) with_10\IN|acetaminophen (r_prep) pretreatment_9\NN|:|1|with|) (r_nsubj) increased_16\VBD|that|pretreatment|interval|reduced (l_dobj) interval_18\NN|the|between (l_prep) between_19\IN|administration (l_pobj) administration_21\NN|the|of|ip|and|onset (l_conj) onset_33\NN|the|of|by|;|and|pretreatment (l_prep) of_34\IN|convulsions (l_pobj) convulsions_36\NNS|fatal
D000082_D012640 NONE acetaminophen_11\NN|mg/kg (r_pobj) with_10\IN|acetaminophen (r_prep) pretreatment_9\NN|:|1|with|) (r_nsubj) increased_16\VBD|that|pretreatment|interval|reduced (l_conj) reduced_54\VBD|incidence|(|ip|) (l_dobj) incidence_56\NN|the|of (l_prep) of_57\IN|seizures (l_pobj) seizures_59\NNS|audiogenic|produced
D000082_D012640 NONE acetaminophen_49\NN|mg/kg (r_pobj) with_48\IN|acetaminophen (r_prep) pretreatment_47\NN|2|with|) (r_conj) onset_33\NN|the|of|by|;|and|pretreatment (l_prep) of_34\IN|convulsions (l_pobj) convulsions_36\NNS|fatal
D000082_D012640 NONE acetaminophen_49\NN|mg/kg (r_pobj) with_48\IN|acetaminophen (r_prep) pretreatment_47\NN|2|with|) (r_conj) onset_33\NN|the|of|by|;|and|pretreatment (r_conj) administration_21\NN|the|of|ip|and|onset (r_pobj) between_19\IN|administration (r_prep) interval_18\NN|the|between (r_dobj) increased_16\VBD|that|pretreatment|interval|reduced (l_conj) reduced_54\VBD|incidence|(|ip|) (l_dobj) incidence_56\NN|the|of (l_prep) of_57\IN|seizures (l_pobj) seizures_59\NNS|audiogenic|produced
D000082_D012640 NONE acetaminophen_21\NN| (r_pobj) by_20\IN|acetaminophen (r_agent) reduced_14\VBN|frequency|was|from|by|. (l_nsubjpass) frequency_1\NN|the|of|after (l_prep) of_2\IN|seizures (l_pobj) seizures_6\NNS|induced
D000082_D012640 NONE acetaminophen_6\FW|mg/kg|) (r_nsubj) modify_15\VB|in|,|acetaminophen|did|not|seizures|and|alter|. (l_dobj) seizures_17\NNS|the|induced
D002110_D012640 CID caffeine_23\NN| (r_pobj) of_22\IN|caffeine (r_prep) administration_21\NN|the|of|ip|and|onset (l_conj) onset_33\NN|the|of|by|;|and|pretreatment (l_prep) of_34\IN|convulsions (l_pobj) convulsions_36\NNS|fatal
D002110_D012640 CID caffeine_23\NN| (r_pobj) of_22\IN|caffeine (r_prep) administration_21\NN|the|of|ip|and|onset (r_pobj) between_19\IN|administration (r_prep) interval_18\NN|the|between (r_dobj) increased_16\VBD|that|pretreatment|interval|reduced (l_conj) reduced_54\VBD|incidence|(|ip|) (l_dobj) incidence_56\NN|the|of (l_prep) of_57\IN|seizures (l_pobj) seizures_59\NNS|audiogenic|produced
D002110_D012640 CID caffeine_65\NN| (r_pobj) of_64\IN|caffeine (r_prep) presence_63\NN|the|of (r_pobj) in_61\IN|presence (r_prep) produced_60\VBN|in (r_acl) seizures_59\NNS|audiogenic|produced (r_pobj) of_57\IN|seizures (r_prep) incidence_56\NN|the|of (r_dobj) reduced_54\VBD|incidence|(|ip|) (r_conj) increased_16\VBD|that|pretreatment|interval|reduced (l_dobj) interval_18\NN|the|between (l_prep) between_19\IN|administration (l_pobj) administration_21\NN|the|of|ip|and|onset (l_conj) onset_33\NN|the|of|by|;|and|pretreatment (l_prep) of_34\IN|convulsions (l_pobj) convulsions_36\NNS|fatal
D002110_D012640 CID caffeine_65\NN| (r_pobj) of_64\IN|caffeine (r_prep) presence_63\NN|the|of (r_pobj) in_61\IN|presence (r_prep) produced_60\VBN|in (r_acl) seizures_59\NNS|audiogenic|produced
D002110_D012640 CID caffeine_12\NN|12.5 (r_pobj) after_7\IN|caffeine (r_prep) frequency_1\NN|the|of|after (l_prep) of_2\IN|seizures (l_pobj) seizures_6\NNS|induced
D002110_D012640 CID caffeine_4\NN| (r_pobj) of_3\IN|caffeine (r_prep) absence_2\NN|the|of (r_pobj) In_0\IN|absence (r_prep) modify_15\VB|in|,|acetaminophen|did|not|seizures|and|alter|. (l_dobj) seizures_17\NNS|the|induced
D010433_D012640 CID pentylenetetrezol_30\NN| (r_pobj) of_29\IN|pentylenetetrezol (r_prep) dose_28\NN|the|convulsant|of|in|tests (r_dobj) alter_25\VB|did|not|dose (r_conj) modify_15\VB|in|,|acetaminophen|did|not|seizures|and|alter|. (l_dobj) seizures_17\NNS|the|induced
19211690
D013739_D006973 NONE Testosterone_0\NN| (r_npadvmod) dependent_2\JJ|testosterone|- (r_amod) hypertension_3\NN|dependent|and|upregulation|.
D013739_D006973 NONE Testosterone_0\NN| (r_nsubj) contributes_1\VBZ|testosterone|to|through|. (l_prep) to_2\IN|development (l_pobj) development_4\NN|the|of (l_prep) of_5\IN|hypertension (l_pobj) hypertension_6\NN|and|injury|in
D017673_D006973 NONE salt_11\NN| (r_npadvmod) sensitive_13\JJ|salt|- (r_amod) rats_14\NNS|dahl|sensitive (r_pobj) in_9\IN|rats (r_prep) upregulation_5\NN|of|in (r_conj) hypertension_3\NN|dependent|and|upregulation|.
D013739_D007674 NONE testosterone_24\NN| (r_pobj) by_23\IN|testosterone (r_agent) mediated_22\VBN|by (r_acl) angiotensinogen_21\NN|intrarenal|mediated (r_pobj) of_19\IN|angiotensinogen (r_prep) upregulation_18\NN|induced|of (r_pobj) in_14\IN|upregulation (r_prep) dimorphism_13\NN|a|sexual|in|causes (l_relcl) causes_27\VBZ|that|also|increases (l_dobj) increases_28\NNS|in (l_prep) in_29\IN|bp (l_pobj) BP_30\NNP|and|injury (l_conj) injury_33\NN|renal
D013739_D007674 NONE Testosterone_0\NN| (r_compound) replacement_1\NN|testosterone|in (r_nsubj) increased_6\VBD|replacement|bp|. (l_npadvmod) BP_7\NNP|,|injury (l_appos) injury_10\NN|renal|,|and|upregulation
D013739_D007674 NONE Testosterone_0\NN| (r_nsubj) contributes_1\VBZ|testosterone|to|through|. (l_prep) to_2\IN|development (l_pobj) development_4\NN|the|of (l_prep) of_5\IN|hypertension (l_pobj) hypertension_6\NN|and|injury|in (l_conj) injury_9\NN|renal
D000809_D006973 NONE angiotensin_25\NN|renin|- (r_compound) system_26\NN|the|intrarenal|angiotensin (r_pobj) of_20\IN|system (r_prep) upregulation_19\NN|of (r_pobj) through_18\IN|possibly|upregulation (r_prep) contributes_1\VBZ|testosterone|to|through|. (l_prep) to_2\IN|development (l_pobj) development_4\NN|the|of (l_prep) of_5\IN|hypertension (l_pobj) hypertension_6\NN|and|injury|in
D000809_D007674 NONE angiotensin_25\NN|renin|- (r_compound) system_26\NN|the|intrarenal|angiotensin (r_pobj) of_20\IN|system (r_prep) upregulation_19\NN|of (r_pobj) through_18\IN|possibly|upregulation (r_prep) contributes_1\VBZ|testosterone|to|through|. (l_prep) to_2\IN|development (l_pobj) development_4\NN|the|of (l_prep) of_5\IN|hypertension (l_pobj) hypertension_6\NN|and|injury|in (l_conj) injury_9\NN|renal
8302922
D000527_D007022 CID E1_5\NNP|prostaglandin|or|trimethaphan (r_pobj) during_3\IN|e1 (r_prep) flow_2\NN|epidural|blood|during (r_nsubj) induced_8\VBD|flow|hypotension|. (l_dobj) hypotension_9\NN|
D000527_D007022 CID E1_6\NNP| (r_nmod) PGE1_8\NNP|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN|pge1 (r_prep) effect_3\NN|the|of (r_dobj) evaluate_1\VB|to|effect (r_csubj) induced_15\VBN|evaluate|hypotension|during (l_dobj) hypotension_16\NN|on
D000527_D007022 CID PGE1_8\NNP|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN|pge1 (r_prep) effect_3\NN|the|of (r_dobj) evaluate_1\VB|to|effect (r_csubj) induced_15\VBN|evaluate|hypotension|during (l_dobj) hypotension_16\NN|on
D000527_D007022 CID PGE1_2\NNP|or|tmp|product (r_dobj) starting_1\VBG|pge1 (r_pcomp) After_0\IN|starting (r_prep) decreased_14\VBD|after|significantly|compared|,|and|remained (l_conj) remained_34\VBD|degree|constant|until|. (l_nsubj) degree_28\NN|the|of|due (l_prep) of_29\IN|hypotension (l_pobj) hypotension_30\NN|
D000527_D007022 CID PGE1_33\NNP| (r_pobj) to_32\IN|pge1 (r_pcomp) due_31\IN|to (r_prep) degree_28\NN|the|of|due (l_prep) of_29\IN|hypotension (l_pobj) hypotension_30\NN|
D000527_D007022 CID PGE1_4\NNP| (r_nsubj) be_6\VB|that|pge1|may|preferable|decreased (l_acomp) preferable_7\JJ|tmp (l_xcomp) TMP_9\VB|to|for (l_prep) for_10\IN|anaesthesia (l_pobj) anaesthesia_12\NN|hypotensive|in (l_amod) hypotensive_11\JJ|
D014294_D007022 CID trimethaphan_7\RB| (r_conj) E1_5\NNP|prostaglandin|or|trimethaphan (r_pobj) during_3\IN|e1 (r_prep) flow_2\NN|epidural|blood|during (r_nsubj) induced_8\VBD|flow|hypotension|. (l_dobj) hypotension_9\NN|
D014294_D007022 CID trimethaphan_11\NN|tmp (r_conj) PGE1_8\NNP|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN|pge1 (r_prep) effect_3\NN|the|of (r_dobj) evaluate_1\VB|to|effect (r_csubj) induced_15\VBN|evaluate|hypotension|during (l_dobj) hypotension_16\NN|on
D014294_D007022 CID TMP_13\NNP|(|) (r_appos) trimethaphan_11\NN|tmp (r_conj) PGE1_8\NNP|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN|pge1 (r_prep) effect_3\NN|the|of (r_dobj) evaluate_1\VB|to|effect (r_csubj) induced_15\VBN|evaluate|hypotension|during (l_dobj) hypotension_16\NN|on
D014294_D007022 CID TMP_4\NNP|,|map (r_conj) PGE1_2\NNP|or|tmp|product (r_dobj) starting_1\VBG|pge1 (r_pcomp) After_0\IN|starting (r_prep) decreased_14\VBD|after|significantly|compared|,|and|remained (l_conj) remained_34\VBD|degree|constant|until|. (l_nsubj) degree_28\NN|the|of|due (l_prep) of_29\IN|hypotension (l_pobj) hypotension_30\NN|
D014294_D007022 CID TMP_9\VB|to|for (l_prep) for_10\IN|anaesthesia (l_pobj) anaesthesia_12\NN|hypotensive|in (l_amod) hypotensive_11\JJ|
D014294_D007022 CID TMP_17\NNP| (r_nsubj) decreased_18\VBD|because|tmp|ebf (r_advcl) be_6\VB|that|pge1|may|preferable|decreased (l_acomp) preferable_7\JJ|tmp (l_xcomp) TMP_9\VB|to|for (l_prep) for_10\IN|anaesthesia (l_pobj) anaesthesia_12\NN|hypotensive|in (l_amod) hypotensive_11\JJ|
D007530_D007022 NONE isoflurane_47\JJ| (r_amod) anaesthesia_48\NN|isoflurane (r_pobj) under_46\IN|anaesthesia (r_prep) fusion_45\NN|lateral|interbody|under (r_dobj) underwent_40\VBD|who|fusion (r_relcl) patients_38\NNS|30|underwent (r_pobj) in_36\IN|patients (r_prep) using_31\VBG|method|in (r_advcl) measured_30\VBN|induced|,|ebf|was|using|. (l_advcl) induced_15\VBN|evaluate|hypotension|during (l_dobj) hypotension_16\NN|on
16337777
D010862_D004827 NONE pilocarpine_12\NN| (r_pobj) by_11\IN|pilocarpine (r_agent) induced_10\VBN|by (r_acl) model_7\NN|the|experimental|of|induced (l_prep) of_8\IN|epilepsy (l_pobj) epilepsy_9\NN|
D010862_D013226 NONE pilocarpine_49\NN| (r_amod) model_50\NN|the|pilocarpine|of (r_pobj) of_47\IN|model (r_prep) phase_46\NN|the|chronic|of (r_pobj) in_43\IN|phase (r_prep) provoke_18\VB|to|abnormalities|in (r_xcomp) sufficient_16\JJ|provoke (r_acomp) be_15\VB|whether|generation|would|sufficient (l_nsubj) generation_8\NN|increased|of|during (l_prep) during_11\IN|epilepticus (l_pobj) epilepticus_13\NN|status
D010862_D004833 CID pilocarpine_49\NN| (r_amod) model_50\NN|the|pilocarpine|of (l_prep) of_51\IN|epilepsy (l_pobj) epilepsy_54\NN|temporal|lobe
2070391
D008012_D010146 CID lidocaine_6\NN|buffered (r_dobj) using_4\VBG|lidocaine|as (r_acl) Reduction_0\NN|in|using|. (l_prep) in_1\IN|pain (l_pobj) pain_3\NN|injection
D008012_D010146 CID lidocaine_11\NN| (r_pobj) of_10\IN|lidocaine (r_prep) injection_9\NN|the|of (r_pobj) with_7\IN|injection (r_prep) associated_6\VBN|with (r_acl) pain_5\NN|associated
D008012_D010146 CID lidocaine_14\NN| (r_pobj) of_13\IN|lidocaine (r_prep) pH_12\NN|the|of (r_dobj) adjust_10\VB|to|ph|into (r_relcl) solution_8\NN|a|buffering|adjust (r_pobj) of_5\IN|solution (r_prep) addition_4\NN|the|of (r_nsubj) reduce_20\VB|if|addition|would|pain|during (l_dobj) pain_21\NN|
D008012_D010146 CID lidocaine_13\NN|standard (r_dobj) receiving_11\VBG|lidocaine|in|and|lidocaine (r_pcomp) after_10\IN|receiving (r_prep) quantify_5\VB|to|severity|after (l_dobj) severity_7\NN|the|of (l_prep) of_8\IN|pain (l_pobj) pain_9\NN|
D008012_D010146 CID lidocaine_20\NN|buffered|in (r_conj) receiving_11\VBG|lidocaine|in|and|lidocaine (r_pcomp) after_10\IN|receiving (r_prep) quantify_5\VB|to|severity|after (l_dobj) severity_7\NN|the|of (l_prep) of_8\IN|pain (l_pobj) pain_9\NN|
D008012_D010146 CID lidocaine_6\NN|buffered (r_pobj) for_4\IN|lidocaine (r_prep) score_3\NN|the|mean|pain|for (l_compound) pain_2\NN|
D008012_D010146 CID lidocaine_16\NN|standard (r_pobj) for_14\IN|lidocaine (r_prep) score_13\NN|the|mean|for|(|+/-|,|p|) (r_pobj) than_10\IN|score (r_prep) lower_9\JJR|significantly|than (r_acomp) was_7\VBD|score|lower|. (l_nsubj) score_3\NN|the|mean|pain|for (l_compound) pain_2\NN|
D008012_D010146 CID lidocaine_5\NN|standard (r_pobj) of_3\IN|lidocaine (r_prep) adjustment_2\NN|the|ph|of (r_nsubjpass) accomplished_8\VBN|adjustment|can|be|easily|in|. (l_prep) in_10\IN|laboratory (l_pobj) laboratory_13\NN|the|catheterization|before (l_prep) before_14\IN|injection (l_pobj) injection_15\NN|and|results|in (l_prep) in_18\IN|reduction (l_pobj) reduction_20\NN|a|of (l_prep) of_21\IN|pain (l_pobj) pain_23\NN|the|occurring
7834920
D012293_D005921 CID rifampin_6\NN| (r_amod) therapy_7\NN|intermittent|rifampin|for (r_pobj) with_4\IN|therapy (r_prep) associated_3\VBN|with (r_acl) glomerulonephritis_2\NN|associated
D012293_D005921 CID rifampin_17\NN| (r_pobj) with_16\IN|rifampin (r_prep) treated_15\VBN|with (r_acl) patient_14\NN|a|treated (r_pobj) in_12\IN|patient (r_prep) finding_6\NN|an|unusual|of|in|had (l_prep) of_7\IN|glomerulonephritis (l_pobj) glomerulonephritis_11\NN|proliferative|crescentic
D012293_D005921 CID rifampin_20\NN| (r_pobj) with_19\IN|rifampin (r_prep) treated_18\VBN|with (r_acl) patient_17\NN|a|treated (r_pobj) in_15\IN|patient (r_prep) occurrence_5\NN|the|unusual|of|in (l_prep) of_6\IN|glomerulonephritis (l_pobj) glomerulonephritis_9\NN|progressive|with
D012293_D005921 CID rifampin_20\NN| (r_pobj) with_19\IN|rifampin (r_prep) treated_18\VBN|with (r_acl) patient_17\NN|a|treated (r_pobj) in_15\IN|patient (r_prep) occurrence_5\NN|the|unusual|of|in (l_prep) of_6\IN|glomerulonephritis (l_pobj) glomerulonephritis_9\NN|progressive|with (l_prep) with_10\IN|crescents (l_pobj) crescents_11\NNS|and|glomerulonephritis (l_conj) glomerulonephritis_14\NN|fibrillar
D012293_D014397 NONE rifampin_6\NN| (r_amod) therapy_7\NN|intermittent|rifampin|for (l_prep) for_8\IN|tuberculosis (l_pobj) tuberculosis_10\NN|pulmonary
D012293_D014397 NONE rifampin_7\NN| (r_pobj) of_6\IN|rifampin (r_prep) regimen_5\NN|a|10-month|of (r_dobj) underwent_2\VBD|patient|regimen|and|isoniazid|and|discovered|. (l_conj) isoniazid_9\NN|for (l_prep) for_10\IN|tuberculosis (l_pobj) tuberculosis_12\NN|pulmonary
D012293_D051437 CID rifampin_7\NN| (r_pobj) of_6\IN|rifampin (r_prep) regimen_5\NN|a|10-month|of (r_dobj) underwent_2\VBD|patient|regimen|and|isoniazid|and|discovered|. (l_conj) discovered_15\VBN|was|developed (l_xcomp) developed_18\VBN|to|have|signs|after (l_dobj) signs_19\NNS|of (l_prep) of_20\IN|failure (l_pobj) failure_23\NN|severe|renal
D007538_D014397 NONE isoniazid_9\NN|for (l_prep) for_10\IN|tuberculosis (l_pobj) tuberculosis_12\NN|pulmonary
D007538_D051437 NONE isoniazid_9\NN|for (r_conj) underwent_2\VBD|patient|regimen|and|isoniazid|and|discovered|. (l_conj) discovered_15\VBN|was|developed (l_xcomp) developed_18\VBN|to|have|signs|after (l_dobj) signs_19\NNS|of (l_prep) of_20\IN|failure (l_pobj) failure_23\NN|severe|renal
12789195
D008914_D004194 NONE minoxidil_9\NN| (r_pobj) of_8\IN|minoxidil (r_prep) use_7\NN|the|term|of (r_pobj) by_2\IN|use (r_agent) induced_1\VBN|pseudoacromegaly|by|. (l_nsubj) Pseudoacromegaly_0\NNS|
D008914_D004194 NONE minoxidil_15\NN| (r_pobj) of_14\IN|minoxidil (r_prep) use_13\NN|the|term|of|at (r_pobj) from_8\IN|use (r_prep) resulted_7\VBD|that|from (r_relcl) patient_3\NN|a|with|resulted (l_prep) with_4\IN|pseudoacromegaly (l_pobj) pseudoacromegaly_5\NNS|
D008914_D004194 NONE minoxidil_13\JJ| (r_amod) use_14\NN|minoxidil (r_pobj) of_12\IN|use (r_prep) effect_11\NN|a|side|of (r_pobj) as_8\IN|effect (r_prep) report_5\NN|the|first|case|of|as (l_prep) of_6\IN|pseudoacromegaly (l_pobj) pseudoacromegaly_7\NNS|
3693336
D014229_D001714 CID Triazolam_0\NNP| (r_npadvmod) induced_2\VBN|triazolam|-|episodes|. (l_dobj) episodes_4\NNS|brief|of|in (l_prep) of_5\IN|mania (l_pobj) mania_7\NN|secondary
D014229_D001714 CID triazolam_3\NN| (r_pobj) of_2\IN|triazolam (r_prep) doses_1\NNS|large|of (r_nsubj) induced_5\VBD|doses|repeatedly|episodes|. (l_dobj) episodes_7\NNS|brief|of|in (l_prep) of_8\IN|mania (l_pobj) mania_9\NN|
D014229_D001714 CID triazolam_10\NN| (r_pobj) of_9\IN|triazolam (r_prep) action_8\NN|of (r_pobj) of_7\IN|action (r_prep) duration_6\NN|the|of (r_pobj) with_4\IN|duration (r_prep) coincident_3\JJ|with (r_acomp) was_2\VBD|excitement|coincident|. (l_nsubj) excitement_1\NN|manic (l_amod) Manic_0\JJ|
D014229_D003866 NONE Triazolam_0\NNP| (r_npadvmod) induced_2\VBN|triazolam|-|episodes|. (l_dobj) episodes_4\NNS|brief|of|in (l_prep) in_8\IN|patient (l_pobj) patient_11\NN|a|depressed (l_amod) depressed_10\JJ|
D014229_D003866 NONE triazolam_3\NN| (r_pobj) of_2\IN|triazolam (r_prep) doses_1\NNS|large|of (r_nsubj) induced_5\VBD|doses|repeatedly|episodes|. (l_dobj) episodes_7\NNS|brief|of|in (l_prep) in_10\IN|woman (l_pobj) woman_14\NN|a|depressed|elderly (l_amod) depressed_12\JJ|
7862923
D002220_D012559 NONE Carbamazepine_0\NNP| (r_nsubjpass) switched_2\VBN|carbamazepine|was|to|among|. (l_prep) among_8\IN|patients (l_pobj) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ|or|organic
D002220_D019965 NONE Carbamazepine_0\NNP| (r_nsubjpass) switched_2\VBN|carbamazepine|was|to|among|. (l_prep) among_8\IN|patients (l_pobj) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ|
C036006_D012559 NONE oxcarbazepine_7\NN|its|analogue (r_pobj) to_3\IN|oxcarbazepine (r_prep) switched_2\VBN|carbamazepine|was|to|among|. (l_prep) among_8\IN|patients (l_pobj) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ|or|organic
C036006_D019965 NONE oxcarbazepine_7\NN|its|analogue (r_pobj) to_3\IN|oxcarbazepine (r_prep) switched_2\VBN|carbamazepine|was|to|among|. (l_prep) among_8\IN|patients (l_pobj) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ|
D006220_D012559 NONE haloperidol_22\NN|,|chlorpromazine (r_dobj) using_20\VBG|concomitantly|haloperidol (r_acl) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ|or|organic
D006220_D019965 NONE haloperidol_22\NN|,|chlorpromazine (r_dobj) using_20\VBG|concomitantly|haloperidol (r_acl) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ|
D002746_D012559 NONE chlorpromazine_24\NN|or|clozapine (r_conj) haloperidol_22\NN|,|chlorpromazine (r_dobj) using_20\VBG|concomitantly|haloperidol (r_acl) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ|or|organic
D002746_D019965 NONE chlorpromazine_24\NN|or|clozapine (r_conj) haloperidol_22\NN|,|chlorpromazine (r_dobj) using_20\VBG|concomitantly|haloperidol (r_acl) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ|
D003024_D012559 NONE clozapine_26\NN| (r_conj) chlorpromazine_24\NN|or|clozapine (r_conj) haloperidol_22\NN|,|chlorpromazine (r_dobj) using_20\VBG|concomitantly|haloperidol (r_acl) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ|or|organic
D003024_D019965 NONE clozapine_26\NN| (r_conj) chlorpromazine_24\NN|or|clozapine (r_conj) haloperidol_22\NN|,|chlorpromazine (r_dobj) using_20\VBG|concomitantly|haloperidol (r_acl) patients_19\NNS|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ|
15233872
C007145_D009203 NONE Crataegus_5\NNP| (r_pobj) of_4\IN|crataegus (r_prep) tincture_3\NN|of (r_pobj) of_2\IN|tincture (r_prep) effect_1\NN|cardioprotective|of|on|. (l_prep) on_6\IN|infarction (l_pobj) infarction_11\NN|induced|myocardial|in
C007145_D009203 NONE TCR_11\NNP| (r_pobj) of_10\IN|tcr (r_prep) effect_9\NN|the|protective|of|on (l_prep) on_12\IN|infarction (l_pobj) infarction_16\NN|induced|myocardial|in
D007545_D009203 CID isoproterenol_7\NN| (r_npadvmod) induced_9\VBN|isoproterenol|- (r_amod) infarction_11\NN|induced|myocardial|in
19445921
C066201_D009203 NONE A_5\NN|acid|on (l_prep) on_6\IN|infarction (l_pobj) infarction_11\NN|induced|myocardial|in
C066201_D009203 NONE A_13\NN|acid (r_pobj) of_10\IN|salvianolic|a (r_prep) potential_9\NN|the|cardioprotective|of|on (l_prep) on_14\IN|infarction (l_pobj) infarction_19\NN|induced|myocardial|in
C066201_D009203 NONE A_9\DT|acid|possessing (r_appos) salvianolic_7\JJ|that|a (r_nsubj) has_13\VBZ|salvianolic|effect (l_dobj) effect_17\NN|a|significant|protective|against (l_prep) against_18\IN|infarction (l_pobj) infarction_23\NN|induced|myocardial
D007545_D009203 CID isoproterenol_7\NN| (r_npadvmod) induced_9\VBN|isoproterenol|- (r_amod) infarction_11\NN|induced|myocardial|in
D007545_D009203 CID isoproterenol_15\NN| (r_npadvmod) induced_17\VBN|isoproterenol|- (r_amod) infarction_19\NN|induced|myocardial|in
D007545_D009203 CID isoproterenol_19\NN| (r_npadvmod) induced_21\VBN|isoproterenol|- (r_amod) infarction_23\NN|induced|myocardial
D000244_D012131 NONE ADP_13\NNP| (r_nmod) O_15\NNP|adp|/ (r_conj) ratio_11\NN|decreased|control|and|o (r_pobj) by_7\IN|ratio (r_agent) characterized_6\VBN|by (r_acl) dysfunction_5\NN|mitochondrial|respiratory|characterized
D007545_D012131 NONE isoproterenol_19\NN| (r_npadvmod) treated_21\VBN|isoproterenol|- (r_amod) rats_22\NNS|treated (r_pobj) in_18\IN|rats (r_prep) observed_17\VBN|in|,|dysfunction|was|in|. (l_nsubjpass) dysfunction_5\NN|mitochondrial|respiratory|characterized
C066201_D006331 NONE A_4\NN|acid (r_appos) Administration_0\NN|of|a|for|dysfunction|and|improved (l_conj) dysfunction_17\NN|attenuated|induced|cardiac|and|injury
C066201_D009202 NONE A_4\NN|acid (r_appos) Administration_0\NN|of|a|for|dysfunction|and|improved (l_conj) dysfunction_17\NN|attenuated|induced|cardiac|and|injury (l_conj) injury_20\NN|myocardial
C066201_D009202 NONE A_6\NN|acid (r_pobj) of_3\IN|salvianolic|a (r_prep) role_2\NN|the|protective|of|against (l_prep) against_7\IN|damage (l_pobj) damage_12\NN|induced|myocardial
D007545_D006331 NONE isoproterenol_13\NN| (r_npadvmod) induced_15\VBN|isoproterenol|- (r_amod) dysfunction_17\NN|attenuated|induced|cardiac|and|injury
D007545_D009202 NONE isoproterenol_13\NN| (r_npadvmod) induced_15\VBN|isoproterenol|- (r_amod) dysfunction_17\NN|attenuated|induced|cardiac|and|injury (l_conj) injury_20\NN|myocardial
D007545_D009202 NONE isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|isoproterenol|- (r_amod) damage_12\NN|induced|myocardial
1527456
D008012_D014012 NONE lignocaine_7\NN|lidocaine (r_pobj) of_6\IN|lignocaine (r_prep) instillation_5\NN|intratympanic|of (r_pobj) by_3\IN|instillation (r_prep) Treatment_0\NN|of|by|2|through|. (l_prep) of_1\IN|tinnitus (l_pobj) tinnitus_2\NN|
D008012_D014012 NONE lidocaine_9\NN|(|) (r_appos) lignocaine_7\NN|lidocaine (r_pobj) of_6\IN|lignocaine (r_prep) instillation_5\NN|intratympanic|of (r_pobj) by_3\IN|instillation (r_prep) Treatment_0\NN|of|by|2|through|. (l_prep) of_1\IN|tinnitus (l_pobj) tinnitus_2\NN|
D008012_D014012 NONE lignocaine_12\NN|lidocaine (r_pobj) of_11\IN|lignocaine (r_prep) instillation_10\NN|intratympanic|of (r_pobj) by_8\IN|instillation (r_prep) treating_6\VBG|ist|by (l_dobj) IST_7\NNP|
D008012_D014012 NONE lidocaine_14\NN|(|) (r_appos) lignocaine_12\NN|lidocaine (r_pobj) of_11\IN|lignocaine (r_prep) instillation_10\NN|intratympanic|of (r_pobj) by_8\IN|instillation (r_prep) treating_6\VBG|ist|by (l_dobj) IST_7\NNP|
9523805
D011318_D009422 CID prilocaine_11\NN|and|bupivacaine (r_pobj) with_10\IN|prilocaine (r_prep) incidence_9\NN|a|lower|with|than (r_appos) symptoms_2\NNS|transient|neurologic|after|:|incidence|.
D011318_D009422 CID prilocaine_11\JJ|with (l_prep) with_12\IN|lidocaine (l_pobj) lidocaine_13\NN|and|bupivacaine (l_conj) bupivacaine_15\NN|with (l_prep) with_16\IN|respect (l_pobj) respect_17\NN|to (l_prep) to_18\IN|duration (l_pobj) duration_19\NN|of (l_prep) of_20\IN|action (l_pobj) action_21\NN|and|risk (l_conj) risk_24\NN|relative|of (l_prep) of_25\IN|tnss (l_pobj) TNSs_26\NNS|
D011318_D009422 CID prilocaine_15\NN|(|p|) (r_dobj) receiving_14\VBG|prilocaine (r_acl) patients_13\NNS|30|receiving (r_nsubj) had_21\VBD|:|patients|,|patients|them|,|and|had (l_nsubj) patients_4\NNS|30|receiving (l_acl) receiving_5\VBG|lidocaine|tnss (l_dobj) TNSs_8\NNS|experienced
D011318_D009422 CID prilocaine_15\NN|(|p|) (r_dobj) receiving_14\VBG|prilocaine (r_acl) patients_13\NNS|30|receiving (r_nsubj) had_21\VBD|:|patients|,|patients|them|,|and|had (l_conj) had_31\VBD|none|tnss|. (l_dobj) TNSs_32\NNS|
D011318_D009422 CID Prilocaine_0\NNP| (r_nsubj) be_2\VB|prilocaine|may|preferable|has|. (l_advcl) has_12\VBZ|because|it|duration (l_dobj) duration_15\NN|a|similar|of|but|incidence (l_conj) incidence_21\NN|a|lower|of (l_prep) of_22\IN|tnss (l_pobj) TNSs_23\NNS|
D002045_D009422 NONE bupivacaine_13\NN| (r_conj) prilocaine_11\NN|and|bupivacaine (r_pobj) with_10\IN|prilocaine (r_prep) incidence_9\NN|a|lower|with|than (r_appos) symptoms_2\NNS|transient|neurologic|after|:|incidence|.
D002045_D009422 NONE bupivacaine_19\NN| (r_pobj) with_18\IN|bupivacaine (r_prep) infrequent_17\JJ|with (r_acomp) are_16\VBP|infrequent (r_conj) follow_11\VBP|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS|transient|neurologic|(|tnss|)
D002045_D009422 NONE bupivacaine_19\NN| (r_pobj) with_18\IN|bupivacaine (r_prep) infrequent_17\JJ|with (r_acomp) are_16\VBP|infrequent (r_conj) follow_11\VBP|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS|transient|neurologic|(|tnss|) (l_appos) TNSs_8\NNS|
D002045_D009422 NONE bupivacaine_15\NN|with (l_prep) with_16\IN|respect (l_pobj) respect_17\NN|to (l_prep) to_18\IN|duration (l_pobj) duration_19\NN|of (l_prep) of_20\IN|action (l_pobj) action_21\NN|and|risk (l_conj) risk_24\NN|relative|of (l_prep) of_25\IN|tnss (l_pobj) TNSs_26\NNS|
D002045_D009422 NONE bupivacaine_30\NN| (r_dobj) receiving_29\VBG|bupivacaine (r_acl) patients_28\NNS|30|receiving (r_pobj) of_26\IN|patients (r_prep) none_25\NN|of (r_nsubj) had_31\VBD|none|tnss|. (r_conj) had_21\VBD|:|patients|,|patients|them|,|and|had (l_nsubj) patients_4\NNS|30|receiving (l_acl) receiving_5\VBG|lidocaine|tnss (l_dobj) TNSs_8\NNS|experienced
D002045_D009422 NONE bupivacaine_30\NN| (r_dobj) receiving_29\VBG|bupivacaine (r_acl) patients_28\NNS|30|receiving (r_pobj) of_26\IN|patients (r_prep) none_25\NN|of (r_nsubj) had_31\VBD|none|tnss|. (l_dobj) TNSs_32\NNS|
D008012_D009422 CID lidocaine_16\NN| (r_pobj) with_15\IN|lidocaine (r_prep) than_14\IN|with (r_prep) incidence_9\NN|a|lower|with|than (r_appos) symptoms_2\NNS|transient|neurologic|after|:|incidence|.
D008012_D009422 CID lidocaine_12\NN| (r_amod) anesthesia_14\NN|lidocaine|spinal (r_dobj) follow_11\VBP|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS|transient|neurologic|(|tnss|)
D008012_D009422 CID lidocaine_12\NN| (r_amod) anesthesia_14\NN|lidocaine|spinal (r_dobj) follow_11\VBP|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS|transient|neurologic|(|tnss|) (l_appos) TNSs_8\NNS|
D008012_D009422 CID lidocaine_13\NN|and|bupivacaine (l_conj) bupivacaine_15\NN|with (l_prep) with_16\IN|respect (l_pobj) respect_17\NN|to (l_prep) to_18\IN|duration (l_pobj) duration_19\NN|of (l_prep) of_20\IN|action (l_pobj) action_21\NN|and|risk (l_conj) risk_24\NN|relative|of (l_prep) of_25\IN|tnss (l_pobj) TNSs_26\NNS|
D008012_D009422 CID lidocaine_6\NN| (r_dobj) receiving_5\VBG|lidocaine|tnss (l_dobj) TNSs_8\NNS|experienced
D008012_D009422 CID lidocaine_6\NN| (r_dobj) receiving_5\VBG|lidocaine|tnss (r_acl) patients_4\NNS|30|receiving (r_nsubj) had_21\VBD|:|patients|,|patients|them|,|and|had (l_conj) had_31\VBD|none|tnss|. (l_dobj) TNSs_32\NNS|
D008012_D009422 CID lidocaine_5\NN|to|for (r_xcomp) preferable_3\JJ|lidocaine (r_acomp) be_2\VB|prilocaine|may|preferable|has|. (l_advcl) has_12\VBZ|because|it|duration (l_dobj) duration_15\NN|a|similar|of|but|incidence (l_conj) incidence_21\NN|a|lower|of (l_prep) of_22\IN|tnss (l_pobj) TNSs_23\NNS|
137340
D009020_D006948 CID morphine_5\NN| (r_npadvmod) induced_7\VBN|morphine|- (r_amod) increase_8\NN|induced|in (l_prep) in_9\IN|activity (l_pobj) activity_11\NN|locomotor|of
D009020_D006948 CID morphine_7\NN| (r_npadvmod) induced_9\VBN|morphine|- (r_amod) increase_10\NN|the|induced|in (l_prep) in_11\IN|activity (l_pobj) activity_13\NN|locomotor|of
D009020_D006948 CID morphine_7\NN| (r_compound) HC1_9\NNP|morphine|- (r_pobj) of_6\IN|hc1 (r_prep) mg/kg_5\NN|10|of (r_pobj) of_3\IN|mg/kg (r_prep) administration_2\NN|the|subcutaneous|of (r_nsubj) produced_10\VBD|administration|increase|. (l_dobj) increase_13\NN|a|marked|in (l_prep) in_14\IN|activity (l_pobj) activity_16\NN|locomotor|in
D009020_D006948 CID morphine_1\NN| (r_npadvmod) induced_3\VBN|morphine|- (r_amod) hyperactivity_4\NN|the|induced
D009020_D006948 CID morphine_26\NN| (r_pobj) by_25\IN|morphine (r_agent) produced_24\VBN|by (r_acl) hyperactivity_23\NN|the|produced
D012601_D006948 CID scopolamine_8\NN| (r_pobj) by_7\IN|scopolamine (r_agent) potentiated_6\VBN|hyperactivity|was|by|and|attenuated|. (l_nsubjpass) hyperactivity_4\NN|the|induced
D010830_D006948 NONE physostigmine_12\NN| (r_pobj) by_11\IN|physostigmine (r_agent) attenuated_10\VBN|by (r_conj) potentiated_6\VBN|hyperactivity|was|by|and|attenuated|. (l_nsubjpass) hyperactivity_4\NN|the|induced
D019832_D006948 NONE methscopolamine_4\NN|both|and|neostigmine|,|penetrate (r_nsubj) had_18\VBD|in|,|methscopolamine|,|effect|. (l_dobj) effect_20\NN|no|on (l_prep) on_21\IN|hyperactivity (l_pobj) hyperactivity_23\NN|the|produced
D009388_D006948 NONE neostigmine_6\NN| (r_conj) methscopolamine_4\NN|both|and|neostigmine|,|penetrate (r_nsubj) had_18\VBD|in|,|methscopolamine|,|effect|. (l_dobj) effect_20\NN|no|on (l_prep) on_21\IN|hyperactivity (l_pobj) hyperactivity_23\NN|the|produced
D010134_D006948 NONE chlorophenylalamine_9\NN|p|-|(|i.p.|,|hr|) (r_pobj) with_6\IN|chlorophenylalamine (r_prep) pretreatment_5\NN|with (r_nsubj) caused_25\VBD|on|,|pretreatment|,|depletor|,|change|. (l_dobj) change_28\NN|no|significant|in (l_prep) in_29\IN|hyperactivity (l_pobj) hyperactivity_31\NN|the
D012701_D006948 NONE serotonin_22\NN| (r_compound) depletor_23\NN|a|serotonin (r_nsubj) caused_25\VBD|on|,|pretreatment|,|depletor|,|change|. (l_dobj) change_28\NN|no|significant|in (l_prep) in_29\IN|hyperactivity (l_pobj) hyperactivity_31\NN|the
18162529
D012313_D006966 NONE acid_5\NN|ribonucleic (r_compound) levels_6\NNS|hypothalamic|prolactin|messenger|acid|,|signaling (l_conj) signaling_9\NN|prolactin|,|and|inhibition (l_conj) inhibition_13\NN|hyperprolactinemic|of (l_amod) hyperprolactinemic_12\JJ|
D004958_D006966 NONE estradiol_22\NN| (r_pobj) on_21\IN|estradiol (r_prep) dependent_20\JJ|on (r_acomp) are_19\VBP|levels|dependent|. (l_nsubj) levels_6\NNS|hypothalamic|prolactin|messenger|acid|,|signaling (l_conj) signaling_9\NN|prolactin|,|and|inhibition (l_conj) inhibition_13\NN|hyperprolactinemic|of (l_amod) hyperprolactinemic_12\JJ|
D004958_D006966 NONE estradiol_30\NN| (r_pobj) of_29\IN|estradiol (r_prep) levels_28\NNS|chronic|low|of (r_pobj) of_25\IN|levels (r_prep) presence_24\NN|the|of (r_pobj) in_22\IN|only|presence (r_conj) caused_8\VBD|hyperprolactinemia|frequency|,|but|in|. (l_nsubj) hyperprolactinemia_1\NN|chronic|induced
D004967_D006966 NONE estrogen_20\NN| (r_npadvmod) induced_22\VBN|estrogen|- (r_amod) surge_24\NN|the|induced|lh (r_conj) secretion_17\NN|pulsatile|lh|and|surge (r_appos) parameters_9\NNS|two|neuroendocrine|necessary|:|secretion (r_dobj) inhibited_6\VBD|whether|hyperprolactinemia|parameters (l_nsubj) hyperprolactinemia_5\NN|chronic
D004298_D006966 NONE dopamine_5\NN| (r_compound) antagonist_6\NN|dopamine (r_compound) sulpiride_7\NN|the|antagonist (r_pobj) by_3\IN|sulpiride (r_agent) induced_2\VBN|by (r_acl) hyperprolactinemia_1\NN|chronic|induced
D013469_D006966 CID sulpiride_7\NN|the|antagonist (r_pobj) by_3\IN|sulpiride (r_agent) induced_2\VBN|by (r_acl) hyperprolactinemia_1\NN|chronic|induced
D013256_D006966 NONE steroid_14\NN| (r_npadvmod) dependent_16\JJ|steroid|- (r_amod) manner_17\NN|a|dependent (r_pobj) in_12\IN|manner (r_prep) inhibited_8\VBN|that|frequency|is|by|in (l_agent) by_9\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_11\NN|chronic
16904497
D013256_D011128 NONE steroid_5\NN| (r_compound) injection_6\NN|epidural|steroid (r_pobj) after_3\IN|injection (r_prep) syndrome_2\NN|equina|after|:|report|.
D013256_D011843 NONE steroid_11\NN| (r_compound) injections_12\NNS|epidural|steroid|,|medications (r_conj) therapy_8\NN|physical|,|injections (r_attr) are_6\VBP|methods|therapy|. (l_nsubj) methods_2\NNS|conventional|treatment|of (l_prep) of_3\IN|radiculopathy (l_pobj) radiculopathy_5\NN|lumbusacral
D014221_D011128 NONE triamcinolone_16\NN|and|bupivacaine (r_pobj) of_15\IN|triamcinolone (r_prep) injection_14\NN|epidural|of (r_pobj) by_12\IN|injection (r_agent) caused_11\VBN|possibly|by (r_acl) report_5\NN|a|of|caused (l_prep) of_6\IN|syndrome (l_pobj) syndrome_9\NN|cauda|equina
D002045_D011128 CID bupivacaine_18\NN| (r_conj) triamcinolone_16\NN|and|bupivacaine (r_pobj) of_15\IN|triamcinolone (r_prep) injection_14\NN|epidural|of (r_pobj) by_12\IN|injection (r_agent) caused_11\VBN|possibly|by (r_acl) report_5\NN|a|of|caused (l_prep) of_6\IN|syndrome (l_pobj) syndrome_9\NN|cauda|equina
D013256_D017116 NONE steroid_16\NN| (r_compound) injection_17\NN|epidural|steroid (r_pobj) for_14\IN|injection (r_prep) scheduled_13\VBN|woman|was|for|. (l_nsubjpass) woman_4\NN|a|old|with (l_prep) with_5\IN|pain (l_pobj) pain_11\NN|back|leg
D013256_D010146 NONE steroid_16\NN| (r_compound) injection_17\NN|epidural|steroid (r_pobj) for_14\IN|injection (r_prep) scheduled_13\VBN|woman|was|for|. (l_nsubjpass) woman_4\NN|a|old|with (l_prep) with_5\IN|pain (l_pobj) pain_11\NN|back|leg
D013256_D009422 NONE steroid_10\NN| (r_compound) injections_11\NNS|epidural|steroid (r_pobj) after_8\IN|injections (r_prep) vigilance_4\NN|continued|for|after (l_prep) for_5\IN|deterioration (l_pobj) deterioration_7\NN|neurologic
19884587
D013449_D000757 CID Sulfonamides_0\NNS| (r_nsubjpass) associated_2\VBN|sulfonamides|were|with (l_prep) with_3\IN|aor (l_pobj) AOR_9\NNP|anencephaly|(|adjusted|or|[|]|3.4 (l_amod) anencephaly_4\NNS|
D013449_D018636 CID Sulfonamides_0\NNS| (r_nsubjpass) associated_2\VBN|sulfonamides|were|with (r_ccomp) interval_17\NN|associated|;|%|confidence|ci|,|1.3|)|,|syndrome (l_appos) syndrome_30\NN|hypoplastic|left|heart
D009582_D000853 CID Nitrofurantoins_0\NNS| (r_nsubjpass) associated_2\VBN|nitrofurantoins|were|with|aor|. (l_prep) with_3\IN|anophthalmia (l_pobj) anophthalmia_4\NN|or|microphthalmos
D009582_D008850 CID Nitrofurantoins_0\NNS| (r_nsubjpass) associated_2\VBN|nitrofurantoins|were|with|aor|. (l_prep) with_3\IN|anophthalmia (l_pobj) anophthalmia_4\NN|or|microphthalmos (l_conj) microphthalmos_6\NNS|
D009582_D018636 CID Nitrofurantoins_0\NNS| (r_nsubjpass) associated_2\VBN|nitrofurantoins|were|with|aor|. (l_appos) AOR_8\NNP|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) syndrome_24\NN|hypoplastic|left|heart
D009582_D006344 CID Nitrofurantoins_0\NNS| (r_nsubjpass) associated_2\VBN|nitrofurantoins|were|with|aor|. (l_appos) AOR_8\NNP|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) AOR_26\NNP|(|=|4.2|;|ci|)|,|defects|(|aor|;|ci|)|,|and|lip (l_appos) defects_41\NNS|atrial|septal
D009582_D002971 CID Nitrofurantoins_0\NNS| (r_nsubjpass) associated_2\VBN|nitrofurantoins|were|with|aor|. (l_appos) AOR_8\NNP|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) AOR_26\NNP|(|=|4.2|;|ci|)|,|defects|(|aor|;|ci|)|,|and|lip (l_conj) lip_58\NN|cleft|with
D009582_D002972 CID Nitrofurantoins_0\NNS| (r_nsubjpass) associated_2\VBN|nitrofurantoins|were|with|aor|. (l_appos) AOR_8\NNP|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) AOR_26\NNP|(|=|4.2|;|ci|)|,|defects|(|aor|;|ci|)|,|and|lip (l_conj) lip_58\NN|cleft|with (l_prep) with_59\IN|palate (l_pobj) palate_61\NN|cleft
D010406_D000014 NONE penicillins_2\NNS|,|erythromycins|,|used|, (r_nsubjpass) associated_18\VBN|reassuringly|,|penicillins|were|not|with|. (l_prep) with_19\IN|defects (l_pobj) defects_22\NNS|many|birth
D004917_D000014 NONE erythromycins_4\NNS|,|and|cephalosporins (r_conj) penicillins_2\NNS|,|erythromycins|,|used|, (r_nsubjpass) associated_18\VBN|reassuringly|,|penicillins|were|not|with|. (l_prep) with_19\IN|defects (l_pobj) defects_22\NNS|many|birth
D002511_D000014 NONE cephalosporins_7\NNS| (r_conj) erythromycins_4\NNS|,|and|cephalosporins (r_conj) penicillins_2\NNS|,|erythromycins|,|used|, (r_nsubjpass) associated_18\VBN|reassuringly|,|penicillins|were|not|with|. (l_prep) with_19\IN|defects (l_pobj) defects_22\NNS|many|birth
D013449_D000014 CID Sulfonamides_0\NNS|and|nitrofurantoins (r_nsubjpass) associated_4\VBN|sulfonamides|were|with|,|indicating|. (l_prep) with_5\IN|defects (l_pobj) defects_8\NNS|several|birth
D009582_D000014 CID nitrofurantoins_2\NNS| (r_conj) Sulfonamides_0\NNS|and|nitrofurantoins (r_nsubjpass) associated_4\VBN|sulfonamides|were|with|,|indicating|. (l_prep) with_5\IN|defects (l_pobj) defects_8\NNS|several|birth
7248170
D010634_D006529 CID Phenobarbitone_0\NNP| (r_npadvmod) induced_2\VBN|phenobarbitone|- (r_amod) enlargement_3\NN|induced|of|:|relationship|. (l_prep) of_4\IN|liver (l_pobj) liver_6\NN|the|in
D010634_D006529 CID phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|phenobarbitone|- (r_amod) rat_63\NN|the|primed (r_pobj) in_58\IN|rat (r_prep) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_conj) increased_65\VBN|was|from|by (l_prep) by_72\IN|giving (l_pcomp) giving_73\VBG|calibrating|at (l_prep) at_83\IN|peak (l_pobj) peak_85\NN|the|of (l_prep) of_86\IN|enlargement (l_pobj) enlargement_91\NN|the|induced|of (l_prep) of_92\IN|liver (l_pobj) liver_94\NN|the
D010634_D006529 CID phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|phenobarbitone|- (r_amod) enlargement_91\NN|the|induced|of (l_prep) of_92\IN|liver (l_pobj) liver_94\NN|the
D010634_D005355 NONE Phenobarbitone_0\NNP| (r_npadvmod) induced_2\VBN|phenobarbitone|- (r_amod) enlargement_3\NN|induced|of|:|relationship|. (l_appos) relationship_12\NN|its|to (l_prep) to_13\TO|cirrhosis (l_pobj) cirrhosis_18\NN|carbon|induced
D002251_D006529 NONE tetrachloride_15\NN| (r_advmod) induced_17\VBN|tetrachloride|- (r_amod) cirrhosis_18\NN|carbon|induced (r_pobj) to_13\TO|cirrhosis (r_prep) relationship_12\NN|its|to (r_appos) enlargement_3\NN|induced|of|:|relationship|. (l_prep) of_4\IN|liver (l_pobj) liver_6\NN|the|in
D002251_D006529 NONE tetrachloride_55\NN| (r_advmod) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_conj) increased_65\VBN|was|from|by (l_prep) by_72\IN|giving (l_pcomp) giving_73\VBG|calibrating|at (l_prep) at_83\IN|peak (l_pobj) peak_85\NN|the|of (l_prep) of_86\IN|enlargement (l_pobj) enlargement_91\NN|the|induced|of (l_prep) of_92\IN|liver (l_pobj) liver_94\NN|the
D002251_D006529 NONE tetrachloride_82\NN| (r_advmod) calibrating_77\VBG|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG|calibrating|at (l_prep) at_83\IN|peak (l_pobj) peak_85\NN|the|of (l_prep) of_86\IN|enlargement (l_pobj) enlargement_91\NN|the|induced|of (l_prep) of_92\IN|liver (l_pobj) liver_94\NN|the
D002251_D005355 NONE tetrachloride_15\NN| (r_advmod) induced_17\VBN|tetrachloride|- (r_amod) cirrhosis_18\NN|carbon|induced
D002251_D008103 CID tetrachloride_55\NN| (r_advmod) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_nsubj) yield_1\NN|the|of (l_prep) of_2\IN|cirrhosis (l_pobj) cirrhosis_4\NN|severe|of (l_prep) of_5\IN|liver (l_pobj) liver_7\NN|the|(|defined|,
D002251_D008103 CID tetrachloride_82\NN| (r_advmod) calibrating_77\VBG|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG|calibrating|at (r_pcomp) by_72\IN|giving (r_prep) increased_65\VBN|was|from|by (r_conj) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_nsubj) yield_1\NN|the|of (l_prep) of_2\IN|cirrhosis (l_pobj) cirrhosis_4\NN|severe|of (l_prep) of_5\IN|liver (l_pobj) liver_7\NN|the|(|defined|,
D002251_D001201 NONE tetrachloride_55\NN| (r_advmod) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin
D002251_D001201 NONE tetrachloride_82\NN| (r_advmod) calibrating_77\VBG|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG|calibrating|at (r_pcomp) by_72\IN|giving (r_prep) increased_65\VBN|was|from|by (r_conj) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin
D002251_D013163 NONE tetrachloride_55\NN| (r_advmod) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_conj) albumin_27\NN|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ|2|,|and|atrophy|after
D002251_D013163 NONE tetrachloride_82\NN| (r_advmod) calibrating_77\VBG|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG|calibrating|at (r_pcomp) by_72\IN|giving (r_prep) increased_65\VBN|was|from|by (r_conj) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_conj) albumin_27\NN|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ|2|,|and|atrophy|after
D002251_D001284 NONE tetrachloride_55\NN| (r_advmod) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_conj) albumin_27\NN|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ|2|,|and|atrophy|after (l_conj) atrophy_44\NN|testicular|weight|)
D002251_D001284 NONE tetrachloride_82\NN| (r_advmod) calibrating_77\VBG|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG|calibrating|at (r_pcomp) by_72\IN|giving (r_prep) increased_65\VBN|was|from|by (r_conj) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_conj) albumin_27\NN|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ|2|,|and|atrophy|after (l_conj) atrophy_44\NN|testicular|weight|)
D010634_D008103 CID phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|phenobarbitone|- (r_amod) rat_63\NN|the|primed (r_pobj) in_58\IN|rat (r_prep) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_nsubj) yield_1\NN|the|of (l_prep) of_2\IN|cirrhosis (l_pobj) cirrhosis_4\NN|severe|of (l_prep) of_5\IN|liver (l_pobj) liver_7\NN|the|(|defined|,
D010634_D008103 CID phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|phenobarbitone|- (r_amod) enlargement_91\NN|the|induced|of (r_pobj) of_86\IN|enlargement (r_prep) peak_85\NN|the|of (r_pobj) at_83\IN|peak (r_prep) giving_73\VBG|calibrating|at (r_pcomp) by_72\IN|giving (r_prep) increased_65\VBN|was|from|by (r_conj) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_nsubj) yield_1\NN|the|of (l_prep) of_2\IN|cirrhosis (l_pobj) cirrhosis_4\NN|severe|of (l_prep) of_5\IN|liver (l_pobj) liver_7\NN|the|(|defined|,
D010634_D001201 NONE phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|phenobarbitone|- (r_amod) rat_63\NN|the|primed (r_pobj) in_58\IN|rat (r_prep) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin
D010634_D001201 NONE phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|phenobarbitone|- (r_amod) enlargement_91\NN|the|induced|of (r_pobj) of_86\IN|enlargement (r_prep) peak_85\NN|the|of (r_pobj) at_83\IN|peak (r_prep) giving_73\VBG|calibrating|at (r_pcomp) by_72\IN|giving (r_prep) increased_65\VBN|was|from|by (r_conj) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin
D010634_D013163 NONE phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|phenobarbitone|- (r_amod) rat_63\NN|the|primed (r_pobj) in_58\IN|rat (r_prep) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_conj) albumin_27\NN|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ|2|,|and|atrophy|after
D010634_D013163 NONE phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|phenobarbitone|- (r_amod) enlargement_91\NN|the|induced|of (r_pobj) of_86\IN|enlargement (r_prep) peak_85\NN|the|of (r_pobj) at_83\IN|peak (r_prep) giving_73\VBG|calibrating|at (r_pcomp) by_72\IN|giving (r_prep) increased_65\VBN|was|from|by (r_conj) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_conj) albumin_27\NN|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ|2|,|and|atrophy|after
D010634_D001284 NONE phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|phenobarbitone|- (r_amod) rat_63\NN|the|primed (r_pobj) in_58\IN|rat (r_prep) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_conj) albumin_27\NN|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ|2|,|and|atrophy|after (l_conj) atrophy_44\NN|testicular|weight|)
D010634_D001284 NONE phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|phenobarbitone|- (r_amod) enlargement_91\NN|the|induced|of (r_pobj) of_86\IN|enlargement (r_prep) peak_85\NN|the|of (r_pobj) at_83\IN|peak (r_prep) giving_73\VBG|calibrating|at (r_pcomp) by_72\IN|giving (r_prep) increased_65\VBN|was|from|by (r_conj) given_56\VBN|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ|yield|greater|,|albumin (l_conj) albumin_27\NN|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ|2|,|and|atrophy|after (l_conj) atrophy_44\NN|testicular|weight|)
3782049
D008972_D012206 CID molindone_6\NN| (r_compound) administration_7\NN|molindone (r_pobj) following_5\VBG|administration (r_prep) rhabdomyolysis_4\NN|massive|following
D008972_D012206 CID molindone_18\NN| (r_compound) administration_19\NN|molindone (r_pobj) following_17\VBG|administration (r_prep) rhabdomyolysis_11\NN|massive|and|failure|following
D008972_D012559 NONE molindone_18\NN| (r_compound) administration_19\NN|molindone (r_pobj) following_17\VBG|administration (r_prep) rhabdomyolysis_11\NN|massive|and|failure|following (r_dobj) illustrate_9\VB|to|rhabdomyolysis (r_xcomp) reported_7\VBN|case|is|illustrate|. (l_nsubjpass) case_1\NN|the|of (l_prep) of_2\IN|patient (l_pobj) patient_5\NN|a|schizophrenic (l_amod) schizophrenic_4\JJ|
D008972_D058186 CID molindone_18\NN| (r_compound) administration_19\NN|molindone (r_pobj) following_17\VBG|administration (r_prep) rhabdomyolysis_11\NN|massive|and|failure|following (l_conj) failure_16\NN|subsequent|acute|renal
17608141
D008694_D020258 NONE methamphetamine_2\NN| (r_npadvmod) induced_4\VBN|attenuation|methamphetamine|-|neurotoxicity|. (l_dobj) neurotoxicity_7\NN|nigrostriatal|dopaminergic|in|by
D008694_D020258 NONE methamphetamine_23\NN| (r_npadvmod) induced_25\VBN|methamphetamine|- (r_amod) neurotoxicity_28\NN|the|induced|nigrostriatal|dopamine
D008694_D020258 NONE methamphetamine_15\NN| (r_npadvmod) induced_17\VBN|methamphetamine|- (r_amod) neurotoxicity_20\NN|induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_11\NN| (r_compound) pretreatment_12\NN|lipopolysaccharide (r_pobj) by_10\IN|pretreatment (r_prep) neurotoxicity_7\NN|nigrostriatal|dopaminergic|in|by
D008070_D020258 NONE lipopolysaccharide_9\NN| (r_pobj) of_8\IN|lipopolysaccharide (r_prep) roles_7\NNS|the|of|,|factor (l_appos) factor_17\NN|a|inflammatory|,|treatment (l_conj) treatment_19\NN|in (l_prep) in_20\IN|modulating (l_pcomp) modulating_21\VBG|neurotoxicity (l_dobj) neurotoxicity_28\NN|the|induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_8\NN| (r_compound) pretreatment_9\NN|systemic|lipopolysaccharide|in (l_prep) in_10\IN|exerting (l_pcomp) exerting_11\VBG|protection (l_dobj) protection_13\NN|effective|against (l_prep) against_14\IN|neurotoxicity (l_pobj) neurotoxicity_20\NN|induced|nigrostriatal|dopamine
D008694_D009422 NONE methamphetamine_10\NN| (r_npadvmod) induced_12\VBN|methamphetamine|- (r_amod) damage_15\NN|induced|dopaminergic|terminal
D004298_D020258 NONE dopamine_27\NN| (r_compound) neurotoxicity_28\NN|the|induced|nigrostriatal|dopamine
D004298_D020258 NONE dopamine_19\NN| (r_compound) neurotoxicity_20\NN|induced|nigrostriatal|dopamine
D008070_D005334 NONE Lipopolysaccharide_0\JJ| (r_compound) pretreatment_1\NN|lipopolysaccharide (r_nsubj) affect_4\VB|pretreatment|did|not|temperature|later|. (l_dobj) temperature_8\NN|the|basal|body|or|hyperthermia (l_conj) hyperthermia_13\NN|elicited
D008694_D005334 CID methamphetamine_10\NN| (r_npadvmod) elicited_12\VBN|methamphetamine|- (r_amod) hyperthermia_13\NN|elicited
9088814
D000527_D007022 CID E1-induced_5\JJ| (r_amod) hypotension_6\NN|prolonged|prostaglandin|e1-induced|and|haemodilution|on
D000527_D007022 CID E1_5\NN|prolonged|prostaglandin|hypotension (l_appos) hypotension_8\NN|(|pge1)-induced|and|haemodilution
D000527_D007022 CID PGE1)-induced_7\JJ| (r_amod) hypotension_8\NN|(|pge1)-induced|and|haemodilution
D000527_D007022 CID PGE1_10\NNP| (r_pobj) with_9\IN|pge1 (r_prep) induced_8\VBN|hypotension|was|with|maintain|. (l_nsubjpass) hypotension_1\NN|controlled|in
D000527_D007022 CID PGE1-induced_13\JJ| (r_amod) hypotension_14\NN|pge1-induced|and|haemodilution
D000527_D020141 NONE E1-induced_5\JJ| (r_amod) hypotension_6\NN|prolonged|prostaglandin|e1-induced|and|haemodilution|on (l_conj) haemodilution_8\NN|
D000527_D020141 NONE E1_5\NN|prolonged|prostaglandin|hypotension (l_appos) hypotension_8\NN|(|pge1)-induced|and|haemodilution (l_conj) haemodilution_10\NN|on
D000527_D020141 NONE PGE1)-induced_7\JJ| (r_amod) hypotension_8\NN|(|pge1)-induced|and|haemodilution (l_conj) haemodilution_10\NN|on
D000527_D020141 NONE PGE1-induced_13\JJ| (r_amod) hypotension_14\NN|pge1-induced|and|haemodilution (l_conj) haemodilution_17\NN|moderate
D003911_D020141 NONE dextran_23\NN| (r_amod) solution_24\NN|dextran (r_pobj) of_22\IN|solution (r_prep) amount_21\NN|the|same|of (r_pobj) with_18\IN|amount (r_prep) replacing_16\VBG|it|with (r_conj) withdrawing_9\VBG|ml|and|replacing (r_pcomp) by_8\IN|withdrawing (r_prep) produced_7\VBN|haemodilution|was|by|,|and|were (l_nsubjpass) Haemodilution_0\NN|in
D001663_D007022 NONE bilirubin_68\NN|total (r_conj) LDH_65\NNP|and|bilirubin (r_conj) SGPT_63\NNP|,|ldh (r_appos) SGOT_61\NNP|,|sgpt (r_nsubj) showed_69\VBD|sgot|increases|. (r_conj) showed_23\VBD|showed|,|akbr|decrease|and|at|after|,|and|showed (l_prep) after_42\IN|start|and|at|after (l_pobj) start_44\NN|the|of (l_prep) of_45\IN|hypotension (l_pobj) hypotension_46\NN|
D000527_D008107 CID PGE1-induced_13\JJ| (r_amod) hypotension_14\NN|pge1-induced|and|haemodilution (r_pobj) of_12\IN|hypotension (r_prep) min_11\NN|120|of (r_pobj) of_7\IN|min (r_prep) combination_6\NN|a|prolonged|of (r_nsubj) cause_19\VB|that|combination|would|impairment (l_dobj) impairment_20\NN|of (l_prep) of_21\IN|function (l_pobj) function_23\NN|hepatic
3615541
D000661_D006948 CID amphetamine_6\NN| (r_npadvmod) induced_8\VBN|amphetamine|- (r_amod) hyperactivity_9\NN|induced
D002116_D006948 NONE calcitonin_12\NN| (r_compound) injections_13\NNS|intracerebral|calcitonin (r_pobj) by_10\IN|injections (r_prep) antagonism_4\NN|the|of|by (l_prep) of_5\IN|hyperactivity (l_pobj) hyperactivity_9\NN|induced
2572625
C084599_D056486 CID Clotiazepam_0\NNP| (r_npadvmod) induced_2\VBN|clotiazepam|- (r_amod) hepatitis_4\NN|induced|acute|.
C084599_D056486 CID clotiazepam_24\NN| (r_pobj) of_23\IN|clotiazepam (r_prep) administration_22\NN|of (r_pobj) of_21\IN|administration (r_prep) onset_20\NN|the|of (r_pobj) after_18\IN|months|onset (r_prep) developed_8\VBD|who|hepatitis|with|after (l_dobj) hepatitis_10\NN|acute
C084599_D056486 CID clotiazepam_9\NN|to (r_xcomp) related_7\VBN|chemically|clotiazepam (r_acl) administration_1\NN|the|of|,|related (r_nsubj) interfere_13\VB|administration|,|did|not|with|and|induce|. (l_conj) induce_19\VB|did|not|relapse (l_dobj) relapse_21\NN|any|of (l_prep) of_22\IN|hepatitis (l_pobj) hepatitis_23\NN|
C084599_D056486 CID clotiazepam_4\NN| (r_nsubj) induce_6\VB|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN|acute
C084599_D056486 CID clotiazepam_4\NN| (r_nsubj) induce_6\VB|that|clotiazepam|can|hepatitis|and|suggests (l_conj) suggests_10\VBZ|is (l_ccomp) is_13\VBZ|that|there|hepatotoxicity (l_attr) hepatotoxicity_16\NN|cross|between
C084599_D056486 CID clotiazepam_18\NN|and|benzodiazepines (r_pobj) between_17\IN|clotiazepam (r_prep) hepatotoxicity_16\NN|cross|between (r_attr) is_13\VBZ|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ|is (r_conj) induce_6\VB|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN|acute
C084599_D056486 CID clotiazepam_18\NN|and|benzodiazepines (r_pobj) between_17\IN|clotiazepam (r_prep) hepatotoxicity_16\NN|cross|between
C084599_D047508 NONE clotiazepam_24\NN| (r_pobj) of_23\IN|clotiazepam (r_prep) administration_22\NN|of (r_pobj) of_21\IN|administration (r_prep) onset_20\NN|the|of (r_pobj) after_18\IN|months|onset (r_prep) developed_8\VBD|who|hepatitis|with|after (l_prep) with_11\IN|necrosis (l_pobj) necrosis_14\NN|extensive|hepatocellular|,
C013295_D056486 NONE thienodiazepine_27\NN| (r_amod) derivative_28\NN|a|thienodiazepine (r_appos) patient_6\NN|a|developed|,|derivative (l_relcl) developed_8\VBD|who|hepatitis|with|after (l_dobj) hepatitis_10\NN|acute
C013295_D047508 NONE thienodiazepine_27\NN| (r_amod) derivative_28\NN|a|thienodiazepine (r_appos) patient_6\NN|a|developed|,|derivative (l_relcl) developed_8\VBD|who|hepatitis|with|after (l_prep) with_11\IN|necrosis (l_pobj) necrosis_14\NN|extensive|hepatocellular|,
D001569_D056486 NONE benzodiazepines_4\NNS|several (r_pobj) of_2\IN|benzodiazepines (r_prep) administration_1\NN|the|of|,|related (r_nsubj) interfere_13\VB|administration|,|did|not|with|and|induce|. (l_conj) induce_19\VB|did|not|relapse (l_dobj) relapse_21\NN|any|of (l_prep) of_22\IN|hepatitis (l_pobj) hepatitis_23\NN|
D001569_D056486 NONE benzodiazepines_21\NNS|several (r_conj) clotiazepam_18\NN|and|benzodiazepines (r_pobj) between_17\IN|clotiazepam (r_prep) hepatotoxicity_16\NN|cross|between (r_attr) is_13\VBZ|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ|is (r_conj) induce_6\VB|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN|acute
D001569_D056486 NONE benzodiazepines_21\NNS|several (r_conj) clotiazepam_18\NN|and|benzodiazepines (r_pobj) between_17\IN|clotiazepam (r_prep) hepatotoxicity_16\NN|cross|between
6229975
D013999_D009203 NONE timolol_8\NN| (r_compound) treatment_9\NN|term|timolol|after (l_prep) after_10\IN|infarction (l_pobj) infarction_12\NN|myocardial
D013999_D009203 NONE timolol_6\NN| (r_compound) treatment_7\NN|term|timolol|on (r_pobj) of_2\IN|treatment (r_prep) effect_1\NN|the|of|after (l_prep) after_11\IN|infarction (l_pobj) infarction_13\NN|myocardial
D013999_D009203 NONE timolol_33\NN|115|) (r_conj) evaluated_15\VBN|effect|was|by|in|timolol|. (l_nsubjpass) effect_1\NN|the|of|after (l_prep) after_11\IN|infarction (l_pobj) infarction_13\NN|myocardial
D013999_D001919 NONE timolol_6\NN| (r_npadvmod) induced_8\VBN|timolol|- (r_amod) bradycardia_9\NN|induced|and|increase
D013999_D007238 NONE timolol_17\NN| (r_compound) group_18\NN|the|timolol (r_pobj) in_15\IN|group (r_prep) remained_13\VBD|unchanged|in (r_conj) increased_7\VBD|after|,|size|in|and|remained|. (l_punct) ,_4\,|infarction (l_punct) infarction_3\NN|-
891050
D003276_D006463 CID contraceptives_17\NNS|oral (r_dobj) taking_15\VBG|contraceptives (r_acl) woman_14\NN|a|taking (r_pobj) in_12\IN|woman (r_prep) syndrome_8\NN|the|hemolytic|uremic|(|hus|)|in
D003276_D006463 CID contraceptives_17\NNS|oral (r_dobj) taking_15\VBG|contraceptives (r_acl) woman_14\NN|a|taking (r_pobj) in_12\IN|woman (r_prep) syndrome_8\NN|the|hemolytic|uremic|(|hus|)|in (l_appos) HUS_10\NNP|
D006493_D001002 NONE heparin_4\JJ|,|dipyridamole (r_pobj) with_3\IN|heparin (r_prep) treated_2\VBN|she|was|with|;|and|rose (l_conj) rose_20\VBD|after|,|output|above|;|and|stopped|. (l_conj) stopped_37\VBN|after|,|treatment|was (l_prep) after_28\IN|months|onset (l_pobj) onset_30\NN|the|of (l_prep) of_31\IN|anuria (l_pobj) anuria_32\NN|
D004176_D001002 NONE dipyridamole_6\NN|and|hemodialysis (r_conj) heparin_4\JJ|,|dipyridamole (r_pobj) with_3\IN|heparin (r_prep) treated_2\VBN|she|was|with|;|and|rose (l_conj) rose_20\VBD|after|,|output|above|;|and|stopped|. (l_conj) stopped_37\VBN|after|,|treatment|was (l_prep) after_28\IN|months|onset (l_pobj) onset_30\NN|the|of (l_prep) of_31\IN|anuria (l_pobj) anuria_32\NN|
2894766
D012460_D008180 CID Sulfasalazine_0\NNP| (r_npadvmod) induced_2\VBN|sulfasalazine|- (r_amod) erythematosus_4\NN|induced|lupus|.
D012460_D008180 CID sulfasalazine_7\RB| (r_npadvmod) induced_9\VBN|sulfasalazine|- (r_amod) lupus_10\NN|induced|,|manifested
D012460_D008180 CID sulfasalazine_3\NN| (r_dobj) use_2\VBP|who|sulfasalazine|treat (r_relcl) Physicians_0\NNS|use (r_nsubj) be_12\VB|physicians|should|aware|. (l_acomp) aware_13\JJ|of (l_prep) of_14\IN|signs (l_pobj) signs_16\NNS|the|of (l_prep) of_17\IN|syndrome (l_pobj) syndrome_22\NN|induced|lupus
D012460_D008180 CID sulfasalazine_18\NN| (r_npadvmod) induced_20\VBN|sulfasalazine|- (r_amod) syndrome_22\NN|induced|lupus
D012460_D011014 CID sulfasalazine_29\NN| (r_compound) therapy_30\NN|term|sulfasalazine (r_dobj) receiving_25\VBG|who|was|therapy|for (r_relcl) man_21\NN|a|old|,|receiving (r_pobj) in_16\IN|man (r_prep) developed_15\VBN|in (r_acl) autoantibodies_14\NNS|positive|developed (r_conj) evidence_7\NN|echocardiographic|of|,|and|autoantibodies (r_appos) effusions_4\NNS|pneumonitis|,|bilateral|pleural|,|evidence|. (l_dep) Pneumonitis_0\NNP|
D012460_D010996 CID sulfasalazine_29\NN| (r_compound) therapy_30\NN|term|sulfasalazine (r_dobj) receiving_25\VBG|who|was|therapy|for (r_relcl) man_21\NN|a|old|,|receiving (r_pobj) in_16\IN|man (r_prep) developed_15\VBN|in (r_acl) autoantibodies_14\NNS|positive|developed (r_conj) evidence_7\NN|echocardiographic|of|,|and|autoantibodies (r_appos) effusions_4\NNS|pneumonitis|,|bilateral|pleural|,|evidence|.
D012460_D002305 CID sulfasalazine_29\NN| (r_compound) therapy_30\NN|term|sulfasalazine (r_dobj) receiving_25\VBG|who|was|therapy|for (r_relcl) man_21\NN|a|old|,|receiving (r_pobj) in_16\IN|man (r_prep) developed_15\VBN|in (r_acl) autoantibodies_14\NNS|positive|developed (r_conj) evidence_7\NN|echocardiographic|of|,|and|autoantibodies (l_prep) of_8\IN|tamponade (l_pobj) tamponade_10\NN|cardiac
D012460_D003093 NONE sulfasalazine_29\NN| (r_compound) therapy_30\NN|term|sulfasalazine (r_dobj) receiving_25\VBG|who|was|therapy|for (l_prep) for_31\IN|colitis (l_pobj) colitis_34\NN|chronic|ulcerative
D012460_D012700 NONE sulfasalazine_7\RB| (r_npadvmod) induced_9\VBN|sulfasalazine|- (r_amod) lupus_10\NN|induced|,|manifested (l_relcl) manifested_13\VBD|which|with|in (l_prep) with_14\IN|serositis (l_pobj) serositis_15\NN|and|involvement
D012460_D015212 NONE sulfasalazine_3\NN| (r_dobj) use_2\VBP|who|sulfasalazine|treat (l_xcomp) treat_5\VB|to|patients (l_dobj) patients_6\NNS|with (l_prep) with_7\IN|disease (l_pobj) disease_10\NN|inflammatory|bowel
D012460_D015212 NONE sulfasalazine_18\NN| (r_npadvmod) induced_20\VBN|sulfasalazine|- (r_amod) syndrome_22\NN|induced|lupus (r_pobj) of_17\IN|syndrome (r_prep) signs_16\NNS|the|of (r_pobj) of_14\IN|signs (r_prep) aware_13\JJ|of (r_acomp) be_12\VB|physicians|should|aware|. (l_nsubj) Physicians_0\NNS|use (l_relcl) use_2\VBP|who|sulfasalazine|treat (l_xcomp) treat_5\VB|to|patients (l_dobj) patients_6\NNS|with (l_prep) with_7\IN|disease (l_pobj) disease_10\NN|inflammatory|bowel
6727060
D008787_D004409 CID metoclopramide_7\NN| (r_pobj) by_6\IN|metoclopramide (r_agent) caused_5\VBN|by (r_acl) dyskinesia_4\JJ|tardive|caused
D008787_D004409 CID metoclopramide_23\RB| (r_dobj) took_22\VBD|after|he|metoclopramide|for|in (r_advcl) appeared_3\VBD|movements|in|took|. (l_nsubj) movements_2\NNS|abnormal|involuntary
D008787_D004409 CID metoclopramide_2\JJ| (r_compound) administration_3\NN|the|metoclopramide (r_nsubjpass) discontinued_5\VBN|when|administration|was (r_advcl) improved_11\VBD|discontinued|,|movements|gradually|to|. (l_nsubj) movements_9\NNS|the|abnormal
D008787_D005767 NONE metoclopramide_23\RB| (r_dobj) took_22\VBD|after|he|metoclopramide|for|in (l_prep) for_24\IN|disorder (l_pobj) disorder_26\NN|gastrointestinal
2696505
D007741_D007022 CID labetalol_4\NN|and|nitroprusside (l_conj) nitroprusside_6\RB|for (l_prep) for_7\IN|hypotension (l_pobj) hypotension_9\NN|induced
D007741_D007022 CID labetalol_5\RB| (r_npadvmod) induced_7\VBN|labetalol|- (r_amod) hypotension_8\NN|induced|and|hypotension
D007741_D007022 CID labetalol_5\RB| (r_npadvmod) induced_7\VBN|labetalol|- (r_amod) hypotension_8\NN|induced|and|hypotension (l_conj) hypotension_13\NN|induced
D009599_D007022 CID nitroprusside_6\RB|for (l_prep) for_7\IN|hypotension (l_pobj) hypotension_9\NN|induced
D009599_D007022 CID nitroprusside_10\RB| (r_advmod) induced_12\VBN|nitroprusside|- (r_amod) hypotension_13\NN|induced (r_conj) hypotension_8\NN|induced|and|hypotension
D009599_D007022 CID nitroprusside_10\RB| (r_advmod) induced_12\VBN|nitroprusside|- (r_amod) hypotension_13\NN|induced
D009599_D016534 CID nitroprusside_31\NN| (r_pobj) of_30\IN|nitroprusside (r_prep) discontinuation_29\NN|of (r_pobj) after_28\IN|discontinuation (r_prep) observed_24\VBN|associated|;|hypertension|was|in|after|. (l_ccomp) associated_3\VBN|infusion|was|with|increase (l_advcl) increase_13\NN|in (l_prep) in_14\IN|rate (l_pobj) rate_16\NN|heart|and|output (l_conj) output_19\NN|cardiac
D009599_D006973 NONE nitroprusside_31\NN| (r_pobj) of_30\IN|nitroprusside (r_prep) discontinuation_29\NN|of (r_pobj) after_28\IN|discontinuation (r_prep) observed_24\VBN|associated|;|hypertension|was|in|after|. (l_nsubjpass) hypertension_22\NN|rebound
17562951
D007479_D051436 NONE iopamidol_14\NN|and|iodixanol (r_pobj) of_13\IN|iopamidol (r_prep) comparison_12\NN|a|multicenter|,|randomized|,|blind|of|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|disease (l_pobj) disease_22\NN|chronic|kidney
C044834_D051436 NONE iodixanol_16\NN| (r_conj) iopamidol_14\NN|and|iodixanol (r_pobj) of_13\IN|iopamidol (r_prep) comparison_12\NN|a|multicenter|,|randomized|,|blind|of|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|disease (l_pobj) disease_22\NN|chronic|kidney
D000111_D003920 NONE acetylcysteine_16\NN|n|- (r_pobj) of_13\IN|acetylcysteine (r_prep) use_12\NN|of (r_appos) volume_5\NN|contrast|,|presence|,|use (l_appos) presence_7\NN|of (l_prep) of_8\IN|mellitus (l_pobj) mellitus_10\NN|diabetes
D007479_D003920 NONE iopamidol_24\NN|and|%|(|patients|) (r_pobj) with_23\IN|iopamidol|with (r_prep) were_14\VBD|dl|%|with|,|increases (r_conj) increases_6\VBZ|in|,|scr|>|were|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|diabetes (l_pobj) diabetes_3\NNS|
D007479_D003920 NONE iopamidol_23\NN|or|iodixanol (r_pobj) of_22\IN|iopamidol (r_prep) administration_21\NN|the|intraarterial|of|to|, (r_pobj) after_18\IN|administration (r_prep) is_14\VBZ|rate|not|different|after|with|. (l_prep) with_32\IN|or|without (l_conj) without_34\IN|mellitus (l_pobj) mellitus_36\NN|diabetes
C044834_D003920 NONE iodixanol_35\NN|(|p=0.11|) (r_pobj) with_34\IN|iodixanol (r_prep) with_23\IN|iopamidol|with (r_prep) were_14\VBD|dl|%|with|,|increases (r_conj) increases_6\VBZ|in|,|scr|>|were|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|diabetes (l_pobj) diabetes_3\NNS|
C044834_D003920 NONE iodixanol_25\NN| (r_conj) iopamidol_23\NN|or|iodixanol (r_pobj) of_22\IN|iopamidol (r_prep) administration_21\NN|the|intraarterial|of|to|, (r_pobj) after_18\IN|administration (r_prep) is_14\VBZ|rate|not|different|after|with|. (l_prep) with_32\IN|or|without (l_conj) without_34\IN|mellitus (l_pobj) mellitus_36\NN|diabetes
D007479_D007674 CID iopamidol_23\NN|or|iodixanol (r_pobj) of_22\IN|iopamidol (r_prep) administration_21\NN|the|intraarterial|of|to|, (r_pobj) after_18\IN|administration (r_prep) is_14\VBZ|rate|not|different|after|with|. (l_nsubj) rate_1\NN|the|of|,|defined|, (l_prep) of_2\IN|nephropathy (l_pobj) nephropathy_6\NN|induced
C044834_D007674 CID iodixanol_25\NN| (r_conj) iopamidol_23\NN|or|iodixanol (r_pobj) of_22\IN|iopamidol (r_prep) administration_21\NN|the|intraarterial|of|to|, (r_pobj) after_18\IN|administration (r_prep) is_14\VBZ|rate|not|different|after|with|. (l_nsubj) rate_1\NN|the|of|,|defined|, (l_prep) of_2\IN|nephropathy (l_pobj) nephropathy_6\NN|induced
1749407
D003042_D009203 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) infarction_4\NN|induced|myocardial|:|observations|.
D003042_D009203 CID cocaine_13\NN| (r_nsubj) result_15\VB|by|cocaine|may|in (l_prep) in_16\IN|infarction (l_pobj) infarction_19\NN|acute|myocardial
D003042_D009203 CID cocaine_26\NN| (r_npadvmod) induced_28\VBN|cocaine|- (r_amod) increase_29\NN|induced|in (r_pobj) with_25\IN|increase (r_prep) associated_24\VBN|with (r_acl) demand_23\NN|myocardial|oxygen|associated (r_pobj) in_20\IN|demand (r_prep) increase_19\NN|an|in (r_pobj) from_17\IN|increase (r_prep) result_16\VB|in|,|infarction|may|from|. (l_nsubj) infarction_14\NN|acute|myocardial
D010100_D009203 NONE oxygen_22\NN| (r_compound) demand_23\NN|myocardial|oxygen|associated (r_pobj) in_20\IN|demand (r_prep) increase_19\NN|an|in (r_pobj) from_17\IN|increase (r_prep) result_16\VB|in|,|infarction|may|from|. (l_nsubj) infarction_14\NN|acute|myocardial
D003042_D013035 NONE cocaine_16\NN| (r_npadvmod) induced_18\VBN|cocaine|- (r_amod) vasoconstriction_19\NN|induced (r_pobj) of_15\IN|vasoconstriction (r_prep) locus_14\NN|the|of (r_nsubj) remains_20\VBZ|locus|speculative|. (r_conj) are_8\VBP|with|,|findings|circumstantial|,|and|remains (l_prep) With_0\IN|regard (l_pobj) regard_1\NN|to (l_prep) to_2\IN|spasm (l_pobj) spasm_3\NN|
D003042_D013927 NONE cocaine_11\NN| (r_pobj) of_10\IN|cocaine (r_prep) effect_9\NN|a|primary|,|thrombotic|of (l_amod) thrombotic_8\JJ|
8595686
D013874_D010146 NONE Thiopentone_0\NN| (r_compound) pretreatment_1\NN|thiopentone|for|. (l_prep) for_2\IN|pain (l_pobj) pain_5\NN|propofol|injection|in
D013874_D010146 NONE thiopentone_17\NN| (r_nsubj) reduces_19\VBZ|whereas|thiopentone|only|severity (r_advcl) reduces_4\VBZ|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN|the|and|severity|of (l_prep) of_9\IN|pain (l_pobj) pain_12\NN|propofol|injection|in
D015742_D010146 CID propofol_3\JJ| (r_amod) pain_5\NN|propofol|injection|in
D015742_D010146 CID propofol_3\JJ| (r_amod) pain_5\NN|propofol|injection|in
D015742_D010146 CID propofol_10\JJ| (r_amod) pain_12\NN|propofol|injection|in
D008012_D010146 NONE lidocaine_3\NN| (r_nsubj) reduces_4\VBZ|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN|the|and|severity|of (l_prep) of_9\IN|pain (l_pobj) pain_12\NN|propofol|injection|in
12198388
D000109_D012640 NONE acetylcholine_4\NN| (r_compound) release_5\NN|hippocampal|acetylcholine|and|sensitivity (l_conj) sensitivity_9\NN|cholinergic|convulsant|in (l_prep) in_10\IN|lines (l_pobj) lines_22\NNS|withdrawal|prone|resistant|selected|mouse (l_amod) prone_14\JJ|seizure|-|and|withdrawal (l_npadvmod) seizure_12\NN|
D000109_D012640 NONE acetylcholine_4\NN| (r_compound) release_5\NN|hippocampal|acetylcholine|and|sensitivity (l_conj) sensitivity_9\NN|cholinergic|convulsant|in (l_prep) in_10\IN|lines (l_pobj) lines_22\NNS|withdrawal|prone|resistant|selected|mouse (l_amod) resistant_19\JJ|seizure|- (l_npadvmod) seizure_17\NN|
D000109_D012640 NONE ACh_1\NNS|hippocampal (r_nsubjpass) measured_4\VBN|ach|also|was|during|. (l_prep) during_5\IN|testing (l_pobj) testing_6\VBG|for (l_prep) for_7\IN|convulsions (l_pobj) convulsions_11\NNS|induced
D000109_D012640 NONE ACh_2\NNS|hippocampal (r_nsubjpass) measured_4\VBN|when|ach|was|during (l_prep) during_5\IN|testing (l_pobj) testing_6\VBG|for (l_prep) for_7\IN|convulsions (l_pobj) convulsions_11\NNS|induced
D000109_D012640 NONE ACh_14\NNS|extracellular (r_nsubjpass) elevated_17\JJ|measured|,|ach|was|significantly|%|in|,|but|elevated|. (l_advcl) measured_4\VBN|when|ach|was|during (l_prep) during_5\IN|testing (l_pobj) testing_6\VBG|for (l_prep) for_7\IN|convulsions (l_pobj) convulsions_11\NNS|induced
D000431_D012640 NONE alcohol_6\NN| (r_compound) na_8\TO|alcohol|- (r_aux) ve_9\VB|na|mice (l_dobj) mice_23\NNS|prone|(|wsr|) (l_nmod) Prone_13\NNP|withdrawal|seizure|-|(|wsp|and|resistant (l_compound) Seizure_11\NN|
D000431_D012640 NONE ethanol_18\NN| (r_compound) withdrawal_19\NN|ethanol (r_compound) severity_20\NN|withdrawal (r_pobj) with_17\IN|severity (r_prep) associated_16\VBN|that|differences|may|be|with|and|implicate (l_nsubjpass) differences_4\NNS|in (l_prep) in_5\IN|activity (l_pobj) activity_7\NN|cholinergic|and|sensitivity (l_conj) sensitivity_10\NN|postsynaptic|to (l_prep) to_11\IN|convulsants (l_pobj) convulsants_13\NNS|cholinergic
D000431_D012640 NONE alcohol_26\NN| (r_compound) withdrawal_27\NN|alcohol (r_pobj) in_25\IN|withdrawal (r_prep) mechanisms_24\NNS|cholinergic|in (r_dobj) implicate_22\VB|mechanisms (r_conj) associated_16\VBN|that|differences|may|be|with|and|implicate (l_nsubjpass) differences_4\NNS|in (l_prep) in_5\IN|activity (l_pobj) activity_7\NN|cholinergic|and|sensitivity (l_conj) sensitivity_10\NN|postsynaptic|to (l_prep) to_11\IN|convulsants (l_pobj) convulsants_13\NNS|cholinergic
D009538_D014202 NONE nicotine_3\NN|,|carbachol (r_dobj) administered_2\VBN|animals|were|nicotine|,|and|recorded (l_conj) recorded_25\VBN|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS|the|onset (l_relcl) onset_19\VB|to|of (l_prep) of_20\IN|tremor (l_pobj) tremor_21\NN|and|clonus
D002217_D014202 NONE carbachol_5\NN|,|or|neostigmine (r_conj) nicotine_3\NN|,|carbachol (r_dobj) administered_2\VBN|animals|were|nicotine|,|and|recorded (l_conj) recorded_25\VBN|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS|the|onset (l_relcl) onset_19\VB|to|of (l_prep) of_20\IN|tremor (l_pobj) tremor_21\NN|and|clonus
D009388_D014202 NONE neostigmine_8\JJ|via (r_conj) carbachol_5\NN|,|or|neostigmine (r_conj) nicotine_3\NN|,|carbachol (r_dobj) administered_2\VBN|animals|were|nicotine|,|and|recorded (l_conj) recorded_25\VBN|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS|the|onset (l_relcl) onset_19\VB|to|of (l_prep) of_20\IN|tremor (l_pobj) tremor_21\NN|and|clonus
D009538_D012640 CID nicotine_7\NN|,|carbachol (r_pobj) by_6\IN|nicotine (r_agent) induced_5\VBN|by (r_acl) endpoints_4\NNS|several|convulsion|induced (l_compound) convulsion_3\NN|
D002217_D012640 CID carbachol_9\NN| (r_conj) nicotine_7\NN|,|carbachol (r_pobj) by_6\IN|nicotine (r_agent) induced_5\VBN|by (r_acl) endpoints_4\NNS|several|convulsion|induced (l_compound) convulsion_3\NN|
D009388_D012640 CID neostigmine_12\NN| (r_conj) Sensitivity_0\NN|to|,|and|neostigmine (l_prep) to_1\IN|endpoints (l_pobj) endpoints_4\NNS|several|convulsion|induced (l_compound) convulsion_3\NN|
18791946
D002939_D013921 CID ciprofloxacin_7\NNS| (r_pobj) with_6\IN|ciprofloxacin (r_prep) associated_5\VBN|with (r_acl) thrombocytopenia_1\JJ|severe|and|anaemia|associated
D002939_D013921 CID ciprofloxacin_5\NNS| (r_nsubj) precipitate_7\VB|that|ciprofloxacin|may|thrombocytopenia|,|in (l_dobj) thrombocytopenia_11\JJ|threatening|and|anaemia
D002939_D000743 CID ciprofloxacin_7\NNS| (r_pobj) with_6\IN|ciprofloxacin (r_prep) associated_5\VBN|with (r_acl) thrombocytopenia_1\JJ|severe|and|anaemia|associated (l_conj) anaemia_4\NN|haemolytic
D002939_D000743 CID ciprofloxacin_5\NNS| (r_nsubj) precipitate_7\VB|that|ciprofloxacin|may|thrombocytopenia|,|in (l_dobj) thrombocytopenia_11\JJ|threatening|and|anaemia (l_conj) anaemia_14\NN|haemolytic
D002939_D015746 CID ciprofloxacin_16\NNS|oral (r_pobj) of_14\IN|ciprofloxacin (r_prep) administration_13\NN|3-day|of|for (r_pobj) after_11\IN|administration (r_prep) reported_5\VBN|man|with|after|. (l_prep) with_6\IN|pain (l_pobj) pain_8\NN|abdominal|and|jaundice
D002939_D007565 CID ciprofloxacin_16\NNS|oral (r_pobj) of_14\IN|ciprofloxacin (r_prep) administration_13\NN|3-day|of|for (r_pobj) after_11\IN|administration (r_prep) reported_5\VBN|man|with|after|. (l_prep) with_6\IN|pain (l_pobj) pain_8\NN|abdominal|and|jaundice (l_conj) jaundice_10\NN|
D002939_D014552 NONE ciprofloxacin_16\NNS|oral (r_pobj) of_14\IN|ciprofloxacin (r_prep) administration_13\NN|3-day|of|for (l_prep) for_17\IN|suspect (l_pobj) suspect_19\NN|a|of (l_prep) of_20\IN|infection (l_pobj) infection_23\NN|urinary|tract
7890216
D015282_D042882 CID octreotide_7\NN| (r_pobj) with_6\IN|octreotide (r_prep) associated_5\VBN|with (r_acl) stones_4\NNS|gall|bladder|associated
D015282_D042882 CID Octreotide_0\NNP|,|treatment (r_nsubj) induces_8\VBZ|octreotide|,|stones|in|. (l_dobj) stones_11\NNS|gall|bladder
D015282_D042882 CID octreotide_28\NN|14 (r_pobj) in_26\IN|octreotide (r_prep) methods_25\NNS|direct|in (r_pobj) by_21\IN|methods (r_agent) investigated_20\VBN|is|,|this|was|by|treated|. (l_conj) treated_29\VBD|patients|with (l_prep) with_32\IN|stones (l_pobj) stones_34\NNS|gall
D015282_D042882 CID octreotide_3\NN| (r_advmod) induced_4\VBN|in|,|octreotide|stones|are|have (l_dobj) stones_6\NNS|gall
D015282_D042882 CID octreotide_3\NN| (r_advmod) induced_4\VBN|in|,|octreotide|stones|are|have (l_ccomp) are_7\VBP|generally|small|although|,|in|, (l_prep) in_18\IN|common (l_pobj) common_19\JJ|with (l_prep) with_20\IN|disease (l_pobj) disease_24\NN|spontaneous|gall|stone
D015282_D042882 CID octreotide_3\NN| (r_advmod) induced_4\VBN|in|,|octreotide|stones|are|have (l_conj) have_31\VB|at|patients|will|duct|. (l_dobj) duct_35\NN|a|blocked|cystic|and|stones (l_conj) stones_39\NNS|some|gall|containing
D014580_D042882 NONE acid_13\NN|ursodeoxycholic (r_pobj) to_10\IN|acid (r_prep) response_9\NN|to (r_appos) Composition_0\NN|of|:|response|. (l_prep) of_1\IN|stones (l_pobj) stones_4\NNS|gall|bladder|associated
D015282_D000172 NONE Octreotide_0\NNP|,|treatment (l_appos) treatment_4\NN|an|effective|for (l_prep) for_5\IN|acromegaly (l_pobj) acromegaly_6\NNS|
D015282_D000172 NONE octreotide_28\NN|14 (r_pobj) in_26\IN|octreotide (r_prep) methods_25\NNS|direct|in (r_pobj) by_21\IN|methods (r_agent) investigated_20\VBN|is|,|this|was|by|treated|. (l_conj) treated_29\VBD|patients|with (l_dobj) patients_31\NNS|acromegalic (l_compound) acromegalic_30\JJ|
D002784_D042882 NONE cholesterol_21\NN|%|by (r_conj) %_17\NN|71|and|cholesterol (r_dobj) contained_15\VBD|that|they|% (r_ccomp) showed_12\VBD|analysis|,|contained|. (l_nsubj) analysis_1\NN|chemical|of (l_prep) of_2\IN|stones (l_pobj) stones_4\NNS|gall|retrieved
D002784_D042882 NONE cholesterol_36\NN| (r_nsubj) rich_37\JJ|cholesterol (r_acomp) were_35\VBD|that|stones|rich (r_ccomp) suggesting_31\VBG|were (r_advcl) showed_12\VBD|after|,|five|dissolution|,|suggesting|. (l_dobj) dissolution_29\NN|either|partial|gall|stone (l_compound) stone_28\NN|
D002784_D042882 NONE cholesterol_14\NN| (r_conj) multiple_11\JJ|,|and|cholesterol|rich (r_conj) small_9\JJ|,|multiple (r_acomp) are_7\VBP|generally|small|although|,|in|, (r_ccomp) induced_4\VBN|in|,|octreotide|stones|are|have (l_dobj) stones_6\NNS|gall
D002784_D042882 NONE cholesterol_14\NN| (r_conj) multiple_11\JJ|,|and|cholesterol|rich (r_conj) small_9\JJ|,|multiple (r_acomp) are_7\VBP|generally|small|although|,|in|, (l_prep) in_18\IN|common (l_pobj) common_19\JJ|with (l_prep) with_20\IN|disease (l_pobj) disease_24\NN|spontaneous|gall|stone
D002784_D042882 NONE cholesterol_14\NN| (r_conj) multiple_11\JJ|,|and|cholesterol|rich (r_conj) small_9\JJ|,|multiple (r_acomp) are_7\VBP|generally|small|although|,|in|, (r_ccomp) induced_4\VBN|in|,|octreotide|stones|are|have (l_conj) have_31\VB|at|patients|will|duct|. (l_dobj) duct_35\NN|a|blocked|cystic|and|stones (l_conj) stones_39\NNS|some|gall|containing
D002118_D042882 NONE calcium_41\NN| (r_dobj) containing_40\VBG|calcium (r_acl) stones_39\NNS|some|gall|containing (r_conj) duct_35\NN|a|blocked|cystic|and|stones (r_dobj) have_31\VB|at|patients|will|duct|. (r_conj) induced_4\VBN|in|,|octreotide|stones|are|have (l_dobj) stones_6\NNS|gall
D002118_D042882 NONE calcium_41\NN| (r_dobj) containing_40\VBG|calcium (r_acl) stones_39\NNS|some|gall|containing (r_conj) duct_35\NN|a|blocked|cystic|and|stones (r_dobj) have_31\VB|at|patients|will|duct|. (r_conj) induced_4\VBN|in|,|octreotide|stones|are|have (l_ccomp) are_7\VBP|generally|small|although|,|in|, (l_prep) in_18\IN|common (l_pobj) common_19\JJ|with (l_prep) with_20\IN|disease (l_pobj) disease_24\NN|spontaneous|gall|stone
D002118_D042882 NONE calcium_41\NN| (r_dobj) containing_40\VBG|calcium (r_acl) stones_39\NNS|some|gall|containing
11679859
D011346_D017109 CID prochlorperazine_3\NN|by (r_pobj) of_2\IN|prochlorperazine (r_prep) administration_1\NN|intravenous|of (r_nsubj) affect_12\VB|administration|does|not|incidence|. (l_dobj) incidence_14\NN|the|of (l_prep) of_15\IN|akathisia (l_pobj) akathisia_16\NN|:|trial
D011346_D017109 CID prochlorperazine_12\NN|intravenous|as (r_pobj) of_10\IN|prochlorperazine (r_prep) administration_9\NN|of (r_pobj) after_8\IN|administration (r_prep) akathisia_7\NN|after
D011346_D017109 CID prochlorperazine_10\NN| (r_nsubjpass) administered_12\VBN|when|prochlorperazine|was|by (r_advcl) reduction_3\NN|a|%|in|administered (l_prep) in_4\IN|incidence (l_pobj) incidence_6\NN|the|of (l_prep) of_7\IN|akathisia (l_pobj) akathisia_8\NN|
D011346_D006261 NONE prochlorperazine_8\NN|for (l_prep) for_9\IN|headache (l_pobj) headache_10\NN|,|nausea
D011346_D006261 NONE prochlorperazine_3\NN| (r_pobj) of_2\IN|prochlorperazine (r_prep) efficacy_1\NN|the|of|in (l_prep) in_4\IN|treatment (l_pobj) treatment_6\NN|the|of (l_prep) of_7\IN|headache (l_pobj) headache_8\NN|and|nausea
D011346_D009325 NONE prochlorperazine_8\NN|for (l_prep) for_9\IN|headache (l_pobj) headache_10\NN|,|nausea (l_conj) nausea_12\NN|,|or|vomiting
D011346_D009325 NONE prochlorperazine_3\NN| (r_pobj) of_2\IN|prochlorperazine (r_prep) efficacy_1\NN|the|of|in (l_prep) in_4\IN|treatment (l_pobj) treatment_6\NN|the|of (l_prep) of_7\IN|headache (l_pobj) headache_8\NN|and|nausea (l_conj) nausea_10\NN|
D011346_D014839 NONE prochlorperazine_8\NN|for (l_prep) for_9\IN|headache (l_pobj) headache_10\NN|,|nausea (l_conj) nausea_12\NN|,|or|vomiting (l_conj) vomiting_15\NN|
1967484
D013469_D004421 CID Sulpiride_0\NNP| (r_npadvmod) induced_2\VBN|sulpiride|-|dystonia|. (l_dobj) dystonia_4\NN|tardive
D013469_D004421 CID sulpiride_17\NN| (r_compound) therapy_18\NN|sulpiride (r_dobj) starting_16\VBG|therapy (r_pcomp) after_15\IN|starting (r_prep) developed_8\VBD|who|dystonia|within|after (l_dobj) dystonia_11\NN|persistent|segmental
D013469_D004421 CID sulpiride_8\NN| (r_npadvmod) induced_10\VBN|sulpiride|- (r_amod) dystonia_12\NN|induced|tardive
D013469_D004409 NONE sulpiride_11\NN| (r_npadvmod) induced_13\VBN|thought|,|sulpiride|-|dyskinesia (l_dobj) dyskinesia_15\JJ|tardive|and|parkinsonism
D013469_D010302 NONE sulpiride_11\NN| (r_npadvmod) induced_13\VBN|thought|,|sulpiride|-|dyskinesia (l_dobj) dyskinesia_15\JJ|tardive|and|parkinsonism (l_conj) parkinsonism_17\NN|
12716030
D006493_D002543 NONE heparin_7\VBN| (r_nsubj) enhanced_8\VBD|in|,|heparin|volume|. (l_prep) In_0\IN|induction (l_pobj) induction_2\NN|ich|using (l_compound) ICH_1\NNP|
D006493_D002543 NONE heparin_7\VBN| (r_nsubj) enhanced_8\VBD|in|,|heparin|volume|. (l_dobj) volume_11\NN|the|hematoma|3.4-fold|over (l_prep) over_13\IN|that (l_pobj) that_14\DT|seen (l_acl) seen_15\VBN|in (l_prep) in_16\IN|control (l_pobj) control_17\NN|animals (l_dobj) animals_19\NNS|ich|and|bleeding (l_compound) ICH_18\NNP|
D006493_D006406 CID heparin_7\VBN| (r_nsubj) enhanced_8\VBD|in|,|heparin|volume|. (l_dobj) volume_11\NN|the|hematoma|3.4-fold|over (l_compound) hematoma_10\NN|
D006493_D006470 NONE heparin_7\VBN| (r_nsubj) enhanced_8\VBD|in|,|heparin|volume|. (l_dobj) volume_11\NN|the|hematoma|3.4-fold|over (l_prep) over_13\IN|that (l_pobj) that_14\DT|seen (l_acl) seen_15\VBN|in (l_prep) in_16\IN|control (l_pobj) control_17\NN|animals (l_dobj) animals_19\NNS|ich|and|bleeding (l_conj) bleeding_22\NN|the|7.6-fold
10520387
D004809_D007022 NONE ephedrine_11\NN| (r_pobj) of_10\IN|ephedrine (r_prep) doses_9\NNS|different|of (r_dobj) adding_7\VBG|doses|propofol (l_xcomp) propofol_13\NN|to|in (l_prep) in_14\IN|order (l_pobj) order_15\NN|obtund (l_acl) obtund_17\VB|to|response (l_dobj) response_20\NN|the|hypotensive (l_amod) hypotensive_19\JJ|
D004809_D007022 NONE ephedrine_3\NN| (r_pobj) of_2\IN|ephedrine (r_prep) addition_1\NN|the|of|propofol (r_nsubj) appears_6\VBZ|addition|be|. (l_xcomp) be_8\VB|to|method (l_attr) method_11\NN|an|effective|of (l_prep) of_12\IN|obtunding (l_pcomp) obtunding_13\VBG|response|propofol (l_dobj) response_16\NN|the|hypotensive (l_amod) hypotensive_15\JJ|
D015742_D007022 CID propofol_13\NN|to|in (l_prep) in_14\IN|order (l_pobj) order_15\NN|obtund (l_acl) obtund_17\VB|to|response (l_dobj) response_20\NN|the|hypotensive (l_amod) hypotensive_19\JJ|
D015742_D007022 CID propofol_5\NN|to (r_acl) addition_1\NN|the|of|propofol (r_nsubj) appears_6\VBZ|addition|be|. (l_xcomp) be_8\VB|to|method (l_attr) method_11\NN|an|effective|of (l_prep) of_12\IN|obtunding (l_pcomp) obtunding_13\VBG|response|propofol (l_dobj) response_16\NN|the|hypotensive (l_amod) hypotensive_15\JJ|
D015742_D007022 CID propofol_18\NN|to|at (r_advcl) obtunding_13\VBG|response|propofol (l_dobj) response_16\NN|the|hypotensive (l_amod) hypotensive_15\JJ|
D004809_D013610 CID ephedrine_9\NN| (r_pobj) of_8\IN|ephedrine (r_prep) use_7\NN|the|of|in (r_pobj) with_5\IN|use (r_prep) associated_4\VBN|with (r_acl) tachycardia_3\NNS|marked|associated
D004809_D013610 CID ephedrine_24\NN| (r_nmod) mixtures_28\NNS|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN|mixtures (r_prep) any_21\DT|of (r_pobj) of_20\IN|any (r_prep) patients_19\NNS|elderly|of (r_pobj) in_17\IN|patients (r_prep) use_16\NN|the|in|studied (r_dobj) recommend_14\VB|due|,|we|would|not|use|. (l_prep) Due_0\IN|to|risk (l_pobj) risk_3\NN|the|of (l_prep) of_4\IN|tachycardia (l_pobj) tachycardia_6\NN|this|inducing
D015742_D013610 CID propofol_13\NN| (r_pobj) with_12\IN|propofol (r_prep) combination_11\NN|with (r_pobj) in_10\IN|combination (r_prep) use_7\NN|the|of|in (r_pobj) with_5\IN|use (r_prep) associated_4\VBN|with (r_acl) tachycardia_3\NNS|marked|associated
D015742_D013610 CID propofol_26\NN| (r_nmod) mixtures_28\NNS|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN|mixtures (r_prep) any_21\DT|of (r_pobj) of_20\IN|any (r_prep) patients_19\NNS|elderly|of (r_pobj) in_17\IN|patients (r_prep) use_16\NN|the|in|studied (r_dobj) recommend_14\VB|due|,|we|would|not|use|. (l_prep) Due_0\IN|to|risk (l_pobj) risk_3\NN|the|of (l_prep) of_4\IN|tachycardia (l_pobj) tachycardia_6\NN|this|inducing
D004809_D017202 NONE ephedrine_24\NN| (r_nmod) mixtures_28\NNS|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN|mixtures (r_prep) any_21\DT|of (r_pobj) of_20\IN|any (r_prep) patients_19\NNS|elderly|of (r_pobj) in_17\IN|patients (r_prep) use_16\NN|the|in|studied (r_dobj) recommend_14\VB|due|,|we|would|not|use|. (l_prep) Due_0\IN|to|risk (l_pobj) risk_3\NN|the|of (l_prep) of_4\IN|tachycardia (l_pobj) tachycardia_6\NN|this|inducing (l_acl) inducing_7\VBG|ischemia (l_dobj) ischemia_9\NN|myocardial
D015742_D017202 NONE propofol_26\NN| (r_nmod) mixtures_28\NNS|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN|mixtures (r_prep) any_21\DT|of (r_pobj) of_20\IN|any (r_prep) patients_19\NNS|elderly|of (r_pobj) in_17\IN|patients (r_prep) use_16\NN|the|in|studied (r_dobj) recommend_14\VB|due|,|we|would|not|use|. (l_prep) Due_0\IN|to|risk (l_pobj) risk_3\NN|the|of (l_prep) of_4\IN|tachycardia (l_pobj) tachycardia_6\NN|this|inducing (l_acl) inducing_7\VBG|ischemia (l_dobj) ischemia_9\NN|myocardial
19058010
D010936_D009203 NONE tea_3\NN|green|and|e (r_nmod) combination_7\NN|tea|in (r_pobj) of_1\IN|combination (r_prep) Effect_0\NN|of (r_nsubj) induced_10\VBN|effect|infarction|. (l_dobj) infarction_12\NN|myocardial|in
D010936_D009203 NONE tea_12\NN|green|and|e (r_pobj) of_10\IN|tea (r_prep) effects_9\NNS|the|combined|of|on|,|weight|bound (r_dobj) investigate_6\VB|to|effects (r_xcomp) aimed_4\VBN|study|was|investigate|iso)-induced|. (l_parataxis) ISO)-induced_39\VBN|(|infarction (l_dobj) infarction_41\NN|myocardial|in
D010936_D009203 NONE tea_9\NN|green|and|e (r_pobj) of_7\IN|tea (r_prep) effect_6\NN|the|synergistic|protective|of|during (r_dobj) indicate_2\VBP|findings|effect|induced|. (l_ccomp) induced_15\VBN|infarction (l_dobj) infarction_17\NN|myocardial|in
D014810_D009203 NONE E_6\NN|vitamin (r_conj) tea_3\NN|green|and|e (r_nmod) combination_7\NN|tea|in (r_pobj) of_1\IN|combination (r_prep) Effect_0\NN|of (r_nsubj) induced_10\VBN|effect|infarction|. (l_dobj) infarction_12\NN|myocardial|in
D014810_D009203 NONE E_15\NN|vitamin (r_conj) tea_12\NN|green|and|e (r_pobj) of_10\IN|tea (r_prep) effects_9\NNS|the|combined|of|on|,|weight|bound (r_dobj) investigate_6\VB|to|effects (r_xcomp) aimed_4\VBN|study|was|investigate|iso)-induced|. (l_parataxis) ISO)-induced_39\VBN|(|infarction (l_dobj) infarction_41\NN|myocardial|in
D014810_D009203 NONE E_12\NN|vitamin (r_conj) tea_9\NN|green|and|e (r_pobj) of_7\IN|tea (r_prep) effect_6\NN|the|synergistic|protective|of|during (r_dobj) indicate_2\VBP|findings|effect|induced|. (l_ccomp) induced_15\VBN|infarction (l_dobj) infarction_17\NN|myocardial|in
D007545_D009203 CID isoproterenol_9\JJ| (r_pobj) in_8\IN|isoproterenol (r_prep) combination_7\NN|tea|in (r_pobj) of_1\IN|combination (r_prep) Effect_0\NN|of (r_nsubj) induced_10\VBN|effect|infarction|. (l_dobj) infarction_12\NN|myocardial|in
D007545_D009203 CID isoproterenol_37\NN| (r_pobj) in_36\IN|isoproterenol (r_prep) bound_34\VBN|atpases|in (r_acl) effects_9\NNS|the|combined|of|on|,|weight|bound (r_dobj) investigate_6\VB|to|effects (r_xcomp) aimed_4\VBN|study|was|investigate|iso)-induced|. (l_parataxis) ISO)-induced_39\VBN|(|infarction (l_dobj) infarction_41\NN|myocardial|in
D007545_D009203 CID ISO)-induced_39\VBN|(|infarction (l_dobj) infarction_41\NN|myocardial|in
D007545_D009203 CID ISO_14\NN| (r_pobj) during_13\IN|iso (r_prep) effect_6\NN|the|synergistic|protective|of|during (r_dobj) indicate_2\VBP|findings|effect|induced|. (l_ccomp) induced_15\VBN|infarction (l_dobj) infarction_17\NN|myocardial|in
6203452
D002945_D002277 NONE cisplatin_24\NN| (r_pobj) with_23\IN|cisplatin (r_prep) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_nsubj) patients_1\NNS|five|with (l_prep) with_2\IN|carcinoma (l_pobj) carcinoma_3\NN|
D002945_D057049 NONE cisplatin_24\NN| (r_pobj) with_23\IN|cisplatin (r_prep) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized
D002945_D051437 NONE cisplatin_24\NN| (r_pobj) with_23\IN|cisplatin (r_prep) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized (l_acl) characterized_8\VBN|(|by|,|anemia|) (l_agent) by_9\IN|insufficiency (l_pobj) insufficiency_11\NN|renal
D002945_D051437 NONE cisplatin_30\VB| (r_amod) nephrotoxicity_31\NN|cisplatin|and|anemia|and|thrombocytopenia (r_pobj) to_29\IN|nephrotoxicity (r_prep) ascribed_28\VBN|because|failure|may|be|to (l_nsubjpass) failure_25\NN|renal
D002945_D000743 NONE cisplatin_24\NN| (r_pobj) with_23\IN|cisplatin (r_prep) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized (l_acl) characterized_8\VBN|(|by|,|anemia|) (l_conj) anemia_15\NN|microangiopathic|hemolytic|,|and|thrombocytopenia
D002945_D013921 NONE cisplatin_24\NN| (r_pobj) with_23\IN|cisplatin (r_prep) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized (l_acl) characterized_8\VBN|(|by|,|anemia|) (l_conj) anemia_15\NN|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\JJ|usually
D002945_D013921 NONE cisplatin_30\VB| (r_amod) nephrotoxicity_31\NN|cisplatin|and|anemia|and|thrombocytopenia (l_conj) thrombocytopenia_36\NN|to
D001761_D002277 NONE bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_nsubj) patients_1\NNS|five|with (l_prep) with_2\IN|carcinoma (l_pobj) carcinoma_3\NN|
D001761_D057049 NONE bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized
D001761_D051437 NONE bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized (l_acl) characterized_8\VBN|(|by|,|anemia|) (l_agent) by_9\IN|insufficiency (l_pobj) insufficiency_11\NN|renal
D001761_D000743 NONE bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized (l_acl) characterized_8\VBN|(|by|,|anemia|) (l_conj) anemia_15\NN|microangiopathic|hemolytic|,|and|thrombocytopenia
D001761_D013921 NONE bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized (l_acl) characterized_8\VBN|(|by|,|anemia|) (l_conj) anemia_15\NN|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\JJ|usually
D014748_D002277 NONE alkaloid_31\NN| (r_amod) vinca_30\JJ|a|alkaloid (r_conj) bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_nsubj) patients_1\NNS|five|with (l_prep) with_2\IN|carcinoma (l_pobj) carcinoma_3\NN|
D014748_D057049 NONE alkaloid_31\NN| (r_amod) vinca_30\JJ|a|alkaloid (r_conj) bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized
D014748_D051437 NONE alkaloid_31\NN| (r_amod) vinca_30\JJ|a|alkaloid (r_conj) bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized (l_acl) characterized_8\VBN|(|by|,|anemia|) (l_agent) by_9\IN|insufficiency (l_pobj) insufficiency_11\NN|renal
D014748_D000743 NONE alkaloid_31\NN| (r_amod) vinca_30\JJ|a|alkaloid (r_conj) bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized (l_acl) characterized_8\VBN|(|by|,|anemia|) (l_conj) anemia_15\NN|microangiopathic|hemolytic|,|and|thrombocytopenia
D014748_D013921 NONE alkaloid_31\NN| (r_amod) vinca_30\JJ|a|alkaloid (r_conj) bleomycin_26\NNS|,|and|vinca (r_conj) treatment_22\NN|with|,|bleomycin (r_pobj) after_21\IN|treatment (r_prep) developed_4\VBD|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN|thrombotic|characterized (l_acl) characterized_8\VBN|(|by|,|anemia|) (l_conj) anemia_15\NN|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\JJ|usually
D002945_D007674 CID cisplatin_30\VB| (r_amod) nephrotoxicity_31\NN|cisplatin|and|anemia|and|thrombocytopenia
D002945_D000740 NONE cisplatin_30\VB| (r_amod) nephrotoxicity_31\NN|cisplatin|and|anemia|and|thrombocytopenia (l_conj) anemia_34\NN|the
D002945_D001855 NONE cisplatin_30\VB| (r_amod) nephrotoxicity_31\NN|cisplatin|and|anemia|and|thrombocytopenia (l_conj) thrombocytopenia_36\NN|to (l_prep) to_37\IN|suppression (l_pobj) suppression_43\NN|induced|marrow
12684739
D020888_D019966 NONE GVG_35\NNP|chronic|dose|on (r_pobj) of_29\IN|gvg (r_prep) effects_28\NNS|the|of (r_dobj) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk
D020888_D005128 CID GVG_35\NNP|chronic|dose|on (r_pobj) of_29\IN|gvg (r_prep) effects_28\NNS|the|of (r_dobj) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk (l_conj) risk_11\NN|the|increased|of (l_prep) of_12\IN|defects (l_pobj) defects_15\NNS|visual|field|vfd|associated
D020888_D005128 CID GVG_35\NNP|chronic|dose|on (r_pobj) of_29\IN|gvg (r_prep) effects_28\NNS|the|of (r_dobj) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk (l_conj) risk_11\NN|the|increased|of (l_prep) of_12\IN|defects (l_pobj) defects_15\NNS|visual|field|vfd|associated (l_appos) VFD_17\NNP|(|)
D003042_D019966 NONE cocaine_37\NN| (r_npadvmod) induced_39\VBN|cocaine|- (r_amod) increases_40\NNS|induced|in (r_pobj) on_36\IN|increases (r_prep) GVG_35\NNP|chronic|dose|on (r_pobj) of_29\IN|gvg (r_prep) effects_28\NNS|the|of (r_dobj) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk
D003042_D005128 NONE cocaine_37\NN| (r_npadvmod) induced_39\VBN|cocaine|- (r_amod) increases_40\NNS|induced|in (r_pobj) on_36\IN|increases (r_prep) GVG_35\NNP|chronic|dose|on (r_pobj) of_29\IN|gvg (r_prep) effects_28\NNS|the|of (r_dobj) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk (l_conj) risk_11\NN|the|increased|of (l_prep) of_12\IN|defects (l_pobj) defects_15\NNS|visual|field|vfd|associated
D003042_D005128 NONE cocaine_37\NN| (r_npadvmod) induced_39\VBN|cocaine|- (r_amod) increases_40\NNS|induced|in (r_pobj) on_36\IN|increases (r_prep) GVG_35\NNP|chronic|dose|on (r_pobj) of_29\IN|gvg (r_prep) effects_28\NNS|the|of (r_dobj) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk (l_conj) risk_11\NN|the|increased|of (l_prep) of_12\IN|defects (l_pobj) defects_15\NNS|visual|field|vfd|associated (l_appos) VFD_17\NNP|(|)
D004298_D019966 NONE dopamine_47\NN|nacc|)|(|da|) (r_appos) accumbens_43\NNS|(|dopamine (r_oprd) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk
D004298_D019966 NONE DA_49\NNP| (r_appos) dopamine_47\NN|nacc|)|(|da|) (r_appos) accumbens_43\NNS|(|dopamine (r_oprd) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk
D004298_D005128 NONE dopamine_47\NN|nacc|)|(|da|) (r_appos) accumbens_43\NNS|(|dopamine (r_oprd) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk (l_conj) risk_11\NN|the|increased|of (l_prep) of_12\IN|defects (l_pobj) defects_15\NNS|visual|field|vfd|associated
D004298_D005128 NONE dopamine_47\NN|nacc|)|(|da|) (r_appos) accumbens_43\NNS|(|dopamine (r_oprd) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk (l_conj) risk_11\NN|the|increased|of (l_prep) of_12\IN|defects (l_pobj) defects_15\NNS|visual|field|vfd|associated (l_appos) VFD_17\NNP|(|)
D004298_D005128 NONE DA_49\NNP| (r_appos) dopamine_47\NN|nacc|)|(|da|) (r_appos) accumbens_43\NNS|(|dopamine (r_oprd) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk (l_conj) risk_11\NN|the|increased|of (l_prep) of_12\IN|defects (l_pobj) defects_15\NNS|visual|field|vfd|associated
D004298_D005128 NONE DA_49\NNP| (r_appos) dopamine_47\NN|nacc|)|(|da|) (r_appos) accumbens_43\NNS|(|dopamine (r_oprd) explored_26\VBD|given|,|we|effects|accumbens|. (l_prep) Given_0\VBN|success (l_pobj) success_3\NN|its|preclinical|for (l_prep) for_4\IN|treating (l_pcomp) treating_5\VBG|abuse (l_dobj) abuse_7\NN|substance|and|risk (l_conj) risk_11\NN|the|increased|of (l_prep) of_12\IN|defects (l_pobj) defects_15\NNS|visual|field|vfd|associated (l_appos) VFD_17\NNP|(|)
19889778
9727773
D001067_D006976 CID suppressants_9\NNS|appetite|in (r_pobj) with_7\IN|suppressants (r_prep) associated_6\VBN|with (r_acl) incidence_1\NN|high|of|associated|. (l_prep) of_2\IN|hypertension (l_pobj) hypertension_5\NN|primary|pulmonary
D001067_D006976 CID suppressant_21\NN|appetite (r_compound) drugs_22\NNS|suppressant (r_pobj) of_19\IN|drugs (r_prep) intake_18\NN|the|of (r_pobj) with_16\IN|intake (r_prep) associated_15\VBN|which|has|been|with (r_relcl) disease_10\NN|a|rare|,|associated (r_attr) is_3\VBZ|hypertension|disease|. (l_nsubj) hypertension_2\NN|primary|pulmonary
D001067_D006976 CID suppressants_18\NNS|appetite (r_dobj) taken_16\VBN|was|,|5|had|suppressants|. (l_ccomp) was_9\VBD|in|diagnosis|uncertain (l_nsubj) diagnosis_4\NN|the|of (l_prep) of_5\IN|hypertension (l_pobj) hypertension_8\NN|primary|pulmonary
D001067_D006976 CID suppressants_7\NNS|appetite (r_pobj) of_5\IN|suppressants (r_prep) prescription_4\NN|unrestricted|of (r_pobj) of_2\IN|prescription (r_prep) policy_1\NN|a|of (r_nsubj) lead_9\VB|policy|may|to|. (l_prep) to_10\IN|incidence (l_pobj) incidence_13\NN|a|high|of (l_prep) of_14\IN|hypertension (l_pobj) hypertension_18\NN|associated|primary|pulmonary
14513889
D007654_D009422 NONE Ketoconazole_0\NNP| (r_npadvmod) induced_2\VBN|ketoconazole|-|sequelae|. (l_dobj) sequelae_4\NNS|neurologic
983936
D001241_D009202 NONE acid_3\NN|acetylsalicylic|,|dipyridamole (l_conj) dipyridamole_5\NN|,|and|hydrocortisone (l_conj) hydrocortisone_8\NN|on (l_prep) on_9\IN|injury (l_pobj) injury_14\NN|induced|myocardial|in
D004176_D009202 NONE dipyridamole_5\NN|,|and|hydrocortisone (l_conj) hydrocortisone_8\NN|on (l_prep) on_9\IN|injury (l_pobj) injury_14\NN|induced|myocardial|in
D006854_D009202 NONE hydrocortisone_8\NN|on (l_prep) on_9\IN|injury (l_pobj) injury_14\NN|induced|myocardial|in
D004837_D009202 CID epinephrine_10\NN| (r_npadvmod) induced_12\VBN|epinephrine|- (r_amod) injury_14\NN|induced|myocardial|in
D004837_D009202 CID epinephrine_9\NN| (r_amod) infusion_10\NN|(|epinephrine (r_appos) injury_7\NN|diffuse|myocardial|infusion
D004837_D009203 NONE epinephrine_9\NN| (r_amod) infusion_10\NN|(|epinephrine (r_appos) injury_7\NN|diffuse|myocardial|infusion (r_dobj) producing_4\VBG|injury (r_pcomp) for_3\IN|producing (r_prep) model_2\NN|a|reproducible|for|) (r_nsubjpass) developed_14\VBN|model|has|been|study|. (l_advcl) study_16\VB|to|effects (l_dobj) effects_19\NNS|the|cardioprotective|of (l_prep) of_20\IN|agents (l_pobj) agents_21\NNS|or|maneuvers|alter (l_relcl) alter_26\VB|which|might|evolution (l_dobj) evolution_28\NN|the|of (l_prep) of_29\IN|infarction (l_pobj) infarction_32\NN|acute|myocardial
18182964
D003000_D001289 NONE Clonidine_0\NNP|for|ii (l_prep) for_1\IN|disorder (l_pobj) disorder_7\NN|hyperactivity
D003000_D001289 NONE clonidine_7\NN| (r_pobj) of_6\IN|clonidine (r_prep) safety_3\NN|the|and|tolerability|of (r_dobj) examine_1\VB|to|safety (r_csubj) used_8\VBN|examine|alone|or|with (l_conj) with_11\IN|methylphenidate (l_pobj) methylphenidate_12\NN|in|with (l_prep) with_15\IN|disorder (l_pobj) disorder_21\NN|hyperactivity|(|adhd|)
D003000_D001289 NONE clonidine_7\NN| (r_pobj) of_6\IN|clonidine (r_prep) safety_3\NN|the|and|tolerability|of (r_dobj) examine_1\VB|to|safety (r_csubj) used_8\VBN|examine|alone|or|with (l_conj) with_11\IN|methylphenidate (l_pobj) methylphenidate_12\NN|in|with (l_prep) with_15\IN|disorder (l_pobj) disorder_21\NN|hyperactivity|(|adhd|) (l_appos) ADHD_23\NNP|
D003000_D001289 NONE clonidine_18\NN|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS|122|with (l_prep) with_12\IN|adhd (l_pobj) ADHD_13\NNP|
D003000_D001289 NONE clonidine_32\NN|and|methylphenidate (r_conj) methylphenidate_25\NN|(|n|29|)|,|clonidine|(|n|32|,|or|placebo (r_conj) clonidine_18\NN|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS|122|with (l_prep) with_12\IN|adhd (l_pobj) ADHD_13\NNP|
D003000_D001289 NONE Clonidine_0\NNP|,|used|, (r_nsubj) appears_8\VBZ|clonidine|safe|and|tolerated|. (l_conj) tolerated_12\VBN|well|in (l_prep) in_13\IN|adhd (l_pobj) ADHD_15\NNP|childhood
D008774_D001289 NONE methylphenidate_12\NN|in|with (l_prep) with_15\IN|disorder (l_pobj) disorder_21\NN|hyperactivity|(|adhd|)
D008774_D001289 NONE methylphenidate_12\NN|in|with (l_prep) with_15\IN|disorder (l_pobj) disorder_21\NN|hyperactivity|(|adhd|) (l_appos) ADHD_23\NNP|
D008774_D001289 NONE methylphenidate_25\NN|(|n|29|)|,|clonidine|(|n|32|,|or|placebo (r_conj) clonidine_18\NN|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS|122|with (l_prep) with_12\IN|adhd (l_pobj) ADHD_13\NNP|
D008774_D001289 NONE methylphenidate_34\NN| (r_conj) clonidine_32\NN|and|methylphenidate (r_conj) methylphenidate_25\NN|(|n|29|)|,|clonidine|(|n|32|,|or|placebo (r_conj) clonidine_18\NN|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS|122|with (l_prep) with_12\IN|adhd (l_pobj) ADHD_13\NNP|
D008774_D001289 NONE methylphenidate_6\NN| (r_pobj) with_5\IN|methylphenidate (r_conj) used_2\VBN|alone|or|with (r_acl) Clonidine_0\NNP|,|used|, (r_nsubj) appears_8\VBZ|clonidine|safe|and|tolerated|. (l_conj) tolerated_12\VBN|well|in (l_prep) in_13\IN|adhd (l_pobj) ADHD_15\NNP|childhood
D003000_D001919 CID clonidine_10\NN| (r_pobj) with_9\IN|clonidine (r_prep) treated_8\VBN|with|compared (r_acl) subjects_7\NNS|treated (r_pobj) in_6\IN|subjects (r_prep) incidents_3\NNS|more|of|in (l_prep) of_4\IN|bradycardia (l_pobj) bradycardia_5\NN|
D003000_D001919 CID clonidine_17\NN| (r_pobj) with_16\IN|clonidine (r_prep) treated_15\VBN|not|with (r_acl) those_13\DT|treated|%|but|differences (r_pobj) with_12\IN|those (r_prep) compared_11\VBN|with (r_prep) treated_8\VBN|with|compared (r_acl) subjects_7\NNS|treated (r_pobj) in_6\IN|subjects (r_prep) incidents_3\NNS|more|of|in (l_prep) of_4\IN|bradycardia (l_pobj) bradycardia_5\NN|
D003000_D001919 CID clonidine_2\NN| (r_dobj) prescribing_1\VBG|clonidine (r_acl) Physicians_0\NNS|prescribing (r_nsubj) monitor_4\VB|physicians|should|for|and|advise|. (l_prep) for_5\IN|bradycardia (l_pobj) bradycardia_6\NN|
D003000_D006970 NONE clonidine_4\NN| (r_pobj) on_3\IN|clonidine (r_prep) was_1\VBD|drowsiness|common|on|,|but|resolved|. (l_nsubj) Drowsiness_0\NN|
D003000_D006970 NONE clonidine_2\NN| (r_dobj) prescribing_1\VBG|clonidine (r_acl) Physicians_0\NNS|prescribing (r_nsubj) monitor_4\VB|physicians|should|for|and|advise|. (l_conj) advise_8\VB|patients (l_dobj) patients_9\NNS|about (l_prep) about_10\IN|likelihood (l_pobj) likelihood_13\NN|the|high|of (l_prep) of_14\IN|drowsiness (l_pobj) drowsiness_16\NN|initial
2950248
D004176_D017202 NONE Dipyridamole_0\NNP| (r_npadvmod) induced_2\VBN|dipyridamole|- (r_amod) ischemia_4\NN|induced|myocardial|.
D004176_D017202 NONE dipyridamole_16\NN| (r_compound) therapy_17\NN|preoperative|dipyridamole (r_pobj) of_14\IN|therapy (r_prep) effect_13\NN|a|side|of (r_pobj) as_10\IN|effect (r_prep) reported_9\VBN|to|,|this|has|not|previously|been|as|,|demonstrated|. (l_advcl) demonstrated_27\VBN|although|ischemia|has|been|occur (l_nsubjpass) ischemia_24\NN|induced|myocardial
D004176_D017202 NONE dipyridamole_20\NN| (r_dep) induced_22\VBN|dipyridamole|- (r_amod) ischemia_24\NN|induced|myocardial
D004176_D000787 CID dipyridamole_10\NN|oral (r_pobj) of_8\IN|dipyridamole (r_prep) administration_7\NN|of (r_pobj) after_6\IN|administration (r_prep) occurred_5\VBD|angina|after|in|. (l_nsubj) Angina_0\NNP|and|changes
D004176_D003324 NONE dipyridamole_16\NN| (r_compound) therapy_17\NN|preoperative|dipyridamole (r_pobj) of_14\IN|therapy (r_prep) effect_13\NN|a|side|of (r_pobj) as_10\IN|effect (r_prep) reported_9\VBN|to|,|this|has|not|previously|been|as|,|demonstrated|. (l_advcl) demonstrated_27\VBN|although|ischemia|has|been|occur (l_xcomp) occur_29\VB|to|in|with (l_prep) with_34\IN|disease (l_pobj) disease_37\NN|coronary|artery
D004176_D003324 NONE dipyridamole_20\NN| (r_dep) induced_22\VBN|dipyridamole|- (r_amod) ischemia_24\NN|induced|myocardial (r_nsubjpass) demonstrated_27\VBN|although|ischemia|has|been|occur (l_xcomp) occur_29\VB|to|in|with (l_prep) with_34\IN|disease (l_pobj) disease_37\NN|coronary|artery
D004176_D007511 NONE dipyridamole_23\NN| (r_npadvmod) induced_25\VBN|dipyridamole|- (r_amod) ischemia_26\NN|the|induced
3828020
D010665_D002544 CID phenylpropanolamine_8\NN| (r_pobj) of_7\IN|phenylpropanolamine (r_prep) dose_6\NN|a|single|oral|of (r_pobj) with_2\IN|dose (r_prep) infarction_1\NN|cerebral|with|.
D010665_D002544 CID PPA_20\NNP| (r_pobj) of_19\IN|ppa (r_prep) dose_18\NN|a|single|oral|of (r_dobj) taking_14\VBG|dose (r_pcomp) after_13\IN|taking (r_prep) suffered_9\VBD|who|infarction|after (l_dobj) infarction_12\NN|a|cerebral
15325671
D003520_D066126 NONE cyclophosphamide_9\NN| (r_npadvmod) based_11\VBN|cyclophosphamide|- (r_amod) chemotherapy_12\NN|dose|based|for (r_pobj) with_5\IN|chemotherapy (r_prep) association_4\NN|with (r_pobj) in_3\IN|association (r_prep) observed_2\VBD|toxicity|in|. (l_nsubj) toxicity_1\NN|cardiac
D003520_D066126 NONE cyclophosphamide_3\NN| (r_npadvmod) related_5\VBN|cyclophosphamide|- (r_amod) toxicity_7\NN|transient|related|cardiac|(|%|)
D003520_D001943 NONE cyclophosphamide_9\NN| (r_npadvmod) based_11\VBN|cyclophosphamide|- (r_amod) chemotherapy_12\NN|dose|based|for (l_prep) for_13\IN|cancer (l_pobj) cancer_16\NN|metastatic|breast
D003520_D001943 NONE cyclophosphamide_9\NN|dose|,|thiotepa (l_conj) thiotepa_11\NNS|,|and|carboplatin (l_conj) carboplatin_14\VB|in|regimen (l_dobj) regimen_22\NN|a|triple|sequential|dose|for (l_prep) for_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|cancer (l_pobj) cancer_28\NN|metastatic|breast
D003520_D001943 NONE cyclophosphamide_16\NN|96-h|infusional (r_dobj) receiving_13\VBG|cyclophosphamide|as (r_acl) cancer_12\NN|responsive|metastatic|breast|receiving|and|characteristics
D017239_D001943 NONE paclitaxel_2\NN|combined|,|melphalan (l_conj) melphalan_4\NN|and|cyclophosphamide (l_conj) cyclophosphamide_9\NN|dose|,|thiotepa (l_conj) thiotepa_11\NNS|,|and|carboplatin (l_conj) carboplatin_14\VB|in|regimen (l_dobj) regimen_22\NN|a|triple|sequential|dose|for (l_prep) for_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|cancer (l_pobj) cancer_28\NN|metastatic|breast
D008558_D001943 NONE melphalan_4\NN|and|cyclophosphamide (l_conj) cyclophosphamide_9\NN|dose|,|thiotepa (l_conj) thiotepa_11\NNS|,|and|carboplatin (l_conj) carboplatin_14\VB|in|regimen (l_dobj) regimen_22\NN|a|triple|sequential|dose|for (l_prep) for_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|cancer (l_pobj) cancer_28\NN|metastatic|breast
D013852_D001943 NONE thiotepa_11\NNS|,|and|carboplatin (l_conj) carboplatin_14\VB|in|regimen (l_dobj) regimen_22\NN|a|triple|sequential|dose|for (l_prep) for_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|cancer (l_pobj) cancer_28\NN|metastatic|breast
D016190_D001943 NONE carboplatin_14\VB|in|regimen (l_dobj) regimen_22\NN|a|triple|sequential|dose|for (l_prep) for_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|cancer (l_pobj) cancer_28\NN|metastatic|breast
D003520_D006333 CID cyclophosphamide_16\NN|96-h|infusional (r_dobj) receiving_13\VBG|cyclophosphamide|as (l_prep) as_17\IN|part (l_pobj) part_18\NN|of (l_prep) of_19\IN|regimen (l_pobj) regimen_26\NN|a|triple|sequential|dose|assess (l_acl) assess_28\VB|to|association (l_dobj) association_29\NN|between (l_prep) between_30\IN|presence (l_pobj) presence_31\NN|of (l_prep) of_32\IN|failure (l_pobj) failure_36\NN|peritransplant|heart|chf
D003520_D006333 CID cyclophosphamide_16\NN|96-h|infusional (r_dobj) receiving_13\VBG|cyclophosphamide|as (l_prep) as_17\IN|part (l_pobj) part_18\NN|of (l_prep) of_19\IN|regimen (l_pobj) regimen_26\NN|a|triple|sequential|dose|assess (l_acl) assess_28\VB|to|association (l_dobj) association_29\NN|between (l_prep) between_30\IN|presence (l_pobj) presence_31\NN|of (l_prep) of_32\IN|failure (l_pobj) failure_36\NN|peritransplant|heart|chf (l_appos) CHF_38\NNP|(|)
D003520_D006333 CID cyclophosphamide_16\NN|infusional (r_dobj) following_14\VBG|cyclophosphamide|with (r_prep) developed_8\VBD|six|grade|following|. (l_dobj) grade_11\NN|reversible|chf (l_appos) CHF_13\NNP|3
D003520_D006333 CID cyclophosphamide_5\NN|infusional (r_pobj) during_3\IN|cyclophosphamide (r_prep) monitoring_2\NN|ekg|during (r_nsubj) predict_8\VB|monitoring|did|not|development|. (l_dobj) development_10\NN|chf (l_compound) CHF_9\NNP|
D003520_D006973 NONE cyclophosphamide_16\NN|96-h|infusional (r_dobj) receiving_13\VBG|cyclophosphamide|as (r_acl) cancer_12\NN|responsive|metastatic|breast|receiving|and|characteristics (l_conj) characteristics_44\NNS|the|following|pretreatment|:|presence (l_appos) presence_46\NN|of|,|history (l_prep) of_47\IN|electrocardiogram (l_pobj) electrocardiogram_48\NN|(|ekg|abnormalities (l_appos) abnormalities_52\NNS|,|age|hypertension (l_appos) hypertension_56\NN|
D003520_D003920 NONE cyclophosphamide_16\NN|96-h|infusional (r_dobj) receiving_13\VBG|cyclophosphamide|as (r_acl) cancer_12\NN|responsive|metastatic|breast|receiving|and|characteristics (l_conj) characteristics_44\NNS|the|following|pretreatment|:|presence (l_appos) presence_46\NN|of|,|history (l_appos) history_60\NN|prior|cardiac|,|smoking (l_conj) smoking_62\NN|,|mellitus (l_conj) mellitus_65\NN|diabetes|,|use
D018943_D001943 NONE anthracyclines_70\NNS| (r_pobj) of_69\IN|anthracyclines (r_prep) use_68\NN|prior|of|,|and|irradiation (r_conj) mellitus_65\NN|diabetes|,|use (r_conj) smoking_62\NN|,|mellitus (r_conj) history_60\NN|prior|cardiac|,|smoking (r_appos) presence_46\NN|of|,|history (r_appos) characteristics_44\NNS|the|following|pretreatment|:|presence (r_conj) cancer_12\NN|responsive|metastatic|breast|receiving|and|characteristics
D018943_D006333 NONE anthracyclines_70\NNS| (r_pobj) of_69\IN|anthracyclines (r_prep) use_68\NN|prior|of|,|and|irradiation (r_conj) mellitus_65\NN|diabetes|,|use (r_conj) smoking_62\NN|,|mellitus (r_conj) history_60\NN|prior|cardiac|,|smoking (r_appos) presence_46\NN|of|,|history (r_appos) characteristics_44\NNS|the|following|pretreatment|:|presence (r_conj) cancer_12\NN|responsive|metastatic|breast|receiving|and|characteristics (l_acl) receiving_13\VBG|cyclophosphamide|as (l_prep) as_17\IN|part (l_pobj) part_18\NN|of (l_prep) of_19\IN|regimen (l_pobj) regimen_26\NN|a|triple|sequential|dose|assess (l_acl) assess_28\VB|to|association (l_dobj) association_29\NN|between (l_prep) between_30\IN|presence (l_pobj) presence_31\NN|of (l_prep) of_32\IN|failure (l_pobj) failure_36\NN|peritransplant|heart|chf
D018943_D006333 NONE anthracyclines_70\NNS| (r_pobj) of_69\IN|anthracyclines (r_prep) use_68\NN|prior|of|,|and|irradiation (r_conj) mellitus_65\NN|diabetes|,|use (r_conj) smoking_62\NN|,|mellitus (r_conj) history_60\NN|prior|cardiac|,|smoking (r_appos) presence_46\NN|of|,|history (r_appos) characteristics_44\NNS|the|following|pretreatment|:|presence (r_conj) cancer_12\NN|responsive|metastatic|breast|receiving|and|characteristics (l_acl) receiving_13\VBG|cyclophosphamide|as (l_prep) as_17\IN|part (l_pobj) part_18\NN|of (l_prep) of_19\IN|regimen (l_pobj) regimen_26\NN|a|triple|sequential|dose|assess (l_acl) assess_28\VB|to|association (l_dobj) association_29\NN|between (l_prep) between_30\IN|presence (l_pobj) presence_31\NN|of (l_prep) of_32\IN|failure (l_pobj) failure_36\NN|peritransplant|heart|chf (l_appos) CHF_38\NNP|(|)
D018943_D006973 NONE anthracyclines_70\NNS| (r_pobj) of_69\IN|anthracyclines (r_prep) use_68\NN|prior|of|,|and|irradiation (r_conj) mellitus_65\NN|diabetes|,|use (r_conj) smoking_62\NN|,|mellitus (r_conj) history_60\NN|prior|cardiac|,|smoking (r_appos) presence_46\NN|of|,|history (l_prep) of_47\IN|electrocardiogram (l_pobj) electrocardiogram_48\NN|(|ekg|abnormalities (l_appos) abnormalities_52\NNS|,|age|hypertension (l_appos) hypertension_56\NN|
D018943_D003920 NONE anthracyclines_70\NNS| (r_pobj) of_69\IN|anthracyclines (r_prep) use_68\NN|prior|of|,|and|irradiation (r_conj) mellitus_65\NN|diabetes|,|use
3503576
D003676_D006311 NONE deferoxamine_8\NN| (r_compound) therapy_9\NN|deferoxamine (r_dobj) receiving_7\VBG|therapy (r_acl) patients_6\NNS|receiving (r_pobj) in_5\IN|patients (r_prep) studies_1\NNS|serial|of|in|. (l_prep) of_2\IN|neurotoxicity (l_pobj) neurotoxicity_4\NN|auditory
D003676_D006311 NONE deferoxamine_26\NN|daily|subcutaneous (r_pobj) with_23\IN|deferoxamine (r_prep) receiving_19\VBG|who|were|therapy|with (r_relcl) anemia_16\NN|dependent|receiving (r_pobj) with_12\IN|anemia (r_prep) patients_11\NNS|89|with (r_pobj) in_7\IN|patients (r_prep) documented_6\VBN|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN|visual
D003676_D006311 NONE deferoxamine_9\NN| (r_compound) doses_10\NNS|deferoxamine (r_dobj) receiving_8\VBG|since|18|were|initially|doses|in (r_advcl) restarted_24\VBN|receiving|,|therapy|was|with|,|and|demonstrated (l_prep) with_25\IN|doses (l_pobj) doses_27\NNS|lower|,|mg/kg|depending (l_prep) depending_36\VBG|on (l_prep) on_37\IN|degree (l_pobj) degree_39\NN|the|of (l_prep) of_40\IN|abnormality (l_pobj) abnormality_42\NN|auditory
D003676_D006311 NONE deferoxamine_14\NN| (r_dobj) receiving_13\VBG|not|deferoxamine (r_conj) receiving_10\VBG|and|receiving (r_acl) patients_9\NNS|individual|receiving (r_pobj) in_7\IN|patients (r_prep) demonstrated_5\VBD|deterioration|,|serially|in|,|respectively|,|provided|. (l_prep) provided_18\VBD|convincing (l_pcomp) convincing_19\JJ|evidence (l_dobj) evidence_20\NN|for (l_prep) for_21\IN|relation (l_pobj) relation_28\NN|a|cause|between (l_prep) between_29\IN|administration (l_pobj) administration_31\NN|deferoxamine|and|ototoxicity (l_conj) ototoxicity_33\NN|
D003676_D006311 NONE deferoxamine_30\NN| (r_compound) administration_31\NN|deferoxamine|and|ototoxicity (l_conj) ototoxicity_33\NN|
D007501_D014786 NONE iron_20\NN| (r_compound) therapy_22\NN|iron|chelation (r_dobj) receiving_19\VBG|who|were|therapy|with (r_relcl) anemia_16\NN|dependent|receiving (r_pobj) with_12\IN|anemia (r_prep) patients_11\NNS|89|with (r_pobj) in_7\IN|patients (r_prep) documented_6\VBN|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN|visual
D007501_D006311 NONE iron_20\NN| (r_compound) therapy_22\NN|iron|chelation (r_dobj) receiving_19\VBG|who|were|therapy|with (r_relcl) anemia_16\NN|dependent|receiving (r_pobj) with_12\IN|anemia (r_prep) patients_11\NNS|89|with (r_pobj) in_7\IN|patients (r_prep) documented_6\VBN|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN|visual
D007501_D000740 NONE iron_20\NN| (r_compound) therapy_22\NN|iron|chelation (r_dobj) receiving_19\VBG|who|were|therapy|with (r_relcl) anemia_16\NN|dependent|receiving
D003676_D014786 NONE deferoxamine_26\NN|daily|subcutaneous (r_pobj) with_23\IN|deferoxamine (r_prep) receiving_19\VBG|who|were|therapy|with (r_relcl) anemia_16\NN|dependent|receiving (r_pobj) with_12\IN|anemia (r_prep) patients_11\NNS|89|with (r_pobj) in_7\IN|patients (r_prep) documented_6\VBN|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN|visual
D003676_D000740 NONE deferoxamine_26\NN|daily|subcutaneous (r_pobj) with_23\IN|deferoxamine (r_prep) receiving_19\VBG|who|were|therapy|with (r_relcl) anemia_16\NN|dependent|receiving
D003676_D064420 NONE deferoxamine_9\NN| (r_compound) doses_10\NNS|deferoxamine (r_dobj) receiving_8\VBG|since|18|were|initially|doses|in (r_advcl) restarted_24\VBN|receiving|,|therapy|was|with|,|and|demonstrated (l_conj) demonstrated_55\VBN|with|toxicity|was|. (l_nsubjpass) toxicity_53\NN|no|further
16330293
8996652
D000617_D006311 NONE aminoglycosides_17\NNS|particularly|and|furosemide (r_appos) administration_7\NN|a|prolonged|and|dose|,|aminoglycosides (r_pobj) to_4\IN|administration (r_prep) related_3\JJ|closely|to (r_oprd) appeared_1\VBD|ototoxicity|related|. (l_nsubj) Ototoxicity_0\NN|
D000617_D006311 NONE aminoglycosides_17\NNS|particularly|and|furosemide (r_appos) administration_7\NN|a|prolonged|and|dose|,|aminoglycosides (l_conj) dose_11\NN|higher|total|of (l_prep) of_12\IN|drugs (l_pobj) drugs_14\NNS|ototoxic (l_compound) ototoxic_13\JJ|
D005665_D006311 NONE furosemide_19\NN| (r_conj) aminoglycosides_17\NNS|particularly|and|furosemide (r_appos) administration_7\NN|a|prolonged|and|dose|,|aminoglycosides (r_pobj) to_4\IN|administration (r_prep) related_3\JJ|closely|to (r_oprd) appeared_1\VBD|ototoxicity|related|. (l_nsubj) Ototoxicity_0\NN|
D005665_D006311 NONE furosemide_19\NN| (r_conj) aminoglycosides_17\NNS|particularly|and|furosemide (r_appos) administration_7\NN|a|prolonged|and|dose|,|aminoglycosides (l_conj) dose_11\NN|higher|total|of (l_prep) of_12\IN|drugs (l_pobj) drugs_14\NNS|ototoxic (l_compound) ototoxic_13\JJ|
14596845
D000661_D019966 NONE amphetamine_15\NN| (r_pobj) of_14\IN|amphetamine (r_prep) dose_13\NN|a|low|of (r_pobj) to_10\IN|dose (r_prep) sensitization_9\NN|behavioral|cross|-|to (r_dobj) causes_5\VBZ|diet|sensitization|. (l_nsubj) diet_1\NN|a|promoting (l_acl) promoting_2\VBG|dependency (l_dobj) dependency_4\NN|sugar
D000661_D006948 CID amphetamine_15\NN| (r_pobj) of_14\IN|amphetamine (r_prep) dose_13\NN|a|low|of (r_pobj) to_10\IN|dose (r_prep) sensitization_9\NN|behavioral|cross|-|to
D000661_D006948 CID amphetamine_24\NN| (r_pobj) of_23\IN|amphetamine (r_prep) dose_22\NN|a|low|of (r_pobj) to_19\IN|dose (r_prep) show_14\VB|whether|rats|would|sensitization|to (l_dobj) sensitization_18\NN|behavioral|cross|-
D000661_D006948 CID amphetamine_14\NN| (r_pobj) to_13\IN|amphetamine (r_prep) response_12\NN|to (r_pobj) in_11\IN|response (r_prep) were_9\VBD|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ|
D000661_D006948 CID amphetamine_30\NN| (r_compound) injection_31\NN|amphetamine (r_pobj) by_29\IN|injection (r_agent) followed_28\VBN|by (r_acl) sucrose_25\NN|libitum|%|and|chow|followed (r_appos) groups_19\NNS|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN|groups (r_prep) compared_15\VBN|with (r_prep) were_9\VBD|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ|
D000661_D006948 CID amphetamine_37\NN| (r_compound) injection_38\NN|amphetamine (r_pobj) by_36\IN|injection (r_agent) followed_35\VBN|by (r_acl) chow_34\NN|cyclic|followed (r_appos) groups_19\NNS|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN|groups (r_prep) compared_15\VBN|with (r_prep) were_9\VBD|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ|
D000661_D006948 CID amphetamine_44\NN|,|or|sucrose (r_pobj) with_43\IN|amphetamine (r_prep) chow_42\NN|ad|libitum|with (r_appos) groups_19\NNS|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN|groups (r_prep) compared_15\VBN|with (r_prep) were_9\VBD|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ|
D013395_D006948 CID sucrose_6\NN|cyclic|and|chow (r_dobj) experienced_4\VBN|that|had|sucrose (r_relcl) animals_1\NNS|the|experienced (r_nsubj) were_9\VBD|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ|
D013395_D006948 CID sucrose_25\NN|libitum|%|and|chow|followed (r_appos) groups_19\NNS|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN|groups (r_prep) compared_15\VBN|with (r_prep) were_9\VBD|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ|
D013395_D006948 CID sucrose_50\NN|cyclic|%|and|chow|with (r_conj) amphetamine_44\NN|,|or|sucrose (r_pobj) with_43\IN|amphetamine (r_prep) chow_42\NN|ad|libitum|with (r_appos) groups_19\NNS|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN|groups (r_prep) compared_15\VBN|with (r_prep) were_9\VBD|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ|
3719553
D005472_D004342 NONE 5-fluorouracil_3\CD| (r_punct) infusion_4\NN|5-fluorouracil (r_pobj) to_2\IN|infusion (r_prep) reaction_1\NN|allergic|to|.
D005472_D004342 NONE 5-fluorouracil_11\CD| (r_punct) reaction_2\NN|an|allergic|consisting|5-fluorouracil
D005472_D000799 CID 5-fluorouracil_11\CD| (r_punct) reaction_2\NN|an|allergic|consisting|5-fluorouracil (l_acl) consisting_3\VBG|of (l_prep) of_4\IN|angioneurotic|edema (l_pobj) edema_6\NN|secondary
D005472_D009062 NONE 5-fluorouracil_11\CD| (r_punct) reaction_2\NN|an|allergic|consisting|5-fluorouracil (r_nsubj) occurred_12\VBD|reaction|in|. (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|carcinoma (l_pobj) carcinoma_18\NN|recurrent|of (l_prep) of_19\IN|cavity (l_pobj) cavity_22\NN|the|oral|,|cirrhosis
D005472_D005355 NONE 5-fluorouracil_11\CD| (r_punct) reaction_2\NN|an|allergic|consisting|5-fluorouracil (r_nsubj) occurred_12\VBD|reaction|in|. (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|carcinoma (l_pobj) carcinoma_18\NN|recurrent|of (l_prep) of_19\IN|cavity (l_pobj) cavity_22\NN|the|oral|,|cirrhosis (l_conj) cirrhosis_24\NN|,|and|function
D005472_D007674 NONE 5-fluorouracil_11\CD| (r_punct) reaction_2\NN|an|allergic|consisting|5-fluorouracil (r_nsubj) occurred_12\VBD|reaction|in|. (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|carcinoma (l_pobj) carcinoma_18\NN|recurrent|of (l_prep) of_19\IN|cavity (l_pobj) cavity_22\NN|the|oral|,|cirrhosis (l_conj) cirrhosis_24\NN|,|and|function (l_conj) function_32\NN|induced|impaired|renal
D002945_D004342 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|cisplatin|- (r_amod) function_32\NN|induced|impaired|renal (r_conj) cirrhosis_24\NN|,|and|function (r_conj) cavity_22\NN|the|oral|,|cirrhosis (r_pobj) of_19\IN|cavity (r_prep) carcinoma_18\NN|recurrent|of (r_pobj) with_16\IN|carcinoma (r_prep) patient_15\NN|a|with (r_pobj) in_13\IN|patient (r_prep) occurred_12\VBD|reaction|in|. (l_nsubj) reaction_2\NN|an|allergic|consisting|5-fluorouracil
D002945_D000799 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|cisplatin|- (r_amod) function_32\NN|induced|impaired|renal (r_conj) cirrhosis_24\NN|,|and|function (r_conj) cavity_22\NN|the|oral|,|cirrhosis (r_pobj) of_19\IN|cavity (r_prep) carcinoma_18\NN|recurrent|of (r_pobj) with_16\IN|carcinoma (r_prep) patient_15\NN|a|with (r_pobj) in_13\IN|patient (r_prep) occurred_12\VBD|reaction|in|. (l_nsubj) reaction_2\NN|an|allergic|consisting|5-fluorouracil (l_acl) consisting_3\VBG|of (l_prep) of_4\IN|angioneurotic|edema (l_pobj) edema_6\NN|secondary
D002945_D009062 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|cisplatin|- (r_amod) function_32\NN|induced|impaired|renal (r_conj) cirrhosis_24\NN|,|and|function (r_conj) cavity_22\NN|the|oral|,|cirrhosis
D002945_D005355 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|cisplatin|- (r_amod) function_32\NN|induced|impaired|renal (r_conj) cirrhosis_24\NN|,|and|function
D002945_D007674 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|cisplatin|- (r_amod) function_32\NN|induced|impaired|renal
D004155_D004342 NONE diphenhydramine_1\NN|oral|and|prednisone (r_nsubj) were_4\VBD|diphenhydramine|ineffective|in|. (l_prep) in_6\IN|preventing (l_pcomp) preventing_7\VBG|recurrence (l_dobj) recurrence_9\NN|the|of (l_prep) of_10\IN|reaction (l_pobj) reaction_13\NN|the|allergic
D011241_D004342 NONE prednisone_3\NNP| (r_conj) diphenhydramine_1\NN|oral|and|prednisone (r_nsubj) were_4\VBD|diphenhydramine|ineffective|in|. (l_prep) in_6\IN|preventing (l_pcomp) preventing_7\VBG|recurrence (l_dobj) recurrence_9\NN|the|of (l_prep) of_10\IN|reaction (l_pobj) reaction_13\NN|the|allergic
8649546
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|levodopa|- (r_amod) dyskinesia_5\NN|induced
D007980_D004409 CID levodopa_14\RB| (r_npadvmod) induced_16\VBN|levodopa|- (r_amod) dyskinesia_20\NN|induced|ballistic|in
D007980_D010300 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|levodopa|- (r_amod) dyskinesia_5\NN|induced (r_pobj) of_1\IN|dyskinesia (r_prep) Improvement_0\NN|of|by|. (l_prep) by_6\IN|propranolol (l_pcomp) propranolol_7\NN|in (l_prep) in_8\IN|disease (l_pobj) disease_11\NN|parkinson
D007980_D010300 NONE levodopa_14\RB| (r_npadvmod) induced_16\VBN|levodopa|- (r_amod) dyskinesia_20\NN|induced|ballistic|in (l_prep) in_21\IN|pd (l_pobj) PD_22\NNP|
D011433_D004409 NONE propranolol_7\NN|in (r_pcomp) by_6\IN|propranolol (r_prep) Improvement_0\NN|of|by|. (l_prep) of_1\IN|dyskinesia (l_pobj) dyskinesia_5\NN|induced
D011433_D004409 NONE propranolol_18\NN|dose|as (r_dobj) received_14\VBN|patients|propranolol|. (l_nsubj) patients_1\NNS|seven|suffering (l_acl) suffering_2\VBG|from|with (l_prep) with_10\IN|dyskinesia (l_pobj) dyskinesia_13\NN|disabling
D011433_D010300 NONE propranolol_7\NN|in (l_prep) in_8\IN|disease (l_pobj) disease_11\NN|parkinson
D011433_D010300 NONE propranolol_18\NN|dose|as (r_dobj) received_14\VBN|patients|propranolol|. (l_nsubj) patients_1\NNS|seven|suffering (l_acl) suffering_2\VBG|from|with (l_prep) from_3\IN|disease (l_pobj) disease_6\NN|parkinson|(|pd|)
D011433_D010300 NONE propranolol_18\NN|dose|as (r_dobj) received_14\VBN|patients|propranolol|. (l_nsubj) patients_1\NNS|seven|suffering (l_acl) suffering_2\VBG|from|with (l_prep) from_3\IN|disease (l_pobj) disease_6\NN|parkinson|(|pd|) (l_appos) PD_8\NNP|
9812111
D006220_D011618 NONE haloperidol_11\NN|for (l_prep) for_12\IN|psychosis (l_pobj) psychosis_13\NN|and|behaviors|in
D006220_D011618 NONE haloperidol_17\NN|and|placebo (r_pobj) of_16\IN|haloperidol (r_prep) doses_15\NNS|two|of (r_pobj) of_13\IN|doses (r_prep) efficacy_9\NN|the|and|effects|of (r_dobj) compare_7\VB|to|efficacy|in (l_prep) in_20\IN|treatment (l_pobj) treatment_22\NN|the|of|in (l_prep) of_23\IN|psychosis (l_pobj) psychosis_24\NN|and|behaviors
D006220_D011618 NONE haloperidol_12\NN|dose (r_appos) A_7\NNP|phase|,|haloperidol (r_dobj) completed_5\VBD|who|a (r_relcl) patients_3\NNS|the|60|completed (r_pobj) For_0\IN|patients (r_prep) was_13\VBD|for|efficacious|. (l_acomp) efficacious_14\JJ|and|superior|to (l_prep) to_17\IN|haloperidol (l_pobj) haloperidol_22\NN|both|dose|and|placebo|for (l_prep) for_25\IN|scores (l_pobj) scores_26\NNS|on (l_prep) on_27\IN|factor|and|on (l_pobj) factor_34\NN|the|brief|scale|psychosis (l_compound) psychosis_33\NN|
D006220_D011618 NONE haloperidol_22\NN|both|dose|and|placebo|for (l_prep) for_25\IN|scores (l_pobj) scores_26\NNS|on (l_prep) on_27\IN|factor|and|on (l_pobj) factor_34\NN|the|brief|scale|psychosis (l_compound) psychosis_33\NN|
D006220_D011618 NONE haloperidol_6\NN| (r_pobj) with_5\IN|haloperidol (r_prep) observed_4\VBN|window|with (r_nsubj) apply_9\VB|observed|may|also|to|. (l_prep) to_10\IN|neuroleptics (l_pobj) neuroleptics_12\NNS|other|used (l_acl) used_13\VBN|in (l_prep) in_14\IN|patients (l_pobj) patients_18\NNS|alzheimer|disease|with (l_prep) with_19\IN|psychosis (l_pobj) psychosis_20\NN|and|behaviors
D006220_D019958 NONE haloperidol_11\NN|for (l_prep) for_12\IN|psychosis (l_pobj) psychosis_13\NN|and|behaviors|in (l_conj) behaviors_16\NNS|disruptive
D006220_D019958 NONE haloperidol_17\NN|and|placebo (r_pobj) of_16\IN|haloperidol (r_prep) doses_15\NNS|two|of (r_pobj) of_13\IN|doses (r_prep) efficacy_9\NN|the|and|effects|of (r_dobj) compare_7\VB|to|efficacy|in (l_prep) in_20\IN|treatment (l_pobj) treatment_22\NN|the|of|in (l_prep) of_23\IN|psychosis (l_pobj) psychosis_24\NN|and|behaviors (l_conj) behaviors_27\NNS|disruptive
D006220_D019958 NONE haloperidol_6\NN| (r_pobj) with_5\IN|haloperidol (r_prep) observed_4\VBN|window|with (r_nsubj) apply_9\VB|observed|may|also|to|. (l_prep) to_10\IN|neuroleptics (l_pobj) neuroleptics_12\NNS|other|used (l_acl) used_13\VBN|in (l_prep) in_14\IN|patients (l_pobj) patients_18\NNS|alzheimer|disease|with (l_prep) with_19\IN|psychosis (l_pobj) psychosis_20\NN|and|behaviors (l_conj) behaviors_23\NNS|disruptive
D006220_D000544 NONE haloperidol_11\NN|for (l_prep) for_12\IN|psychosis (l_pobj) psychosis_13\NN|and|behaviors|in (l_prep) in_17\IN|disease (l_pobj) disease_20\NN|alzheimer
D006220_D000544 NONE haloperidol_17\NN|and|placebo (r_pobj) of_16\IN|haloperidol (r_prep) doses_15\NNS|two|of (r_pobj) of_13\IN|doses (r_prep) efficacy_9\NN|the|and|effects|of (r_dobj) compare_7\VB|to|efficacy|in (l_prep) in_20\IN|treatment (l_pobj) treatment_22\NN|the|of|in (l_prep) in_28\IN|patients (l_pobj) patients_29\NNS|with (l_prep) with_30\IN|disease (l_pobj) disease_33\NN|alzheimer
D006220_D000544 NONE haloperidol_20\NN|,|day|(|dose|) (r_appos) phase_16\NN|(|a|)|,|haloperidol|,|and|haloperidol (r_preconj) In_0\IN|trial|phase (r_prep) compared_48\VBN|in|,|were|in|. (l_prep) in_49\IN|outpatients (l_pobj) outpatients_51\NNS|71|with (l_prep) with_52\IN|disease (l_pobj) disease_55\NN|alzheimer
D006220_D000544 NONE haloperidol_34\NN|,|day|(|dose|) (r_conj) phase_16\NN|(|a|)|,|haloperidol|,|and|haloperidol (r_preconj) In_0\IN|trial|phase (r_prep) compared_48\VBN|in|,|were|in|. (l_prep) in_49\IN|outpatients (l_pobj) outpatients_51\NNS|71|with (l_prep) with_52\IN|disease (l_pobj) disease_55\NN|alzheimer
D006220_D000544 NONE haloperidol_6\NN| (r_pobj) with_5\IN|haloperidol (r_prep) observed_4\VBN|window|with (r_nsubj) apply_9\VB|observed|may|also|to|. (l_prep) to_10\IN|neuroleptics (l_pobj) neuroleptics_12\NNS|other|used (l_acl) used_13\VBN|in (l_prep) in_14\IN|patients (l_pobj) patients_18\NNS|alzheimer|disease|with (l_compound) disease_17\NN|
D006220_D011595 NONE haloperidol_12\NN|dose (r_appos) A_7\NNP|phase|,|haloperidol (r_dobj) completed_5\VBD|who|a (r_relcl) patients_3\NNS|the|60|completed (r_pobj) For_0\IN|patients (r_prep) was_13\VBD|for|efficacious|. (l_acomp) efficacious_14\JJ|and|superior|to (l_prep) to_17\IN|haloperidol (l_pobj) haloperidol_22\NN|both|dose|and|placebo|for (l_prep) for_25\IN|scores (l_pobj) scores_26\NNS|on (l_prep) on_27\IN|factor|and|on (l_conj) on_36\IN|agitation (l_pobj) agitation_38\NN|psychomotor
D006220_D011595 NONE haloperidol_22\NN|both|dose|and|placebo|for (l_prep) for_25\IN|scores (l_pobj) scores_26\NNS|on (l_prep) on_27\IN|factor|and|on (l_conj) on_36\IN|agitation (l_pobj) agitation_38\NN|psychomotor
D006220_D001480 CID haloperidol_8\NN| (r_pobj) for_7\IN|haloperidol (r_prep) profile_6\NN|a|favorable|therapeutic|for|in (r_dobj) indicated_2\VBD|results|profile|,|developed|. (l_advcl) developed_22\VBD|although|subgroup|moderate (l_acomp) moderate_23\JJ|to (l_prep) to_24\TO|signs (l_pobj) signs_27\NNS|severe|extrapyramidal
3560096
D013467_D006947 CID sulindac_3\NN| (r_compound) therapy_4\NN|sulindac (r_pobj) with_2\IN|therapy (r_prep) associated_1\VBN|with (r_acl) Hyperkalemia_0\NNP|associated|.
D013467_D006947 CID sulindac_22\NN| (r_compound) administration_23\NN|sulindac (r_pobj) of_21\IN|administration (r_prep) days_20\NNS|8|of (r_pobj) within_16\IN|days (r_prep) developed_15\VBD|hyperkalemia|within (l_nsubj) hyperkalemia_6\VBD|in|ranging
D013467_D006947 CID sulindac_29\NN|and|hyperkalemia (l_conj) hyperkalemia_31\NN|
D007213_D006947 CID indomethacin_17\NN| (r_pobj) as_16\IN|such|indomethacin (r_prep) NSAID_13\NNP|(|)|as (r_appos) agents_11\NNS|nonsteroidal|antiinflammatory|nsaid (r_pobj) of_8\IN|agents (r_prep) complication_7\NN|a|of (r_pobj) as_5\IN|complication (r_prep) recognized_4\VBN|hyperkalemia|has|recently|been|as|. (l_nsubjpass) Hyperkalemia_0\NNP|
D011188_D006947 NONE potassium_8\NN|serum (r_dobj) effect_6\NN|to|potassium (r_xcomp) known_4\VBN|effect (r_acl) medications_3\NNS|no|other|known (r_nsubjpass) given_11\VBN|as|medications|had|been|concomitantly (r_advcl) is_18\VBZ|given|,|course|suggestive|. (l_acomp) suggestive_19\JJ|of (l_prep) of_20\IN|relationship (l_pobj) relationship_27\NN|a|cause|between (l_prep) between_28\IN|sulindac (l_pobj) sulindac_29\NN|and|hyperkalemia (l_conj) hyperkalemia_31\NN|
2096243
C017367_D019965 CID Carmofur_0\NN| (r_npadvmod) induced_2\VBN|carmofur|- (r_amod) disorders_5\NNS|induced|organic|mental|.
C017367_D019965 CID carmofur_19\NN| (r_npadvmod) induced_21\VBN|carmofur|- (r_amod) leukoencephalopathy_22\NN|induced (r_pobj) of_18\IN|leukoencephalopathy (r_prep) onset_17\NN|the|of (r_pobj) after_15\IN|onset (r_prep) period_14\NN|the|prognostic|after (r_pobj) in_11\IN|period (r_prep) female_10\NN|a|old|in (r_pobj) in_5\IN|female (r_prep) observed_4\VBN|disorder|was|in|. (l_nsubjpass) disorder_2\NN|organic|mental
C017367_D056784 CID carmofur_19\NN| (r_npadvmod) induced_21\VBN|carmofur|- (r_amod) leukoencephalopathy_22\NN|induced
C017367_D056784 CID carmofur_2\NN| (r_npadvmod) induced_4\VBN|carmofur|- (r_amod) leukoencephalopathy_5\JJ|induced
C017367_D010554 NONE carmofur_2\NN| (r_npadvmod) induced_4\VBN|carmofur|- (r_amod) leukoencephalopathy_5\JJ|induced (r_nsubj) result_8\VB|consequently|,|leukoencephalopathy|may|uncommonly|in|. (l_prep) in_9\IN|syndrome (l_pobj) syndrome_12\NN|personality|in
14657095
D000666_D002311 CID B_6\NNP| (r_compound) therapy_7\NN|amphotericin|b (r_pobj) to_4\IN|therapy (r_prep) related_3\VBN|to (r_acl) cardiomyopathy_2\NN|reversible|dilated|related|.
D000666_D002311 CID B_20\NNP|amphotericin|amb (r_pobj) with_18\IN|b (r_prep) developed_5\VBD|who|failure|after|with|for (l_dobj) failure_12\NN|dilated|cardiomyopathy|heart (l_amod) cardiomyopathy_7\NN|and|clinical
D000666_D002311 CID AmB_22\NNP|(|) (r_appos) B_20\NNP|amphotericin|amb (r_pobj) with_18\IN|b (r_prep) developed_5\VBD|who|failure|after|with|for (l_dobj) failure_12\NN|dilated|cardiomyopathy|heart (l_amod) cardiomyopathy_7\NN|and|clinical
D000666_D006333 CID B_20\NNP|amphotericin|amb (r_pobj) with_18\IN|b (r_prep) developed_5\VBD|who|failure|after|with|for (l_dobj) failure_12\NN|dilated|cardiomyopathy|heart
D000666_D006333 CID AmB_22\NNP|(|) (r_appos) B_20\NNP|amphotericin|amb (r_pobj) with_18\IN|b (r_prep) developed_5\VBD|who|failure|after|with|for (l_dobj) failure_12\NN|dilated|cardiomyopathy|heart
D000666_D006333 CID AmB._12\NN| (r_pobj) for_11\IN|amb. (r_prep) substituted_10\VBN|after|posaconazole|was|for (r_advcl) resolved_6\VBD|substituted (r_acl) abnormalities_2\NNS|his|echocardiographic|and|failure|resolved (l_conj) failure_5\NN|heart
D000666_D003047 NONE B_20\NNP|amphotericin|amb (r_pobj) with_18\IN|b (r_prep) developed_5\VBD|who|failure|after|with|for (l_prep) for_24\IN|coccidioidomycosis (l_pobj) coccidioidomycosis_26\NN|disseminated
D000666_D003047 NONE AmB_22\NNP|(|) (r_appos) B_20\NNP|amphotericin|amb (r_pobj) with_18\IN|b (r_prep) developed_5\VBD|who|failure|after|with|for (l_prep) for_24\IN|coccidioidomycosis (l_pobj) coccidioidomycosis_26\NN|disseminated
C101425_D006333 NONE posaconazole_8\NN| (r_nsubjpass) substituted_10\VBN|after|posaconazole|was|for (r_advcl) resolved_6\VBD|substituted (r_acl) abnormalities_2\NNS|his|echocardiographic|and|failure|resolved (l_conj) failure_5\NN|heart
D000666_D064420 NONE AmB._12\NN| (r_pobj) of_11\IN|amb. (r_prep) toxicity_10\NN|the|rare|of
18023325
D004221_D014826 CID disulfiram_6\NN| (r_compound) intoxication_7\NN|acute|disulfiram (r_pobj) after_4\IN|intoxication (r_prep) palsy_3\JJ|acute|fold|after|.
D004221_D014826 CID disulfiram_6\NN| (r_compound) overdose_7\NN|a|disulfiram (r_pobj) by_4\IN|overdose (r_agent) caused_3\VBN|by (r_acl) neuropathy_2\NN|acute|peripheral|caused (r_nsubj) is_8\VBZ|neuropathy|rare|and|is (l_conj) is_13\VBZ|there|report|. (l_attr) report_15\NN|no|of|leading (l_acl) leading_18\VBG|to (l_prep) to_19\IN|palsy (l_pobj) palsy_22\JJ|fold
D004221_D010523 CID disulfiram_6\NN| (r_compound) overdose_7\NN|a|disulfiram (r_pobj) by_4\IN|overdose (r_agent) caused_3\VBN|by (r_acl) neuropathy_2\NN|acute|peripheral|caused
D004221_D062787 NONE disulfiram_6\NN| (r_compound) overdose_7\NN|a|disulfiram
D004221_D010243 NONE disulfiram_24\NN| (r_compound) intoxication_25\NN|dose|disulfiram (r_pobj) by_20\IN|intoxication (r_agent) caused_19\VBN|by (r_acl) polyneuropathy_18\NN|severe|acute|sensorimotor|axonal|caused (r_dobj) superimposed_13\VBN|polyneuropathy (r_conj) was_1\VBD|this|case|and|superimposed|. (l_attr) case_3\NN|a|of (l_prep) of_4\IN|palsy (l_pobj) palsy_6\JJ|acute|of
D004221_D011115 NONE disulfiram_24\NN| (r_compound) intoxication_25\NN|dose|disulfiram (r_pobj) by_20\IN|intoxication (r_agent) caused_19\VBN|by (r_acl) polyneuropathy_18\NN|severe|acute|sensorimotor|axonal|caused
2484011
D000547_D003866 NONE amantadine_4\JJ| (r_nmod) activity_7\NN|amantadine|depressed|locomotor (l_amod) depressed_5\JJ|
D000547_D011596 CID amantadine_2\NN| (r_pobj) of_1\IN|amantadine (r_prep) Readministration_0\NN|of (r_nsubj) increased_12\VBN|readministration|,|after|,|motility|from|in|with|. (l_prep) with_21\IN|exception (l_pobj) exception_22\NN|of (l_prep) of_23\IN|mice (l_pobj) mice_28\NNS|the|c|occurred (l_relcl) occurred_33\VBD|where|suppression (l_nsubj) suppression_30\NN|of (l_prep) of_31\IN|motility (l_pobj) motility_32\NN|
D000547_D011596 CID amantadine_45\NN| (r_pobj) by_44\IN|amantadine (r_agent) caused_43\VBN|by|in (r_acl) depression_42\NN|a|behavioral|caused
D000588_D011596 NONE amines_6\NNS|brain|biogenic|of (r_pobj) of_3\IN|amines (r_prep) results_2\NNS|the|biochemical|of (r_nsubj) suggest_13\VBP|results|decrease|. (l_dobj) decrease_16\NN|a|probable|of|by|and|increase (l_conj) increase_29\NN|a|resulting|in|account (l_relcl) account_38\VB|which|may|for (l_prep) for_39\IN|depression (l_pobj) depression_42\NN|a|behavioral|caused
D002395_D011596 NONE catecholamine_18\NN| (r_compound) rate_20\NN|catecholamine|turnover|and/or|metabolism (r_pobj) of_17\IN|rate (r_prep) decrease_16\NN|a|probable|of|by|and|increase (l_conj) increase_29\NN|a|resulting|in|account (l_relcl) account_38\VB|which|may|for (l_prep) for_39\IN|depression (l_pobj) depression_42\NN|a|behavioral|caused
D009638_D011596 NONE norepinephrine_35\NN| (r_pobj) of_34\IN|norepinephrine (r_prep) methylation_33\NN|o|-|of (r_pobj) in_30\IN|methylation (r_prep) increase_29\NN|a|resulting|in|account (l_relcl) account_38\VB|which|may|for (l_prep) for_39\IN|depression (l_pobj) depression_42\NN|a|behavioral|caused
7420681
D014031_D007674 NONE tobramycin_3\JJ| (r_pobj) of_2\IN|tobramycin (r_prep) nephrotoxicity_1\NN|clinical|of|and|gentamicin|.
D014031_D007674 NONE sulfate_4\NN|tobramycin (r_conj) sulfate_1\NN|gentamicin|and|sulfate (r_nsubj) continue_5\VBP|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB|to|ototoxicity (l_dobj) ototoxicity_8\NN|and|nephrotoxicity|in (l_conj) nephrotoxicity_10\NN|
D005839_D007674 NONE gentamicin_5\NN| (r_conj) nephrotoxicity_1\NN|clinical|of|and|gentamicin|.
D005839_D007674 NONE sulfate_1\NN|gentamicin|and|sulfate (r_nsubj) continue_5\VBP|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB|to|ototoxicity (l_dobj) ototoxicity_8\NN|and|nephrotoxicity|in (l_conj) nephrotoxicity_10\NN|
D005839_D006311 NONE sulfate_1\NN|gentamicin|and|sulfate (r_nsubj) continue_5\VBP|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB|to|ototoxicity (l_dobj) ototoxicity_8\NN|and|nephrotoxicity|in
D014031_D006311 NONE sulfate_4\NN|tobramycin (r_conj) sulfate_1\NN|gentamicin|and|sulfate (r_nsubj) continue_5\VBP|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB|to|ototoxicity (l_dobj) ototoxicity_8\NN|and|nephrotoxicity|in
D005839_D051437 CID sulfate_25\NN|gentamicin|or|sulfate|for (r_pobj) of_23\IN|sulfate (r_prep) day_22\NN|of (r_appos) kg_20\NNS|5|mg|/|/|day (r_pobj) with_14\IN|kg (r_prep) treated_13\VBN|with (r_conj) patients_5\NNS|62|with|and|treated (r_nsubjpass) followed_36\VBN|in|,|patients|were|up|prospectively|for|. (l_prep) for_39\IN|development (l_pobj) development_41\NN|the|of (l_prep) of_42\IN|failure (l_pobj) failure_47\NN|related|renal|,|defined
D005839_D051437 CID gentamicin_23\NN| (r_npadvmod) treated_25\VBN|gentamicin|- (r_amod) patients_26\NNS|the|treated (r_pobj) of_21\IN|patients (r_prep) 16_14\CD|of|%|)|of (r_nsubj) had_27\VBD|five|16|failure|. (l_dobj) failure_29\NN|renal
D005839_D051437 CID gentamicin_2\NN| (r_nsubjpass) associated_4\VBN|thus|,|gentamicin|was|with|was|. (l_prep) with_5\IN|failure (l_pobj) failure_7\NN|renal
D014031_D051437 CID sulfate_28\NN|tobramycin (r_conj) sulfate_25\NN|gentamicin|or|sulfate|for (r_pobj) of_23\IN|sulfate (r_prep) day_22\NN|of (r_appos) kg_20\NNS|5|mg|/|/|day (r_pobj) with_14\IN|kg (r_prep) treated_13\VBN|with (r_conj) patients_5\NNS|62|with|and|treated (r_nsubjpass) followed_36\VBN|in|,|patients|were|up|prospectively|for|. (l_prep) for_39\IN|development (l_pobj) development_41\NN|the|of (l_prep) of_42\IN|failure (l_pobj) failure_47\NN|related|renal|,|defined
D014031_D051437 CID tobramycin_9\RB| (r_npadvmod) treated_11\VBN|tobramycin|- (r_amod) patients_12\NNS|the|treated (r_pobj) of_7\IN|patients (r_prep) %_5\NN|33|(|15|)|of|and (r_pobj) of_1\IN|% (r_prep) Five_0\CD|of (r_nsubj) had_27\VBD|five|16|failure|. (l_dobj) failure_29\NN|renal
D014031_D051437 CID tobramycin_16\JJ| (r_acomp) was_15\VBD|often|as|tobramycin (r_advcl) associated_4\VBN|thus|,|gentamicin|was|with|was|. (l_prep) with_5\IN|failure (l_pobj) failure_7\NN|renal
D000617_D051437 NONE aminoglycoside_43\NN| (r_npadvmod) related_45\VBN|aminoglycoside|- (r_amod) failure_47\NN|related|renal|,|defined
347884
D006220_D019967 NONE haloperidol_6\NN| (r_pobj) with_5\IN|haloperidol (r_prep) study_4\NN|the|double|blind|with (r_pobj) In_0\IN|study (r_prep) found_11\VBN|in|,|substances|were|be|. (l_xcomp) be_13\VB|to|effective (l_acomp) effective_15\JJ|highly|in (l_prep) in_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|syndromes (l_pobj) syndromes_21\NNS|psychotic|belonging (l_acl) belonging_22\VBG|predominantly|to (l_prep) to_24\IN|group (l_pobj) group_27\NN|the|schizophrenia
1420741
D005672_D003424 NONE acid_7\NN|fusidic (r_pobj) with_5\IN|acid (r_prep) disease_4\NN|crohn|with
D005672_D003424 NONE acid_28\NN| (r_compound) treatment_29\NN|fusidic|acid|in (r_pobj) of_26\IN|treatment (r_prep) tolerability_25\NN|of (r_conj) pharmacodynamics_23\NNS|the|and|tolerability (r_dobj) estimate_21\VB|to|pharmacodynamics (r_advcl) undertaken_19\VBN|because|,|study|was|estimate|. (l_prep) Because_0\IN|of|need (l_pobj) need_3\NN|the|for (l_prep) for_4\IN|development (l_pobj) development_6\NN|the|of (l_prep) of_7\IN|treatments (l_pobj) treatments_9\NNS|new|for (l_prep) for_10\IN|disease (l_pobj) disease_13\NN|crohn
D005672_D003424 NONE acid_9\NN| (r_nsubj) be_11\VB|that|fusidic|acid|may|of|in (l_prep) in_14\IN|patients (l_pobj) patients_21\NNS|selected|chronic|active|crohn|disease|is (l_compound) disease_20\NN|
D016572_D003424 NONE cyclosporin_16\NN| (r_pobj) to_15\IN|cyclosporin (r_prep) similar_14\JJ|to (r_amod) properties_13\NNS|immunosuppressive|similar (r_pobj) with_11\IN|properties (r_prep) antibiotic_10\NN|an|with (r_appos) Treatment_0\NN|of|:|antibiotic|. (l_prep) of_1\IN|disease (l_pobj) disease_4\NN|crohn|with
D005672_D015212 NONE acid_13\NN|fusidic (r_pobj) of_11\IN|acid (r_prep) use_10\NN|the|of|at (l_prep) at_14\IN|level (l_pobj) level_17\NN|the|cytokine|in (l_prep) in_18\IN|disease (l_pobj) disease_21\NN|inflammatory|bowel
17400887
D013726_D020078 NONE terbutaline_6\JJ| (r_compound) treatment_7\NN|neonatal|terbutaline|in (r_pobj) after_4\IN|treatment (r_prep) abnormalities_3\NNS|neuroinflammation|after|:|implications|. (l_nmod) Neuroinflammation_0\NN|and|behavioral
D013726_D001523 NONE terbutaline_6\JJ| (r_compound) treatment_7\NN|neonatal|terbutaline|in (r_pobj) after_4\IN|treatment (r_prep) abnormalities_3\NNS|neuroinflammation|after|:|implications|.
D013726_D001321 CID terbutaline_6\JJ| (r_compound) treatment_7\NN|neonatal|terbutaline|in (r_pobj) after_4\IN|treatment (r_prep) abnormalities_3\NNS|neuroinflammation|after|:|implications|. (l_appos) implications_11\NNS|for (l_prep) for_12\IN|autism (l_pobj) autism_13\NN|
D013726_D001321 CID Terbutaline_0\NNP|,|agonist|, (r_nsubjpass) associated_13\VBN|terbutaline|has|been|with|. (l_prep) with_14\IN|concordance (l_pobj) concordance_16\NN|increased|for (l_prep) for_17\IN|autism (l_pobj) autism_18\NN|in
D013726_D007752 NONE Terbutaline_0\NNP|,|agonist|, (l_appos) agonist_4\NN|a|beta2-adrenoceptor|used (l_acl) used_5\VBN|arrest (l_xcomp) arrest_7\VB|to|labor (l_dobj) labor_9\NN|preterm
1130930
D002512_D007674 NONE cephalothin_3\NN| (r_compound) gentamicin_5\NN|cephalothin|- (r_compound) regimen_6\NN|combined|gentamicin (r_pobj) of_1\IN|regimen (r_prep) Nephrotoxicity_0\NN|of|.
D005839_D007674 NONE gentamicin_5\NN|cephalothin|- (r_compound) regimen_6\NN|combined|gentamicin (r_pobj) of_1\IN|regimen (r_prep) Nephrotoxicity_0\NN|of|.
D002512_D007683 CID sodium_23\NN|cephalothin (r_pobj) of_21\IN|sodium (r_prep) combination_20\NN|a|of (r_dobj) receiving_18\VBG|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN|acute|tubular|,|characterized
D002512_D009846 NONE sodium_23\NN|cephalothin (r_pobj) of_21\IN|sodium (r_prep) combination_20\NN|a|of (r_dobj) receiving_18\VBG|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN|acute|tubular|,|characterized (l_acl) characterized_7\VBN|by (l_agent) by_9\IN|clinically|failure (l_pobj) failure_13\NN|acute|oliguric|renal
D002512_D051437 NONE sodium_23\NN|cephalothin (r_pobj) of_21\IN|sodium (r_prep) combination_20\NN|a|of (r_dobj) receiving_18\VBG|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN|acute|tubular|,|characterized (l_acl) characterized_7\VBN|by (l_agent) by_9\IN|clinically|failure (l_pobj) failure_13\NN|acute|oliguric|renal
D005839_D007683 CID sulfate_26\NN| (r_compound) therapy_27\NN|sulfate (r_dobj) gentamicin_25\NN|therapy (r_conj) receiving_18\VBG|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN|acute|tubular|,|characterized
D005839_D009846 NONE sulfate_26\NN| (r_compound) therapy_27\NN|sulfate (r_dobj) gentamicin_25\NN|therapy (r_conj) receiving_18\VBG|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN|acute|tubular|,|characterized (l_acl) characterized_7\VBN|by (l_agent) by_9\IN|clinically|failure (l_pobj) failure_13\NN|acute|oliguric|renal
D005839_D051437 NONE sulfate_26\NN| (r_compound) therapy_27\NN|sulfate (r_dobj) gentamicin_25\NN|therapy (r_conj) receiving_18\VBG|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN|acute|tubular|,|characterized (l_acl) characterized_7\VBN|by (l_agent) by_9\IN|clinically|failure (l_pobj) failure_13\NN|acute|oliguric|renal
19581773
C417083_D009157 CID interferon_6\NN|and|ribavirin (r_nmod) treatment_9\NN|pegylated|interferon|for (r_pobj) during_4\IN|treatment (r_prep) Development_0\NN|of|during (l_prep) of_1\IN|myasthenia (l_pobj) myasthenia_3\NN|ocular
C417083_D009157 CID alpha-2b_10\CD|pegylated|ifn|and|ribavirin|for (r_pobj) of_7\IN|alpha-2b (r_prep) therapy_6\NN|combination|of (r_pobj) with_4\IN|therapy (r_prep) associated_3\VBN|with (r_acl) myasthenia_2\NN|the|ocular|associated
C417083_D009157 CID IFN_35\NNP| (r_compound) therapy_36\NN|ifn (r_pobj) of_34\IN|therapy (r_prep) complications_33\NNS|the|various|eye|of (r_pobj) of_29\IN|complications (r_prep) review_28\NN|a|of (r_pobj) with_26\IN|review (r_prep) present_23\VBP|reported|;|therefore|,|we|case|with|. (l_ccomp) reported_18\VBN|myasthenia|is|rarely (l_nsubjpass) myasthenia_2\NN|the|ocular|associated
C417083_D019698 NONE interferon_6\NN|and|ribavirin (r_nmod) treatment_9\NN|pegylated|interferon|for (l_prep) for_10\IN|c. (l_pobj) C._13\NNP|chronic|hepatitis
C417083_D019698 NONE alpha-2b_19\CD|and|ribavirin (r_conj) IFN_17\NNP|(|)|alpha-2b (r_appos) interferon_15\NN|pegylated|ifn (r_pobj) of_13\IN|interferon (r_prep) administration_12\NN|of (r_pobj) of_11\IN|administration (r_prep) weeks_10\NNS|9|of (r_pobj) after_8\IN|weeks (r_prep) diplopia_7\NN|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN|c (l_pobj) C_25\NNP|chronic|hepatitis|(|chc|)
C417083_D019698 NONE alpha-2b_19\CD|and|ribavirin (r_conj) IFN_17\NNP|(|)|alpha-2b (r_appos) interferon_15\NN|pegylated|ifn (r_pobj) of_13\IN|interferon (r_prep) administration_12\NN|of (r_pobj) of_11\IN|administration (r_prep) weeks_10\NNS|9|of (r_pobj) after_8\IN|weeks (r_prep) diplopia_7\NN|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN|c (l_pobj) C_25\NNP|chronic|hepatitis|(|chc|) (l_appos) CHC_27\NNP|
C417083_D019698 NONE alpha-2b_10\CD|pegylated|ifn|and|ribavirin|for (l_prep) for_13\IN|chc (l_pobj) CHC_14\NNP|
C417083_D019698 NONE IFN_35\NNP| (r_compound) therapy_36\NN|ifn (r_pobj) of_34\IN|therapy (r_prep) complications_33\NNS|the|various|eye|of (r_pobj) of_29\IN|complications (r_prep) review_28\NN|a|of (r_pobj) with_26\IN|review (r_prep) present_23\VBP|reported|;|therefore|,|we|case|with|. (l_ccomp) reported_18\VBN|myasthenia|is|rarely (l_nsubjpass) myasthenia_2\NN|the|ocular|associated (l_acl) associated_3\VBN|with (l_prep) with_4\IN|therapy (l_pobj) therapy_6\NN|combination|of (l_prep) of_7\IN|alpha-2b (l_pobj) alpha-2b_10\CD|pegylated|ifn|and|ribavirin|for (l_prep) for_13\IN|chc (l_pobj) CHC_14\NNP|
D012254_D009157 CID ribavirin_8\JJ| (r_conj) interferon_6\NN|and|ribavirin (r_nmod) treatment_9\NN|pegylated|interferon|for (r_pobj) during_4\IN|treatment (r_prep) Development_0\NN|of|during (l_prep) of_1\IN|myasthenia (l_pobj) myasthenia_3\NN|ocular
D012254_D009157 CID ribavirin_12\RB| (r_conj) alpha-2b_10\CD|pegylated|ifn|and|ribavirin|for (r_pobj) of_7\IN|alpha-2b (r_prep) therapy_6\NN|combination|of (r_pobj) with_4\IN|therapy (r_prep) associated_3\VBN|with (r_acl) myasthenia_2\NN|the|ocular|associated
D012254_D019698 NONE ribavirin_8\JJ| (r_conj) interferon_6\NN|and|ribavirin (r_nmod) treatment_9\NN|pegylated|interferon|for (l_prep) for_10\IN|c. (l_pobj) C._13\NNP|chronic|hepatitis
D012254_D019698 NONE ribavirin_21\RB| (r_conj) alpha-2b_19\CD|and|ribavirin (r_conj) IFN_17\NNP|(|)|alpha-2b (r_appos) interferon_15\NN|pegylated|ifn (r_pobj) of_13\IN|interferon (r_prep) administration_12\NN|of (r_pobj) of_11\IN|administration (r_prep) weeks_10\NNS|9|of (r_pobj) after_8\IN|weeks (r_prep) diplopia_7\NN|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN|c (l_pobj) C_25\NNP|chronic|hepatitis|(|chc|)
D012254_D019698 NONE ribavirin_21\RB| (r_conj) alpha-2b_19\CD|and|ribavirin (r_conj) IFN_17\NNP|(|)|alpha-2b (r_appos) interferon_15\NN|pegylated|ifn (r_pobj) of_13\IN|interferon (r_prep) administration_12\NN|of (r_pobj) of_11\IN|administration (r_prep) weeks_10\NNS|9|of (r_pobj) after_8\IN|weeks (r_prep) diplopia_7\NN|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN|c (l_pobj) C_25\NNP|chronic|hepatitis|(|chc|) (l_appos) CHC_27\NNP|
D012254_D019698 NONE ribavirin_12\RB| (r_conj) alpha-2b_10\CD|pegylated|ifn|and|ribavirin|for (l_prep) for_13\IN|chc (l_pobj) CHC_14\NNP|
C417083_D004172 NONE alpha-2b_19\CD|and|ribavirin (r_conj) IFN_17\NNP|(|)|alpha-2b (r_appos) interferon_15\NN|pegylated|ifn (r_pobj) of_13\IN|interferon (r_prep) administration_12\NN|of (r_pobj) of_11\IN|administration (r_prep) weeks_10\NNS|9|of (r_pobj) after_8\IN|weeks (r_prep) diplopia_7\NN|a|old|experienced|sudden|after|for|.
D012254_D004172 NONE ribavirin_21\RB| (r_conj) alpha-2b_19\CD|and|ribavirin (r_conj) IFN_17\NNP|(|)|alpha-2b (r_appos) interferon_15\NN|pegylated|ifn (r_pobj) of_13\IN|interferon (r_prep) administration_12\NN|of (r_pobj) of_11\IN|administration (r_prep) weeks_10\NNS|9|of (r_pobj) after_8\IN|weeks (r_prep) diplopia_7\NN|a|old|experienced|sudden|after|for|.
88336
D002719_D013375 NONE chlormethiazole_6\NN| (r_pobj) of_5\IN|chlormethiazole (r_prep) doses_4\NNS|high|of (r_dobj) received_2\VBD|patients|doses|for|,|and|took (l_prep) for_7\IN|symptoms (l_pobj) symptoms_10\NNS|withdrawal
D002719_D062787 NONE chlormethiazole_6\NN| (r_pobj) of_5\IN|chlormethiazole (r_prep) doses_4\NNS|high|of (r_dobj) received_2\VBD|patients|doses|for|,|and|took (l_conj) took_14\VBD|one|overdose|. (l_dobj) overdose_17\NN|a|suicidal|of
D002719_D062787 NONE chlormethiazole_10\NN| (r_compound) intoxication_11\NN|chlormethiazole (r_pobj) with_9\IN|intoxication (r_prep) those_8\DT|with (r_pobj) of_7\IN|those (r_prep) two_6\CD|of (r_conj) overdose_4\NN|nitrazepam|and|two
D000431_D013375 NONE alcohol_8\NN| (r_compound) withdrawal_9\NN|alcohol (r_compound) symptoms_10\NNS|withdrawal
D000431_D062787 NONE alcohol_8\NN| (r_compound) withdrawal_9\NN|alcohol (r_compound) symptoms_10\NNS|withdrawal (r_pobj) for_7\IN|symptoms (r_prep) received_2\VBD|patients|doses|for|,|and|took (l_conj) took_14\VBD|one|overdose|. (l_dobj) overdose_17\NN|a|suicidal|of
D009567_D013375 NONE nitrazepam_19\NN| (r_pobj) of_18\IN|nitrazepam (r_prep) overdose_17\NN|a|suicidal|of (r_dobj) took_14\VBD|one|overdose|. (r_conj) received_2\VBD|patients|doses|for|,|and|took (l_prep) for_7\IN|symptoms (l_pobj) symptoms_10\NNS|withdrawal
D009567_D062787 CID nitrazepam_19\NN| (r_pobj) of_18\IN|nitrazepam (r_prep) overdose_17\NN|a|suicidal|of
D009567_D062787 CID nitrazepam_3\JJ| (r_amod) overdose_4\NN|nitrazepam|and|two
D009567_D003128 CID nitrazepam_3\JJ| (r_amod) overdose_4\NN|nitrazepam|and|two (r_pobj) with_2\IN|overdose (r_prep) patient_1\NN|the|with (r_nsubj) conformed_12\VBD|patient|to|,|showing|. (l_prep) to_13\IN|criteria (l_pobj) criteria_15\NNS|the|of (l_prep) of_16\IN|'|coma|' (l_pobj) coma_19\NN|alpha
D002719_D003128 CID chlormethiazole_10\NN| (r_compound) intoxication_11\NN|chlormethiazole (r_pobj) with_9\IN|intoxication (r_prep) those_8\DT|with (r_pobj) of_7\IN|those (r_prep) two_6\CD|of (r_conj) overdose_4\NN|nitrazepam|and|two (r_pobj) with_2\IN|overdose (r_prep) patient_1\NN|the|with (r_nsubj) conformed_12\VBD|patient|to|,|showing|. (l_prep) to_13\IN|criteria (l_pobj) criteria_15\NNS|the|of (l_prep) of_16\IN|'|coma|' (l_pobj) coma_19\NN|alpha
12483326
D016190_D005128 NONE carboplatin_9\NN| (r_pobj) of_8\IN|carboplatin (r_prep) injection_7\NN|intracarotid|of|for (r_pobj) after_5\IN|injection (r_prep) toxicity_4\NN|severe|ocular|after|.
D016190_D005128 NONE carboplatin_2\NN| (r_nsubjpass) said_4\VBN|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ|are|well (l_auxpass) are_18\VBP|toxicity (l_nsubj) toxicity_17\NN|whose|ocular
D016190_D005128 NONE carboplatin_16\NN| (r_pobj) of_15\IN|carboplatin (r_prep) injection_14\NN|intracarotid|of|,|reported (r_pobj) after_12\IN|injection (r_prep) experienced_3\VBD|however|,|we|case|after|. (l_dobj) case_5\NN|a|of (l_prep) of_6\IN|toxicity (l_pobj) toxicity_11\NN|severe|ocular
D016190_D005128 NONE carboplatin_5\NN| (r_pobj) of_4\IN|carboplatin (r_prep) injection_3\NN|intracarotid|of (r_dobj) performing_1\VBG|when|injection (r_advcl) be_9\VB|performing|,|we|must|aware|. (l_acomp) aware_10\JJ|of (l_prep) of_11\IN|toxicity (l_pobj) toxicity_16\NN|its|blinding|ocular
D016190_D009916 NONE carboplatin_9\NN| (r_pobj) of_8\IN|carboplatin (r_prep) injection_7\NN|intracarotid|of|for (r_pobj) after_5\IN|injection (r_prep) toxicity_4\NN|severe|ocular|after|.
D016190_D009916 NONE carboplatin_2\NN| (r_nsubjpass) said_4\VBN|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ|are|well (l_auxpass) are_18\VBP|toxicity (l_nsubj) toxicity_17\NN|whose|ocular
D016190_D009916 NONE carboplatin_16\NN| (r_pobj) of_15\IN|carboplatin (r_prep) injection_14\NN|intracarotid|of|,|reported (r_pobj) after_12\IN|injection (r_prep) experienced_3\VBD|however|,|we|case|after|. (l_dobj) case_5\NN|a|of (l_prep) of_6\IN|toxicity (l_pobj) toxicity_11\NN|severe|ocular
D016190_D005909 NONE carboplatin_9\NN| (r_pobj) of_8\IN|carboplatin (r_prep) injection_7\NN|intracarotid|of|for (l_prep) for_10\IN|glioblastomas (l_pobj) glioblastomas_12\NNS|recurrent
D016190_D005909 NONE carboplatin_10\NN| (r_pobj) of_9\IN|carboplatin (r_prep) injection_8\NN|an|intracarotid|of|for|in (l_prep) for_11\IN|glioblastomas (l_pobj) glioblastomas_13\NNS|recurrent
D002945_D005128 NONE cisplatin_11\NN| (r_pcomp) than_10\IN|cisplatin (r_prep) effects_9\NNS|milder|side|than|, (r_dobj) have_6\VB|to|effects (r_xcomp) said_4\VBN|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ|are|well (l_auxpass) are_18\VBP|toxicity (l_nsubj) toxicity_17\NN|whose|ocular
D002945_D009916 NONE cisplatin_11\NN| (r_pcomp) than_10\IN|cisplatin (r_prep) effects_9\NNS|milder|side|than|, (r_dobj) have_6\VB|to|effects (r_xcomp) said_4\VBN|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ|are|well (l_auxpass) are_18\VBP|toxicity (l_nsubj) toxicity_17\NN|whose|ocular
D016190_D064420 NONE carboplatin_7\NN| (r_amod) toxicity_8\NN|carboplatin
17919553
C106791_D056486 CID telithromycin_6\NNS|to (r_relcl) exposure_4\NN|telithromycin (r_pobj) after_3\IN|exposure (r_prep) attack_2\NN|acute|hepatitis|after|. (l_compound) hepatitis_1\NNP|
C106791_D056486 CID telithromycin_19\NNS| (r_compound) usage_20\NN|telithromycin (r_pobj) after_18\IN|usage (r_prep) occurred_17\VBD|suffered|,|"|that|after|. (l_ccomp) suffered_3\VBN|patient|had|episode (l_dobj) episode_6\NN|a|previous|of (l_prep) of_7\IN|hepatitis (l_pobj) hepatitis_10\NN|"|acute|of
C106791_D056486 CID telithromycin_15\NNS| (r_nsubj) was_16\VBD|based|,|telithromycin|cause|,|and|suggested (l_attr) cause_19\NN|the|probable|of (l_prep) of_20\IN|hepatitis (l_pobj) hepatitis_22\NN|acute|in
C106791_D056486 CID telithromycin_15\NNS| (r_nsubj) was_16\VBD|based|,|telithromycin|cause|,|and|suggested (l_conj) suggested_30\VBD|findings|hepatitis|. (l_dobj) hepatitis_35\NN|induced|toxic
C106791_D056486 CID telithromycin_21\NNS| (r_dobj) prescribed_20\VBD|who|telithromycin|time (r_relcl) physician_18\NN|the|attending|prescribed (r_pobj) to_15\IN|physician (r_prep) communicated_14\VBN|if|incident|had|been|to (r_advcl) avoided_7\VBN|recurrence|might|have|been|communicated|. (l_nsubjpass) Recurrence_0\NN|of (l_prep) of_1\IN|attack (l_pobj) attack_3\NN|hepatitis (l_compound) hepatitis_2\NN|
C106791_D056486 CID telithromycin_14\NNS| (r_pobj) of_13\IN|telithromycin (r_prep) administration_12\NN|the|of (r_pobj) with_10\IN|administration (r_prep) associated_9\VBN|probably|with (r_acl) case_4\NN|a|of|associated (l_prep) of_5\IN|hepatitis (l_pobj) hepatitis_7\NN|acute
C106791_D064420 NONE telithromycin_15\NNS| (r_nsubj) was_16\VBD|based|,|telithromycin|cause|,|and|suggested (l_prep) Based_0\VBN|on (l_prep) on_1\IN|score (l_pobj) score_3\NN|a|of|on (l_prep) on_6\IN|scale (l_pobj) scale_13\NN|the|probability (l_compound) probability_12\NN|reaction (l_compound) reaction_11\NN|naranjo|adverse|drug
2522601
D002220_D004342 CID carbamazepine_2\NN| (r_pobj) to_1\IN|carbamazepine (r_prep) Hypersensitivity_0\NN|to|presenting|.
D002220_D004342 CID carbamazepine_8\NN| (r_pobj) to_7\IN|carbamazepine (r_prep) hypersensitivity_6\NN|to
D002220_D007955 CID carbamazepine_2\NN| (r_pobj) to_1\IN|carbamazepine (r_prep) Hypersensitivity_0\NN|to|presenting|. (l_acl) presenting_3\VBG|with (l_prep) with_4\IN|reaction (l_pobj) reaction_7\NN|a|leukemoid|,|eosinophilia|failure
D002220_D007955 CID carbamazepine_8\NN| (r_pobj) to_7\IN|carbamazepine (r_prep) hypersensitivity_6\NN|to (r_nsubj) presented_9\VBN|in|hypersensitivity|with (r_relcl) patient_3\NN|a|presented|,|reaction (l_conj) reaction_17\NN|a|severe|leukemoid|,|eosinophilia
D002220_D004802 NONE carbamazepine_2\NN| (r_pobj) to_1\IN|carbamazepine (r_prep) Hypersensitivity_0\NN|to|presenting|. (l_acl) presenting_3\VBG|with (l_prep) with_4\IN|reaction (l_pobj) reaction_7\NN|a|leukemoid|,|eosinophilia|failure (l_conj) eosinophilia_9\NN|,|erythroderma
D002220_D004802 NONE carbamazepine_8\NN| (r_pobj) to_7\IN|carbamazepine (r_prep) hypersensitivity_6\NN|to (r_nsubj) presented_9\VBN|in|hypersensitivity|with (r_relcl) patient_3\NN|a|presented|,|reaction (l_conj) reaction_17\NN|a|severe|leukemoid|,|eosinophilia (l_conj) eosinophilia_19\NN|,|hyponatremia
D002220_D003873 CID carbamazepine_2\NN| (r_pobj) to_1\IN|carbamazepine (r_prep) Hypersensitivity_0\NN|to|presenting|. (l_acl) presenting_3\VBG|with (l_prep) with_4\IN|reaction (l_pobj) reaction_7\NN|a|leukemoid|,|eosinophilia|failure (l_conj) eosinophilia_9\NN|,|erythroderma (l_conj) erythroderma_11\NN|,|and
D002220_D003873 CID carbamazepine_8\NN| (r_pobj) to_7\IN|carbamazepine (r_prep) hypersensitivity_6\NN|to (r_nsubj) presented_9\VBN|in|hypersensitivity|with (l_prep) with_10\IN|erythroderma (l_pobj) erythroderma_12\NN|generalized
D002220_D051437 CID carbamazepine_2\NN| (r_pobj) to_1\IN|carbamazepine (r_prep) Hypersensitivity_0\NN|to|presenting|. (l_acl) presenting_3\VBG|with (l_prep) with_4\IN|reaction (l_pobj) reaction_7\NN|a|leukemoid|,|eosinophilia|failure (l_conj) failure_15\NN|renal
D002220_D051437 CID carbamazepine_8\NN| (r_pobj) to_7\IN|carbamazepine (r_prep) hypersensitivity_6\NN|to (r_nsubj) presented_9\VBN|in|hypersensitivity|with (r_relcl) patient_3\NN|a|presented|,|reaction (l_conj) reaction_17\NN|a|severe|leukemoid|,|eosinophilia (l_conj) eosinophilia_19\NN|,|hyponatremia (l_conj) hyponatremia_21\NN|,|and|failure (l_conj) failure_25\NN|renal
D002220_D007010 CID carbamazepine_8\NN| (r_pobj) to_7\IN|carbamazepine (r_prep) hypersensitivity_6\NN|to (r_nsubj) presented_9\VBN|in|hypersensitivity|with (r_relcl) patient_3\NN|a|presented|,|reaction (l_conj) reaction_17\NN|a|severe|leukemoid|,|eosinophilia (l_conj) eosinophilia_19\NN|,|hyponatremia (l_conj) hyponatremia_21\NN|,|and|failure
19820426
C558899_D066126 NONE ritonavir_10\NNS| (r_compound) therapy_11\NN|ritonavir (r_appos) lopinavir_8\NNS|/|therapy (r_pobj) to_7\IN|lopinavir (r_prep) related_6\VBN|to (r_acl) toxicity_5\NN|cardiac|related
C558899_D006327 CID ritonavir_15\NNS| (r_compound) therapy_16\NN|ritonavir|,|agent (r_appos) lopinavir_13\NNS|/|therapy (r_pobj) to_12\IN|lopinavir (r_prep) related_11\VBN|to (r_acl) cardiomyopathy_10\NN|dilated|related (r_conj) block_7\NN|complete|heart|and|cardiomyopathy
C558899_D002311 CID ritonavir_15\NNS| (r_compound) therapy_16\NN|ritonavir|,|agent (r_appos) lopinavir_13\NNS|/|therapy (r_pobj) to_12\IN|lopinavir (r_prep) related_11\VBN|to (r_acl) cardiomyopathy_10\NN|dilated|related
C558899_D001919 CID ritonavir_15\NNS| (r_compound) therapy_16\NN|ritonavir|,|agent (r_appos) lopinavir_13\NNS|/|therapy (r_pobj) to_12\IN|lopinavir (r_prep) related_11\VBN|to (r_acl) cardiomyopathy_10\NN|dilated|related (r_conj) block_7\NN|complete|heart|and|cardiomyopathy (r_dobj) developed_4\VBD|one|block|,|developed|. (l_advcl) developed_29\VBD|while|twin|bradycardia (l_dobj) bradycardia_31\NNS|mild
11928786
D016642_D064420 NONE Bupropion_0\NNP| (r_nmod) toxicity_4\NN|bupropion|(|zyban|)|.
D016642_D064420 NONE Zyban_2\NNP| (r_nmod) toxicity_4\NN|bupropion|(|zyban|)|.
D003975_D012640 NONE diazepam_5\NN|and|tachycardia (r_pobj) with_4\IN|diazepam (r_prep) treated_3\VBN|seizures|were|with|treated|. (l_nsubjpass) seizures_1\NNS|recurrent
D003975_D013610 NONE diazepam_5\NN|and|tachycardia (l_conj) tachycardia_9\NN|broad|complex
D000241_D012640 NONE adenosine_14\NN| (r_pobj) with_13\IN|adenosine (r_prep) treated_12\VBN|was|successfully|with (r_conj) treated_3\VBN|seizures|were|with|treated|. (l_nsubjpass) seizures_1\NNS|recurrent
D000241_D013610 NONE adenosine_14\NN| (r_pobj) with_13\IN|adenosine (r_prep) treated_12\VBN|was|successfully|with (r_conj) treated_3\VBN|seizures|were|with|treated|. (l_prep) with_4\IN|diazepam (l_pobj) diazepam_5\NN|and|tachycardia (l_conj) tachycardia_9\NN|broad|complex
D016642_D020258 NONE Zyban_0\NNP| (r_nsubj) caused_1\VBD|zyban|toxicity|. (l_dobj) toxicity_6\NN|significant|neurological|in
D016642_D002318 NONE Zyban_0\NNP| (r_nsubj) caused_1\VBD|zyban|toxicity|. (l_dobj) toxicity_6\NN|significant|neurological|in
D016642_D062787 NONE Zyban_0\NNP| (r_nsubj) caused_1\VBD|zyban|toxicity|. (l_dobj) toxicity_6\NN|significant|neurological|in (l_prep) in_7\IN|overdose (l_pobj) overdose_8\NN|
15036754
D010755_D012640 NONE Organophosphate_0\NNP| (r_npadvmod) induced_2\VBN|organophosphate|- (r_amod) convulsions_3\NNS|induced|and|prevention|of|.
D010755_D004194 NONE Organophosphate_0\NNP| (r_npadvmod) induced_2\VBN|organophosphate|- (r_amod) convulsions_3\NNS|induced|and|prevention|of|. (l_prep) of_6\IN|damages (l_pobj) damages_8\NNS|neuropathological
D010755_D064420 NONE OPs_4\NNS| (r_pobj) of_3\IN|ops (r_prep) toxicity_2\NN|the|acute|of
D010755_D064420 NONE OP_10\NN| (r_npadvmod) induced_12\VBN|op|- (r_amod) signs_14\NNS|severe|typical|induced|toxicity (l_compound) toxicity_13\NN|
D000109_D064420 NONE acetylcholine_25\NN| (r_nmod) levels_29\NNS|acetylcholine|(|ach|) (r_dobj) elevates_24\VBZ|which|levels (r_relcl) system_18\NN|the|central|nervous|(|cns|)|,|elevates (r_pobj) in_14\IN|system (r_prep) AChEs_13\NNP|in (r_pobj) with_12\IN|aches (r_prep) binding_11\NN|their|irreversible|with (r_pobj) of_8\IN|binding (r_prep) result_7\NN|the|of (r_attr) is_5\VBZ|toxicity|result|. (l_nsubj) toxicity_2\NN|the|acute|of
D000109_D064420 NONE ACh_27\NNS| (r_nmod) levels_29\NNS|acetylcholine|(|ach|) (r_dobj) elevates_24\VBZ|which|levels (r_relcl) system_18\NN|the|central|nervous|(|cns|)|,|elevates (r_pobj) in_14\IN|system (r_prep) AChEs_13\NNP|in (r_pobj) with_12\IN|aches (r_prep) binding_11\NN|their|irreversible|with (r_pobj) of_8\IN|binding (r_prep) result_7\NN|the|of (r_attr) is_5\VBZ|toxicity|result|. (l_nsubj) toxicity_2\NN|the|acute|of
D007531_D064420 NONE DFP_4\NNP| (r_compound) atropine_6\NN|dfp|- (r_pobj) with_3\IN|atropine (r_prep) treated_2\VBD|rats|with|showed|. (l_conj) showed_7\VBD|signs (l_dobj) signs_14\NNS|severe|typical|induced|toxicity (l_compound) toxicity_13\NN|
D007531_D064420 NONE DFP_10\NNP| (r_compound) toxicity_11\NN|dfp
D007531_D064420 NONE DFP_26\NNP| (r_pobj) of_25\IN|dfp (r_prep) toxicity_24\NN|the|of|in
D001285_D064420 NONE atropine_6\NN|dfp|- (r_pobj) with_3\IN|atropine (r_prep) treated_2\VBD|rats|with|showed|. (l_conj) showed_7\VBD|signs (l_dobj) signs_14\NNS|severe|typical|induced|toxicity (l_compound) toxicity_13\NN|
D001285_D064420 NONE Atropine_0\NNP| (r_compound) MK801_2\NNP|atropine|- (r_nsubj) offer_5\VB|mk801|did|not|protection|. (l_dobj) protection_8\NN|any|additional|against (l_prep) against_9\IN|toxicity (l_pobj) toxicity_11\NN|dfp
D001285_D064420 NONE atropine_11\NN| (r_pobj) with_10\IN|atropine (r_prep) combination_9\NN|with (r_pobj) in_8\IN|combination (r_prep) diazepam_5\NN|and|2pam|in (r_conj) CPA_3\NN|,|diazepam (r_nsubj) prevented_12\VBD|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD|thus|toxicity (l_dobj) toxicity_24\NN|the|of|in
C048599_D011041 NONE CPA_1\NN| (r_nsubjpass) given_7\VBN|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN|or|shortened (l_conj) shortened_20\VBN|occurrence (l_dobj) occurrence_22\NN|the|of (l_prep) of_23\IN|signs (l_pobj) signs_25\NNS|serious|of (l_prep) of_26\IN|poisoning (l_pobj) poisoning_27\NN|
C048599_D011041 NONE CPA_3\NN|,|diazepam (r_nsubj) prevented_12\VBD|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN|the|of (l_prep) of_15\IN|signs (l_pobj) signs_17\NNS|serious|of (l_prep) of_18\IN|poisoning (l_pobj) poisoning_19\NN|
D003975_D011041 NONE diazepam_3\NN|or|2pam (r_nsubjpass) given_7\VBN|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN|or|shortened (l_conj) shortened_20\VBN|occurrence (l_dobj) occurrence_22\NN|the|of (l_prep) of_23\IN|signs (l_pobj) signs_25\NNS|serious|of (l_prep) of_26\IN|poisoning (l_pobj) poisoning_27\NN|
D003975_D011041 NONE diazepam_5\NN|and|2pam|in (r_conj) CPA_3\NN|,|diazepam (r_nsubj) prevented_12\VBD|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN|the|of (l_prep) of_15\IN|signs (l_pobj) signs_17\NNS|serious|of (l_prep) of_18\IN|poisoning (l_pobj) poisoning_19\NN|
D011220_D011041 NONE 2PAM_5\CD| (r_conj) diazepam_3\NN|or|2pam (r_nsubjpass) given_7\VBN|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN|or|shortened (l_conj) shortened_20\VBN|occurrence (l_dobj) occurrence_22\NN|the|of (l_prep) of_23\IN|signs (l_pobj) signs_25\NNS|serious|of (l_prep) of_26\IN|poisoning (l_pobj) poisoning_27\NN|
D011220_D011041 NONE 2PAM_7\CD| (r_conj) diazepam_5\NN|and|2pam|in (r_conj) CPA_3\NN|,|diazepam (r_nsubj) prevented_12\VBD|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN|the|of (l_prep) of_15\IN|signs (l_pobj) signs_17\NNS|serious|of (l_prep) of_18\IN|poisoning (l_pobj) poisoning_19\NN|
D007531_D011041 NONE DFP_10\NNP| (r_compound) atropine_12\NN|dfp|- (r_pobj) after_9\IN|atropine (r_prep) given_7\VBN|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN|or|shortened (l_conj) shortened_20\VBN|occurrence (l_dobj) occurrence_22\NN|the|of (l_prep) of_23\IN|signs (l_pobj) signs_25\NNS|serious|of (l_prep) of_26\IN|poisoning (l_pobj) poisoning_27\NN|
D007531_D011041 NONE DFP_26\NNP| (r_pobj) of_25\IN|dfp (r_prep) toxicity_24\NN|the|of|in (r_dobj) reduced_22\VBD|thus|toxicity (r_conj) prevented_12\VBD|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN|the|of (l_prep) of_15\IN|signs (l_pobj) signs_17\NNS|serious|of (l_prep) of_18\IN|poisoning (l_pobj) poisoning_19\NN|
D001285_D011041 NONE atropine_12\NN|dfp|- (r_pobj) after_9\IN|atropine (r_prep) given_7\VBN|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN|or|shortened (l_conj) shortened_20\VBN|occurrence (l_dobj) occurrence_22\NN|the|of (l_prep) of_23\IN|signs (l_pobj) signs_25\NNS|serious|of (l_prep) of_26\IN|poisoning (l_pobj) poisoning_27\NN|
D001285_D011041 NONE atropine_11\NN| (r_pobj) with_10\IN|atropine (r_prep) combination_9\NN|with (r_pobj) in_8\IN|combination (r_prep) diazepam_5\NN|and|2pam|in (r_conj) CPA_3\NN|,|diazepam (r_nsubj) prevented_12\VBD|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN|the|of (l_prep) of_15\IN|signs (l_pobj) signs_17\NNS|serious|of (l_prep) of_18\IN|poisoning (l_pobj) poisoning_19\NN|
D016291_D064420 NONE MK801_2\NNP|atropine|- (r_nsubj) offer_5\VB|mk801|did|not|protection|. (l_dobj) protection_8\NN|any|additional|against (l_prep) against_9\IN|toxicity (l_pobj) toxicity_11\NN|dfp
C048599_D064420 NONE CPA_3\NN|,|diazepam (r_nsubj) prevented_12\VBD|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD|thus|toxicity (l_dobj) toxicity_24\NN|the|of|in
D003975_D064420 NONE diazepam_5\NN|and|2pam|in (r_conj) CPA_3\NN|,|diazepam (r_nsubj) prevented_12\VBD|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD|thus|toxicity (l_dobj) toxicity_24\NN|the|of|in
D011220_D064420 NONE 2PAM_7\CD| (r_conj) diazepam_5\NN|and|2pam|in (r_conj) CPA_3\NN|,|diazepam (r_nsubj) prevented_12\VBD|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD|thus|toxicity (l_dobj) toxicity_24\NN|the|of|in
9199746
D000583_D064420 NONE amikacin_4\RB|toxicity|. (l_nsubj) toxicity_1\NN|macula|after
D000617_D009877 NONE aminoglycosides_2\NNS|intravitreal (r_nsubj) improved_5\VBN|although|aminoglycosides|have|substantially|prognosis (l_dobj) prognosis_7\NN|visual|in (l_prep) in_8\IN|endophthalmitis (l_pobj) endophthalmitis_9\NN|
D000617_D007238 NONE aminoglycosides_2\NNS|intravitreal (r_nsubj) improved_5\VBN|although|aminoglycosides|have|substantially|prognosis (r_advcl) impair_14\VB|improved|,|infarction|may|recovery|. (l_nsubj) infarction_12\NN|macular
D000583_D012164 CID amikacin_6\JJ|toxicity (l_pobj) toxicity_8\NN|retinal
D000583_D012164 CID amikacin_12\JJ|and|vancomycin (r_pobj) with_11\IN|amikacin (r_prep) treatment_10\NN|with (r_pobj) following_9\VBG|treatment (r_prep) presumed_5\VBN|amikacin|following (l_prep) amikacin_6\JJ|toxicity (l_pobj) toxicity_8\NN|retinal
D000583_D013290 NONE amikacin_6\JJ|toxicity (r_prep) presumed_5\VBN|amikacin|following (l_prep) following_9\VBG|treatment (l_pobj) treatment_10\NN|with (l_prep) with_11\IN|amikacin (l_pobj) amikacin_12\JJ|and|vancomycin (l_conj) vancomycin_14\NNP|for (l_prep) for_15\IN|endophthalmitis (l_pobj) endophthalmitis_20\NN|haemolytic|streptococcal
D000583_D013290 NONE amikacin_12\JJ|and|vancomycin (l_conj) vancomycin_14\NNP|for (l_prep) for_15\IN|endophthalmitis (l_pobj) endophthalmitis_20\NN|haemolytic|streptococcal
D014640_D012164 NONE vancomycin_14\NNP|for (r_conj) amikacin_12\JJ|and|vancomycin (r_pobj) with_11\IN|amikacin (r_prep) treatment_10\NN|with (r_pobj) following_9\VBG|treatment (r_prep) presumed_5\VBN|amikacin|following (l_prep) amikacin_6\JJ|toxicity (l_pobj) toxicity_8\NN|retinal
D014640_D013290 NONE vancomycin_14\NNP|for (l_prep) for_15\IN|endophthalmitis (l_pobj) endophthalmitis_20\NN|haemolytic|streptococcal
D019793_D013684 NONE fluorescein_1\NN| (r_amod) angiography_2\NN|fluorescein (r_nsubj) confirmed_3\VBD|fundus|angiography|closure|. (l_dobj) closure_6\NN|macular|capillary|and|telangiectasis (l_conj) telangiectasis_8\NN|
18951540
D007980_D004409 CID levodopa_5\NN| (r_npadvmod) induced_7\VBN|levodopa|- (r_amod) dyskinesias_8\NNS|induced|in
D007980_D010300 NONE levodopa_5\NN| (r_npadvmod) induced_7\VBN|levodopa|- (r_amod) dyskinesias_8\NNS|induced|in (l_prep) in_9\IN|disease (l_pobj) disease_12\NN|parkinson
17111419
C102006_D064420 NONE citrate_1\JJ| (r_compound) toxicity_2\NN|severe|citrate
C102006_D064420 NONE citrate_6\JJ| (r_compound) toxicity_7\NN|severe|citrate
C102006_D064420 NONE citrate_22\JJ| (r_compound) toxicity_23\NN|citrate
D002125_C536214 NONE gluconate_5\NN|intravenous|calcium (r_pobj) with_2\IN|gluconate (r_prep) treatment_1\NN|empirical|with (r_nsubjpass) initiated_7\VBN|treatment|was|,|and|subsided (l_conj) subsided_13\VBD|contractions|slowly|over|. (l_nsubj) contractions_11\NNS|muscle
D002118_D006996 NONE calcium_9\NN| (r_compound) chelation_10\NN|calcium (r_pobj) to_8\IN|chelation (r_prep) reaction_7\NN|a|severe|to|by|resulting (l_acl) resulting_15\VBG|in (l_prep) in_16\IN|hypocalcemia (l_pobj) hypocalcemia_19\NN|symptomatic|systemic
C102006_D006996 CID citrate_13\NN|sodium (r_compound) anticoagulant_14\NN|citrate (r_pobj) by_11\IN|anticoagulant (r_prep) reaction_7\NN|a|severe|to|by|resulting (l_acl) resulting_15\VBG|in (l_prep) in_16\IN|hypocalcemia (l_pobj) hypocalcemia_19\NN|symptomatic|systemic
C102006_D006996 CID citrate_22\JJ| (r_compound) toxicity_23\NN|citrate (r_pobj) to_21\IN|toxicity (r_pcomp) due_20\IN|to (r_amod) reactions_19\NNS|severe|due (r_dobj) prevent_17\VB|reactions (r_xcomp) help_16\VB|to|prevent (r_xcomp) recommended_14\VBN|that|screening|is|help (l_nsubjpass) screening_4\NN|careful|for (l_prep) for_5\IN|medications (l_pobj) medications_6\NNS|and|conditions (l_conj) conditions_9\NNS|underlying|predisposing (l_acl) predisposing_10\VBG|to (l_prep) to_11\IN|hypocalcemia (l_pobj) hypocalcemia_12\NN|
D002034_D006996 NONE bumetanide_9\NN| (r_nsubj) is_10\VBZ|that|bumetanide|loop (l_attr) loop_12\NN|a|diuretic|cause (l_relcl) cause_16\VB|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN|significant
D049994_D006996 NONE diuretic_13\NN| (r_amod) loop_12\NN|a|diuretic|cause (l_relcl) cause_16\VB|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN|significant
18560792
D010479_D006349 NONE pergolide_11\NN| (r_pobj) with_10\IN|pergolide (r_prep) treated_9\VBN|disease|with|. (l_nsubj) disease_2\NN|valvular|heart|in
D010479_D006349 NONE pergolide_17\NN| (r_pobj) with_16\IN|pergolide (r_prep) treated_15\VBN|with (r_acl) patients_7\NNS|with|treated (r_pobj) in_6\IN|patients (r_prep) reported_5\VBN|abnormalities|have|been|in|. (l_nsubjpass) abnormalities_2\NNS|valvular|heart
D010479_D006349 NONE pergolide_12\NN| (r_pobj) of_11\IN|pergolide (r_prep) role_10\NN|the|of (r_pobj) of_8\IN|role (r_prep) suggestive_7\JJ|of (r_amod) pattern_2\NN|a|restrictive|of|,|suggestive (l_prep) of_3\IN|regurgitation (l_pobj) regurgitation_5\NN|valvular
D010479_D006349 NONE Pergolide_0\NNP| (r_nsubjpass) discontinued_2\VBN|pergolide|was|in|,|resulting|returned|. (l_prep) in_3\IN|patients (l_pobj) patients_5\NNS|10|with (l_prep) with_6\IN|disease (l_pobj) disease_9\NN|valvular|heart
D010479_D006349 NONE pergolide_15\NN| (r_pobj) with_14\IN|pergolide (r_prep) treated_13\VBN|with|and|reveals (r_acl) frequency_5\NN|the|high|of|treated (l_prep) of_6\IN|regurgitation (l_pobj) regurgitation_9\NN|restrictive|valve|in
D010479_D010300 NONE pergolide_11\NN| (r_pobj) with_10\IN|pergolide (r_prep) treated_9\VBN|disease|with|. (l_nsubj) disease_2\NN|valvular|heart|in (l_prep) in_3\IN|patients (l_pobj) patients_4\NNS|with (l_prep) with_5\IN|disease (l_pobj) disease_8\NN|parkinson
D010479_D010300 NONE pergolide_17\NN| (r_pobj) with_16\IN|pergolide (r_prep) treated_15\VBN|with (r_acl) patients_7\NNS|with|treated (l_prep) with_8\IN|disease (l_pobj) disease_11\NN|parkinson|(|pd|)
D010479_D010300 NONE pergolide_17\NN| (r_pobj) with_16\IN|pergolide (r_prep) treated_15\VBN|with (r_acl) patients_7\NNS|with|treated (l_prep) with_8\IN|disease (l_pobj) disease_11\NN|parkinson|(|pd|) (l_appos) PD_13\NNP|
D010479_D010300 NONE pergolide_9\NN| (r_pobj) with_8\IN|pergolide (r_prep) treated_7\VBN|patients|with (l_nsubj) patients_2\NNS|all|pd|in (l_compound) PD_1\NNP|
D010479_D010300 NONE pergolide_15\NN| (r_pobj) with_14\IN|pergolide (r_prep) treated_13\VBN|with|and|reveals (r_acl) frequency_5\NN|the|high|of|treated (l_prep) of_6\IN|regurgitation (l_pobj) regurgitation_9\NN|restrictive|valve|in (l_prep) in_10\IN|patients (l_pobj) patients_12\NNS|pd (l_compound) PD_11\NNP|
D010479_D006333 NONE pergolide_12\NN| (r_pobj) of_11\IN|pergolide (r_prep) role_10\NN|the|of (r_pobj) of_8\IN|role (r_prep) suggestive_7\JJ|of (r_amod) pattern_2\NN|a|restrictive|of|,|suggestive (r_nsubjpass) observed_15\VBN|pattern|,|was|in|patients|. (l_dobj) patients_22\NNS|including (l_prep) including_23\VBG|two (l_pobj) two_24\CD|with (l_prep) with_25\IN|failure (l_pobj) failure_27\NN|heart
D010479_D006333 NONE Pergolide_0\NNP| (r_nsubjpass) discontinued_2\VBN|pergolide|was|in|,|resulting|returned|. (l_advcl) resulting_11\VBG|in (l_prep) in_12\IN|grade (l_pobj) grade_16\NN|a|lower|regurgitation|p=0.01|at (l_prep) at_20\IN|transthoracic (l_pobj) transthoracic_23\NN|the|second|echocardiography|and|patients (l_conj) patients_28\NNS|the|two|with (l_prep) with_29\IN|failure (l_pobj) failure_31\NN|heart
D004298_D006349 NONE dopamine_33\NN| (r_compound) agonists_34\NNS|ergot|dopamine (r_pobj) to_29\IN|agonists (r_prep) converted_28\VBN|when|treatment|is|to (r_advcl) is_22\VBZ|that|improvement|usual|converted (r_ccomp) reveals_17\VBZ|is (r_conj) treated_13\VBN|with|and|reveals (r_acl) frequency_5\NN|the|high|of|treated (l_prep) of_6\IN|regurgitation (l_pobj) regurgitation_9\NN|restrictive|valve|in
D004298_D010300 NONE dopamine_33\NN| (r_compound) agonists_34\NNS|ergot|dopamine (r_pobj) to_29\IN|agonists (r_prep) converted_28\VBN|when|treatment|is|to (r_advcl) is_22\VBZ|that|improvement|usual|converted (r_ccomp) reveals_17\VBZ|is (r_conj) treated_13\VBN|with|and|reveals (r_acl) frequency_5\NN|the|high|of|treated (l_prep) of_6\IN|regurgitation (l_pobj) regurgitation_9\NN|restrictive|valve|in (l_prep) in_10\IN|patients (l_pobj) patients_12\NNS|pd (l_compound) PD_11\NNP|
11569530
D016593_D016171 CID terfenadine_19\NN|e.g.|and|terodiline (r_appos) market_16\NN|the|(|terfenadine|) (r_pobj) from_14\IN|market (r_prep) withdrawal_10\NN|of|from (r_pobj) to_9\IN|withdrawal (r_prep) led_8\VBN|that|has|to (r_relcl) effect_5\NN|a|side|-|led (r_attr) is_1\VBZ|tdp|effect|. (l_nsubj) TDP_0\NNP|
D016593_D016171 CID terfenadine_13\NN|,|terodiline (r_appos) investigated_11\VBN|tdp|were|:|terfenadine (l_nsubjpass) TDP_9\NNP|
D016593_D016171 CID terfenadine_10\NN|,|terodiline (r_appos) clinic_8\NN|the|(|terfenadine|) (r_pobj) in_6\IN|clinic (r_prep) shown_4\VBN|that|have|tdp|in (l_dobj) TDP_5\NNP|
C010637_D016171 CID terodiline_21\NN| (r_conj) terfenadine_19\NN|e.g.|and|terodiline (r_appos) market_16\NN|the|(|terfenadine|) (r_pobj) from_14\IN|market (r_prep) withdrawal_10\NN|of|from (r_pobj) to_9\IN|withdrawal (r_prep) led_8\VBN|that|has|to (r_relcl) effect_5\NN|a|side|-|led (r_attr) is_1\VBZ|tdp|effect|. (l_nsubj) TDP_0\NNP|
C010637_D016171 CID terodiline_15\NN|,|cisapride (r_conj) terfenadine_13\NN|,|terodiline (r_appos) investigated_11\VBN|tdp|were|:|terfenadine (l_nsubjpass) TDP_9\NNP|
C010637_D016171 CID terodiline_12\NN|,|cisapride (r_conj) terfenadine_10\NN|,|terodiline (r_appos) clinic_8\NN|the|(|terfenadine|) (r_pobj) in_6\IN|clinic (r_prep) shown_4\VBN|that|have|tdp|in (l_dobj) TDP_5\NNP|
D020117_D016171 CID cisapride_17\NN|and|e4031 (r_conj) terodiline_15\NN|,|cisapride (r_conj) terfenadine_13\NN|,|terodiline (r_appos) investigated_11\VBN|tdp|were|:|terfenadine (l_nsubjpass) TDP_9\NNP|
D020117_D016171 CID cisapride_14\JJ| (r_conj) terodiline_12\NN|,|cisapride (r_conj) terfenadine_10\NN|,|terodiline (r_appos) clinic_8\NN|the|(|terfenadine|) (r_pobj) in_6\IN|clinic (r_prep) shown_4\VBN|that|have|tdp|in (l_dobj) TDP_5\NNP|
C063968_D016171 NONE E4031_19\NNP| (r_conj) cisapride_17\NN|and|e4031 (r_conj) terodiline_15\NN|,|cisapride (r_conj) terfenadine_13\NN|,|terodiline (r_appos) investigated_11\VBN|tdp|were|:|terfenadine (l_nsubjpass) TDP_9\NNP|
